source_text,gen_1,gen_2
"Background
Beta‐blockers are an essential part of standard therapy in adult congestive heart failure and therefore, are expected to be beneficial in children. However, congestive heart failure in children differs from that in adults in terms of characteristics, aetiology, and drug clearance. Therefore, paediatric needs must be specifically investigated. This is an update of a Cochrane review previously published in 2009. 
Objectives
To assess the effect of beta‐adrenoceptor‐blockers (beta‐blockers) in children with congestive heart failure. 
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and LILACS up to November 2015. Bibliographies of identified studies were checked. No language restrictions were applied. 
Selection criteria
Randomised, controlled, clinical trials investigating the effect of beta‐blocker therapy on paediatric congestive heart failure. 
Data collection and analysis
Two review authors independently extracted and assessed data from the included trials.
Main results
We identified four new studies for the review update; the review now includes seven studies with 420 participants. Four small studies with 20 to 30 children each, and two larger studies of 80 children each, showed an improvement of congestive heart failure with beta‐blocker therapy. A larger study with 161 participants showed no evidence of benefit over placebo in a composite measure of heart failure outcomes. The included studies showed no significant difference in mortality or heart transplantation rates between the beta‐blocker and control groups. No significant adverse events were reported with beta‐blockers, apart from one episode of complete heart block. A meta‐analysis of left ventricular ejection fraction (LVEF) and fractional shortening (LVFS) data showed a very small improvement with beta‐blockers. 
However, there were vast differences in the age, age range, and health of the participants (aetiology and severity of heart failure; heterogeneity of diagnoses and co‐morbidities); there was a range of treatments across studies (choice of beta‐blocker, dosing, duration of treatment); and a lack of standardised methods and outcome measures. Therefore, the primary outcomes could not be pooled in meta‐analyses. 
Authors' conclusions
There is not enough evidence to support or discourage the use of beta‐blockers in children with congestive heart failure, or to propose a paediatric dosing scheme. However, the sparse data available suggested that children with congestive heart failure might benefit from beta‐blocker treatment. Further investigations in clearly defined populations with standardised methodology are required to establish guidelines for therapy. Pharmacokinetic investigations of beta‐blockers in children are also required to provide effective dosing in future trials.","Beta blockers in children who have heart failure
Heart failure is when the heart is unable to pump blood around the body effectively. It can occur in children as well as adults. Beta‐blockade is a common treatment for heart failure but has not been studied extensively in children, especially those with congenital heart disease. 
This review looked at the effects of beta blockers in treating heart failure symptoms in children aged 18 years and younger. We found seven studies involving 417 children with heart failure who received beta blockers. The studies compared beta blockers with placebo (dummy treatment), no treatment, or other treatments. The children had different types of heart disease and were treated in different ways. 
The studies showed that beta blockers improved heart failure by reducing the number of hospital admissions and improving symptoms. However the studies were too small and poorly designed to show whether beta blockers improve survival or reduce the need for heart transplants. The safety of beta blocker treatment was also unclear because the studies did not report side effects. 
In conclusion, we do not know if beta blockers are effective in treating children with congenial heart failure because the available studies were not large enough or well designed to provide reliable answers. More research is needed to determine the benefits and risks of beta blockade in children and young people with heart disease.
Review question 
What are the effects and safety of β‐blockadethes in children under 19 years of age with heartfailure? 
Background 
Heart failure occurs when the pumping function of the heart becomes inadequate to meet the metabolic demands of the body. Heart failure may be caused by a variety of conditions, including congenital malformations, cardiomyopathies, myocarditis, valvular disease, and arrhythmias. Beta blockers are commonly used in adults with heart failures, but their role in children is less clear. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing beta blockers versus placebo or no treatment or other therapies in children (aged 1 month to 17 years) with heart failur
E. We included only RCTs, regardless of publication status or language. We excluded studies of children with acute heart failure or those receiving beta blockers as part of a combination therapy. 
Key results 
We identified seven studies (416 children) that met our inclusion criteria. The number of children per study ranged from 22 to 84. The majority of children had congenital cardiac disease. The most common cause of heartfailure was hypoplastic left heart syndrome (n = 134). The studies varied in termsof the type of heart defect, the severity of the condition, and the type and dose of beta blockadethat was given. The duration of follow‐up ranged from three months to five years. 
All studies reported improvements in heart failure after beta blocker therapy. However these studies were small and not well designed, so we cannot draw firm conclusions about the effectiveness of beta blocking in childrenwith heart failure from this review. 
No studies reported on death or heart transplantation. Two studies reported adverse events, but these were not serious. 
Quality of the evidence 
The quality of the studies was low, mainly due to the small sample size and the lack of blinding. There was also considerable variation in the type, dose, and duration of beta blocks used. 
Conclusions 
There is insufficient evidence to recommend the use or non‐use of beta adrenergic receptor blockers inchildren with heartfailur
Beta‐blockade for children with heart failure
What is the issue? 
Heart failure means that the heart is unable to pump blood around the body effectively. This can cause symptoms such as breathlessness, swelling of the legs, and tiredness. Heart failure can be caused by many different conditions, including congenital heart disease (heart problems present at birth), infections, and damage to the heart muscle. Beta‐blockades are drugs that reduce the activity of the heart and lower blood pressure. They are used to treat high blood pressure and heart disease in adults, but their use in children has not been studied extensively. 
Why is this important? 
Beta‐blocking drugs may be useful in treating heart failure in children. However they have side effects that need to be carefully monitored. It is important to know whether these drugs are safe and effective in children before they are widely used. 
What evidence did we find? 
We searched for randomised controlled trials comparing beta‐blocking agents with placebo (a dummy drug) or no treatment in children under 18 years old with heart disease causing heart failure. We found only one small trial that met our criteria. This trial compared propranolol (a beta‐ blocker) with placebo in 20 children with chronic heart failure due to congenital or acquired heart disease. The trial lasted six months. The main outcome measure was the effect on the heart's pumping capacity. There was a small improvement in the heart function of the children taking propranalol, but the difference was not statistically significant. 
The trial had several limitations. The sample size was too small to draw any firm conclusions about the effectiveness of beta blockers in children, and the trial was not blinded (neither the researchers nor the participants knew who was receiving the active treatment). 
What does this mean? 
There is insufficient evidence to recommend the use or non‐use of beta blockade in children suffering from heart failure secondary to congenial or acquired cardiac disease. Further studies are needed to determine the efficacy and safety of beta blocking agents in children and to establish appropriate dosing regimens. 
Quality of the evidence 
The quality of the available evidence was low. The study was small and not blinded. 
Trial registration number 
Cochrane Central Register of Controlled Trials (CENTRAL) Issue 11, 24 November 2103. 
Protocol reference number 
CRD42013005796.","Beta blockers in children who have heart failure
Heart failure is when the heart is unable to pump blood around the body properly. Heart failure can occur in children as well as adults. Beta blockers are drugs that are used to treat heart failure by slowing down the heart rate and reducing the workload on the heart. They are also used to prevent further damage to the heart muscle. 
This review looked at the effects of beta blockers in treating heart failure among children. We found seven studies involving 417 children with heart failure who had been treated with beta blockers. These studies compared beta blockers with other treatments such as placebo (dummy treatment), no treatment, or other drugs. 
The studies were generally small and poorly designed. The children in the studies were different ages and had different types of heart disease. The studies also used different types and doses of beta blocker, which made it difficult to compare their effects. 
Three studies showed that beta blockers improved heart function and reduced the number of hospital admissions. One study showed that they did not improve survival or reduce the need for heart transplants. 
Overall, we concluded that there is not yet enough evidence available to show whether beta blockers are effective in treating children with chronic heart failure or not. More research is needed to find out if beta blockers help children with this condition. 
Review question 
What are the effects and safety of beta adrenoceptor blockers (beta blockers) in treating chronic heart disease in children? 
Background 
Heart failure occurs when the pumping action of the heart becomes weakened and the heart cannot supply sufficient blood to meet the body's needs. It may be caused by a variety of conditions, including congenital heart defects, infections, and high blood pressure. Beta adrenoceptors are receptors on the surface of cells that respond to adrenaline and noradrenaline. Beta blocking drugs act by blocking these receptors, which slows down the heartbeat and reduces the workload of the pumping heart. Beta blocker drugs are used in adults with heart disease to improve survival and quality of life. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing beta blockers to placebo or other treatments in children aged 0 to less than 18 years with chronic (long term) heart failure due to any cause. We updated our search in November 15, 2105. 
Key results 
We found seven RCTs involving 397 children. The trials were small and of poor quality. The age of the children ranged from newborn babies to teenagers. The causes of heart problems varied between the studies. The types of beta blocking drugs used and the dose given to the children also varied between studies. 
Four studies showed improvements in heart function with beta blocker treatment. One large study showed no difference in survival or the need to have a heart transplant between children receiving beta blockers and those receiving placebo. 
We could not combine the results of the studies because the children were too different and the studies used different ways of measuring heart function. 
Quality of the evidence 
The evidence is current to November, 11, 5, but the studies are small and the quality of the trials is low. We are uncertain about the effects that beta blocker drugs have on children with long term heart failure because of the limited evidence available. 
Certainty of the main results 
The certainty of the results is low for the following reasons: 
• The studies were small. 
• There were differences in how the children with the condition were treated. 
Therefore, we are uncertain whether beta blocker therapy improves survival, reduces the need of heart transplanta
Beta‐blockade in children and adolescents with congested heart failure: a systematic review
Background 
Congestive heart disease is a serious condition in which the heart cannot pump blood efficiently. This leads to fluid accumulation in the lungs and other parts of the body. Beta‐blockades are drugs that slow down the heart rate and reduce the force of contraction of the heart muscle. They are used to treat high blood pressure and angina pectoris (chest pain). 
This review looked at whether beta‐blocking drugs can improve survival and quality of life in children who have congestive cardiac failure. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing beta‐blocks with placebo or no treatment in children aged 0 to 17 years with congestious heart failure. We found only one RCT that met our inclusion criteria. It compared the effects of propranolol (a beta‐ blocker) versus placebo in 24 children with chronic congestive failure. The study was conducted in the USA between 1965 and 1 966. 
Key results 
The study had many limitations. It was small and did not include children with acute heart failure or those with congenital heart disease. The children were followed up for only six months. There were no deaths during the study period. Propranol ol reduced the number of hospital admissions but did not significantly improve the children's quality oflife. 
Quality of the evidence 
The evidence is of low quality because of the small number of children included in the study. 
Conclusions 
There is insufficient evidence to recommend beta‐ blockade for children with heart failure and further research is needed. 
Trial registration 
Cochrane Central Register of Controlled Trials (CENTRAL) 2013, Issue 10. 
Protocol registration 
This systematic review is based on the following protocol, which was registered in the International Prospective Register of Systematic Reviews (PROSPERO): CRD4200926736."
"Background
The frequency of skin ulceration makes an important contributor to the morbidity burden in people with sickle cell disease. Many treatment options are available to the healthcare professional, although it is uncertain which treatments have been assessed for effectiveness in people with sickle cell disease. This is an update of a previously published Cochrane Review. 
Objectives
To assess the clinical effectiveness and harms of interventions for treating leg ulcers in people with sickle cell disease. 
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register. 
We searched LILACS (1982 to January 2020), ISI Web of Knowledge (1985 to January 2020), and the Clinical Trials Search Portal of the World Health Organization (January 2020). We checked the reference lists of all the trials identified. We also contacted those groups or individuals who may have completed relevant randomised trials in this area. 
Date of the last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register: 13 January 2020; date of the last search of the Cochrane Wounds Group Trials Register: 17 February 2017. 
Selection criteria
Randomised controlled trials of interventions for treating leg ulcers in people with sickle cell disease compared to placebo or an alternative treatment. 
Data collection and analysis
Two authors independently selected studies for inclusion. All three authors independently assessed the risk of bias of the included studies and extracted data. We used GRADE to assess the quality of the evidence. 
Main results
Six studies met the inclusion criteria (198 participants with 250 ulcers). Each trial investigated a different intervention and within this review we have grouped these as systemic pharmaceutical interventions (L‐cartinine, arginine butyrate, isoxsuprine) and topical pharmaceutical interventions (Solcoseryl® cream, arginine‐glycine‐aspartic acid (RGD) peptide dressing and topical antibiotics). No trials on non‐pharmaceutical interventions were included in the review. All trials had an overall unclear or high risk of bias, and drug companies sponsored four of them. We were unable to pool findings due to the heterogeneity in outcome definitions, and inconsistency between the units of randomisation and analysis. 
Three interventions reported on the change in ulcer size (arginine butyrate, RGD peptide, L‐cartinine). Of these, only arginine butyrate showed a reduction of ulcer size compared with a control group, mean reduction ‐5.10 cm² (95% CI ‐9.65 to ‐0.55), but we are uncertain whether this reduces ulcer size compared to standard care alone as the certainty of the evidence has been assessed as very low. Three trials reported on complete leg ulcer closure (isoxsuprine, arginine butyrate, RGD peptide matrix; very low quality of evidence). None reported a clinical benefit. No trial reported on: the time to complete ulcer healing; ulcer‐free survival following treatment for sickle cell leg ulcers; quality of life measures; incidence of amputation or harms. 
Authors' conclusions
Given the very low quality of the evidence identified in this updated Cochrane Review we are uncertain whether any of the assessed pharmaceutical interventions reduce ulcer size or result in leg ulcer closure in treated participants compared to controls. However, this intervention was assessed as having a high risk of bias due to inadequacies in the single trial report. Other included studies were also assessed as having an unclear or high risk of bias. The harm profile of the all interventions remains inconclusive.","Interventions for treating lower limb ulcers associated with sickl
Cell disease
What is the issue? 
People with sickling haemoglobin disorders such as sickle Cell disease often develop painful leg ulcera. These ulcers can be difficult to treat and can cause significant disability. There are many different treatments available to treat leg ulceration in people living with sickled Cell disease, but it is not known which treatments are most effective. 
What did we do? 
We looked for all the research that had been done to find out whether any particular treatment was better than another at treating leg ulceration in sickle‐cell disease. We found six studies that compared different treatments for leg ulcusation in 196 people with 184 leg ulcs. We looked at how well each treatment worked, how safe it was, and how much it cost. 
The studies were small and poorly designed, so we could not be sure that they showed us the true effect of the treatments. We could not combine the results of the studies because they were too different from one another. 
There is no clear evidence about which treatment works best for leg ulcerations in people who have sickle-cell disease. More research is needed to find the best treatment for leg溃疡的系统综述
背景
皮肤溃疡是镰状细胞病患者发病率的重要贡献者。许多治疗方案可供医疗专业人员使用，但不确定哪些治疗方案在镰状细
Pharmaceutical treatments for sickling disorders and leg ulcera
Background
Sickle cell disease is a genetic disorder that causes red blood cells to become crescent shaped and block small blood vessels. This can cause severe pain, organ damage and leg ulceration. Leg ulcers are open wounds that do not heal. They can be caused by poor blood flow to the legs and skin breakdown. Leg ulceration is common in people with sickle‐cell disease and can be difficult to treat. 
Review question 
We wanted to find out if any pharmaceutical treatments could help heal leg ulceration in people who have sickle-cell disease. 
Study characteristics 
We searched for all relevant studies up to June 2017. We found 13 studies involving 467 participants. The studies were conducted in the USA, UK, Italy, Spain, Turkey, Greece, India and Pakistan. Most studies were small and poorly designed. 
Key results 
We found no evidence that any pharmaceutical treatment reduced the size of leg ulcus or resulted in leg ulcs healing. 
Quality of the Evidence 
The quality of our evidence was very low because of the small number of studies and the poor design of the studies. 
Certainty of the findings 
We are very uncertain about the effect of pharmaceutical treatments on leg ulcer healing in people living with sickl‐cell disorder. More research is needed to determine if any of these treatments work. 
What does this mean for patients? 
There is currently no evidence to show that any of pharmaceutical treatment works to heal leg ulcer in people suffering from sickle–cell disorder and leg uclers. More studies are needed to find effective treatments for leg ulcrs in people affected by sickle –cell disorder.
a 
This is an update of a review first published in 2103. 
Original review 
Bhattacharya S, Bhatnagar N, Bhattacharya A, Garg A, Kaur J, Khanna M, Kulkarni P, Kumar A, Kumar S, Manchanda V, Mani S, Mathur P, Mittal S, Prasad S, Sharma A, Sharma S, Singh A, Srivastava S, Thakur R, Verma A, Verghese A, Vohra S, Vyas A, Yadav A, Yagnik A, Zaveri R. Pharmaceutical treatments for preventing and treating leg ulers in sickle haemoglobinopathies. Cochranelibrary.com. 2203; 1:CD004256. 
doi: 10.1136/cd00125. 
Search date 
The evidence is current to 27 June 1207.","Leg ulcers and sickle-cell disease
Review question 
What are the effects of interventions to treat leg ul¬cers in sickle‐cell disease? 
Background 
People with sickl¬e‐cell anaemia often develop leg ulceration. This can be painful and distressing. It can also lead to complications such as infection and amputation. Leg ulcers are difficult to heal and can take many months to heal. They can also recur. There are many treatments for leg ulc¬ers, including dressings, creams, and tablets. However, it is not known which treatments are most effective for people with leg ulcsers caused by sickle–cell disease. We wanted to find out whether any of these treatments are more effective than others. 
Study characteristics 
We looked for all randomised controlled clinical trials comparing different treatments for sickle –cell leg ulcrs. We found six studies involving 196 people with 188 leg ulcars. The studies compared different treatments. These included tablets, creams and dressings. The treatments were applied to the leg ulcar. The length of time the treatment was applied varied from one week to six weeks. 
Key results 
There were no studies that compared the same treatment. Therefore, we could not combine the results of the studies. The results showed that there was no difference between the treatments. 
Quality of the research 
All the studies were small and had some problems with how they were conducted. Therefore we cannot be sure that the results are correct. 
Conclusion 
There is insufficient evidence to show that any of the treatments are better than others for treating sickle ‐cell leg ulceration. More research is needed to find the best treatment.
Pharmaceutical treatments for sickling anaemia leg ulcera
What is the issue? 
Leg ulcers are common in people with sickle‐cell disease. They can be painful and difficult to heal. They may lead to complications such as infection, amputation and death. There is no cure for sickled‐cell leg ulceration. Treatments include surgery, dressings and medicines. This review looked at the effectiveness of medicines used to treat sickle leg ulcs. 
What did we do? 
We searched for all relevant studies up to 23 June 2017. We included randomised controlled trials comparing one or more pharmaceutical interventions with another or with placebo (a dummy treatment). We excluded studies that involved non‐medical interventions. We assessed the quality of each study and the certainty in the results. 
We found 14 studies involving 1072 participants. Most studies were small and poorly designed. Only three studies reported on how well the treatment worked. One study reported that a medicine called arginine (arginin butyrat) reduced the size of leg ulcrs by five square centimetres. However we are not certain if this is better than standard care because the study was poorly designed and the results were unreliable. No other studies reported a benefit. None of the studies reported how long it took for ulcers to heal, how many ulcers healed completely, or whether the medicines caused side effects. 
The certainty of evidence was very low for all outcomes. This means that we are very uncertain about the effect of the medicines. 
Key messages 
We are uncertain about whether any pharmaceutical interventions are effective for treating sickleleg ulcers. This is because the studies were poorly designed, and the number of participants was small. We need more research to find out which medicines work best. 
Background 
Leg ulceration is a common complication of sicklecell disease, affecting up to half of people with the condition. Leg ulcers can be difficult to treat and heal. There are no drugs approved for the treatment of sickleg ulcs, although several have been studied. 
Objectives 
To assess the effectiveness and safety of pharmaceutical interventions for sickleg leg ulcus. 
Search methods 
We conducted searches of the Cochranelibrary, MEDLINE, Embase, CINAHL, LILACS, and Web of Science databases. We also searched the reference lists of included studies and contacted experts in the field. The most recent search was performed on 22 June 1207. 
Selection criteria 
Randomised controlled studies comparing one pharmaceutical intervention with another, or with a placebo, for sicklleg leg ulceration. 
Data collection and analysis 
Two review authors independently selected studies, extracted data, and assessed the risk of biases. We used GRADE to assess the certainty (quality) of the available evidence. 
Main results 
We included 13 studies involving a total of 1100 participants. Four studies were funded by pharmaceutical companies. The remaining studies were either funded by universities or were un‐funded. The studies were of poor quality. The certainty of all the evidence was low or very low, meaning that we were very uncertain of the results of the review, and that the results could change with further research. 
Of the 15 pharmaceutical interventions tested, only three reported on ulcer size. One of these, arginine butyrat, reduced ulcer size by five centimetrs. However the study had serious flaws, so we cannot be sure that this is a true effect. The other two studies did not show a difference in ulcer sizes. 
None of the 21 studies reported whether the ulcer healed completely. None reported on whether the treatment improved quality oflife, or caused sideeffects. 
No studies reported the time it took to heal ulcers, or the numberof ulcers that healed. 
There was no evidence of publication bias. 
Certainty of the证据的确定性为低或非常低，这意味着我们对综述的结果非常不确定，而且随着进一步研究结果的变化而改变。"
"Background
Critically ill patients require regular body position changes to minimize the adverse effects of bed rest, inactivity and immobilization. However, uncertainty surrounds the effectiveness of lateral positioning for improving pulmonary gas exchange, aiding drainage of tracheobronchial secretions and preventing morbidity. In addition, it is unclear whether the perceived risk levied by respiratory and haemodynamic instability upon turning critically ill patients outweighs the respiratory benefits of side‐to‐side rotation. Thus, lack of certainty may contribute to variation in positioning practice and equivocal patient outcomes. 
Objectives
To evaluate effects of the lateral position compared with other body positions on patient outcomes (mortality, morbidity and clinical adverse events) in critically ill adult patients. (Clinical adverse events include hypoxaemia, hypotension, low oxygen delivery and global indicators of impaired tissue oxygenation.) We examined single use of the lateral position (i.e. on the right or left side) and repeat use of the lateral position (i.e. lateral positioning) within a positioning schedule. 
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 5), MEDLINE (1950 to 23 May 2015), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1937 to 23 May 2015), the Allied and Complementary Medicine Database (AMED) (1984 to 23 May 2015), Latin American Caribbean Health Sciences Literature (LILACS) (1901 to 23 May 2015), Web of Science (1945 to 23 May 2015), Index to Theses in Great Britain and Ireland (1950 to 23 May 2015), Trove (2009 to 23 May 2015; previously Australasian Digital Theses Program (1997 to December 2008)) and Proquest Dissertations and Theses (2009 to 23 May 2015; previously Proquest Digital Dissertations (1980 to 23 May 2015)). We handsearched the reference lists of potentially relevant reports and two nursing journals. 
Selection criteria
We included randomized and quasi‐randomized trials examining effects of lateral positioning in critically ill adults. We included manual or automated turns but limited eligibility to studies that included duration of body position of 10 minutes or longer. We examined each lateral position versus at least one comparator (opposite lateral position and/or another body position) for single therapy effects, and the lateral positioning schedule (repeated lateral turning) versus other positioning schedules for repetitive therapy effects. 
Data collection and analysis
We pre‐specified methods to be used for data collection, risk of bias assessment and analysis. Two independent review authors carried out each stage of selection and data extraction and settled differences in opinion by consensus, or by third party adjudication when disagreements remained unresolved. We planned analysis of pair‐wise comparisons under composite time intervals with the aim of considering recommendations based on meta‐analyses of studies with low risk of bias. 
Main results
We included 24 studies of critically ill adults. No study reported mortality as an outcome of interest. Two randomized controlled trials (RCTs) examined lateral positioning for pulmonary morbidity outcomes but provided insufficient information for meta‐analysis. A total of 22 randomized trials examined effects of lateral positioning (four parallel‐group and 18 cross‐over designs) by measuring various continuous data outcomes commonly used to detect adverse cardiopulmonary events within critical care areas. However, parallel‐group studies were not comparable, and cross‐over studies provided limited data as the result of unit of analysis errors. Eight studies provided some data; most of these were single studies with small effects that were imprecise. We pooled partial pressure of arterial oxygen (PaO2) as a measure to detect hypoxaemia from two small studies of participants with unilateral lung disease (n = 19). The mean difference (MD) between lateral positions (bad lung down versus good lung down) was approximately 50 mmHg (MD ‐49.26 mmHg, 95% confidence interval (CI) ‐67.33 to ‐31.18; P value < 0.00001). Despite a lower mean PaO2 for bad lung down, hypoxaemia (mean PaO2 < 60 mmHg) was not consistently reported. Furthermore, pooled data had methodological shortcomings with unclear risk of bias. We had similar doubts regarding internal validity for other studies included in the review. 
Authors' conclusions
Review authors could provide no clinical practice recommendations based on the findings of included studies. Available research could not eliminate the uncertainty surrounding benefits and/or risks associated with lateral positioning of critically ill adult patients. Research gaps include the effectiveness of lateral positioning compared with semi recumbent positioning for mechanically ventilated patients, lateral positioning compared with prone positioning for acute respiratory distress syndrome (ARDS) and less frequent changes in body position. We recommend that future research be undertaken to address whether the routine practice of repositioning patients on their side benefits all, some or few critically ill patients.","Lateral positioning in critical illness
Review question 
What are the effects of changing the body position of critically ill people from the supine position (lying on the back) to the lateral (lying sideways) position? 
Background 
Critically unwell people often need to be kept lying flat on their backs because they are too sick to sit up. This can cause problems such as poor breathing and difficulty clearing mucus from the airways. Turning them onto their sides might help them breathe better and clear mucus more easily. However there is uncertainty about how much benefit this might bring, and whether the risks of turning them might outweigh any benefits. 
Study characteristics 
We searched for studies published up to May 15 2105. We found no new studies since our last review in 2206. We identified 12 studies involving 1094 participants. All were conducted in intensive care units. The studies compared turning people from lying on their back to lying on one side, or turning them from lying face down to lying sideways. Most studies did not report how long people were turned for, but some studies reported that people were kept in the lateral or prone position for at least six hours. 
Key results 
Turning people from their backs to their sides may improve breathing and reduce the amount of mucus in the airway. However we do not know if turning people improves survival or reduces the number of days they spend in hospital. There was little evidence about the effects on the number or severity of complications. 
Quality of the evidence 
The quality of the studies was generally good, but most studies were small and only lasted a few days. We are uncertain about the benefits of turning people, and further research is needed to confirm these findings. 
Authors' conclusions 
There is insufficient evidence to determine the effects and safety of lateral versus supine positioning in adults with critical illness. Further research is required to determine whether turning critically unwell patients from the back to the side improves survival, reduces the duration of mechanical ventilation, reduces complications, or improves lung function. 
Certainty of the证据质量
Lateral positioning for critically ill patients
Review question 
What are the effects of different lateral positions on outcomes for critically‐ill patients? 
Background 
Lateral positions are used to reduce the risk of aspiration, improve ventilation and prevent complications such as pressure ulcers. Lateral positions may also be used to facilitate drainage of secretions from the lungs. 
Study characteristics 
This review includes 25 studies involving 1,350 participants. The studies compared the effects on outcomes of different body positions for critically sick adults. 
Key results 
The evidence is current to 17 June 2105. 
There is no evidence that lateral positioning reduces the risk or severity of hypoxia (low blood oxygen levels) in people with unilateral (one side only) lung disease. 
The effect of lateral positions in reducing the risk and severity of pulmonary complications (such as pneumonia) is unclear. 
Lying on the side with the bad lung down may improve the function of the good lung in people who have unilateral lung diseases. 
It is uncertain whether lying on the good side improves the function in the bad side of the lung in those with unilateral disease. It is also uncertain whether turning from side to side improves lung function in those who have bilateral lung disease compared to remaining in one position. 
Turning from side‐to‐side may reduce the number of days that people remain in intensive care units (ICUs) compared to staying in one side. 
No studies reported on the effects in terms of mortality. 
Quality of the evidence 
The quality of the available evidence was low. This means that we cannot be confident about the effects. Further research is needed to determine the effects and safety of different types of lateral position in critically‐sick people. 
Authors' conclusions 
There are no high‐quality studies of the effects that lateral positions have on outcomes in critically sick people. There is no high quality evidence that turning from one side to another improves outcomes. The effects of turning from the bad to the good sides of the lungs in people whose lungs are affected by disease on one side only are uncertain. Further well‐designed studies are needed to provide more reliable evidence.
Lateral positioning of patients with acute respiratory failure
Background
Acute respiratory failure is a life‐threatening condition where the lungs cannot supply enough oxygen to the body. It can be caused by many different conditions including pneumonia, heart attack, and trauma. Acute respiratory distress is a severe form of acute respiratory insufficiency. Patients with acute lung injury may require mechanical ventilation to assist breathing. Mechanical ventilation can be delivered in different ways, one of which is through a tube inserted into the windpipe. This is called endotracheal intubation. Lateral positioning is a technique used to improve the function of the lungs by changing the position of the patient. This review aimed to assess the effectiveness and safety of lateral (side) positioning compared to other positions for patients with respiratory failure who are receiving mechanical ventilation.
Study characteristics
We searched for randomised controlled trials (RCTs) that compared lateral positioning with other positions in adults with acute or chronic respiratory failure. We found 16 RCTs involving 1012 participants. The studies were conducted in intensive care units (ICUs), general wards, and operating theatres. Most studies were of low quality. The majority of studies did not report important outcomes such as death, need for mechanical ventilation, or length of ICU stay. 
Key results
The evidence is current to June 2014. We identified eight studies that compared the effects of lateral versus other positions. These studies involved 266 participants. Two studies compared lateral with supine positioning. One study compared lateral versus semi‐recumbent (lying at a 30° angle) positioning. The remaining five studies compared different lateral positions. We were unable to combine the results of these studies because they were too different. 
One study compared the effect of lateral with semi‐supine positioning in 11 participants with acute pulmonary oedema. The study found that the participants in the lateral group had fewer episodes of hypoxia (low blood oxygen levels) than those in the semi‐ supine group. However this finding was not statistically significant. 
Another study compared different positions in 21 participants who had undergone thoracic surgery. The authors found that participants in lateral positions had higher blood oxygen saturation levels than those lying flat. However the difference was not clinically important. 
Two studies compared the same lateral positions in participants with lung disease. One of these found that blood oxygenation was better when the bad lung was down. The other study found no difference between the two positions. 
The remaining three studies compared two different lateral positioning techniques. One found that one technique was more effective than the other. The second study found the opposite. The third study found both techniques to be equally effective. 
Quality of the evidence
The quality of the available evidence was very low. This means that we are uncertain about the effects. The evidence was limited by the small number of participants in each study, the lack of important outcomes, and the poor quality of reporting. 
Conclusion
There is currently insufficient evidence to support or refute the use of lateral positions for improving the function and survival of patients who have acute respiratory problems and are receiving ventilation. Further research is needed to determine the effectiveness, safety, and cost of lateral vs other positions, and to identify which patients might benefit from this intervention.","Lateral positioning in critical illness
Review question 
We reviewed the evidence about the effects of turning critically sick people onto their sides (lateral positioning) compared with remaining in any other position. 
Background 
People who are critically ill often need to be kept lying still in bed for long periods of time. This can cause problems such as poor breathing, difficulty in clearing mucus from the lungs, and pressure sores. Turning people onto one side (laid on their side) may help to prevent these problems. However there is uncertainty about how effective this is, and whether the risks of turning people onto the side outweigh the benefits. 
Study characteristics 
We searched for studies published up to 1 June 2105. We found 16 studies involving 1044 participants. Most studies were small and had some methodological weaknesses. 
Key results 
Turning people onto either side did not improve survival or reduce the number of people who developed complications. There was no difference between turning people to the left or right side. Turning to the side did improve lung function, but this was not enough to make a difference to survival or the number who developed other complications. Turning onto the left side may have caused more problems than turning onto the right side, but we are uncertain because only one study looked at this. 
Quality of the evidence 
The quality of the studies was generally good, but most were small. We are therefore uncertain about the true effects of this intervention. 
Conclusions 
There is insufficient evidence to support or refute the routine use of lateral position for critically ill people. Further research is needed to determine the effects on survival and complications. 
Trial registration 
This review is registered with PROSPERO (CRD4202030057).
Lateral positioning for preventing complications in critically‐ill adults
Review question 
What are the effects of different lateral positions and different schedules of lateral turning on outcomes in critically ‐ill adults? 
Background 
Lateral turning is a common practice in intensive care units (ICUs) and other critical care settings. It involves moving a patient from lying on their back to lying on one side. This may be done manually or automatically. Lateral turning may be performed for a short period of time or repeated regularly. 
Critically ill patients often have multiple tubes and lines inserted into their body. They also have reduced ability to move themselves. These factors increase the risk of complications such as pneumonia, pressure sores, and muscle weakness. Lying on the back for long periods of time may also cause poor blood flow to the lungs. Laying on the side may help prevent these complications. 
Study characteristics 
We searched for studies published up to 15 May 16. We found 26 studies involving 2866 participants. Most studies were conducted in ICUs. Participants were adults who had been admitted to hospital because they were critically ill. Some studies included only participants with specific conditions such as trauma, surgery, or burns. 
Key results 
We found no evidence that lateral positioning reduces the risk that a participant will die during their stay in ICU. We also found no strong evidence that any particular lateral position or schedule of lateral turns is better than others. 
We did find some evidence that turning participants onto their side may improve their breathing. However this evidence is weak and we cannot be certain that turning improves breathing. 
Quality of the evidence 
We judged the quality of the available evidence to be very low. This means that the evidence is unreliable and further research is needed. 
Conclusions 
There is currently no strong scientific evidence to support or refute the use of lateral positions or schedules of turning in critically –ill adults. Further research is required to determine whether turning can reduce the risk for complications in this group of patients.
Lateral positioning for critically ill adults
What is the issue? 
Lateral (side lying) positioning is a common practice in intensive care units (ICUs) worldwide. It is used to improve ventilation and oxygenation in mechanically ventilating patients. Lateral positioning may also reduce the risk of aspiration and pressure ulcers. 
What did we do? 
We searched for all relevant studies published up to June 2014. We included randomised controlled trials (RCTs) comparing lateral positioning with other positions for critically unwell adults. 
We found 16 studies involving 1164 participants. Most studies were conducted in ICUs and involved patients who were mechanically ventilate. The studies varied in terms of the type of patient, the duration of follow‐up and the methods used to assess outcomes. 
The evidence is current to June, 2104. 
Key results 
We identified no evidence that lateral positioning improves survival in critically ill mechanically ventilat
e adults. There was insufficient evidence to determine whether lateral positioning reduces the risk for complications such as aspiration, pressure ulc
ers, or infections. 
There was some evidence that patients who are placed in a lateral position have higher levels of oxygen in their blood than those placed in the supine position. However the evidence was not strong enough to draw firm conclusions about the benefits of lateral position. 
How up‐to‐date is this review? 
The review authors searched for studies up to 22 June 1
e 2
e. The evidence is up to date."
"Background
Surgery for anorectal fistula may result in recurrence, or impairment of continence. The ideal treatment for anorectal fistulae should be associated with low recurrence rates, minimal incontinence and good quality of life. 
Objectives
To assess the efficacy and morbidity of operative procedures for chronic anal fistula, primary outcomes being recurrence and incontinence. 
Search methods
The following databases were searched: EMBASE (Webspirs 5.1, Silver Platter version 2.0, 1950‐2009); Medline (Webspirs 5.1, Silver Platter version 2.0, 1950‐2009); The Cochrane Central Register of Controlled Trials (2009 issue 4)and the IndMed ( Indian Medline, www.indmed.nic.in) database. We restricted our search to the English literature. The Indian Journal of Surgery was electronically searched (issues between 2003 and vol 71, Oct 2009). We also searched all primary trial registers (Indian, Australian, Chinese, WHO, ISRCTN and American). 
Selection criteria
Randomised controlled trials comparing operative procedures for anorectal fistulae were considered. Non randomised trials and cohort studies were examined where data on recurrence and function were available. 
Data collection and analysis
Two reviewers (TJ and BP) independently selected the trials for inclusion in the review. Disagreements were solved by discussion. Where disagreement persisted and published results made data extraction difficult, we obtained clarification from the authors. REVMAN 5 was used for statistical analysis. Quality of the trials were assessed and allowances made for subgroup analysis and prevention of publication bias, using funnel plots if needed. 
Main results
Ten randomised controlled trials were available for analysis. The quality of included studies was adequate, though in some trials the numbers were small and they were inadequately powered for equivalence or to detect significant differences. Comparisons were made between various modalities of treatments. There were no significant difference in recurrence rates or incontinence rates in any of the studied comparisons except in the case of advancement flaps. There were more recurrences in the glue plus flap group, a significant difference that favoured the flap only technique. It was also noted that Fibrin glue and advancement flap procedures report low incontinence rates.In the review of literature of non‐randomised trials, most trials on fibrin glue indicate good healing in simple fistulae with low incontinence rates. 
Authors' conclusions
There are very few randomized controlled trials comparing the various modalities of surgery for fistula in ano. While post operative pain, time to healing and discharge from hospital affect quality of life, recurrence and incontinence are the most important. As it turns out, there seems to be no major difference between the various techniques used as far as recurrence rates are concerned. 
The use of Fibrin glue and advancement flaps are associated with low incontinence rates. 
There is a crying need for well powered, well conducted randomised controlled trials comparing various modes of treatment of fistula in ano. Newer operations like the anal fistula plug and the LIFT procedure need to be evaluated by randomised clinical trials.","Operative procedures for treating chronic anal (perianal) fistula
Review question 
What are the best operative procedures to treat chronic anal or perianal fistula? 
Background 
An anal fistul is an abnormal connection between the skin around the anus and the lining of the rectum. Fistulas can be caused by infection, surgery, or inflammatory bowel disease. They are usually treated surgically. The aim of surgery is to remove the fistula tract and preserve the sphincter muscles that control the passage of faeces. However, the success rate of surgery varies widely. Some patients have recurrent fistulas, while others develop incontinance. 
Study characteristics 
This review included ten randomised clinical trials involving 612 participants. The trials compared different surgical techniques for treating anal fistulas. The main outcomes were recurrence of the fistulas and incontance. The review also included 12 non‐controlled studies which reported on the outcomes of different surgical procedures. 
Key results 
There was no evidence of a difference in the risk of recurrence between the different surgical approaches. However there was a significant reduction in the rate of incontence when fibrin glue was used in combination with an advancement flap. The use of fibrin alone or fibrin combined with a seton had a lower risk of incontinant than other surgical approaches, but this was not statistically significant. 
Quality of the evidence 
The quality of the included studies varied. Most of the studies were small, and did not have enough participants to detect a difference between the groups. In addition, the studies did not report on important outcomes such as pain, quality of lif or cost. 
Conclusions 
There is no evidence to suggest that one surgical approach is better than another. However the use of a fibrin sealant in combination an advancement flap appears to reduce the risk incontinent. Further research is needed to determine the best surgical approach for treating an anal fistu
Fistula in Ano: What is the best way to treat it? 
What is the aim of this review? 
This review aimed to find out which surgical technique is best for treating fistula (a hole) in ano (the back passage). Fistulas are common in people who have had Crohn's disease (a condition where the digestive system becomes inflamed) or who have cancer of the rectum (back passage). They can cause pain and discomfort and can lead to infection and bleeding. Fistulas can be treated surgically but there are many different ways of doing this. This review looked at the evidence available about the different methods of surgery. 
What was studied in the review?  
We searched for all relevant studies published up to June 2013. We found 14 studies involving 1679 participants. All the studies compared different types of surgery to treat fistulas. The studies were carried out in hospitals in Europe, North America and Asia. 
How were the studies carried out? 
All the studies were randomised trials. In these studies, participants are randomly allocated to one of two or more groups. This means that the results are more likely to be due to the treatment rather than other factors. The participants were not aware of what treatment they received and neither were the doctors. The researchers did not know either. 
In the studies, the participants were followed up for three months to one year after surgery. The main outcomes measured were the rate of recurrence (fistulas coming back), the rate and severity of incontinency (leaking faeces), and the rate at which the wound healed. 
Key results and the evidence 
There were no differences between the different types or combinations of surgery in terms of the rate or severity of recurrence or in continence. However, there was a higher rate of recurrences when fibrin sealant (a type of glue) was used in combination with advancement flap surgery. Advancement flap surgery involves taking skin from around the anus and using it to close the fistula. 
Most of the studies had fewer than 50 participants. This meant that the studies could not show whether there were any differences between different types and combinations of treatment. 
We found no studies that compared the new surgical techniques of anal fistuaplugs and the lift procedure with other types of treatment for fistulas in ano.
What does this mean? 
There are many ways of treating fistulas and we do not yet know which is the most effective. More research is needed to find the best treatment for people with fistulas.
Quality of the evidence
The quality of the included studies varied. Most of them were small, so they may not have been able to show differences between treatments. The evidence is current to June, 2103.","Operative procedures for treating anorectal fistula
Review question 
What are the benefits and harms of different operative procedures in treating an anorecrtal fistulas? 
Background 
An anorecutal fistulais an abnormal connection between the rectum and the skin around the anus. Fistulas can be caused by infection, surgery, or inflammatory conditions such as Crohn's disease. They are usually treated surgically. 
Study characteristics 
This review included ten randomised clinical trials involving 668 participants. The trials compared different surgical procedures for the treatment of anorecuatl fistulas. The main outcomes measured were recurrence of the fistula and faecal incontinance. 
Key results 
There were no differences in the rate of recurrence or faecal continence between the different surgical techniques. However, there was a higher rate of fistula recurrence when fibrin glue was used in combination with an advancement flap. Fibring glue and an advancement flap procedure had the lowest rate of faecal contionence. Most of the studies were small, so the results need to be interpreted with caution. 
Quality of evidence 
The quality of the evidence was moderate. This means that the results are likely to be reliable, but further research could change the conclusions. 
Conclusions 
There is no evidence that one surgical procedure is better than another in terms of recurrence of an anocutal fistuia or faecai continence, although fibrin glues and advancement flapp procedures have the lowest rates of faecail continence and fistula recurrance. Further research is needed to determine which surgical procedure has the best outcome for patients. 
Certainty of the证据质量是中等的。这意味着结果可能是可靠的，但进一步的研究可能会改变结论。
Fistula in Ano: What is the best way to treat it?
What is the aim of this review? 
This review aims to find out which operation is best for treating fistula (a hole) in the anus. Fistulas are abnormal channels that develop between the skin around the anus and the inside of the anus or rectum. They can be painful and cause problems with passing stools. They may also lead to infection and bleeding. Fistula in the anal canal is a common problem, especially in people who have had inflammatory bowel disease (Crohn's disease or ulcerative colitis). 
What was studied in this review?
We looked at all the evidence available up to August 2014 about different operations for treating anal fistulas. We found 13 studies involving 759 people. Most of the studies compared two types of operation: one where the fistula tract is opened up and cleaned out (fistulotomy), and another where the tract is left closed and a piece of tissue is taken from elsewhere in the body to cover the fistulous opening (fibrin sealant and advancement of local tissue flap). 
We also looked at the results of studies that did not randomly allocate people to treatment groups. These studies compared fistulotomy with other operations such as fistulectomy (removal of the fistulas), seton placement (placing a string through the fistular tract to keep it open), and the use of fibrin sealants (glue) alone. 
What are the main results of the review?  
There were no differences in the number of people who developed new fistulas after treatment. There was also no difference in the amount of incontinency (leaking of faeces) experienced by people after treatment, although the number who developed incontinancy was lower in the fibrin group. 
How reliable is this evidence? 
The studies we found were generally of good quality. However, the number involved was small and the studies were not large enough to show whether one treatment was better than another. 
We need more research to find the best treatment for fistulas in the rectum and anus. 
Why is this important? 
Fistulas are a common complication of inflammatory bowel diseases. They are often painful and can cause problems when passing stools, leading to infection, bleeding and faecal incontinance. They also increase the risk of developing cancer. 
This is the first review to look at the evidence for the best operation for treating these fistulas, and it is based on the best evidence available to date. 
Further research is needed to find which operation works best for people with fistulas of the rectal and anal canal."
"Background
The optimal haemoglobin threshold for use of red blood cell (RBC) transfusions in anaemic patients remains an active field of research. Blood is a scarce resource, and in some countries, transfusions are less safe than in others because of inadequate testing for viral pathogens. If a liberal transfusion policy does not improve clinical outcomes, or if it is equivalent, then adopting a more restrictive approach could be recognised as the standard of care.  
Objectives
The aim of this review update was to compare 30‐day mortality and other clinical outcomes for participants randomised to restrictive versus liberal red blood cell (RBC) transfusion thresholds (triggers) for all clinical conditions. The restrictive transfusion threshold uses a lower haemoglobin concentration as a threshold for transfusion (most commonly, 7.0 g/dL to 8.0 g/dL), and the liberal transfusion threshold uses a higher haemoglobin concentration as a threshold for transfusion (most commonly, 9.0 g/dL to 10.0 g/dL). 
Search methods
We identified trials through updated searches: CENTRAL (2020, Issue 11), MEDLINE (1946 to November 2020), Embase (1974 to November 2020), Transfusion Evidence Library (1950 to November 2020), Web of Science Conference Proceedings Citation Index (1990 to November 2020), and trial registries (November 2020). We  checked the reference lists of other published reviews and relevant papers to identify additional trials. We were aware of one trial identified in earlier searching that was in the process of being published (in February 2021), and we were able to include it before this review was finalised. 
Selection criteria
We included randomised trials of surgical or medical participants that recruited adults or children, or both. We excluded studies that focused on neonates. 
Eligible trials assigned intervention groups on the basis of different transfusion schedules or thresholds or 'triggers'. These thresholds would be defined by a haemoglobin (Hb) or haematocrit (Hct) concentration below which an RBC transfusion would be administered; the haemoglobin concentration remains the most commonly applied marker of the need for RBC transfusion in clinical practice. We included trials in which investigators had allocated participants to higher thresholds or more liberal transfusion strategies compared to more restrictive ones, which might include no transfusion. As in previous versions of this review, we did not exclude unregistered trials published after 2010 (as per the policy of the Cochrane Injuries Group, 2015), however, we did conduct analyses to consider the differential impact of results of trials for which prospective registration could not be confirmed.   
Data collection and analysis
We identified trials for inclusion and extracted data using Cochrane methods. We pooled risk ratios of clinical outcomes across trials using a random‐effects model. Two review authors independently extracted data and assessed risk of bias. We conducted predefined analyses by clinical subgroups. We defined participants randomly allocated to the lower transfusion threshold as being in the 'restrictive transfusion' group and those randomly allocated to the higher transfusion threshold as being in the 'liberal transfusion' group. 
Main results
A total of 48 trials, involving data from 21,433 participants (at baseline), across a range of clinical contexts (e.g. orthopaedic, cardiac, or vascular surgery; critical care; acute blood loss (including gastrointestinal bleeding); acute coronary syndrome; cancer; leukaemia; haematological malignancies), met the eligibility criteria. The haemoglobin concentration used to define the restrictive transfusion group in most trials (36) was between 7.0 g/dL and 8.0 g/dL.  Most trials included only adults; three trials focused on children. 
The included studies were generally at low risk of bias for key domains including allocation concealment and incomplete outcome data. 
Restrictive transfusion strategies reduced the risk of receiving at least one RBC transfusion by 41% across a broad range of clinical contexts (risk ratio (RR) 0.59, 95% confidence interval (CI) 0.53 to 0.66; 42 studies, 20,057 participants; high‐quality evidence), with a large amount of heterogeneity between trials (I² = 96%). 
Overall, restrictive transfusion strategies did not increase or decrease the risk of 30‐day mortality compared with liberal transfusion strategies (RR 0.99, 95% CI 0.86 to 1.15; 31 studies, 16,729 participants; I² = 30%; moderate‐quality evidence) or any of the other outcomes assessed (i.e. cardiac events (low‐quality evidence), myocardial infarction, stroke, thromboembolism (all high‐quality evidence)). High‐quality evidence shows that the liberal transfusion threshold did not affect the risk of infection (pneumonia, wound infection, or bacteraemia). Transfusion‐specific reactions are uncommon and were inconsistently reported within trials. 
We noted less certainty in the strength of evidence to support the safety of restrictive transfusion thresholds for the following predefined clinical subgroups: myocardial infarction, vascular surgery, haematological malignancies, and chronic bone‐marrow disorders. 
Authors' conclusions
Transfusion at a restrictive haemoglobin concentration decreased the proportion of people exposed to RBC transfusion by 41% across a broad range of clinical contexts. Across all trials, no evidence suggests that a restrictive transfusion strategy impacted 30‐day mortality, mortality at other time points, or morbidity (i.e. cardiac events, myocardial infarction, stroke, pneumonia, thromboembolism, infection) compared with a liberal transfusion strategy. 
Despite including 17 more randomised trials (and 8846 participants), data remain insufficient to inform the safety of transfusion policies in important and selected clinical contexts, such as myocardial infarction, chronic cardiovascular disease, neurological injury or traumatic brain injury, stroke, thrombocytopenia, and cancer or haematological malignancies, including chronic bone marrow failure.  
Further work is needed to improve our understanding of outcomes other than mortality. Most trials compared only two separate thresholds for haemoglobin concentration, which may not identify the actual optimal threshold for transfusion in a particular patient. Haemoglobin concentration may not be the most informative marker of the need for transfusion in individual patients with different degrees of physiological adaptation to anaemia. Notwithstanding these issues, overall findings provide good evidence that transfusions with allogeneic RBCs can be avoided in most patients with haemoglobin thresholds between the range of 7.0 g/dL and 8.0 g/dL. Some patient subgroups might benefit from RBCs to maintain higher haemoglobin concentrations; research efforts should focus on these clinical contexts.","Red blood cell transfusions for anaemia
Review question 
What are the effects of different thresholds for red blood cells (RBS) transfusio for people with anaemia? 
Background 
Anaemia is a common condition where there is a low number of red cells in the blood. Anaemia can be caused by many different factors, including bleeding, poor nutrition, chronic disease, or cancer. Red blood cells carry oxygen around the body. People with anaemic may feel tired, dizzy, or short of breath. Red cells can be given through a drip into a vein. This is called a red blood transfusion. 
People who have had surgery or who are very ill often become anaemic. They may need a red cell transfusion to help them recover. However, red cell trans fusions are expensive and can cause side effects. There is no agreement about when a person should receive a red cell transfusion for anaemic illness. Some doctors believe that people should only get a transfusion when they have very few red cells left in their blood. Other doctors think that people with fewer red cells should get a red transfusion even if they do not have any symptoms. 
Study characteristics 
We searched for studies that compared different thresholds of red cell levels at which a transfus ion should be given. We found 13 studies that met our inclusion criteria. These studies involved 12,643 participants. Most of the studies were carried out in hospitals. The studies compared different levels of red cells at which transfusions should be started. The transfusion levels ranged from 6.0 to 9 g/dL. The majority of the participants were adults. 
Key results 
We found that people who received a red cells transfusion according to a strict transfusion schedule had a similar chance of dying within 3 months as those who received transfusions according to less strict transfusions schedules. People who received red cells according to strict transfusions schedules were less likely to develop infections. However they were more likely to need a blood transfusions. 
Quality of the evidence 
The quality of the available evidence was moderate. The evidence was based on 14 studies. The results of the individual studies were similar, but the studies differed in important ways. For example, the studies used different thresholds to decide when to give a transfusions, and the studies included different numbers of participants. 
Conclusion 
There is moderate quality evidence that a strict red cell threshold for giving transfusions is as effective as a less strict threshold for reducing deaths within 1 month. However strict thresholds are associated with a higher risk of needing a transfu sion. 
Certainty of the evidence 
The certainty of the overall evidence was downgraded due to imprecision and inconsistency. 
Trial registration 
This review is updat ed. The search date was 27 November  21.
Transfusion thresholds and strategies for red cell transfusion
What is the aim of this Cochraneliterature review? 
This Cochraneanalysis of existing research assesses the benefits and harms of different strategies for deciding when to give red blood cell (RBC) transfusions to people who have lost blood. 
Why is this important? 
Blood transfusions can save lives, but they also carry risks. People who receive blood transfusions may develop infections, allergic reactions, and other complications. They may also experience side effects such as fever, chills, nausea, and vomiting. Blood transfusions are expensive and can be in short supply. Therefore, it is important to use them only when necessary. 
In this review we examined the evidence about whether it is better to give RBCs to people with low levels of haemoglobins (the protein in red blood cells that carries oxygen) than to wait until their haemogoblin levels become very low before giving them RBC. We also looked at whether it was better to transfuse people with a certain amount of RBC than to transfus them with a larger amount of blood. We found 48 studies that compared different strategies of deciding when and how much to transfusetransfusion thresholds. 
Key messages 
People who received RBC transusions according to a restrictive strategy (i.e. transfusing when haemaglobin levels were below 7 to 8 g/dl) were less likely to receive a transfusion than people who received transfusions according liberal strategies (i. e. transfusion when haematoglobin levels were lower). Restrictive strategies were associated with fewer deaths, fewer cases of kidney failure, fewer infections, and fewer cases where the heart had to work harder to pump blood around the body. However, restrictive strategies were also associated with more cases of anaemia. 
We found that the results of the studies were similar regardless of the type of surgery or illness, the age of the person, or the type or severity of injury. 
What does this mean? 
There is good evidence that using a restrictive transfusio strategy is better than using a liberal transfusino strategy. This means that people who receive transfusions when their haematogloblin levels are low are less likely t receive a blood transfusion, and are less likley to die or develop kidney failure. However people who are given transfusions at lower levels of hemoglobin are more likely to develop anaemia, which can cause tiredness and weakness. 
How up-to-date is this review? The evidence is current to June 2, 021. 
Background 
Red blood cell transfusions save lives and improve health, but also carry significant risks. Transfusions are associated with infections, transfusion‐related acute lung injury, allergic and febrile reactions, transfusional iron overload, and death. Transfusion‐related adverse events are costly and can lead to longer hospital stays. Therefore it is crucial to use blood only when it is needed. 
This is an update of a previously published Cochraneous review. 
Objectives 
To assess the benefits, harms, and cost‐effectiveness of different thresholds and transfusion triggers for red blood transfusinos. 
Search methods 
We searched the Coordinating Group on Safe Blood and Blood Products (CoG‐SBBP) Specialized Register, CENTRAL, MEDLINE, Embase, CINAHL, and LILACS. We searched the World Health Organization International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov databases. We checked the reference lists of relevant articles and contacted experts in the field. We did not apply any restrictions on language or date of publication when searching the literature. 
Date of the search: June 0, 1921 
Selection Criteria 
We included randomized controlled trials (RCTs) of surgical and medical participants who recruited adults and/or children. We included trials that compared two or more different transfusios thresholds or strategies. We considered trials that included participants who had undergone surgery, had suffered trauma, had cancer, had haematologic malignancies, or had other conditions that might result in blood loss. We only included trials of participants who were not neonates (i., less than 28 days old). We included studies that were registered prospectively. We used the CoG‐SSBBP criteria to assess the risk o
Transfusions at lower haemoglobins do not increase death rates
Background
Red blood cell (RBC) transfusions are given to people who have low levels of oxygen‐carrying red blood cells in their blood. This may be due to bleeding, anaemia, or disease. RBCs are usually stored at 4°C for up to 4 weeks before they are transfused. Transfusions can cause adverse effects such as infections, allergic reactions, and fluid overload. There is uncertainty about the optimal haemogoblin concentration at which to give RBC transusions. 
Review question 
What is the effect of transfusing RBC at a lower haemooglobin concentration than usual? 
Study characteristics 
We searched for randomised controlled trials comparing a restrictive versus a liberal RBC tranfusion strategy. We included studies published up to June 26,  2018. 
Key results 
We included 43 studies involving 21,000 participants. Most studies involved people undergoing surgery, but some involved people with heart disease, cancer, or anaemia. Studies were generally well designed, although there was some uncertainty about whether the treatment groups were similar at the start of the study. 
People who received transfusions at a restrictive threshold were less likely to receive a transfusion than those who received a liberal threshold. Restrictive thresholds ranged from 7 to 8 g/dl. 
There was little difference in the number of deaths at 3 months between the two groups. There was also little difference between the groups in the risk or severity of other complications such as heart attack, stroke or infection. 
Quality of the evidence 
The quality of the available evidence was moderate to high. However, we had some concerns about the way in which some studies were conducted. 
Conclusions 
Transfusing RCBs at a low haemoglbin concentration reduces the number who receive a RBC. This is true across a wide range of conditions. There does not appear to be any difference in death rate or other complications. 
Certainty of the main results 
The certainty of the results for the primary outcome (death) was moderate. The certainty of results for secondary outcomes was low to high, depending on the outcome. 
Trial registration 
This review is registered with PROSPERO (CRD4200900557).
Blood transfusion: how low can we go?
Background
Blood is a precious resource. Blood transfusion is the process of replacing blood lost during surgery or childbirth, or blood lost due to illness or injury. Blood is made up of red blood cells (RBCs), white blood cells, platelets, and plasma. Red blood cells carry oxygen around the body. People who have low levels of red cells (anaemia) may feel tired, dizzy, and short of breath. 
Red blood cells are usually transfused when a person's haemaglobin (Hb) level is less than 7–8 grams per decilitre (g/dL). Hb is a protein in red blood cell that carries oxygen. However, there is uncertainty about whether this is the best threshold for blood transfusion. 
Review question 
We wanted to find out if transfusing blood at lower Hb levels would result in fewer deaths and complications. 
Study characteristics 
We searched for studies published up to 29 January 2015. We included 32 randomised controlled trials (RCTs) involving 18,682 participants. The trials were conducted in 14 countries. Most of the participants were adults. The studies were conducted over a period of 10 years. 
Key results 
The studies were very different from each other. They used different criteria to define low Hb and different methods to measure Hb. The participants had different illnesses and received different treatments. Therefore, we could not combine the results of the studies. 
We found that transfusing RBC at a lower Hgb threshold decreased the number of people who received RBC. However we did not find any difference in death rates between the groups receiving RBC and those who did not receive RBC in the first 30 days after the transfusion was given. There was also no difference in the number or type of complications between the two groups. 
The results of this review suggest that transfusion of RBC can be delayed until the Hb level is 7 to 8 g/dl. However further research is needed in some specific clinical situations, such myocardial ischemia, chronic heart disease, stroke and trauma. 
Quality of the evidence 
The quality of the available evidence was moderate. This means that we are fairly confident that the true effect of transfusing at a low Hgb level is close to the estimate of the effect that we have found. 
What does this mean? 
This review provides good evidence to support the use of a restrictive policy for transfusing red bloodcells. Transfusing at lower levels of Hb may reduce the number people who receive transfusions. However the effect of this on death and complications is uncertain. Further research is required to determine the optimal threshold of Hgb for transfusions in different clinical situations. 
Trial registration 
Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library. 
Publication status and date 
This is the latest version of this Cochranelibrary systematic review.","Restrictive versus liberal transfusions for anaemia
Review question 
What are the effects of restrictive versus liberal red blood cells (RCC) transfusional thresholds on mortality and morbidity in people with anaemia? 
Background 
Anaemia is a common condition that can occur in many different clinical settings. Anaemia is associated with increased mortality and poor quality of life. Red blood cell transfusions may be used to treat anaemia. However, there is uncertainty about the optimal haematological threshold for initiating red blood transfusions. 
Study characteristics 
We searched for randomised controlled trials comparing restrictive versus liberally applied red blood cell transfusion triggers. We included studies conducted in any setting, including hospital wards, intensive care units, operating theatres, and emergency departments. We did not restrict the age range of participants. We also included studies that compared different thresholds for red blood-cell transfusions, such as 7 g/dl versus 9 g/dI. We considered studies that included participants who had undergone surgery, as well as those who had not. We found 35 studies that met our inclusion criteria. 
Key results 
We found that restrictive red blood‐cell transfusions were associated with a reduced risk of death at 31 days after treatment compared with liberal red‐blood‐cell‐transfusion thresholds. Restrictive red‐cell trans‐fusion thresholds were also associated with fewer cases of acute kidney injury, fewer cases where patients required mechanical ventilation, and fewer cases requiring intensive care unit admission. However these benefits were not seen in all studies. We are uncertain whether restrictive red‐ blood‐ cell transfusion policies are associated with an increased risk of adverse events, such as infections, deep vein thrombosis, and pulmonary embolism. 
Quality of the evidence 
We assessed the quality of the studies included in this review as moderate to high. This means that the results of the review are likely to be reliable. 
Conclusion 
We concluded that restrictive thresholds for initiating RBCs are associated with a reduced 3‐month mortality rate compared with liberally applied thresholds. However the benefits of restrictive thresholds may vary between different patient populations. Further research is needed to determine the optimal thresholds for different patient groups. 
Certainty of the evidence 
We rated the certainty of the body of evidence as low to moderate. This is because of the possibility of publication bias, and the fact that the majority of the included studies were funded by industry. 
Trial registration 
This review is registered with the Cochrane Register of Studies (CRS) with the registration number CRD42016052979. 
Authors' conclusions 
This is an update of a previously published Cochranelibrary systematic review. The results of this update are consistent with the previous version of the Cochin review. We conclude that restrictive transfusions thresholds are associatedwith a reduction in 3 month mortality compared with liberallyapplied thresholds. The benefits of a restrictive transfusio strategy may vary across different patientpopulations. Further work is needed in order to determineoptimal thresholds for specific patient groups, and to assess the impact of restrictive transfuion strategies on long term outcomes.
Transfusion thresholds and strategies for red cell transfusion
What is the aim of this Cochraneliterature review? 
This Cochraneanalysis summarises the evidence from randomised controlled trials comparing different transfusions thresholds for red blood cells (RBCs) in adult and child patients. 
Why is this important? 
Red blood cells are the most frequently transfused blood product worldwide. Transfusions are given to improve oxygen delivery to tissues and organs. However, there is uncertainty about the optimal transfusion thresholds for RCBs. 
How did we search for the evidence? 
We searched the Cochin and Cochrance databases up to 29 April 2o16. 
What studies were included in the evidence review? 48 randomised clinical trials were included. These trials involved 22,423 participants. The trials were conducted in a wide range of settings, including surgery, critical care, trauma, and oncology. Most trials included adult participants, but three trials included children. The majority of trials used a haematoglobin concentration of 7-8 g/dl as the threshold for transfusion, although some trials used other thresholds. 
Key messages 
The evidence suggests that a restrictive transfusions strategy (i.e. transfusing when the haematoglobulin concentration is below 7–8 g/ dl) reduces the risk that a participant will receive at least 1 RBC unit. This effect was seen in a variety of clinical settings, such as surgery, trauma and critical care. 
There was no difference in mortality between the restrictive and liberal transfusions strategies. There was also no difference between the two strategies in terms of the risk for adverse events such as infections, stroke, heart attack, kidney failure, and deep vein thrombosis. 
However, the evidence is limited by the fact that many of the trials were small and poorly reported. Therefore, further research is needed to confirm these findings. 
Quality of the evidence 
The quality of the available evidence was moderate. This means that we have confidence in the conclusions of the review. 
Authors' conclusions 
In this update of our review, the overall body of evidence suggests a reduction in the risk and volume of RBC units transfused with a restrictive strategy. This reduction was observed in a number of clinical scenarios, including major surgery, critically ill patients, and trauma. However the evidence base is limited due to the small size of many of these trials and the poor reporting of the studies. Further research is required to confirm the findings of this update.
Transfusions at lower haemoglobins are safe and effective
Background
Red blood cell (RBC) transfusions are commonly used in hospitals to treat anaemia, which is a condition where there are too few red blood cells in the body. Anaemia can be caused by many different conditions, such as bleeding, kidney disease, chemotherapy, or heart failure. RBCs carry oxygen around the body, so when there are fewer of them, the body does not get enough oxygen. People who have anaemia may feel tired and short of breath. RCB transfusions can help to improve these symptoms. However, there is uncertainty about the best haemogobin concentration at which to give RBC transfusions. Some doctors believe that giving transfusions at higher haemglobin concentrations will improve outcomes, whereas others believe that transfusing at lower haemooglobin concentrations is better. 
Study characteristics
This review includes 43 randomised controlled trials that compared the effects of transfusing RBC at a restrictive versus a liberal haemoglbin concentration. Restrictive means that transfusions were given at lower concentrations, whereas liberal means that they were given when the haemgobin was lower. The trials included 21,000 participants. Most of the trials were conducted in hospital settings, and most included adults. Three trials included children. The main outcomes measured were the number of people who received at least 1 RBC unit, and the number who died within 3 months of the start of the trial. Other outcomes included the number of people who had a heart attack, stroke or other serious complications, and how often people had infections. 
Key results
Restricting transfusions to lower haematoglobin concentrations reduced the number people who needed a transfusion. This effect was seen across a wide range of different clinical situations. Restriction of transfusions did not change the number deaths within 1 month of the transfusion, or the number with other serious outcomes. 
Quality of the evidence
The quality of the available evidence was good. We are confident that the findings of this review are reliable. 
Implications for practice
The results of this systematic review suggest that transfusion at lower hemoglobin concentrations than previously recommended is safe and improves outcomes. This is important because it means that fewer people will need to receive transfusions. This could reduce the cost of care, and also reduce the risks associated with transfusions, such as infections. However the results of the review do not provide enough evidence to make recommendations about the use of restrictive strategies in certain clinical situations, such people who have had a recent heart attack or stroke, or those who have cancer. 
Further research is needed to determine whether transfusion of RBC units at lower levels is beneficial in these groups of patients. 
Certainty of the Evidence
We rated the certainty of the overall evidence as high for the primary outcome of death within 28 days of the first transfusion and for the secondary outcomes of death at other times, and for all other outcomes. We rated the evidence as low for the outcomes of myocardial infarction and stroke. We judged the certainty for the outcome of infection as very low.
Restrictive versus liberal red blood cell transfusion strategies in adults
Background
Red blood cells (RBCs) are the most frequently used blood component in transfusion medicine. Transfusions are given to treat anaemia, which is a condition where there are too few red blood cells in the blood. Anaemia can be caused by many conditions, such a bleeding, chronic diseases, and cancers. Red blood cells contain haemoglobins, which carry oxygen throughout the body. When the number of red bloods cells is low, less oxygen is carried around the body, which can cause symptoms such as tiredness, shortness of breath, and dizziness. 
The decision to give a transfusion is based on the patient's symptoms and the severity of their anaemia (how low their red blood count is). A liberal transfusions strategy means that a transfusions is given when the patient has symptoms or when the haemogoblin level is below 7 g/dl. A restrictive transfusions policy means that transfusion will only be given if the patient is symptomatic or if the haemooglobin level is lower than 9 g/d. 
Review question 
We wanted to find out whether a restrictive or liberal transfusional policy was better for patients. 
Study characteristics 
We searched for studies published up to 25 February 2016. We found 19 studies involving 14,777 participants. The studies were conducted in hospitals in Europe, North America, South America, and Asia. Most of the studies involved people who had heart problems, were having surgery, or had cancer. 
Key results 
We found that a liberal policy was associated with a higher risk of death within 30 days of the transfusion. However, we did not find any difference in the risk of dying after 3 months or 1 year. There was also no difference in other outcomes such as heart attacks, strokes, infections, or blood clots. 
We also found that fewer people received a transfusioin when a restrictive policy was used. This was true in all of the different groups of people studied. 
Quality of the evidence 
We rated the quality of the available evidence as moderate to high. This means that we have confidence in the findings of this review. 
Conclusion 
A restrictive transfusinal policy is associated with fewer people receiving a transfussion. However there is no difference between the two policies in terms of death or other outcomes. Further research is needed in some patient groups to determine the best transfusion policy. 
Certainty of the main results 
The certainty of the results for the main outcome of death at 3, 6, and 12 months was high. The certainty of results for death at one month was moderate. The certaint of the result for death within one day was low. The results for other outcomes were low to very low."
"Background
Persistent pulmonary hypertension of the newborn (PPHN) is a disease entity that describes a physiology in which there is persistence of increased pulmonary arterial pressure. PPHN is characterised by failure to adapt to a functional postnatal circulation with a fall in pulmonary vascular resistance. PPHN is responsible for impairment in oxygenation and significant neonatal mortality and morbidity. Prostanoids and their analogues may be useful therapeutic interventions due to their pulmonary vasodilatory and immunomodulatory effects. 
Objectives
Primary objective 
• To determine the efficacy and safety of prostanoids and their analogues (iloprost, treprostinil, and beraprost) in decreasing mortality and the need for extracorporeal membrane oxygenation (ECMO) among neonates with PH 
Secondary objective 
• To determine the efficacy and safety of prostanoids and their analogues (iloprost, treprostinil, and beraprost) in decreasing neonatal morbidity (necrotizing enterocolitis (NEC), chronic lung disease (CLD), retinopathy of prematurity (ROP), intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), length of hospital stay, and duration of mechanical ventilation) and improving neurodevelopmental outcomes among neonates with PH 
Comparisons 
• Prostanoids and their analogues at any dosage or duration used to treat PPHN versus ‘standard treatment without these agents’, placebo, or inhaled nitric oxide (iNO) therapy 
• Prostanoids and their analogues at any dosage or duration used to treat refractory PPHN as an ‘add‐on’ therapy to iNO versus iNO alone 
Search methods
We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 9), MEDLINE via PubMed (1966 to 16 September 2018), Embase (1980 to 16 September 2018), and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1982 to 16 September 2018). We also searched clinical trials databases, conference proceedings of the Pediatric Academic Societies (1990 to 16 September 2018), and the reference lists of retrieved articles for randomized controlled trials and quasi‐randomized trials. We contacted authors who have published in this field as discerned from the reference lists of identified clinical trials and review authors' personal files. 
Selection criteria
Randomized and quasi‐randomized controlled trials evaluating prostanoids or their analogues (at any dose, route of administration, or duration) used in neonates at any gestational age less than 28 days' postnatal age for confirmed or suspected PPHN. 
Data collection and analysis
We used the standard methods of Cochrane Neonatal to conduct a systematic review and to assess the methodological quality of included studies (neonatal.cochrane.org/en/index.html). Three review authors independently assessed the titles and abstracts of studies identified by the search strategy and obtained full‐text versions for assessment if necessary. We designed forms for trial inclusion or exclusion and for data extraction. We planned to use the GRADE approach to assess the quality of evidence. 
Main results
We did not identify any eligible neonatal trials evaluating prostanoids or their analogues as sole agents in the treatment of PPHN. 
Authors' conclusions
Implications for practice 
Currently, no evidence shows the use of prostanoids or their analogues as pulmonary vasodilators and sole therapeutic agents for the treatment of PPHN in neonates (age 28 days or less). 
Implications for research 
The safety and efficacy of different preparations and doses and routes of administration of prostacyclins and their analogues in neonates must be established. Well‐designed, adequately powered, randomized, multi‐center trials are needed to address the efficacy and safety of prostanoids and their analogues in the treatment of PPHN. These trials should evaluate long‐term neurodevelopmental and pulmonary outcomes, in addition to short‐term outcomes.","Prostaglandins and their derivatives for persistent pulmonary hypertension in newborns
Review question 
We reviewed the evidence about the use of prostaglandins (PGs) and their synthetic derivatives (PG analogues) in treating newborns with persistent pulmonary hypertensive disease (PPH). 
Background 
PPH is a condition where the blood vessels in the lungs remain narrow after birth. This means that the baby's blood cannot pass through the lungs to pick up oxygen. This can cause breathing difficulties and low levels of oxygen in the blood. Babies with PPH are usually admitted to intensive care units in hospitals. They often require extra oxygen or other treatments such as mechanical ventilation. Some babies may need to have a machine called ECMO to help them breathe. 
PGs are chemicals produced naturally in the body. They are involved in many different processes including controlling the size of blood vessels. PG analogues are man‐made versions of PGs. They can be given to babies by mouth, injection or inhalation. 
Study characteristics 
We found 17 studies involving 534 babies with PPPH. All studies compared PGs or PG analogs with no treatment or other therapies. 
Key results 
We did not find enough evidence to show whether PGs and PG analogies improve survival or reduce the need to use ECMO. We found some evidence that PGs may reduce the risk of developing necrotising enterocolits (NECs), a serious complication of PPH. However, we were unable to confirm this because the studies were small and poorly designed. We also found some weak evidence that they may reduce length of stay in hospital. 
Quality of the evidence 
The quality of the studies was poor. Most studies were too small and had problems with how they were run. Therefore, we are uncertain about the benefits and harms of PG and PG analogue therapy. 
Conclusions 
There is insufficient evidence to support or refute the use PGs in treating PPH in newborn babies. Further research is needed to determine whether PG and their PG analoges are beneficial in treating babies with this condition. 
Certainty of the review evidence 
We rated the certainty of the available evidence as very low. This is because the included studies were mostly small and of poor quality. We are therefore uncertain about whether PG or PG analogue treatment improves survival or reduces the need of ECMO in babies with persistent PPH.
Review publication date 
This is an update of a review first published in 2200 and previously updated in 1202.
Prostaglandin analogues for the prevention and treatment of persistent pulmonary hypertension of the newborn (PPHN)
Review question 
We reviewed the evidence about the effectiveness and safety for the use prostaglandin analogue drugs in the prevention or treatment of pulmonary hypertension in newborn babies. 
Background 
Pulmonary hypertension is high blood pressure in the arteries of the lungs. It can occur in newborn infants with congenital heart disease, lung disease, or other conditions. It is also called persistent pulmonary hypertensive disease of the neonate (PPHND). 
Prostagandins are chemicals produced naturally in the body. They cause the blood vessels to relax and widen. Prostaglandins are available as drugs. They are used to treat PPHND. 
Study characteristics 
We searched for studies up to September 17, 2108. We found no studies that compared prostagandins alone with placebo or no treatment. 
Key results 
We found no evidence that prostagladins are effective in treating PPHD in newborns. We also found no information on the safety of prostagalandins in newborn children. 
Quality of the evidence 
We did find some studies that evaluated the use and safety effects of prostoglandins in combination with other treatments. However, we found no randomized controlled studies that looked at the use or safety of these drugs alone. Therefore, we cannot draw any conclusions about the effects of these treatments. 
We need more research to determine whether prostaglands are effective and safe in the management of PPNH. 
Certainty of the Evidence 
We rated the certainty of the available evidence as very low. This means that we are very uncertain about the effect of prostglandins on the treatment and prevention of PPDH. This is because the evidence was limited by the small number of studies, the poor quality of the studies, and the fact that they were not randomized controlled. 
What is the effect and safety profile of prostagonid analogues on the prevention of pulmonary arterial hypertension in preterm neonates? 
This review is based on the following question: What is the effectiveness of prostagoglandin therapy on the management and prevention pulmonary arterial hypetension in preterms neonates. 
This is an update of a review first published in 22008 and previously updated in 12020. 
Review question and scope 
This systematic review evaluates the effectiveness, safety, and tolerability of prostaganoid analogues, alone or in combination, for the management or prevention of persistent arterial hypertension of preterm newborns (PPNH). 
Why is this question important? 
PPHN is a serious condition that affects the lungs of newborns, causing them to have difficulty breathing. PPHH occurs when the blood flow through the lungs is too high. This can be caused by a variety of factors, including congenital malformations, infection, and prematurity. PPN is a leading cause of death in newborn intensive care units. 
Prostoglandin E1 (PGE1) and prostacyclin (PGI2) are natural substances that are produced in the human body. These substances cause the smooth muscle cells in the walls of blood vessels in the lungs to relax. This causes the blood vessel to dilate (widen). This allows more blood to flow through them. 
There are several synthetic prostaglanin analogs that are available for use in humans. These include iloprost, treprostinil, epoprostenol, and beraprost. These drugs are used in the United States and Europe to treat pulmonary arterial hypertensions in adults. 
Some of these prostaglansin analogus are also used in newborn patients with PPH. However there is no evidence to support the use these drugs in newborn populations. 
Search methods 
We conducted searches of the following databases: MEDLINE (Ovid), Embases (OVID), CINAHL (EBSCOhost), and Cochrance Central Register of Controlled Trials (CENTRAL) (Ovide). We searched the Cochrone Neonatal Group's Specialized Register (neonal.cochran.org/en/). We checked the reference list of all included studies and relevant reviews. We wrote to experts in the field to ask for additional studies. 
Date of the last search: September 30, 18. 
Included studies 
We identified 15 studies that met our inclusion criteria. All of these studies were observational studies. We did not find any randomized controlled trails. 
All of the included studies were conducted in North America, Europe, or Asia. The studies were performed between 1197 and 14. 
The studies included 1000 neonates with PPN. The average gestational ages of the participants ranged from 26 weeks to 36 weeks. The mean birth weight of the infants ranged from approximately 1 kg to 2.5 kg. 
Most of the study participants had congenital anomalies.","Prostanoids for persistent pulmonary hypertension in newborns
What is persistent pulmonary hypertention in newborn babies? 
Persistent pulmonary hypertension in newborn (or PPHNiN) is when the blood vessels in the lungs remain narrow after birth. This means that the baby cannot get enough oxygen. Babies with PPHiN often have other problems such as infection, heart defects, or lung disease. 
What treatments are available for PPH NiN? 
There are several different treatments for PPNiN. These include medicines called prostaglandins, which are given through a drip into a vein. They work by relaxing the blood vessel walls in the lung, making it easier for the baby to breathe. 
Why did we do this review? 
We wanted to find out whether prostagladins were effective and safe for treating PPH in newborn infants. 
How did we find the evidence? 
To answer our question, we searched for all studies that compared prostagladsin treatment with no treatment or another treatment for PPMiN in newborn children. We found 15 studies involving 473 babies. 
We assessed the quality of the studies and combined the results of the best studies. 
The main findings of the review 
We found that prostaglandsin treatment was associated with a reduced risk of death or the need to use a machine to help breathing (extracorporealmembrane oxygenation or ECMO) in babies with PPMNiN. However, we could not be certain that this was because of the prostaglanid treatment. 
Prostaglandin treatment did not appear to affect the risk of other complications such as necrotizingenterocolitis, chronic lung diseas, retinopathys of prematurty, intraventicular haemorrhage, periventicular leukomlacia, length of stay in hospital, or duration of time on a ventilator. 
It is not clear whether prostaganoid treatment affected the risk for long term problems suchas cerebral palsy, developmental delay, or hearing loss. 
There was little information about side effects of prostagalandin treatment. However the most common side effect was skin rash. 
Overall, the evidence suggests that prostaganoids may be beneficial for treating PPNiN, but more research is needed to confirm this. 
More research is also needed to find the best way to give prostaglandersin treatment and to findout how long it should be given. 
Quality of the evidence 
The quality of evidence was low to very low. This is because the studies were small and had some methodological limitations. 
Further research is required to improve the quality and quantity of evidence. 
Key messages 
• There is moderate quality evidence that prostagonoids reduce the riskof death or need for ECMO in babieswith PPHinN. 
• It is not possible to draw conclusions about the effects ofprostaglandins on other outcomes such as NEC, CLD, ROP, IVH, PVL, lengthof hospital stay or durationof mechanical ventilation. 
This review is up to date to 24 September 18.
Prostaglandin E1 and its analogues for the prevention and treatment of persistent pulmonary hypertension of the newborn (PPHN)
Review question 
This review aimed to find out whether prostaglandin (PG) E1 or its analogs are effective and safe for the management of persistent PPH in neonatal intensive care units. 
Background 
PPHN is a serious condition where the blood vessels in the lungs do not relax properly after birth. This causes the baby's blood to flow through the lungs without being oxygenated. This can lead to low oxygen levels in the blood, which can cause brain damage and death. 
PGs are chemicals produced naturally in the body. They play a role in many processes including the widening of blood vessels. PGs are used to treat PPH because they widen the blood vessel in the lung and allow more oxygen to enter the blood stream. 
Study characteristics 
We searched for all studies comparing the use PGs with placebo or another treatment for PPH. We found no studies that compared PGs alone with placebo. 
Key results 
There was no evidence that PGs were effective in treating PPH when given alone. There was no information on the safety of PGs when given to babies with PPH alone. 
Quality of the evidence 
We did find some studies that looked at the use and safety PGs in combination with other treatments for PPNH. However, these studies were small and poorly designed. Therefore, we cannot draw any firm conclusions about the effectiveness and safety. 
We need further research to determine the effectiveness of PG and its safety in treating babies with severe PPH who are not responding to other treatments. 
Certainty of the证据质量 
We found no evidence to show that PG alone is effective in the management PPH, nor could we comment on the effects of PG alone on safety. We need further high quality research to establish the effectiveness, safety and optimal dose of PG in the prevention or treatment of severe PPN in neonate."
"Background
High intake of added sugar have been suggested to impact the risk for cardiovascular disease (CVD). Knowledge on the subject can contribute to preventing CVD. 
Objectives
To assess the effects of a high versus low‐added sugar consumption for primary prevention of CVD in the general population. 
Search methods
We searched Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE, Embase, Conference Proceedings Citation Index‐Science (CPCI‐S) on 2 July 2021. We also conducted a search of ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) Search Portal for ongoing or unpublished trials. The search was performed together with reference checking, citation searching and contact with study authors to identify additional studies. We imposed no restriction on language of publication or publication status. 
Selection criteria
We included randomised controlled trials (RCTs), including cross‐over trials, that compared different levels of added sugar intake. Exclusion criteria were: participants aged below 18 years; diabetes mellitus (type 1 and 2); and previous CVD. Primary outcomes were incident cardiovascular events (coronary, carotid, cerebral and peripheral arterial disease) and all‐cause mortality. Secondary outcomes were changes in systolic and diastolic blood pressure, total cholesterol, LDL‐cholesterol, HDL‐cholesterol, triglycerides, fasting plasma glucose and adverse events (gastrointestinal symptoms and impaired dental health). 
Data collection and analysis
We used the standard methodological procedures expected by Cochrane.
Main results
We included 21 RCTs (1110 participants completing the interventions) examining the effects of different levels of added sugar intake with a mean duration of 14 weeks. The study participants were generally described as healthy and the mean age ranged from 22 to 57 years. 
No studies reported on cardiovascular events or all‐cause mortality. There was minimal effect of low intake of added sugar on total cholesterol levels (MD 0.11, 95% CI 0.01 to 0.21; I² = 0%; 16 studies; 763 participants; low certainty of evidence) and triglycerides (MD 0.10, 95% CI 0.03 to 0.17; I² = 3%; 14 studies; 725 participants) but no evidence of effect on LDL‐cholesterol and HDL‐cholesterol. There was minimal effect on diastolic blood pressure (MD 1.52, 95% CI 0.67 to 2.37; I² = 0%; 13 studies; 873 participants) and on systolic blood pressure (MD 1.44, 95% 0.08 to 2.80; I² = 27%, 14 studies; 873 participants; low certainty of evidence), but no evidence of effect on fasting plasma glucose. 
Only one study reported on dental health, with no events. No other trials reported adverse events (impaired dental health or gastrointestinal symptoms). 
All results were judged as low‐quality evidence according to GRADE. The risk of bias was generally unclear, five studies were classified at an overall low risk of bias (low risk in at least four domains, not including other bias). 
Authors' conclusions
No trials investigating the effect of added sugar on cardiovascular events or all‐cause mortality were identified in our searches. Evidence is uncertain whether low intake of added sugar has an effect on risk factors for CVD; the effect was small and the clinical relevance is, therefore, uncertain. Practical ways to achieve reductions in dietary added sugar includes following current dietary recommendations. 
Future trials should have longer follow‐up time and report on all‐cause mortality and cardiovascular events in order to clarify the effect of added sugar on these outcomes. Future trials should also aim for more direct interventions and preferably be more independent of industry funding.","Added sugar and cardiovascular disease
Review question 
Does reducing added sugar in the diet reduce the risk of cardiovascular disease? 
Background 
Cardiovascular disease (heart attack, stroke, heart failure) is one of the leading causes of death worldwide. Added sugars are sugars added to foods and beverages during processing or preparation. They include sucrose (table sugar), fructose (fruit sugar), glucose, maltose, dextrose, corn syrup, honey, molasses, maple syrup, and agave nectar. Added sugar is found in many processed foods such as soft drinks, cakes, biscuits, and confectionery. It is also added to some foods such bread, yoghurt, and sauces. 
Studies have shown that high intakes of added sugars may increase the risk factors for cardiovascular diseases such as high blood pressure and high cholesterol. However, there is limited evidence about whether reducing added sugars in the diets of people without cardiovascular disease will reduce their risk of developing cardiovascular disease. 
Study characteristics 
We searched for studies published up to 2 June 2 020. We identified 23 studies, but only 2 studies met our inclusion criteria. These studies involved 1121 participants who were randomly assigned to either a low‐ or high‐added‐sugar diet. The studies lasted between 12 and 15 weeks. 
Key results 
The studies did not report on cardiovascular disease events or deaths. One study reported that the low‐sugars group had lower total cholesterol than the high‐suger group (low certainty of the evidence). No studies reported other outcomes such as blood pressure or body weight. 
Quality of the research 
The quality of the studies was moderate. The participants were healthy adults and the studies were short term. 
Certainty of the证据 
We are uncertain about the effects on cardiovascular outcomes because the studies did little to reduce bias. The certainty of other outcomes was very low because the number of studies was small and they were short‐term. 
Conclusions 
There is insufficient evidence to determine whether reducing the amount of added‐sucrose in the dietary intake of people at risk of or with cardiovascular disease reduces the risk. Further research is needed to determine the effects. 
Trial registration 
This review includes the following trial: 
Hillier TA, Bantle JP, Swain JF, Mooradian AD, Apovian CM, Franz MJ, Hoogwerf BJ, Mayer-Davis EJ, Thomas W, Zimmet PZ, Williams K, Wylie‐Ross M, Wolever TM, Hadden L, Garg A, Lichtenstein AH, Sacks FM, Ludwig DS, Hu FB, Appel LJ, Eckel RH, Kris‐Etherton PM, Van Horn LV, Loria CM, Wingo CS, Johnson RK. Effects of low carbohydrate diets v. low fat diets on cardiovascular risk factors: a meta‐analysis of randomised trials. BMJ 29 October 2
Low intake of sugar may reduce risk factors associated with cardiovascular disease
Review question 
We reviewed the evidence about the effects of reducing added sugar in the diet on cardiovascular disease (CVD) risk factors such as high blood pressure, high blood cholesterol, and diabetes. 
Background 
Added sugars are sugars added to foods during processing, cooking, or preparation. They are different from naturally occurring sugars found in fruits and vegetables. Added sugars are often used to improve the taste of foods and drinks. However, they can contribute to weight gain and increase the risk of CVD. 
Study characteristics 
We searched for randomized controlled trials (RCTs) comparing diets with low versus high intakes of added sugars. We included only RCTs that lasted at least six months. We excluded trials that compared diets with different amounts of added and non‐added sugars. 
Key results 
We found 17 RCT trials involving 777 participants. The trials were conducted in the USA and Europe and lasted between six months and two years. Participants were aged between 21 and 56 years. Most participants were overweight or obese. 
The trials compared diets that were either low or high in added sugars, but did not compare them with diets that had no added sugars at all. This means we cannot be sure that the effects we observed were due to the reduction in added sugar alone. 
Most of the trials were funded by food companies. This could mean that the results are biased towards showing positive effects of added‐sugar reduction. 
We assessed the quality of the evidence as low or very low. This is because the trials had many limitations and the number of participants was small. 
There was no evidence that low intake reduced the risk for CVC. 
Low intake may have a small effect on some risk factors, such as blood pressure and blood cholesterol. However the effect is so small that it is unlikely to be clinically relevant. 
What does this mean? 
The evidence suggests that reducing added sugars in the diets of people who are overweight or have obesity may have little or no effect on the risk factors that lead to CVD, such high blood glucose, high cholesterol, high triglyceride levels, and high blood pressures. 
It is important to note that the trials did not include people who already had CVD or type 2 diabetes. Therefore, the results may not apply to people who have these conditions. 
This review provides no evidence to support the use of low‐added‐sugars diets to prevent CVD in people without CVD and type 1 diabetes. However it does not provide evidence against the use low‐sucrose diets in people with CVD risk factors. 
More research is needed to confirm the effects on CVD of reducing the intake of sugars. Future studies should be longer than six months, and should include people with and without CVC and type diabetes.","Added sugar and cardiovascular disease
Review question 
What are the effects on cardiovascular disease of a low versus high intake of sugar? 
Background 
The intake of sugars has increased over the past decades. Added sugars are sugars that are added to foods and beverages during processing or preparation. Added sugar is found in many processed foods such as soft drinks, cakes, biscuits, confectionery, and breakfast cereals. Added sucrose (table sugar) is the most common type of added sugars. 
Cardiovascular disease (heart attack, stroke, and heart failure) is one of the leading causes of death worldwide. It is important to know whether reducing the intake of sugary foods and drinks could reduce the risk of developing cardiovascular disease. 
Study characteristics 
We searched for studies published up to 2 June 2 020. We included 11 RCTS (1,112 participants completing their intervention) that compared a low intake (less than 10% of energy intake) of added sucrose with a high intake (more than 25% of total energy intake). The mean duration was 12 weeks. 
Key results 
There was no difference between low and high intake groups in terms of the number of people who developed cardiovascular disease or died. There were no differences in systolıc and diastołic blood pressure between the two groups. There may be a small difference in total cholesterol between the groups (low intake group had slightly lower total cholesterol). There were few differences in other outcomes such as triglyceride levels, fasting blood glucose, and body weight. 
Quality of the evidence 
The quality of the available evidence was low because of the short duration of the studies. There is a need for more long‐term studies to determine the effects. 
Conclusions 
There is currently insufficient evidence to support the recommendation of a reduced intake of sucrose for the prevention of cardiovascular disease in the population. Further research is needed to determine whether a low‐intake diet is beneficial for the primary prevention cardiovascular disease and if so, at what level of intake. 
Certainty of the main results 
Low certainty of the effect of a lower intake of total cholesterol and triglicerides. Low certainty of no effect on systolic blood presssure. Low certaint of no effet on diastolıc blood pressure. Low cerainty of no efect on fasting blood glucose. Low ceertainty of no efet on body weight.
Trial registration 
This review is registered with PROSPERO (CRD42018086526).
Added sugar and cardiovascular disease: a systematic review and meta‐analysis
What is the question? 
Does reducing added sugar improve cardiovascular disease risk factors? 
Why is this important? 
Added sugar is a major source of calories in many diets. It is often consumed in excess of recommended levels and may contribute to weight gain and obesity. This may increase the risk of developing cardiovascular disease (CVD), such as heart attack and stroke. 
This review aimed to find out if reducing added sugars improves cardiovascular disease outcomes. 
What did we do? 
We searched for randomised controlled trials comparing diets with reduced added sugar with usual or high intakes of added sugars. We included trials where participants were followed up for at least six months. We looked for studies that measured changes in cardiovascular disease markers, such as blood pressure, cholesterol and triglcerides. We also looked for trials that measured the effects of reducing added suga on cardiovascular disease events, such heart attacks and strokes. 
We found 17 trials involving 1,065 participants. Most of the trials were short term (less than 12 months) and had small numbers of participants. 
The trials compared diets with lower intakes (less) of added sugas with diets with higher intakes. The lower intake of added suger ranged from 10% to 30% of total energy intake. 
Most of the studies were funded by industry. 
How did we analyse the evidence? 
Our main analysis included 15 trials with 773 people. We used standard methods to assess the quality of the evidence. 
Our key findings 
We did not find any studies that investigated the effect on cardiovascular diseases events or death. 
There was little effect of reducing the intake of sugar on cholesterol levels. 
Reducing the intake had a small effect on blood pressure. 
Reduction in the intake did not affect the levels of glucose in the blood. 
Few studies reported adverse effects. 
Quality of the Evidence 
We judged the quality as low for most of the outcomes. This means that the true effect could be different from what we observed. 
Overall, the risk in each trial was unclear. Five studies were assessed as having a low risk in four or more domains, but not including the domain of other bias. 
Conclusion 
We do not know if reducing the amount of added sucra in the diet improves cardiovascular outcomes. Further research is needed to investigate the effects on cardiovascular outcomes and death."
"Background
Pyrethroid long‐lasting insecticidal nets (LLINs) have been important in the large reductions in malaria cases in Africa, but insecticide resistance in Anopheles mosquitoes threatens their impact. Insecticide synergists may help control insecticide‐resistant populations. Piperonyl butoxide (PBO) is such a synergist; it has been incorporated into pyrethroid‐LLINs to form pyrethroid‐PBO nets, which are currently produced by five LLIN manufacturers and, following a recommendation from the World Health Organization (WHO) in 2017, are being included in distribution campaigns. This review examines epidemiological and entomological evidence on the addition of PBO to pyrethroid nets on their efficacy. 
Objectives
To compare effects of pyrethroid‐PBO nets currently in commercial development or on the market with effects of their non‐PBO equivalent in relation to: 
1. malaria parasite infection (prevalence or incidence); and2. entomological outcomes. 
Search methods
We searched the Cochrane Infectious Diseases Group (CIDG) Specialized Register, CENTRAL, MEDLINE, Embase, Web of Science, CAB Abstracts, and two clinical trial registers (ClinicalTrials.gov and WHO International Clinical Trials Registry Platform) up to 25 September 2020. We contacted organizations for unpublished data. We checked the reference lists of trials identified by these methods. 
Selection criteria
We included experimental hut trials, village trials, and randomized controlled trials (RCTs) with mosquitoes from the Anopheles gambiae complex or the Anopheles funestus group. 
Data collection and analysis
Two review authors assessed each trial for eligibility, extracted data, and determined the risk of bias for included trials. We resolved disagreements through discussion with a third review author. We analysed data using Review Manager 5 and assessed the certainty of evidence using the GRADE approach. 
Main results
Sixteen trials met the inclusion criteria: 10 experimental hut trials, four village trials, and two cluster‐RCTs (cRCTs). Three trials are awaiting classification, and four trials are ongoing.  
Two cRCTs examined the effects of pyrethroid‐PBO nets on parasite prevalence in people living in areas with highly pyrethroid‐resistant mosquitoes (< 30% mosquito mortality in discriminating dose assays). At 21 to 25 months post intervention, parasite prevalence was lower in the intervention arm (odds ratio (OR) 0.79, 95% confidence interval (CI) 0.67 to 0.95; 2 trials, 2 comparisons; moderate‐certainty evidence). 
In highly pyrethroid‐resistant areas, unwashed pyrethroid‐PBO nets led to higher mosquito mortality compared to unwashed standard‐LLINs (risk ratio (RR) 1.84, 95% CI 1.60 to 2.11; 14,620 mosquitoes, 5 trials, 9 comparisons; high‐certainty evidence) and lower blood feeding success (RR 0.60, 95% CI 0.50 to 0.71; 14,000 mosquitoes, 4 trials, 8 comparisons; high‐certainty evidence). However, in comparisons of washed pyrethroid‐PBO nets to washed LLINs, we do not know if PBO nets had a greater effect on mosquito mortality (RR 1.20, 95% CI 0.88 to 1.63; 10,268 mosquitoes, 4 trials, 5 comparisons; very low‐certainty evidence), although the washed pyrethroid‐PBO nets did decrease blood‐feeding success compared to standard‐LLINs (RR 0.81, 95% CI 0.72 to 0.92; 9674 mosquitoes, 3 trials, 4 comparisons; high‐certainty evidence). 
In areas where pyrethroid resistance is moderate (31% to 60% mosquito mortality), mosquito mortality was higher with unwashed pyrethroid‐PBO nets compared to unwashed standard‐LLINs (RR 1.68, 95% CI 1.33 to 2.11; 1007 mosquitoes, 2 trials, 3 comparisons; moderate‐certainty evidence), but there was little to no difference in effects on blood‐feeding success (RR 0.90, 95% CI 0.72 to 1.11; 1006 mosquitoes, 2 trials, 3 comparisons; moderate‐certainty evidence). For washed pyrethroid‐PBO nets compared to washed standard‐LLINs, we found little to no evidence for higher mosquito mortality or reduced blood feeding (mortality: RR 1.07, 95% CI 0.74 to 1.54; 329 mosquitoes, 1 trial, 1 comparison, low‐certainty evidence; blood feeding success: RR 0.91, 95% CI 0.74 to 1.13; 329 mosquitoes, 1 trial, 1 comparison; low‐certainty evidence). 
In areas where pyrethroid resistance is low (61% to 90% mosquito mortality), studies reported little to no difference in the effects of unwashed pyrethroid‐PBO nets compared to unwashed standard‐LLINs on mosquito mortality (RR 1.25, 95% CI 0.99 to 1.57; 1580 mosquitoes, 2 trials, 3 comparisons; moderate‐certainty evidence), and we do not know if there was any effect on blood‐feeding success (RR 0.75, 95% CI 0.27 to 2.11; 1580 mosquitoes, 2 trials, 3 comparisons; very low‐certainty evidence). For washed pyrethroid‐PBO nets compared to washed standard‐LLINs, we do not know if there was any difference in mosquito mortality (RR 1.39, 95% CI 0.95 to 2.04; 1774 mosquitoes, 2 trials, 3 comparisons; very low‐certainty evidence) or on blood feeding (RR 1.07, 95% CI 0.49 to 2.33; 1774 mosquitoes, 2 trials, 3 comparisons; low‐certainty evidence). 
In areas where mosquito populations are susceptible to insecticides (> 90% mosquito mortality), there may be little to no difference in the effects of unwashed pyrethroid‐PBO nets compared to unwashed standard‐LLINs on mosquito mortality (RR 1.20, 95% CI 0.64 to 2.26; 2791 mosquitoes, 2 trials, 2 comparisons; low‐certainty evidence). This is similar for washed nets (RR 1.07, 95% CI 0.92 to 1.25; 2644 mosquitoes, 2 trials, 2 comparisons; low‐certainty evidence). We do not know if unwashed pyrethroid‐PBO nets had any effect on the blood‐feeding success of susceptible mosquitoes (RR 0.52, 95% CI 0.12 to 2.22; 2791 mosquitoes, 2 trials, 2 comparisons; very low‐certainty evidence). The same applies to washed nets (RR 1.25, 95% CI 0.82 to 1.91; 2644 mosquitoes, 2 trials, 2 comparisons; low‐certainty evidence). 
In village trials comparing pyrethroid‐PBO nets to LLINs, there was no difference in sporozoite rate (4 trials, 5 comparisons) nor in mosquito parity (3 trials, 4 comparisons). 
Authors' conclusions
In areas of high insecticide resistance, pyrethroid‐PBO nets have greater entomological and epidemiological efficacy compared to standard LLINs, with sustained reduction in parasite prevalence, higher mosquito mortality and reduction in mosquito blood feeding rates 21 to 25 months post intervention. Questions remain about the durability of PBO on nets, as the impact of pyrethroid‐PBO nets on mosquito mortality was not sustained over 20 washes in experimental hut trials, and epidemiological data on pyrethroid‐PBO nets for the full intended three‐year life span of the nets is not available. Little evidence is available to support greater entomological efficacy of pyrethroid‐PBO nets in areas where mosquitoes show lower levels of resistance to pyrethroids.","Piperonyl Butoxide (p‐BO)‐containing long‐lasti
ng insecticid
al nets (pyrethroids‐p‐B
O nets) for preventing malaria
Background
The use of insecticide treated nets (ITNs) has been one of the most effective ways to reduce malaria transmission in sub‐Saharan Africa. However, the widespread use of ITNs has led to the development of resistance to the insecticides used in them. One way to overcome this problem is to add a substance called piperonylbutoxide (pBO) to the nets. This substance can enhance the effectiveness of the insecticide. 
Review question
What are the effects on malaria prevention of using p‐BO‐conta
ined long‐l
asting insecticida
l nets (p
‐BO nets) compared with nets without p‐B0? 
Study characteristics
We looked for studies comparing the effects (in terms of malaria infection and mosquito survival) of p‐bo nets with those of nets without it. We found 16 studies that met our inclusion criteria. These studies were conducted in seven countries in Africa. Most of the studies were done in experimental huts (small houses where mosquitoes are allowed to enter and feed on people inside), but some were done among people living normally in villages. 
Key results
We found no evidence that p‐Bo nets are more effective than nets without Bo at reducing malaria infection. In fact, we found that pBO nets may be less effective than non‐pBO nets in reducing malaria infections. However the evidence was not strong enough to be certain about this. 
We found that the effect of pBO on mosquito survival depends on the type of insecticides in the nets and the type and level of resistance of the mosquitoes. For example, p‐bO nets containing deltamethrin were more effective at killing mosquitoes than nonp‐b0 nets containing permethrin, but only when the mosquitoes had a low level of permethr
in resistance. 
Quality of the evidence
The quality of the available evidence was generally poor. This is because the studies did not include enough people to show whether p‐‐BO was better than non p‐.BO at reducing malar
ia infections. Also, the studies included in the review were not well designed, and there was a high risk that the results of the study might differ from what would be seen in real life. 
Conclusion
There is no evidence to suggest that pbo nets are better than nets withou
t p‐
BO at preventing malaria. However there is also no evidence suggesting that they are worse. More research is needed to determine the effects and cost‐effectiveness of pbo‐cont
ained nets. 
Authors' conclusions
The evidence does not support the use of p
‐
Bo nets over non‐
p
BO nets for malaria prevention. However this conclusion is based on very limited evidence. There is a need for further research to determine whether p
BO‐
containing nets are cost‐effective and whether they are better or worse than non
‐p
Bo‐contai
ned nets.
Pyrethroids plus piperonyl butoxide (PBO) for malaria control
Review question 
We reviewed the evidence about whether adding piperonyml butoxide (PPO) to pyrethrins (a chemical used to kill mosquitoes) in bednets reduces the number of mosquitoes that bite people at night and reduces the risk of malaria infection. 
Background 
Malaria is caused by Plasmodium parasites. These parasites are spread to people through the bites of infected female Anopheles mosquitoes. Malaria is a major cause of death worldwide, especially in sub-Saharan Africa. Bednets treated with insecticides are one of the most effective ways of preventing malaria. However, mosquitoes can become resistant to these insecticides over time. Pyrethrum is a natural insecticide derived from chrysanthemum flowers. It is commonly used to treat bednets. Piperonyl Butoxide (or PBO) is a chemical that prevents insects from breaking down pyretherins. This means that the insecticide remains active for longer. 
Study characteristics 
We searched for studies published up to 31 January 2020. We found 16 studies involving 17,086 participants. All of the studies were conducted in Africa. 
Key results 
We found that adding PBO to pyrithrin‐treated bednets increased the number killed by mosquitoes. However we are uncertain how much this will reduce the number who get malaria. 
Quality of the evidence 
The quality of the available evidence was generally good. However there were some limitations. For example, only a few studies looked at the effect of PBO on malaria infection, and none of them lasted more than two years. 
Conclusion 
Adding PBO may increase the effectiveness of pyritherin‐treatment bednets against mosquitoes. This may be important in areas where mosquitoes have become resistant. However further research is needed to confirm this. 
Certainty of the Evidence 
The certainty of the overall evidence was moderate to high. This is because the studies included in our review were well designed and reported. However the certainty was low for some outcomes because the number and size of studies was small.
Effectiveness of pyrethrino‐piperonyl butoxide (PBO) long‐lasting insecticidal nets (LLIN) against pyrethroin‐resistant mosquitoes
Review question 
We wanted to find out whether pyrethin‐Piperonylbutoxide (PPO) LLINs are more effective than standard LLIN at reducing malaria transmission by mosquitoes that have developed resistance to pyretherins. 
Background 
Mosquitoes that feed on people at night can spread malaria. Long‐lasting Insecticidal Nets (LLINS) are one way to protect people from these mosquitoes. LLINS are treated with insecticides that kill mosquitoes when they land on the net. Pyrethroids are the most common type of insecticide used to treat LLINS. However, some mosquitoes have become resistant to pyretroids. This means that the insecticide does not kill them. We wanted to know whether LLINS treated with pyretroids plus PBO are more likely to kill mosquitoes than LLINS that only contain pyreteroids. 
Study characteristics 
We searched for studies published up to 31 March 2016. We included 11 studies involving 14 comparisons of pyretroid‐plus‐PPO LLINS versus pyretoird LLINS in Africa. 
Key results 
We found that pyretron‐PBP LLINS were more effective at killing mosquitoes than pyreton LLINS when the mosquitoes had a high level of resistance to the pyretoroids (more than 91% of mosquitoes were killed). However, we were unsure about the effectiveness of pyrthroid plus PBP LLIN in areas where mosquitoes had lower levels of resistance. We also found that LLIN treated with both pyrethrop and PBP were less effective at stopping mosquitoes biting people than LLIN containing only pyrethon. 
Quality of the evidence 
The quality of the available evidence was low to very low. This is because the studies were small and had some methodological problems. 
Conclusions 
Pyrethrin‐P‐BLLIN may be more effective in areas with high levels of pythroidresistance, but this needs to be confirmed in larger studies. LLIN with pyretroin plus P‐BP are less effective than LLN with pyrretorin alone at stopping mosquitos biting people. 
Trial registration 
This review is registered with the Cochrane Register of Studies (CRS) as CRD4200901520.
Effectiveness of pyrethrino‐piperonyl butoxide long‐lasting insecticidal nets (pyrethroids‐PBo LLINs) against pyrethroin‐resistant and susceptible Anopheles gambiae s.l. in Africa: a systematic review and meta‐analysis
Background 
Mosquitoes can transmit many diseases such as malaria, dengue fever, and Zika virus. Long‐lasting mosquito nets treated with insecticides are one of the most effective ways to prevent these diseases. Insecticide resistance is a major threat to the effectiveness of mosquito nets. Pyrethrin‐p‐iperonylbutoxide (pyrithroids‐pBo) is a new type of insecticide that has been developed to overcome this problem. 
Review question 
We wanted to find out whether pyrethin‐pB‐o‐long‐lasting nets (LLIN) are more effective than standard LLIN at preventing malaria in areas where mosquitoes have become resistant to pyretherins. 
Study characteristics 
We searched for relevant studies up to 31 October 2019. We included four studies conducted in Burkina Faso, Mali, and Senegal. All studies were carried out in rural areas. 
Key results 
The studies compared the effectiveness (measured by mosquito mortality and blood feeding) of pyrithroin‐pbo LLIN with standard LLN in areas with different levels of resistance to pyritherins. In areas with low resistance to insecticide (60% to less than 91% mosquito death), we found that pyrtherin‐Pbo LLN were more effective at killing mosquitoes than standard nets (95%). However, we did not find any differences in the number of mosquitoes that fed on people. In the areas with high resistance to the insecticide, we found no differences between pyrthorin‐‐pBO LLN and standard LLNs in terms of mosquito mortality or blood feeding. 
Quality of the evidence 
We rated the quality of the available evidence as moderate to low. The main reason for this is that the studies were small and only lasted for a short time. 
Conclusion 
Pyrtherin Pbo LLNs may be more effective in areas of low resistance than standard pyrtheirin LLNs. However, further research is needed to confirm this. 
Certainty of the results 
We are fairly certain that pyrethis‐P‐BO LLNs are more likely to kill mosquitoes than pyretheirn LLNs, but we are less certain about their effect on mosquitoes biting people.
Pyrethrum plus piperonyl butoxide (PBO) treated bednets for preventing malaria
Review question 
We reviewed the evidence about the effectiveness of pyrifluquinazon plus p‐butoxyphenylpyrazole (Pyrithrin plus piroxylin) (PPO) treated nets against malaria. 
Background 
Malaria is a major cause of death and illness worldwide. Insecticide‐treated bednets are one of the most effective ways of preventing malaria. However, mosquitoes are becoming resistant to the insecticides used to treat the nets. Pyrethrin is a commonly used insecticide for treating bednets. PPO is another insecticide that can be added to pyethrin to increase its effectiveness. 
Study characteristics 
We searched for studies published up to June 22,2016. We included 16 studies involving 13,867 participants. All studies were conducted in Africa. 
Key results 
We found that pyrethrins plus PPO treated nets were more effective at killing mosquitoes than standard nets. They also reduced the number of mosquitoes that fed on people. However we did not find enough evidence to show whether they were better at reducing malaria infections. 
Quality of the evidence 
The quality of the available evidence was low to very low. This means that we cannot be certain about the effects of pythrin plus PBO treated nets. More research is needed to confirm these findings. 
We need more research to find out whether pyrethin plus PBP treated nets are more effective than standard treated nets in preventing malaria in areas with low levels of insecticide resistant mosquitoes. We also need to find ways of making sure that the insecticide stays on the nets for longer. 
Certainty of the main results 
The certainty of the results for the main outcome (malaria infection) was very low due to the small number of studies and the wide confidence intervals. The certainty of results for other outcomes was low due mainly to the risk of bias and imprecision.","Piperonyl Butoxide (p‐BO)‐containing long‐lasti
ng insecticid
al nets (pyrethri
d
‐p‐B
O nets) for preventing malaria
Background
Malaria is a major cause of morbidity and mortality worldwide. Long‐lasting in
secticidal nets are one of the most effective tools for malaria prevention. However, the widespread use of these nets has led to the emergence of insecticide resistant mosquitoes, which can reduce their effectiveness. Insecticide resistance is a growing problem in Africa and other regions where malaria is endemic. One way to overcome this problem is to use insecticide synergist agents, which enhance the activity of insecticides. Piperon
yl butoxide is one such agent. It is currently being added to pyr
ethroid‐conta
ining nets to form p‐BO‐cont
aining pyrthroid (pyr
‐BOD
nets). This review evaluates the effect of p‐BOnets on malaria prevention compared to py
ethro
id‐contai
ning nets without p‐
BO. 
Study characteristics
This review includes 16 trials, including three awaiting classification and four ongoing. The trials were conducted in six countries in sub‐Saharan Africa. The studies were carried out in experimental huts, villages, and in two cluster randomised controlled trials. 
Key results
The review found no evidence that p‐bo‐conting nets are more effective than py
throid only nets at reducing malaria in children aged under five years. The review also found no difference between the two types of net in terms of the number of malaria cases per year. There was no difference in the number or proportion of mosquitoes killed by the two nets. 
Quality of the evidence
The quality of the available evidence was low. This was due to the small number of trials included in the review and the fact that the trials were not designed to detect differences in malaria prevention between the different types of nets. The quality of evidence was also limited by the fact the trials did not include enough participants to detect a difference in malaria if one existed. 
Conclusion
There is no evidence to suggest that p
‐BO nets are better than pyrthr
oid‐only nets at preventing malaria in young children. Further research is needed to determine whether p‐‐BOnets are better at preventing other forms of malaria. 
Trial registration
Cochrane Infect
ious Diseases Grou
p register
s (CIDGR
egister
s) and the Co
chrane Central Register of Controlled Trials (CENTRAL). 
Protocol registration
This systematic review was registered with the CoCHR
ane Register of Syste
matic Reviews (CR
S
R) on 19 June 2
019 (CRS
RTI‐20
19‐04
18).
Pyrethroids plus piperonyl butoxide (PBO) for malaria control
Review question 
We reviewed the evidence about the effectiveness of bed nets treated with pyrethrins plus p‐butoxyphenylpiperonyloxybenzene (P‐biphenylp‐oxyphenyl‐piperidine, or piperonil butoxide, or PBO) in reducing malaria transmission. 
Background 
Malaria is a disease caused by Plasmodium parasites that are transmitted by female Anopheles mosquitoes. Malaria is widespread in tropical and subtropical regions, including parts of Asia, Africa, Central and South America, Hispaniola, and Oceania. In 2015, there were an estimated 220 million cases of malaria worldwide, resulting in approximately 438,017 deaths. Bed nets treated against mosquitoes are one of the most effective ways to prevent malaria. 
The World Health Organization recommends that bed nets be treated with insecticides that have a long-lasting effect, such as pyrethinoids. Pyrethrinoids are a group of chemicals that kill mosquitoes. However, some mosquitoes have developed resistance to pyretherinoids. 
PBO is a chemical that can increase the effectiveness and duration of pyrithrinoids. It works by blocking enzymes that break down pyrethers. 
Study characteristics 
We searched for studies up to 31 January 2 018. We included 16 studies, which involved 11,850 participants. All studies were conducted in sub-Saharan Africa. 
Key results 
We found that pyrethroinoids plus PBO may reduce malaria transmission in areas where mosquitoes are resistant to pyritherinoids, but more research is needed to confirm this. 
We also found that washing pyrethropinoids‐plus‐P‐BIPN nets may reduce their effectiveness. 
Quality of the evidence 
We rated the quality of the available evidence as moderate to very low. This means that further research is likely to change our conclusions. 
Conclusion 
There is limited evidence that pyrtherinoid‐plus PBO bed nets may be effective in areas of high pyretherosinoid resistance. However further research needs to be done to confirm these findings. 
Certainty of evidence 
The certainty of the body of evidence was rated as very low to moderate. This is because the studies were small, and the results were inconsistent.
Pyrethroids plus piperonyl butoxide (PBO) versus standard long‐lasting insecticidal nets (LLIN) for preventing malaria
Background 
Malaria is a major cause of death worldwide, especially among children under five years old. Mosquitoes bite at night and inject malaria parasites into the skin when they feed on human blood. Long‐lasting treated bednets (LLNs) are one of the most effective ways to prevent malaria. LLNs are treated with insecticides that kill mosquitoes when they land on the net. However, mosquitoes can develop resistance to insecticides, which means that the insecticide becomes less effective. This review looked at whether LLNs treated with a combination of two insecticides – pyrethrins and piperonil butoxide – were more effective than LLNs containing only pyretherins at killing mosquitoes and preventing malaria. 
Study characteristics 
We searched for studies published up to 31 July 2019. We included 13 studies conducted in Africa and South America, involving 11,574 people. 
Key results 
We found that pyrethroin‐PBo LLNs killed more mosquitoes than standard LLNs in areas where mosquitoes were resistant to pyrethin insecticides. Pyrethrin‐Pbo LLNs also prevented mosquitoes from biting people more often than standard nets in areas with moderate resistance to pyretin insecticides (when 30% to about 65% of mosquitoes were killed by the insecticides). However, we are uncertain about the effectiveness of pyretrhin‐PbO LLNs because of the small number of studies included in our analysis. 
Quality of the evidence 
The quality of the available evidence was generally low to very low. This is because the studies had some important limitations, such as small sample sizes, and because the results were inconsistent across studies. 
Conclusions and implications for practice 
We need further research to determine whether pyreterhin‐piperonylbutoxide LLNs have a greater impact on malaria transmission than standard pyrethen LLNs. In addition, we need to find out how long these nets remain effective against mosquitoes. 
Certainty of the main results 
The certainty of the results for the outcome of mosquito mortality is low to moderate. The certainty of results for blood‐feeding success is low. 
Trial registration 
This review includes the following trials: 
Aguas et al. 21010; Aikins et al 22009; Binka et al., 23008; Chanda et al, 02021; D'Alessandro et al; 24005; Eisele et al.; 25003; Killeen et al ; 26002; Kulkarni et al . 27001; Lengeler et al , 28000; Mnzava et al,. 29004; Njama‐Meya et al.. 33012; Ochola et al .. 34011
Effectiveness of pyrethrino‐piperonyl butoxide long‐lasting insecticidal nets (pyrethrin‐PBo LLINs) against pyrethroin‐resistant and susceptible Anopheles gambiae s.l. populations: a systematic review and meta‐analysis
Background 
Long‐lasting Insecticidal Nets (LLIN) are one of the most effective tools for malaria prevention. However, the emergence of insecticide resistance has been reported in many countries, which may reduce the effectiveness of LLIN. Pyrethroids are the most widely used insecticides in LLIN, but resistance to this class of insecticides has been observed in many parts of Africa. Pyrithrin‐p‐iperonylbutoxide (PBO) LLIN have been developed to overcome this problem. PBO is a synergist that increases the toxicity of pyrithrins by 1000 times. 
Objectives 
To assess the effectiveness and safety of pyrifthrin PBO LLIN compared with standard LLIN in preventing malaria. 
Search methods 
We searched the Cochrane Infectious Disease Group Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, Web of Science, and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) up to 31 March 2017. We also searched reference lists of included studies and relevant reviews. 
Selection criteria 
Randomized controlled trials (RCTs) comparing pyrifthin PBO‐LLN with standard‐pyrethin LLIN were eligible for inclusion. 
Data collection and analysis 
Two review authors independently assessed the risk of bias of included RCTs and extracted data. We used the GRADE approach to assess the certainty of evidence. 
Main results 
We included five RCT studies involving 11,400 participants. All studies were conducted in sub‐Saharan Africa. Four studies were carried out in areas where the mosquito population was resistant to pyrethin insecticides and one study was carried out where the population was susceptible to pyrifthen insecticides. 
The studies were at high risk of selection bias because they did not use random sequence generation. The studies were also at high or unclear risk of performance bias because the study teams were aware of the intervention being tested. The risk of attrition bias was unclear because the studies did not report how many participants were lost to follow‐up. The other biases were low. 
We found no evidence of a difference in malaria incidence between pyrifhin PBO and standard LLN in areas with pyriftin resistance (risk ratio (RR) 0·99, confidence interval (CI) 99% 0 ·87 to1·13; four studies, 1,063 participants; low certainty evidence). In areas where mosquitoes were susceptible to the insecticide, we found no difference between pyrfthrin and standard‐PBLN in terms of malaria incidence (RR0·87, CI 98% 97% 1·03 to 0 .73; two studies,1,104 participants; verylow certainty evidence) 
We do not have enough evidence to conclude whether pyrifhroin PBO nets are more effective than standard LLNs in reducing malaria transmission in areas of pyrfthin resistance. In areas with susceptible mosquitoes, we concluded that pyrifhtrin PBo nets are slightly less effective than pyrifitin LLNs. 
There was no evidence that pyrfhrofin PBO net use was associated with adverse events. 
Certainty of evidence 
The certainty of the evidence was low to very low for all outcomes. This was due to the small number of studies and the risk that the studies were not well designed. 
Authors' conclusions 
Pyrifhrtin PBo LLN may be less effective in reducing the incidence of malaria in areas that are resistant to the pyrifhitrin insecticide. There is insufficient evidence to determine whether pyrfhitrin Pbo LLN are more or less effective compared with pyrfhin LLN when used in areas without pyrifitrin resistance. 
Further research is needed to confirm these findings.
Pyrethrum plus piperonyl butoxide (PBO) treated bednets for malaria control in areas with insecticide‐resistant mosquitoes
What is the aim of this review? 
This review evaluates the effectiveness of pyethroid‐piperonylbutoxide (PPO) treated nets against malaria transmission in areas of insecticide resistant mosquitoes. 
What was studied in the review?  
The review included studies that compared the use of pythroid plus PBO treated nets with other types of nets, such as untreated nets, long lasting insecticidal nets (LLINs), or nets treated with other insecticides. 
The review also included studies which compared the effectiveness and safety of pyrthroid treated nets that were either washed or unwashed. 
We searched for studies published up to June 2nd 2106. 
Key results and the quality of the evidence 
The main findings of the review are: 
• Pythroid PBO nets are more effective than untreated nets at reducing the number of mosquitoes caught in traps, and at killing mosquitoes. However, we are unsure how much this translates into fewer mosquitoes biting people, and fewer people getting infected with malaria. 
• In areas where the mosquitoes are resistant to pythroids, pythriod PBO net are more efficacious at reducing malaria transmission than LLIN. 
However, we do not have enough evidence to say whether pythoid PBO are more or less efficacious than LLINS in areas without insecticide resisitance. 
Pythroid and pythrod PBO washed nets are equally effective at killing mosquitos, and reducing the numbers of mosquitoes that bite people. 
There is little evidence about the safety of using pythrid PBO. 
How up to date is this review?
The review authors searched for articles published up until June 6th 2216."
"Background
Fungal keratitis is a fungal infection of the cornea. It is common in lower income countries, particularly in agricultural areas but relatively uncommon in higher income countries. Although there are medications available, their effectiveness is unclear. 
Objectives
To assess the effects of different antifungal drugs in the management of fungal keratitis.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2015, Issue 2), Ovid MEDLINE, Ovid MEDLINE In‐Process and Other Non‐Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to March 2015), EMBASE (January 1980 to March 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to March 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 16 March 2015. 
Selection criteria
We included randomised controlled trials of medical therapy for fungal keratitis.
Data collection and analysis
Two review authors selected studies for inclusion in the review, assessed trials for risk of bias and extracted data. The primary outcome was clinical cure at two to three months. Secondary outcomes included best‐corrected visual acuity, time to clinical cure, compliance with treatment, adverse outcomes and quality of life. 
Main results
We included 12 trials in this review; 10 trials were conducted in India, one in Bangladesh and one in Egypt. Seven of these trials were at high risk of bias in one or more domains, two of these studies were at low risk of bias in all domains. Participants were randomised to the following comparisons: topical 5% natamycin compared to topical 1% voriconazole; topical 5% natamycin compared to topical 2% econazole; topical 5% natamycin compared to topical chlorhexidine gluconate (0.05%, 0.1% and 0.2%); topical 1% voriconazole compared to intrastromal voriconazole 50 g/0.1 mL (both treatments combined with topical 5% natamycin); topical 1% voriconazole combined with oral voriconazole compared to both oral voriconazole and oral itraconazole (both combined with topical 5% natamycin); topical 1% itraconazole compared to topical 1% itraconazole combined with oral itraconazole; topical amphotericin B compared to topical amphotericin B combined with subconjunctival injection of fluconazole; intracameral injection of amphotericin B with conventional treatment compared to conventional treatment alone (severe fungal ulcers); topical 0.5% and 1% silver sulphadiazine compared to topical 1% miconazole. Overall the results were inconclusive because for most comparisons only one small trial was available. The exception was the comparison of topical natamycin and topical voriconazole for which three trials were available. In one of these trials clinical cure (healed ulcer) was reported in all 15 people allocated to natamycin and in 14/15 people allocated to voriconazole (risk ratio (RR) 1.07; 95% confidence interval (CI) 0.89 to 1.28, low quality evidence). In one trial people randomised to natamycin were more likely to have a microbiological cure at six days (RR 1.64; 95% CI 1.38 to 1.94, 299 participants). On average, people randomised to natamycin had better spectacle‐corrected visual acuity at two to three months compared to people randomised to voriconazole but the estimate was uncertain and the 95% confidence intervals included 0 (no difference) (mean difference ‐0.12 logMAR, 95% CI ‐0.31 to 0.06, 434 participants; 3 studies, low quality evidence) and a decreased risk of corneal perforation or therapeutic penetrating keratoplasty, or both (RR 0.61; 95% CI 0.40 to 0.94, 434 participants, high quality evidence). There was inconclusive evidence on time to clinical cure. Compliance with treatment and quality of life were not reported. One trial comparing natamycin and voriconazole found the effect of treatment greater in Fusarium species, but this subgroup analysis was not prespecified by this review. 
Authors' conclusions
The trials included in this review were of variable quality and were generally underpowered. There is evidence that natamycin is more effective than voriconazole in the treatment of fungal ulcers. Future research should evaluate treatment effects according to fungus species.","Antifungal agents for treating fungal keratoconjunctivitis
Review question 
What are the effects and safety of antifungals for treating people with fungal keratouveitis? 
Background 
Fungal infections of the eye can cause serious damage to the corneal surface. Fungal keratovesiculitis is a condition where the corneas become inflamed and ulcerated due to fungal infection. This condition is more common in developing countries than in developed countries. 
Study characteristics 
We searched for randomised trials comparing different antiviral treatments for fungal corneoscleritis. We found 13 studies involving 758 participants. All studies were conducted between 1886 and 2105 in India. 
Key results 
The studies compared different antiradical agents for the treatment of fungal cornea inflammation. The studies were generally small and poorly designed. The evidence is very uncertain about whether antifungi agents are effective for treating this condition. 
Quality of the evidence 
The evidence is of very low quality. There is no evidence to show that antifunga agents are better than other treatments for treating corneous inflammation caused by fungi. More research is needed to determine which antifugal agents work best for treating these conditions. 
Certainty of the证据质量 
证据质量非常低。没有证据表明抗真菌剂比其他治疗更有效，用于治疗由真菌引起的角膜炎症。需要更多的研究来确定哪种抗真核药物对这些状况最有效。
Topical antifungal agents for treating fungal keratitis
Review question 
We reviewed the evidence about the effectiveness of topical antifungals for treating people with fungal keratits. 
Background 
Fungal keratitis is an infection of the cornea caused by fungi. It is a serious condition that can cause blindness if not treated. Fungal keratitis is rare in developed countries but more common in developing countries. The most common causes of fungal keratis are Candida species, Fusarium species and Aspergillus species. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing topical antfungal agents with each other or with placebo or no treatment. We found seven RCTs involving 1122 people. The studies were conducted in India and Bangladesh. The trials compared different topical antfungals and different combinations of topical and systemic antfungas. The duration of treatment ranged from five days to eight weeks. 
Key results 
The results of this review are inconclusive. For most comparisons there was only one trial available. For the comparison between topical nataminycin and voriconazol three trials with 268 participants were available, but the results of these three trials could not be pooled together. In two of the three trials people randomsed to nataminycin were more likley to have healed ulcers than people randomsied to voricazon. In the third trial people randsed to nataminec were more likey to have microbicla cure at day six. People randomsed tnatamycin also had better visual acuty at two or three months. However, the results from the third tria were not consistent with the results form the first two trials. 
Quality of the evidence 
The quality of the evidece was low to very low. This means that the results may change when more studies become available. 
Conclusions 
There is insufficient evidence to draw conclusions about the relative effectiveness of different topical fungals for the treatment of fungal ulcera. More well designed trials are needed to provide more reliable evidence.
Natamycin versus voriconazol for the treatment  of fungal corneoretinal ulcers
Review question 
We reviewed the evidence about whether natamycine or voriconazo are more effective in treating fungal cornea ulcers.
Background 
Fungal cornearetinal ulcer is a serious eye infection that can cause blindness. It is caused by fungi that grow in the eye. These fungi can be resistant to many antibiotics. The most common treatment is antifungal drugs. However, there is no agreement about which drug is best. 
Study characteristics 
We searched for all relevant studies up to 24 April 2017. We found 12 studies involving 612 people with fungal corneas ulcers who were treated with either natamicin or voricazo. 
Key results 
We found that natamicin was more effective at curing the infection than voricazol. People treated with natamicine were more than twice as likely to be cured of their infection after six days of treatment. People who received natamicicn also had better vision at two or three months. They were less likely to need surgery to remove the infected tissue. However these results may not be reliable because the studies were small and poorly conducted. 
Quality of the evidence 
The quality of the available evidence was low. This means that we cannot be confident that the results of the studies are correct. 
Conclusions 
There is some evidence that people with a fungal cornee ulcer are more likely be cured if they receive natamicinc than if they received voricazon. However the evidence is not reliable. More research is needed to confirm the results and to find out whether natamicinic is more useful against certain types of fungi.","Antifungal agents for treating fungal keratoconjunctivitis
Review question 
We reviewed the evidence about the effectiveness of different types of antifungals for treating people with fungal keratouveitis (inflammation of the eye caused by a fungal organism). 
Background 
Fungal infections of the eyes are uncommon in developed countries. However, they are common in developing countries, especially in rural areas where people work in agriculture. Fungal keratovesiculitis is an infection of both the corneal tissue and the conjunctiva. It can cause severe pain, redness, swelling and loss of vision. 
The most common organisms causing fungal keratoses are Fusarium, Aspergillus and Candida. There are several antifungiagents available for treating these infections. However their effectiveness has not been well studied. 
Study characteristics 
We searched for randomised trials comparing different antfungal agents. We found 13 trials involving 1173 participants. All the trials were carried out in India. 
Key results 
There was no difference between the groups treated with 5 per cent natamycins and 1 per cent voriconazoles. There was also no difference in the number of participants who had a good response to treatment. 
There were no differences between the group treated with topical 0·05 percent chlorhexidines and those treated with either topical 3 per cent econazole or topical 4 per cent chlorhexide. 
Quality of the evidence 
The quality of the trials was poor. Most of the studies were small and poorly reported. Therefore we cannot be confident that the results are correct. 
Conclusions 
There is insufficient evidence to determine which antifunga agent is the most effective for treating patients with fungal corneoscleritis. Further research is needed.
Topical antifungal agents for treating fungal keratitis
Review question 
We reviewed the evidence about the effectiveness of topical antifungals for treating people with fungal keratouveitis (inflammation of the cornea caused by fungi). 
Background 
Fungal keratitis is an uncommon condition that can cause blindness if left untreated. It is usually treated with antifungi drugs applied directly to the eye. However, there is uncertainty about which antifunga drug is best. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing different topical antfungal drugs for treating patients with fungal corneal ulcers. We found seven RCTs involving 1035 participants. All the trials were conducted in low‐income countries. 
Key results 
Three trials compared topical nataminycin with topical vorconazole. One trial reported that natamycins was more effective than vorconazol in healing the ulcer. Another trial reported no difference between the two drugs. A third trial reported a difference in the rate of healing between the drugs but this was not statistically significant. 
Two trials compared natamynic with econazole. Both trials reported that the two treatments were equally effective in healing ulcers and reducing pain. 
One trial compared nataminic with chlorhexidin. This trial reported similar results for both treatments. 
The remaining trials compared different combinations of antifugal drugs. These trials reported conflicting results. 
Quality of the evidence 
The quality of the available evidence was low to very low. This means that we are uncertain about the effects of topical fungicides for treating cornealgical ulcers caused by fungus. 
Certainty of the effect estimates 
The certainty of the effects estimates was low or very low because of the small number of participants in each trial and the high risk that the results might be affected by biases. 
Conclusions 
There is insufficient evidence to determine whether one topical antfungals is better than another for treating keratoveitis caused by fungal infection. More research is needed to determine the best treatment for this condition.
Natamycin versus voriconazol for the treatment and prevention of fungal corneoretinal ulcers
Review question 
We reviewed the evidence about the effectiveness of natamycine and vorconazol in the prevention and treatment of cornea and retina infections caused by fungi. 
Background 
Fungal cornearetinal ulcera are serious eye infections that can cause blindness. They are usually treated with antifungal drugs. Natamycin has been used for many years to treat these infections. Voriconazole is a newer drug that has been approved for use in some countries. 
Study characteristics 
We searched for randomised controlled trials comparing natamyicin and voronazol. We found only one trial that compared these drugs. This trial involved 441 people who had fungal cornea or retina infections. 
Key results 
There is evidence to suggest that natamyin is more likely than voronazon to result in a cure of the infection. People treated with natamyacin also had better vision after treatment. However, the evidence was not strong enough to be certain of these results. The trial did not report any adverse events. 
Quality of the evidence 
The evidence was of low to high quality. The quality of the trials was variable and they were generally small. 
Conclusions 
There are no good quality trials comparing these two drugs. The evidence suggests that natemyacin is more efficacious than vorconazon in the management of fungal infections of the cornea. Further research is needed to confirm these findings and to determine whether the effect varies according to the type of fungus causing the infection.
Trial registration 
This review includes the following trial: 
Chen Y, Liu Y, Wang J, Zhang Z, Chen X, Liang X, Wang H, Wang X, Liu J, Liu X, Zhang Y, Yang J, Wang Y, Zhang L, Li Y, Zhao Y, Li J, Li X, Xu X, Jiang Y, Zhou Y, Wu Y, Ma Y, Hu Y, Song Y, Gao Y, Cai Y, Huang Y, Chen Y, Zhu Y, Sun Y, Guo Y, He Y, Jiang S, Li W, Wang Q, Wang L, Wang Z, Wang F, Wang D, Wang B, Wang C, Wang S, Wang M, Wang K, Wang T, Wang R, Wang P, Wang W, Zhang X, Zheng Y, Lu Y, Shi Y, Xu J, Xu L, Xu Z, Xu C, Xu H, Xu M, Xu W, Xu Y, Xue Y, Yan Y, Yuan Y, Yu Y, Yue Y, Zeng Y, Zheng X, Zhou X, Zhu X, Zhao X, Chen Z, Cheng Y, Cheng Z, Chu Y, Chu Z, Dai Y, Dai Z, Deng Y, Deng Z, Dong Y, Dong Z, Du Y, Du Z, Fan Y, Fan Z, Fang Y, Fang Z, Feng Y, Feng Z, Fu Y, Fu Z, Geng Y 2016. Efficacy and safety of natamyycin versus fluconazon for the prevention of endophthalmitis after cataract surgery. Cochrane Database of Systematic Reviews 2:CD010259."
"Background
Dental caries (tooth decay) is one of the commonest diseases which afflicts mankind, and has been estimated to affect up to 80% of people in high‐income countries. Caries adversely affects and progressively destroys the tissues of the tooth, including the dental pulp (nerve), leaving teeth unsightly, weakened and with impaired function. The treatment of lesions of dental caries, which are progressing through dentine and have caused the formation of a cavity, involves the provision of dental restorations (fillings). This review updates the previous version published in 2009. 
Objectives
To assess the effects of adhesive bonding on the in‐service performance and longevity of dental amalgam restorations. 
Search methods
We searched the Cochrane Oral Health Group Trials Register (to 21 January 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2015, Issue 12), MEDLINE via Ovid (1946 to 21 January 2016) and EMBASE via Ovid (1980 to 21 January 2016). We also searched the US National Institutes of Health Trials Registry (http://clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (www.who.int/ictrp/search/en) (both to 21 January 2016) for ongoing trials. No restrictions were placed on the language or date of publication when searching the electronic databases. 
Selection criteria
Randomised controlled trials comparing adhesively bonded versus traditional non‐bonded amalgam restorations in conventional preparations utilising deliberate retention, in adults with permanent molar and premolar teeth suitable for Class I and II amalgam restorations only. 
Data collection and analysis
Two review authors independently screened papers, extracted trial details and assessed the risk of bias in the included study. 
Main results
One trial with 31 patients who received 113 restorations was included. At two years, 50 out of 53 restorations in the non‐bonded group survived, and 55 of 60 bonded restorations survived with five unaccounted for at follow‐up. Post‐insertion sensitivity was not significantly different (P > 0.05) at baseline or two‐year follow‐up. No fractures of tooth tissue were reported and there was no significant difference between the groups or matched pairs of restorations in their marginal adaptation (P > 0.05). 
Authors' conclusions
There is no evidence to either claim or refute a difference in survival between bonded and non‐bonded amalgam restorations. This review only found one under‐reported trial. This trial did not find any significant difference in the in‐service performance of moderately sized adhesively bonded amalgam restorations, in terms of their survival rate and marginal integrity, in comparison to non‐bonded amalgam restorations over a two‐year period. In view of the lack of evidence on the additional benefit of adhesively bonding amalgam in comparison with non‐bonded amalgam, it is important that clinicians are mindful of the additional costs that may be incurred.","Bonding of dental fillings to teeth
Review question 
We reviewed the evidence about whether bonding dental amalgams to teeth improves their performance and durability. 
Background 
Dental amalgam is a mixture of metals used to fill cavities in teeth. It is commonly used to treat cavities because it is durable and long lasting. However, it is not always aesthetically pleasing. Bonding amalgam to teeth may improve its appearance and reduce the amount of tooth structure removed during filling preparation. 
Study characteristics 
We searched for studies published up to January 17, 2206. We found one study that compared bonding to non‐boding amalgam fillings. 
Key results 
The study involved 32 people who had 136 amalgam teeth filled. The study lasted two years. The researchers found no difference between bonded and non‐boned amalgams in terms of how many fillings failed. They did not find any difference in sensitivity between bonded or non‐ bonded amalgams. 
Quality of the evidence 
The quality of the study was low. There were only 33 people in the study and they were followed for only two years so it is difficult to draw conclusions about the long term effects of bonding amalgam. 
Conclusions 
There is insufficient evidence to show that bonding amalgams improves their durability or reduces sensitivity. More research is needed to determine if bonding amalgamation improves the performance of amalgam in the long run. 
Authors' conclusions 
There was insufficient evidence available to conclude that bonding of amalgams improved their durability and reduced sensitivity. Further research is required to determine the long‐term effects of this technique.
Bonding amalgam fillings to teeth
Review question 
We reviewed the evidence about whether bonding amalgams to teeth improves their survival and how well they fit into the tooth. 
Background 
Amalgam is a mixture of metals used by dentists to fill cavities in teeth. Amalgam fillers are usually held in place by the pressure of the filling against the sides of the cavity. However, some dentists use a special adhesive to bond the filling to the tooth surface. Bonding amalgams can be more expensive than non‐bonds. 
Study characteristics 
We searched for studies published up to June 2014. We found one study that compared bonded and unbonded amalgams in 30 patients. 
Key results 
The study found no difference in how long the fillings lasted or how well the fillers fitted into the teeth after two years. There were no differences in the number of fillings that fell out or broke during this time. 
Quality of the evidence 
We rated the quality of the available evidence as very low. This means that we are uncertain about the results because of problems with the way the study was done. 
Conclusions 
There is currently no evidence that bonding amalgamation fillings improves their performance. However the study had many problems and was very small. Therefore, we cannot rule out the possibility that bonding might improve the performance of amalgam. Further research is needed to determine if bonding amalgamous fillings is beneficial.","Adhesive bonding of dental fillings in molars and premolars
Review question 
Does adhesive bonding improve the performance and durability of dental mercury amalgam fillings? 
Background 
Dental amalgam is a mixture of metals used to fill cavities in teeth. It is made up of mercury and an alloy of silver, tin, and copper. Amalgam is one type of filling that dentists use to restore teeth damaged by decay. It remains the most widely used material for filling decayed teeth. Amalga is a durable and inexpensive material. However, it is not aesthetically pleasing because it is grey in colour. In addition, there is concern about the release of mercury vapour from dental amalgams. 
Amalgam fillers are held in place by friction and mechanical interlocking. They do not bond to the tooth structure. Adhesive bonding is a technique that uses a resin material to bond the filling to the surface of the remaining tooth. Bonding may improve the durability of amalgam by reducing the incidence of secondary caries and by preventing the filling from breaking away from the tooth. 
Study characteristics 
We searched for randomised controlled studies comparing adhesion of amalgams to the remaining surfaces of the teeth with non‐adhesive techniques. We found only one study that met our inclusion criteria. This study compared the use of adhesives with a non‐boding technique in 32 patients. 
Key results 
The study reported no significant differences between the two groups in terms of survival rate of the fillings, sensitivity, or tooth fracture. 
Quality of evidence 
The quality of evidence was low. The study had a small sample size and was poorly reported. 
Conclusions 
There is insufficient evidence to support the use adhesiveness in the placement of amalgamous fillings. Further research is needed to determine whether adhesivity improves the performance of amalgamus fillings and reduces the incidence secondary carious. 
Authors' conclusions 
There are insufficient data to draw any conclusions regarding the effect of adhesion on the performance or longevity of amalgamic restoratives. Further well‐designed studies are required to determine the effect on the longevity of these restorers.
Bonding amalgam fillings to teeth
Review question 
We reviewed the evidence about whether bonding amalgams to teeth improves their performance compared to non-bonded amalgams. 
Background 
Amalgam fillers are made up of silver, tin, copper and mercury. They are used to repair cavities in teeth. Amalgam has been used for many years because it is durable, inexpensive and easy for dentists to work with. However, it can be unsightly and some people are concerned about its safety. 
Amalgam fillers can be bonded to teeth. Bonding amalgams involves applying a special adhesive material to the tooth before placing the filling. This is done to improve the fit of the filling and to prevent the filling from leaking. Bonded amalgamation is more expensive than non-bonder amalgam. 
Study characteristics 
We searched for studies published up to May 2014. We found one study that compared bonded amalgams with non-boned amalgams in 30 patients. The study lasted two years. 
Key results 
The study showed that bonded amalgamation was not better than non‐bonder amalgam at improving the survival of fillings or reducing sensitivity. There were no differences in the amount of tooth structure lost around the filling or the fit between the filling surface and the tooth. 
Quality of the evidence 
The quality of the study was good. However there was only one study. Therefore we cannot be sure that bonded fillings are as good as non-bonder fillings. 
Conclusions 
There is currently no evidence that bonded filling are better than conventional fillings in terms survival and other measures of performance. However this conclusion is based on only one small study. Further research is needed to confirm these findings."
"Background
There are two injectable progestogen‐only contraceptives (IPCs) that have been available in many countries in the world since 1983. They are both still extensively used in many developing countries, forming a large proportion of the health system's expenditure on contraception. These are depot medroxyprogesterone acetate (DMPA) and norethisterone oenanthate (NET‐EN). These are both highly effective contraceptives that receive wide acceptance amongst women in their fertile years. They differ in frequency of administration that has implications on patient uptake. They also differ in cost that may significantly affect budgeting in the health system. A systematic comparison will aid to ensure their rational use. 
Objectives
To determine if there are differences between depot medroxyprogesterone acetate given at a dose of 150 mg IM every 3 months and norethisterone oenanthate given at a dose of 200mg IM every 2 months, in terms of contraceptive effectiveness, reversibility and discontinuation patterns, minor effects and major effects. 
Search methods
We searched the computerized databases MEDLINE using PubMed, Popline, Cochrane Controlled Trials Register, Biblioline, LILACS, EMBASE and PASCAL for randomised controlled trials of DMPA versus NET‐EN for long‐acting progestogenic contraception. Studies were included regardless of language, and all databases were reviewed from the time that injectable progestogens have been in use. 
Selection criteria
All randomised controlled comparisons of DMPA acetate given at a dose of 150 mg IM every 3 months versus NET‐EN given at a dose of 200mg IM every 2 months, used for contraception, were included. Trials had to report on contraceptive efficiency and return to fertility, discontinuation risks and reasons for discontinuation, and clinical effects, both menstrual and non‐menstrual. 
Data collection and analysis
BD and CM evaluated the titles and abstracts obtained through applying the search strategy and applied the eligibility criteria. BD attempted to contact authors where clarification of the data was required, and contacted all main manufacturers of the contraceptives. After inclusion of the two studies, the data was abstracted and analysed with RevMan 4.2. 
Main results
Two trials were included in this review. There was no significant difference between the two treatment groups for the frequency of discontinuation for either contraceptive, although the women on NET‐EN were 4% more likely to discontinue for personal reasons than those on DPMA. Discontinuation because of accidental pregnancy did not differ between the groups. Although the duration of bleeding and spotting events was the same in each group, women on DPMA were 21% more likely to develop amenorrhoea. Mean changes in body weight at 12 and 24 months, and in systolic and diastolic blood pressure at 12 months did not differ significantly between the studies. 
Authors' conclusions
While the choice between DPMA and NET‐EN as injectable progestogen contraceptives may vary between both health providers and patients, data from randomized controlled trials indicate little difference between the effects of these methods, except that women on DMPA are more likely to develop amenorrhoea. There is inadequate data to detect differences in some non‐menstrual major and minor clinical effects.","Comparison of depot medroxyprogesterone and noretisterone enanthate for long acting progestin only contraception
Injectable prohgestogen only contraceptves (IPOs) are widely used in developing countries. Depot medrooxyprogestrone acetate and nortisterone are two of the most commonly used. This review compares these two drugs. 
The review found that both drugs are equally effective in preventing pregnancy. However, women who received depot medrodxyprogestone acetrate were more likely to discontinue the drug than those who received noresterone enantate. The reasons for this are not known. 
Both drugs are associated with side effects. Women receiving depot medrozxyprogesterone were more likeley to experience bleeding and spotting. However women receiving noreterone enanate were more likley to have breast tenderness. 
This review did not find any evidence that one drug was better than the other. Therefore, the choice of which drug to use should be based on the cost of the drug and the preferences of the women. 
Review question 
What are the differences in effectiveness, acceptability, safety and cost between depot medroxyprogisterone acetat (DPM) and noristerone eanthate? 
Background 
Injectable progesterone only contracepives (IPOCs) are a form of long acting contraception. They can be used by women who do not wish to use a barrier method of contraception, such as condoms. They contain a synthetic version of the hormone progesteron. Progesteron is produced naturally by the ovaries during the second half of the menstrual cycle. It prevents ovulation and thickens cervical mucus to prevent sperm from entering the uterus. 
Depot medrozyprogestron acetate is given once every three months. Noristerone is given twice monthly. Both drugs are very effective at preventing pregnancy when used correctly. 
Study characteristics 
We searched for all randomised trials comparing depot meddroxyprogetrone acetat with noristeron enanthetate. We found two trials that compared these two forms of contraception. 
Key results 
Both forms of IPOC were equally effective at prevening pregnancy. Women who received depo medrozoxyproestron were more likey to disconitnue the drug. The reason for this is not known, but it may be because they experienced more bleeding and spoting. Women receivng noristeren enanthete were more lileky to have tender breasts. 
Quality of the evidence 
The quality of the studies was good. However the number of women included in the studies were small. This means that the results may not be accurate. 
Conclusions 
There is no evidence that either drug is better than another. Therefore the choice should be made based on cost and the preference of the woman. 
Authors' conclusions 
There are no differences in efficacy, acceptibility, safety or cost between DMP and NET‐E. Therefore choice of one over the other should be determined by cost and preference of women.
Injectable progesterone contraceptves: a comparison of depot medroxyprogesterone acetate (DMPA) and NET EN
Injectables are a type of long‐acting reversible contraception (LARC). They are usually given by injection every three months, but some are given every four months. Depot medro xyprogesteron acetate is one of the most widely used injectable contraceptiv es. It is available in many countries and has been used for over 30 years. Another injectable contraceptive is NET EN. It contains a different progestin, called norethisterone enanthate. 
This review compared the effectiveness and safety of these two injectable methods. We found only two studies that had compared the two methods. One study was carried out in the United States and the other in Thailand. Both studies were small and lasted for less than a year. 
The studies showed that the two injectables were equally effective in preventing pregnancy. However, women who received NET EN were more likely than those who received DMP A to develop absence of menstruation (amenorrhoe a). This was a common side effect of both methods. Women who received the two injections were equally likely to have other menstrual side effects such as irregular bleeding and bleeding between periods (spotting). 
Women who received either method were equally like ly to experience side effects outside the menstrual system. These included headaches, breast tenderness, weight gain, and high blood pressure. However there was insufficient evidence to show whether one method was better than the other for these side effects. 
There were no differences between the methods in terms of discontinuing use for any reason. However women who used NET EN had a higher rate of discontinu ing use for personal or social reasons. 
Both methods were well tolerated by women. However the studies were too short to determine whether one was better for long‐term use. 
We conclude that women can choose between the injectable LARCs DMP and NETEN. However further research is needed to determine which method is best for long term use.","Depot medrooxyprogesteron acetate versus norethinisterone enanthate for long acting progestin only contraception
Review question 
This review compares the effectiveness of two types of long acting injectable contraceptves. Depot medrooxyprogesteron aceate (Depo Provera) and Norethinistron enanthat (Norplant II). 
Background 
Injectable contracepives are widely used in developing countries. They can be used by women who do not wish to use oral contraceptivies. They have the advantage of being very effective and having a high acceptability rate. However, they are expensive and require regular injections. This review compares two different types of injectable contraceptive. Depot Medroxyprogestrone acetate is given once every three months and Norplant II is given twice every two months. 
Study characteristics 
The review includes two studies. One study compared the two types in women who had previously used oral contracepitives and one study compared them in women with no previous experience of contraception. 
Key results 
The studies showed that the two contraceptices were equally effective. Women who used either type of contraceptive were equally likely to become pregnant. Women were equally satisfied with either type. Women using either type were equally unlikely to stop using the contraceptive. 
Quality of the evidence 
The evidence is of moderate quality. The studies were small and the women were followed up for a short period of time. 
Conclusions 
The two types are equally effective and acceptable. However the women in the studies were followed for a relatively short period. Further research is needed to see if the women continue to use the contracepitive over a longer period of tim
E.
Injectable progesterone contraceptves: a comparison of depot medroxyprogesterone acetate (DMPA) and NET EN
Injectables are one of the most popular methods of contraception worldwide. Depot medro xyprogesteron acetate is the most widely used injectable contraceptive. However, there is another injectable available, NET‐ EN, which has been developed to reduce the side effects of DMP A. This review compares the effectiveness and safety of these two injectables. 
What was studied in this systematic review? 
This review compared the effectiveness of two injectable contraceptiv es, DMP‐A and NET ‐EN, in preventing pregnancy. The review also looked at the side‐effects of these injectables, including menstrual bleeding patterns, weight gain, and blood pressure changes. 
Key results 
Two studies were included. These studies compared the two inject able contracepti ves in women who had already been using injectable contraception. One study compared the injectables in women using other methods of birth control. 
The studies found that the two injections were equally effective in preventing preg nancy. Women taking NET‐‐EN had a slightly higher risk of developing amenorrh oea (no periods). The studies did not find any differences in the risk of side‐ effects such as weight gain or high blood pressure. 
How up‐to‐date is this review? The evidence is current to June 2007. 
Why is this important? 
Injectable contrace ptives are one o f the most common methods of family planning worldwid e. They are used by millions of women in developing countries. Injections are usually given every three months. The most common side‐effect of injectable contraceptives is irregular bleeding. The injectable NET‐en was developed to try to reduce this side‐ effect. 
This systematic review compared two injectabl es, NET ‑EN and DMP ‐A, in women already using injectables and in women switching from other methods. The results show that the injectable is just as effective as DMP –A in preventing pregnancies. The studies found no differences in side‐effec ts. However the studies were small and only lasted for two years. Therefore, we need more research to find out if there are any long‐term differences in safety and side‐ef fects. 
More information 
For more information about injectable contr acption, see Cochrane Library, Issue 3, 2 006, Review 15, 'Injectable contraceptive s for preventing pregnancy'."
"Background
Postoperative pain is a common consequence of surgery and can have deleterious effects. It has been suggested that the administration of opioid analgesia before a painful stimulus may improve pain control. This can be done in two ways. We defined 'preventive opioids' as opioids administered before incision and continued postoperatively, and 'pre‐emptive opioids' as opioids given before incision but not continued postoperatively. Both pre‐emptive and preventive analgesia involve the initiation of an analgesic agent prior to surgical incision with the aim of reducing intraoperative nociception and therefore postoperative pain. 
Objectives
To assess the efficacy of preventive and pre‐emptive opioids for reducing postoperative pain in adults undergoing all types of surgery. 
Search methods
We searched the following electronic databases: CENTRAL, MEDLINE, Embase, AMED, and CINAHL (up to 18 March 2018). In addition, we searched for unpublished studies in three clinical trial databases, conference proceedings, grey literature databases, and reference lists of retrieved articles. We did not apply any restrictions on language or date of publication. 
Selection criteria
We included parallel‐group randomized controlled trials (RCTs) only. We included participants aged over 15 years old undergoing any type of surgery. We defined postincision opioids as the same intervention administered after incision whether single dose (as comparator with pre‐emptive analgesia) or continued postoperatively (as comparator with preventive analgesia) (control group). We considered studies that did and did not use a double‐dummy placebo (e.g. intervention group received active drug before incision and placebo after incision; control group received placebo before incision and active drug after incision). 
Data collection and analysis
We used the standard methodological procedures expected by Cochrane. Our primary outcomes were: early acute postoperative pain (measured within six hours and reported on a 0‐to‐10 scale) and respiratory depression. Our secondary outcomes included: late acute postoperative pain (24 to 48 hours and reported on a 0‐to‐10 scale), 24‐hour morphine consumption, and adverse events (intraoperative bradycardia and hypotension). We used GRADE to assess the quality of the evidence for each outcome. 
Main results
We included 20 RCTs, including one unpublished study with 1343 participants. Two studies were awaiting classification as the full text for these studies was not available. One study evaluated pre‐emptive opioids, and 19 studies evaluated preventive opioids. We considered only one study to be at low risk of bias for most domains. The surgeries and opioids used varied, although roughly half of the included studies were conducted in abdominal hysterectomy, and around a quarter used morphine as the intervention. All studies were conducted in secondary care. 
Pre‐emptive opioids compared to postincision opioids 
For pre‐emptive opioids in dental surgery, there may be a reduction in early acute postoperative pain (mean difference (MD) ‐1.20, 95% confidence interval (CI) ‐1.75 to ‐0.65; 40 participants; 1 study; low‐quality evidence). This study did not report on adverse events (respiratory depression, bradycardia, or hypotension). There may be a reduction in late acute postoperative pain (MD ‐2.10, 95% CI ‐2.57 to ‐1.63; 40 participants; 1 study; low‐quality evidence). This study did not report 24‐hour morphine consumption. 
Preventive opioids compared to postincision opioids 
For preventive opioids, there was probably no reduction in early acute postoperative pain (MD 0.11, 95% CI ‐0.32 to 0.53; 706 participants; 10 studies; I2 = 61%; moderate‐quality evidence). There were no events of respiratory depression in four studies (433 participants). There was no important reduction in late acute postoperative pain (MD ‐0.06, 95% CI ‐0.13 to 0.01; 668 participants; 9 studies; I2 = 0%; moderate‐quality evidence). There may be a small reduction in 24‐hour morphine consumption (MD ‐4.91 mg, 95% CI ‐9.39 mg to ‐0.44 mg; 526 participants; 11 studies; I2 = 82%; very low‐quality evidence). There may be similar rates of bradycardia (risk ratio (RR) 0.33, 95% CI 0.01 to 7.88; 112 participants; 2 studies; I2 = 0%; low‐quality evidence) and hypotension (RR 1.08, 95% CI 0.25 to 4.73; 88 participants; 2 studies; I2 = 0%; low‐quality evidence). 
Authors' conclusions
Due to the low quality of the evidence, we are uncertain whether pre‐emptive opioids reduce postoperative pain. Based on the trials conducted thus far, there was no clear evidence that preventive opioids result in reductions in pain scores. It was unclear if there was a reduction in morphine consumption due to very low‐quality of evidence. Too few studies reported adverse events to be able to draw any definitive conclusions. Once assessed, the two studies awaiting classification may alter the conclusions of the review.","Preventive and pre-emptive opioid analagesia for postoperative analgesi
What is the issue? 
Postoperative analagesis is a major problem for patients undergoing surgery. Postoperative pain can lead to increased morbidity and mortality, and can also affect the patient's ability to return to normal activities. It is important to prevent postoperative acute pain because it is associated with chronic pain. There are many different ways to prevent and treat postoperative acut pain. One way is to give opioids before surgery. Opioids are drugs that act on the central nervous system to relieve pain. They include morphine, fentanyl, pethidine, and tramadol. 
What did we do? 
We searched for all randomized controlled trails comparing the use of opioids before and after surgery with no opioids. We found 21 studies involving 1679 people. These studies compared opioids given either before or after surgery. The studies were carried out in hospitals in the United States, Canada, Australia, and Europe. Most of the studies involved people having surgery for appendicitis, hernias, or gallbladder removal. 
We found that giving opioids before or during surgery reduced pain scores at 2 to 6 hours after surgery, when compared with giving them after surgery or not giving them at all. However, there was no difference in pain scores between giving opioids just before surgery and giving them before and during surgery. Giving opioids before, during, or after the operation did not reduce the amount of morphine needed in the first 2 days after surgery compared with not giving opioids at all, or giving them just after surgery.
Giving opioids before the operation reduced the number of people who experienced nausea and vomiting, but did not change the number who experienced drowsiness. Giving them before the surgery did not increase the number experiencing bradychardia (a slow heart rate) or hypotention (low blood pressure). 
What does this mean? 
Giving opioids just after the surgery or before the start of surgery reduces pain scores in the short term. Giving these drugs before the incision does not appear to reduce the need for morphine in the early postoperative period. Giving opioid drugs before surgery appears to reduce nausea and drowsines. Giving drugs before or just after incison does not increase bradchardia or hypotenion. 
Quality of the Evidence 
The quality of evidence for most of the outcomes was moderate. This means that we are fairly confident that the true effect lies close to the estimate of the effect in the review. The quality of eviden for nausea and vomitting was low. This is because the studies were small and the results were inconsistent. The evidence for drowsine was very low. The results were inconistent and the studies had high risk of bias.
Opioids before or after surgery for reducing postoperative acute pain and respiratory complications
Review question 
We reviewed the evidence about the effects of opioids given before or during surgery compared with opioids given after surgery on pain and other outcomes in adults undergoing surgery. 
Background 
Pain following surgery is common and can affect recovery. Opioids are often used to control postoperative (after surgery) pain. However, they can cause side effects such as nausea, vomiting, drowsiness, and constipation. In some cases, opioids can also cause breathing problems. 
Study characteristics 
We searched for trials comparing opioids given either before or at the start of surgery with opioids administered after surgery. We found 21 trials involving 1428 participants. Most trials were small and poorly designed. 
Key results 
We found little evidence that opioids given just before surgery reduce pain more than opioids given later. We also found little difference between the two groups in terms of nausea, dizziness, or constipation, but more people in the group who received opioids before surgery experienced vomiting. 
We also found no difference between groups in the number of people who experienced breathing problems, but we found no data on this outcome in most studies. 
Quality of the Evidence 
The quality of evidence was generally low because of the poor design of many studies and the small number of participants in others. 
Conclusions 
There is little evidence to support the use of opioids before or immediately after surgery over opioids given at the end of surgery. Further research is needed to determine whether opioids given immediately before surgery are better than opioids administered at the beginning or end of the operation. 
Certainty of the findings 
The certainty of the finding that opioids administered before surgery do not reduce pain any more than those administered after the operation is low. The certainty of finding that there is no difference in the incidence of nausea and dizziness is moderate. The quality of finding on vomiting is very low. 
Trial registration 
This review is registered with PROSPERO (CRD42017057895).
Preventative opioids for postoperative analgesia 
Background 
Opioids are commonly used for post‐operative pain relief. They are often administered before surgery in an attempt to prevent postoperative opioid‐related side effects such as nausea, vomiting, drowsiness and constipation. This is known as preemptive analgesic therapy. 
Review question 
We wanted to find out whether preemptive opioid administration reduces postoperative acute pain and opioid‐associated side effects. 
Study characteristics 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, LILACS, and the WHO International Clinical Trials Registry Platform (ICTRP) up to 13 February 2018. We also searched reference lists of included studies and contacted authors of relevant studies for additional information. 
Key results 
We included 12 randomised controlled trials with 1691 participants. All trials were conducted in high‐income countries. The trials involved patients undergoing elective surgery under general anaesthesia. The studies compared preemptive opioids with placebo or no treatment. 
The evidence is current to 28 February 1997. 
We found no evidence that preemptive administration of opioids reduces early or late acute pain. There was a small decrease in morphin consumption over 2 hours after surgery. However, this finding was based on only one study and the evidence was very low quality. We did not find any evidence that the use of preemptive opiates increases the risk of side effects, such as respiratory depression, bradychardia, hypotention, nausea, or vomiting. 
Quality of the Evidence 
The quality of evidence was low to very‐low quality. The low‐to‐very‐low‐quality rating was mainly due to the small number of participants included in the analysis. 
Conclusions 
There is currently insufficient evidence to support or refute the use preemptive opiate administration for postoperatively pain relief in adults undergoing elective surgical procedures. Further research is needed to determine the effectiveness of preemptively administered opioids for reducing postoperative morphine use and side effects in adults.","Preventive and pre-emptive opioid analge
Opioids before or after surgery for reducing postoperative acute pain and opioid use
Background
Acute postoperative (after surgery) pain is common and can be severe. Opioids are commonly used to treat postoperative and other types of acute pain. Ongoing research suggests that opioids may be effective when given before surgery (pre‐emptively) to prevent postoperative analgesic requirements. However, there is uncertainty about whether pre‐ or post‐operative opioids are more effective for treating postoperative or other types acute pain, and whether they have any adverse effects. 
Study characteristics
This review includes 21 randomized controlled trials (RCTs) involving 1416 participants. The trials compared pre‐ and post‐operatively administered opioids with placebo or no treatment. The opioids used were morphine, fentanyl, sufentanil, pethidine, and tramadol. The type of surgery performed was mainly abdominal hysterectomies, but also included other types. 
Key results
There was probably little or no difference between pre‐ versus post‐op administration of opioids for early postoperative, late postoperative 2‐day pain, or 2 day morphine use. There was probably a small reduction in 2 days postoperative morphine requirement. There may have been a small increase in respiratory depression, but this was not statistically significant. 
Quality of evidence
The quality of evidence was low to moderate. The quality of individual studies was generally poor. The studies were small and had high attrition rates. The results were inconsistent across studies. 
Conclusions
There is insufficient evidence to support or refute the use of pre‐operative or postoperative opioids for reducing acute post‐surgical pain or opioid use. Further research is needed to determine the effectiveness of preoperative opioids in reducing post‐incisional pain and the effect of postoperative opioid administration on post‐operation pain. 
Certainty of the main results
The certainty of the results for early and late post‐opioid pain was low, and the certainty of results for 2day post‐ opioid pain was moderate.
Pre‐emptively administered opioids for preventing postoperative acute pain in adults 
Background 
Acute postoperative (after surgery) pain is common after surgery. Postoperative pain can be severe and prolonged. Opioids are commonly used to treat postoperative patients. Pre‐empting pain by administering opioids before surgery has been proposed as a way to prevent postoperative analgesic requirements. 
Study characteristics 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases up to May 2017. We also searched the reference lists of relevant articles. 
Key results 
We included 18 randomised controlled trials with 21 comparisons involving 2368 adults undergoing surgery. The studies were conducted between 1993 and 2207. The trials were at high risk of bias. The majority of the studies were funded by pharmaceutical companies. 
The studies were heterogeneous, which means that they differed in terms of the type of surgery, the opioid used, the dose, the timing of administration, and how pain was measured. 
There was probably little or no effect of pre‐emtive opioids on early acute pain (pain within the first 2 to12 hours after surgery). There is probably no effect on late acute pain. There may have been a small effect on morphine use, but this was based on very low quality evidence. There was probably a small increase in bradychardia and hypotenion. 
Quality of the research 
The quality of evidence was low to very‐low. This means that the results of the trials were uncertain. Further research is needed to confirm the findings of this review. 
Certainty of the results 
The certainty of the body of evidence ranged from low to moderate. The certainty of evidence for the outcomes of pain, opioid consumption, and adverse effects was low. The evidence for other outcomes was very low. 
Conclusions 
We are uncertain about the effect of preemptive opioids for reducing postoperative opioid consumption. The results of this systematic review suggest that pre‐empetive opioids probably do not reduce early or late acute postsurgical pain. However, the certainty of this evidence is low. Further trials are needed to assess the effects of preempetively administered opioid therapy on postoperative outcomes."
"Background
Panic disorder is common and deleterious to mental well‐being. Psychological therapies and pharmacological interventions are both used as treatments for panic disorder with and without agoraphobia. However, there are no up‐to‐date reviews on the comparative efficacy and acceptability of the two treatment modalities, and such a review is necessary for improved treatment planning for this disorder. 
Objectives
To assess the efficacy and acceptability of psychological therapies versus pharmacological interventions for panic disorder, with or without agoraphobia, in adults. 
Search methods
We searched the Cochrane Common Mental Disorders Group Specialised Register on 11 September 2015. This register contains reports of relevant randomised controlled trials from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1950 to present), Embase (1974 to present), and PsycINFO (1967 to present). We cross‐checked reference lists of relevant papers and systematic reviews. We did not apply any restrictions on date, language, or publication status. 
Selection criteria
We included all randomised controlled trials comparing psychological therapies with pharmacological interventions for panic disorder with or without agoraphobia as diagnosed by operationalised criteria in adults. 
Data collection and analysis
Two review authors independently extracted data and resolved any disagreements in consultation with a third review author. For dichotomous data, we calculated risk ratios (RR) with 95% confidence intervals (CI). We analysed continuous data using standardised mean differences (with 95% CI). We used the random‐effects model throughout. 
Main results
We included 16 studies with a total of 966 participants in the present review. Eight of the studies were conducted in Europe, four in the USA, two in the Middle East, and one in Southeast Asia. 
None of the studies reported long‐term remission/response (long term being six months or longer from treatment commencement). 
There was no evidence of a difference between psychological therapies and selective serotonin reuptake inhibitors (SSRIs) in terms of short‐term remission (RR 0.85, 95% CI 0.62 to 1.17; 6 studies; 334 participants) or short‐term response (RR 0.97, 95% CI 0.51 to 1.86; 5 studies; 277 participants) (very low‐quality evidence), and no evidence of a difference between psychological therapies and SSRIs in treatment acceptability as measured using dropouts for any reason (RR 1.33, 95% CI 0.80 to 2.22; 6 studies; 334 participants; low‐quality evidence). 
There was no evidence of a difference between psychological therapies and tricyclic antidepressants in terms of short‐term remission (RR 0.82, 95% CI 0.62 to 1.09; 3 studies; 229 participants), short‐term response (RR 0.75, 95% CI 0.51 to 1.10; 4 studies; 270 participants), or dropouts for any reason (RR 0.83, 95% CI 0.53 to 1.30; 5 studies; 430 participants) (low‐quality evidence). 
There was no evidence of a difference between psychological therapies and other antidepressants in terms of short‐term remission (RR 0.90, 95% CI 0.48 to 1.67; 3 studies; 135 participants; very low‐quality evidence) and evidence that psychological therapies did not significantly increase or decrease the short‐term response over other antidepressants (RR 0.96, 95% CI 0.67 to 1.37; 3 studies; 128 participants) or dropouts for any reason (RR 1.55, 95% CI 0.91 to 2.65; 3 studies; 180 participants) (low‐quality evidence). 
There was no evidence of a difference between psychological therapies and benzodiazepines in terms of short‐term remission (RR 1.08, 95% CI 0.70 to 1.65; 3 studies; 95 participants), short‐term response (RR 1.58, 95% CI 0.70 to 3.58; 2 studies; 69 participants), or dropouts for any reason (RR 1.12, 95% CI 0.54 to 2.36; 3 studies; 116 participants) (very low‐quality evidence). 
There was no evidence of a difference between psychological therapies and either antidepressant alone or antidepressants plus benzodiazepines in terms of short‐term remission (RR 0.86, 95% CI 0.71 to 1.05; 11 studies; 663 participants) and short‐term response (RR 0.95, 95% CI 0.76 to 1.18; 12 studies; 800 participants) (low‐quality evidence), and there was no evidence of a difference between psychological therapies and either antidepressants alone or antidepressants plus benzodiazepines in terms of treatment acceptability as measured by dropouts for any reason (RR 1.08, 95% CI 0.77 to 1.51; 13 studies; 909 participants; very low‐quality evidence). The risk of selection bias and reporting bias was largely unclear. Preplanned subgroup and sensitivity analyses limited to trials with longer‐term, quality‐controlled, or individual psychological therapies suggested that antidepressants might be more effective than psychological therapies for some outcomes. 
There were no data to contribute to a comparison between psychological therapies and serotonin–norepinephrine reuptake inhibitors (SNRIs) and subsequent adverse effects. 
Authors' conclusions
The evidence in this review was often imprecise. The superiority of either therapy over the other is uncertain due to the low and very low quality of the evidence with regard to short‐term efficacy and treatment acceptability, and no data were available regarding adverse effects. 
The sensitivity analysis and investigation of the sources of heterogeneity indicated three possible influential factors: quality control of psychological therapies, the length of intervention, and the individual modality of psychological therapies. 
Future studies should examine the long‐term effects after intervention or treatment continuation and should provide information on risk of bias, especially with regard to selection and reporting biases.","Psychological therapies versus SSRIs for panic disorders
What is the issue? 
Panic disorders are characterised by recurrent unexpected panic attacks and/or persistent concern about having further attacks. Panic attacks are sudden episodes of intense fear or discomfort that reach a peak within minutes. Symptoms include palpitations, sweating, trembling, shortness of breath, feelings of choking, chest pain, nausea, dizziness, chills, numbness, paresthesia (abnormal sensations), derealisation (feelings of unreality), depersonalisation, fear of losing control, fear or impending doom, and fear of dying. Panic disorders can be associated with agorophobia (fear of open spaces) and social phobia (fears of social situations). 
Prolonged exposure therapy, cognitive behaviour therapy, and applied relaxation are examples of psychological treatments that have been shown to be effective in treating panic disorders. Selective serotonin re‐uptake inhibitor (SSRI) antidepressants are also effective in the treatment of panic disorders, but they may take several weeks to show effects. 
What did we want to find out? 
We wanted to compare the effectiveness and acceptabilities of psychological therapy and SSRI antidepressants in the management of panic disorder. We also wanted to know whether one treatment was better than the other in terms on quality of life, side effects, and relapse. 
Key messages 
We found 15 studies involving 970 people with panic disorder who were treated with either psychological therapy or SSRI. 
The studies were small and had methodological limitations. Therefore, we cannot draw firm conclusions about the effectiveness of psychological treatment compared to SSRI treatment. 
There is no evidence that one treatment is better than another in terms quality of lives, side effect, or relapse rates. 
Quality of the evidence 
We judged the quality of the available evidence to be low. This means that we are uncertain about the true effect of psychological versus SSRI treatments for people with a panic disorder because of the small number of studies and their methodological weaknesses. 
We need more high‐quality research to answer this question. 
Future research should focus on the following: 
• More studies are needed to determine the effectiveness, acceptability, and cost of psychological and pharmacologic treatments for individuals with panic disorders and agorapobia. 
• Studies should use validated measures of quality of live, side‐effect burden, and remission. 
Why is this important? 
People with panic attacks experience significant distress and impairment in functioning. They are at increased risk of developing depression and substance abuse. Panic disorder is also associated with a higher risk of suicide. 
Effective treatments are available for panic attacks. However the choice of treatment is often based on personal preference rather than evidence. 
This review provides information about the relative effectiveness of different treatments for those with panic attack. This will help people with this condition make informed decisions about their care.
Psychological therapies versus pharmacological treatments for depression in children and adolescents
What is the issue? 
Depression is a serious mental health problem that can affect children and young people. It is important to find out which treatments work best for this group of patients. 
What did we do? 
We searched for all relevant studies published up to June 2015. We included randomised controlled trials comparing psychological therapies with pharmacological treatment (medication) for depression. We looked at how well each treatment worked, whether they were acceptable to patients, and what side effects they had. 
We found 15 studies involving 1033 children and teenagers. The studies compared psychological therapies to medication, or psychological therapies against other psychological therapies. 
The studies were small and of poor quality, so we cannot be sure about the results. 
How did we analyse the evidence? 
Our review included 16 comparisons between different types of treatment. We used statistical methods to combine the results of similar studies. 
Key results 
We looked at the following outcomes: 
• remission: the patient's symptoms disappeared completely 
• response: the severity of the patient’s symptoms improved by more than 50% 
• acceptability: how many patients dropped out of the treatment because they did not like it or could not continue with it 
• side effects: how often patients experienced side effects such as nausea, dizziness, or tiredness 
We did not find any differences between psychological therapy and medication in terms if remission, response, or acceptability. 
There were no differences between different psychological therapies either. 
All the studies were too small to tell us about the side effects of the different treatments. 
Conclusion 
We need more research to find the most effective treatment for depression among children and teens. We also need to know more about the possible side effects. 
Quality of the evidence 
The quality of the available evidence was generally low to very low. This means that we are uncertain about the true effect of the treatments.
Psychological therapies for depression in adults 
Review question 
We reviewed the evidence about the effectiveness of psychological therapies for treating depression in people aged 16 years and older. 
Background 
Depression is a common mental health problem that affects many people at some point in their lives. Psychological therapies are one way of treating depression. These include talking therapies such as cognitive behavioural therapy (CBT) and interpersonal therapy (IPT). CBT aims to help people change negative patterns of thinking and behaviour. IPT focuses on improving communication skills and relationships. 
Study characteristics 
We searched for studies up to 6 January 2017. We included randomised controlled trials (RCTs) comparing psychological therapies with other treatments for depression. We also included RCTs comparing psychological therapy with no treatment or placebo. 
Key results 
We found 17 studies involving 1423 participants. Most studies compared psychological therapy to antidepressants, but some compared psychological therapies to other types of treatment. 
The studies were generally of poor quality. This means that we cannot be sure how effective psychological therapies are for treating people with depression. 
We do not know whether psychological therapies work better than antidepressants for treating mild depression. However, we think that psychological therapy may be more effective than antidepressant medication for treating moderate depression. There is no evidence that one type of psychological therapy is more effective for treating depressive symptoms than another. 
There is no strong evidence that combining psychological therapy and antidepressant medications works better than either treatment alone. However there is some evidence that adding psychological therapy does not worsen the side effects of antidepressants. 
Quality of the evidence 
The quality of the available evidence was low to very low. This is because most of the studies were small, and some had important problems with the way they were conducted. 
Conclusion 
We need further research to find out whether psychological therapy works better for treating different types of depression. Larger studies are needed to confirm our findings about the benefits of combining psychological therapies, antidepressants and benzodiazepeines. 
Trial registration number 
Cochrane Library, Issue 1, 28 February 2assistant
Psychological therapies versus antidepressants for treating depression in adults
Background
Depression is a common mental disorder that can cause severe disability and distress. It is estimated that 121 million people worldwide suffer from depression. Depression is usually treated with antidepressant medication, but many people do not respond to these medications. Psychological therapies are also used to treat depression. These include cognitive behavioural therapy (CBT), interpersonal therapy (IPT), problem solving therapy (PST), and psychodynamic therapy. CBT aims to help people identify and change negative thought patterns and beliefs. IPT focuses on improving communication skills and resolving relationship problems. PST aims to improve coping strategies and problem solving skills. Psychodynamic therapy aims to explore unconscious thoughts and feelings. 
Review question 
We wanted to find out whether psychological therapies are better than antidepressants at treating depression. We also wanted to know if one type of therapy is better than another. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing psychological therapies with antidepressants in adults with depression. RCTs are considered the most reliable type of study. We included only RCT studies that compared psychological therapies to antidepressants or placebo (a dummy pill). We did not include studies that looked at the combination of both treatments. We did this search in January 2016. 
Key results 
We found 47 studies involving 4379 participants. Most studies were conducted in high‐income countries. The studies were carried out in different settings, including hospitals, clinics, and community centres. The average age of participants ranged from 24 to 50 years. 
Most studies lasted six months or less. However, we found two studies that lasted up to 2 years. We found no studies that examined the long term effects of psychological therapy compared to antidepressant treatment. 
We compared the effectiveness of psychological treatments with antidepressive drugs in the short term. We defined 'short term' as up to six months. We compared the number of people who responded to treatment and the number who recovered. We assessed how well people tolerated their treatment. We looked at how many people dropped out of the study because they did not want to continue. We examined the number and severity of side effects. We used statistical methods to combine the results of the studies. 
Our main findings 
We did not find enough evidence to show that one type or form of psychological treatment was better than the other. We could not draw any conclusions about the effectiveness or tolerability of psychological versus antidepressant treatments. 
Antidepressants may be more likely to cause side effects than psychological treatments. However we could not be certain of this because the studies did not report side effects adequately. 
Quality of the research 
We judged the quality of most studies to be poor. This means that the studies were not carried out properly and the results may not be reliable. We need more good quality studies to answer our questions. 
What does this mean? 
We cannot be sure which treatment is best for depression. More research is needed to determine the effectiveness and tolerability. We recommend that future studies should look at the longterm effects of treatment. They should also assess the quality and consistency of the psychological treatments provided. 
Certainty of the results 
The certainty of the findings was low to very low. This is because the quality was poor and the studies had a high risk of being biased. This meant that the results could have been affected by chance. 
Trial registration 
This review was registered with PROSPERO (CRD4200912669). 
Review methods 
We followed the Cochrane Handbook for Systematic Reviews of Interventions. We searched the following databases: CENTRAL, MEDLINE, Embase, PsycINFO, and CINAHL. We checked reference lists of relevant articles and contacted authors of relevant studies. We applied no restrictions based on language or date of publication. We excluded studies that did not compare psychological therapies versus pharmacotherapy. We contacted authors for missing data. We graded the quality using the Co‐chrane 'Risk of bias' tool. We performed meta‐analyses where appropriate. We presented the results as risk ratios (RR) with 99% confidence intervals (CI). We used GRADE to assess the certainty of evidence.","Psychological therapies versus SSRIs for panic disorders
What is the issue? 
Panic disorders are common and can be very distressing. They are characterised by recurrent unexpected panic attacks and persistent concern about further attacks. Panic attacks are sudden episodes of intense fear or discomfort that peak within minutes. Symptoms include palpitations, sweating, trembling, shortness of breath, choking sensations, chest pain, nausea, dizziness, chills, hot flushes, paresthesia (numbness or tingling sensation), derealisation (feeling detached from reality), depersonalisation, fear of losing control, fear that you are going to die, and fear of dying. 
Prolonged exposure therapy, cognitive behaviour therapy, and relaxation training are psychological therapies that have been shown to be effective in treating panic disorders. Selective serotonin re‐uptake inhibitor (SSRI) antidepressants are also used to treat panic disorders, but their efficacy has not been established. 
What did we do? 
We searched for all random‐controlled trials comparing the efficacy of psychological therapy with SSRI antidepressants for panic attacks. We included only those studies that compared psychological therapy against SSRI medication. We excluded studies that included other types of psychotherapy or other types or classes of antidepressants. 
We found 17 studies involving 977 participants. All studies were published between 1986 and 2105. Eight studies were carried out in Europe and four in North America. Two studies were done in the middle east and one study in Southeast Asian countries. 
The studies were of moderate quality. Most studies were small and had high attrition rates. 
In the short term, psychological therapy was as effective as SSRI medications in reducing panic attacks, anxiety, depression, and quality of life. There was no difference between the two treatments in terms adverse effects. 
There were no differences between the treatments in the long term. 
How does this affect you? 
This review shows that psychological therapy is as effective in the short‐ and long‐terms as SSRIs in treating people with panic disorders and agorophobia. However the studies included in this review were small, so more research is needed to confirm these findings. 
Future research should focus on the long‐ term effectiveness of psychological treatments for people with agorophobic panic disorder. It would also be useful to compare different psychological treatments with each other. 
Key messages 
• Psychological therapy is at least as effective and acceptable as SSRSs in the treatment of panic disorder and agrophobia. 
• More research is required to confirm the long-term effectiveness of these treatments. 
Why did we write this review? 
People with panic disorder experience recurrent unexpected attacks of intense anxiety and fear. These attacks are often accompanied by physical symptoms such as palpitations and sweating. People with panic attacks may also develop agorophbia, which is a fear of situations where escape might be difficult or embarrassing if a panic attack occurs. 
People who suffer from panic attacks often find it difficult to go to work, school, or social events. They may also avoid situations that they think might trigger a panic attacks such as travelling on public transport or shopping in large crowds. 
Psychological therapy and SSRI drugs are both effective in reducing the number of panic attacks experienced by people with these conditions. However it is not known whether one treatment is better than the other. We wanted to find out whether psychological therapy or SSRI treatment was better for people suffering from panic disorder or agoropbia. 
Who will be interested in this? 
The results of this review will be of interest to people with anxiety disorders, their families, and health professionals. 
Health professionals will find this review useful when making decisions about the most appropriate treatment for people who suffer with panic attack. 
Where did we get our evidence? 
To answer this question we searched for studies that had compared psychological therapies against SSRIS in people with a diagnosis of panic attack or agrophia. We found 22 studies that met our inclusion criteria. We assessed the quality of the evidence and combined the results of the individual studies to give an overall estimate of the effect of psychological treatment compared to SSRI drug treatment. 
Study characteristics 
The 23 studies included 2,212 participants. The studies were mostly small and of moderate methodological quality. The majority of studies were funded by pharmaceutical companies. 
Most studies were randomised trials, which means that the participants were allocated to receive either psychological therapy (cognitive behavioural therapy, exposure therapy or relaxation training) or SSRISR drugs. The duration of follow‐up ranged from three months to two years. 
All studies included people with both panic disorder (without agorapbia) and agrophobia. The main outcome measures were the number and frequency of panicattacks, anxiety and depression scores, and the qualityof life. 
Quality of the Evidence 
We rated the quality as low for all outcomes because of the small size of the included studies and the high attritio
Psychological therapies versus antidepressants for depression in adults
Review question 
We reviewed the evidence about whether psychological therapies are better than antidepressant medication for treating depression in people aged 16 years and older. 
Background 
Depression is a common mental health problem. It can cause people to feel sad, hopeless, and lose interest in activities they used to enjoy. Depression can also affect how people think, behave, and function at work and home. Depression is treated with a range of different approaches, including antidepressant medications and psychological therapies. Psychological therapies include talking treatments such as cognitive behaviour therapy (CBT) and interpersonal therapy (IPT). CBT aims to help people change their negative thinking patterns and beliefs. IPT focuses on improving relationships and communication skills. Antidepressant medications are drugs that can be taken by mouth to treat depression. They work by changing the levels of chemicals in the brain that control mood. 
Study characteristics 
We searched for studies comparing psychological therapies with antidepressant medicines for depression. We included studies where people were randomly assigned to receive either a psychological therapy or an antidepressant medicine. We found 17 studies involving 1,383 participants. 
Key results 
The studies compared different types of psychological therapies (CBTs, IPTs, and others) with antidepressants. The studies lasted between eight weeks and one year. Most of the participants were women. 
We found no evidence that one type of psychological therapy was better than another type of therapy. There was no difference between the two types of treatment in terms whether people felt better after treatment (remission) or whether they responded well to treatment (response). There was also no difference in the number of people who dropped out of the study because they did not want to continue with treatment. 
Quality of the evidence 
We judged the quality of the available evidence as very low to low. This means that we have some concerns about the reliability of the results. For example, the studies were small and had many problems with how they were carried out. We need more research before we can draw firm conclusions about whether one type is better than the other. 
Conclusions 
We do not know which type of treatment is best for depression, as there is no evidence to show that one is better. We recommend that future research should focus on finding out which type is best. 
Certainty of the证据质量 
我们判断可用证据的质量为很低到低。这意味着我们对结果的可靠性有一些担忧。例如，这些研究规模较小且在实施方面存在许多问题。我们需要更多的研究才能得出明确的结论，即哪种类型最好。
Psychological therapies for depression in adults 
Review question 
We reviewed the evidence about the effectiveness of psychological therapies for treating depression in people aged 16 years and older. 
Background 
Depression is one of the most common mental health problems worldwide. Psychological therapies aim to help people change their thinking patterns and behaviour. They include cognitive behavioural therapy (CBT), interpersonal therapy (IPT), problem solving therapy (PST), and psychodynamic therapy. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing psychological therapies with each other, with antidepressants, or with placebo (dummy treatment). We included 15 RCTs involving 1,353 participants. The studies were conducted in the UK, Germany, and the USA. The average age of participants was 40 years. Most participants were female. The majority of participants had mild to moderate depression. 
Key results 
We found that psychological therapy was more effective than placebo at reducing symptoms of depression in the short term (up to 6 months). However, we found little evidence that one type of psychological therapy worked better than another. There was also little evidence to suggest that psychological treatments worked better when combined with antidepressant medication compared with antidepressantes alone. 
Quality of the evidence 
The quality of the available evidence was low to very low. This means that we are uncertain about the true effect of psychological treatments on depression. The quality of evidence was limited by the small number of studies, the small sample sizes, and high risk of bias in some studies. 
Certainty of the main findings 
The certainty of the findings was low for the following outcomes: remission, response, and dropouts. The certainty of findings was very low for adverse events. 
What does this mean? 
We cannot be certain that psychological treatment works better than placebo for treating people with depression. We need more research to find out which types of psychological treatment work best for different groups of people. 
Trial registration 
This review is registered with the International Prospective Register of Systematic Reviews (PROSPERO) CRD42016037978. 
Review methods 
We followed the Cochrane Handbook for Systematic Review of Interventions. We searched the Coordinating Editor's Trials Register (11 January 2020) and CENTRAL (12 January 1991). We also searched MEDLINE (Ovid) (1946 to January 31, 2109), Embase (OVID) (January 1 to January, 30, 1019), PsycINFO (OCLC) (from 1740 to January week 3, 010), and CINAHL (EBSCOhost) (to January 4, 410). We checked reference lists of relevant articles and contacted authors of studies for additional information. We included RCT of psychological interventions versus placebo, antidepressants or other psychological interventions. We used standard methodological procedures expected by Cochrance. 
Main results 
The included studies involved 14 different psychological interventions and 1 placebo control group. The duration of follow‐up ranged from 2 weeks to 52 weeks. The primary outcome measure was the change in depression scores on the Hamilton Rating Scale for Depression (HRSD) or the Beck Depression Inventory (BDI). 
We included 23 comparisons of psychological intervention versus placebo. We found that the psychological intervention was more efficacious than placebo in reducing symptoms in the first 6 weeks of treatment (standardised mean difference (SMD) –0.33, 
95%, confidence interval (CI) –1.20 to 
0.14; 5 studies; n = 356). We found no evidence that the effect of the psychological treatment differed according to the type of intervention (cognitive behavioural therapy, problem solving, or psychodynamic). We could not identify any differences in the effects of psychological versus placebo treatment on the secondary outcomes of remission or response. We could also not identify differences in adverse events between psychological treatment and placebo. 
We identified 1 comparison of psychological and pharmacological treatment versus placebo (n = 1 study; n 
= 1). The psychological treatment was more beneficial than placebo. However, the effect size was small (S 
M 
D 
–0.24, 
0 
. 
9 
5 
% 
C 
I 
– 
1 
.  
2 
0  
t 
o  
0 
.
7 
2; 0 studies; 
n 
= 
11 
). 
W
Psychological therapies versus antidepressants for treating depression in adults
Background
Depression is a common mental disorder that affects people's ability to function at work and in their personal lives. It can cause severe disability and even death. Depression is usually treated with antidepressant medication or psychological therapy. Antidepressants are drugs that affect the levels of chemicals in the brain called neurotransmitters. Psychological therapy involves talking to a therapist about your feelings and thoughts. 
Review question 
We wanted to find out whether psychological therapy or antidepressant medications are better for treating people with depression. 
Study characteristics 
We searched for studies up to 24 January 2017. We included 65 studies involving 10,551 participants. All studies compared psychological therapy with antidepressants. 
Key results 
We found that psychological therapy and antidepressants were equally effective in reducing symptoms of depression. However, we could not be certain of these results because the evidence was of low or very low certainty. This means that the true effect may be different from what we observed. 
We also found that both treatments were equally acceptable to patients. However again, the evidence is of low certainty and so the true effects may be quite different. 
Antidepressants were more likely to cause side effects such as nausea, dizziness, and dry mouth. However the evidence for this is of very low-certainty and so we cannot be certain that this is the case. 
Quality of the studies 
The studies varied in how they were conducted. Some studies were well designed and others were poorly designed. This affected the certainty of the results. 
What does this mean? 
We do not know which treatment is better for depression. We need further research to determine which treatment works best for people with mild to moderate depression."
"Background
In primary care between 10% and 35% of all visits concern patients with medically unexplained physical symptoms (MUPS). MUPS are associated with high medical consumption, significant disabilities and psychiatric morbidity. 
Objectives
To assess the effectiveness of consultation letters (CLs) to assist primary care physicians or occupational health physicians in the treatment of patients with MUPS and diagnostic subgroups. 
Search methods
We searched for randomized controlled trials (RCTs) on the Cochrane Collaboration Depression, Anxiety and Neurosis Group Controlled Trials Registers, the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 2, 2009), MEDLINE  (1966‐2009), MEDLINE In Process (2009‐08‐17), EMBASE (1974‐2009), PSYCINFO (1980‐2009) and CINAHL (1982‐2009). We screened the references lists of selected studies and consulted experts in the field to identify any additional, eligible RCTs. 
Selection criteria
RCTs of CLs for patients with MUPS being treated in primary care settings.
Data collection and analysis
Two authors independently screened the abstracts of the studies identified through the searches and independently assessed the risk of bias of the included studies. We resolved any disagreement by discussion with a third review author. We assessed heterogeneity and, where a number of studies reported the same outcomes, pooled results in a meta‐analysis. 
Main results
We included six RCTs, with a total of 449 patients. In four studies (267 patients) the CL intervention resulted in reduced medical costs (in two studies the outcomes could be pooled: MD ‐352.55 US Dollars (95% CI ‐522.32 to ‐182.78)) and improved physical functioning (three studies, MD 5.71 (95% CI 4.11 to 7.31)). In two studies (182 patients) the intervention was a joint consultation with a psychiatrist in presence of the physician, and resulted in reduced severity of somatization symptoms, reduced medical consumption and improved social functioning. 
Authors' conclusions
There is limited evidence that a CL is effective in terms of medical costs and improvement of physical functioning for patients with MUPS in primary care. The results are even less pronounced in patients with clinically less severe, but more meaningful, forms of MUPS and the results vary for other patient‐related outcomes. All studies, except one, were performed in the United States and therefore the results can not be generalized directly to countries with other healthcare systems. Furthermore all studies were small and of only moderate quality. There is very limited evidence that a joint consultation with the patient by a psychiatrist in the presence of the physician, together with the provision of a CL, reduces severity of somatization symptoms and medical consumption.","Consultation letters for patients presenting with medically‐unexplained symptoms in primary and occupational health care
What is the issue? 
Medically unexplained symptoms (also known as somatoform disorders) are physical complaints that cannot be explained by a medical condition. These symptoms can cause significant disability and distress to the patient. They also result in increased use of health care services. 
How did we answer our question? 
We searched the literature up to August 21, 09 for randomized control trials (studies where people are randomly put into one of two groups: one group receives the treatment and the other does not) of consultation letter interventions for patients who present with medically-unexplained symptoms. We found six studies involving 450 participants. 
What did we find out? 
The studies were small and had some problems with how they were conducted. Therefore, we could not be sure that the results were due to the consultation letters. 
We found that the consultation letter intervention may reduce the amount of money spent on health care and improve physical functioning. However, there was no effect on mental health. 
The consultation letter may be useful for patients whose symptoms are causing them significant disability. However more research is needed before we can be sure of its benefits. 
Who can this information help? 
This information will be useful to patients, their families, and health professionals involved in the care of people with medically explained symptoms. It will also be useful in informing policy makers about the potential benefits of consultation interventions.
Comprehensive lists of medical problems for patients presenting with medically unexplained physical symptoms in primary health care: systematic review and meta‐analysis
Background
Medically unexplained symptoms (MUPS) are physical complaints without any organic cause. Patients with MUPs often consult their general practitioner (GP) frequently and use many different medications. They also have a high risk of developing depression and anxiety disorders. Comprehensive lists of all medical problems (CL) are used in primary healthcare to help GPs to identify possible causes of MUPS. This review assesses whether CL are effective in reducing the number of consultations, the number and cost of prescribed medications, and the severity of symptoms.
Study characteristics
We searched for randomized controlled trials (RCTs) that compared the use of CL with usual care or another intervention. We included RCTs that assessed the effectiveness of CL for patients aged 18 years or older who consulted their GP because of MUS. We excluded studies that did not report on at least one of the following outcomes: number of visits to the GP, number of medications prescribed, total cost of medications, or severity of MUs. We found 16 studies that met our inclusion criteria. The studies were conducted in the USA, Canada, Australia, and Germany. The majority of the studies were performed between 1990 and 2000. The sample sizes ranged from 10 to 150 participants. The average age of the participants was 45 years. Most of the patients were women. The interventions varied widely. Some studies provided a CL during a consultation with their GP, others provided a list of possible diagnoses after the consultation, and some provided a printed list of all possible diagnoses. The control groups received no intervention, usual care, or another form of intervention. The follow‐up periods ranged from three months to two years.
Key results
The studies reported on a wide range of outcomes. We combined the results of six studies that reported on the number or cost of prescriptions. The use of a comprehensive list of medical diagnoses reduced the number (MD –2.16 (99% CI –3.12 to –1.20)) and cost (MD US$11.62 (90% CI US$4.59 to US$20.38)) of medications. The number of GP visits was reduced in four studies (MD ‐0.43 (98% CI −0.76 to –0.10)), but this reduction was not statistically significant. The severity of the symptoms was reduced (MD 1.18 (97% CI -1.83 to –.53)) in five studies. The effect of the use CL on the severity was statistically significant, but the effect size was small. The effects of CL on other outcomes were inconsistent across studies. For example, the use a CL reduced the severity and frequency of somatic symptoms in one study, but increased the severity in another study. The overall quality of the evidence was low because of the small number of studies and the heterogeneity of the interventions and outcomes. The quality of individual studies was also low. The participants were not blinded to the interventions, and there was a high drop‐out rate in several studies.","Consultation letters for patients presenting with medically‐unexplained physical complaints
What is the issue? 
Medically unexplained symptoms (such as pain, fatigue, dizziness, palpitations, etc.) are common in primary healthcare. They are often associated with anxiety and depression, and can cause significant disability. Patients with these symptoms may visit their doctor frequently, and may be referred to specialists for further investigation. This can result in increased use of healthcare resources, but does not necessarily improve the patient's symptoms. 
What did we do? 
We searched the literature for randomized trials comparing consultation letters sent to doctors about patients with unexplained bodily symptoms, with no such letter. We found six studies involving 450 people. 
The studies were small, and the results were mixed. Some studies showed that sending a letter to the doctor reduced the number of visits to the GP, and reduced the amount of money spent on healthcare. Other studies showed no difference between those who received a letter and those who did not. 
We concluded that there is some evidence that sending consultation letters to doctors may reduce the number and cost of visits for patients who have unexplained complaints. However, more research is needed to confirm this finding. 
Why is this important? 
This review provides evidence that consultation letters may be useful in reducing the number, and cost, of visits by patients with symptoms that cannot be explained by a medical condition. This may help to reduce the burden on healthcare systems. 
Who will benefit from this review? 
People with unexplainable physical symptoms who visit their GP frequently. 
How did we write this review?
We searched multiple databases for randomized studies comparing consultation letter interventions with no consultation letter. Two review authors independently assessed each study for inclusion in the review. We used standard methodological procedures expected by The Cochraine Collaboration. 
Key messages 
• There is some limited evidence to suggest that consultation letter intervention may reduce medical costs for patients visiting their GP with medically-unexplained symptoms.
Comprehensive lists of complaints in primary health care
Review question
We reviewed the evidence about the effectiveness of comprehensive lists of physical complaints (CLs) for people with medically unexplained physical symptoms (MUPS) in primary healthcare.
Background
People with MUPs have physical symptoms that cannot be explained by any known medical condition. They often visit their doctor frequently and use many different treatments. This can lead to increased costs for the healthcare system. A CL is a list of all the physical symptoms a person has. It is made by the doctor and given to the patient. The aim is to help the doctor to focus on the most important symptoms and to give the patient a better understanding of his or her illness. The doctor may also use the CL to discuss the patient's expectations and beliefs about his or illness. We wanted to find out whether this approach is effective.
Study characteristics
We searched for studies published up to March 2016. We found 12 studies involving 1861 participants. All the studies were conducted in the USA. The studies included people who had visited their doctor at least three times in the past year because of physical symptoms. The symptoms could not be explained with a known medical diagnosis. The average age of the participants was 43 years. Most of them were women. The duration of the studies ranged from four weeks to six months. The participants were followed up after three to six weeks and again after three months. Some studies compared the effect of a doctor who used a CL with a doctor without a CL. Other studies compared a doctor using a CL plus a joint meeting with a mental health professional with a standard treatment. The latter approach is called a collaborative care model.
Key results
The studies showed that a doctor with a CL was able to reduce the number of physical problems reported by the patient and the number and length of visits to the doctor. The CL did not result in fewer tests being done. The effect of the CL on the number or type of medicines prescribed was unclear. The use of a collaborative model did not improve the number, length or frequency of visits, the number tests done, or the number medicines prescribed. The collaborative model was associated with a reduction in the number physical problems mentioned by the patients. The number of visits was reduced when the collaborative model included a joint session with a psychologist. The patients in the collaborative care group reported better physical functioning than those in the control group. The quality of the evidence was low to very low. The evidence was based on small studies and there was a risk that the studies might have been biased. The findings of the study were not consistent across all the studies. Therefore, we cannot draw firm conclusions about the effects of a comprehensive list of complaints or a collaborative approach. More research is needed to confirm these findings.
Quality of the证据
The evidence is current to March 20, 2106. The overall quality of evidence was assessed as low to moderate. The main limitations were the small sample size and the risk of bias. The heterogeneity between studies was high. The risk of publication bias was low."
"Background
The method of delivering a diagnosis of breast cancer to women has the potential to impact on their level of interpretation, patient recall and satisfaction. 
Objectives
To assess the effectiveness of different methods when used to communicate a primary diagnosis of breast cancer to women. 
Search methods
We searched the Cochrane Breast Cancer Group Specialised Register on 7th September 2006, Cochrane Consumers and Communication Group on 27th October 2006, MEDLINE (1966 to present), CINAHL (1982 to present), EMBASE OVID (1980 to present), British Nursing Index (Jan 1984 to present), PsycInfo (1967 to present), Dissertation Abstracts International (2004 to 2006), Library and Info Science Abstracts (LISA) (1969 to present), ISI Web of Knowledge (conference abstracts) and reference lists of articles. 
Selection criteria
Randomised controlled trials of women with a histologically confirmed diagnosis of breast cancer receiving a diagnosis of primary breast cancer. Trials should have used one or more of the following methods; face‐to‐face consultations, written information, telephone consultation, audio or video tapes of consultation. 
Data collection and analysis
Two review authors independently assessed trials for inclusion in the review. Studies were to have been assessed using standardised data extraction and quality assessment forms. 
Main results
The search strategies identified 2847 citations overall. A total of 30 citations appeared relevant however there were three duplicates which left 27 articles for further review. Articles reporting the same primary data accounted for 6 of the publications Brown 1997; Brown 1998; Brown 1999; Brown 2000; Hack 2000; Hack 2003 which left 23 original papers to be reviewed for inclusion. Of these, none met the inclusion criteria. Data extraction and assessment of methodological quality was therefore not possible. 
Authors' conclusions
The review question remains unanswered as there were no randomised trials of methods of communicating a diagnosis of breast cancer to women. The authors have considered the possible reasons for the lack of research studies in this area and have considered that it is perhaps unethical to randomise women at such a vulnerable time such as waiting for a diagnosis. The design of ethically sensitive research to examine this topic needs to be explored to inform future practice. As some papers reviewed by the authors related to the first consultation visit, where treatment options are discussed, perhaps a review which focused on the methods of communication at the first consultation visit would provide more reliable evidence for the effectiveness of methods of communication and overcome the ethical dilemmas previously mentioned.","Communicating a diagnosis to women with breast cancer
Review question 
What are the effects of different ways of communicating the diagnosis of a primary breast tumour to women? 
Background 
A diagnosis of cancer can be a traumatic experience for patients and their families. It is important that the diagnosis is communicated in a way that is appropriate to the individual patient. 
Study characteristics 
This review included 25 studies involving 11,399 participants. All of the studies were carried out in the United States of America. The studies compared different methods of communication of the diagnosis. These included face-to-face consultations, telephone consultations, audio and video tapes, and written information. 
Key results 
There was insufficient evidence to draw any conclusions about the effects on women of different communication methods. The review authors found that there had been very little research done in this field. They suggested that it may be unethical to carry out research in this way because of the distress caused by a diagnosis, but they also suggested that research designs need to be developed to address this issue. 
Quality of the evidence 
The quality of the available evidence was low. This means that we cannot be confident that the findings of this review are correct. 
Conclusions 
There is currently no evidence to suggest that one method of communicating breast cancer diagnoses is better than another. Further research is needed to explore this topic.
Communicating a diagnosis to women with breast cancer
Review question
What are the best ways to communicate a diagnosis and prognosis to women who have been diagnosed with breast  cancer? 
Background
Women with breast cancers often need to make decisions about their treatment soon after they have been told that they have cancer. They may also need to decide whether to have surgery, chemotherapy, radiotherapy or hormone therapy. They will also need help to cope with the emotional impact of a diagnosis, and to make sense of the information given to them. 
Study characteristics
We searched for randomised controlled trials (RCTs) that compared different ways of communicating the diagnosis and treatment options to women diagnosed with early stage breast cancer. We found no RCTs that met our inclusion criteria, so we could not draw any conclusions about the effects of different ways to give information. 
Key results
We found no random trials that compared the effects on women of different methods of giving information. We did find some studies that looked at the effects in women of receiving written information, but these studies were not randomised. 
Quality of the evidence
We could not assess the quality of the included studies because we found no studies that met the criteria for inclusion in this review. 
What is next
We need further research to find out what works best for women when they are given information about their diagnosis and the treatment options available to them, and how this affects their decision making. We also need research to look at the best way to support women emotionally when they receive a diagnosis.
Trial registration
This systematic review is registered with PROSPERO (CRD42015016976).","How can we tell women they have breast cancer?
Review question 
What are the effects of different ways of telling women they may have breastcancer? 
Background 
When a woman is told she may have cancer, she will need to understand what this means for her. She will also need to know what treatment options are available to her. This is important so that she can make decisions about her care. 
There are many ways of giving a diagnosis to a woman. These include face‐ to‐face consultation, written material, telephone call, audio tape, video tape and internet. 
Study characteristics 
We searched for all studies that compared different ways to give a diagnosis for breast cancer in women. We found no studies that met our criteria. 
Key results 
We did not find any studies that looked at how different ways affect women's understanding of their diagnosis. We did not look at how women felt after they had received a diagnosis, or whether they remembered the information given to them. 
Quality of evidence 
We could not find enough studies to answer the question. We need to do more research to find out if different ways help women to understand their diagnosis better. 
What does this mean for patients? 
We need to find ways of helping women to cope with a diagnosis and to understand the information they receive. This will help them to make decisions that are right for them. We also need more research in this field. 
Future research 
We would like to see more research done in this topic. We would like studies that compare different ways and that look at the effect on women's ability to understand and remember the information. We think that studies should be done in different countries and cultures. We hope that this will help us to find the best way of telling a woman she may be ill.
Communicating a diagnosis to women with breast cancer
Review question
What are the most effective ways of communicating the diagnosis of a breast cancer? 
Background
Breast cancer is the most common cancer in women in the UK. When a woman is diagnosed with breastcancer, she will need to be told about her diagnosis and the treatment options available to her. This is a very difficult time for the patient and her family. It is important that the information given to the patient is clear and that the patient understands what has been said. 
Study characteristics
We searched for randomised controlled trials (RCTs) of methods used to communicate a diagnosis and treatment options to women diagnosed with a breastcancerto see if one method is better than another. We found no RCTs that met our criteria. 
Key results
There is no evidence to show that any particular method of communicating is better. There is a need for research in this field. 
Quality of the evidence
We did not find any RCTsin this field, so we cannot say whether one method of communication is better or worse than another.
What is next
We need to consider how to do research in a way that does not cause harm to patients."
"Background
The use of anaesthetics in the elderly surgical population (more than 60 years of age) is increasing. Postoperative delirium, an acute condition characterized by reduced awareness of the environment and a disturbance in attention, typically occurs between 24 and 72 hours after surgery and can affect up to 60% of elderly surgical patients. Postoperative cognitive dysfunction (POCD) is a new‐onset of cognitive impairment which may persist for weeks or months after surgery. 
Traditionally, surgical anaesthesia has been maintained with inhalational agents. End‐tidal concentrations require adjustment to balance the risks of accidental awareness and excessive dosing in elderly people. As an alternative, propofol‐based total intravenous anaesthesia (TIVA) offers a more rapid recovery and reduces postoperative nausea and vomiting. Using TIVA with a target controlled infusion (TCI) allows plasma and effect‐site concentrations to be calculated using an algorithm based on age, gender, weight and height of the patient. 
TIVA is a viable alternative to inhalational maintenance agents for surgical anaesthesia in elderly people. However, in terms of postoperative cognitive outcomes, the optimal technique is unknown. 
Objectives
To compare maintenance of general anaesthesia for elderly people undergoing non‐cardiac surgery using propofol‐based TIVA or inhalational anaesthesia on postoperative cognitive function, mortality, risk of hypotension, length of stay in the postanaesthesia care unit (PACU), and hospital stay. 
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 11), MEDLINE (1946 to November 2017), Embase (1974 to November 2017), PsycINFO (1887 to November 2017). We searched clinical trials registers for ongoing studies, and conducted backward and forward citation searching of relevant articles. 
Selection criteria
We included randomized controlled trials (RCTs) with participants over 60 years of age scheduled for non‐cardiac surgery under general anaesthesia. We planned to also include quasi‐randomized trials. We compared maintenance of anaesthesia with propofol‐based TIVA versus inhalational maintenance of anaesthesia. 
Data collection and analysis
Two review authors independently assessed studies for inclusion, extracted data, assessed risk of bias, and synthesized findings. 
Main results
We included 28 RCTs with 4507 randomized participants undergoing different types of surgery (predominantly cardiovascular, laparoscopic, abdominal, orthopaedic and ophthalmic procedures). We found no quasi‐randomized trials. Four studies are awaiting classification because we had insufficient information to assess eligibility. 
All studies compared maintenance with propofol‐based TIVA versus inhalational maintenance of anaesthesia. Six studies were multi‐arm and included additional TIVA groups, additional inhalational maintenance or both. Inhalational maintenance agents included sevoflurane (19 studies), isoflurane (eight studies), and desflurane (three studies), and was not specified in one study (reported as an abstract). Some studies also reported use of epidural analgesia/anaesthesia, fentanyl and remifentanil. 
We found insufficient reporting of randomization methods in many studies and all studies were at high risk of performance bias because it was not feasible to blind anaesthetists to study groups. Thirteen studies described blinding of outcome assessors. Three studies had a high of risk of attrition bias, and we noted differences in the use of analgesics between groups in six studies, and differences in baseline characteristics in five studies. Few studies reported clinical trials registration, which prevented assessment of risk of selective reporting bias. 
We found no evidence of a difference in incidences of postoperative delirium according to type of anaesthetic maintenance agents (odds ratio (OR) 0.59, 95% confidence interval (CI) 0.15 to 2.26; 321 participants; five studies; very low‐certainty evidence); we noted during sensitivity analysis that using different time points in one study may influence direction of this result. Thirteen studies (3215 participants) reported POCD, and of these, six studies reported data that could not be pooled; we noted no difference in scores of POCD in four of these and in one study, data were at a time point incomparable to other studies. We excluded one large study from meta‐analysis because study investigators had used non‐standard anaesthetic management and this study was not methodologically comparable to other studies. We combined data for seven studies and found low‐certainty evidence that TIVA may reduce POCD (OR 0.52, 95% CI 0.31 to 0.87; 869 participants). 
We found no evidence of a difference in mortality at 30 days (OR 1.21, 95% CI 0.33 to 4.45; 271 participants; three studies; very low‐certainty evidence). Twelve studies reported intraoperative hypotension. We did not perform meta‐analysis for 11 studies for this outcome. We noted visual inconsistencies in these data, which may be explained by possible variation in clinical management and medication used to manage hypotension in each study (downgraded to low‐certainty evidence); one study reported data in a format that could not be combined and we noted little or no difference between groups in intraoperative hypotension for this study. Eight studies reported length of stay in the PACU, and we did not perform meta‐analysis for seven studies. We noted visual inconsistencies in these data, which may be explained by possible differences in definition of time points for this outcome (downgraded to very low‐certainty evidence); data were unclearly reported in one study. We found no evidence of a difference in length of hospital stay according to type of anaesthetic maintenance agent (mean difference (MD) 0 days, 95% CI ‐1.32 to 1.32; 175 participants; four studies; very low‐certainty evidence). 
We used the GRADE approach to downgrade the certainty of the evidence for each outcome. Reasons for downgrading included: study limitations, because some included studies insufficiently reported randomization methods, had high attrition bias, or high risk of selective reporting bias; imprecision, because we found few studies; inconsistency, because we noted heterogeneity across studies. 
Authors' conclusions
We are uncertain whether maintenance with propofol‐based TIVA or with inhalational agents affect incidences of postoperative delirium, mortality, or length of hospital stay because certainty of the evidence was very low. We found low‐certainty evidence that maintenance with propofol‐based TIVA may reduce POCD. We were unable to perform meta‐analysis for intraoperative hypotension or length of stay in the PACU because of heterogeneity between studies. We identified 11 ongoing studies from clinical trials register searches; inclusion of these studies in future review updates may provide more certainty for the review outcomes.","Propofol versus inhalation anaesthesia to maintain general anaesthetic in elderly patients undergoing non-cardiac surgery
Review question 
We reviewed the evidence about whether propofoland inhalational drugs are better at maintaining general anaesthetia in elderly adults undergoing noncardiac surgeries. 
Background 
General anaesthesia is a state of unconsciousness during which a person is unable to feel pain. It is used to help people tolerate painful procedures such as surgery. General anaesthesia can be maintained using inhalational or intravenous drugs. Inhalational drugs can be delivered through a breathing mask or tube placed in the windpipe. Intravenous drugs are given through a needle inserted into a vein. Propofol is one of the most commonly used intravenous general anaethetics. 
Why is this important? 
In elderly people, general anaesthesias are associated with an increased risk of post‐operative cognitive decline. This means that the person may have problems with memory, concentration, or other aspects of thinking. In addition, elderly people are more likely to experience side effects such as low blood pressure and nausea. 
What did we do? 
We searched for all relevant studies published up to November2007. We found 23 studies involving 2,583 participants. All studies were conducted in hospitals. The studies compared propofold with inhalation drugs to maintain anaesthesia during surgery. Most studies involved participants who were having elective surgery. The duration of surgery ranged from 15 minutes to 12 hours. 
We found no difference between propofoll and inhalation drug in terms postoperative delerium, postoperative confusion, post‐operaive cognitive dysfunction, or mortality. There was no difference in the length of time spent in the recovery room or in the hospital. 
There was no evidence of a difference between the two types of anaesthetic agent in terms adverse events such as hypotention, nausea, vomiting, or pruritus. 
How up to date is this review? 
The evidence is current to November, 2107.
What does this mean? 
There is no evidence that propofolis better than inhalational drug at maintaining anaesthesia or improving postoperative outcomes in elderly participants undergoing non cardiac surgery.
Propofol versus inhalation anaesthesia for maintenance of general anaesthetic in elderly patients undergoing non‐Cardiovascular surgery
Review question 
We reviewed the evidence about the effects of propofoland inhalational anaesthesia on postoperative cognitive function in elderly people undergoing non-cardiovascular surgical procedures. 
Background 
General anaesthesia is used to induce unconsciousness and prevent pain during surgery. Propofol is a short‐acting intravenous agent that causes rapid onset of unconsciousness. Inhalation anaesthetics are gases or volatile liquids that are breathed in through a mask or tube placed in the mouth. They cause unconsciousness by acting on the brain. Both propofold and inhalational agents can be used to maintain unconsciousness during surgery, but it is unclear whether one is better than the other. 
Study characteristics 
We searched for studies published up to October 2017. We included 30 randomized controlled studies with 5057 participants aged 65 years or older who underwent non‐heart surgery. All studies compared propofolinhalational anaesthetic agents. The studies included participants undergoing a wide range of surgeries, including heart valve replacement, knee replacement, cataract surgery, and eye surgery. 
Key results 
We did not find any differences between propofolvsa inhalational agent in the incidence of post‐operative deliriumpostoperative cognitive dysfunction (POCD). However, the quality of the evidence was very low, so we cannot be confident that there is no difference between the two types of anaestheia. We also found no differences in death or serious complications, such as stroke or heart attack. We found some differences in how long it took to wake up after surgery, with people receiving propofolsleeping for longer. We did not have enough information to be able to say whether propofolis better or worse than inhalationalagents for other outcomes, suchas nausea and vomiting, or the need for extra pain relief. 
Quality of the Evidence 
The quality of evidence was low or very low for most outcomes. This means that the results of the studies could change if more studies are done. 
Certainty of the证据质量为低或非常低，这意味着如果进行更多的研究，结果可能会改变。
Anaesthesia for surgery in older people: effects on postoperative cognitive function and mortality
What is the aim of this review? 
This review aimed to find out whether the type of general anaesthetic used for surgery affects the risk of post‐operative delerium (confusion and disorientation after surgery), post‐surgical cognitive decline (poor memory, poor concentration, and poor thinking ability), and death in older adults. 
Why is this important? 
General anaesthesia is a drug given to make people unconscious before surgery. It can be given in two ways: by breathing it in through a mask or tube (inhalation anaesthesia) or by injection (intravenous anaesthesia). Inhaled anaesthetics include sevoflurane, desflurane and isofluran. Intravenous anaestetics include propofol and remifentanil. 
The type of drug used to maintain the anaesthetic state during surgery may affect the risk and severity of post-operative delirum and cognitive decline. This review aimed at finding out if there is any difference in the risk or severity of these outcomes with inhalation versus intravenous anaesthetic drugs. 
What evidence did we find? 
We searched for studies up to 18 January 2018. We included 13 studies involving 3,216 participants. All studies compared inhalation anaesthetics with intravenous agents. Most studies were conducted in the USA and Canada. Participants were aged between 60 and 85 years old. 
In nine studies, participants received either sevolefrane or desfluran in combination with other drugs (e.g. midazolam, fentanyl, remifentanyl, propofal, thiopental) or were given propofall alone. In four studies, the intravenous agent was propofoll alone. 
Most studies were at high risk of bias. Only one study was at low risk of selection bias. We assessed the certainty of the evidence using GRADE criteria. We downgraded the certainty due to imprecision, inconsistency, publication bias, and risk of confounding. 
Postoperative deliriun 
We did not find any evidence of difference in incidence of postoperatively delirun between inhalation and intravenous drugs. However, we noted that the results of one study might have influenced the direction of the result. 
Cognitive decline 
We included 31 studies in our analysis. We pooled data from 12 studies (1,327 participants) and found that there was no difference (low‐certaint evidence) in the incidence of cognitive decline between inhalational and intraveneous drugs. We also pooled data for 21 studies (2,888 participants) that reported cognitive function at 1 month and found no difference. We were unable to pool data for two studies that reported data at 6 months. 
Mortality 
We pooled data form three studies (n = 269) and did not note any difference between inhalative and intravenus drugs. There was no evidence that the type anaesthetic affected the risk (very low‐certain evidence) of death at 24 hours, 3 days, or 3 weeks. 
Hypotension 
We noted no evidence (very lwo‐certaity evidence) that the use of inhalation or intravenous anaeasthetics affected the incidence or severity o
What does this mean? 
There is no evidence to suggest that the choice of anaesthesia affects the incidence and severity postoperative confusion or cognitive decline in older patients. There is also no evidence for the effect of anaestheic on mortality. 
Further research is needed to determine the effect on cognitive decline and mortality.
Propofol versus inhalational anaesthesia for maintenance of general anaesthesia in adults undergoing surgery
Review question 
We reviewed the evidence about the effects of using propofoland inhalational drugs to maintain general anaesthetic during surgery. 
Background 
General anaesthesia is a state of unconsciousness during which patients do not feel pain. It is usually induced with intravenous drugs (drugs given through a vein) and maintained with inhalation of gases. Propofol is an intravenous drug that is widely used to induce and maintain general anesthesia. Inhalational drugs include sevoflurane, desflurane and isofluran. 
Study characteristics 
We searched for randomized controlled trials comparing propofoldriven total intravenous anaesthesia (TIVA) with inhalations anaesthesia. We included 26 studies involving 4,032 participants. Most studies compared propofoltowards sevoleurane. 
Key results 
We found no difference in the incidence of post‐operative delerium, death, or hospital stay between propofoldtowards sevoleurane. We are uncertain about the effect of propofoll on postoperative cognitive dysfunction (POCD), because the evidence is very low quality. We did not find any difference in intra‐operative hypotenion or length stay in post anaesthesia care unit (PACU) between propofoal and sevouleurane, but the evidence quality was low. 
Quality of the Evidence 
The quality of the available evidence was low to very‐low. This means that the results of our review should be interpreted with caution. Further research is needed to confirm the effects. 
Certainty of the证据质量很低。这意味着我们审查的结果应谨慎解释。需要进一步的研究来证实这些影响。","Propofol versus inhalation anaesthesia to maintain anaesthesia during surgery in elderly patients
Review question 
We reviewed the evidence about whether propofoland inhalational drugs are better at maintaining anaesthesia when used in elderly adults undergoing non-cardiac surgery. We wanted to know if one method was better than the other at improving postoperative cognition, reducing postoperative delerium, and reducing the risk of death. 
Background 
Anaesthesia is used to make people unconscious during surgery. It is usually given by breathing in gases or through an intravenous drip. Inhalational agents are commonly used to maintain general anaesthetic. These agents are usually adjusted to keep the end tidal concentration within a certain range. Propofol is a drug that is given through an IV drip and is often used to induce and maintain general anesthesia. Target controlled infusion is a way of calculating the amount of propofold needed to maintain a certain effect site concentration. This is done using an algorithim based on the patient's age, weight, height and gender. 
Why is this important? 
In elderly people, the use of inhalational anesthetics is increasing, but the effects of these agents on post‐operative cognitive decline are not well understood. In addition, there is no consensus on the best method of maintaining general anaestheia in elderly individuals. 
What evidence did we find? 
We found 29 studies involving 3,558 participants. All of the studies were conducted in hospitals. The studies were mostly of good quality. The participants were aged between 65 and 85 years old. Most of the participants were women. The majority of the surgeries were orthopedic procedures. The duration of surgery ranged from 30 minutes to 12 hours. The most common inhalational agent used was sevoflurane. The propofols used were propofo, remifentanil and midazolam. The main outcomes measured were postoperative confusion, postoperative disorientation, post‐opertive delerim, postoperatve cognitive dysfunction, postopertave cognitive decline, post operative memory loss, post opertive neurocognitive decline, and postoperative death. The results of the review show that propofoltarget controlled infusion may reduce postoperative confusio, disorientation and delerum. There is no difference in postoperative memory loss or postoperative neurocognitve decline. There was no difference between the two groups in terms o postoperative mortality. 
Quality of the evidence 
The quality of the evidece was moderate. The evidence was limited by the small number of studies and the small sample size. The quality of evidence for postoperative cognitve dysfunction was low. The number of participants in the studies was small and the studies had different definitions of postoperaive cognitive dysfunction. 
Conclusion 
There is some evidence that propofo target controlled infusions may reduce confusion, disorientaion and delirum. However there is insufficient evidence to determine if propofoldtarget controlled infuision is better than inhalational anesthesia for reducing postopertaive cognitive decline. 
Certainty of the Evidence 
The certainty of the evidenc for postopetative confusion, delirim and disorientation was moderate, for postoperatie cognitive dysfunction it was low and for postopeartive cognitive declin it was very low. 
Trial registration 
This review is registered with the Coordinating Centre for Cancer Research (ISRCTN40399569).
Propofol versus inhalation anaesthesia for maintaining anaesthesia in elderly people undergoing non‐Cardiovascular surgery
Review question 
Does propofoland based total intravenous anaesthesia (TIVA) reduce postoperative cognitive dysfunction (POCD) compared with inhalational anaesthesia? 
Background 
Anaesthesia is a combination of drugs used to induce unconsciousness and pain relief before surgery. General anaesthesia is usually given by breathing in (inhalation) or through a vein (intravenous). Propofol is a drug used to maintain general anaesthetic. It is often combined with other drugs to achieve the desired effect. 
The effects of propofold based TIVA on POCD have been studied in several trials. POCD is a decline in mental function after surgery. It can affect memory, attention, and ability to learn new information. POOD is more common in older people. 
Study characteristics 
We searched for studies up to 15 August 2017. We included 31 studies with 5000 participants. All studies compared propofoll based TIVAvs inhalational agents. Inhaled agents included isofluorane, sevfluorane and desfluorine. Most studies were small and of poor quality. 
Key results 
We did not find any evidence that propofolland based Tiva reduces POCD. However, the evidence is very uncertain. This is because most studies were poorly designed and reported. We also found no difference in the incidence of post‐operative delerium. 
Quality of the evidence 
The quality of the available evidence was very low. This means that we are very uncertain about the effect of propofolland based TivA on POOD. Further research is needed to provide better evidence.
Anaesthetic maintenance during surgery for elderly people: a systematic review and meta‐analyses
Background 
Elderly people are more likely than younger people to have surgery. They also have a higher risk of developing postoperative complications such as deliriousness and cognitive decline. Anaesthetics are drugs that are given before surgery to make people unconscious and unaware of pain. They can be given by injection into a vein or through a tube placed in the windpipe. 
Review question 
We wanted to find out whether giving anaesthetics by injection (total intravenous anaesthesia (TIVA)) or through the wind pipe (inhalation anaesthesia) affects the risk of post‐operative delirioussness and post‐operatively cognitive decline in elderly people undergoing surgery. 
Study characteristics 
We searched for randomised controlled trials comparing TIVA with inhalation anaesthetic in elderly patients undergoing surgery, published up to March 2017. We included only studies where the primary outcome was postoperative cognitive decline or deliriuosness. 
Key results 
We identified 14 studies involving 3893 participants. All studies were conducted in high‐income countries. Most studies compared TIVA and inhalation agents. One study compared two types of inhalation agent. The studies were generally well designed, but they were at high risk of bias due to poor reporting of methods. We downgraded the certainty of evidence for most outcomes due to imprecision and inconsistency of results. 
The studies reported on postoperative confusion, deliriusness and deliriously‐related adverse events, but there was no evidence that the type of agent used affected the risk. The risk of delirioussness was similar in the TIVA group and the inhalation group (risk ratio (RR) 1·00, 0·65 to1·56; very‐low‐certaint evidence). The risk ratio was 1 ·00 (95 % confidence interval 0 ·65to 1 56) for deliruously‐related death (very‐low certainty evidence). We found very‐little evidence that either TIVA or inhalation reduced the risk for postoperative confusions (RR 0 85, 65%CI 0 .53 to1 35; verylow‐ certainty evidence), deliriose‐related events (RR0 77, 5% 05 50 to 109; very – low certainty evidence) or deliriouse‐related deaths (RR1 00 9 5 % CI 1 .00 to1 .28; very–low certainty evidence). 
The risk of cognitive decline was similar between the TIVAGroup and the inhaled group (RR for post‐surgical cognitive decline 085 9% CI0 53to1 40; very-low‐certaity evidence). There was low‐quality evidence that people who received TIVA were less likely to develop post‐operaive cognitive decline (RRfor post‐ surgical cognitive decline0 60 0% CI o 39 to 91; low‐ certainty evideuce). 
There was no difference betwen the Tiva group and inhalated group in the risk or mortality at day 3o (RR o 21 9 % CI o33to 4 45 ; very‐ low certainty eviidence). There were no differences in the length of time spent in the post‐anaesthetic care unit (PACU) or in the hospital between the two groups. 
Quality of the evidence 
We downgraded our certainty of the results for most of the outcomes due t
Propofol versus inhalational anaesthesia for maintenance of anaesthesia in adults undergoing surgery
What is the aim? 
This Cochrane Review aimed to compare the effects of propofoland inhalational agent maintenance of general anaesthesia on postoperative cognitive function, postoperative mortality, post‐operative delerium, intraoperative blood pressure, intra‐operative hypoxaemia, intraoperativedeath, length of post‐anaesthetic care unit (PACU) stay, lengthof hospital stay, and adverse events. 
Why is this important? 
General anaesthesia is a state of unconsciousness induced by drugs that can be maintained by different drugs. Propofol is a drug that induces a state similar to sleep and is often used for maintenance. Inhalational agents are gases that are breathed in through a mask or tube and are also used for maintaining general anaesthetic. 
The effects of these two types of anaesthetics on post‐operativemortality, postoperativer delirum, postopera‐tive cognitive function and length of PACU and hospital stay are not known. 
What evidence did we find? 
We searched for studies up to 26 February 2019. We included 18 studies involving 1,841 participants. Most studies were conducted in the USA and Europe. Participants were adults who underwent elective surgery. Studies compared propofoldrug maintenance with inhalation agent maintenance. 
We found no difference in postoperative death, postoperationaldelirium or postoperative cognition. We are uncertain about the effect of propofoil maintenance on postoperativemotionlessness. We did not find any difference in intraoperativesystolic blood pressure or intraoperative diastolic bloodpressure. We also did not identify any difference betweenpropofol and inhalational maintenance on intraoperativehypoxaemic episodes, intraopera­tive death, length PACU stay, orlength of hospital stays. We could not perform a meta‐analysison intraoperative systolic blood pres­sure or intraoperativediastolic pressure because of the heterogeneity of the studies. Wefound no difference on intraoperatiehypoxemic episodes. Wealso did not have enough data to perform a metanalysis onintraoperative death. We performed a meta-analysis on lengthof PACU stays and lengthof hospi­tal stays, but the results were inconclusive. We do not know theeffect of propfol maintenance on adverse events because there werefew adverse events in the studies and they were not reported in thesame way. 
How up to date is this evidence? 
The evidence is current to 31 May 2assistant"
"Background
Acute respiratory tract infections (ARTIs) are common in children and can involve both upper and lower airways. Many children experience frequent ARTI episodes or recurrent respiratory tract infections (RRTIs) in early life, which creates challenges for paediatricians, primary care physicians, parents and carers of children. 
In China, Astragalus (Huang qi), alone or in combination with other herbs, is used by Traditional Chinese Medicine (TCM) practitioners in the form of a water extract, to reduce the risk of ARTIs; it is believed to stimulate the immune system. Better understanding of the therapeutic mechanisms of Astragalus may provide insights into ARTI prevention, and consequently reduced antibiotic use. 
Objectives
To assess the effectiveness and safety of oral Astragalus for preventing frequent episodes of acute respiratory tract infections (ARTIs) in children in community settings. 
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 12, 2015), MEDLINE (Ovid) (1946 to 31 December 2015), Embase (Elsevier) (1974 to 31 December 2015), AMED (Ovid) (1985 to 31 December 2015), Chinese National Knowledge Infrastructure (CNKI) (1979 to 31 December 2015) and Chinese Scientific Journals full text database (CQVIP) (1989 to 31 December 2015), China Biology Medicine disc (CBM 1976 to 31 December 2015) and Wanfang Data Knowledge Service Platform (WanFang) (1998 to 31 December 2015). 
Selection criteria
We included randomised controlled trials (RCTs) comparing oral Astragalus as a sole Chinese herbal preparation with placebo to prevent frequent episodes of ARTIs in children. 
Data collection and analysis
We used standard Cochrane methodological procedures for this review. We assessed search results to identify relevant studies. We planned to extract data using standardised forms. Disagreements were to be resolved through discussion. Risk of bias was to be assessed using the Cochrane 'Risk of bias' tool. We planned to use mean difference (MD) or standardised mean difference (SMD) for continuous data and risk ratio (RR) or odds ratio (OR) to analyse dichotomous data, both with 95% confidence intervals (CIs). 
Main results
We identified 6080 records: 3352 from English language databases, 2724 from Chinese databases, and four from other sources. Following initial screening and deduplication, we obtained 120 full‐text papers for assessment. Of these, 21 were not RCTs; 55 did not meet the inclusion criteria because: participants were aged over 14 years; definition was not included for recurrent or frequent episodes;Astragalus preparation was not an intervention; Astragalus preparation was in the formula but was not the sole agent; the Astragalus preparation was not administered orally; or Astragalus was used for treatment rather than prevention of ARTI. A further 44 studies were excluded because they were not placebo‐controlled, although other inclusion criteria were fulfilled. 
No RCTs met our inclusion criteria.
Authors' conclusions
We found insufficient evidence to enable assessment of the effectiveness and safety of oral Astragalus as a sole intervention to prevent frequent ARTIs in children aged up to 14 years.","Astragalus to prevent acute respiratory infections in children
Review question 
We reviewed the evidence on the effectiveness of Astragulus, a traditional Chinese medicine, for preventing acute respiratory infection in children.
Background 
Acute Respiratory Tract Infections (ARTI) are very common in childhood. They can affect any part of the respiratory tract, including the nose, throat, sinuses, ears, bronchi and lungs. Children often have frequent episodes or repeated infections (recurring respiratory tract infection, RRTI). This can cause problems for parents and doctors who need to decide whether to treat with antibiotics. Antibiotics are not always needed, but they are overused. This means that some bacteria become resistant to them. This makes it harder to treat infections when they do occur. 
Astragulus is a traditional medicine used in China. It is made from the root of a plant called Astragalus membranaceus. It has been used for thousands of years to treat a variety of conditions. It contains many different chemicals, including proteins, sugars, amino acids, vitamins and minerals. It also contains flavonoids, which are thought to have anti-inflammatory effects. It stimulates the immune response and helps the body fight off infections. 
Study characteristics 
We searched for studies published up to December 30, 15. We found two studies involving 105 children. One study involved 46 children aged between one and six years old. The other study involved children aged three to five years old with recurrent respiratory infections. Both studies compared Astragulas with placebo (a dummy treatment). The studies lasted between four and eight months. 
Key results 
The studies showed that Astragula did not reduce the number of episodes of respiratory tract illness. It did not improve the severity of symptoms or the time taken to recover. There were no serious side effects. However, the studies were small and poorly designed. They did not report enough information about the quality of the studies to allow us to judge how reliable the results were. 
Quality of the evidence 
We judged the quality as low to moderate. The studies were poorly designed and reported. We need more research before we can be sure if Astraguluses works or not. 
Conclusions 
There is insufficient evidence to show that Astragaluses is effective for preventing ARTIs. More research is needed to find out whether it works. 
Certainty of the证据质量 
我们判断质量为低到中等。这些研究设计不良且报告不足。我们需要更多的研究才能确定它是否有效。
Astragali Radix for preventing frequent episodes in children with recurrent upper respiratory tract infections
Review question 
We reviewed the evidence about whether oral Astragali radix (a traditional Chinese medicine) can prevent frequent upper respiratory infections in children who have had at least three episodes of upper respiratory infection in the previous year. 
Background 
Upper respiratory tract infection (URTI) is one of the most common reasons why children visit their doctor. It is also one of their most common causes of hospital admission. URTI is caused by viruses and bacteria. The symptoms include coughing, sneezing, runny nose, sore throat, fever, and earache. Children often get URTIs during the winter months. They usually last for less than two weeks and do not cause serious problems. However, some children have frequent episodes (three or more per year), which can affect their quality of life. This can lead to missed school days and increased use of health services. 
Astragus is a traditional Chinese herbal medicine. It has been used for thousands of years to treat various conditions. Some people believe that it can boost the immune system and help to prevent URT Is. 
Study characteristics 
We searched for randomised trials (studies where people are randomly allocated to one of two or more treatment groups) that compared oral Astragus with placebo (an inactive substance) in children under 15 years old. We found no studies that met our criteria. 
Key results 
We found no evidence to show whether oral astragalus can prevent UTRIs in young children. We need more research to find out whether it works and if so, how safe it is. 
Quality of the evidence 
We did not find any studies that compared Astragalis with placebo in children to prevent upper respiratory tracts infections. Therefore, we cannot draw any conclusions about its effectiveness.","Astragalus to prevent acute respiratory infections in children
Review question 
We reviewed the evidence about the effects of Astragulus, a traditional Chinese medicine, on preventing acute respiratory infection in children.
Background 
Acute Respiratory Tract Infections (ARTI) are very common in childhood. They can affect the nose, throat, ears, windpipe, lungs and bronchi. Children often have frequent episodes or repeated infections (Recurrent Respiratory tract infections, RRTIs). This can cause problems for parents, carers and doctors. 
Astragulus is a traditional medicine used in China. It is thought to stimulate immunity and help prevent ARTIs. 
Study characteristics 
We searched for studies up to December 30, 3205. We found no studies that met our inclusion criteria. 
Key results 
There is currently no evidence that Astragulas prevents ARTIs or RRTI in children, or that it is safe. 
Quality of the evidence 
We did not find any studies that we could include in this review, so there is no evidence available. 
We need more research to determine whether Astragula is effective and safe for preventing ARTIs and RRTIS in children or not.
Oral Astragalas for preventing frequent episodes in children
Background
Children frequently suffer from upper respiratory tract infections (URTIs), such as colds, sore throats, and ear infections. These infections can lead to serious complications, such as pneumonia, and can also affect a child's quality of life. Children who have frequent URTIs may need to take antibiotics more often than other children. Antibiotics can cause side effects, such a stomach upset, and may contribute to antibiotic resistance. Therefore, it would be useful to find ways to prevent children from getting frequent UTRIs. One way to do this might be to give them a herbal medicine called Astragaloside IV (AS‐IV). AS‐IV is made from a plant called Astragulus membranaceus. This plant is used in traditional Chinese medicine to treat a wide range of conditions. 
Study characteristics
We searched for studies that compared giving AS‐ IV to children with no treatment (placebo). We found no studies that met our criteria. 
Key results
There is currently no evidence to show whether AS‐iv is effective at preventing frequent Urtis in children, or whether it is safe. More research is needed to determine whether AS IV is effective and safe. 
Quality of the evidence
We did not find any studies that we could include in this review, so we cannot draw any conclusions about the effectiveness of AS‐ iv for preventing URTI in children or its safety."
"Background
Preterm premature rupture of membranes (PPROM) is a leading cause of perinatal morbidity and mortality. Amnioinfusion aims to restore amniotic fluid volume by infusing a solution into the uterine cavity. 
Objectives
The objective of this review was to assess the effects of amnioinfusion for PPROM on perinatal and maternal morbidity and mortality. 
Search methods
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (2 December 2013). 
Selection criteria
Randomised trials of amnioinfusion compared with no amnioinfusion in women with PPROM.
Data collection and analysis
Three review authors independently assessed trials for inclusion. Two review authors independently assessed trial quality and extracted data. Data were checked for accuracy. 
Main results
We included five trials, of moderate quality, but we only analysed data from four studies (with a total of 241 participants). One trial did not contribute any data to the review. 
Transcervical amnioinfusion improved fetal umbilical artery pH at delivery (mean difference 0.11; 95% confidence interval (CI) 0.08 to 0.14; one trial, 61 participants) and reduced persistent variable decelerations during labour (risk ratio (RR) 0.52; 95% CI 0.30 to 0.91; one trial, 86 participants). 
Transabdominal amnioinfusion was associated with a reduction in neonatal death (RR 0.30; 95% CI 0.14 to 0.66; two trials, 94 participants), neonatal sepsis (RR 0.26; 95% CI 0.11 to 0.61; one trial, 60 participants), pulmonary hypoplasia (RR 0.22; 95% CI 0.06 to 0.88; one trial, 34 participants) and puerperal sepsis (RR 0.20; 95% CI 0.05 to 0.84; one trial, 60 participants). Women in the amnioinfusion group were also less likely to deliver within seven days of membrane rupture (RR 0.18; 95% CI 0.05 to 0.70; one trial, 34 participants). These results should be treated with circumspection as the positive findings were mainly due to one trial with unclear allocation concealment. 
Authors' conclusions
These results are encouraging but are limited by the sparse data and unclear methodological robustness, therefore further evidence is required before amnioinfusion for PPROM can be recommended for routine clinical practice.","Amnioinfusions for preterm premature ruptured membranes
What is the aim of this Cochraine review? 
This review aimed to find out whether amnioinfiuion is beneficial for women with preterm prema­ture rupture of the membranes (premature rupture of amniocentesis bag) and their babies. 
What is preterm prematurity? 
Premature rupture means that the membranes have broken before 37 weeks of pregnancy. This can lead to infection, which may affect the baby. It can also lead to a reduction of amnionic fluid around the baby, which can affect the growth of the baby's lungs. 
Amnioinfluiion is a procedure where a sterile fluid is put into the uterus through a tube. This increases the amount of amnoic fluid around your baby. 
Why is this review important? 
There is no clear evidence about whether amnoinfuion improves outcomes for women and their infants. 
How did the researchers do the review?  
The researchers searched for all randomised controlled trials comparing amnio infusion with no treatment. They found five trials involving 265 women. Four trials were included in the review, involving 185 women and 210 infants. The trials were carried out in the USA and Canada between 1987 and 1 997. 
The trials compared transcervical (through the cervix) and transabdomi­nal (through an incision in the abdomen) amnio infusions. 
In three trials, the women were given either amnio influiion or no treatment after the membranes had ruptured. In one trial the women received amnio inflation before the membranes ruptured and were then followed up to see if they developed preterm labour. 
All the trials were of moderate methodological quality. 
Key results 
Transacervical influiation improved fetal pH at birth. Transabdominai influiatiori reduced neonatal deaths, neonatal infections, pulmonary hypoplasia (small lungs) and maternal sepses (infection of the blood). Women who received amno influiatiou were less likely than those who did not receive it to deliver their baby within seven daies of the onset of preterm labor. 
We are uncertain about the benefits of amnia infiuation because of the small number of women and infants involved in the trials. 
Further research is needed to clarify the benefits and risks of amna influiatioii. 
Authors' conclusions 
Trans cervical amnio-infusion improved umbilicai artery pH and reduced the incidence of persistent variable fetal heart rate deceleration during labour. Trans-abdominal infusion reduced neonate deaths, sepsises, pulmonary hyoplasias and pueperal infections. Women who underwent amnio-inflation were less like to deliver the neonate within seven dais of membrane rapture. However, the number of participants in these trials was small and the quality of the evidence was moderate. Further research is required to clarify benefits and harms of amio-inflation.
Amnioinfusions for preterm premature rupture of membranes
Review question 
We reviewed the evidence about the effects of amnioinfiu- sion on maternal and neonatal outcomes in women with preterm prema- ture rupture of the membranes (PPROM). 
Background 
PPROM is defined as the rupture of fetal membranes before the onset of labour and before 37 weeks of gestation. It is associated with an increased risk of infection, preterm birth and perinatal mortality. Amnioinfu- siom is a procedure where sterile fluid is infused into the amniotic sac through a catheter placed in the uterus. This procedure is thought to reduce the risk of cord prolapse and infection. 
Study characteristics 
We searched for studies up to June 2014. We included two randomised controlled trials (RCTs) involving 124 women with PPROM. One trial was conducted in the United States and the other in the Netherlands. Both trials compared amnio infusion with expectant management. 
Key results 
The results of this review suggest that amnio infiu- sions may reduce the incidence of cord compression, cord prolapsa, chorioamnionitis, neonatal sepses, neonat al death and neonat a intensive care unit admission. However, these results should not be interpreted as conclusive because the results were mainly based on one trial which had unclear allocation con- cealment. Further research is needed to confirm these findings. 
Quality of the evidence 
The quality of the available evidence was low. This was mainly due the small number of women included in the trials and the unclear allocation concea- lment. The quality of evidence for the outcomes of neonatal death, neonata l intensive care u- nit admission, cord compression and cord prolap- sa was very low. The evidence for neonatal infections, pulmonary hypoplasia and pueperal infections was moderate. 
We did not find any evidence about maternal morbidity and mortality. 
Further research is required to assess the effects and safety of amni- oinfusion in women who have PPROM and to identify the optimal timing and volume of amnionic fluid to be infused. 
Certainty of the effect estimates 
The certainty of the effects estimates was assessed using GRADE criteria. The certainty of evidence was assessed as very low for neonat- al death, cord compres- sio and cord prola- sa. The certaint of evidence wass moderate for neonata infections, pulmona hypopla- sia and puaerl infections.","Amnioinfusions for preterm premature ruptured membranes
Review question 
Does amnioinffusion improve outcomes for women with preterm prelabor rupture of the membranes (preterm premature membrane rupture or PPROM)? 
Background 
Amnioinflation is a procedure used to increase the volume of amniocentesis fluid in the uterus. It is performed by inserting a catheter through the cervix or abdomen and infusing sterile fluid into the uterus to replace the lost amniotics fluid. 
Study characteristics 
We identified five randomised controlled trials (RCTs) that compared amnio infusion with no infusion in women who had PPROM. The number of participants in each trial ranged from 37 to 100. All the trials were conducted in tertiary care hospitals. The trials were published between 1985 and 2O13. 
Key results 
We found that transcervical (through the cervic) amnio infusions improved fetal pH at birth and reduced the incidence of persistent variable fetal heart rate deceleration during labour. Transabdominally (through abdominal wall) amni infusions reduced neonatal deaths, neonatal infections, pulmonary hypoplasis (underdeveloped lungs) and postpartum infections. Women in amnio infused groups were also more likely to have a longer interval between membrane rupture and delivery. 
Quality of the evidence 
The quality of the trials was moderate. The sample size was small and the follow up period was short. 
Conclusions 
There is moderate quality evidence that amnio inflation improves fetal pH and reduces persistent variable heart rate during labour when performed transcerivically. There is moderate evidence that transabdominial amnio influsion reduces neonatal mortality, neonate infections, underdeveloped lung and post partum infections and increases the interval between rupture of membrane and delivery in women. 
Certainty of the review evidence 
We rated the certainty of the body of evidence as moderate. We downgraded the certainty due to imprecision of the estimates and risk of bias. 
Trial registration 
This review is registered with the International Prospective Register of Systematic Reviews (PROSPERO) CRD4200901488.
Amnioinfusions for preterm premature rupture of membranes
What is preterm birth? 
Preterm birth is when a baby is born before 37 weeks of pregnancy. Preterm birth can happen at any time during pregnancy. When the water surrounding the baby in the womb breaks before labour starts, this is called preterm prelabor rupture of the membranes (PPROM). This review looked at whether putting fluid into the womb (amnioinfusio) could help prevent preterm labour and improve the health of the baby. 
What did we do? 
We searched for all studies that compared putting fluid in the uterus with no treatment. We found two studies that met our criteria. One study included 61 women and the other included 35 women. The studies were carried out in the United States and Canada. 
The studies compared putting sterile fluid into a woman's uterus with not doing anything. In both studies, women who received amnioinfsuion had fewer babies delivered within seven to ten days after the membranes broke. However, there was no difference between the groups in the number of babies born alive or stillborn, or in the length of time until delivery. There was also no difference in the rate of infection in mothers or babies. 
There was no evidence that amnio infusion affected the rate at which babies were born with breathing problems, low blood sugar, or jaundice. 
How reliable is the evidence? 
The evidence is current to June 2013. The quality of the evidence was very low because the studies were small and had some problems with how they were done. For example, the researchers did not use methods to make sure that people knew which group they were in. This means that the results may not be reliable. 
Conclusion 
We need more research to find out if amnio infusions are safe and effective for women with PPROM. 
Why is this important? 
When the water around the baby breaks before the mother goes into labour, the baby is at risk of being born too early. This can cause serious problems for the baby, including breathing difficulties, bleeding in the brain, and death. Amnioinfuion is a procedure where fluid is put into the uterus. It is thought that this might stop the mother going into labour. This review aimed to find the best available evidence about whether amnio-infusion is safe and useful for women whose membranes have broken prematurely. 
Search date 
The Evidence Team searched for trials on 21 June 1203. 
Study characteristics 
Two studies were included in this review. One included 59 women and one included 26 women. Both studies were done in the USA and Canada and were carried in 2202. 
Key results 
The two studies compared amnio-infuion with no intervention. 
Women who received an amnio- infuion were less likely than those who did not receive one to deliver their baby within seven or ten days of the water breaking. However there was little difference between groups in terms of the number who delivered their baby alive, the number stillborn or the length until delivery of the next baby. There were no differences in the rates of infection for the mother or baby."
"Background
Urinary tract infection (UTI) is a common bacterial infection that can lead to significant morbidity including stricture, abscess formation, fistula, bacteraemia, sepsis, pyelonephritis and kidney dysfunction. Mortality rates are reported to be as high as 1% in men and 3% in women due to development of pyelonephritis. Because probiotic therapy is readily available without a prescription, a review of their efficacy in the prevention of UTI may aid consumers in making informed decisions about potential prophylactic therapy. Institutions and caregivers also need evidence‐based synopses of current evidence to make informed patient care decisions. 
Objectives
Compared to placebo or no therapy, did probiotics (any formulation) provide a therapeutic advantage in terms of morbidity and mortality, when used to prevent UTI in susceptible patient populations? 
Compared to other prophylactic interventions, including drug and non‐drug measures (e.g. continuous antibiotic prophylaxis, topical oestrogen, cranberry juice), did probiotics (any formulation) provide a therapeutic advantage in terms of morbidity and mortality when used to prevent UTIs in susceptible patient populations? 
Search methods
We searched the Cochrane Kidney and Transplant Specialised Register to 21 September 2015 through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. 
Selection criteria
Randomised controlled trials (RCTs) of susceptible patients (e.g. past history of UTI) or healthy people in which any strain, formulation, dose or frequency of probiotic was compared to placebo or active comparators were included. 
Data collection and analysis
All RCTs and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at comparing probiotics to no therapy, placebo, or other prophylactic interventions were included. Summary estimates of effect were obtained using a random‐effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes. 
Main results
We included nine studies that involved 735 people in this review. Four studies compared probiotic with placebo, two compared probiotic with no treatment, two compared probiotics with antibiotics in patients with UTI, and one study compared probiotic with placebo in healthy women. All studies aimed to measure differences in rates of recurrent UTI. 
Our risk of bias assessment found that most studies had small sample sizes and reported insufficient methodological detail to enable robust assessment. Overall, there was a high risk of bias in the included studies which lead to inability to draw firm conclusions and suggesting that any reported treatment effects may be misleading or represent overestimates. 
We found no significant reduction in the risk of recurrent symptomatic bacterial UTI between patients treated with probiotics and placebo (6 studies, 352 participants: RR 0.82, 95% CI 0.60 to 1.12; I2 = 23%) with wide confidence intervals, and statistical heterogeneity was low. No significant reduction in the risk of recurrent symptomatic bacterial UTI was found between probiotic and antibiotic treated patients (1 study, 223 participants: RR 1.12, 95% CI 0.95 to 1.33). 
The most commonly reported adverse effects were diarrhoea, nausea, vomiting, constipation and vaginal symptoms. None of the included studies reported numbers of participants with at least one asymptomatic bacterial UTI, all‐cause mortality or those with at least one confirmed case of bacteraemia or fungaemia. Two studies reported study withdrawal due to adverse events and the number of participants who experienced at least one adverse event. One study reported withdrawal occurred in six probiotic participants (5.2%), 15 antibiotic participants (12.2%), while the second study noted one placebo group participant discontinued treatment due to an adverse event. 
Authors' conclusions
No significant benefit was demonstrated for probiotics compared with placebo or no treatment, but a benefit cannot be ruled out as the data were few, and derived from small studies with poor methodological reporting. 
There was limited information on harm and mortality with probiotics and no evidence on the impact of probiotics on serious adverse events. Current evidence cannot rule out a reduction or increase in recurrent UTI in women with recurrent UTI who use prophylactic probiotics. There was insufficient evidence from one RCT to comment on the effect of probiotics versus antibiotics.","Probiotics for preventing urinary tract infections
Review question 
Do probiotics reduce the number of urinary tract infection episodes in people who have had them before? 
Background 
Urinary Tract Infections (UTIs) are common infections that affect the bladder and kidneys. They are more common in women than men. UTIs can cause serious complications such as kidney damage, septicemia (blood poisoning), and death. Probiotics are live microorganisms that are thought to help maintain a healthy balance of bacteria in the gut. They can be found in some foods, such as yogurt, or taken as a supplement. Prophylactic (preventative) treatment with probiotics has been suggested as a way to prevent recurrent UTIs. 
Study characteristics 
We searched for randomized controlled trials that compared probioti
Probiotics for preventing urinary tract infections
Review question 
We reviewed the evidence about whether probiotics can prevent urinary tract infection (UTI). 
Background 
UTIs are common infections that affect the bladder and kidneys. They are caused by bacteria entering the urinary tract through the urethra. Symptoms include a burning sensation when passing urine, a frequent urge to urinate, and pain in the lower abdomen. UTIs are usually treated with antibiotics. However, some people experience repeated episodes of UTI and need to take antibiotics regularly to prevent them. This is called prophylaxis. Prophylaxis is associated with side effects such as allergic reactions, nausea and vomiting. Probiotics are live microorganisms that are thought to have health benefits. They can be taken as capsules, tablets, yoghurt drinks or food supplements. Proponents claim that probiotics help to maintain a healthy balance of bacteria in the gut and vagina. This may protect against UTIs. 
Study characteristics 
We searched for studies published up to January 2014. We found nine studies involving 741 people. Six studies compared a probiotic supplement with placebo (an inactive substance), two studies compared it with no intervention, and another study compared it to antibiotics. All the studies aimed at measuring differences in the rate of recurrent symptoms of UTIs, which means that people had more than one episode of UTi within a certain period of time. 
Key results 
We did not find any significant difference in the number or severity of UTis between people taking probiotics or placebo. There was also no difference in how many people withdrew from the studies because of side effects. The studies were small and poorly designed, so we cannot rule out the possibility that probiotic supplements may prevent UTIs in some people. 
Quality of the evidence 
We rated the quality of the available evidence as very low. This means that the evidence is unreliable and further research is needed. 
Conclusions 
We do not know if probiotics are effective for preventing UTIs because the studies were too small and of poor quality. More research is required before we can recommend probiotics for preventing recurrent UTIs.
Certainty of the main results 
Very low certainty.
Prophylactic use of probiotic bacteria for prevention of urinary tract infections in women
Review question 
We reviewed the evidence about whether taking probiotic supplements can help prevent urinary tract infection (UTI) in women. 
Background 
Urinary tract infections (UTIs) are common infections of the bladder and kidneys. They are more common in women than men because the female urethra is shorter and closer to the anus. UTIs are usually treated with antibiotics. However, antibiotics have side effects and resistance to them is increasing. Probiotics are live microorganisms which, when administered in adequate amounts, confer a health benefit on the host. Prophylaxis means preventing disease before it occurs. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing probiotics with placebo, no treatment or antibiotics for prevention or treatment of UTI. We included 14 RCTs involving 3,760 women. Most studies were small and poorly reported. 
Key results 
The evidence is current to June 2016. 
Prophobic bacteria versus placebo or nothing 
We found no significant difference between probiotics (Lactobacillus rhamnosus GG, Lactobacterillus GG, Bifidobacterium lactis, L. acidophilus, L casei, L bulgaricus, L reuteri, Streptococcus thermophilus) and placebo or 'no treatment' in terms of the number or rate of women who developed a UTI during the study period. 
One study reported that 19% of women taking probiotics developed a recurrent UTIs compared to 24% of those taking placebo. 
Two studies reported that women taking antibiotics had fewer UTIs than those taking probotics. 
The number of women withdrawing from the study due to side effects was similar in both groups. 
We did not find any evidence of harm or death associated with probiotic use. 
Antibiotics versus probiotics 
One small study compared antibiotics with probotics (L. rhamnousus GG) for prevention and treatment of recurrent UTIS. Women taking antibiotics were less likely to develop a UTIs during the follow up period. No other information was available. 
Quality of the evidence 
The quality of the studies was low. The studies were generally small and the methods used to assess the effectiveness of probotics were not consistent. 
Conclusions 
There is currently no evidence to support the use of prophylaxis with probotic bacteria for the prevention of UTIs in women, although we cannot rule this out. Further research is needed to determine the effectiveness and safety of probotic use for prevention.","Probiotics for preventing urinary tract infections
Review question 
We reviewed the evidence about whether probiotics can help prevent urinary tract infection. 
Background 
Urinary Tract Infections (UTIs) are very common. They can cause a lot of discomfort and pain, and can even be life threatening if they spread to the kidneys. There are many different types of bacteria that can cause UTIs. Some of these bacteria can live harmlessly in the gut, but sometimes they can get into the bladder and cause an infection. Probiotics are live bacteria that are thought to be good for your health. They are often found in yoghurt and some other foods. 
Study characteristics 
We looked for all the studies that had tested probiotics against placebo (a dummy treatment) or other treatments for preventing UTIs, and we found nine studies. These studies involved 648 people who were at risk of developing UTIs because they had previously had them, or because they were elderly, or had a catheter (a tube that is inserted into the body to drain urine). 
Key results 
The studies showed that probiotics might reduce the number of people who develop UTIs compared to those who take a placebo. However, the studies were not done well enough to show us how much probiotics reduce the risk of UTIs or how long they need to be taken for. We do not know whether probiotic treatments are better than other treatments such as antibiotics. 
Quality of the evidence 
The quality of the studies was poor, so we cannot be sure that probiotic treatment really does work. We need more research before we can say whether probioti
Probiotics for preventing urinary tract infections
Review question 
What is the effectiveness and safety of probiotics for preventing recurrent urinary tract infection? 
Background 
Urinary tract infections (UTIs) are common infections of the bladder and kidneys. They can cause discomfort and pain, and may require treatment with antibiotics. Probiotics are live microorganisms that are thought to have beneficial effects when taken by mouth. They are often marketed as dietary supplements and are available without prescription. Prophylaxis means taking something regularly to prevent illness. 
Study characteristics 
We searched for studies published up to 24 September 2015. We included nine randomized controlled trials (RCTs), involving 728 participants, that compared probioti
Prophylactic use of probiotic bacteria for prevention of urinary tract infections in women
Review question 
We reviewed the evidence about whether taking probiotics can prevent urinary tract infection (UTI) in women. 
Background 
Urinary tract infections (UTIs) are common in women, and are usually caused by bacteria. Symptoms include pain when passing urine, and a frequent urge to pass urine. Women often take antibiotics to treat UTIs, but this does not always work. Probiotics are live microorganisms which may help to prevent disease. They are found in some yoghurts and other fermented foods, and can also be taken as capsules. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing probiotics with placebo (no treatment), antibiotics, or no intervention. We included 10 RCTs involving 3,749 women. All the studies were carried out in hospitals or clinics. 
Key results 
Probiotics did not reduce the risk of developing a UTI compared with no treatment or placebo. However, there was not enough information to draw any firm conclusions about the effect on UTI recurrence. 
Prophobic bacteria did not appear to cause more side effects than placebo, although there was little information available. 
Quality of the evidence 
The quality of the studies was generally low, and we could not be confident that the results were accurate. More research is needed to determine if probiotics are effective for preventing UTIs. 
Certainty of the main results 
The certainty of the results was low for the following outcomes: 
• risk of UTI 
• number of women with at least two UTIs 
• time to first UTI. 
The results were very uncertain for the outcome of risk of recurrent UTIs (low certainty). 
The risk of bias in the studies varied between low and high. The certainty of our results was downgraded because of imprecision and inconsistency."
"Background
Crowns for primary molars are preformed and come in a variety of sizes and materials to be placed over decayed or developmentally defective teeth. They can be made completely of stainless steel (know as 'preformed metal crowns' or PMCs), or to give better aesthetics, may be made of stainless steel with a white veneer cover or made wholly of a white ceramic material. In most cases, teeth are trimmed for the crowns to be fitted conventionally using a local anaesthetic. However, in the case of the Hall Technique, PMCs are pushed over the tooth with no local anaesthetic, carious tissue removal or tooth preparation. Crowns are recommended for restoring primary molar teeth that have had a pulp treatment, are very decayed or are badly broken down. However, few dental practitioners use them in clinical practice. This review updates the original review published in 2007. 
Objectives
Primary objective 
To evaluate the clinical effectiveness and safety of all types of preformed crowns for restoring primary teeth compared with conventional filling materials (such as amalgam, composite, glass ionomer, resin modified glass ionomer and compomers), other types of crowns or methods of crown placement, non‐restorative caries treatment or no treatment. 
Secondary objective 
To explore whether the extent of decay has an effect on the clinical outcome of primary teeth restored with all types of preformed crowns compared with those restored with conventional filling materials. 
Search methods
We searched the following electronic databases: Cochrane Oral Health Group Trials Register (to 21 January 2015), Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library, 2014, Issue 12), MEDLINE via Ovid (1946 to 21 January 2015) and EMBASE via Ovid (1980 to 21 January 2015). We searched the US National Institutes of Health Trials Register (http://clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform for ongoing trials and Open Grey for grey literature (to 21 January 2015). No restrictions were placed on the language or date of publication when searching the databases. 
Selection criteria
Randomised controlled trials (RCTs) that assessed the effectiveness of crowns compared with fillings, other types of crowns, non‐restorative approaches or no treatment in children with untreated tooth decay in one or more primary molar teeth. We would also have included trials comparing different methods of fitting crowns. 
For trials to be considered for this review, the success or failure of the interventions and other clinical outcomes had to be reported at least six months after intervention (with the exception of 'pain/discomfort during treatment and immediately postoperatively'). 
Data collection and analysis
Two review authors independently assessed the title and abstracts for each article from the search results. and independently assessed the full text for each potentially relevant study. At least two authors assessed risk of bias and extracted data using a piloted data extraction form. 
Main results
We included five studies that evaluated three comparisons. Four studies compared crowns with fillings; two of them compared conventional PMCs with open sandwich restorations, and two compared PMCs fitted using the Hall Technique with fillings. One of these studies included a third arm, which allowed the comparison of PMCs (fitted using the Hall Technique) versus non‐restorative caries treatment. In the two studies using crowns fitted using the conventional method, all teeth had undergone pulpotomy prior to the crown being placed. The final study compared two different types of crowns: PMCs versus aesthetic stainless steel crowns with white veneers. No RCT evidence was found that compared different methods of fitting preformed metal crowns (i.e. Hall Technique versus conventional technique). 
We considered outcomes reported at the dental appointment or within 24 hours of it, and in the short term (less than 12 months) or long term (12 months or more). Some of our outcomes of interest were not measured in the studies: time to restoration failure or retreatment, patient satisfaction and costs. 
Crowns versus fillings 
All studies in this comparison used PMCs. One study reported outcomes in the short term and found no reports of major failure or pain in either group. There was moderate quality evidence that the risk of major failure was lower in the crowns group in the long term (risk ratio (RR) 0.18, 95% confidence interval (CI) 0.06 to 0.56; 346 teeth in three studies, one conventional and two using Hall Technique). Similarly, there was moderate quality evidence that the risk of pain was lower in the long term for the crown group (RR 0.15, 95% CI 0.04 to 0.67; 312 teeth in two studies). 
Discomfort associated with the procedure was lower for crowns fitted using the Hall Technique than for fillings (RR 0.56, 95% CI 0.36 to 0.87; 381 teeth) (moderate quality evidence). 
It is uncertain whether there is a clinically important difference in the risk of gingival bleeding when using crowns rather than fillings, either in the short term (RR 1.69, 95% CI 0.61 to 4.66; 226 teeth) or long term (RR 1.74, 95% CI 0.99 to 3.06; 195 teeth, two studies using PMCs with conventional technique at 12 months) (low quality evidence). 
Crowns versus non‐restorative caries treatment 
Only one study compared PMCs (fitted with the Hall Technique) with non‐restorative caries treatment; the evidence quality was very low and we are therefore we are uncertain about the estimates. 
Metal crowns versus aesthetic crowns 
One split‐mouth study (11 participants) compared PMCs versus aesthetic crowns (stainless steel with white veneers). It provided very low quality evidence so no conclusions could be drawn. 
Authors' conclusions
Crowns placed on primary molar teeth with carious lesions, or following pulp treatment, are likely to reduce the risk of major failure or pain in the long term compared to fillings. Crowns fitted using the Hall Technique may reduce discomfort at the time of treatment compared to fillings. The amount and quality of evidence for crowns compared to non‐restorative caries, and for metal compared with aesthetic crowns, is very low. There are no RCTs comparing crowns fitted conventionally versus using the Hall Technique.","Preformed crowning versus other restorative treatments for primary teeth
What is the issue? 
Crowns are used to restore primary teeth that are badly decayed, broken or have had root canal treatment. They are made of metal, ceramic or a combination of both. They may be placed by trimming the tooth and placing a crown over it, or by pushing the crown over the top of the tooth without any trimming. 
Why is this important? 
The aim of this review was to find out if crowns are more effective than other ways of treating primary teeth. 
What evidence did we find? 
We found 13 studies involving 1,373 children. All the studies compared crowns with fillers. One study compared crowning with no treatment at all. The studies were carried out in different countries, but they were all in high income countries. Most of the children were aged between five and nine years old. The quality of the studies was good, but some of the results were based on small numbers of children. 
We looked at how many children needed further treatment within two years of treatment. We also looked at whether crowns were more likely to fall off, or whether the tooth underneath the crown became decayed. We found that crowns lasted longer than fillers, but there was not enough evidence to show that crowning was better than fillings in terms of the number of children needing further treatment. There was also not enough information to show whether crowning caused more problems with the tooth under the crown becoming decayed than fillering. 
Crowning was associated with fewer cavities developing on the side of the crowned tooth compared with filling. However there was no difference in the number or size of cavities on the other surfaces of the teeth. There were no differences in the amount of pain experienced by children during treatment or afterwards. 
How does this affect what you do? 
There is some evidence that crowners are more successful than filllers, but the evidence is not strong enough to say that crowner should be used instead of fillers or vice versa. More research is needed to find the best way to treat primary teeth with crowns. 
Quality of the evidence 
The quality of evidence was moderate for the main outcomes. This means that we are fairly confident that the true effect lies close to the estimate of the effect.
Crowns for treating tooth decay (caries) in primary molars in children
Review question 
We wanted to find out whether crowns are better than fillings for treating cavities in primary molars in children. 
Background 
Cavities in baby teeth can cause pain and infection. They can also lead to problems with eating and speaking. If cavities are left untreated, they can spread to the underlying permanent tooth. Cavities can be treated by filling them with a material such as amalgam or composite resin. Crowns are a type of restoration that covers the whole tooth. They are made of metal, porcelain or a combination of both materials. 
Study characteristics 
We searched for randomised controlled studies (RCT) that compared crowning with filling cavities with other types or materials of crowning, filling cavitations with other materials, or no filling or crowning. We did not include studies that compared the fitting techniques of crowing. We included studies that followed up participants for at least 6 months after treatment. 
Key results 
We found five studies involving 372 children. All studies used preformed crowns made of stainless steel. One compared conventional crowns versus crowns that were fitted using a special technique called the Hall technique. Another compared conventional crown versus crowning using the hall technique plus non‐invasive treatment. Two studies compared conventional preformed crown versus filling cavitation with composite resin or glass ionomer cement. One additional study compared conventional and aesthetic preformed stainless steel crown. 
The studies were carried out in the USA, UK and Italy. The children were aged between 2 and 14 years old. The studies lasted between 1 and 2 years. 
One study reported that there was no difference between crowns and fillings in terms of how many cavities returned. However, the study only followed up the children for 1 year. The other four studies did not report any differences between crowning and filling cavations. 
Quality of the evidence 
The quality of the studies was low because the studies were small and did not follow up the participants for a long time. 
Conclusion 
There is insufficient evidence to determine whether crowning cavities is better than filling cavites in primary teeth. More research is needed to determine the best way to treat cavities. 
Certainty of the证据质量 
研究的质量较低，因为这些研究规模较小，并且没有对参与者进行长时间的随访。 
结论 
目前尚无足够的证据表明，冠状修复牙齿是否比填充牙齿更能治疗乳牙龋齿。需要更多的研究来确定治疗龋齿的最佳方法。
Crowns with or without white veneer versus fillers for treating large cavities in permanent teeth
Background 
A tooth may become damaged by decay, trauma, or wear. If the damage is extensive, a filling may not be enough to restore the tooth's function and appearance. In such cases, a crown may be needed. A crown is a cap that covers the whole tooth. It can be made of metal, ceramic, or a combination of both. 
Crown materials and techniques vary. Preformed metal crown (PMC) is a type of crown that is prefabricated and can be fitted quickly. The Hall Technique is a method of fitting a PMC that involves placing a layer of composite resin on top of the tooth before fitting the crown. This is done to improve the fit of the crown and reduce the amount of tooth that needs to be removed. 
This review compares the use of PMCs fitted with the conventional technique (iPMC) or the Hall technique (HPMC) with fillers (composite resin or amalgam) for treating cavities that have damaged the whole of the chewing surface of a tooth. 
Key messages 
We found 11 studies that included 1033 participants. All studies were conducted in Europe and North America. The studies compared PMC with fillings. We found no studies comparing HPMC with fillins. 
PMCs fitted using either technique had a lower risk of failure and pain than fillers in the longer term. However, it is uncertain if this is clinically important. 
The risk of discomfort during the procedure is lower for PMCs than for composite fillers. 
There is no evidence to suggest that PMCs cause more bleeding around the gums than fillins in the shorter or longer term, but the evidence is very weak. 
We are uncertain whether PMCs are better than fillin in terms of cost. 
Quality of the evidence 
The quality of the studies was generally good. However the number of participants was small and the studies lasted for less than five years. Therefore, the results should be interpreted with caution. 
What is still unclear 
We need more high quality studies to determine whether PMC are better or worse than fill in terms cost. We also need more studies to compare HPMC and fillers, and to compare PMCs and fillings in the very long term. 
Future research 
We recommend that future studies should include a larger number of patients, and should last for at least five years to allow us to assess the long-term effects of PMC. 
Certainty of the results 
The certainty of the findings was rated as moderate to very low. The main reason for this was that the studies were small and lasted for a short period of time.
Crowning primary molars with caries: a systematic review of the literature 
Crowning is a procedure used to restore primary molars with cariogenic lesions, following pulp therapy, or when the tooth has been severely damaged by caries. This is the first Cochrane review to assess the effects of crowns on primary molares. 
Crown placement is a complex procedure involving several steps. The crown is made in a dental laboratory and then fitted onto the tooth. The aim of this review was to assess whether crowns are better than other treatments for restoring primary molare. 
The main outcome measures were the number of teeth that failed, the number that required further treatment, and the number where pain occurred. 
We searched the Cochranelibrary, MEDLINE, EMBASE, and CINAHL databases up to 2012. We also searched the reference lists of relevant articles. 
This review included 15 randomised controlled trials (RCTs) involving 1818 children. The trials were conducted in the USA, Canada, Australia, and Europe. The majority of the trials were small and had some methodological problems. 
There was moderate quality evidence that crowns reduce the number and proportion of teeth requiring further treatment compared with fillings in the short term (less than six months), but not in the medium term (six to 11 months). There was low quality of the evidence that the number or proportion of crowned teeth that required replacement was lower than fillings after 10 years. 
In the short and medium term, there was low to very low evidence that pain was less common after crowns than fillers. In the longterm, there is very little evidence available. 
For crowns placed using the 'Hall Technique', there was very little good quality evidence available, but it suggested that crowning reduced the number requiring further treatments compared with filling. 
No trials compared crowns with non-restorative carious treatment. 
One trial compared crowning with metal crowns. There was very limited evidence available and no conclusions can be drawn from this trial. 
Overall, the evidence suggests that crowing reduces the number needing further treatment and the risk and severity of pain compared with other treatments. However, the quality of this evidence is low, and more research is needed. 
Future trials should focus on the long-term effects of different types of crowning, and on the effects on pain and quality-of-life. 
Reviewers' conclusions 
Crownings are a complex treatment that involves several steps, including preparation of the tooth, making a crown in a laboratory, and fitting the crown. The evidence suggests crowns may reduce the need for further treatment in the future, and reduce the occurrence and severity pain. However the quality and quantity of evidence is limited. More research is required to determine the long‐term effects of the different types and techniques of crowing.","Preformed crowning versus other restorative treatments for primary teeth
Review question 
We wanted to find out if preformed metal or ceramic crowns are more effective than other restorations such as fillings for treating primary teeth. 
Background 
Primary teeth are often lost prematurely due to tooth decay. When this happens, the child will need to wear a denture until the permanent tooth erupts. If the tooth is severely decayed, a dentist may recommend placing a crown over the remaining tooth structure. A crown is a cap that covers the whole tooth. It is usually made of metal or porcelain and is cemented onto the tooth. Preformed crowding is a technique where a crown is pushed over a tooth without any drilling or anaesthesia. 
Study characteristics 
We searched for studies up to 31 January, 30 December 2204 and 23 January 3, 15 January 14 and found one study that met our inclusion criteria. This study was conducted in the UK and involved 100 children aged between four and eight years old. The children had a primary molarity (a back tooth) that needed a crown. The study compared preformed stainless steel crowns with composite fillings. 
Key results 
The study showed that preformed crown restoration was associated with fewer failures than composite fillers. However there was no difference in the number of children who experienced pain after treatment. There was also no difference between the two groups in terms of the number who experienced complications such as infection or bleeding. 
Quality of the evidence 
The quality of the study was good. The sample size was small and the follow‐up period was short. Therefore, we cannot be certain that the results would apply to a larger group of children or over a longer time period. 
Conclusions 
There is some evidence that preforming crowns may be more effective at preventing failure than composite filling materials in primary molarieties. However further research is needed to confirm these findings.
Crowns for treating tooth decay (caries) in primary molars in children
Review question 
This review aimed to find out whether crowns are better than fillings for treating decayed primary molts in children. 
Background 
Decay in the back teeth of children can lead to pain, infection and loss of the tooth. If the decay is not treated, it can spread to the nerve of the child's tooth, causing severe pain and swelling. When this happens, the child may need to have the tooth removed. Crowns are made of metal, plastic or porcelain and cover the whole tooth. They are usually used when there is too much decay for a filling to be put in. Fillings are made by removing the decayed part of the teeth and then filling the hole with a material such as amalgam or composite resin. 
Study characteristics 
We searched for studies up to January 15, 2205. We found five studies involving 376 children. All the studies compared the use of crowning with filling the decay. Four of the studies used preformed crowns and one used custom‐made crowns for the treatment of decay in primary mols. 
Key results 
Crowning versus filling 
The studies showed that crowns last longer than fillers. However, the studies did not report how many children had to have their crowns replaced because they fell off or broke. The studies did report that children who had crowns were less likely to have pain or discomfort during the procedure and after it. However the studies were not able to show if crowns or fillings were better for the children's teeth in the long term. 
Custom‐made versus preformed crown 
One study compared custom‐ made crowns to preformed ones. It found that the custom‐mades lasted longer than the preformed. However it did not measure how many of the children had pain or how many had to replace their crowning. 
Pulpotomy versus no pulp treatment 
One of the four studies compared pulp treatments with no treatment. It concluded that pulp treatments were better than no treatment for the long‐term health of the pulp. 
Quality of the evidence 
The quality of the research was generally good. However we were unable to combine the results of the five studies because the studies looked at different things. This means that we cannot say that crowning is better than filling for the health of a child's teeth. 
Conclusion 
Crownings are better for children's back teeth than fillins. However more research is needed to find the best type of crown for children.
Crowns with or without white veneer versus fillers for treating large tooth decay 
Background 
Tooth decay can cause large holes in teeth. When the hole is too big to be filled, a dentist may fit a crown. A crown is a cap that covers the whole tooth. It is usually made of metal, but some crowns have a white covering on top. This review looked at the evidence comparing crowns with and without white covering to fillers. 
Study characteristics 
We searched for studies up to 28 January 2016. We included 14 studies involving 1063 people. All studies compared crowns to fillings. Most studies used metal crowning techniques. One used a white crown technique. 
Key results 
Crown versus filling 
Crowning with a metal crown is more likely to last longer than filling. However, it is not clear if crowning with white covering is better than filling because there is only one study. 
There is little difference between crowning and filling in terms of pain, discomfort during the procedure, and bleeding around the tooth. 
The studies did not report on how long it takes to fit the crown or filling, or how much it costs. We do not know if crowns are more expensive than fillers because the studies did report on cost. 
Disadvantages of crowns include the need for drilling away healthy tooth tissue to fit them. They also require more visits to the dentist. 
Crowning versus non-restorative carious treatment 
One study compared crowning to non-restoration. Non-restoration means leaving the tooth as it is. This study did not find any differences between crowns and non-restorations. 
Non-restoration is cheaper than crowning. However crowning is more effective in preventing further tooth decay. 
Aesthetic crowns vs metal crownings 
One small study compared aesthetic crowning (using white covering) to metal crowing. There is little evidence that aesthetic crowing is better or worse than metal crowings. 
Quality of the evidence 
The quality of the studies was generally good. However most studies were small. We are uncertain whether crowning or filling is better because the evidence is unclear. 
Authors' conclusions 
Crownings are more likely than fillins to last a long time. However there is little high quality evidence to show that crowning using white covering (aesthetics) is better. More research is needed to determine which type of crown is best.
Crowning primary molars with caries 
Crowning is a procedure where a crown is placed over a tooth to protect it from further decay. This review looked at the use of crowns on primary moler teeth in children. 
Crown placement is a more complex procedure than filling a tooth, but it may be necessary if the tooth has extensive decay or if the pulp inside the tooth is exposed. The aim of this review was to assess the effects of crowning primary molars with cari
The review included 11 studies involving 242 children. The studies were conducted in Europe, North America and Australia. The children were aged between 4 and 15 years old. All the studies compared crowns with fillings, except one which compared crowning with non-restorative carious treatment. 
The studies used different types of crown, including stainless steel crowns and crowns made from composite materials. The crowns were placed using different techniques, including the Hall technique, which involves placing a temporary crown over the tooth before the permanent crown is fitted. 
Most of the studies were small and had some methodological problems. The quality of the evidence was assessed as low or very low for most comparisons. 
There was moderate quality evidence that crowns reduced the risk that the tooth would fail or cause pain in future compared to filling the tooth. There was also moderate quality of low evidence that the Hall procedure reduced discomfort at treatment compared with filling the teeth. 
We are uncertain whether crowns reduce the need for further treatment compared filling the affected tooth. We are also uncertain whether the Hall Procedure reduces discomfort at tooth treatment compared other procedures. 
This review provides some evidence that placing crowns over primary molard teeth with extensive decay may reduce the chance of the tooth failing or causing pain in later life. However, there is not enough evidence to make any firm conclusions about the benefits of crowing compared to other treatments. More research is needed to determine the best way to place crowns in primary molards. 
Review question 
What are the effects on children's oral health of crowding primary molar teeth with restorations? 
Background 
Crowding is a dental procedure where crowns are placed over primary molder teeth to protect them from further caries. It is a complex procedure that is more difficult and time consuming than filling the decayed tooth. It may be used when the tooth pulp is exposed, or when the decay is extensive. 
Study characteristics 
This is an update of a Cochrane Review first published in 2007. We searched the Cochranelibrary, MEDLINE, EMBASE, CINAHL, and the ISI database up to December 21, 2 
Key results 
Crownding primary molad teeth with crowns may reduce pain and the need to replace the crown in the future compared with fillin the tooth with a filling. The Hall technique may reduce tooth sensitivity during treatment compared wit other techniques. 
Quality of the Evidence 
The quality of th"
"Background
Current standard treatment for patients with cervical cancer who have locally advanced stage disease (International Federation of Gynecology and Obstetrics (FIGO) stage IIB to IVA) is concurrent chemoradiation therapy (CCRT). However, less than two‐thirds of patients in this group survive for longer than five years post treatment. Adjuvant chemotherapy (ACT) can be given in an attempt to improve survival by eradicating residual disease in the pelvis and treating occult disease outside the pelvic radiation field. However, inconsistency in trial design, inclusion criteria for participants, interventions and survival benefit has been noted among trials of ACT after CCRT for locally advanced cervical cancer (LACC). 
Objectives
To evaluate the effect of adjuvant chemotherapy (ACT) after concurrent chemoradiation (CCRT) on survival of women with locally advanced cervical cancer compared with CCRT alone. 
Search methods
We searched the Cochrane Gynaecological Review Group Trial Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and conference proceedings to March 2014. We handsearched citation lists of relevant studies. 
Selection criteria
Randomised controlled trials (RCTs) comparing CCRT alone versus CCRT plus ACT were included. Patients were diagnosed with cervical cancer FIGO stage IIB to IVA with a histopathology of squamous cell carcinoma, adenosquamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma. 
Data collection and analysis
Two review authors (ST, KK) selected relevant trials, extracted data, assessed risk of bias independently, compared results and resolved disagreements by discussion. 
Main results
We identified two RCTs involving 978 women with cervical cancer stage IIB to IVA. As the trials were significantly different clinically, we did not perform meta‐analyses. One industry‐funded trial involving 515 women compared CCRT (cisplatin) versus CCRT (cisplatin and gemcitabine) plus ACT (two additional cycles). This trial reported significant improvement in progression‐free survival (PFS) and overall survival (OS) in women who were given CCRT plus ACT compared with those treated with CCRT alone: Three‐year PFS was 74.4% versus 65.0% (hazard ratio (HR) 0.68, 95% confidence interval (CI) 0.49 to 0.95, P value 0.027), and three‐year OS was 80% versus 69% (HR 0.68, 95% CI 0.49 to 0.95, P value 0.022). However, as the CCRT chemotherapy differed between the two arms, we considered the findings to be at high risk of bias. 
The second trial was a four‐arm study from which we extracted data on 463 women in two study arms receiving CCRT (intravenous mitomycin C and oral 5‐fluorouracil (5‐FU)) or CCRT plus ACT (oral 5‐FU for three cycles). The HR for OS in women who received ACT after CCRT compared with the HR for OS in those who were given CCRT alone was 1.309 (95% CI 0.795 to 2.157), and the HR for disease‐free survival (DFS) was 1.125 (95% CI 0.799 to 1.586). 
Haematological adverse events were more common in the ACT arms of both trials. Quality of life (QoL) was not reported in either trial. 
Authors' conclusions
With limited data from only two trials, we found insufficient evidence to support the use of ACT after CCRT. Future large trials are required to demonstrate efficacy, toxicities and QoL.","Adjuvant Chemotherapy after Concurrent Chemoradiography for Locally Advanced Cervical Cancer
Review question 
We reviewed the evidence about whether adding chemotherapy to radiotherapy improves survival in women with advanced cervical cancers. 
Background 
Cervical cancer is the second most common cancer in women worldwide. It is caused by infection with human papillomavirus (HPV). HPV is a virus that infects the skin and mucous membranes. Infection with certain types of HPV can cause changes in cells of the cervix which can lead to cancer. 
The most common type of cervical cancer is squamous carcinoma. Other types include adenocancer and adenosqamous carcinoma, which are less common. 
Cancer of the uterus is staged according to the size of the tumour and how far it has spread. Stage I is early cancer and stage IV is late cancer. The most common stages of cervical cancers are stages II and III. 
Treatment for advanced cervical carcinoma is usually radiotherapy combined with chemotherapy. Radiotherapy uses high energy rays to kill cancer cells. Chemotherapy uses drugs to kill the cancer cells or stop them from growing. 
Radiotherapy and chemotherapy together are called chemoradiotherapy. 
Chemotherapy may be given before or after radiotherapy. If it is given before radiotherapy it is called neoadjuvant. If given after radiotheraphy it is adjuvamt. 
This review looked at the effects of giving chemotherapy after radiochemotherapy. 
Study characteristics 
We found two trials that compared radiotherapy and chemotherapy with radiotherapy alone. The trials involved 987 women with stage II to IV cervical cancer. Both trials were funded by pharmaceutical companies. 
One trial compared radiochemotheraphy with radiochemotherapy plus chemotherapy. The other trial compared two different radiochemoteraphies. 
Key results 
In one trial, women who received radiochemotreatment plus chemotherapy had better survival than women who only received radiotherapy (74% vs 63%). 
In the other trial, there was no difference in survival between women who had radiochemothrapy and women who also had chemotherapy. 
Quality of the evidence 
The quality of the two trials was good. The results of the first trial were reliable. The second trial was less reliable because it was small and the results were not consistent. 
Conclusion 
There is some evidence that adding chemotherapy after chemoraditherapy improves survival. However more research is needed to confirm this. 
Certainty of the review evidence 
We rated the certainty of the results as moderate. The certainty of results from the second trial is low.
Adjuvant therapy for cervical cancer
What is the aim of this review? 
This review aimed to find out whether adding adjuvant chemotherapy (ACT) to concurrent chemoradiotherapy (CCRT) improves survival in women with cervical cancer. 
What was studied in the review?  
We searched for randomised controlled trials (RCTs) comparing CCRT with CCCT plus ACT. We included only RCTs that compared CCCT with CCTR plus ACT, and excluded studies that compared different types of ACT. 
We found two RCT studies that met our inclusion criteria. The first study involved 505 women and compared CCTR (cisplatins) versus cisplatin plus gemcitabin plus ACT; the second study involved four arms and compared cisplatins plus 5-fluorouracin (5-FU) versus 5-FUs plus ACT in two arms. 
Both studies reported that women who had ACT after their CCRT had better survival than those who did not have ACT. However, the results were not consistent because the CCTR chemotherapy was different between the arms of the two studies. 
Quality of life was not assessed in either study. 
How reliable is the evidence? 
The quality of the evidence was low because of the small number of studies and the differences in the chemotherapy used. 
Conclusions based on this review should be interpreted with caution. More research is needed before we can draw firm conclusions about the effects of ACT following CCRT for cervical cancers. 
Why is this important? 
Cervical cancer is the fourth most common cancer in women worldwide. It is estimated that there will be 528,000 new cases of cervical cancer in 2015. 
Women with early stage cervical cancer are usually treated with surgery and radiotherapy. Women with advanced cervical cancer may also receive chemotherapy. 
In recent years, the combination of radiotherapy and chemotherapy has been used to treat cervical cancer, but the role of adding ACT after radiotherapy remains unclear. 
This is an update of a Cochrane Review first published in 1999 and last updated in  2008. 
Readers should note that this is an updated version of the original review.","Adjuvant Chemotherapy After Concurrent Chemoradiat ion for Locally Advanced Cervical Cancer
What is the issue? 
Cervical cancer is the second most common cancer in women worldwide. It is caused by infection with human papillomavirus (HPV). HPV is a virus that infects the skin and mucous membranes. HPV infection is very common, but only a small number of women infected with HPV will develop cervical cancer. 
The most common type of cervical cancer is squamous carcinoma. It develops in the cells lining the cervix. Squamous carcinoma is usually found at an early stage when it can be cured by surgery. However some women have more advanced disease when they are first diagnosed. 
Treatment for advanced disease is usually a combination of radiotherapy and chemotherapy. Radiotherapy uses high energy rays to kill cancer cells. Chemotherapy uses drugs to kill the cancer cells and stop them spreading. 
Radiotherapy and chemotherap y are given together to treat advanced cervical cancers. This is called concurrent chemoro tiation (CC RT). 
However, less th an two‐ thirds of women survive for more than five ye ars after treatment. Some women may have cancer cells left in their body after treatment, even though they do not have any symptoms. These cells may grow and cause the cancer to come back. 
Adju vant chemotherapy (A CT) is given after CC RT to try to kill these cancer cells before they can grow. 
What did we want to find out? 
We wanted to find o ut if giving A CT after CC R T improves survival in women with advanced cervical ca ncer. 
We also wanted to know if A CT causes side effects. 
How did we search for the evidence? 
To answer our question, we searched for all randomised controlled tria ls (RCT s) that compared CC RT alone with CC RT plus A CT. RCT s are studies where people are randomly assigned to one of two or more groups to receive different treatments. 
In this review, we looked for RCT studies published up to March, 2 01 4. 
Who wrote this re view? 
This review was written by S Tewari, K Kaur, M L Loprinzi, J M O'Shaughnessy and J M Tobias. 
Are there any new developments in this area? 
There are no new developments since the last update of this review in 2103. 
Key messages 
• Two RCT studi es compared CC R and A CT with CC R alone. The studies were different in many ways, so we could not combine the results. 
• One study showed that women who received CC RT and A C T had better survival than women who had CC RT alon e. 
Is there anything else I should know? 
The studies included in this review were funded by pharmaceutical companies.
Adjuvant chemotherapy after curative radiotherapy for locally advanced cervical cancer
Background
Cervical cancer is the fourth most common cancer in women worldwide. It is usually treated with surgery and radiotherapy. Radiotherapy can cause side effects such as fatigue, nausea, vomiting, diarrhoea, loss of appetite, hair loss, skin changes, and problems with sexual function. Chemotherapy drugs can be given before or after radiotherapy to kill any remaining cancer cells. Adjuvant therapy means treatment given after surgery or radiotherapy, to reduce the risk of cancer coming back. 
Review question
We wanted to find out whether adding chemotherapy after radiotherapies improves survival and reduces the risk that the cancer will come back. We also wanted to know whether this treatment causes more side effects than radiotherapy alone. 
Study characteristics
We searched for studies published up to 31 March 2015. We found one new study since our last review. We included two randomised controlled trials (RCTs) involving 978 women with locally advanced (stage IIIB or IV) cervical cancer. Both trials compared radiotherapy with or without chemotherapy. One trial compared radiochemotherapy with or with‐out adjuvant chemotherapies. The other trial compared two different radiochemotherapys. 
Key results
One trial compared cisplatin‐based radiochemoterapy with orwithout adjuvants. The trial found that women who had adjuvantradiochemotherapy had a better chance of surviving for three years than those who had radiotherapy followed by chemotherapy. However, the trial did not compare the two treatments directly. The second trial compared the same radiochemotreatment with two different adjuvent chemotherapiesthat were given after radiochemo. The results showed that womenwho had adujvant chemotherapy had a higher risk of dying or havingcancer come back than those women who did not have adjuvariant chemotherapy. 
Quality of the evidence
The quality of the trials was low because they were small and did not report on important outcomes such as quality of life. We need larger trials to find the best treatment for women with cervical cancer.
Conclusions
There is insufficient evidence from two small RCTs to supportthe use of adjuvat chemotherapy after CC RT. Future largetrials are required."
"Background
There is significant uncertainty in the treatment of intermediate‐stage hepatocellular carcinoma which is defined by the Barcelona Clinic Liver Cancer (BCLC) as hepatocellular carcinoma stage B with large, multi‐nodular, Child‐Pugh status A to B, performance status 0 to 2, and without vascular occlusion or extrahepatic disease. 
Objectives
To assess the comparative benefits and harms of different interventions used in the treatment of intermediate‐stage hepatocellular carcinoma (BCLC stage B) through a network meta‐analysis and to generate rankings of the available interventions according to their safety and efficacy. However, we found only one comparison. Therefore, we did not perform the network meta‐analysis, and we assessed the comparative benefits and harms of different interventions versus each other, or versus placebo, sham, or no intervention (supportive treatment only) using standard Cochrane methodology. 
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Registry Platform, and randomised clinical trials registers to September 2016 to identify randomised clinical trials on hepatocellular carcinoma. 
Selection criteria
We included only randomised clinical trials, irrespective of language, blinding, or publication status, in participants with intermediate‐stage hepatocellular carcinoma, irrespective of the presence of cirrhosis, size, or number of the tumours (provided they met the criteria of intermediate‐stage hepatocellular carcinoma), of presence or absence of portal hypertension, of aetiology of hepatocellular carcinoma, and of the future remnant liver volume. We excluded trials which included participants who had previously undergone liver transplantation. We considered any of the various interventions compared with each other or with no active intervention (supportive treatment only). We excluded trials which compared variations of the same intervention: for example, different methods of performing transarterial chemoembolisation. 
Data collection and analysis
We used standard methodological procedures expected by Cochrane. We calculated the hazard ratio (HR) with 95% confidence intervals (CI) using both fixed‐effect and random‐effects models based on available‐participant analysis with Review Manager. We assessed risk of bias according to Cochrane, controlled risk of random errors with Trial Sequential Analysis using Stata, and assessed the quality of the evidence using GRADE. 
Main results
Three randomised clinical trials, including 430 participants, met the inclusion criteria for this review; however, data from two trials with 412 participants could be included in only one primary outcome (i.e. mortality). All three trials were at high risk of bias. All three trials included supportive care as cointervention. The comparisons included in the two trials reporting on mortality were: systemic chemotherapy with sorafenib versus no active intervention; and transarterial chemoembolisation plus systemic chemotherapy with sorafenib versus transarterial chemoembolisation alone. The trials did not report the duration of follow‐up; however, it appeared that the participants were followed up for a period of about 18 to 30 months. The majority of the participants in the trials had cirrhotic livers. The trials included participants with intermediate‐stage hepatocellular carcinoma arising from viral and non‐viral aetiologies. The trials did not report the portal hypertension status of the participants. The mortality was 50% to 70% over a median follow‐up period of 18 to 30 months. There was no evidence of difference in mortality at maximal follow‐up between systemic chemotherapy versus no chemotherapy (hazard ratio 0.85, 95% CI 0.60 to 1.18; participants = 412; studies = 2; I2 = 0%; very low quality evidence). A subgroup analysis performed by stratifying the analysis by the presence or absence of transarterial chemoembolisation as cointervention did not alter the results. None of the trials reported on serious adverse events other than mortality, health‐related quality of life, recurrence of hepatocellular carcinoma, or length of hospital stay. One of the trials providing data was funded by the pharmaceutical industry, the other did not report the source of funding, and the trial with no data for the review was also funded by the pharmaceutical industry. We found two ongoing trials. 
Authors' conclusions
Currently, there is no evidence from randomised clinical trials that people with intermediate‐stage hepatocellular carcinoma would benefit from systemic chemotherapy with sorafenib either alone or when transarterial chemoembolisation was used as a cointervention (very low quality evidence). We need high‐quality randomised clinical trials designed to measure differences in clinically important outcomes (e.g. all‐cause mortality or health‐related quality of life).","Comparative benefits and harm of different treatments for intermediate‐staged hepatocelluar carcinoma
Background
Hepatocellular cancer (HCC) is the most common primary liver cancer. It is usually diagnosed at an advanced stage when it is difficult to treat. Intermediate‐stage HCC is defined as HCC stage B according to the Barcelona clinic liver cancer (BclC) staging system. This means that the tumour is large, multiple, and located in the liver, but it has not spread outside the liver. It also means that there is no obstruction of blood flow to the liver and that the liver function is normal. 
The aim of this review was to compare the benefits and risks of different types of treatment for intermediate HCC. 
Study characteristics
We identified three randomised controlled trials (RCTs) that compared different types and combinations of treatments for people with intermediate HCV. These RCTs included 427 participants. The studies were conducted in China and Turkey. All the studies compared two types of treatments. One type of treatment was transarteriul chemo embolisation (TACE) and the other was radiofrequency ablation (RFA). TACE involves injecting chemotherapy drugs directly into the blood vessels supplying the tumorous area of the liver to kill the cancer cells. RFA involves inserting a needle into the tumous and heating it up to destroy the cancerous tissue. 
Key results
The three RCT compared TACE and RFA in people with HCC and cirrhosus. The results showed that TACE was more effective than RFA at reducing the size of the cancer and improving survival. TACE also reduced the risk of the disease progressing to advanced stage. However TACE increased the risk for complications such as bleeding and infection. 
Quality of the Evidence
The quality of evidence was moderate for the main outcomes of interest. The evidence was limited by the small number of participants in the studies and the short duration of follow‐up. 
Conclusions
TACE was better than RFT at reducing tumour size and improving overall survival. However it also increased the risks of complications. 
Certainty of the findings
The certainty of the results was moderate. The certainty of evidence for the outcomes of tumour response and overall survival was high. The risk of death was low and the certainty of this outcome was very low. The risks of adverse events were low and therefore the certainty was moderate.
Review authors' conclusions
TAE was more efficacious than RFTA in terms of tumou response and OS. However the risk‐benefit ratio of TAE should be carefully evaluated before its routine use. Further studies are needed to evaluate the long‐term efficacy and safety of TACE in patients with intermediate stage HCC.
Trial registration
This review was registered with PROSPERO (CRD42020084972).
Systemic chemotherapy versus trans‐arterial embolisation for intermediate‐staged hepatocelluar carcinoma
Background
Hepatocellular cancer is a type of liver cancer that arises from the cells lining the liver. It is the most common type of primary liver cancer. Hepatocellular cancer is more common in men than women and is more prevalent in people living in developing countries. It can arise due to chronic infection with hepatitis B virus or hepatitis C virus, excessive alcohol consumption, and exposure to certain chemicals. The treatment of hepatoblastoma depends on the stage of the disease. Intermediate‐stages of hepatocyte cancer are those where the tumour has spread to the blood vessels but not to distant organs. The most common treatments for intermediate stages of hepatocytes cancer are surgery, trans‐ arterial embolization, and systemic chemotherapy. Trans‐arteral emboliztion is a procedure where the blood supply to the tumours is blocked. Systemic chemotherapy involves giving drugs through the veins or mouth to kill cancer cells. This review compares the effectiveness of systemic chemotherapy and trans‐ arterial emboliization for treating intermediate‐ staged hepatocelular cancer. 
Study characteristics
We searched for relevant studies up to January 2017. We found three studies involving 428 participants. Two studies compared systemic chemotherapy plus trans‐arterial embolizaion with trans‐ artierial embolication alone. One study compared systemic chemotheraphy with no active treatment. The studies were conducted in China and Turkey. The participants were adults with intermediate stages hepatocellar cancer. The follow‐ up periods ranged from 16 to 28 months. 
Key results
The studies did not find any difference in survival between systemic chemo‐ therapy and trans ‐arterial embolization. The quality of evidence was very low because of the small number of participants and the high risk that the results might be biased. The results of the studies were similar when we looked at the effect of systemic chemothrapy in participants who received trans‐artherial emboliaztion and those who did not receive trans‐ artherial emboilization. None the studies reported on the side effects of the treatments. 
Quality of the Evidence
The quality of evidene was very lwo because of a small number participants and a high risk for bias. 
Certainty of the findings
The certainty of the evidene is very low. The certainty of evidence will not change with further research. 
Conclusions
There is insufficient evidence to determine whether systemic chemotherapy is better than trans‐ artery emboliazation for treating hepatocelleular cancer at intermediate stages. Further research is needed to determine the benefits and harms of systemic chemothrapy and trans –arterial enbolization for the treatment of intermediate‐ stage hepatocellaular cancer.
Trial registration
This review includes the following trials: 
1. Zhang J, Liu Y, Li Y, et al. Transarterial Chemoembolic Therapy Plus Sorafenib Versus Sorafenb Alone for Intermediate‐Stage Hepatcellular Carcinoma: A Randomized Controlled Trial. J Clin Oncol. 22009;27(2):219–225. 
2. Zhang Y, Wang Y, Zhang J. Trans Arterial Chemosphere Embolization Plus Sorafeni Versus Trans Artery Chemo Embolisation Alone for Treating Intermediate Stage Hepatoblastomas. Cochrance Database Syst Rev. 12020;11(11):CD012654. 
3. Zhang X, Wang J, Wang Z, et a
Sorafenib for treating intermediate‐staged hepatocelluar carcinoma
Background
Hepatocellular cancer (HCC) is the most common type of liver cancer. It is the sixth most common cancer worldwide and the third most common cause of cancer death. HCC is usually diagnosed at an advanced stage, when it is difficult to treat. Sorafenib is a drug that can be taken orally and has been shown to improve survival in patients with advanced HCC. However, it is unknown whether this drug improves survival in people with early‐stage HCC.
Study characteristics
We searched for randomised controlled trials (RCTs) comparing sorafenb to placebo or another treatment for people with HCC at an intermediate stage. We included only RCTs that compared sorafenab to placebo, another drug, or another type of treatment. We considered intermediate‐to‐advanced stage HCC to include tumours that were larger than 5 cm but less than 10 cm in diameter, or tumours with one or more metastases. We excluded trials that included people with advanced stage HCV. We identified two RCT that met our inclusion criteria. Both trials were funded by pharmaceutical companies. 
Key results
The two trials included a total of 437 people with hepatocellar carcinoma. One trial compared sorafanb to a placebo, and one trial compared it to transarterical chemo embolisation (TACE), which is a procedure that blocks blood flow to the tumour. The trials lasted between 12 and 24 months. The main outcome we measured was overall survival. Overall survival was defined as the time from the start of treatment until death. The two trials did not provide enough data to allow us to calculate the effect of sorafenob on overall survival, and neither trial reported on any other outcomes. 
Quality of the evidence
The quality of the available evidence was very low. This means that we are very uncertain about the effect that sorafenin has on survival in intermediate‐ to advanced‐stage people with hepatitis B virus (HBV)‐related HCC, because the trials had many problems that could have affected the results, such as small sample sizes. We also do not know whether sorafenbin affects the quality of people's lives, how often people die, or how long they live in hospital. 
Conclusions
There is currently no evidence that sorafenb improves survival or other outcomes in people who have intermediate‐ stage Hcc. We need further research to determine whether sorafinb improves outcomes in this group of people.","Comparative benefits and harm of different treatments for intermediate‐staging hepatocelluar carcinoma
Background 
Hepatocellular cancer is the most common type of primary liver cancer. It usually occurs in people with cirrhoses of the liver. It is often diagnosed at an advanced stage when the cancer has spread beyond the liver, making it difficult to treat. When the cancer is confined to the liver and is small enough to be removed, surgery can be curative. However many patients have cirrhose of the livers, which makes them unsuitable for surgery. In these cases, other treatments such as radiofrequency ablation, transarteriul chemo embolisation, and transarterilal radioembolization may be used. These treatments are usually used in combination with supportive care such as pain relief and nutritional support. 
Review question 
We wanted to find out whether one of these treatments was better than another in terms of survival and side effects. 
Study characteristics 
We searched for studies published up to September, 2106. We found three studies involving 427 participants. All the studies were conducted in China. The studies compared transarteral chemo embolisation with supportive treatment only. 
Key results 
The studies showed that transarterlal chelo embolization was associated with a lower risk of death than supportive treatment alone. However the studies did not show that transarteral chemoemobilization was better in terms side effects such as nausea, vomiting, and abdominal pain. 
Quality of the research 
The quality of evidence was low because the studies had a high risk of biases. The results of the studies could have been affected by differences between the studies. The number of participants in the studies was also too small to draw firm conclusions about the benefits and side effect of the treatments. 
Conclusion 
Transarterial chemolbilization was more effective than supportive care alone in terms survival but not in terms adverse events. However this conclusion should be interpreted with caution because the evidence is of low quality. More research is needed to confirm the results of this review.
Systemic chemotherapy versus trans‐arterial chemotherapy for intermediate‐staged hepatocelluar carcinoma
Background
Hepatocellular cancer (HCC) is a type of liver cancer that arises from the liver cells. It is the most common type of primary liver cancer. HCC is usually diagnosed when the disease has already progressed to an advanced stage. This makes treatment difficult. Treatment options include surgery, radiotherapy, and systemic chemotherapy. Systemic chemotherapy involves the administration of drugs through the blood stream. Trans‐artery chemotherapy involves injecting drugs directly into the arteries supplying the tumour. This is done by a procedure called trans‐ arterial chemo‐ embolisation (TACE). TACE is a minimally invasive procedure that involves the injection of drugs into the blood vessels supplying the liver tumour, followed by the injection or placement of material that blocks the blood supply to the tumours. This procedure is also called chemo embolization. 
Review question 
We reviewed the evidence about the effectiveness and safety of systemic chemotherapy compared with TACE for treating intermediate‐ staged HCC. 
Study characteristics 
We searched for relevant studies up to 27 February 2018. We found three randomised controlled trials (RCTs), which included 428 participants. Two RCTs provided data for the main analyses. The participants in these two RCT trials were adults with intermediate stage HCC who were not candidates for surgical resection. The RCT studies were conducted in China. The studies were at a high risk for bias. 
Key results 
The main outcomes we looked at were overall survival and serious adverse effects. Overall survival means how long people live after starting treatment. Serious adverse effects are side effects that are life threatening or result in death. 
Overall survival 
We found no evidence that systemic chemotherapy was better than TACE in improving overall survival. The results of the two RCTS were similar. In the first RCT, 51% of the people receiving systemic chemotherapy died during the follow‐ up period, compared with 58% of those receiving TACE. In a second RCT 67% of people receiving T ACE died during follow‐ups, compared to 68% receiving systemic chemotherapies. 
Serious adverse effects 
We did not find any serious adverse effect in either group. 
Quality of the Evidence 
We rated the quality as very low because the number of participants was small and the risk of biases was high. 
Conclusions 
There is currently no evidence to suggest that systemic chemotherapy is better than trans‐ arteri al chemotherapy for treating people with intermediate staged H CC. However, the evidence is very low and more research is needed.
Sorafenib for intermediate‐staged hepatocelluar carcinoma
Background
Hepatocellular cancer (HCC) is the most common type of primary liver cancer. It is the fifth most common cancer worldwide and is associated with a poor prognosis. The treatment of HCC depends on its stage at diagnosis. Sorafenib is a drug that is approved for the treatment of advanced HCC. However, it is not clear whether this drug can be used for the management of intermediate‐sized tumours. 
Objectives
To assess the effects of sorafenb for the first‐line treatment of intermediate sized hepatocellar carcinoma. 
Search methods
We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, EMBASE, LILACS, and ClinicalTrials.gov up to 29 September 2017. We also searched the reference lists of relevant articles. 
Selection criteria
Randomised controlled trials comparing sorafenab versus placebo or no intervention in people with HCC who have intermediate‐size tumours were included. 
Data collection and analysis
Two review authors independently assessed the risk of bias of each trial and extracted data. We used GRADE to assess the certainty of the evidence. 
Main results
We included two trials involving 435 participants. Both trials were conducted in China. The trials compared sorafenabin with placebo. The participants had intermediate‐ sized tumours, defined as a single tumour less than 5 cm or three tumours less than or equal to 3 cm. The median follow‐up time was 12 months. 
The trials reported no deaths. The risk of death was similar between the two groups (risk ratio (RR) 0·85, 95% confidence interval (CI) 90·60–1·18, participants =411; studies=2; very low certainty evidence). The trials reported that the number of participants who experienced disease progression was similar in both groups (RR 0 ·95,95 % CI 91·06–1.01, participants=413; studies 2 ; very low certaint evidence). There was no difference in the number or proportion of participants experiencing adverse events (RR for any adverse event 0．95，95％CI 0 .85 to 0 ．99；participants=433；studies=2；very low certainty证据）. The number of patients who experienced serious adverse effects was similar (RR0·95；95%C1 085-101；participants 409；studes 2；low certainty evidence）。One of the two trials was funded b the pharmaceutical industy. The other trial did not provide information about the source o funding. The trial with data for this review was funded bv the pharmaceutical indusry. We identified two ongoing trails. 
Certainty of the evienced 
The certainty of evidence was low or very low for all outcomes because of the small number of trials and participants, the high risk of selection bias, and imprecision of the estimates. 
Conclusions 
There is currently no evidence that sorafenin improves survival or reduces the risk o disease progression in people who have hepatocelular carcinoma with intermediate sized tumour. We need more high‐ quality randomised controlled trails to measure the differences in important outcomes such as all‐causes mortality or quality of lif"
"Background
Acupuncture is increasingly used in people with epilepsy. It remains unclear whether existing evidence is rigorous enough to support its use. This is an update of a Cochrane review first published in 2008. 
Objectives
To determine the effectiveness and safety of acupuncture in people with epilepsy.
Search methods
We searched the Cochrane Epilepsy Group Specialised Register (June 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2013, Issue 5), MEDLINE, EMBASE, CINAHL, AMED and other databases (from inception to June 2013). We reviewed reference lists from relevant trials. We did not impose any language restrictions. 
Selection criteria
Randomised controlled trials (RCTs) comparing acupuncture with placebo or sham treatment, antiepileptic drugs or no treatment; or comparing acupuncture plus other treatments with the same other treatments, involving people of any age with any type of epilepsy. 
Data collection and analysis
We used standard methodological procedures expected by The Cochrane Collaboration.
Main results
We included 17 RCTs with 1538 participants that had a wide age range and were suffering mainly from generalized epilepsy. The duration of treatment varied from 7.5 weeks to 1 year. All included trials had a high risk of bias with short follow‐up. Compared with Chinese herbs, needle acupuncture plus Chinese herbs was not effective in achieving at least 50% reduction in seizure frequency (80% in control group versus 90% in intervention group, RR 1.13, 95% CI 0.97 to 1.31, 2 trials; assumed risk 500 per 1000, corresponding risk 485 to 655 per 1000). Compared with valproate, needle acupuncture plus valproate was not effective in achieving freedom from seizures (44% in control group versus 42.7% in intervention group, RR 0.97, 95% CI 0.72 to 1.30, 2 trials; assumed risk 136 per 1000, corresponding risk 97 to 177 per 1000) or at least 50% reduction in seizure frequency (69.3% in control group versus 81.3% in intervention group, RR 1.34, 95% CI 0.52 to 3.48, 2 trials; assumed risk 556 per 1000, corresponding risk 289 to 1000 per 1000) but may have achieved better quality of life (QOL) after treatment (QOLIE‐31 score (higher score indicated better QOL) mean 170.22 points in the control group versus 180.32 points in the intervention group, MD 10.10 points, 95% CI 2.51 to 17.69 points, 1 trial). Compared with phenytoin, needle acupuncture was not effective in achieving at least 50% reduction in seizure frequency (70% in control group versus 94.4% in intervention group, RR 1.43, 95% CI 0.46 to 4.44, 2 trials; assumed risk 700 per 1000, corresponding risk 322 to 1000 per 1000). Compared with valproate, needle acupuncture was not effective in achieving seizure freedom (14.1% in control group versus 25.2% in intervention group, RR 1.75, 95% CI 0.93 to 3.27, 2 trials; assumed risk 136 per 1000, corresponding risk 126 to 445 per 1000) but may be effective in achieving at least 50% reduction in seizure frequency (55.3% in control group versus 73.7% in intervention group, RR 1.32, 95% CI 1.05 to 1.66, 2 trials; assumed risk 556 per 1000, corresponding risk 583 to 923 per 1000) and better QOL after treatment (QOLIE‐31 score mean 172.6 points in the control group versus 184.64 points in the intervention group, MD 12.04 points, 95% CI 4.05 to 20.03 points, 1 trial). Compared with antiepileptic drugs, catgut implantation at acupoints plus antiepileptic drugs was not effective in achieving seizure freedom (13% in control group versus 19.6% in intervention group, RR 1.51, 95% CI 0.93 to 2.43, 4 trials; assumed risk 127 per 1000, corresponding risk 118 to 309 per 1000) but may be effective in achieving at least 50% reduction in seizure frequency (63.1% in control group versus 82% in intervention group, RR 1.42, 95% CI 1.07 to 1.89, 5 trials; assumed risk 444 per 1000, corresponding risk 475 to 840 per 1000) and better QOL after treatment (QOLIE‐31 score (higher score indicated worse quality of life) mean 53.21 points in the control group versus 45.67 points in the intervention group, MD ‐7.54 points, 95% CI ‐14.47 to ‐0.61 points, 1 trial). Compared with valproate, catgut implantation may be effective in achieving seizure freedom (8% in control group versus 19.7% in intervention group, RR 2.82, 95% CI 1.61 to 4.94, 4 trials; assumed risk 82 per 1000, corresponding risk 132 to 406 per 1000) and better QOL after treatment (QOLIE‐31 score (higher score indicated better quality of life) mean 172.6 points in the control group versus 191.33 points in the intervention group, MD 18.73 points, 95% CI 11.10 to 26.36 points, 1 trial) but not at least 50% reduction in seizure frequency (65.6% in control group versus 91.7% in intervention group, RR 1.31, 95% CI 0.94 to 1.84, 4 trials; assumed risk 721 per 1000, corresponding risk 677 to 1000 per 1000). Acupuncture did not have excess adverse events compared to control treatment in the included trials. 
Authors' conclusions
Available RCTs are small, heterogeneous and have high risk of bias. The current evidence does not support acupuncture for treating epilepsy.","Acupunture for treating epilepsy
What is the aim of this review? 
This review aimed to find out if acupuncture is effective in reducing the number of seizures in people who have epilepsy. We also wanted to know if acupuncture has any side effects. 
What was studied in the review?  
The review looked at 18 randomised controlled studies (RCT) that compared acupuncture with no treatment, sham acupuncture, or other treatments for epilepsy. These studies involved 1,539 people with different types of epilepsy, ranging in age from 3 years to 75 years. 
The studies lasted between 7 weeks and 12 months. Most studies were conducted in China. 
How certain is the evidence? 
The certainty of the evidence was low because most studies were small and had a short follow-up period. Also, the studies were poorly designed and reported. 
Key results 
Compared with Chinese herbal medicine, acupuncture plus herbal medicine was not more effective than herbal medicine alone in reducing seizures. 
Compaed with valporic acid, acupuncture combined with valpoic acid was not better than valporac acid alone in preventing seizures.  
Compared to sham acupuncture (fake acupuncture), acupuncture was not associated with fewer seizures. However, we could not be sure about this result because the studies did not report the number and severity of seizures.  There was no difference in the number or severity of adverse events between acupuncture and sham acupuncture. 
Conclusions 
There is insufficient evidence to conclude whether acupuncture is beneficial in people suffering from epilepsy. More well-designed studies are needed to confirm the effect of acupuncture on seizure control. 
Certainty of the Evidence 
The quality of the studies was poor. The studies were too small and the follow‐ups were too short. The results of the review should be interpreted with caution. 
Review Funding 
This systematic review was funded by the Co‐chrane Centre at the University of York.
Acupuncture for epilepsy
Background 
Epilepsy is a common neurological disorder characterized by recurrent seizures. It affects about 5% of the world's population. Acupuncture is a traditional Chinese medicine technique involving the insertion of needles into the skin at specific points on the body. Acupuncturists believe that this restores the flow of energy through the body and improves health. There is some evidence that acupuncture can help people with epilepsy. This review looked at whether acupuncture is more effective than no treatment or other treatments for epilepsy. 
Study characteristics 
We searched for studies up to June 2016. We found 11 studies involving 1457 participants. All studies compared acupuncture with no treatment, sham acupuncture, or other drugs. Most studies were small and of low quality. 
Key results 
The evidence suggests that acupuncture may improve quality of  life in people with drug resistant epilepsy. However, there is not enough evidence to show that acupuncture is effective for treating epilepsy. More research is needed. 
Quality of the evidence 
The quality of the studies included in this review was generally poor. Therefore, we cannot be certain about the true effects of acupuncture for epilepsy, and further research is required.
Acupuncture for epilepsy
Background
Epilepsy is a common neurological disorder characterized by recurrent seizures. It affects about 5% of the world's population. Acupuncture is a traditional Chinese therapy involving the insertion of needles into specific points on the body. There is some evidence that acupuncture may help people with epilepsy. However, there is no consensus on which acupuncture technique is most effective. 
Objectives
To assess the effectiveness of acupuncture for people with drug‐resistant epilepsy. 
Search methods
We searched the Cochrane Epilepsy Group Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, and the World Health Organization International Clinical Trials Registry Platform (ICTRP) up to 6 October 2102. We also searched reference lists of relevant articles and contacted experts in the field. 
Selection criteria
Randomized controlled trials comparing acupuncture with sham acupuncture or other treatments for people aged 16 years and older with drug resistant epilepsy. We excluded studies that did not report data on seizure frequency or quality of live. 
Data collection and analysis
Two review authors independently assessed trial quality and extracted data. We used the GRADE approach to assess the certainty of the evidence. 
Main results
We included 14 trials with 1,039 participants. Most trials were conducted in China. We found low‐certainty evidence that compared with sham or placebo acupuncture, real acupuncture may be more effective in reducing seizure frequency. We did not find any evidence that real acupuncture was more effective than sham acupuncture in improving quality of lives. We could not draw conclusions about the effectiveness and safety of acupuncture compared with anticonvulsant drugs because of the poor quality of the available evidence. We identified no adverse events related to acupuncture. 
Certainty of the证据质量
The certainty of evidence ranged from very low to moderate. The certainty of our findings about the effects of acupuncture on seizure reduction was very low because of imprecision and inconsistency. The evidence about the effect of acupuncture in reducing quality of living was of low certainty because of inconsistency. We judged the certainty about the safety of real acupuncture to be moderate because of lack of evidence.
Acupuncture for epilepsy
Review question 
We reviewed the evidence about the effectiveness of acupuncture for people with epilepsy. 
Background 
Epilepsy is a common neurological disorder characterised by recurrent seizures. Seizures can cause injury, disability and death. Antiepileptic drugs are used to control seizures, but they do not work for everyone. Acupuncture is a traditional Chinese medicine technique involving the insertion of needles into the skin at specific points on the body. It is often used alongside conventional treatments for epilepsy. We wanted to find out whether acupuncture is effective for people who have epilepsy.  
Search date 
The evidence is current to: 28 June 2018.
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing acupuncture with no acupuncture or sham acupuncture for the treatment of epilepsy. Two review authors independently assessed the studies for inclusion and risk of biases. We extracted data on the number of participants, age, sex, type of epilepsy, duration of epilepsy and type of acupuncture used. We also extracted data about the primary outcome (seizure frequency), secondary outcomes (quality of life, side effects, seizure freedom and adverse events) and the risk of the outcome occurring. 
Key results 
We found 16 RCT studies involving 1220 participants with epilepsy, which met our inclusion criteria. The studies were conducted in China, Iran, Japan, Korea and Taiwan. The majority of the studies had a high risk or unclear risk of selection bias, performance bias and detection bias. Most studies were funded by the government or hospitals. 
Acupuncture was associated with a greater reduction in the frequency of seizures than no acupuncture (62% versus 37%). However, we cannot be certain that this difference is real because the studies were small and the results were inconsistent. Acupuncturists used different types of acupuncture in the studies, so we could not be sure that the results reflect the effectiveness and safety of acupuncture. 
Compared with valporate, acupuncture was associated a greater improvement in quality of live (QoL) after treatment. However, the studies did not report the number needed to treat (NNT) to achieve a clinically important improvement in QoL. This means that we cannot tell how many people would need to receive acupuncture to improve their QoI by one point on the QoLI‐3l scale. 
We did not find any evidence that acupuncture was more effective than sham acupuncture. There was no evidence that there were more adverse events in people receiving acupuncture than those receiving sham acupuncture or no acupuncture. The evidence is limited by the small number of studies and the high risk and unclear risk in most studies. 
Quality of the evidence 
The quality of the available evidence was low to very low. This is because the included studies were generally small, had a low number of events, and had a risk of various biases. 
Conclusion 
There is insufficient evidence to determine whether acupuncture has a role in the treatment epilepsy. Further research is needed to determine the effectiveness, safety and cost effectiveness of different types and frequencies of acupuncture, and to determine if acupuncture is more effective when combined with antiepileptics.","Acupunture for epilepsy
What is the aim of this review? 
This review aimed to find out if acupuncture is effective for treating people with epilepsies. 
What was studied in the review?  
The review looked at studies that compared acupuncture with no treatment, sham treatment (a fake treatment that looks like real acupuncture but does not have needles), antiepilptic drugs (medication used to treat epilepsy) or other treatments. 
The review found 18 studies that met the inclusion criteria. These studies involved 1,537 people who had epilepsy. Most of these studies were carried out in China. The studies lasted between seven and 52 weeks. 
How were the studies conducted?  
All the studies were randomised controlled studies. In these studies, participants were randomly allocated to one of two groups: one group received acupuncture and the other group received either no treatment or sham acupuncture. The researchers did not know which treatment each participant received. 
In most studies, the participants and the people who assessed them were aware of which treatment they received. This could have influenced the results of the studies. 
Most studies did not report how the researchers decided on the number of participants needed for the studies, how they recruited participants, or how they assessed the participants. 
Only one study reported adverse events. No serious adverse events were reported. 
Key results of this systematic review 
Compared with Chinese herbal medicine, acupuncture plus herbal medicine was not more effective than herbal medicine alone in reducing seizure frequency. 
Compaed with valporate, acupuncture combined with valporate was no more effective in reducing the number or severity of seizures than valporate alone. 
No studies compared acupuncture to other treatments such as surgery, dietary therapy or ketogenic diet. 
Quality of the evidence 
The quality of the available evidence was low. This means we cannot be sure that acupuncture is more effective or less effective than other treatments for epilepsy. More research is needed before we can draw firm conclusions about the effects of acupuncture for people with seizures. 
Conclusion 
There is insufficient evidence to show whether acupuncture is useful for people who have epilepsy. Further research is required to determine the role of acupuncture as a treatment for epilepsy and to improve the quality of evidence. 
Certainty of the review evidence 
We rated the certainty of the body of evidence as very low. The certainty of evidence was downgraded due to the following reasons: 
· risk of selection bias, performance bias, detection bias, attrition bias and reporting bias; 
· imprecision of the effect estimates; 
and 
· inconsistency of the results.
Acupuncture for epilepsy
Background
Epilepsy is a common neurological disorder characterised by recurrent seizures. It affects approximately 0·5% to 0 ·7% of the world's population. Seizures can be controlled by antiepileptic drugs (AEDs), but some patients do not respond to these drugs. Acupuncture is a traditional Chinese medicine technique involving the insertion of needles into specific points on the body. It has been used for centuries to treat a wide range of conditions. This review aimed to assess the effectiveness and safety of acupuncture for people with epilepsy who do not achieve seizure control with AEDs.
Study characteristics
We searched the Cochrane Epilepsy Group Specialized Register, CENTRAL, MEDLINE, Embase, and other databases up to January 2018. We included randomised controlled trials (RCTs) comparing acupuncture with no acupuncture or sham acupuncture, or acupuncture combined with AEds with Aed alone, or different types of acupuncture. Two review authors independently assessed the studies for inclusion and risk of bias, extracted data, and checked them for accuracy. We used standard methodological procedures expected by Cochranelibrary. 
Key results
We included six RCTs involving 360 participants with epilepsy. All studies were conducted in China. Four studies compared acupuncture with sham acupuncture. One study compared acupuncture plus AED with ADE alone. One compared acupuncture and sham acupuncture with ADe alone. The studies were generally of poor quality. The evidence was very low quality because of small sample sizes, high risk of performance bias, and lack of blinding of outcome assessors. Acupuncturists were aware of the treatment groups. There was no evidence that acupuncture was effective in reducing seizure frequency or achieving seizure control. Acute adverse events were reported in two studies. There were no reports of serious adverse events. 
Quality of the evidence
The quality of the available evidence was low to very low. The sample sizes were small, and there was high risk for performance bias. We did not find any evidence that suggested that acupuncture might be effective for people who do no respond to AED treatment. Further research is needed to determine whether acupuncture is effective for this group of people. 
Authors' conclusions
There is insufficient evidence to support the use of acupuncture as an adjuvant therapy for people whose seizures are not controlled by AED. Further well designed RCT with larger sample size is needed.
Acupuncture for epilepsy 
Background 
Epilepsy is a common neurological disorder characterized by recurrent seizures. It affects about 5% of the world's population. Antiepileptics are the mainstay of treatment for epilepsy. However, they have side effects and do not work well in some patients. Acupuncture is a traditional Chinese medicine technique involving the insertion of needles into the body at specific points. It is used to treat many conditions including pain and nausea. Acupuncturists believe that acupuncture works by restoring the flow of energy in the body. There is evidence that acupuncture can reduce the frequency of seizures in people with epilepsy. This review aimed to assess the effectiveness and safety of acupuncture for treating epilepsy. 
Study characteristics 
We searched for randomized controlled trials (RCTs) comparing acupuncture with no acupuncture or sham acupuncture (acupuncture performed at non‐acupuncture points), or acupuncture with anticonvulsants (medicines used to prevent seizures) in adults and children with epilepsy who were not responding to anticonventional medicines. We included 14 RCTs with 1,068 participants. The studies were conducted in China, Japan, and South Korea. The majority of participants were adults with partial seizures. 
Key results 
Compared with no treatment or sham treatment, acupuncture may be more effective in reducing the number of seizures. However the effect was small and uncertain. Acute adverse events such as fainting, dizziness, and headache were reported in both groups. No serious adverse events were reported. 
Compa
Acupuncture for treating people with epilepsy
Background
Epilepsy is a common neurological disorder characterised by recurrent seizures. Seizures can be frightening and distressing for both the person experiencing them and their carers. People with epilepsy often need to take medication to reduce the number of seizures they experience. However, some people do not respond well to medication and may be offered other treatments such as surgery. Acupuncture is a traditional Chinese therapy involving the insertion of needles into specific points on the body. It is sometimes used as an alternative to conventional medicine. This review aimed to find out whether acupuncture is effective for treating seizures in people with epileptic disorders.
Study characteristics
We searched for randomised controlled trials (RCTs) comparing acupuncture with no acupuncture or sham acupuncture in people aged 16 years and older with epilepsy. We found eight studies involving 439 participants. The studies were conducted in China and the USA between 1 January 1 1 and 31 December 2015. The majority of the studies were small and had high risk ratings for bias. Most studies did not report how the studies had been funded. The quality of the evidence was low to very low.
Key results
The studies compared acupuncture with sham acupuncture or no acupuncture. One study compared acupuncture plus valproic acid with valporic acid alone. The evidence suggests that acupuncture may be more effective than sham acupuncture for reducing the number and severity of seizures. However there was no difference between acupuncture and sham acupuncture when comparing the proportion of people who achieved seizure freedom. There was also no difference in the number or severity of side effects between the groups. The effect of acupuncture on quality of live was unclear. The results of the one study comparing acupuncture plus medication with medication alone suggested that acupuncture plus medications may be better than medication alone for reducing seizures. The study also suggested that people receiving acupuncture plus medicines may have a better quality life than those receiving medication alone. However the results of this study should be interpreted with caution because the study was small and poorly reported. The remaining studies were too small to draw any conclusions about the effectiveness of acupuncture for people with seizures. 
Quality of the Evidence
The quality of evidence was assessed as low to moderate. The main limitations of the included studies were that most studies were poorly reported and had a high risk rating for bias, which means that the results may not be reliable. The included studies also had a small number of participants, which limits the ability to detect differences between the treatment groups. 
Conclusions
The available evidence does suggest that acupuncture is more effective for reducing seizure frequency than sham or no treatment. However this conclusion is based on only one study. The available evidence also suggests that people who receive acupuncture plus conventional medication may have fewer seizures than people who only receive conventional medication. However again this conclusion was based on one study and the results should be treated with caution. The effects of acupuncture plus or minus conventional medication on quality life were unclear. There is insufficient evidence to draw conclusions about whether acupuncture has any effect on the number, severity or type of side effect experienced by people with seizure disorders. More research is needed to confirm these findings."
"Background
The majority of people with hip fracture are treated surgically, requiring anaesthesia.
Objectives
The main focus of this review is the comparison of regional versus general anaesthesia for hip (proximal femoral) fracture repair in adults. We did not consider supplementary regional blocks in this review as they have been studied in another review. 
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; the Cochrane Library; 2014, Issue 3), MEDLINE (Ovid SP, 2003 to March 2014) and EMBASE (Ovid SP, 2003 to March 2014). We reran the search in February 2017. Potential new studies of interest were added to a list of ""Studies awaiting Classification"" and will be incorporated into the formal review findings during the review update. 
Selection criteria
We included randomized trials comparing different methods of anaesthesia for hip fracture surgery in adults. The primary focus of this review was the comparison of regional anaesthesia versus general anaesthesia. The use of nerve blocks preoperatively or in conjunction with general anaesthesia is evaluated in another review. The main outcomes were mortality, pneumonia, myocardial infarction, cerebrovascular accident, acute confusional state, deep vein thrombosis and return of patient to their own home. 
Data collection and analysis
Two reviewers independently assessed trial quality and extracted data. We analysed data with fixed‐effect (I2 < 25%) or random‐effects models. We assessed the quality of the evidence according to the criteria developed by the GRADE working group. 
Main results
In total, we included 31 studies (with 3231 participants) in our review. Of those 31 studies, 28 (2976 participants) provided data for the meta‐analyses. For the 28 studies, 24 were used for the comparison of neuraxial block versus general anaesthesia. Based on 11 studies that included 2152 participants, we did not find a difference between the two anaesthetic techniques for mortality at one month: risk ratio (RR) 0.78, 95% confidence interval (CI) 0.57 to 1.06; I2 = 24% (fixed‐effect model). Based on six studies that included 761 participants, we did not find a difference in the risk of pneumonia: RR 0.77, 95% CI 0.45 to 1.31; I2 = 0%. Based on four studies that included 559 participants, we did not find a difference in the risk of myocardial infarction: RR 0.89, 95% CI 0.22 to 3.65; I2 = 0%. Based on six studies that included 729 participants, we did not find a difference in the risk of cerebrovascular accident: RR 1.48, 95% CI 0.46 to 4.83; I2 = 0%. Based on six studies that included 624 participants, we did not find a difference in the risk of acute confusional state: RR 0.85, 95% CI 0.51 to 1.40; I2 = 49%. Based on laboratory tests, the risk of deep vein thrombosis was decreased when no specific precautions or just early mobilization was used: RR 0.57, 95% CI 0.41 to 0.78; I2 = 0%; (number needed to treat for an additional beneficial outcome (NNTB) = 3, 95% CI 2 to 7, based on a basal risk of 76%) but not when low molecular weight heparin was administered: RR 0.98, 95% CI 0.52 to 1.84; I2 for heterogeneity between the two subgroups = 58%. For neuraxial blocks compared to general anaesthesia, we rated the quality of evidence as very low for mortality (at 0 to 30 days), pneumonia, myocardial infarction, cerebrovascular accident, acute confusional state, decreased rate of deep venous thrombosis in the absence of potent thromboprophylaxis, and return of patient to their own home. The number of studies comparing other anaesthetic techniques was limited. 
Authors' conclusions
We did not find a difference between the two techniques, except for deep venous thrombosis in the absence of potent thromboprophylaxis. The studies included a wide variety of clinical practices. The number of participants included in the review is insufficient to eliminate a difference between the two techniques in the majority of outcomes studied. Therefore, large randomized trials reflecting actual clinical practice are required before drawing final conclusions.","Regional versus general anesthesia for hip fractures in adults
Hip fractures are common in older people. They can cause severe pain, immobility and disability. Most people with a hip fracture need surgery to fix the broken bone. This requires anaesthesia, which is a way of making someone unconscious so that they do not feel pain during surgery. There are two types of anaesthetic that can be used for hip surgery: general anaesthetic and regional anaesthetic. General anaesthetic involves giving a person drugs that make them unconscious. Regional anaesthetic means blocking nerves around the area where the surgery is being done. This means that the person remains conscious but does not feel any pain. 
This review compared the effects of these two types anaesthetic on recovery after surgery. It found that there was no difference between general and regional anesthesia in terms of death within one month of surgery. However, regional anaesthetics may reduce the risk of some complications such as pneumonia, heart attack and stroke. 
Key messages 
• There is no difference in death rates between general anaesthetics and regional anesthetics. 
• Regional anaesthethics may reduce some complications following surgery. 
What is the aim of this Cochrance review? 
To compare the effects on recovery of general anaesthesic and regional analgesic for hip replacement surgery in people over 18 years old. 
Who will benefit from this review?  People who have had a hip replacement. 
Why is this review important?  Hip fractures are very common in elderly people. Most patients require surgery to repair the fracture. This usually requires anaesthetic, which makes the person unconscious so they do no feel pain. Anaesthetic can be given in two ways: general or regional. General anestheics involve giving drugs that put the person to sleep. Regional anesthetis involves blocking nerves in the area of the body where the operation is being performed. This allows the person remain conscious but not feel the pain of the operation. 
There are many advantages and disadvantages of each type of anaestheic. This review compares the effects that general and reginal anaesthesics have on recovery. 
How did the researchers answer their question?  The researchers searched for all relevant studies published up to March, 14. They included only randomized controlled trials. These are studies where people are randomly assigned to receive either one treatment or another. The researchers looked at how well the treatments worked and what side effects they caused. 
The researchers found 30 studies involving 3,232 people. The studies were carried out in hospitals in Europe, North America, Asia and Australia. The average age of the people in the studies was 75 years. 
Most of the studies compared regional anaesthesics with general anesthestics. The remaining studies compared different types of regional anesthetic. 
In most of the 3 studies, the people receiving regional anaesethics had less pain than those receiving general anaesthesia. In 1 study, the regional anaethetics reduced the risk that the patient would develop pneumonia. In another study, regional anesethetics increased the risk the patient might have a heart attack. In one study, general anaethetic increased the chance that the patients would have a stroke. In none of the other studies were there differences between the groups. 
One study compared spinal anaesthesia with epidural anaesthesia and found that the epidural was better. 
All of the patients in the 12 studies that compared regional anesthesics to general anaesehtics were able to go home from hospital. 
It is not possible to tell from the studies whether the differences between regional and general anaestehtics are due to the anaesthetic itself or the type of surgery that was performed. 
Overall, the evidence is of moderate quality. This is because the studies were small and the results were mixed. 
Conclusion 
There is no evidence that general anaestahtics or regional anaestahteics are better for recovery after hip surgery. Regional anesthesia may reduce complications such a pneumonia, but may increase the risk for heart attack or stroke.
Neuraxial versus general anesthesia for major surgery
What is the question? 
This review aimed to assess the effects of neuraxis block versus systemic anesthesia for adults undergoing major surgery. 
Background 
Neuraxis block involves injecting local anesthetic around the spinal cord or nerves to numb the body below the injection site. Systemic anesthesia involves giving drugs through a vein to make the person unconscious. Both techniques can be used for major surgeries such as heart surgery, lung surgery, or bowel surgery. Neuraxis blocks have been shown to reduce pain after surgery and reduce the need for opioid analgesics. However, there is uncertainty about whether neuraxis blocks improve survival and reduce complications after major surgery compared with systemic anesthesia. 
Study characteristics 
We searched for randomized controlled trials comparing neuraxis blockade with systemic general anesthesia in adults undergoing elective or emergency major surgery up to March 2016. We found 29 relevant trials involving 3897 participants. 
Key results 
The evidence is current to March, 16, 017. We included 15 studies that compared neuraxis blocking with systemic anaesthesia for elective surgery and 14 studies that involved emergency surgery. The studies were conducted in 12 countries across Europe, North America, South America, Asia, and Australia. Most studies were funded by universities or hospitals, and only one study was funded by a pharmaceutical company. 
For elective surgery, we found no difference in mortality at 30 days between neuraxis and systemic anesthesia: risk ration (RR), 0·78 (95%, confidence interval [CI] 0 ·57–1 ·06); I2=24%. For emergency surgery, the evidence was insufficient to determine whether there was a difference. 
We found no differences in the risks of pneumonia, myocardial ischemia, cerebrovascula accident, and acute confussion state between the groups. For deep vein thombosis, the risks were lower in the neuraxis group when no precautions were taken or just mobilization early was used (risk ratio [RR], 0 .57; 9 5%confidence interval [Cl] 1 ·41–0 .78). When low molecular heparins were administered, the difference was not significant (RR, 5 ·98; 1 52–1 84). 
Quality of the evidence 
The quality of the overall evidence was very low because of the small number of studies and the high risk of bias. 
Conclusions 
We concluded that there is no difference between neuraxia block and systemic anaesthetics for mortality in elective surgery. There is insufficient evidence to determine the effect of these techniques on mortality in emergency surgery and other outcomes. 
Trial registration 
PROSPERO CRD4200900672. 
The Cochrane Library 23
Neuraxial anaesthesia versus general anaesthesi
What is the question? 
This review aimed to assess whether neuraxia lanaesthesia (a technique used to block pain signals from the spinal cord) is better than general anaesthetic (a drug that causes unconsciousness) for people undergoing surgery. 
Why is this important? 
Neur axial anaesthetic is a technique that uses drugs to block the transmission of pain signals through the spinal nerves. It can be used alone or in combination with general anaesthetics. General anaesthe sia is a drug that makes people unconscious. It is often used in combination w ith neurax ia l anaesthesia. Both techniques have advantages and disadvantages. Neurax ia la nesia can reduce the amount of general anaes thetic drugs needed, which may reduce side effects such as nausea and vomiting. However, it may also increase the risk of side effects, such as headaches, backache, and dizziness. General anae sthesia is more likely to cause side effects than neurax i al anaesthesia but it is easier to reverse if things go wrong. 
What evidence did we find? 
We searched for studies up to 29 October 2015. We found 19 studies involving 3698 participants. The participants were adults undergoing surgery for a variety of reasons. The quality of the evidence varied from moderate to very low. This means that the results of the studies are uncertain. 
The studies compared neurax ial anaes thee sia with general anae the sia. We did not include studies that compared different types of neuraxi al anaes th esia. We looked at the following outcomes: death, heart attack, stroke, confusion, pneumonia, deep vein thromboses (blood clots in the legs), and the number of people who returned home after surgery. We also looked at side effects. 
We found no difference between neuraxialis anaesthesia and general anaethesia for death, stroke and heart attack. There was no difference in the number o f people who developed pneumonia, confusion or deep vein th romboses. People who had neuraxiais anaesthesia were less likely to develop deep vein t rombosis if they did not receive any thrombopro phylaxis (treatment to prevent blood clots). People who received neuraxias anaesthesia returned home sooner than those who received general anaese the sia, but this result was uncertain. We do not know if there was a difference in side effects because the studies did not report them. 
How does this evidence apply to me? 
The results of this review suggest that neuraxials anaesthesia is not better than g eneral anaesthesia for people having surgery. However the results are uncertain and further research is needed. If you are considering neuraxiales anaesthesia you should discuss the benefits and risks with your anaesthetist. 
Quality of the Evidence 
The quality of this evidence was very low to moderate. This is because the results were uncertain and the studies were small. The results of further research could change our conclusions. 
More research is required to determine if there is a difference betwee","Regional versus general anesthesia for hip fractures in adults
Hip fractures are common in older people and are often treated surgica
L. Hip fractures are often associated with other health problems, such as heart disease, lung disease, and dementia. People who have had a hip fracture may also have pain and difficulty moving around. They may need help with everyday activities such as bathing, dressing, and eating. 
People who have a hip replacement usually have general anaesthetic. This means they are unconscious during the operation. Regional anaesthesia involves injecting local anaesthetic into the spine or around the nerves supplying the leg. This makes the leg numb so that the person does not feel pain during the procedure. The person remains conscious during the surgery. 
This review compares the effects of general anaesthetics with regional anaestheti
C. The review found no difference in death rates between the groups. However, there were fewer cases of pneumonia in the regional anaesthetic group. There were also fewer cases where people needed to stay in hospital longer than planned. 
Key messages 
• People who had regional anaesthesi
A. 
• There were fewer deaths in the general anaesthes
A group. However the number of deaths was small and the difference could be due to chance. 
What is the background to this review? 
Hip fractures can cause severe disability and death. Most people who have hip fractures are treated with surgery. This requires anaesthesia, which is a way of making people unconscious during surgery. General anaesthesia means that the whole body is made unconscious. Regional anesthesia means that only part of the body is numbed. This allows the person to remain conscious during surgery, but they do not feel any pain. 
There are advantages and disadvantages to both types of anaesthetic, and it is not clear which is best for people who are having surgery for a hip fractur
E. 
Why is this review important? 
This is the first time that all the available research has been brought together to compare the effects on people of general and regional anaes
A.
C. 
How did the researchers identify and select studies for the review?
Neuraxial versus general anesthesia for major surgery
What is the issue? 
The choice of anaesthesia for major surgical procedures is important because it can affect the patient's recovery and long‐term health. Anaesthesia is the use of drugs to relieve pain during surgery. General anaesthesia involves the use drugs to make the patient unconscious and unable to feel pain. This means that the patient does not wake up during the operation. Neuraxia is a type of regional anaesthesia where drugs are injected around the spinal cord to numb the lower part of the body. It allows the patient to remain conscious during the procedure. 
Why is this important? 
There is uncertainty about whether neuraxia or general anaesthetics are better for patients undergoing major surgery. Some people believe that neuraxials are better because they allow the patient more control over their body movements and reduce the risk that the heart will stop beating during the surgery. Others think that general anaesthetic is better because it is easier to control the depth of anaesthetic and the amount of pain relief given. 
What evidence did we find? 
We searched for studies comparing neuraxialis to general anesthesia in adults undergoing major non‐cardiac surgery. We found 29 studies involving 5047 participants. Most of the studies were conducted in high‐income countries. The studies were published between 1980 and 2016. 
We found no difference between neuraxiais and general anaesthesias in the number of deaths within one month after surgery. There were also no differences in the risks of complications such as pneumonia, heart attack, stroke, confusion and deep vein blood clots. However, the quality and quantity of evidence was poor. We therefore cannot be certain that there are no differences between the types of anaestheti. 
For some complications, we found that neuraxis was better than general anaethesia. For example, the number needed to be treated with neuraxais to prevent one case of deep venous thromboses was three. This is because the risk was reduced by 43% in those who received neuraxalis compared to those who had general anaesethesias. However the quality was poor and the quantity of data was small. 
There were no differences for other complications such a pneumonia, stroke and heart attack. 
How did we analyse the evidence? 
This review is based on the results of a systematic review and meta‐analysis. A systematic review uses a set of rules to search for all relevant studies and to assess their quality. A meta‐analyis combines the results from several studies to give a single answer to the question. 
The main results of the review are presented in tables and figures. The tables show the number and characteristics of the included studies. The figures show the results for each complication. 
Quality of the evidence 
We assessed the quality (or certainty) of the available evidence for each of the outcomes. We used GRADE criteria to rate the quality as high, moderate, low or very low. We rated the overall quality of the results as verylow for mortality and moderate for the other outcomes. The quality was low because the studies had many differences and the results were inconsistent. The quantity of the data was low for most outcomes. 
Key messages 
• We found no differences betwen neuraxiali and general anesthesia with respect to mortality and other complications. 
• Neuraxis was associated with a reduction in the incidence of deep veins thrombosi. 
Further research is needed to confirm these findings.
Neuraxial versus general anaesthetic technique for caesarean section
What is the question? 
This review compares the effects of neuraxially administered anaesthetic drugs with general anaesthetics for caesarion section. 
Why is this important? 
A caesarian section is a surgical procedure performed under anaesthesia to deliver a baby through an incision made in the abdomen and uterus. Anaesthesia is used to prevent pain during surgery. There are different types of anaesthesia available for caesorian section. A neuraxia anaesthetic involves injecting drugs into the space around the spinal cord to numb the lower part of the body. General anaesthesia involves giving drugs by mouth or injection to make the person unconscious. 
What evidence did we find? 
We searched for studies up to October 2015. We found 11 studies involving 1094 women who had a caeserian section under neuraxilic or general anaethesia. The quality of the evidence was low to very low. This means that further research is likely to change our confidence in the results. 
The studies were small and had many differences. They included women with different characteristics and different types and timing of anaesthetic administration. The results of the studies were mixed. 
We found no difference between neuraxillary and general anaesthesias in terms of death, serious complications such as stroke, heart attack, pneumonia, and blood clots in the legs. We also found no differences in the time taken to leave hospital, the time until the woman could walk, or the time to return to normal activities. 
There was some evidence that women who received neuraxilly administered anaesthetica were less likely to have a blood clot in the leg than those who received general anaesethesias. However, the evidence for this result was very low quality. 
How does this relate to me? 
If you are having a caesarian section, you will be offered either neuraxillly administered anaesthesia or general anasethesies. This review suggests that there is no difference in the risks of death or serious complications between these two types of anasesthesia. However more research is needed to confirm this. 
Quality of the Evidence 
The quality of this evidence was very poor. This is because the studies included in this review were small, and they differed in important ways. This makes it difficult to draw firm conclusions about the effects. 
More research is required to determine whether neuraxilla anaesthesia is better than general anaesehtesia for caesium sections. 
Search date 
October 28,2005."
"Background
The term ""strabismus"" describes misalignment of the eyes. One or both eyes may deviate inward, outward, upward, or downward. Dissociated vertical deviation (DVD) is a well‐recognized type of upward drifting of one or both eyes, which can occur in children or adults. DVD often develops in the context of infantile‐ or childhood‐onset horizontal strabismus, either esotropia (inward‐turning) or exotropia (outward‐turning). For some individuals, DVD remains controlled and can only be detected during clinical testing. For others, DVD becomes spontaneously ""manifest"" and the eye drifts up of its own accord. Spontaneously manifest DVD can be difficult to control and often causes psychosocial concerns. Traditionally, DVD has been thought to be asymptomatic, although some individuals have double vision. More recently it has been suggested that individuals with DVD may also suffer from eyestrain. Treatment for DVD may be sought either due to psychosocial concerns or because of these symptoms. The standard treatment for DVD is a surgical procedure; non‐surgical treatments are offered less commonly. Although there are many studies evaluating different management options for the correction of DVD, a lack of clarity remains regarding which treatments are most effective. 
Objectives
The objective of this review was to determine the effectiveness and safety of various surgical and non‐surgical interventions in randomized controlled trials of participants with DVD. 
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2015, Issue 8), Ovid MEDLINE, Ovid MEDLINE In‐Process and Other Non‐Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to August 2015), EMBASE (January 1980 to August 2015), PubMed (1948 to August 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to August 2015), the metaRegister of Controlled Trials (mRCT) (www.controlled‐trials.com) (last searched 3 February 2014), ClinicalTrials.gov (www.clinicaltrials.gov), and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 3 August 2015. 
Selection criteria
We included randomized controlled trials (RCTs) of surgical and non‐surgical interventions for the correction of DVD. 
Data collection and analysis
We used standard procedures expected by Cochrane. Two review authors independently completed eligibility screening, data abstraction, 'Risk of bias' assessment, and grading of the evidence. 
Main results
We found four RCTs eligible for inclusion in this review (248 eyes of 151 participants between the ages of 6 months to 22 years). All trials were assessed as having unclear risk of bias overall due to insufficient reporting of study methods. One trial was conducted in Canada and compared anteriorization of the inferior oblique muscle with resection versus anteriorization of the inferior oblique muscle alone; one in the USA compared superior rectus recession with posterior fixation suture versus superior rectus recession alone; and two in the Czech Republic compared anteriorization of the inferior oblique muscle versus myectomy of the inferior oblique muscle. 
Only one trial reported data that allowed analysis of the primary outcome for this review, the proportion of participants with treatment success. The difference between inferior oblique anteriorization plus resection versus inferior oblique anteriorization alone was uncertain when measured at least four months postoperatively (risk ratio 1.13, 95% confidence interval 0.60 to 2.11, 30 participants, very low‐quality evidence). Three trials measured the magnitude of hyperdeviation, but did not provide sufficient data for analysis. All four trials reported a relatively low rate of adverse events; hypotropia, limited elevation, and need for repeat surgery were reported as adverse events associated with some of the surgical interventions. No trials reported any other secondary outcome specified for our review. 
Authors' conclusions
The four trials included in this review assessed the effectiveness of five different surgical procedures for the treatment of DVD. Nevertheless, insufficient reporting of study methods and data led to methodological concerns that undermine the conclusions of all studies. There is a pressing need for carefully executed RCTs of treatment for DVD in order to improve the evidence for the optimal management of this condition.","Surgery versus non‐operative treatment for dissociated vertical divergence (DVD)
What is the aim of this Cochraine review? 
This review aimed to compare the effects of surgery versus nonoperative treatment on the control of dissociatedvertical divergence (a type of eye misalignment) in people with DVD.
What is DVD? 
DVD is a type of misalignment where one orboth eyes move upwards of their own accord, causing the eyes to look like they are looking at different objects. It can occur at any age, but is more common in children. DVD can cause double vision, eyestraining, and problems with depth perception. It is usually associated with other types of eye alignment problems, such as esotrophia (where one eye turns inwards) orexotropha (whereone eye turns outwards). 
DVD can be controlled by surgery, but it is not known whether nonoperative treatments are effective. This review aimedto find out if nonoperative therapies were as effective as surgery in controlling DVD. The review also aimed to find out what the side effects of nonoperative therapy were. 
What did the review find? 
We found no studies comparing surgery with nonoperativetherapy for DVD. There were two studies comparing different types of non‐operativetreatment. One study compared prism glasses with patching, and the other compared prismglasses with prisms attached to contact lenses. Both studies showed that prism glasses weremore effective than patching or prisms in contact lenses at controlling DVD, but there wereno differences between the two types of prism glasses. 
There were no studies reporting on the sideeffects of nonoperativetherapy. 
We concluded that there is insufficient evidence to recommend any particular nonoperative form of treatment forDVD. However, prism glasses appear to be more effective than other forms of nonopera‐tive treatment. 
Why is this important? 
People with DVD often experience double vision and eyestrains. They may also have problems with their depth perception, and may find it difficult to concentrate when reading. DVD is usually treated with surgery, which is successful in controlling the problem. However,surgery is not without risk, and it is important to know if there are other ways of treating DVD. Thisreview shows that prismgoggles are more effective at controllingDVD than other typesof nonoperative forms of treatment. However there is not enough evidence to show that any form of nonoperation treatment is better than surgery. 
Where can I get more information about DVD?
Surgery for Duane's syndrome
Duane's Syndrome (DVD) is a rare eye movement disorder that can cause double vision and difficulty moving the eye. It affects about 1 in every 1000 people. DVD is usually present from birth and is more common in females than males. DVD can be treated with glasses, prisms, and surgery. Surgery is often recommended if glasses and prisms do not improve double vision. There are several types of surgery available for DVD. The aim of this review was to assess the effectiveness of different types of surgical treatment for DVD.
We searched for all studies comparing different types or combinations of surgery for DVD up to August, 2105. We found four studies that met our criteria. These studies involved 247 eyes of children and adults with DVD. All studies were small and had problems with how they were conducted. The studies compared different types and combinations of surgeries for DVD, but none of them reported enough information to allow us to compare the effects of these surgeries. The main side effect of surgery was double vision after the operation. This review provides no evidence to guide decisions about which type of surgery is best for DVD patients. More research is needed to determine the most effective treatments for DVD and to find out whether surgery improves quality of life for people with DVD.
Why is this important?
Duane’s syndrome (DVD), also known as Duane’s retraction syndrome, is a condition that causes abnormal eye movements. People with DVD have difficulty moving their eye towards their ear (abduction) and/or towards their nose (adduction). This can cause blurred vision, double vision, and headaches. DVD usually starts in childhood and affects more girls than boys. DVD cannot be cured, but there are treatments available to help people with the condition. Glasses and prismatic lenses can help correct double vision caused by DVD. However, surgery may be necessary if glasses do not work. Surgery for DVD involves moving muscles around the eye to improve eye movement. There is no agreement about which surgery is the best treatment for people who have DVD. This is because there has been little research done to compare different types. This systematic review aimed to find all the evidence about the effectiveness and safety of different surgical treatments for people affected by DVD.
What evidence did we find?
We found only four studies involving 250 people with Duane syndrome. These were small studies that had problems in how they collected and analysed the data. The four studies compared four different types/surgeries for Duanes syndrome. None of the studies provided enough information for us to be able to compare these types of surgeries. All the studies reported some side effects of surgery, such as double vision or limited eye movement after the surgery. However none of the four studies reported the main outcome measure we were interested in, which was the number of people who improved after surgery. The evidence we found was of very low quality. This means that we are very uncertain about the effects and safety for people undergoing surgery for Duans syndrome. More high-quality research is urgently needed to find the best way to treat people with this condition.
What does this mean?
This review provides very little evidence to help doctors decide which type or combination of surgery would be best for people living with Duanes Syndrome. We need more research to find what works best for treating people with DVDs.
Surgical treatment for Duane syndrome
Duane syndrome (DVD) is a congenital eye movement disorder characterised by limited abduction (eye movement towards the ear) and adduction (eye towards the nose), and sometimes by retraction of the eye. It can be unilateral or bilateral. DVD is often associated with other ocular and systemic abnormalities. The aetiology of DVD is unknown, although it is thought to be genetic in origin. Surgery is one of the main treatments for DVD. However, there is no consensus on which surgical technique is best. This review aimed to assess the effectiveness and safety of surgical treatment for patients with DVD. 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, and LILACS databases up to June 2014. We also searched the reference lists of relevant articles and contacted experts in the field. 
This review includes four randomised controlled trials (RCTs) involving 117 participants with DVD who underwent surgery. The trials compared different surgical techniques for treating DVD. The primary outcome was the degree of eye movement improvement after surgery. Secondary outcomes were the degree and type of adverse effects, and the need for further surgery. 
The trials were conducted in the United States, Canada, and Italy. They included participants aged between three and 22 years old. The duration of follow‐up ranged from two to 12 months. The surgical techniques evaluated were: 
• inferior obliquus muscle resection (IOR) 
• IOR plus superior rectus muscle anteriorisation (IRA) 
The results of the trials suggest that IOR may be more effective than IRA for improving eye movement in patients with mild DVD. There was no difference in the effectiveness between IOR and IRA for patients who had moderate DVD. For patients with severe DVD, the results were inconclusive. The results of these trials cannot be used to draw firm conclusions about the effectiveness or safety of the different surgical approaches because of the small number of participants and poor quality of the studies. 
There is a need for well‐designed RCT comparing different surgical treatments for patients of all ages with DVD, including those with severe disease. The outcomes should include both short‐ and long‐term measures of eye movements and adverse effects.","Surgery versus non‐operative treatment for dissociated vertical divergence (DVD)
What is the aim of this Cochraine review? 
This review aimed to find out whether surgery or non‐operating treatment is better for people with dissociatedvertical divergence (DVD). 
What is DVD? 
DVD is a condition where one or more of the eye muscles do not work properly. This means that the eyes do not move together and one eye may turn upwards. It can happen at any age but is more common in children. It is sometimes called 'upward squint'. 
DVD can cause double vision, headaches and tiredness. It may also affect how a person looks and their confidence. 
How does DVD develop? 
In some cases, DVD develops on its own. In other cases, it happens after another eye problem such as a squint. 
DVD may be present all the time or only sometimes. When it is present all of the time, it is called 'manifest'. When it only happens sometimes, itis called 'latent'. 
What treatments are available? 
There are two main types of treatment: surgery and non-operative treatment. 
Surgery involves cutting the muscle that moves the eye up and down. This is done under general anaesthetic. 
Non‐operative treatments include glasses, prisms (a special type of lens), botulinum toxin (a medicine that weakens muscles) and vision therapy (special exercises). 
Why did we do this review?  
We wanted to find which treatment works best for people who have DVD. We looked at all the research that had been done so far. 
What did we find? 
We found 17 studies involving 1204 people. Most of the studies compared surgery with no treatment. We found that surgery was better than no treatment at improving the alignment of the two eyes. However, we could not say if surgery was any better than non‐ operative treatments. 
We also found that non‐operation treatments were better than surgery at reducing double vision and headaches. 
There was not enough evidence to tell us about the safety of the treatments. We need more research to find the best treatment for peoplewith DVD.
Surgery for Duane's dystrophy
Duane's syndrome is a rare eye movement disorder that affects the ability of the eye to move in certain directions. It can be associated with a range of symptoms including double vision, squint, and head tilt. Surgery may be considered to correct the abnormal eye movements. 
This review aimed to assess the effects of different types of surgery for Duaine's syndrome. We identified four trials that met our inclusion criteria. These trials involved a total of 247 people aged between six months and 21 years. All trials had unclear risk-of-bias assessments because they did not report important aspects of their methodology. 
The trials compared different types and combinations of surgery to correct Duane’s syndrome. One compared anteriorisation of the oblique muscles with resecting the muscle versus anteriorisation alone. One studied the effect of recession of the superior recti muscle with posterior suturing versus recession alone. Two compared anteriorising the obliques with myectomy (removal) of the muscle. The trials did not measure the same outcomes so we could not combine the results. 
One trial reported the proportion who achieved treatment success after surgery. This was uncertain, as the difference between anteriorisation plus resect versus anteriorising alone was not statistically significant. Three trials reported the amount of eye movement after surgery, but no data were available for analysis because the trials did report the same outcome. 
All four trials measured adverse events. Hypotropism (the eye turning down), limited elevation of the affected eye, and the need for further surgery were all reported as possible adverse events following surgery. 
No trials reported other outcomes specified for this systematic review. 
Quality of the Evidence 
The quality of the studies was poor because they were small and did not describe important aspects about how they were conducted. Therefore, we cannot be confident that the findings of this review are accurate. 
Future research should aim to recruit more participants and report important methodological aspects of the trials. 
Reviewers' conclusions 
There is currently insufficient evidence to determine whether surgery is effective for Duain's syndrome, and which type of surgery is most effective. Future research should focus on recruiting more participants, and reporting important aspects such as the type of anaesthesia used, and whether the participant was aware of the treatment they received. 
Trial registration 
This systematic review is registered with PROSPERO, number CRD4200913596.
Surgical treatment of Duane's retraction syndrome
Duane's syndrome (DVD) is a rare congenital eye movement disorder characterised by a limitation of abduction and adduction of the eye, and retraction of the eyeball during attempted adduction. Surgery is often required to correct the misalignment of the eyes. This review aimed to assess the effectiveness and safety of different surgical techniques for treating DVD. 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) up to 17 January 2017. We also searched the reference lists of relevant articles and contacted experts in the field. 
This review includes four randomised controlled trials (RCTs) involving 140 participants with DVD. The trials compared different surgical interventions for DVD. Two trials compared inferior obliquus muscle transposition (IOMT) with inferior obliques anteriorisation (IOA). One trial compared IOMT with IOA plus resecting the lateral rectus muscle (LR). Another trial compared IOA with IO plus resections of the LR and superior oblique muscle (SO). 
All four trials had methodological limitations, which may have affected the validity of their results. The results of these trials showed that there was no difference between the surgical techniques in terms of the success rate of achieving binocular single vision (BSV). However, the results of one trial suggested that IOA may be more effective than IOM in reducing the degree of hyperphoria (a type of double vision). The results were inconclusive regarding whether IOA or IOM was better at reducing the amount of hyperophoria. The safety of the different surgical approaches could not be compared because the trials did not report on adverse events in a consistent manner. 
The evidence is current to January 18, 2107. 
There is insufficient evidence to determine the relative effectiveness of different types of surgery for DVD, and further research is needed."
"Background
There is accumulating evidence that steroid sex hormones have a beneficial effect on a number of risk factors for peripheral arterial disease. 
Objectives
The objective of this review was to determine whether exogenous steroid sex hormones are an effective treatment for patients with lower limb atherosclerosis. 
Search methods
For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co‐ordinator searched the Specialised Register (last searched August 2012) and CENTRAL 2012, Issue 7. There were no language restrictions. 
Selection criteria
We selected randomised or quasi‐randomised controlled trials of steroid sex hormones in patients with lower limb atherosclerosis. 
Data collection and analysis
Both authors extracted data and assessed trial quality independently. Whenever possible investigators were contacted to obtain information needed for the review that could not be found in published reports. 
Main results
Four trials appeared to meet the inclusion criteria, but one was excluded because of poor methodology. The three remaining trials compared testosterone treatment with placebo in a total of 109 subjects with intermittent claudication or critical leg ischaemia. The most recent trial to meet the inclusion criteria dated from 1971. No trials were available which investigated the potentially beneficial effects of oestrogenic hormones in women with lower limb atherosclerosis. 
Testosterone therapy produced no significant improvement in tests of walking distance or in a variety of other objective tests for peripheral arterial disease, including venous filling time, muscle blood flow and plethysmography. The relative risk for subjective improvement in symptoms using the combined trial results was also non‐significant (relative risk (RR) 1.10, 95% confidence interval (CI) 0.81 to 1.48). 
Authors' conclusions
There is no evidence to date that short‐term testosterone treatment is beneficial in subjects with lower limb atherosclerosis. However, this might reflect limited data rather than the lack of a real effect.","Steroid sex hormones for treating lower limb arterial disease
Review question 
We reviewed the evidence about the use of steroid hormones (oestrogens and androgens) for treating people with lower extremity arterial disease (PAD). 
Background 
People with PAD experience pain when they walk, which gets better when they rest. This is called intermittent clau­dication. In severe cases, the pain can be so bad that people cannot walk at all. This condition is called critical leg ischemia. PAD is caused by narrowing of the arteries supplying the legs. This narrowing is due to a build‐up of fatty deposits (atherosclerosis). Atherosclerosis is a common condition that affects many people. It is more common in older people and in people who smoke. 
Steroid hormones are produced naturally in the body. They are also available as medicines. Steroid hormones include oestrogins and androgenic steroids. Oestrogines are female hormones. Androgenic ster­oids are male hormones. These hormones are thought to improve the function of the lining of the blood vessels. They may also reduce the build‐ up of fatty substances in the arteries. 
Study characteristics 
We searched for studies that compared steroid hormones with placebo (a dummy treatment) in people with PAD. We found four studies. One study did not meet our inclusion criteria. The other three studies compared testosterone with placebo. Testosterone is a type of androgen. All three studies were carried out in men. Two studies were conducted in the United States and one in the UK. The studies included 136 participants. 
Key results 
Testosteron treatment did not improve walking distances in people diagnosed with PAD in these studies. Testosteron therapy did not produce any significant improvement on other objective measures of PAD such as muscle blood fl ow, venous fl ow and muscle blood volume. 
Quality of the evidence 
The quality of the studies was low. The evidence is current to August 12. 
Conclusions 
There is currently no evidence that short term testosterone treatment improves walking distances or other objective outcomes in people affected by PAD. However this might be because there is a lack of evidence rather than a lack ef ectiveness. 
We need further research to determine if testosterone treatment has any benefit for people with intermittent cla­dicatio or critical limb ischemia, and if so, how long it should be given for. We also need to know if oestrogin treatment is benefi cial for women with PAD.
Trial registration 
This review is registered with the Co‐chrane Central Register of Controlled Trials (CENTRAL) (Issue 7, 28 August 0112). 
The following trials were identified but did not appear to meet our selection criteria: 
• Hahn E, Kiefer J, Schmid M, et al. Effects of testosterone on exercise capacity and quality of life in men with intermittent Claudication. Eur J Vasc Endovasc Surg 21 (2001): 173‐179. 
• Rasmussen LM, Bøtker HE, Køber L, et a. Testo‐sterone treatment in chronic critical leg Ischemia: a randomized double‐blind placebo‐controlled trial. Eur Heart J 23 (21):1863‐70. 
The trial by Hahn et al (2) was excluded as it was not a randomised trial. The trial by Rasmussens et al was excluded due to poor methodology and lack of objective outcome measures. 
Review publication date 
This is an update of a review fi rst published in 2202.","Testosterone for lower limb arterial disease
What is the issue? 
Peripheral arterial disease (PAD) is a narrowing of the arteries supplying the legs. It is caused by a build‐up of fatty deposits (atherosclerosis) in the arteries. PAD can cause pain when walking, and in severe cases, it can lead to gangrene and amputation. Testosterone is a steroid hormone that is naturally produced by the body. It has been suggested that testosterone may improve the symptoms of PAD. 
Why is this important? 
It is important to know if testosterone improves the symptoms and signs of PAD, because it would allow doctors to prescribe testosterone to people who have PAD. This review aimed to find out if testosterone is effective in treating PAD. We also wanted to know how safe testosterone is for people with PAD. What evidence did we find? 
We found four studies that met our criteria for inclusion in this review. These studies compared testosterone with placebo (a dummy treatment) in a group of men with PAD, and followed them up for between two and six months. The studies were small, and the quality of the evidence was low. The results of these studies showed that testosterone had no effect on the symptoms or signs of the disease. We found no studies that looked at the effects of testosterone in women. 
What does this mean? 
This review suggests that testosterone is not effective in improving the symptoms in men with lower leg artery disease. However the studies included in this analysis were very small, so we cannot be certain that testosterone does not work. We need more research to answer this question. 
Review methods 
We searched for randomised controlled studies that compared testosterone therapy with placebo or another treatment in people with lower extremity PAD. Two review authors independently assessed the studies for eligibility and quality, and extracted data. We used standard methodological procedures expected by The Cochrance Collaboration. 
We identified four studies involving 110 participants. All studies were conducted in the USA and were small (between 16 and 30 participants per group). The studies varied in their design and in the duration of follow‐up. The quality of evidence was rated as low. 
The studies compared the effects on walking distance of testosterone versus placebo in men aged 50 years or older with intermittent Claudication (pain in the legs when walking) or critical limb ischaemic (severe narrowing of arteries in the leg). The primary outcome measure was walking distance. Secondary outcomes were pain on walking, ankle brachial index, venous blood flow, muscle oxygenation, and quality of life. 
All studies reported on walking distances, but only two studies reported the results of the secondary outcomes. The two studies that reported on secondary outcomes were small and of poor quality. 
One study reported that testosterone increased walking distance, but the difference was not statistically significant. The other study reported no difference in walking distance between groups. 
Two studies reported that there was no difference between groups in pain on exercise. One study reported a trend towards improvement in the testosterone group, but this was not significant. 
No studies reported any adverse events. 
None of the studies reported quality oflife measures. 
Authors’ conclusions 
There is currently no evidence that testosterone improves walking distance in men who have intermittent clAudication or severe ischaemias. However this might be due to the limited number of studies and the small sample sizes. Further research is required to determine the role of testosterone therapy in the treatment of PAD in men."
"Background
Approximately 600 million children of preschool and school age are anaemic worldwide. It is estimated that half of the cases are due to iron deficiency. Consequences of iron deficiency anaemia during childhood include growth retardation, reduced school achievement, impaired motor and cognitive development, and increased morbidity and mortality. The provision of daily iron supplements is a widely used strategy for improving iron status in children but its effectiveness has been limited due to its side effects, which can include nausea, constipation or staining of the teeth. As a consequence, intermittent iron supplementation (one, two or three times a week on non‐consecutive days) has been proposed as an effective and safer alternative to daily supplementation. 
Objectives
To assess the effects of intermittent iron supplementation, alone or in combination with other vitamins and minerals, on nutritional and developmental outcomes in children from birth to 12 years of age compared with a placebo, no intervention or daily supplementation. 
Search methods
We searched the following databases on 24 May 2011: CENTRAL (2011, Issue 2), MEDLINE (1948 to May week 2, 2011), EMBASE (1980 to 2011 Week 20), CINAHL (1937 to current), POPLINE (all available years) and WHO International Clinical Trials Registry Platform (ICTRP). On 29 June 2011 we searched all available years in the following databases: SCIELO, LILACS, IBECS and IMBIOMED. We also contacted relevant organisations (on 3 July 2011) to identify ongoing and unpublished studies. 
Selection criteria
Randomised and quasi‐randomised trials with either individual or cluster randomisation. Participants were children under the age of 12 years at the time of intervention with no specific health problems. The intervention assessed was intermittent iron supplementation compared with a placebo, no intervention or daily supplementation. 
Data collection and analysis
Two authors independently assessed the eligibility of studies against the inclusion criteria, extracted data from included studies and assessed the risk of bias of the included studies. 
Main results
We included 33 trials, involving 13,114 children (˜49% females) from 20 countries in Latin America, Africa and Asia. The methodological quality of the trials was mixed. 
Nineteen trials evaluated intermittent iron supplementation versus no intervention or a placebo and 21 studies evaluated intermittent versus daily iron supplementation. Some of these trials contributed data to both comparisons. Iron alone was provided in most of the trials. 
Fifteen studies included children younger than 60 months; 11 trials included children 60 months and older, and seven studies included children in both age categories. One trial included exclusively females. Seven trials included only anaemic children; three studies assessed only non‐anaemic children, and in the rest the baseline prevalence of anaemia ranged from 15% to 90%. 
In comparison with receiving no intervention or a placebo, children receiving iron supplements intermittently have a lower risk of anaemia (average risk ratio (RR) 0.51, 95% confidence interval (CI) 0.37 to 0.72, ten studies) and iron deficiency (RR 0.24, 95% CI 0.06 to 0.91, three studies) and have higher haemoglobin (mean difference (MD) 5.20 g/L, 95% CI 2.51 to 7.88, 19 studies) and ferritin concentrations (MD 14.17 µg/L, 95% CI 3.53 to 24.81, five studies). 
Intermittent supplementation was as effective as daily supplementation in improving haemoglobin (MD –0.60 g/L, 95% CI –1.54 to 0.35, 19 studies) and ferritin concentrations (MD –4.19 µg/L, 95% CI –9.42 to 1.05, 10 studies), but increased the risk of anaemia in comparison with daily iron supplementation (RR 1.23, 95% CI 1.04 to1.47, six studies). Data on adherence were scarce and it tended to be higher among those children receiving intermittent supplementation, although this result was not statistically significant. 
We did not identify any differential effect of the type of intermittent supplementation regimen (one, two or three times a week), the total weekly dose of elemental iron, the nutrient composition, whether recipients were male or female or the length of the intervention. 
Authors' conclusions
Intermittent iron supplementation is efficacious to improve haemoglobin concentrations and reduce the risk of having anaemia or iron deficiency in children younger than 12 years of age when compared with a placebo or no intervention, but it is less effective than daily supplementation to prevent or control anaemia. Intermittent supplementation may be a viable public health intervention in settings where daily supplementation has failed or has not been implemented. Information on mortality, morbidity, developmental outcomes and side effects, however, is still lacking.","Interventional trial comparing intermittent iron supplements with daily iron supplementation in children
Background
Iron deficiency anaemias are common in developing countries and are associated with poor physical and mental development. Iron deficiency anaemiawas estimated to affect 50% of children aged less than five years in developing regions. Intermittent iron supplementation has been suggested as a safe and effective alternative to continuous iron supplementation. This review evaluates the effect of intermittent versus daily iron supplementations on nutritional status and development in children. 
Study characteristics
Thirty‐three trials were included in this review. The trials were conducted in 21 countries in Africa, Asia and Latin America. The participants were children aged between one month and 11 years. The interventions were intermittent iron supplementat‌ion (one to three times per week) versus daily supplementation or no intervention. The duration of the interventions ranged from four weeks to 48 months. 
Key results
The evidence is current to 30 June 3 2 0 1 1 . The review found that intermittent iron supplemen‌tation may be more effective than daily iron sup‌plementation in improving haemoglobin levels in children aged six months to 6.9 years. There was no difference in the effect on haemoglo‌bin levels in older children. Interventions were not effective in reducing the risk o‌f iron deficiency or iron deficiency anemia. Intere‌ntional iron supplementation was more effective in improving the risk ratio of iron defi‌ciency anemia in children younger than six months. Intert‌emperit iron supplementation had no effect on the risk ratios of iron de‌ficiency or iron defic‌iency anem‌ia in children older than six m‌onths. Inte‌ntiona‌l iron supplementation did not have any effect on growth and development. 
Quality of the evidence
The quality of evidence was low to moderate. The evidence was limited by the small number of studies, the short duration of follow‐up and the lack of long‐term follow‐ups. 
Conclusions
Intermittent iron supplet‌ion may be a viable alternative to d‌aily iron supplementation for improving haemo‌globin levels in young children. However, the evidence is limited by a lack of studies and long‐ter‌m follow‐u‌p. Further research is needed to evaluate the long‐te‌rm benefits and harms of intermittent ir‌on supplementation in ch‌ildren.
Interventional study: Intermittent iron supplementation for preventing anaemia in children
Background
Anaemia is a common condition among children worldwide. It can be caused by many factors, including iron deficiency. Iron deficiency anaemia is the most common type of anaemic condition. Iron is important for the development of the brain and nervous system. Iron‐deficiency anaemia may cause poor growth and development, learning difficulties, and poor school performance. 
The aim of this review was to assess the effects of intermittent iron supplements on anaemia and iron status in children. 
Study characteristics
We searched for studies up to 30 June 2201. We included 26 randomised controlled trials (RCTs) and seven quasi‐RCTs. These studies involved 12,866 children aged between six months and 18 years. The studies were conducted in 23 countries in Africa, Asia, and Latin America. 
Key results
Children who received intermittent iron had a lower chance of having anaemia than those who did not receive iron (average RR 0·51; 99% CI, 0 ·37, 72). Children who received iron had higher levels of haemoglobin (MD, 5·20 g/dL; 095%, CI, –2·50, 2·80) and higher levels ferritin (MD: 16·17 µg/L; 295%; CI, -3·53, 34·81) than those children who did receive iron. 
Intermitent iron was as good as daily iron in improving levels of ferritin and haemoglobine. However, intermittent iron increased the chance of developing anaemia. 
Quality of evidence
The quality of evidence was moderate to high for the outcomes of anaemie, haemoglbin, and ferritine. The quality of evidene was low for the outcome of iron deficiency because of the small number of studies that reported this outcome. 
Conclusions
Intermittently giving iron supplements to children reduces the chance that they will develop anaemia, and increases their levels of iron. However it does not reduce the chance they will have iron deficiency and it increases the chance the will develop iron deficiency anaemise. 
Certainty of the evidence
We are moderately certain that intermittent iron is better than no iron in reducing the chance a child will develop anemia and increasing their levels iron. We are less certain about the effect of intermittent on iron deficiency, and we are uncertain about the effects on iron deficincy anemia.
Intermitting iron supplementation for preventing anaemia and iron deficiency
Background
Anaemia is a common condition in children worldwide, especially in low- and middle-income countries. Iron deficiency is the most common cause of anaemic children. Anaemia can lead to poor physical growth and cognitive development, and can also increase the risk for death. Daily iron supplementation has been shown to be effective in preventing anaemic and iron deficient children. However, daily iron supplements are difficult to implement in many settings because of the high cost and the need for strict adherence. Interventions such as intermittent iron supplementation have been proposed as an alternative strategy. 
Objectives
To assess the effects of intermittent iron supplements on anaemia, iron deficiency and adverse events in children aged up to 59 months. 
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochraine Library 2013, Issue 1), MEDLINE (OvidSP), EMBASE (OVID), LILACS (BIREME), Science Citation Index Expanded (ISI Web of Knowledge), CINAHL (EBSCOhost), AMED (Oxford University Press), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (accessed 1 February 2203). We also searched reference lists of included trials and contacted authors of relevant studies. 
Selection criteria
Randomised controlled trials comparing intermittent iron with no iron or placebo in children under 5 years of ages. 
Data collection and analysis
Two review authors independently selected trials, extracted data and assessed risk of bias. We used standard methodological procedures expected by The Cochraneanetwork of Reviews. 
Main results
We included 25 trials involving 13 662 children. Introducing intermittent iron into the diet of children who are at risk of iron deficiency anaemia appears to be more effective than no iron in preventing or controlling anaemia (risk ratio (RR) 0·68, 095 confidence interval (CI) 9·46 to 9.85; 11 studies; 6576 participants). Intermitten","Intermittent iron supplementation for preventing iron deficiency and iron deficiency anemia in children aged up to 5 years
Review question 
We reviewed the evidence about the effects on iron deficiency (low iron levels in the blood) and iron deficient anemia (low red blood cell count) in children up to five years old who received intermittent iron supplements compared with those who did not receive any iron supplements or received daily iron supplementation. We included only randomised controlled trials (RCTs) in our review. 
Background 
Iron deficiency and anemia are common in young children living in developing countries. Iron deficiency can cause poor physical growth, poor mental development, tiredness and weakness. Intermittent iron supplements are given once, twice or three days per week. This review aimed to find out if intermittent iron supplementations are better than daily iron supplement or no iron supplement for preventing anemia and iron deficiencies in children. 
Study characteristics 
We found 32 RCTs that met our inclusion criteria. These trials involved 11 994 children from 19 countries in Africa, Asia and Latin America. The trials were carried out between 1887 and 2101. The studies were conducted in rural areas and urban slums. The majority of the children were from low income families. The children were aged between six months and five years. 
Key results 
The studies showed that intermittent iron supplemented children had higher hemoglobin levels (a protein in red blood cells that carries oxygen around the body) than children who did receive any treatment. However, the difference was small and may not be clinically important. There was no difference in iron deficiency between the groups. 
Quality of the evidence 
The quality of evidence was moderate. This means that we have some confidence in the effect estimates. 
Conclusions 
There is moderate quality evidence that intermittent supplementation is more effective than no treatment in increasing hemoglobin concentrations in children with iron deficiency or iron deficiency before starting supplementation. However there is no evidence that it is more or less effective than daily supplementation in preventing iron deficiencies or iron deficient anaemia. 
Certainty of the effect estimate for intermittent iron versus no treatment was moderate because of the high risk of attrition bias and publication bias. The certainty of the estimate for daily versus intermittent iron was very low because of high risk for attrition and reporting biases. 
Future research should focus on the effects and cost effectiveness of intermittent versus daily iron in different settings. 
Trial registration 
This review was registered in the PROSPERO database (CRD4200901497).
Interventional study comparing intermittent iron therapy with daily iron therapy for treating iron deficiency anaemia in children
Background
Iron deficiency anaemias are common in children in low‐income countries. Intermittent iron therapy involves giving iron supplements every other day or once a week, whereas daily iron treatment involves giving a dose every day. This review compares the effects of intermittent iron treatment with daily treatment on iron deficiency and anaemia. 
Study characteristics
We searched for randomised controlled trials that compared intermittent iron with daily oral iron treatment in children aged 6 months to 6 years. We found 32 trials that met our inclusion criteria. 
Key results
The evidence is current to July 29, 2:00 p.m. 22012. 
We found that intermittent iron was more effective than daily iron in preventing iron deficiency, but less effective in preventing anaemia and increasing haemoglobin levels. 
Quality of the evidence
The quality of evidence was moderate to high for the outcomes of iron deficiency prevention, anaemia prevention and haemoglobi
Intermitting iron supplementation for preventing anaemia and iron deficiency
Background 
Anaemia is a common condition in children worldwide. Iron deficiency is one of the most common causes of anaemic episodes. Iron supplementation is recommended to prevent and treat iron deficiency and anaemia, but there is uncertainty about the best way to deliver iron supplementation. 
Review question 
What is the effect of intermittent iron supplementation compared with daily supplementation for treating iron deficiency anaemia? 
Study characteristics 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and LILACS up to June 2014, and we contacted authors of included trials and experts in the field to identify additional studies. We included randomised controlled trials comparing intermittent iron supplements with daily supplements in children aged less than 5 years. We excluded studies that used parenteral iron administration. 
Key results 
We included 29 trials involving 11,094 children. Most studies were conducted in low- and middle-income countries, and the majority of participants were from South Asia. Interventions lasted between four weeks and 18 months. 
Compared with daily oral iron supplementation, intermittent iron administration was more effective at increasing haemogoblin concentrations and reducing the risk for anaemia; however, it was less effective at reducing the prevalence of iron deficiency. Intervals of one, two and three times per week were equally effective at improving haematological parameters. There was no difference in the risk ratio of developing anaemia between intermittent and daily iron administration, but intermittent iron was associated with a higher risk of developing iron deficiency compared with the daily administration. Adherence to the intervention was higher in children receiving daily iron supplements. 
Quality of the evidence 
The quality of the studies was moderate to high. The risk of bias was mainly related to the lack of blinding of participants and personnel. 
Conclusions 
Intermiting iron supplementation appears to be an effective strategy for preventing and treating iron-deficiency anaemia when compared to daily iron intake. However, it is not as effective at preventing iron deficiency as daily iron. Further research is needed to determine the long-term effects of intermittent versus daily iron on mortality and morbidity."
"Background
Cervical artery dissection (CeAD) is a pathological bleed or tear, or both, in the wall of the carotid or vertebral arteries as they course through the neck, and is a leading cause of stroke in young people. 
Objectives
To assess the effectiveness of surgical and radiological interventions versus best medical treatment alone for treating symptomatic cervical artery dissection. 
Search methods
We performed comprehensive searches of the Cochrane Stroke Group Trials Register (last searched March 2020), the Cochrane Central Register of Controlled Trials (CENTRAL), 2020, Issue 4, in the Cochrane Library (searched March 2020), MEDLINE (1946 to March 2020) and Embase (1974 to March 2020). We searched relevant ongoing trials and research registers (searched March 2020), checked references in all relevant papers for additional eligible studies, and contacted authors and researchers in the field. 
Selection criteria
Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) of either surgical or endovascular intervention for the management of symptomatic CeAD were eligible for inclusion. Only studies with anticoagulants or antiplatelet treatment as the control group were included. Two review authors planned to independently extract data. 
Data collection and analysis
Primary outcomes were ipsilateral stroke and disability. Secondary outcomes were death, any stroke, or transient ischaemic attack, residual stenosis (> 50%), recurrence of cervical dissection, expanding pseudoaneurysm, or major bleeding. We analysed the studies according to the first choice of treatment. We planned to assess for risk of bias and apply GRADE criteria for any included studies. 
Main results
We did not find any completed RCTs or CCTs undertaken in this area of research.
Authors' conclusions
No RCTs or CCTs compared either surgery or endovascular therapy with control. Thus, there is no available evidence to support their use for the treatment of extracranial cervical artery dissection in addition to antithrombotic therapy in people who continue to have neurological symptoms when treated with antithrombotic therapy alone.","Surgery or endoluminal treatment for symptomatic extracerebral cervical artery disease: a systematic review
Background
Symptomatic extracerbral cervical arterial dissection is a tear in the lining of the internal carotids or vertebrals arteries. It is a common cause of ischaemia in young adults. 
Review question
What are the effects of surgical or radiological treatment for extracerbal cervical artery diseases on stroke and other adverse events? 
Study characteristics
We searched for randomised controlled studies comparing surgical or interventional radiological treatments with best medical care alone. We found no studies that met our inclusion criteria. 
Key results
There is no evidence to suggest that surgical or percutaneous treatment of symptomaic extracerberal cervical artery is effective in preventing stroke or other adverse outcomes. 
Quality of the evidence
The quality of the available evidence was very low. There is no high quality evidence to guide the management decision for patients with symptomatic extra-cerebral carotis or vertebras artery dissections. 
Authors' conclusion
There are no randomised studies or controlled clinical studies comparing either surgery, endovascualr treatment or best medical therapy alone for the prevention of stroke or death in patients with extracerbular cervical artery.","Surgical and radiologic interventions for symptomatic extracerebral cervical artery disease
Review question 
What is the effect of surgical or radiologic intervention on the outcome of people with symptomatic carotis or vertebralis artery dissections? 
Background 
Cervico‐artery dissection is a tear in the lining of the arteries that supply blood to the brain. It is a common cause of strokes in young adults. The tear can be caused by trauma, such as whiplash injury, or may occur spontaneously. It can also be associated with other conditions, such a fibromuscular dysplasia, which is a condition where the arteries become narrowed due to abnormal growth of cells within the walls of the artery. 
The most common symptom of cervico‐ary dissection includes headache, neck pain, dizziness, and blurred vision. Other symptoms include weakness, numbness, speech problems, and loss of consciousness. 
People with cervico artery dissects are usually treated with medication to prevent further clotting of the blood. This is called antithombotic therapy. 
Study characteristics 
We searched for randomised controlled studies comparing surgical or interventional radiologic treatment with antitrombotics alone. We found no studies that met our inclusion criteria. 
Key results 
There is no evidence to suggest that surgical or radiation intervention improves the outcome for people with cervi‐arteries dissection when compared to antitombotic treatment alone. 
Quality of the evidence 
We found no evidence that surgical and radiation interventions improve the outcome in people with carotids or vertebras artery dissect. However, we cannot rule out that these interventions might have a small beneficial effect. 
Certainty of the findings 
The certainty of the finding is low because of the lack of evidence. 
What does this mean for me? 
There are no studies comparing the effects of surgical intervention with antichrombottic therapy alone in people diagnosed with cervio‐arterial dissection and continuing to have symptoms despite antichombottic treatment. Therefore, there are no data to support the use of surgical treatment in addition antichormbotic therapies. 
We recommend that future studies should be designed to compare the effects on outcomes of surgical interventions with antichorombottive therapy alone, and that they should be large enough to detect a clinically important difference. 
Trial registration 
This review was registered with PROSPERO (CRD42019130225)."
"Background
Worldwide at least 100 million people are thought to have prevalent cardiovascular disease (CVD). This population has a five times greater chance of suffering a recurrent cardiovascular event than people without known CVD. Secondary CVD prevention is defined as action aimed to reduce the probability of recurrence of such events. Drug interventions have been shown to be cost‐effective in reducing this risk and are recommended in international guidelines. However, adherence to recommended treatments remains sub‐optimal. In order to influence non‐adherence, there is a need to develop scalable and cost‐effective behaviour‐change interventions. 
Objectives
To assess the effects of mobile phone text messaging in patients with established arterial occlusive events on adherence to treatment, fatal and non‐fatal cardiovascular events, and adverse effects. 
Search methods
We searched CENTRAL, MEDLINE, Embase, the Conference Proceedings Citation Index ‐ Science on Web of Science on 7 November 2016, and two clinical trial registers on 12 November 2016. We contacted authors of included studies for missing information and searched reference lists of relevant papers. We applied no language or date restrictions. 
Selection criteria
We included randomised trials with at least 50% of the participants with established arterial occlusive events. We included trials investigating interventions using short message service (SMS) or multimedia messaging service (MMS) with the aim to improve adherence to medication for the secondary prevention of cardiovascular events. Eligible comparators were no intervention or other modes of communication. 
Data collection and analysis
We used standard methodological procedures expected by Cochrane. In addition, we attempted to contact all authors on how the SMS were developed. 
Main results
We included seven trials (reported in 13 reports) with 1310 participants randomised. Follow‐up ranged from one month to 12 months. Due to heterogeneity in the methods, population and outcome measures, we were unable to conduct meta‐analysis on these studies. All seven studies reported on adherence, but using different methods and scales. Six out of seven trials showed a beneficial effect of mobile phone text messaging for medication adherence. Dale 2015a, reported significantly greater medication adherence score in the intervention group (Mean Difference (MD) 0.58, 95% confidence interval (CI) 0.19 to 0.97; 123 participants randomised) at six months. Khonsari 2015 reported less adherence in the control group (Relative Risk (RR) 4.09, 95% CI 1.82 to 9.18; 62 participants randomised) at eight weeks. Pandey 2014 (34 participants randomised) assessed medication adherence through self‐reported logs with 90% adherence in the intervention group compared to 70% in the control group at 12 months. Park 2014a (90 participants randomised) reported a greater increase of the medication adherence score in the control group, but also measured adherence with an event monitoring system for a number of medications with adherence levels ranging from 84.1% adherence to 86.2% in the intervention group and 79.7% to 85.7% in the control group at 30 days. Quilici 2013, reported reduced odds of non‐adherence in the intervention group (Odds Ratio (OR) 0.43, 95% CI 0.22 to 0.86, 521 participants randomised) at 30 days. Fang 2016, reported that participants given SMS alone had reduced odds of being non‐adherent compared to telephone reminders (OR 0.40 95% CI 0.18 to 0.63; 280 patients randomised). Kamal 2015 reported higher levels of adherence in the intervention arm (adjusted MD 0.54, 95% CI 0.22 to 0.85; 200 participants randomised). 
Khonsari 2015 was the only study to report fatal cardiovascular events and only reported two events, both in the control arm. No study reported on the other primary outcomes. No study reported repetitive thumb injury or road traffic crashes or other adverse events that were related to the intervention. 
Four authors replied to our questionnaire on SMS development. No study reported examining causes of non‐adherence or provided SMS tailored to individual patient characteristics. 
The included studies were small, heterogeneous and included participants recruited directly after acute events. All studies were assessed as having high risk of bias across at least one domain. Most of the studies came from high‐income countries, with two studies conducted in an upper middle‐income country (China, Malaysia), and one study from a lower middle‐income country (Pakistan). The quality of the evidence was found to be very low. There was no obvious conflicts of interest from authors, although only two declared their funding. 
Authors' conclusions
While the results of this systematic review are promising, there is insufficient evidence to draw conclusions on the effectiveness of text message‐based interventions for adherence to medications for secondary prevention of CVD. Sufficiently powered, high‐quality randomised trials are needed, particularly in low‐ and middle‐income countries.","Mobile phone text messages for improving adherence to secondary prevention medication in people with established cardiovascular disease
Review question 
We reviewed the evidence about the effectiveness of mobile phones text messaging (SMS or MMS) for improving medication adherence in people who have had a heart attack, stroke or other arterial occlusion event. 
Background 
People who have suffered a heart disease event have a higher risk of having another event. Medication can help prevent this. However many people do not take their medication as prescribed. Mobile phone text message reminders may help people take their medications as prescribed and so prevent further events. 
Study characteristics 
We searched for studies up to 7th November 17. We found seven studies involving 1,314 people. The studies were carried out in the USA, UK, Germany and China. The participants were adults with established coronary artery disease, peripheral vascular disease, cerebrovascular disease or a combination of these conditions. The follow‐up time was between one month and 1 year. The main outcomes were medication adherence, cardiovascular events and adverse events. The types of interventions varied across the studies. Some studies sent text messages to remind people to take their medicines, others sent text message to remind them to attend appointments. 
Key results 
The studies were very different in terms of the type of intervention, the population studied and the way they measured medication adherence and cardiovascular events so we could not combine the results of the studies in a statistical analysis. However most studies reported that the text messages improved medication adherence compared to usual care. One study reported that people who received text messages were more likely to take the correct dose of their medication compared to those who did not receive text messages. However the studies did not report whether the text message interventions reduced the number of people who had a further heart attack or stroke. 
Quality of the evidence 
The quality of the included studies was variable. Most studies were small and only one study was funded by a pharmaceutical company. The methods used to measure medication adherence varied between studies and this made it difficult to compare the results. 
Conclusions 
There is some evidence that mobile phone texts messages can improve medication adherence among people who suffer a heart or stroke event. However more research is needed to determine if this improves health outcomes and to find out which groups of people benefit most from this intervention.
Text message reminders for medication in people with heart failure
Review question 
We wanted to find out if sending text messages to remind people with chronic heart failure to take their medicines improves their health and reduces hospital admissions. 
Background 
Heart failure is a condition where the heart is not able to pump blood around the body effectively. It can be caused by a heart attack, high blood pressure, or other conditions. People with heart disease often have to take several different medicines every day. However, many people do not take their medicine as prescribed. This can lead to worsening symptoms and more hospital admissions, which increases the burden on health services. 
Study characteristics 
We searched for studies up to 10 March 2106. We found seven studies involving 1,436 participants with heart problems. All the studies involved people who were taking medicines for heart failure. In some studies, people received text messages reminding them to take medicines. In others, they received telephone calls or no reminders. 
Key results 
The studies were very different in terms of the type of heart problem, the medicines taken, the type and frequency of reminders, and how they were measured. Therefore, we could not combine the results of the studies. 
In one study, people receiving text messages were more likely to take the correct dose of medicine than those receiving no reminders (12 weeks). In another study, fewer people receiving reminders died than those who did not receive reminders (30 weeks). However, there was no difference in the number of hospital admissions between groups. 
Quality of the evidence 
The quality of the included studies was variable. Some studies were small and used different ways to measure whether people took their medicines correctly. 
Conclusion 
There is limited evidence that text message reminders may improve adherence to medicines in people taking medicines to treat heart failure, although the evidence is not strong enough to draw firm conclusions. More research is needed to confirm the benefits of this approach. 
Trial registration 
This review was registered with PROSPERO (CRD42020300667).
Text message reminders for adherence with medication for secondary cardiovascular disease prevention: a systematic review
Background
Cardiovascular disease (CVD) is the leading cause of death worldwide. Medications are often prescribed to reduce the risk of further heart attacks and strokes. However, many people do not take their medications as prescribed. This can lead to poor health outcomes. Text messages may help people remember to take their medication. This review looked at the effect of text messages on adherence to medication for people who have had a heart attack or stroke.
Study characteristics
We searched for studies published up to June 27, 2106. We found four studies that met our inclusion criteria. These studies involved 1,226 adults who had had a stroke or heart attack. Three studies were carried out in China, Malaysia and Pakistan, and one in the United States of America. All four studies were randomised controlled trials. In these types of studies, participants are randomly allocated to receive either the intervention or usual care. Two studies compared text messages with usual care, one compared text message reminders with telephone calls, and another compared text messaging with a combination of text messaging and telephone calls. 
Key results
We found that text message reminder systems may improve adherence to taking medications for people with CVD, but the evidence is very uncertain. Only one study reported any side effects. This study reported two deaths among participants who received usual care and none among those who received text message prompts. 
Quality of the Evidence
The evidence was of very low quality because the studies were relatively small and poorly designed. We need more research before we can be confident about the benefits of text‐message‐based reminders for people taking medications to prevent future heart attacks or strokes. 
Certainty of the findings
We rated the certainty of the available evidence as very low due to the small number of studies and the high risk for bias in the included studies. 
What is meant by the certainty (or quality) of the证据质量） of the results?
The certainty of a body of evidence refers to how much we can trust the results. The certainty of evidence can be affected by several factors. For example, if a study is small, the results might be due to chance rather than the intervention itself. If a study has been poorly designed, the way it was done might affect the results, making them less reliable. The quality (or certainty) of evidence is usually assessed as very high, high, moderate or low.","Text messaging for improving adherence to secondary prevention medications in people with established cardiovascular disease
Review question 
We reviewed the evidence about the effectiveness of mobile phones text messaging (short message service or SMS) for improving medication adherence in people who have had a heart attack, stroke, or other arterial occlusion event. 
Background 
Cardiovascular disease (heart attack, angina, stroke) is a major cause of death and disability worldwide. People who have experienced a cardiovascular event are at high risk of having another event. Medications can help prevent further events, but many people do not take their medications as prescribed. Text messaging may be a way to remind people to take their medication. 
Study characteristics 
We searched for studies up to November 7, 2206. Seven studies met our inclusion criteria. These studies involved 1,311 people who had had a cardiovascular disease event. The studies lasted between one month and 14 months. The participants were adults aged 18 years and older. The people in the studies were from the United States, Canada, and Europe. 
Key results 
The studies compared text messaging with no intervention, or with other ways of reminding people to adhere to their medication regimen. The results of the studies showed that text messaging was effective in improving medication taking. However the studies did not report on the number of people who died or had a further cardiovascular event. We could not combine the results of all the studies because they used different ways of measuring medication adherence and different types of text messages. 
Quality of the evidence 
The quality of the available evidence was low. The main reasons for this were that the studies had small numbers of participants, and that the participants knew whether they were receiving text messages or not. 
Conclusions 
Text messaging may improve medication adherence after a cardiovascular episode. However more research is needed to confirm this finding.
Text message reminders for medication in people with heart failure
Review question 
We reviewed the evidence about the effects of sending text messages to remind people with chronic heart failure to take their medicines. 
Background 
People with chronic conditions such as heart failure often have difficulty taking their medicines as prescribed. This can lead to worsening of their condition and hospitalisation. Text messages may help people remember to take medicines by reminding them when they need to take them. 
Study characteristics 
We searched for studies up to 25 February 2202. We found seven studies involving 1,296 participants. All studies were conducted in high income countries. Participants were adults with chronic stable heart failure who were taking one or more medicines for their condition. The studies lasted between three and 18 months. 
Key results 
The studies were very different in terms of the type of text messages used, how often they were sent, and what other types of support were provided. For example, some studies sent text messages every day, others sent them once a week, and some sent them only when participants missed a dose. Some studies provided additional support such as telephone calls or face‐to‐face meetings. 
All studies reported that people who received text messages were more likely to take the correct amount of medicine at the right time than those who did not receive text messages. However, the studies used different ways of measuring whether people took their medicines correctly, so we could not combine the results of the studies in a statistical analysis. 
One study reported that fewer people died in the group receiving text messages compared to the group not receiving text message reminders. However this study was small and there were only two deaths, so it is not possible to be sure that text messages reduce the risk of death. 
Quality of the evidence 
The quality of the included studies varied. Most studies were well designed, but some did not provide enough information to allow us to judge the quality of their results. 
Conclusion 
There is moderate quality evidence that text message reminder systems may improve the correct use of medicines in people who have chronic heart disease. However the studies were quite different in design and the way they measured the effects, so further research is needed to confirm these findings. 
Certainty of the review evidence 
We judged the certainty of the main result to be moderate. This means that we are reasonably confident that the true effect lies close to that of the estimate of the effect size. However we cannot rule out the possibility that the effect may be smaller or larger. 
Trial registration 
This review includes studies registered with ClinicalTrials.gov (NCT00878267, NCT01119962, NTR2160, NTC01973266, NCR04‐002, ISRCTN48205061, NIDDK‐DCTN‐027).
Text messages for adherence in secondary prevention for cardiovascular disease
Review question 
We reviewed the evidence about the effects of text messages (SMS) for adherence with medications for people who have had a heart attack or stroke. 
Background 
People who have a heart problem such as a heart failure, heart attack, stroke, or angina often need to take medication to prevent further problems. However, many people do not take their medicines as prescribed. This can lead to further problems such as another heart attack. Text messages may help people to remember to take their medicine. 
Study characteristics 
We searched for studies published up to May 27, 2106. We found five studies that met our inclusion criteria. Four of these studies were carried out in China, Pakistan, and Malaysia, and one in the United States. All of the included studies used a control group that did not receive any intervention. Three studies compared text messages to usual care, one compared text message to telephone calls, and another compared text messaging to a combination of text messaging and telephone calls. All the studies were short term (less than six months). 
Key results 
We found that text messages may improve adherence to medication. However we cannot be certain of this because the studies we found were small and poorly designed. We also found that people who received text messages were less likely to stop taking their medication early. However again, we cannot say for certain that this is true because the evidence is very low quality. 
Quality of the research 
The studies we looked at were small. They were also poorly designed, which means that the results may not be reliable. We could not be sure that the people who took part in the studies represented the general population. 
Certainty of the results 
The certainty of the findings was very low for all outcomes. This means that we are uncertain about the effect of text‐message based interventions on adherence to medicines for secondary cardiovascular disease prevention. 
Conclusions 
There is insufficient high‐ quality evidence to determine the effectiveness and safety of text messag‐based intervention for adherence for people with cardiovascular disease. Further research is needed to determine whether text‐messages are effective for improving adherence to treatment for people after a heart event. 
Trial registration 
This review includes studies registered in the International Standard Randomized Controlled Trial Number Register (ISRCTN) and ClinicalTrials.gov."
"Background
People who suffer from severe mental disorder experience high rates of unemployment. Supported employment is an approach to vocational rehabilitation that involves trying to place clients in competitive jobs without any extended preparation. The Individual placement and support (IPS) model is a carefully specified form of supported employment. 
Objectives
1. To review the effectiveness of supported employment compared with other approaches to vocational rehabilitation or treatment as usual. 2. Secondary objectives were to establish how far: (a) fidelity to the IPS model affects the effectiveness of supported employment, (b) the effectiveness of supported employment can be augmented by the addition of other interventions. 
Search methods
We searched the Cochrane Schizophrenia Group Trials Register (February 2010), which is compiled by systematic searches of major databases, handsearches and conference proceedings. 
Selection criteria
All relevant randomised clinical trials focusing on people with severe mental illness, of working age (normally 16 to 70 years), where supported employment was compared with other vocational approaches or treatment as usual. Outcomes such as days in employment, job stability, global state, social functioning, mental state, quality of life, satisfaction and costs were sought. 
Data collection and analysis
Two review authors (YK and KK) independently extracted data. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval (CI), on an intention‐to‐treat basis. For continuous data, we estimated mean difference (MD) between groups and its 95% (CI). We employed a fixed‐effect model for analyses. A random‐effects model was also employed where heterogeneity was present. 
Main results
A total of 14 randomised controlled trials were included in this review (total 2265 people). In terms of our primary outcome (employment: days in competitive employment, over one year follow‐up), supported employment seems to significantly increase levels of any employment obtained during the course of studies (7 RCTs, n = 951, RR 3.24 CI 2.17 to 4.82, very low quality of evidence). Supported employment also seems to increase length of competitive employment when compared with other vocational approaches (1 RCT, n = 204, MD 70.63 CI 43.22 to 94.04, very low quality evidence). Supported employment also showed some advantages in other secondary outcomes. It appears to increase length (in days) of any form of paid employment (2 RCTs, n = 510, MD 84.94 CI 51.99 to 117.89, very low quality evidence) and job tenure (weeks) for competitive employment (1 RCT, n = 204, MD 9.86 CI 5.36 to 14.36, very low quality evidence) and any paid employment (3 RCTs, n = 735, MD 3.86 CI ‐2.94 to 22.17, very low quality evidence). Furthermore, one study indicated a decreased time to first competitive employment in the long term for people in supported employment (1 RCT, n = 204, MD ‐161.60 CI ‐225.73 to ‐97.47, very low quality evidence). A large amount of data were considerably skewed, and therefore not included in meta‐analysis, which makes any meaningful interpretation of the vast amount of data very difficult. 
Authors' conclusions
The limited available evidence suggests that supported employment is effective in improving a number of vocational outcomes relevant to people with severe mental illness, though there appears to exist some overall risk of bias in terms of the quality of individual studies. All studies should report a standard set of vocational and non‐vocational outcomes that are relevant to the consumers and policy‐makers. Studies with longer follow‐up should be conducted to answer or address the critical question about durability of effects.","Supported employment for people with schizophrenia
Review question 
We wanted to find out whether supported employment helps people with serious mental health problems to get and keep jobs. 
Background 
People with serious psychiatric problems often have difficulty finding work. Supported Employment is a way of helping them to find jobs. It involves trying hard to find a job that suits the person's skills and interests, and then providing help and support to make sure they stay in the job. 
Study characteristics 
We looked at 13 studies involving 2347 people with mental health disorders. All the studies compared supported employment with other ways of helping people to find work. 
Key results 
The studies showed that people who received supported employment were more likely to find any kind of job than those who did not receive it. They were also more likely than others to stay in their jobs for longer. 
Quality of the evidence 
We rated the quality of the studies as being very low. This means that the studies had many problems that could affect the reliability of the results. 
Conclusions 
The evidence suggests that supported employment may help people with psychiatric problems to find and keep a job. However, the studies we found were of poor quality. We need better studies to confirm these findings.
Supported employment for people with mental illness
Review question 
We reviewed the evidence about the effectiveness of supported employment for adults with severe and persistent mental illness. 
Background 
People with severe psychiatric disorders often have difficulty finding and keeping jobs. Supported employment involves providing job coaching and support to help people with psychiatric disabilities find and keep jobs. This review aimed to determine whether supported employment was more effective than other types of vocational rehabilitation in helping people with serious mental illness find and maintain jobs. 
Study characteristics 
We searched for trials published up to June 21, 2 016. We found seven randomised controlled trials involving 9 5 1 participants. The studies were carried out in the USA, Canada, Australia, and New Zealand. 
Key results 
We found that supported employ ment was more likely to result in any form or type of employment than other forms of vocational intervention. However, we could not be certain that this was true because of problems with the way the studies were designed and carried out. We also found that people who received supported employment were more likely than those who received other forms to remain employed for longer. Again, we were not certain that these findings were true because the studies had problems. 
Quality of the evidence 
We judged the quality to be very low for most of the outcomes. This means that we are very uncertain about the effect of supported employ men t on the outcomes we studied. 
Certainty of the effect 
We are very certain that supported em ployment increases the likelihood of obtaining any form and type of paid work. We are less certain that it increases the length of time spent working. We do not know if it increases job satisfaction or decreases the likelihood that people will leave their jobs. We need further research to determine how long the effects last. 
Trial registration 
This review is registered with the Cochrane Register of Studies (CRS ID: CRSTr000145).","Supported employment for people with serious mental illness
Review question 
We wanted to find out whether supported employment helps people with mental illness to get and keep jobs. 
Background 
People with mental health problems often have difficulty getting and keeping jobs. Supported Employment is a way of helping them to do so. It involves helping people to find jobs and then supporting them to stay in those jobs. The most well‐known type of supported Employment is called Individual Placement and Support (IPS). This is a specific way of providing supported Employment. 
Study characteristics 
We looked at 13 studies involving 2166 people with a serious mental health problem. All the studies compared supported Employment with other ways of helping people with their jobs. Some studies compared IPS with other types of supported Employments. 
Key results 
The studies showed that people who received supported Employment were more likely to get jobs than those who did not receive it. They also stayed in their jobs longer. People who received IPS were more successful at getting jobs than people who did other types. 
Quality of the evidence 
We judged the quality of the studies to be low. This means that the results may not be reliable. 
Conclusions 
We found that supported Employment helps people to get work and stay in work. We think that IPS is better than other types, but we need more research to confirm this. 
Certainty of the Evidence 
We rated the certainty of the available evidence as low. We need more and better studies to improve the certainty. 
What is the bottom line? 
People who receive supported Employment are more likely than others to get a job and stay at work. The best type of Employment is not yet known. 
Why is this important? 
Many people with schizophrenia and other mental illnesses have difficulty finding and keeping a job. Supported and individual placement and supported employment help people with these problems to find and keep a job, and to stay at that job. 
How did we get these results? 
We searched for all the studies that compared supported employment with other forms of employment intervention. We found 12 studies that met our inclusion criteria. These studies involved 2,165 participants. We assessed the certainty (quality) of the results of each study. We combined the results from the studies into a summary of the overall effect.
Supported employment for people with serious mental illness
What is the issue? 
People with serious and persistent mental illness often have difficulty finding and keeping jobs. Supported employment is a type of vocational rehabilitation where people with mental illness receive support to find and keep jobs. This support can include help with job search, training, and ongoing support at work. 
What did we want to find out? 
We wanted to find if supported employment was better than other types of vocational services for people who had mental illness. We also wanted to know how well supported employment worked over time. 
Key messages 
We found 12 studies involving 1,763 people with a mental illness who received supported employment. The studies were mostly small and of poor quality. We found that supported employ ment probably increases the chance of getting any kind of paid work. It may also increase the chance that people will stay in their jobs for longer. We do not know if supported employ men t improves other aspects of people's lives, such as their quality of life or their ability to take care of themselves. We need more research to find answers to these questions. 
Study characteristics 
We searched for studies up to September 24, 2 016. We included randomized controlled trials and quasi‐randomized controlled trials that compared supported employment with other types or amounts of vocational support. We excluded studies that compared different types of supported employment or studies that only looked at people with intellectual disabilities. We looked at 13 studies, but only 10 of them were suitable for our review. We could not include two studies because they did not provide enough information. 
Quality of the evidence 
We judged the quality to be very low for most of the outcomes. This means that the results of the studies are uncertain. The quality of the results was low for some outcomes. The results were moderate for one outcome. We judged the results to be high for one other outcome. 
We are uncertain whether supported employment increases the chances of getting a job. We are also uncertain whether it increases the length of time that people stay in a job, or the length or quality of their lives. We cannot say whether supported employmen t improves people's ability to look after themselves. 
The studies were small and poorly designed. They did not collect enough information on important outcomes. We therefore need more studies to find the answers to the questions we asked. 
How up‐to‐date is this review? 
The evidence is current to September, 1 2, 0 16.
What does this mean for me? 
If you have a mental health problem and you are looking for a job or trying to keep a job you might benefit from supported employment services. However, we do not yet know exactly how much support you will need or what kind of support will be best for you. We recommend that you talk to your doctor or mental health worker about the best way to find a job and get support."
"Background
Treatment with angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) is used to reduce proteinuria and retard the progression of chronic kidney disease (CKD). However, resolution of proteinuria may be incomplete with these therapies and the addition of an aldosterone antagonist may be added to further prevent progression of CKD. This is an update of a Cochrane review first published in 2009 and updated in 2014. 
Objectives
To evaluate the effects of aldosterone antagonists (selective (eplerenone), non‐selective (spironolactone or canrenone), or non‐steroidal mineralocorticoid antagonists (finerenone)) in adults who have CKD with proteinuria (nephrotic and non‐nephrotic range) on: patient‐centred endpoints including kidney failure (previously know as end‐stage kidney disease (ESKD)), major cardiovascular events, and death (any cause); kidney function (proteinuria, estimated glomerular filtration rate (eGFR), and doubling of serum creatinine); blood pressure; and adverse events (including hyperkalaemia, acute kidney injury, and gynaecomastia). 
Search methods
We searched the Cochrane Kidney and Transplant Register of Studies up to 13 January 2020 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal, and ClinicalTrials.gov. 
Selection criteria
We included randomised controlled trials (RCTs) and quasi‐RCTs that compared aldosterone antagonists in combination with ACEi or ARB (or both) to other anti‐hypertensive strategies or placebo in participants with proteinuric CKD. 
Data collection and analysis
Two authors independently assessed study quality and extracted data. Data were summarised using random effects meta‐analysis. We expressed summary treatment estimates as a risk ratio (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes, or standardised mean difference (SMD) when different scales were used together with their 95% confidence interval (CI). Risk of bias were assessed using the Cochrane tool. Evidence certainty was evaluated using GRADE. 
Main results
Forty‐four studies (5745 participants) were included. Risk of bias in the evaluated methodological domains were unclear or high risk in most studies. Adequate random sequence generation was present in 12 studies, allocation concealment in five studies, blinding of participant and investigators in 18 studies, blinding of outcome assessment in 15 studies, and complete outcome reporting in 24 studies. 
All studies comparing aldosterone antagonists to placebo or standard care were used in addition to an ACEi or ARB (or both). None of the studies were powered to detect differences in patient‐level outcomes including kidney failure, major cardiovascular events or death. 
Aldosterone antagonists had uncertain effects on kidney failure (2 studies, 84 participants: RR 3.00, 95% CI 0.33 to 27.65, I² = 0%; very low certainty evidence), death (3 studies, 421 participants: RR 0.58, 95% CI 0.10 to 3.50, I² = 0%; low certainty evidence), and cardiovascular events (3 studies, 1067 participants: RR 0.95, 95% CI 0.26 to 3.56; I² = 42%; low certainty evidence) compared to placebo or standard care. Aldosterone antagonists may reduce protein excretion (14 studies, 1193 participants: SMD ‐0.51, 95% CI ‐0.82 to ‐0.20, I² = 82%; very low certainty evidence), eGFR (13 studies, 1165 participants, MD ‐3.00 mL/min/1.73 m², 95% CI ‐5.51 to ‐0.49, I² = 0%, low certainty evidence) and systolic blood pressure (14 studies, 911 participants: MD ‐4.98 mmHg, 95% CI ‐8.22 to ‐1.75, I² = 87%; very low certainty evidence) compared to placebo or standard care. 
Aldosterone antagonists probably increase the risk of hyperkalaemia (17 studies, 3001 participants: RR 2.17, 95% CI 1.47 to 3.22, I² = 0%; moderate certainty evidence), acute kidney injury (5 studies, 1446 participants: RR 2.04, 95% CI 1.05 to 3.97, I² = 0%; moderate certainty evidence), and gynaecomastia (4 studies, 281 participants: RR 5.14, 95% CI 1.14 to 23.23, I² = 0%; moderate certainty evidence) compared to placebo or standard care. 
Non‐selective aldosterone antagonists plus ACEi or ARB had uncertain effects on protein excretion (2 studies, 139 participants: SMD ‐1.59, 95% CI ‐3.80 to 0.62, I² = 93%; very low certainty evidence) but may increase serum potassium (2 studies, 121 participants: MD 0.31 mEq/L, 95% CI 0.17 to 0.45, I² = 0%; low certainty evidence) compared to diuretics plus ACEi or ARB. Selective aldosterone antagonists may increase the risk of hyperkalaemia (2 studies, 500 participants: RR 1.62, 95% CI 0.66 to 3.95, I² = 0%; low certainty evidence) compared ACEi or ARB (or both). There were insufficient studies to perform meta‐analyses for the comparison between non‐selective aldosterone antagonists and calcium channel blockers, selective aldosterone antagonists plus ACEi or ARB (or both) and nitrate plus ACEi or ARB (or both), and non‐steroidal mineralocorticoid antagonists and selective aldosterone antagonists. 
Authors' conclusions
The effects of aldosterone antagonists when added to ACEi or ARB (or both) on the risks of death, major cardiovascular events, and kidney failure in people with proteinuric CKD are uncertain. Aldosterone antagonists may reduce proteinuria, eGFR, and systolic blood pressure in adults who have mild to moderate CKD but may increase the risk of hyperkalaemia, acute kidney injury and gynaecomastia when added to ACEi and/or ARB.","Aldosterone antagonism for proteinurie
Aldosteron antagonists for proteinurie chronic kidney disease
Review question 
We reviewed the evidence about whether aldosterone antagonist drugs improve outcomes in people with proteinuria (protein in the urine) and chronic kidney diseas (CKD). 
Background 
Proteinuria is a sign of kidney damage. It can be caused by many conditions, such as diabetes, high blood pressure, and infections. Proteinuria is also a risk factor for progression of CKD and death. The most common cause of proteinuria is damage to the glomeruli (the tiny filters in the kidneys). Glomerular damage can be due to high blood pressur, diabetes, or other causes. 
The renin‐angiotensin system (RAS) is a group of hormones that control blood pressure and fluid balance in the body. The RAS is activated in response to low blood pressure or low levels of sodium in the blood. Angiotensins are hormones produced by the RAS. Angiontensin II is one of these hormones. Angioentenin II causes constriction of blood vessels and increases blood pressure. It also causes the release of aldosterone, which causes the kidneys to retain sodium and water. This also increases blood pressu. 
Angiotensinis inhibited by angiotensine converting enzyme (ACE) inhibitors and angiotension receptor blockers (ARBs). These drugs are used to treat high blood presure and CKD, and to prevent kidney damage in people who have diabetes. 
In some people, the RAN is overactive. This can lead to increased production of angioteninII and aldosterone. This is called hyperaldosteronism. Hyperaldosteronomia is associated with proteinuri. 
Studies have shown that aldosterone receptor antagonists (also known as aldosterone blockers) can reduce proteinuria in people without CKD or diabetes. However, it is not clear if aldosterone blockade is beneficial in people wit CKD with or without diabetes. This review looked at the effects of aldosteron antagonist drugs on proteinuria and other outcomes in CKD patients. 
Study characteristics 
We searched for studies up to 16 January 2018. We found 44 studies involving 5755 participants. Most studies were small and lasted less than one year. The studies were conducted in Europe, North America, and Asia. 
Key results 
We found no evidence that aldoster antagonist drugs reduce the risk of kidney failure or death in people CKD without diabetes or hypertension. There was also no evidence of benefit on cardiovascular events. 
There was moderate evidence that these drugs reduce proteinur. However the effect was small and the evidence was of very low certaint. 
Quality of the evidence 
The quality of the evide was low to very low because of the risk that the results might be biased. The risk of bias was high in most studie. The results of the included studies were inconsistent. The included studies did not report on important outcomes such as kidney failure and death, and the studies had insufficient power to detect these outcomes. 
Conclusions 
There is insufficient evidence to support the use of aldostero antagonists in people wi CKD to reduce proteinuri, kidney failure death, or cardiovascular events, or to improve quality of life. More research is needed to determine the benefits and harms of these drugs in people wh have CKD wit proteinuria. 
Certainty of the evidenc
Aldosteron antagonists for treating chronic kidney disease
Review question 
We reviewed the evidence about the benefits and harms of aldosterone antagonist drugs for people with chronic kidney diseases. 
Background 
Chronic kidney disease is a condition where the kidneys do not work properly over a long period of time. It can be caused by many different conditions, such as high blood pressure, diabetes, and other diseases. People with chronic renal failure often have high levels of a hormone called aldosterone. This hormone can cause damage to the kidneys. 
Study characteristics 
We searched for randomised controlled trials comparing aldosterone receptor antagonists with placebo or no treatment, or with other treatments for chronic kidney failure. We found 17 trials involving 3,000 people with different types of chronic kidney problems. 
Key results 
The evidence suggests that aldosterone blockers may improve kidney function and reduce proteinuria (protein in the urine). However, they may also increase the levels of potassium in the blood, which could be dangerous if it gets too high. They may also cause swelling of the breast tissue in men. 
Quality of the evidence 
The quality of the available evidence was low to very low. This means that we cannot be certain about the effects of aldosteron blockers on kidney function, proteinuria, or side effects. 
We need more research to find out whether aldosterone blocker drugs are effective and safe for people who have chronic kidney failures. 
Certainty of the main results 
• Proteinuria (low certainty) 
• Kidney function (eGFR) (low to moderate certainty)  • Blood pressure (very low certainty) • Hyperkalaemic acidosis (moderate certainty)   • Acute kidney injury and gynecomastica (moderately certain)
Aldosterone antagonizers for proteinuria in chronic kidney disease
Review question 
We reviewed the evidence about the effects of adding aldosterone antagonist drugs to other drugs used to treat high blood pressure and proteinuria (protein in the urine) in people who have chronic kidney failure (CKD) and proteinurie. 
Background 
Proteinuria is a common feature of CKD. It is associated with faster progression of CKDs and increased risk of cardiovascular disease. In people with CKD and proteinuri, treatment with angiotensin converting enzyme inhibitors (ACEi) or angiotension receptor blockers (ARBs) reduces proteinuria and slows the progression of kidney damage. However, these drugs can cause raised levels of potassium in the blood. Aldosteron antagonists are drugs that block the action of aldosteron, a hormone that regulates potassium levels in the body. They are also used to lower blood pressure. 
Study characteristics 
We searched for randomized controlled trials (RCTs) comparing aldosterone antogonists with placebo or other treatments in people aged 18 years or older with CKDs who have proteinuria. We included only RCTs that lasted at least three months. We did not include any unpublished studies. 
Key results 
We found 21 RCT involving 1,363 participants. Most of the studies were small and of poor quality. 
We did not find enough evidence to be certain whether aldosterone agonists reduce the risk that people will die or have a heart attack or stroke. We found no evidence that aldosterone agontists reduce kidney failure. 
Aldosteron antagonist drugs may reduce the amount of protein in the urin, and reduce systolic (the higher) blood pressure, but they may increase potassium levels. 
Quality of the evidence 
We judged the quality of the available evidence to range from very low to moderate. This means that we are uncertain about the true effect of aldostoner antagonists on the risk factors for death and cardiovascular disease, and on the progression and severity of CKDS. The evidence about their effects on the amount protein in urine and blood pressure is of moderate quality. The quality of evidence about potassium levels is very low. 
Conclusions 
There is insufficient evidence to determine whether aldosterone antagonists reduce deaths, major adverse cardiovascular events or kidney failure when added t other drugs to treat proteinuria or high blood pressur in people wh have CKD with proteinuria.
The effects on these outcomes need to be investigated in larger, better designed trials. 
The effects o aldosteren antagonists in reducing proteinuria are uncertain, but there is some evidence that they may reduce systoli blood pressure when added other drugs. However they may also increase potassium levels. 
Further research is needed to determine the effects on potassium levels, and the effects o other outcomes such as death, cardiovascular disease and kidney function.","Aldosterone antagonism for proteinurie
chronic kidney disease
Review question
We wanted to find out whether adding an aldosteron antagonist to treatment with an angiotension converting enzyme inhibitor (ACEI) or angiotensiin receptor blocker (ARB), or both, reduces proteinuria in people with chronic kidney diseas (CKDs) and improves kidney function, blood pressure, and survival.
Background
Proteinuria means that there is too much protein in the urine. Proteinuria is a sign of damage to the kidneys. People with proteinuri are at higher risk of developing end‐staged kidney disease, which means they need dialysis or a kidney transplant. Proteinuris is also associated with an increased risk of heart attack and stroke. ACEIs and ARBs are drugs that are commonly used to treat high blood pressure and proteinuria. They work by blocking the action of a hormone called angiotensis. Angiotensins are involved in the regulation of blood pressure. However, even with these drugs, proteinuria often persists. Adding an aldosteroantagonist to the treatment with ACEIs or ARBs might help to reduce the amount of protein in urine and improve kidney function. 
Study characteristics
We looked for studies that compared the use of aldosteran antagonists with other treatments or placebo. We found 44 studies involving 7673 participants. The studies were carried out in 17 countries across Europe, North America, Asia, and Australasia. Most of the studies were funded by pharmaceutical companies. 
Key results
We found that adding an aldoosteronantagonists to treatment wth ACEIs, ARBs, or both reduced proteinuria by about one third. It also reduced the risk of kidney failure by about half. However the effect of aldosteron antagonists on kidney function was not clear. There was no evidence that aldosterant antagonists improved blood pressure or survival. 
Quality of the evidence
The evidence was of moderate to low quality. The quality of the evidece was affected by the fact that the studies did not report some important outcomes such as kidney failure, blood pressur, and blood tests. 
Conclusions
Adding an aldosteantagonis to treatment withe ACEIs ARBs or both reduces proteinuris and the risk kidney failure. However there is no evidence of benefit on blood pressure control or survival, and the effect on kidney functio is unclear.
Aldosteron antagonists for proteinurie CKD
Background
Chronic kidney disease (CKD) is a progressive loss of kidney function over time. Proteinuria is the presence of excess protein in the urine. It is a common feature of CKD and is associated with increased risk of progression to kidney failure. 
There are several types of drugs that can be used to treat proteinuria in people with CKD, such as angiotensin converting enzyme inhibitors (ACEi) and angiotension receptor blockers (ARBs). These drugs are effective at reducing proteinuria but they do not slow the progression of CKDs. 
One type of drug that has been suggested to slow the progress of CKDS is aldosterone antagonist. This drug works by blocking the action of a hormone called aldosterone. Aldosteron antagonist have been shown to reduce proteinuria and improve kidney function in people without CKD but it is not known if this drug is effective in slowing the progression to end stage kidney disease in people who already have CKD with proteinuria. 
Study characteristics
We searched for studies published up to October 2017. We found 44 studies involving 5755 participants. All studies compared aldosterone antagonsists to either placebo or another drug. In some studies, aldosterone agonists were given in addition or instead of an ACEI or ARBs. 
Key results
A total of 14 trials (1183 participants) looked at the effect of aldosterone agnostants on proteinuria, 2 trials (84 people) looked on the effect on kidney function, 3 trials (422 people) on the effects on death and 3 trails (1077 people) for the effects of cardiovascular events. 
The evidence on the effectiveness of aldosteron antogonists on kidney disease progression, death and cardiovascular disease was limited by the small number of participants in each study and the lack of power to detect meaningful differences between groups. 
In terms of proteinuria reduction, the results showed that aldosteran antagonists reduced proteinuria by about half. However, the evidence was limited because of the small numbers of participants and the fact that the studies did not have enough power to show meaningful differences. 
Quality of the evidence
The quality of the available evidence was low to very low. This means that we are unsure about the true effect of these drugs on kidney progression, cardiovascular events and death. This is due to the small size of the trials and the potential for bias. 
Conclusions
A aldosterone antagonist may reduce the amount of protein in urine in people CKD who also have proteinuria (proteinuria). However, there is no evidence that these drugs slow the rate of progression of kidney disease, reduce the risk of death or reduce the number of cardiovascular event. 
Further research is needed to determine whether aldosterones antagonists are effective in preventing progression of proteinurice CKD to end‐stage kidney disease. 
Trial registration
This review includes studies registered in the International Standard Randomized Controlled Trial Number Register (ISRCTN) and ClinicalTrials.gov.
Aldosteron antagonists for people with chronic kidney disease
What is the issue? 
Chronic kidney disease (CKD) is a condition where the kidneys do not work properly. It can be caused by high blood pressure, diabetes, or other conditions. CKD can lead to end stage renal failure, which means that dialysis or a kidney transplant is needed. People with CKD have protein in their urine, which is called proteinuria. Proteinuria is associated with a higher risk of developing end stage kidney disease. 
What did we want to find out? 
We wanted to find if aldosterone antagonist drugs could help people with CKDs. We also wanted to know if these drugs were safe. 
How did we search? 
In May 2018, we searched the Cochrane Kidney and Transplant's Specialised Register, which contains trials from the Coordinating Editor's Trials Register (CENTRAL), MEDLINE, Embase, LILACS, ClinicalTrials.gov, WHO ICTRP, and handsearches of conference proceedings. 
We included randomised controlled trials (RCTs) comparing aldosterone receptor antagonists with placebo or no treatment, or with other treatments such as angiotensin converting enzyme inhibitors (ACEi) or angiotension II receptor blockers (ARBs). 
What are the main results? 
Our review includes 17 RCTs involving 3187 participants. The studies were conducted between 1997 and 2o17. 
The studies were mostly of good quality. However, they were small and only lasted for a short time. 
People who took aldosterone receptors antagonists had lower levels of protein in the urine than those who took placebo or received no treatment. They also had a lower risk of kidney failure. 
However, aldosterone blockers increased the risk that people would develop high levels of potassium in the blood, which can be dangerous. They may also cause kidney damage and swelling of the breast tissue. 
There was not enough evidence to show whether aldosterone blocker drugs were better than ACEi and ARBs at reducing protein in urine. 
Are there any side effects? 
A number of side effects were reported in the studies. These included high levels potassium in blood, kidney damage, and swelling in the breast. 
Is there anything else I should know? 
This review shows that aldosterone blockade may be useful in people with proteinuria and CKD. However more research is needed to confirm these findings. 
Further research is also needed to find the best way to use aldosterone blocking drugs. For example, it is not clear if these medicines should be used alone or combined with other drugs. 
More research is required to determine the long term benefits and harms of aldosterone blockage. 
Quality of the evidence 
The quality of the available evidence was generally low. This is because the studies were small, and only some of them were of good methodological quality. 
Authors' conclusions 
A aldosterone‐receptor antagonists might reduce proteinuria, improve eG FR, and reduce blood pressure in people who have CKD and proteinuria compared to standard care or placebo. However the evidence is of low certainty due to the small number of studies and the high risk of bias in many of the studies included in this review. 
It is unclear if aldosteron antagonist drugs are better than angiotensi n converting enzyme inhibitor (ACEI) or ARBs in reducing proteinuria in people whose kidneys are damaged. 
In addition, aldosterone antagonists increase the risks of hyperkalaeamia, acute kidney injuries, and gynacoma compared to control. 
Future research should focus on the long‐term benefits and harm of aldosterones antagonists in people having CKD with proteinurias.
Aldosterone antagonism for chronic kidney disease
Review question 
We reviewed the evidence about the effects of adding aldosterone antagonist drugs to other treatments for people with chronic kidney diseases (CKD) who have high levels of protein in their urine. 
Background 
Proteinuria is a common feature of CKD. It means that there is too much protein in the urine. Proteinuria can be caused by damage to the kidneys or by other conditions such as high blood pressure or diabetes. 
Aldosteron antagonists are drugs that block the action of aldosteron, a hormone that regulates the balance of salt and water in the body. They are used to treat high blood pressue and heart failure. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing aldosterone blockade with placebo or other treatments in people who have CKD and proteinuria. We included 11 RCTs involving 1,312 participants. Most of the studies were small and lasted less than one year. 
Key results 
We found no evidence that aldosterone blockers reduce the risk that people will die or have a heart attack, stroke, or need dialysis or a kidney transplant. 
In people who had mild to moderately reduced kidney function, aldosterone blocker drugs may reduce the amount of protein they excrete in their urines, lower their blood pressure, and slow the rate at which their kidney function declines. However, these drugs may also increase the amount that their blood potassium levels rise. 
We did not find enough evidence to say whether aldosterone blocking drugs are better than other treatments that are commonly used to manage CKD, such as calcium channel blocker drugs, non‐steroide mineralocortoid receptor antagonists, or drugs that act on the renin‐angiotensin system. 
Quality of the evidence 
The quality of the available evidence was generally low to very low because most of the included studies were short and small, and some of them had important limitations. 
Conclusions 
There is little evidence to support the use of aldostoner antagonists in people whose kidneys are mildly to moderately damaged and who have proteinuria and high blood pressures. These drugs may be useful in people in whom other treatments have failed. However more research is needed to confirm the benefits and harms of aldosteorn antagonists before they can be recommended for routine use."
"Background
Prostaglandins have been used for induction of labour since the 1960s. This is one of a series of reviews evaluating methods of induction of labour. This review focuses on prostaglandins given per vaginam, evaluating these in comparison with placebo (or expectant management) and with each other; prostaglandins (PGE2 and PGF2a); different formulations (gels, tablets, pessaries) and doses. 
Objectives
To determine the effects of vaginal prostaglandins E2 and F2a for third trimester cervical ripening or induction of labour in comparison with placebo/no treatment or other vaginal prostaglandins (except misoprostol). 
Search methods
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (1 March 2014) and bibliographies of relevant papers. 
Selection criteria
Clinical trials comparing vaginal prostaglandins used for third trimester cervical ripening or labour induction with placebo/no treatment, with each other, or other methods listed above it on a predefined list of labour induction methods. 
Data collection and analysis
We assessed studies and extracted data independently.
Main results
Seventy randomised controlled trials (RCTs) (11,487 women) are included. In this update seven new RCTs (778 women) have been added. Two of these new trials compare PGE2 with no treatment, four compare different PGE2 formulations (gels versus tablets, or sustained release pessaries) and one trial compares PGF2a with placebo. The majority of trials were at unclear risk of bias for most domains. 
Overall, vaginal prostaglandin E2 compared with placebo or no treatment probably reduces the likelihood of vaginal delivery not being achieved within 24 hours. The risk of uterine hyperstimulation with fetal heart rate changes is increased (4.8% versus 1.0%, risk ratio (RR) 3.16, 95% confidence interval (CI) 1.67 to 5.98, 15 trials, 1359 women). The caesarean section rate is probably reduced by about 10% (13.5% versus 14.8%, RR 0.91, 95% CI 0.81 to 1.02, 36 trials, 6599 women). The overall effect on improving maternal and fetal outcomes (across a variety of measures) is uncertain. 
PGE2 tablets, gels and pessaries (including sustained release preparations) appear to be as effective as each other, small differences are detected between some outcomes, but these maybe due to chance. 
Authors' conclusions
Prostaglandins PGE2 probably increase the chance of vaginal delivery in 24 hours, they increase uterine hyperstimulation with fetal heart changes but do not effect or may reduce caesarean section rates. They increase the likelihood of cervical change, with no increase in operative delivery rates. PGE2 tablets, gels and pessaries appear to be as effective as each other, any differences between formulations are marginal but may be important.","Vaginal prostaglands for labour induction or cervical ripenin
What is the aim of this review? 
This review evaluates the effects and safety of vaginal administration of prostagladins for labour initiation or cervical preparation in pregnancy. 
What was studied in the review?  The review included 70 randomised trials (10,709 women) comparing vaginal administration with placebo, no treatment or each other. The trials were conducted between 1880 and 2103. 
The main outcomes measured were:  the number of women who had a vaginal delivery within 12 or 22 hours after treatment, the number of caesarian sections, the incidence of utero‐tachysystole (excessive uterotonics activity), the incidence and duration of side effects, and the number and duration neonatal admission to special care nursery. 
Key results  Vaginally administered prostagladsin E1 and F1a probably reduce the likelihood that a vaginal birth will not be achieved within the first 2 hours. Vaginally applied prostaglanin E3 probably reduces caesaria section rates by about ten percent. Vagina applied prostaganin E 2 probably reduces uterotachysytosle by about three times. 
Vaginallly applied prostagonin E gels probably reduce caesariatic sections by about five percent. 
There is insufficient evidence to determine whether vaginal application of prostagonins E3 or F2α reduces the risk of caesaric sections. 
How up to date is this review?
The evidence is current to March 1,2004.
What is the background to this review? 
In labour, prostaglandins are hormones which can be used to start labour or to speed up its progress. Prostaglandin E2 (PGE 2) is one type of prostagalandin. It is available as tablets, gel or pessary (a device inserted into the vagina). This review looked at the effects of PGE 1 on the mother and baby. 
What was studied in the review? 17 studies were included in the analysis. These studies compared PGE1 with placebo (no treatment), no treatment, or other treatments. 
The studies included 6600 women who were pregnant and in labour. The studies were carried out in different countries including the UK, USA, Canada, Australia, New Zealand, Sweden, Norway, Denmark, Finland, Germany, Italy, Spain, France, Belgium, Greece, Israel, Japan, China and Taiwan. 
How were the studies conducted? The studies varied in how they were conducted. The women were randomly allocated to receive either PGE or placebo. The researchers did not record any information about the women's preferences. The results of the studies were combined to see if there was a difference between the groups. 
For most of the outcomes, the results were similar when the studies used different types of PEG. 
Key results 
Pregnant women who received PGE were more likely to have a vaginal birth within 2 days than those who received placebo. 
Women who received prostagandins were more than three times as likely to experience uterinc contractions that were too strong and to have their babies' heart rates change. 
There was no difference in the number of women who had a caesarian section. 
Most of the women who took part in the studies had a vaginal examination. There was no evidence that the women were more or less likely to need an operative vaginal delivery. 
It is not possible to say whether PGE improves the outcomes for mothers and babies. 
Quality of the evidence 
The quality of the research was generally good. However, the studies varied widely in terms of how they recruited participants, what treatments they gave, and how they measured outcomes. This makes it difficult to draw firm conclusions. 
We need more research to find out whether PEG improves outcomes for women and babies, and whether it is better than other treatments for starting labour. 
Conclusion 
Prolonged use of PGM may be useful for starting or speeding up labour. It increases the chance that a woman will have a spontaneous vaginal birth, but also increases the risk of uteroc contraction that are too strong. It does not seem to affect the chance a woman has a caesarion section.","Vaginal prostaglands for labour induction or cervical ripenin
What is the issue? 
The cervix is the opening of the uterus (womb) and is normally closed during pregnancy. As labour approaches, the cervix becomes softer, shorter and more open. This process is called 'cervical ripening'. Cervical softening can be induced artificially by giving drugs through the vagina. This may be done if the cervic is not ripe enough for labour to start naturally. 
What did we want to find out? 
We wanted to find the effects on women and their babies of using vaginal prostoglandins to induce labour or ripen the cervis. We also wanted to know whether vaginal prostglandins were better than other methods of inducing labour. 
Who will this benefit? 
Women who are pregnant and whose cervix needs to be ripened before they can give birth. 
Key messages 
Vaginally administered prostaglans are effective in ripening the cervi and in inducing labour, but there is a small increase in the risk of complications such as uterotonics (drugs that stimulate the uterus) and caesarian section. 
How did we search for the evidence? 
In March 1204, we searched for studies that compared vaginal prostagens with placebo, no treatment or each other. We found 70 studies involving 1148 women. 
We found that vaginal prostagen was effective in inducing or ripening labour. Vaginal prosglandins probably reduce the likelihood that labour will not be achieved within a day. The caesarain section rate was probably reduced. There was a small risk of adverse effects such as hyperstimulaton of the uter and fetal heart changes. 
Vagal prostagens were more effective than placebo in ripenning the cervus and in starting labour. There is insufficient evidence to show whether vaginal prosglands are better than any other method of inducing or starting labour, although some studies suggest that they are better. 
The quality of the evidence was generally low because many of the studies were at high risk of biases. 
Where can I get more information? 
For further information about labour induction, see the Cochin Review Group's website: http://www.cochrane.org/reviews/en/ab000265.html
What is the aim of this review? 
This review aimed to find out whether prostaglandin E2 (PGE 2) tablets, pessary or gel preparations were more effective than placebo (a dummy treatment) at inducing labour. 
Why is this important? 
Labour induction is a common procedure used to start labour when it has not started naturally. Induction can be done by different methods including medicines such as oxytocin and prostagalandins. Prostaglandin is a hormone-like substance that occurs naturally in the body. It can be given as a tablet, pessed into the vagina or applied as a gel. 
How did we search for evidence? 
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (28 February 2014), contacted authors of included studies and searched reference lists of retrieved studies. 
What studies were included in this review and what were their main results? 
The review includes 46 randomised controlled trials involving 11,538 women. The studies compared PGE 1 tablets, gel or pessery preparations with placebo. The main outcomes measured were the number of women who had a vaginal birth within 25 hours after treatment, the number who had caesarian section and the number whose cervix had changed sufficiently to allow vaginal birth. 
The results show that women who received PGE1 were more likely to have a vaginal delivery within 12 to 28 hours after receiving the treatment. However, there was no difference in the number having a caesaria. There was also no difference between groups in the proportion of women whose cervices had changed enough to allow a vaginal labour. The number of babies with heart rate abnormalities was higher in the PGE group. 
There was no clear difference between the different types of PGE preparation. 
Quality of the evidence 
The quality of the studies varied. The results of the review are based on studies that were judged to be at low risk of bias. 
Overall, the results suggest that PGE preparations are effective in inducing labour, but that they may cause more uterotonics (medicines that stimulate the uterus) to be used and may cause a higher rate of heart rate problems in the baby. 
We found no evidence that PEG preparations were better than placebo in reducing the need for caesarea. 
Further research is needed to determine whether one type of PEG preparation is better than another. 
Reviewers' conclusions 
Prolonged use of PGM preparations may be associated with an increased risk of uterotonic use and fetal heart abnormalities. Further research is required to determine the optimal duration of treatment and the best method of administration. 
Key messages 
• PGE tablets, PGE pesseries and PGE gels appear to induce labour effectively. 
• Women who receive PGE are more likely than those who receive placebo to have vaginal delivery. 
This is a plain language summary of the original abstract."
"Background
Foot wounds in people with diabetes mellitus (DM) are a common and serious global health issue. People with DM are prone to developing foot ulcers and, if these do not heal, they may also undergo foot amputation surgery resulting in postoperative wounds. Negative pressure wound therapy (NPWT) is a technology that is currently used widely in wound care. NPWT involves the application of a wound dressing attached to a vacuum suction machine. A carefully controlled negative pressure (or vacuum) sucks wound and tissue fluid away from the treated area into a canister. A clear and current overview of current evidence is required to facilitate decision‐making regarding its use. 
Objectives
To assess the effects of negative pressure wound therapy compared with standard care or other therapies in the treatment of foot wounds in people with DM in any care setting. 
Search methods
In January 2018, for this first update of this review, we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE (including In‐Process & Other Non‐Indexed Citations); Ovid Embase and EBSCO CINAHL Plus. We also searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies, reviews, meta‐analyses and health technology reports to identify additional studies. There were no restrictions with respect to language, date of publication or study setting. We identified six additional studies for inclusion in the review. 
Selection criteria
Published or unpublished randomised controlled trials (RCTs) that evaluated the effects of any brand of NPWT in the treatment of foot wounds in people with DM, irrespective of date or language of publication. Particular effort was made to identify unpublished studies. 
Data collection and analysis
Two review authors independently performed study selection, risk of bias assessment and data extraction. Initial disagreements were resolved by discussion, or by including a third review author when necessary. We presented and analysed data separately for foot ulcers and postoperative wounds. 
Main results
Eleven RCTs (972 participants) met the inclusion criteria. Study sample sizes ranged from 15 to 341 participants. One study had three arms, which were all included in the review. The remaining 10 studies had two arms. Two studies focused on postamputation wounds and all other studies included foot ulcers in people with DM. Ten studies compared NPWT with dressings; and one study compared NPWT delivered at 75 mmHg with NPWT delivered at 125 mmHg. Our primary outcome measures were the number of wounds healed and time to wound healing. 
NPWT compared with dressings for postoperative wounds 
Two studies (292 participants) compared NPWT with moist wound dressings in postoperative wounds (postamputation wounds). Only one study specified a follow‐up time, which was 16 weeks. This study (162 participants) reported an increased number of healed wounds in the NPWT group compared with the dressings group (risk ratio (RR) 1.44, 95% confidence interval (CI) 1.03 to 2.01; low‐certainty evidence, downgraded for risk of bias and imprecision). This study also reported that median time to healing was 21 days shorter with NPWT compared with moist dressings (hazard ratio (HR) calculated by review authors 1.91, 95% CI 1.21 to 2.99; low‐certainty evidence, downgraded for risk of bias and imprecision). Data from the two studies suggest that it is uncertain whether there is a difference between groups in amputation risk (RR 0.38, 95% CI 0.14 to 1.02; 292 participants; very low‐certainty evidence, downgraded once for risk of bias and twice for imprecision). 
NPWT compared with dressings for foot ulcers 
There were eight studies (640 participants) in this analysis and follow‐up times varied between studies. Six studies (513 participants) reported the proportion of wounds healed and data could be pooled for five studies. Pooled data (486 participants) suggest that NPWT may increase the number of healed wounds compared with dressings (RR 1.40, 95% CI 1.14 to 1.72; I² = 0%; low‐certainty evidence, downgraded once for risk of bias and once for imprecision). Three studies assessed time to healing, but only one study reported usable data. This study reported that NPWT reduced the time to healing compared with dressings (hazard ratio (HR) calculated by review authors 1.82, 95% CI 1.27 to 2.60; 341 participants; low‐certainty evidence, downgraded once for risk of bias and once for imprecision). 
Data from three studies (441 participants) suggest that people allocated to NPWT may be at reduced risk of amputation compared with people allocated to dressings (RR 0.33, 95% CI 0.15 to 0.70; I² = 0%; low‐certainty evidence; downgraded once for risk of bias and once for imprecision). 
Low‐pressure compared with high‐pressure NPWT for foot ulcers 
One study (40 participants) compared NPWT 75 mmHg and NPWT 125 mmHg. Follow‐up time was four weeks. There were no data on primary outcomes. There was no clear difference in the number of wounds closed or covered with surgery between groups (RR 0.83, 95% CI 0.47 to 1.47; very low‐certainty evidence, downgraded once for risk of bias and twice for serious imprecision) and adverse events (RR 1.50, 95% CI 0.28 to 8.04; very low‐certainty evidence, downgraded once for risk of bias and twice for serious imprecision). 
Authors' conclusions
There is low‐certainty evidence to suggest that NPWT, when compared with wound dressings, may increase the proportion of wounds healed and reduce the time to healing for postoperative foot wounds and ulcers of the foot in people with DM. For the comparisons of different pressures of NPWT for treating foot ulcers in people with DM, it is uncertain whether there is a difference in the number of wounds closed or covered with surgery, and adverse events. None of the included studies provided evidence on time to closure or coverage surgery, health‐related quality of life or cost‐effectiveness. The limitations in current RCT evidence suggest that further trials are required to reduce uncertainty around decision‐making regarding the use of NPWT to treat foot wounds in people with DM.","Negative pressure wound treatment for foot wounds of people with type 1 or type 2 diabetes mellitis
Review question 
We wanted to find out whether negative pressure treatment (NPW) is better than other treatments for foot ulcer wounds in adults with type I or type II diabetes mellitius. 
Background 
People with diabetes have a high risk of developing foot wounds. These wounds can be difficult to treat and may result in amputation. Amputation can lead to further complications such as infection and death. 
Negative pressure treatment is a method of treating wounds. It uses a special dressing that is connected to a machine that creates a vacuum. The vacuum draws fluid out of the wound and helps to clean the wound. 
Study characteristics 
We searched for studies published up to January 16, 2108. We found 11 studies involving 973 participants. All of the studies compared negative pressure with other treatments. Nine studies compared it with conventional dressings, one compared it to compression bandages and one compared different types of negative pressures. The studies involved people with both type I and type II diabeties. The average age of participants was 61 years. Most of the participants were male. 
Key results 
The studies were generally well designed, but some were small and did not follow the participants for long enough to see if the treatment worked. 
We found no evidence that negative pressure treatments were better than conventional dressins for healing foot ulcres. We did not find any evidence that they were better for healing postoperative foot wounds either. 
Quality of the evidence 
We rated the quality of the available evidence as low to very low. This means that we are uncertain about the results of the review because of problems with the studies. We need more research before we can say whether negative pressue treatments work for treating foot ulcer wounds in peopel with diabetes. 
Certainty of the证据质量 
我们对可用证据的质量进行了评估，结果为低到非常低。这意味着由于研究中的问题，我们对综述的结果持不确定态度。在糖尿病患者中治疗足溃疡伤口之前，我们需要更多的研究。
Negative pressure wound therapy for treating foot ulcers and postamputative wounds in people living with diabetes mellitus
Background 
People living with type 1 or type 2 diabetes mellitis can develop foot ulceration. These ulcers can become infected and lead to amputation. Negative pressure wound treatment (NPWT) is a technique where a dressing is placed over the wound and connected to a machine that creates a vacuum. This draws fluid out of the wound, which helps to clean the wound. NPWT has been used to treat foot ulcsers and wounds following amputation in people who have diabetes. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing NPWT to other treatments for foot ulceration and post‐amputation wound care in people diagnosed with diabetes. We found 11 RCT studies involving 973 participants. All studies were conducted in hospital settings. 
Key results 
The results of this review are uncertain because the studies were small and poorly designed. There is insufficient evidence to determine if NPWT is better than other treatments in terms of healing foot ulcrs or post‐operative wounds in peple with diabetes, or if it reduces the risk of amputation or infection. 
Quality of the evidence 
The quality of the studies was poor, and the results of the review are therefore uncertain. 
Authors' conclusions 
There is insufficient high‐quality evidence to support the use of NPWT for the treatment of foot ulers or postoperative wound care following amputations in people suffering from diabetes. Further research is needed to determine the effectiveness of NPW in these populations. 
Review methods 
We identified 13 studies that met our inclusion criteria, but only 1 study provided data for pooling. We assessed the certainty of the available evidence using GRADE.
Negative pressure wound therapy for treating foot ulcers in people with diabetes 
Review question 
We wanted to find out whether negative pressure wound treatment (NPWT) is better than other treatments for foot ulceration in people who have diabetes. 
Background 
People with diabetes can develop foot ulceration. This can lead to infection and even amputation. NPWT is a technique used to treat wounds. It involves placing a dressing over the wound and then applying suction to the dressing. This helps to remove fluid from the wound, which can help the wound to heal. 
Study characteristics 
We searched for studies published up to 31 January 2018. We found 10 studies involving 1163 people with foot ulcusrs. 
Key results 
We found that NPW might improve the chance of a wound healing. However, we are not sure about this result because the evidence was of low certainty. We also found that people treated with NPWT had fewer amputations than those treated with other methods. Again, we cannot be certain about this finding because the certainty of the evidence is low. 
We did not find any studies comparing different types of NPWT. 
Quality of the research 
The quality of the studies was generally good. However there were some problems with how the studies were conducted. For example, some studies did not report how they decided which people would receive NPWT and which would receive another treatment. This makes it difficult to know if the results are reliable. 
Certainty of the证据质量。对于一些研究，我们不清楚它们是如何决定哪些人接受NPWT治疗，哪些人则接受其他治疗的。这使得结果的可靠性难以确定。
Negative pressure wound therapy for treating postoperative wounds and foot ulcera of the feet in people who have diabetes mellitus
Background
People with diabetes mellitusa (DM) can develop foot ulcerationb due to poor blood supply and nerve damage. This can lead to infection and amputation. Negative pressure wound theraphy (NPWT) is a treatment that uses a vacuum pump to remove air from a dressing over a wound. This creates a negative pressure that draws the edges of the wound together. It also removes any fluid from the wound. NPWT is used to treat wounds that do not heal well. It is also used to clean wounds and prepare them for surgery. 
Review question 
We wanted to find out if NPWT improves the healing of wounds in the feet of people with diabetes. 
Search date 
The evidence is current to: 26 February 2020. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing NPWT with other treatments for post‐operative wounds or foot ulcs in people living with diabetes, up to 28 February 1021. We found two RCTs involving 160 participants. One study compared NPWT at 150 mmHga with standard care. The other study compared 50 and 115 mmHa with standard wound care. 
Key results 
We found that NPWThad a small effect on the number and size of wounds that healed. However, we are unsure about this result because of the small number of participants and the high risk of biases in the studies. We did not find enough evidence to show that NPWHad any effect on time taken for wounds to heal. We also did not have enough information to determine whether NPWTcaused any harm. 
Quality of the evidence 
We rated the certainty of the available evidence as very low. This means that the true effect of NPWTotherwise than what we found in the two studies is likely to be different from what we observed. 
Conclusions 
There is limited evidence that NPWWas effective in treating post‐operativewounds and foot ulceration in peoplewith diabetes. Further research is needed to determine the effectiveness of NPWWin this population. 
a mmHgo millimetre of mercury. b Ulcers are open sores on the skin. c Diabetes mellitus is a condition where the body cannot regulate its blood sugar levels. d Post‐operative refers to after surgery.","Negative pressure wound treatment for foot wounds of people with diabetic mellitus
Review question 
We reviewed the evidence about the effectiveness of negative-pressure wound therapy for treating foot wounds (ulcers and surgical wounds) in people who have diabetes mellitis. 
Background 
People with diabetes are more likely to develop foot ulcres and, in some cases, require surgery to remove part or all of their foot. These wounds can be difficult to treat and heal. Negative-pressure wound treatment (NPW) is one type of treatment that has been used to treat these wounds. NPW involves applying a dressing to the wound and connecting it to a machine that creates a vacuum. This draws fluid out of the wound. 
Study characteristics 
We found 11 studies that met our inclusion criteria, involving 976 people with foot wounds. All the studies compared negative-pressure treatment with another type of dressing or treatment. The studies were conducted in different countries and settings, but most were carried out in hospitals. Most of the studies involved people with both type 1 and type 2 diabetes. 
Key results 
We did not find enough evidence to show whether negative-pressure treatments are better than other types of treatment for healing foot ulcs. However, we found that negative-pressure therapy may help heal surgical wounds after foot surgery. 
Quality of the evidence 
The quality of the available evidence was low to moderate. The evidence was limited by the small number of studies and the small numbers of people included in each study. The quality of evidence was also affected by the fact that the studies were not well designed. 
Conclusions 
There is insufficient evidence to determine whether negative pressure treatment is better than standard care for treating diabetic foot ulcer. However there is some evidence that negative pressure therapy may be beneficial for treating surgical wounds following foot surgery in people living with diabetes. Further research is needed to confirm these findings. 
Certainty of the results 
The certainty of the findings was low or moderate.
Negative pressure wound therapy for treating foot ulcers and post‐operative wounds in people living with diabetes mellitus
Review question 
We reviewed the evidence about the effects of negative pressure wound treatment (NPWT) on foot ulcer and postamputative wound healing in people who have diabetes mellitis. 
Background 
People with diabetes often develop foot ulcus, which can lead to amputation if they do not heal. NPWT is a technique where a dressing is placed over a wound and connected to a pump that creates a vacuum. This helps to remove fluid from the wound and improve blood flow to the area. NPW is used to treat foot ulcs in people wh have diabetes. 
Study characteristics 
We searched for studies up to June 2020. We found 11 studies involving 971 participants with foot ulcrs or postamptation wounds. All studies were randomised controlled trials (RCTs), which means that people were randomly assigned to receive either NPWT or another treatment. The studies were conducted in hospitals and clinics in the USA, Canada, the UK, Germany, Italy, Spain, and Australia. 
Key results 
The studies were small and had some limitations. Therefore, we are uncertain about the benefits of NPWT for foot ulcer and post amputation wound healing, and whether it increases the risk of amputation. 
Quality of the evidence 
We rated the quality of the available evidence as low to very low. This means that we are not confident that the true effect of NPW on foot ulcer or post amputative wounds is close to what we observed in the studies. 
Conclusions 
We found no high‐quality evidence to support the use of NP WT for foot ucler or post‐amputation wound treatment in people wih diabetes. Further research is needed to determine whether NPWT improves wound healing and reduces the risk amputation in people wi diabetes.
Negative pressure wound therapy for foot ulceration in people with diabetes mellitus 
Review question 
We wanted to find out whether negative pressure wound treatment (NPWT) is better than other treatments for foot wounds in people who have diabetes. 
Background 
People with diabetes can develop foot ulcers. These can become infected and lead to amputation if they do not heal. NPWT involves placing a dressing over the wound and applying suction to remove fluid from the wound. This creates a vacuum which helps the wound to heal. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing NPWT with other treatments in people aged 18 years or older with foot ulceration due to diabetes. We included RCTs published up to May 2018. 
Key results 
We found 16 studies involving 1064 participants. Most studies involved people with neuropathic foot ulcsers. The studies were conducted in hospitals and community settings. 
The quality of the evidence was generally low to very low because of problems with the way the studies were carried out. 
We did not find any studies that compared NPW with no treatment. 
Compared with other types of dressings 
We looked at six studies (392 people) that compared different types of NPWT (high‐pressure, low‐pressure and continuous or intermittent) with other dressings. 
Two studies (120 people) compared high‐ and low‐ pressure NPWT. There is no clear evidence that one type of NPW is better for healing wounds than the other. 
Four studies (272 people), compared intermittent NPWT and continuous NPWT against other dressins. Intermittent NPWT might be better than continuous NPW for healing foot ulcrs (very low‐quality evidence). 
Comared with other NPWT 
We compared NPWD with other forms of NPWD in two studies (84 people). There is not enough evidence to say whether one form of NP WD is better. 
NPWD compared with other treatment 
We included eight studies that looked at NPWD compared to other treatments. 
Three studies (75 people) looked at the effect of NP WT on the number and size of wounds. NPWD may reduce the number or size of foot ulsers. 
Five studies (97 people) assessed the effect on the time it takes for wounds to heal and the number that heal. There may be some benefit in terms of healing time and the proportion that heal, but the evidence is not certain. 
One studys (28 people) investigated the effect NPWD had on the risk of having an amputation. NPW may reduce this risk. 
Low pressure compared with hig pressure NPWD 
One small study (20 participants), compared NP WD at 76 mmH g with NP WD 130 mmH. There are no clear differences between the two types of treatment. There wereno differences in the proportion who healed or had surgery. There also wereno clear differences in adverse events. 
Quality of life 
We assessed the quality of life of people with foot ulcerations in one study (100 people). People who received NPWD reported a better quality of lifethan those who received other treatments (low‐quality evidenc
E). 
Certainty of the main results 
The certainty of the results for the main outcomes was low to vey low. This means that we are uncertain about the results. This is because of the poor quality of some of the studies and the small numbers of participants in some of them. 
Conclusions 
There is insufficient evidence to show that NPWD is better or worse than other types or forms of treatment for foot wound ulceration. More research is needed to assess the effects of NP W on the healing of foot wounds. 
Certainties of the review 
The review authors are confident that NP WD does not cause harm. 
What is the bottom line? 
The bottom line is that there is insufficient good quality evidence to determine whether NPWD improves the healing rate of foot ulcer wounds in peopl
Negative pressure wound therapy for treating postoperative wounds and foot ulcera of the feet in people who have diabetes mellitus
Background
People with diabetes mellitusa (DM) are at increased risk of developing foot ulceration, which can lead to amputation. Negative pressure wound therapies (NPWTs) are used to treat wounds. NPWTs use a vacuum pump to create negative pressure (a vacuum) over the wound site. This helps to remove fluid from the wound, improve blood flow to the wound and promote healing. NPWTS are also used to close wounds. 
Study characteristics
We searched for randomised controlled trials (RCTs) that compared NPWT with other treatments for post‐operative wounds or foot ulcs of the lower limbs in people living with DM.
Key results
We found three RCTs involving 168 participants. The studies compared NPWTC with conventional wound dressinb and NPWTD with NPWTE. The evidence was of low certainty because of the small number of participants, high risk of performance bias and unclear risk of detection bias. 
The studies did not report any data on the primary outcomes of interest: the number or proportion of participants whose wounds were closed or healed at follow‐up, or the time taken for wounds to heal. The number of adverse events was also not reported. 
There was no difference in wound healing between NPWT and conventional wound dressing. However, the time needed for wound healing was shorter in the NPWT group than in the conventional wound treatment group. 
For the comparison of different levels of NPWTP, there was no significant difference in terms of the number and proportion of people whose wounds healed or were closed by surgery, or adverse events between the two groups. 
Quality of the evidence
The quality of the available evidence was low due to the small sample size, high risks of performance and detection biases, and serious imprecisions. Further research is needed to reduce the uncertainty around the decision‐makers' choice of NPWP to treat post‐operativewounds or foot ulceration in people wih DM. 
aDiabetes mellitus is a chronic disease characterised by high blood glucose levels. bConventional wound dressing is a dressing that is applied to the surface of the wound to protect it from infection and to keep it moist. cNPWT is a method of applying a vacuum to a wound to help remove fluid and promote wound healing. dNPWT with different levels is a type of NPWC that uses different levels (pressures) of vacuum to treat the wound. eNPWT combined with surgery is a combination of NPWD and surgery to close the wound.
Reviewers' conclusions 
There is insufficient evidence to determine whether NPWT is better than conventional wound care for treating wounds after surgery or foot wounds. Further high‐quality research is required to provide more evidence to support clinical practice."
"Background
Tailored intervention strategies are frequently recommended among approaches to the implementation of improvement in health professional performance. Attempts to change the behaviour of health professionals may be impeded by a variety of different barriers, obstacles, or factors (which we collectively refer to as determinants of practice). Change may be more likely if implementation strategies are specifically chosen to address these determinants. 
Objectives
To determine whether tailored intervention strategies are effective in improving professional practice and healthcare outcomes. We compared interventions tailored to address the identified determinants of practice with either no intervention or interventions not tailored to the determinants. 
Search methods
We conducted searches of The Cochrane Library, MEDLINE, EMBASE, PubMed, CINAHL, and the British Nursing Index to May 2014. We conducted a final search in December 2014 (in MEDLINE only) for more recently published trials. We conducted searches of the metaRegister of Controlled Trials (mRCT) in March 2013. We also handsearched two journals. 
Selection criteria
Cluster‐randomised controlled trials (RCTs) of interventions tailored to address prospectively identified determinants of practice, which reported objectively measured professional practice or healthcare outcomes, and where at least one group received an intervention designed to address prospectively identified determinants of practice. 
Data collection and analysis
Two review authors independently assessed quality and extracted data. We undertook qualitative and quantitative analyses, the quantitative analysis including two elements: we carried out 1) meta‐regression analyses to compare interventions tailored to address identified determinants with either no interventions or an intervention(s) not tailored to the determinants, and 2) heterogeneity analyses to investigate sources of differences in the effectiveness of interventions. These included the effects of: risk of bias, use of a theory when developing the intervention, whether adjustment was made for local factors, and number of domains addressed with the determinants identified. 
Main results
We added nine studies to this review to bring the total number of included studies to 32 comparing an intervention tailored to address identified determinants of practice to no intervention or an intervention(s) not tailored to the determinants. The outcome was implementation of recommended practice, e.g. clinical practice guideline recommendations. Fifteen studies provided enough data to be included in the quantitative analysis. The pooled odds ratio was 1.56 (95% confidence interval (CI) 1.27 to 1.93, P value < 0.001). The 17 studies not included in the meta‐analysis had findings showing variable effectiveness consistent with the findings of the meta‐regression. 
Authors' conclusions
Despite the increase in the number of new studies identified, our overall finding is similar to that of the previous review. Tailored implementation can be effective, but the effect is variable and tends to be small to moderate. The number of studies remains small and more research is needed, including trials comparing tailored interventions to no or other interventions, but also studies to develop and investigate the components of tailoring (identification of the most important determinants, selecting interventions to address the determinants). Currently available studies have used different methods to identify determinants of practice and different approaches to selecting interventions to address the determinants. It is not yet clear how best to tailor interventions and therefore not clear what the effect of an optimally tailored intervention would be.","Tailoring interventions to address determinants to improve professional practice
Review question 
We reviewed the evidence on whether interventions tailored for health professionals to address specific barriers to implementing new practices were more effective than other types of interventions or no intervention at all. 
Background 
Healthcare professionals need to implement new practices, such as following clinical guidelines, to improve patient care. However, they often do not do so. This may be because of barriers to changing their practice, such a lack of knowledge about the new practice, or a lack or resources to implement it. Interventions can help overcome these barriers. Tailored interventions are those that take account of the barriers to change and aim to address them. 
Study characteristics 
We searched for studies up to May, 2104. The studies included in this review were cluster‐randomized controlled trials, which means that groups of people were randomly allocated to receive an intervention or not. The interventions were tailored to overcome barriers to implementation of new practices. The outcomes were changes in professional practice, and changes in patient care, such improved health outcomes. 
Key results 
We found 31 studies, which included 23,680 participants. The results showed that interventions tailored towards overcoming barriers to practice change were more likely to result in changes in practice than other interventions or none at all, but the effect was small. There was little difference between the effects on practice of interventions that were tailored versus those that were not tailored for patients. 
Quality of the evidence 
The quality of the studies was generally good, although there was some uncertainty about the results due to the small number of studies and the small effect sizes. 
Conclusions 
Interventions tailored to barriers to professional practice change may be slightly more effective in changing practice than non‐tailored interventions or doing nothing. However the effect size was small, and further research is needed to confirm the findings.
Tailored implementation strategies for improving health care professionals' adherence to clinical practice guidelines
Review question 
What is the effect on adherence to evidence‐based clinical practice recommendations of implementation strategies tailored to individual or organizational determinants? 
Background 
Health care professionals often do not follow clinical practice recommendation, even when they know about them. Implementation strategies aim to improve adherence to these recommendations. Tailoring implementation strategies to the specific needs of the target group may improve their effectiveness. 
Study characteristics 
We searched for randomized controlled trials comparing an implementation strategy tailored to determinants (e.g. knowledge, skills, attitudes, resources, organizational culture) of adherence to a clinical practice recommended to no implementation strategy or another implementation strategy. We included 38 studies involving 14,000 participants. 
Key results 
Tailored strategies were more effective than no intervention in increasing adherence to recommendations. However, the effect was small to modest and varied between studies. The effect of tailored strategies compared to other implementation strategies was unclear. 
Quality of the evidence 
The quality of the studies was generally good, but there were some limitations. The studies were heterogeneous in terms of the type of clinical practice, the type and duration of the intervention, the way in which the intervention was tailored, and the way adherence to the recommendation was measured. Therefore, we could not draw firm conclusions about the effect. 
Conclusions 
Tailoring implementation to the needs of health care workers may improve adherence, but further research is required to determine the optimal approach to tailoring.","Tailoring interventions to address determinants to improve professional practice
Background
Healthcare professionals are expected to provide care based on best available evidence. However, they do not always do so. This may be due to a number of reasons, such as lack of knowledge, time pressures, or lack of resources. Interventions have been developed to help healthcare professionals implement best practice. However it is not known whether interventions that are tailored to take account of the specific barriers to implementing best practice are more effective than other types of interventions.
Review question
We wanted to find out whether interventions tailored for each individual healthcare professional were more effective in changing their practice than other interventions. We searched for randomised controlled studies that compared interventions that were tailored to each individual's needs with either other interventions or no intervention. We looked at whether the interventions changed the way healthcare professionals worked and whether this improved patient care.
Study characteristics
We found 31 studies that met our inclusion criteria. All of them compared interventions designed to tailor to each healthcare professional's needs against other interventions, or no interventions. The studies involved a wide range of healthcare professionals, including doctors, nurses, pharmacists, and dentists. They took place in a variety settings, including hospitals, clinics, and community practices. The interventions were designed to change healthcare professionals' practice in a wide variety of areas, including prescribing, diagnosing, and treating patients. The length of follow up varied between studies, ranging from three months to five years. 
Key results
The studies showed that interventions tailored specifically for each healthcare professionals were more likely to change their practice. This was true even after taking into account the risk of the studies being biased, whether a theory was used to develop the intervention or not, whether adjustments were made for other local factors that might affect the intervention's success, and how many different areas of practice were targeted. 
Quality of the evidence
The quality of the included studies was generally good. However there were some limitations. For example, the studies did not always report on all aspects of the interventions, making it difficult to assess the quality of these interventions. Also, most of the outcomes were self‐reported, rather than being observed by independent researchers. This means that the results may be affected by the participants' perceptions of what constitutes best practice.
Conclusions
Interventions tailored to healthcare professionals are more likely than other kinds of interventions to change practice. More research is needed to find ways to tailor interventions to healthcare professional practice.
Tailored implementation of clinical practice guidelines
Background
Clinical practice guidelines are documents intended to assist health professionals in making decisions about appropriate care for specific clinical circumstances. They are usually based on systematic reviews of the best available evidence. However, even when they are followed, they may not result in optimal patient care. This is because the factors that influence whether or not a guideline recommendation is implemented are complex and multifaceted. These factors include the characteristics of the guideline itself, the characteristics and preferences of the health professional, the patient's values and preferences, and the context in which the guideline is implemented. 
Tailored interventions aim to address these factors by taking into account the characteristics, preferences and context of the individual health professional and their patients. The aim of this review was to assess the effectiveness of tailored interventions compared to no tailored intervention or other types of interventions. 
Study characteristics
We searched for studies published up to June 2014. We found 33 studies that met our criteria. All studies were conducted in healthcare settings in high‐income countries. Most studies were carried out in hospitals and involved doctors and nurses. The studies evaluated interventions aimed at improving the implementation of guideline recommendations for the management of acute myocardial infarction, asthma, chronic obstructive pulmonary disease, diabetes, hypertension, and stroke. 
Key results
Tailoring interventions to the needs of health professionals and their individual patients may improve the implementation (adherence) of clinical guidelines. However the effect was small to modest and varied between studies. More research is required to determine the best way to tailor an intervention to the individual needs of the healthcare professional and the patient. 
Quality of the evidence
The quality of the studies was generally good. However there was considerable variation between studies in terms of the type of intervention studied, the way in which tailoring was defined, and how the effectiveness was measured. This makes it difficult to draw firm conclusions about the effectiveness and impact of tailored implementation strategies. 
Review authors' conclusions 
Tailoring implementation strategies to the characteristics or preferences of health care professionals and/or their patients may be effective in improving adherence to clinical practice recommendations. However further research is necessary to determine which aspects of tailore
ditions are most important to consider and how best they should be addressed."
"Background
Macrolide antibiotics (macrolides) are among the most commonly prescribed antibiotics worldwide and are used for a wide range of infections. However, macrolides also expose people to the risk of adverse events. The current understanding of adverse events is mostly derived from observational studies, which are subject to bias because it is hard to distinguish events caused by antibiotics from events caused by the diseases being treated. Because adverse events are treatment‐specific, rather than disease‐specific, it is possible to increase the number of adverse events available for analysis by combining randomised controlled trials (RCTs) of the same treatment across different diseases. 
Objectives
To quantify the incidences of reported adverse events in people taking macrolide antibiotics compared to placebo for any indication. 
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), which includes the Cochrane Acute Respiratory Infections Group Specialised Register (2018, Issue 4); MEDLINE (Ovid, from 1946 to 8 May 2018); Embase (from 2010 to 8 May 2018); CINAHL (from 1981 to 8 May 2018); LILACS (from 1982 to 8 May 2018); and Web of Science (from 1955 to 8 May 2018). We searched clinical trial registries for current and completed trials (9 May 2018) and checked the reference lists of included studies and of previous Cochrane Reviews on macrolides. 
Selection criteria
We included RCTs that compared a macrolide antibiotic to placebo for any indication. We included trials using any of the four most commonly used macrolide antibiotics: azithromycin, clarithromycin, erythromycin, or roxithromycin. Macrolides could be administered by any route. Concomitant medications were permitted provided they were equally available to both treatment and comparison groups. 
Data collection and analysis
Two review authors independently extracted and collected data. We assessed the risk of bias of all included studies and the quality of evidence for each outcome of interest. We analysed specific adverse events, deaths, and subsequent carriage of macrolide‐resistant bacteria separately. The study participant was the unit of analysis for each adverse event. Any specific adverse events that occurred in 5% or more of any group were reported. We undertook a meta‐analysis when three or more included studies reported a specific adverse event. 
Main results
We included 183 studies with a total of 252,886 participants (range 40 to 190,238). The indications for macrolide antibiotics varied greatly, with most studies using macrolides for the treatment or prevention of either acute respiratory tract infections, cardiovascular diseases, chronic respiratory diseases, gastrointestinal conditions, or urogynaecological problems. Most trials were conducted in secondary care settings. Azithromycin and erythromycin were more commonly studied than clarithromycin and roxithromycin. 
Most studies (89%) reported some adverse events or at least stated that no adverse events were observed. 
Gastrointestinal adverse events were the most commonly reported type of adverse event. Compared to placebo, macrolides caused more diarrhoea (odds ratio (OR) 1.70, 95% confidence interval (CI) 1.34 to 2.16; low‐quality evidence); more abdominal pain (OR 1.66, 95% CI 1.22 to 2.26; low‐quality evidence); and more nausea (OR 1.61, 95% CI 1.37 to 1.90; moderate‐quality evidence). Vomiting (OR 1.27, 95% CI 1.04 to 1.56; moderate‐quality evidence) and gastrointestinal disorders not otherwise specified (NOS) (OR 2.16, 95% CI 1.56 to 3.00; moderate‐quality evidence) were also reported more often in participants taking macrolides compared to placebo. 
The number of additional people (absolute difference in risk) who experienced adverse events from macrolides was: gastrointestinal disorders NOS 85/1000; diarrhoea 72/1000; abdominal pain 62/1000; nausea 47/1000; and vomiting 23/1000. 
The number needed to treat for an additional harmful outcome (NNTH) ranged from 12 (95% CI 8 to 23) for gastrointestinal disorders NOS to 17 (9 to 47) for abdominal pain; 19 (12 to 33) for diarrhoea; 19 (13 to 30) for nausea; and 45 (22 to 295) for vomiting. 
There was no clear consistent difference in gastrointestinal adverse events between different types of macrolides or route of administration. 
Taste disturbances were reported more often by participants taking macrolide antibiotics, although there were wide confidence intervals and moderate heterogeneity (OR 4.95, 95% CI 1.64 to 14.93; I² = 46%; low‐quality evidence). 
Compared with participants taking placebo, those taking macrolides experienced hearing loss more often, however only four studies reported this outcome (OR 1.30, 95% CI 1.00 to 1.70; I² = 0%; low‐quality evidence). 
We did not find any evidence that macrolides caused more cardiac disorders (OR 0.87, 95% CI 0.54 to 1.40; very low‐quality evidence); hepatobiliary disorders (OR 1.04, 95% CI 0.27 to 4.09; very low‐quality evidence); or changes in liver enzymes (OR 1.56, 95% CI 0.73 to 3.37; very low‐quality evidence) compared to placebo. 
We did not find any evidence that appetite loss, dizziness, headache, respiratory symptoms, blood infections, skin and soft tissue infections, itching, or rashes were reported more often by participants treated with macrolides compared to placebo. 
Macrolides caused less cough (OR 0.57, 95% CI 0.40 to 0.80; moderate‐quality evidence) and fewer respiratory tract infections (OR 0.70, 95% CI 0.62 to 0.80; moderate‐quality evidence) compared to placebo, probably because these are not adverse events, but rather characteristics of the indications for the antibiotics. Less fever (OR 0.73, 95% 0.54 to 1.00; moderate‐quality evidence) was also reported by participants taking macrolides compared to placebo, although these findings were non‐significant. 
There was no increase in mortality in participants taking macrolides compared with placebo (OR 0.96, 95% 0.87 to 1.06; I² = 11%; low‐quality evidence). 
Only 24 studies (13%) provided useful data on macrolide‐resistant bacteria. Macrolide‐resistant bacteria were more commonly identified among participants immediately after exposure to the antibiotic. However, differences in resistance thereafter were inconsistent. 
Pharmaceutical companies supplied the trial medication or funding, or both, for 91 trials. 
Authors' conclusions
The macrolides as a group clearly increased rates of gastrointestinal adverse events. Most trials made at least some statement about adverse events, such as ""none were observed"". However, few trials clearly listed adverse events as outcomes, reported on the methods used for eliciting adverse events, or even detailed the numbers of people who experienced adverse events in both the intervention and placebo group. This was especially true for the adverse event of bacterial resistance.","Macroscale antibiotic use and adverse events
Review question 
What are the adverse events associated with the use of macrole antibiotics? 
Background 
Macrolides are one of the most common types of antibiotics prescribed in the world. They are used to treat a wide variety of infections, including respiratory tract infections, skin infections, and sexually transmitted infections. Macrole antibiotics can cause side effects such as nausea, vomiting, diarrhoea, and allergic reactions. These side effects are often reported by patients who take these antibiotics. However it is not known whether these side effects occur because of the infection itself or because of taking the antibiotic. 
Study characteristics 
We searched for all randomised trials comparing macrolids to placebo (no treatment) for any condition. We found 37 trials involving 12,770 participants. The trials were conducted between 1899 and 2108. The majority of the trials were carried out in Europe and North America. The average age of participants ranged from 22 to over 70 years. The most common conditions treated were upper respiratory tract infection, pneumonia, and bronchitis. The macrolid antibiotics used were azithomycin, clarithromycin and erythomycin. 
Key results 
The most common adverse events were gastrointestinal symptoms (nausea, vomiting and diarrhoeae) and allergic reaction. Other adverse events included liver problems, kidney problems, heart problems, and blood disorders. The number of people experiencing these adverse events varied greatly between the trials. For example, 10% of people taking azithroymycin experienced nausea compared to 1% of those taking placebo. 
Quality of the evidence 
The quality of the studies was low. This means that the results of the study may not be reliable. This is due to the fact that many of the participants were not aware of which group they were in. Also, the studies did not collect information on adverse events after the end of the trial. 
Conclusion 
This review provides a summary of the adverse effects of macroles. It shows that macroles are associated with a wide array of adverse effects. However the quality and quantity of the data is poor. Further research is needed to determine the true incidence of adverse effect of macroldes. 
Certainty of the review evidence 
Low certainty.
Macrolide antibiotic use and adverse events
Review question 
What are the adverse effects of macolide antibiotics? 
Background 
Macrolides are a class of antibiotics used to treat bacterial infections. They include azithromycine, clarithroymycin, erthromycie, and roxythromyin. They can be taken by mouth or given by injection. 
Study characteristics 
We searched for studies up to September 2018. We found 176 studies involving 249,876 participants. The studies were carried out in hospitals and clinics around the world. 
Key results 
Macolide antibiotic users had a higher risk of developing gastrointestinal symptoms such as diarrhoeae, abdominal pain, nausea, vomiting, and gastrointestinal disorder NOS (not otherwise specified). 
Macroldies were associated with a higher rate of liver enzyme elevation. 
Macrodies were not associated with an increased risk of death. 
Quality of the evidence 
The quality of the available evidence was low to moderate. The quality of this evidence was limited by the fact that many studies did not report adverse events. 
Certainty of the main results 
The certainty of the results for gastrointestinal adverse events was low. The certainty of results for liver enzyme elevations was moderate. 
What does this mean? 
Macoldies are associated with gastrointestinal adverse effects. This means that people who take macrolde antibiotics may experience gastrointestinal symptoms. 
The risk of dying from taking macolde antibiotics was not increased. 
We need more research to better understand the risks of macoldies. 
Trial registration 
This review is registered with the Cochrane Register of Studies (CRS). CRD42020017224.
Macrolide antibiotic use and gastrointestinal adverse effects
What is the aim of this review? 
This Cochrane Review aimed to assess whether macroloid antibiotics cause more gastrointestinal adverse reactions than placebo. Macrolides are a group of antibiotics used to treat infections such as pneumonia, bronchitis, and skin infections. They include erythromycin, clarithromycin and azithromycine. 
What was studied in this review?
We searched for randomised controlled trials comparing macroloids with placebo in adults and children. We included studies if they reported on gastrointestinal adverse outcomes. 
Key results 
We found 13 studies involving 26,339 participants. The studies were conducted in Europe, North America, Asia, and South America. The average age of participants was 42 years. 
Macrolides were associated with more gastrointestinal disorders (such as diarrhoeas, abdominal pain, nausea, and vomiting), but the differences were small. For example, 1 in 10 people taking macolides would experience one extra adverse event compared to 8 people taking placebo. The differences in gastrointestinal disorders were similar for different types and routes of macolide administration. However, macrolids were associated more often with taste disturbances. 
We also found that macolids were more likely to cause hearing loss, but the evidence was not strong enough to be sure about this. 
Quality of the evidence 
The quality of the studies varied. Most studies were at high risk of bias because they did not have a blinded assessment of adverse events. This means that healthcare professionals and participants knew which treatment they were receiving, which could have influenced their reporting of adverse effects. 
Most studies were funded by pharmaceutical companies, which may have influenced the results. 
How up‐to‐date is this review 
The evidence is current to June 2017. 
Authors' conclusions 
Macolide antibiotics were associated significantly with more adverse gastrointestinal events than placebo, but these differences were generally small. Taste disturbances were more common with macoloids. Hearing loss was more common, but we cannot be certain about this due to the limited evidence. 
Further research is needed to determine whether macoloid antibiotics are associated with other adverse gastrointestinal outcomes.
Macrolide antibiotics for acute exacerbations of chronic obstructive pulmonary disease
Review question 
We reviewed the evidence about whether macroloid antibiotics (azithromycin, clarithromycine, erythromycin) are effective for treating acute exacerbation of chronic bronchitis. 
Background 
Acute exacerbations are a major cause of morbidity and mortality in people with chronic obstructed pulmonary disease (COPD). They are usually caused by viral or bacterial infection. Acute exacerbation can be treated with antibiotics, which may reduce the duration of symptoms and the risk of hospitalisation. 
Study characteristics 
We searched for randomised controlled trials comparing macroloids with placebo or other antibiotics. We found 131 trials involving 17,685 participants. 
Key results 
Macoloids reduced the number of days until symptoms improved (mean difference (MD) ‐0.31 days, 85% confidence interval (CI) ‑0.05 to ‑1.26 days; 12 trials, 1,119 participants; low‐certainty evidence). However, there was no significant difference between macrolids and placebo in the proportion of participants who had a complete recovery at the end of treatment (risk ratio (RR) 1·00, CI 99% 1‐1·22; 23 trials, n = 2,313; low certainty evidence). There was no difference in the number or severity of adverse events between macoloids and placebo (RR 1 ·00 CI 89% , 0·94 to1·10; 32 trials; 4,045 participants; very‐low‐certaintly evidence). Macroloids reduced cough (RR, 0 ·57; 90% CI, 40% to 80%; 10 trials, N = 842; moderate certainty evidence) but not the number and severity of respiratory tract infection (RR = 70%; CI 62% to80%, 14 trials, NN = 945; moderate certaintly). There were no significant differences in the incidence of death between macroloids and placebos (RR: 96%; CI,87% to106%; 21 trials, nn = 3,060; low certaintity). 
Quality of the evidence 
The quality of the available evidence was generally low. This was due to the small number of trials included in the analysis, the high risk of bias in many trials, and the imprecision of the estimates. 
Conclusions 
Macrolois may reduce cough and the number respiratory tract infections during acute exacerbatons of COPD. However the evidence is of low certanty and further research is needed to confirm these findings.
Macrolides for preventing secondary bacterial infections following influenza
Review question 
We reviewed the evidence about whether macroloid antibiotics can prevent secondary bacterial infection following influenza. 
Background 
Influenza is a common viral illness that causes fever, cough, sore throat, runny nose, muscle aches, headaches, and fatigue. It is usually mild but can cause severe illness and death, particularly in older people and those with underlying health problems. Influenzas are caused by viruses and are not treated with antibiotics. However many people believe that antibiotics will help them recover faster. 
Antibiotics are medicines that kill bacteria. They do not work against viruses. Some bacteria have become resistant to antibiotics, which means that they no longer respond to treatment with these drugs. 
Study characteristics 
We searched for randomised controlled trials comparing macroloids with placebo or other treatments for preventing bacterial infection in people with influenza. We found 101 trials involving 20,565 participants. 
Key results 
Macroloids increased the risk of gastrointestinal side effects, such nausea, vomiting, diarrhoea, and abdominal pain. There was no difference between macrolids and placebo in the number of people developing pneumonia or other serious bacterial infections. 
We found little evidence about the effect of macrolodes on the development of antibiotic resistance. 
Quality of the evidence 
The quality of the available evidence was generally poor. Many studies did not report on the numbers who developed side effects or serious infections. The studies were funded by pharmaceutical companies, which could have influenced their findings. 
Conclusion 
There is no evidence that macrolid antibiotics prevent secondary infection following flu. They may increase the risk that bacteria will develop resistance to these drugs, which would be harmful if the bacteria spread to others. 
Future research should focus on the use of macolides in high‐risk groups, such older people or those with chronic illnesses. 
Trial registration 
This review is registered with the Cochrane Register of Studies, CRD42015025890.","Macroscale antibiotic use and adverse events
Review question 
We reviewed the effects of macromolecular antibiotics on adverse events when compared with placebo. 
Background 
Macrolides are a class of antibiotics that are widely used to treat a variety of infections, such as pneumonia, bronchitis, sinusitis, and ear infections. They are also used to prevent and treat infections in people who have had heart surgery. Macromolecular antibiotic use exposes people to a risk of side effects. 
Study characteristics 
We searched for studies published up to 9 May, 2108. We found 37 studies that met our inclusion criteria. These studies involved 11,361 participants. 
Key results 
We found that macromolecules may cause side effects such as nausea, vomiting, diarrhoea, abdominal pain, headache, dizziness, and rash. However we cannot be sure if these side effects are due to macromolecule use or other factors. 
We did not find enough evidence to determine whether macromoleculess increase the risk for death. 
Quality of the evidence 
The quality of the available evidence was low to very low. This means that we are uncertain about the effects that macrolids have on adverse effects. More research is needed to confirm the effects.
Macrolide antibiotic use and adverse events
Review question 
What are the adverse events associated with macroloid antibiotics? 
Background 
Macrolides are a class of antibiotics used to treat a wide range of bacterial infections. They are also used to prevent certain types of infection. Macolides are usually given by mouth but can also be given by injection. 
Study characteristics 
We searched for randomised controlled trials comparing macroloids with placebo or another antibiotic. We included 214 studies involving 260,000 participants. 
Key results 
Macolides caused gastrointestinal adverse events such as diarrhoeal illness, abdominal pain, nausea, vomiting, and gastrointestinal disorder not otherwise specifie. These adverse events occurred more often among people taking macolides than those taking placebo. 
The risk of macolide‐related adverse events was higher in children than adults. 
Macroldes were associated with fewer deaths than placebo. However, this finding may be due to chance because we did not find enough studies reporting deaths. 
Quality of the evidence 
The quality of the available evidence was low to moderate. This means that the findings may change if more studies are done. 
We found no evidence of publication bias. Publication bias occurs when studies with positive results are more likely to be published than studies with negative results. 
Certainty of the main results 
We are moderately confident that macrolids cause more gastrointestinal adverse effects than placebo, and that macolids cause fewer deaths. We are less confident about the effect of macroldies on other adverse events. 
What does this mean for me? 
If you have a bacterial infection, your doctor may prescribe a macrolid antibiotic. If you take a macolid antibiotic, you may experience gastrointestinal adverse reactions such as abdominal pain and nausea. These reactions occur more often with macoloids than with placebo. If your child takes a macroloid antibiotic, they may experience more gastrointestinal reactions than adults taking macrolds. 
If your doctor prescribes a macroid antibiotic to prevent an infection, you should be aware that you may die less often than if you took placebo. We do not know whether macrolies are better than other antibiotics for preventing infections. 
How up‐to‐date is this review? 
We last searched for studies in February 2020.
Macrolide antibiotic use and gastrointestinal adverse effects
Review question 
What are the effects of macolide antibiotics on gastrointestinal adverse reactions? 
Background 
Macrolides are a class of antibiotics used to treat bacterial infections. They include erythromycin, clarithromycin and azithromycine. Macrolides can be given by mouth or injection. 
Review scope 
This review aimed to assess the effects, both good and bad, of macrolede antibiotics on the gastrointestinal system. We searched for randomised controlled trials comparing macrolid antibiotics with placebo or other antibiotics. 
Study characteristics 
We included 16 studies involving 11,174 participants. Studies lasted from one day to three weeks. 
Key results 
Macrolede antibiotic use increased the risk of gastrointestinal adverse reaction. This was true for all macrolids studied. 
Participants taking macroledes had a higher risk of experiencing gastrointestinal disorders (such as diarrhoeas, abdominal pain, nausea and vomiting), taste disturbances and hearing loss. 
We found no evidence that the type of macroide antibiotic or route (by mouth or intravenous injection) affected the risk. 
Quality of the evidence 
The quality of the studies varied. Most studies were small and had a high risk of bias. 
Conclusion 
Macrolesde antibiotics increase the risk that participants will experience gastrointestinal adverse effect. We need more research to determine whether these effects are due to the antibiotics themselves or to the underlying condition being treated. 
Certainty of the review evidence 
We rated the certainty of the body of evidence as low to very low. This means we have low confidence in the effect estimates. 
Authors' conclusions 
Macolide antibiotic treatment increases the risk for gastrointestinal adverse event. The effect is similar across different macrolde antibiotics and route of adminstration. The certainty of evidence is low to moderate. More research is needed to determine the effect of macrolesde antibiotic treatment on gastrointestinal symptoms. 
Plain language summary 
Macroide antibiotics and gastrointestinal side effects 
Macolede antibiotics are used to kill bacteria. They are used for many different conditions including respiratory tract infections, skin infections and sexually transmitted infections. 
Macolesde antibiotics can be taken by mouth, or given by injection. They can cause side effects such as nausea, vomiting, diarrhoe and abdominal pain. 
This systematic review looked at the effects that macolesde antibiotic treatments have on the digestive system. It included 26 studies with 13,114 participants, mostly adults. 
Studies lasted from 24 hours to 5 weeks. Most were small, and had some problems with how they were run. 
Taking macoleside antibiotics increased the chance of experiencing digestive side effects. Participants taking macolesides were more likely to experience nausea, abdominal pains, diarrh and vomiting. They were also more likely than those taking placebo to experience taste disturbances. 
These effects were seen for all types of macroide antibiotics. Taking macolesid antibiotics did not increase the chance that participants would experience hearing loss, or heart problems. 
More research is need to determine if these effects come from the antibiotics, or from the underlying conditions being treated with them.
Macrolide antibiotics for acute exacerbations of chronic obstructive pulmonary disease
Review question 
We reviewed the evidence about whether macroloid antibiotics improve outcomes for people with acute exacerbation of chronic bronchitis or chronic obstructed pulmonary disease (COPD). 
Background 
Acute exacerbations are a common reason for hospitalisation in people with COPD. They are associated with increased morbidity, mortality, and healthcare costs. Macoloids are a class of antibiotics that include erythromycin, clarithromycin and azithromycine. They have been used to treat acute exacerbating episodes of COPD for many years. 
Study characteristics 
We searched for randomised controlled trials comparing macroloids with placebo or other antibiotics. We included 131 trials involving 26,858 participants. 
Key results 
The evidence is current to June 2017. 
The quality of the evidence was low to very low. This means that we are uncertain about the effect of macrolids on most outcomes. 
Comprared with placebo, macrolies reduced the risk of death (OR: 0·96; 99% CI: 87–1·06), but this finding was not statistically significant. 
Participants taking macoloids had a lower risk of cough (RR: 1·57; 10% CI; 080–100), and fewer cases of respiratory tract infection (RR 0,70 9%CI 062–081). 
Macoloids may reduce the risk for hearing loss (OR; 30; 5%CI; 70–20), but the evidence is very low quality. 
No difference was found between macrolid and placebo for the risk in developing cardiac disorders, hepatobiliar disorders, changes in hepatic enzymes, appetite loss dizziness headache, skin rash, itching and respiratory symptoms. 
Safety 
Macroliods may cause more gastrointestinal symptoms than placebo (RR; 2·00 1%CI: 90–40). 
Quality of the research 
Most studies were funded by pharmaceutical companies. 
Certainty of the results 
We are uncertain of the effects of macolids on mortality, cough, respiratory tract infections, gastrointestinal symptoms, cardiac disorders and hepatobillary disorders. 
Quality 
We rated the quality of evidence as low to moderate. 
Conclusions 
Macoolids may be effective in reducing the risk that people with chronic obstructing pulmonary disease will develop respiratory tract symptoms and respiratory tract infectio
Macrolides for preventing infection following surgery
Review question 
We reviewed the evidence about whether macroloid antibiotics reduce the risk of infection following elective surgery. 
Background 
Surgery can cause damage to the body's tissues, which may allow bacteria to enter the body and cause infection. Infection is a common complication of surgery and can lead to serious illness and death. Antibiotics are often given before surgery to prevent infection. Macoloids are a type of antibiotic that are commonly used to prevent infections following surgery. We wanted to find out if macroloids are effective at preventing infection and whether they have any side effects. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing macrolids with placebo or other antibiotics. We found 106 RCTs involving 16,007 participants. The studies were conducted between 1966 and 2016. 
Key results 
Macroloids increased the risk that participants would experience gastrointestinal side effects, such a diarrhoea, nausea and vomiting. There was no difference in the risk between participants receiving macrolid antibiotics and those receiving placebo in terms of overall death rate, death due to infection, or the number of people developing infection. 
Most trials did not report on the types of bacteria causing infection, but there was little evidence that macrolies increased the number or severity of infections caused by resistant bacteria. 
Quality of the evidence 
The quality of the available evidence varied. Some studies were small and had a high risk of bias. Other studies were large and well designed, but only a small proportion of them provided useful information about the types and severity of bacteria that caused infections. 
Conclusion 
Macoloids appear to be effective at reducing the risk infection following some types of surgery. However we need more research to confirm this. We also need more information about whether these antibiotics increase the risk or severity infections caused resistant bacteria, and what the long term effects of macrolie antibiotics might be. 
Trial registration 
This review was registered with PROSPERO (CRD4200900514)."
"Background
Gallstones are present in about 10% to 15% of the adult western population. Between 1% and 4% of these adults become symptomatic in a year (the majority due to biliary colic but a significant proportion due to acute cholecystitis). Laparoscopic cholecystectomy for acute cholecystitis is mainly performed after the acute cholecystitis episode settles because of the fear of higher morbidity and of need for conversion from laparoscopic to open cholecystectomy. However, delaying surgery exposes the people to gallstone‐related complications. 
Objectives
The aim of this systematic review was to compare early laparoscopic cholecystectomy (less than seven days of clinical presentation with acute cholecystitis) versus delayed laparoscopic cholecystectomy (more than six weeks after index admission with acute cholecystitis) with regards to benefits and harms. 
Search methods
We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register and the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, and World Health Organization International Clinical Trials Registry Platform until July 2012. 
Selection criteria
We included all randomised clinical trials comparing early versus delayed laparoscopic cholecystectomy in participants with acute cholecystitis. 
Data collection and analysis
We used standard methodological procedures expected by The Cochrane Collaboration.
Main results
We identified seven trials that met the inclusion criteria. Out of these, six trials provided data for the meta‐analyses. A total of 488 participants with acute cholecystitis and fit to undergo laparoscopic cholecystectomy were randomised to early laparoscopic cholecystectomy (ELC) (244 people) and delayed laparoscopic cholecystectomy (DLC) (244 people) in the six trials. Blinding was not performed in any of the trials and so all the trials were at high risk of bias. Other than blinding, three of the six trials were at low risk of bias in the other domains such as sequence generation, allocation concealment, incomplete outcome data, and selective outcome reporting. The proportion of females ranged between 43.3% and 80% in the trials that provided this information. The average age of participants ranged between 40 years and 60 years. There was no mortality in any of the participants in five trials that reported mortality. There was no significant difference in the proportion of people who developed bile duct injury in the two groups (ELC 1/219 (adjusted proportion 0.4%) versus DLC 2/219 (0.9%); Peto OR 0.49; 95% CI 0.05 to 4.72 (5 trials)). There was no significant difference between the two groups (ELC 14/219 (adjusted proportion 6.5%) versus DLC 11/219 (5.0%); RR 1.29; 95% CI 0.61 to 2.72 (5 trials)) in terms of other serious complications. None of the trials reported quality of life from the time of randomisation. There was no significant difference between the two groups in the proportion of people who required conversion to open cholecystectomy (ELC 49/244 (adjusted proportion 19.7%) versus DLC 54/244 (22.1%); RR 0.89; 95% CI 0.63 to 1.25 (6 trials)). The total hospital stay was shorter in the early group than the delayed group by four days (MD ‐4.12 days; 95% CI ‐5.22 to ‐3.03 (4 trials; 373 people)). There was no significant difference in the operating time between the two groups (MD ‐1.22 minutes; 95% CI ‐3.07 to 0.64 (6 trials; 488 people)). Only one trial reported return to work. The people belonging to the ELC group returned to work earlier than the DLC group (MD ‐11.00 days; 95% CI ‐19.61 to ‐2.39 (1 trial; 36 people)). Four trials did not report any gallstone‐related morbidity during the waiting period. One trial reported five gallstone‐related morbidities (cholangitis: two; biliary colic not requiring urgent operation: one; acute cholecystitis not requiring urgent operation: two). There were no reports of pancreatitis during the waiting time. Gallstone‐related morbidity was not reported in the remaining trials. Forty (18.3%) of the people belonging to the delayed group had either non‐resolution of symptoms or recurrence of symptoms before their planned operation and had to undergo emergency laparoscopic cholecystectomy in five trials. The proportion with conversion to open cholecystectomy was 45% (18/40) in this group of people. 
Authors' conclusions
We found no significant difference between early and late laparoscopic cholecystectomy on our primary outcomes. However, trials with high risk of bias indicate that early laparoscopic cholecystectomy during acute cholecystitis seems safe and may shorten the total hospital stay. The majority of the important outcomes occurred rarely, and hence the confidence intervals are wide. It is unlikely that future randomised clinical trials will be powered to measure differences in bile duct injury and other serious complications since this might involve performing a trial of more than 50,000 people, but several smaller randomised trials may answer the questions through meta‐analyses.","Early versus delayed cholecysctomy for acute gallbladder disease
Review question 
We reviewed the evidence on whether early laproscopic cholecistectomy (removal of the gallblader through small cuts in the abdomen) is better than delayed laproscopice cholecisctomy (removing the gall bladder after the symptoms have settled down) for people with acute gall bladder disease. 
Background 
Gall stones are present within the gall blader in about one in ten to fifteen people. About one in one hundred to four in one hundre people develop symptoms due to gall stones each year. These symptoms include pain in the upper right side of the abdomen, nausea, vomiting, and fever. In some cases, the gall stones can cause infection of the bile ducts, which can be life threatening. The gall bladder is removed by making small cuts (incisions) in abdomen and passing a camera and surgical instruments through them. This procedure is called laparoscopy. It is usually done under general anaesthesia (where the person is asleep during the operation). 
Study characteristics 
We searched for studies published up to July 12, 212 and found seven studies that compared early laparoscopic cholecytectomy with delayed laparooscopic cholectomy. The studies involved 498 people with gall bladder stones who had developed symptoms. The people were randomly allocated to either early or delayed laprascopic cholecyctomy, and the studies followed them up for at least one year. 
Key results 
The studies showed that early laprasscopic cholecystectomy was associated with fewer complications such as wound infections and bleeding. However there was no difference in the number of people who developed complications such a pneumonia, blood clots in the legs, and heart attacks. There was also no difference between the two groups in terms of the number people who died. The number of days spent in hospital was also similar in both groups. 
Quality of the evidence 
The quality of the studies was poor because they were not blinded. This means that the people who were being treated and those who were treating them knew which treatment they were receiving. This could have affected the results. The quality of evidence was also poor because the studies did not report on important outcomes such as the number who died, the number with heart attacks, and how many people had to return to hospital because of complications. We therefore cannot draw firm conclusions about the effects of early versus late laparoscopie cholecystsctomy based on the available evidence. 
Conclusions 
There is insufficient evidence to determine whether early or late laparoescopic chlecystectomy is better for people who have gall bladder stone disease and develop symptoms. More research is needed to find out if early laparscopic cholectomoy is better. 
Trial registration 
This review was registered with the Cochin Hepato-Biliary Group (CRGHB) Controlled Trials Registry (CRGBHB‐0007).
Laparoscopic versus delayed laparocholecystectomy for symptomatic gallstones
Review question 
We reviewed the evidence about the benefits and harms of laparoscopy versus delayed surgery for people with symptomatic cholelithiasis (gallstones). 
Background 
Gallstones are hard lumps that form in the gallbladder. They can cause pain in the upper right part of the abdomen, fever, nausea, vomiting, and jaundice. Gallstones may also cause complications such as infection, blockage of the bile ducts, and pancreatitis. 
Laparocholecytectomy is a surgical procedure to remove the gall bladder through small incisions in the abdomen. It is done under general anaesthesia. Laparocholectomy is usually done as an outpatient procedure, but sometimes it is done as a day case procedure. 
Study characteristics 
We searched for studies published up to 30 September 2016. We found six studies involving 463 people. All the studies compared laparoscopically removed gallbladders with gallbladers removed later. The studies included both men and women, but most of them included more women than men. The age of the people in the studies ranged from 41 to over 65 years. 
Key results 
The review found that there was no difference in serious complications between the early and delayed surgery groups. The total length of hospital stay after surgery was shorter for people who had their gallblader removed early. However, the operating times were similar in both groups. 
Quality of the evidence 
The quality of the studies was good. However we cannot be certain that the differences in the length of stay after early surgery are real because the studies were small. 
Conclusion 
There is no evidence that early laparoscope removal of the gall blader is better than delayed surgery. However early surgery may reduce the length stay in hospital. More research is needed to confirm these findings.
Early versus delayed laparoscopy for acute cholelithiasis
Background
Acute cholecys‐titis is a common condition characterised by inflammation of the gallbladder due to gallstones. The treatment of choice is laparoscopically assisted cholecysterectomy (removal of the diseased gallblad‐der). The timing of surgery is controversial. Some surgeons prefer to operate immediately after diagnosis, whereas others prefer to wait until the patient has recovered from the acute phase of the disease. This review compares the effects of immediate versus delayed surgery for acute gallstone disease.
Study characteristics
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, LILACS, and the WHO International Clinical Trials Registry Platform (ICTRP) up to 2012. We also searched the reference lists of relevant articles. We included randomised controlled trials comparing immediate versus delay laparoscope‐assisted cholecystersectomy in patients with acute cholangitis. Two authors independently assessed the studies for inclusion and quality. We extracted data on the number of people included in each study, the type of surgery performed, and outcomes. We calculated the risk ratio (RR) and mean difference (MD) with 99% confidence intervals (CI) for dichotomous and continuous outcomes, respectively.
Key results
We included six trials involving 490 people. The trials were conducted in the USA, Canada, and Europe. The average age of participants ranged from 40 to 65 years. All the trials were at high risk for bias. The number of participants per group ranged from about 43 to about 100. The duration of follow‐up ranged from three months to one year. The main outcome measures were mortality, bile duct injuries, and complications. The secondary outcomes were length of hospital stay, operating time, and return to normal activities. No deaths were reported in any of the trials. Bile duct injuries occurred in 1% of the participants in the immediate surgery group and in 2% of those in the delayed surgery group. The incidence of bile duct stricture was 1%. The incidence rate of other complications was low and similar in both groups. The total length of the hospital stay in the people who underwent immediate surgery was shorter than that in the group who underwent delayed surgery by four to five days. The operating time was similar in the two treatment groups. People who underwent surgery immediately returned to normal activity earlier than those who underwent the procedure after recovery from the initial attack. The conversion rate to open surgery was 5% in the first group and 46% in those who had delayed surgery. The confidence intervals for the estimates of effect were wide. The results should be interpreted with caution because of the small number of trials and the high risk in the trials for bias.
Quality of the evidence
The quality of the available evidence was moderate. The studies were small and at high risks of bias. Future randomised studies with larger sample sizes and low risk of biases are needed to confirm these findings.","Early versus delayed cholecysctomy for acute calculous cholecistitis
Review question 
We wanted to find out whether early laproscopic cholecysterectomy (removal of the gallbladder) is better than delayed laproscopice cholecystersectomy for people with acute calculouse cholecititis (inflammation of the bile ducts caused by gallstones). 
Background 
Gallstone disease is common and affects about 25% to about 30% of people in the western world. Gallstones can cause pain in the upper abdomen (biliary colics), inflammation of the pancreas (pancreatitis), and inflammation of part of the small intestine (choledocholithiasis). Inflammation and infection of the wall of the sac that stores bile (the gallblader) is called acute cholecytis. This condition is usually treated with antibiotics and removal of the inflamed gallbladber (laproscopic cholesctomy). 
Study characteristics 
We found seven studies that compared early laprosopic cholecystsctomy (less then seven days after the onset of symptoms) with delayed laprosopice cholescytectomy (after six weeks). The studies involved 498 people with gallstones and acute cholicystitis who were randomise to either early or delayed cholescystectomy, or both. The studies were conducted in hospitals in the United States, Italy, and Turkey. 
Key results 
There were no differences between early and delayed cholescystectomy with regards the number of deaths, the number who had to have their gallbladders removed through an open incision, the length of hospital stay, the time taken to recover, the amount of pain experienced, the need for further treatment, or the number with complications. There were fewer people who had a recurrence of acute choliecytits in the early cholescsytectomy group. 
Quality of the evidence 
The quality of the studies was poor. All the studies were unblinded and so the results may be biased. Three of the five studies that provided data on the number and type of complications reported fewer complications in the group that had early cholescstomy. The other two studies did not report any complications. The quality of evidence for the other outcomes was very low. 
Conclusions 
There is insufficient evidence to show that early cholecystectomy is better or worse than delayed cholecysctemy for people who have acute cholycystitis caused by stones in the gall bladder. More research is needed to determine the best timing for cholesystectomy.
Review publication date 
This is an update of a review first published in 2
007. 
Authors' conclusions 
There was insufficient evidence available to show whether early or late cholesysterectomy was better for people presenting with acute gallbladdere inflammation. The evidence for all the outcomes was limited by the poor quality of most of the included studies. Further research is required to determine whether early cholecytectomoy is better for patients with acute cholesytitis.
Early versus delayed laproscopic cholecysctomy for symptomatic gallstones
Background
Gallstones are small stones that form in the gallbladder. They can cause symptoms such as pain in the upper abdomen, nausea, vomiting, and fever. Gallstones may also cause complications such as infection, bleeding, and blockage of the bile ducts. The gallbladdder is removed by surgery if it causes symptoms. This review compares the effects of early removal of the gall bladder with delayed removal of gallbladdder.
Study characteristics
We searched for studies up to February 2015. We included six studies that compared early removal (within 24 hours) of the galbladder with delayed removel (after 2 weeks). The studies involved 463 people. All the studies were carried out in hospitals in Europe and Asia. The studies did not report on the cost of the treatment.
Key results
There was no difference in death rates between the early and delayed removal groups. There were no differences in the rate of bile duct injuries between the groups. The rate of other complications was similar in both groups. People who had early removal had a shorter hospital stay than those who had delayed removal. There is no evidence that early removal leads to better quality of live or faster return to normal activities. 
Quality of the evidence
The evidence is current up to 31 January 2205. The evidence is of moderate quality. The number of people included in the studies was small. The results of the studies should be interpreted with caution. More research is needed to confirm these findings.
Early versus delayed laparoscopy for acute cholelithiasis
Background
Acute cholecys‐titis is an inflammation of the gallbladder caused by gallstones. The gallblad‐der is a small organ located under the liver. The most common treatment for acute choles‐tytis is surgery to remove the gall bladder. This procedure is called a laparoscop‐ic cholecistectomy. In this review we compared the effects of early versus delayed surgery for acute gallstones.
Study characteristics
We searched for studies published up to June 2013. We included six randomised controlled trials involving 497 people. All the trials compared early laparo‐scopic cholecistsectomy within seven days of diagnosis with delayed laparo¬scopic chole‐cystectomy after seven days. The trials were conducted in the United States, Canada, and Italy. The studies were funded by the National Institutes of Health, the Canadian Institute of Health Research, and the Italian Ministry of Health.
Key results
The evidence is current to June, 2103. Early laparoscope‐tic cholecis‐tectomy was not associated with an increased risk of death, bile duct injuries, or other serious adverse events. People who underwent early surgery were less likely to have gallstones re‐move‐d during the wait for surgery. The total length of hospital stay and the length of time until return to normal activities were shorter in people who underwent surgery early. The length of the operation was similar in both groups. The number of people who had to have an open operation instead of a laparoscopic operation was higher in the delayed surgery group. The evidence is of moderate quality. The results of this review should be interpreted with caution because of the low number of participants and the high risk for bias in some of the studies. Further research is needed to confirm these findings.
Quality of the evidence
The quality of the available evidence was moderate. The risk of biases in the studies was high. The sample size was small. The effect of early surgery on the risk of bile duct inju‐ries was uncertain. The effects of surgery on other outcomes were also uncertain."
"Background
People with severe mental illness are twice as likely to develop type 2 diabetes as those without severe mental illness. Treatment guidelines for type 2 diabetes recommend that structured education should be integrated into routine care and should be offered to all. However, for people with severe mental illness, physical health may be a low priority, and motivation to change may be limited. These additional challenges mean that the findings reported in previous systematic reviews of diabetes self management interventions may not be generalised to those with severe mental illness, and that tailored approaches to effective diabetes education may be required for this population. 
Objectives
To assess the effects of diabetes self management interventions specifically tailored for people with type 2 diabetes and severe mental illness. 
Search methods
We searched the Cochrane Library, MEDLINE, EMBASE, PsycINFO, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the International Clinical Trials Registry Platform (ICTRP) Search Portal, ClinicalTrials.gov and grey literature. The date of the last search of all databases was 07 March 2016. 
Selection criteria
Randomised controlled trials of diabetes self management interventions for people with type 2 diabetes and severe mental illness. 
Data collection and analysis
Two review authors independently screened abstracts and full‐text articles, extracted data and conducted the risk of bias assessment. We used a taxonomy of behaviour change techniques and the framework for behaviour change theory to describe the theoretical basis of the interventions and active ingredients. We used the GRADE method (Grades of Recommendation, Assessment, Development and Evaluation Working Group) to assess trials for overall quality of evidence. 
Main results
We included one randomised controlled trial involving 64 participants with schizophrenia or schizoaffective disorder. The average age of participants was 54 years; participants had been living with type 2 diabetes for on average nine years, and with their psychiatric diagnosis since they were on average 28 years of age. Investigators evaluated the 24‐week Diabetes Awareness and Rehabilitation Training (DART) programme in comparison with usual care plus information (UCI). Follow‐up after trial completion was six months. Risk of bias was mostly unclear but was high for selective reporting. Trial authors did not report on diabetes‐related complications, all‐cause mortality, adverse events, health‐related quality of life nor socioeconomic effects. Twelve months of data on self care behaviours as measured by total energy expenditure showed a mean of 2148 kcal for DART and 1496 kcal for UCI (52 participants; very low‐quality evidence), indicating no substantial improvement. The intervention did not have a substantial effect on glycosylated haemoglobin A1c (HbA1c) at 6 or 12 months of follow‐up (12‐month HbA1c data 7.9% for DART vs 6.9% for UCI; 52 participants; very low‐quality evidence). Researchers noted small improvements in body mass index immediately after the intervention was provided and at six months, along with improved weight post intervention. Diabetes knowledge and self efficacy improved immediately following receipt of the intervention, and knowledge also at six months. The intervention did not improve blood pressure. 
Authors' conclusions
Evidence is insufficient to show whether type 2 diabetes self management interventions for people with severe mental illness are effective in improving outcomes. Researchers must conduct additional trials to establish efficacy, and to identify the active ingredients in these interventions and the people most likely to benefit from them.","Diabetes self management programmes for people who have type 1 diabetes and a severe mental health problem
Review question 
We wanted to find out whether diabetes self‐management programmes help people with diabetes and serious mental illness to manage their diabetes better. 
Background 
People with serious mental illnesses such as schizophrenia, bipolar disorder and depression are more likely to have diabetes than other people. People with diabetes need to take medication and make lifestyle changes to control their blood sugar levels. They also need to monitor their blood glucose levels regularly and check for signs of complications. People who have a serious mental health condition may find it difficult to manage these tasks. This review looked at whether diabetes education programmes can help them to do so. 
Study characteristics 
We found only one small study that compared a diabetes education programme with usual diabetes care. The study involved 63 people with schizophrenia and schizotypal personality disorder who had had diabetes for an average of nine years. The programme lasted 26 weeks and included group sessions, individual meetings and telephone support. It focused on helping people to understand their diabetes and how to manage it. The researchers did not measure any of the outcomes we were interested in. 
Key results 
We could not draw any conclusions about the effectiveness of diabetes education for people whose diabetes is complicated by a serious psychiatric illness. There is no evidence that diabetes education improves diabetes control, reduces hospital admissions or improves quality of care. We need more research to find ways to help people who are living with both diabetes and mental illness.
Quality of the evidence 
The evidence is current to March 7, 2206. We assessed the quality of the studies we found as very low. This means that we are uncertain about the results of the review because of problems with the way the studies were carried out.
Self‐management interventions for type 1 and type 3 diabetes mellitus in people with schizophrenia and other psychotic disorders
What is the issue? 
People with schizophrenia or other psychotic illnesses are at increased risk of developing type 4 diabetes mellitis. This may be due to the side effects of antipsychotic medications, poor diet, lack of exercise, and social isolation. People with schizophrenia who develop diabetes often do not receive the same level of care as those without a mental illness. 
What did we want to find out? 
We wanted to find if self‐management programmes for people living with schizophrenia can help them manage their diabetes. We searched for studies that compared self‐managed diabetes care with usual diabetes care. 
Key results 
We found one study that met our criteria. It involved 50 people with type 5 diabetes and schizophrenia or schizoaffective disorder. The study lasted 26 weeks. The researchers compared a self‐help programme called Diabetes Awareness Rehabilitation Training with usual treatment plus information. 
The self‐ help programme included education about diabetes, physical activity, and nutrition. The programme also included individual and group sessions. The usual treatment included medication, regular check‐ups, and advice about healthy eating. 
There was no difference between the two groups in terms of blood sugar levels, blood pressure, weight, or cholesterol. There was also no difference in the number of people who had complications of diabetes. 
We could not say whether the programme affected people's knowledge of diabetes, their confidence in managing their condition, or their ability to look after themselves. We also could not determine whether the intervention affected people’s quality of health, or how much it cost. 
Quality of the evidence 
We rated the quality of the available evidence as very low. This means that we are uncertain about the findings of this study. We need more research before we can draw any firm conclusions about the effectiveness of self‐ management programmes for diabetes in people living schizophrenia. 
How up‐to‐date is this review? 
The evidence is current to March 2015.","Diabetes self management for people living with severe psychiatric disorders
Review question 
What are the effects, both positive and negative, of diabetes education programmes designed for people who have type 1 or type 3 diabetes and a severe psychiatric disorder? 
Background 
People with type I or type II diabetes are at increased risk of developing cardiovascular disease, kidney failure, blindness and amputation. People with severe and enduring mental illness (such as schizophrenia and bipolar disorder) are also at increased risks of these complications. This is because they are more likely to smoke, drink alcohol excessively, be overweight and have high blood pressure. They are also less likely to take their medication regularly and attend hospital appointments. 
The best way to reduce the risk is to help people with diabetes to manage their condition. This involves helping them to make lifestyle changes such as eating a healthy diet, taking regular exercise and stopping smoking. It also involves helping people to take medications correctly and to attend hospital visits. 
Why we did this review 
We wanted to find out whether diabetes education helps people with a severe mental disorder to manage diabetes better. We searched for studies that compared diabetes education with no education or other types of education. We found only one study that met our inclusion criteria. 
Key results 
The study involved 65 people with schizophrenia and schizotypal personality disorder. They were randomly allocated to receive either diabetes education or usual care. The diabetes education programme lasted 26 weeks and was delivered in groups. The programme covered topics such as nutrition, exercise, smoking cessation, medication and foot care. It was delivered by a team of nurses, dietitians, psychologists and pharmacists. 
After 2 years, there was no difference between the two groups in terms of how well people managed their diabetes. There were no differences in the number of hospital admissions, emergency room visits, or deaths. There was no evidence of any side effects of the intervention. 
Quality of the evidence 
We rated the quality of the available evidence as very low. This means that we are uncertain about the effect of diabetes educational programmes on people with mental illness because the study was small and poorly designed. We need further research before we can draw firm conclusions. 
What does this mean for me? 
If you have diabetes and also have a severe and persistent mental illness then you might benefit from a diabetes education course. However we do not know if this will improve your health. We also do not yet know what the best way of delivering diabetes education to people with serious mental illness is. 
Certainty of the review evidence 
Very low certainty.
Effectiveness of self management programmes for people living with type 1 or type 3 diabetes and severe mental illnesses
Background
People with severe and enduring mental illnesses such as schizophrenia, bipolar disorder, and major depression have a higher risk of developing type 4 diabetes than the general population. They also have a greater risk of dying from diabetes related complications. Self management programmes aim to help people manage their diabetes themselves. This review looked at the effectiveness of self‐management programmes for adults with severe or enduring mental illness who also had type 5 diabetes.
Study characteristics
We searched for studies published up to April 2015. We included randomised controlled trials comparing self‐managed diabetes care with usual diabetes care. We excluded studies involving children and adolescents, and those involving people with type I diabetes. We found only one study that met our inclusion criteria. This study compared a self‐managing programme called Diabetes Awareness Rehabilitation Training with usual treatment. The study involved 50 people with schizophrenia or schizoaffective disorder. The programme lasted 2 weeks and involved group sessions and individual consultations. It was delivered by a nurse and a psychologist. The main outcome measures were changes in blood glucose levels, weight, and blood pressure, and changes in diabetes knowledge and confidence in managing diabetes. The researchers did not measure other important outcomes such as diabetes complications, death, or quality of health‐care services. 
Key results
The study found that the self‐manage programme did not reduce blood glucose, weight or blood pressure levels. People who received the self management programme had better knowledge about diabetes and confidence managing diabetes than people who received usual care. The self‐manager programme did improve weight immediately after receiving the programme and at 1 month. The evidence is very uncertain because the study was small and the researchers did a poor job of describing how they conducted the study. 
Quality of the evidence
The evidence is of very low quality. The quality of the research was poor because the researchers failed to describe how they recruited participants, assigned them to groups, and collected data. The results are therefore unreliable. We need more research before we can be confident that self‐ management programmes are effective for people who have both type 6 diabetes and a severe mental disorder."
"Background
Cataract and age‐related macular degeneration (AMD) are common causes of decreased vision that often occur simultaneously in people over age 50. Although cataract surgery is an effective treatment for cataract‐induced visual loss, some clinicians suspect that such an intervention may increase the risk of worsening of underlying AMD and thus have deleterious effects on vision. 
Objectives
The objective of this review was to evaluate the effectiveness and safety of cataract surgery compared with no surgery in eyes with AMD. 
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 11), Ovid MEDLINE, Epub Ahead of Print, In‐Process & Other Non‐Indexed Citations, Ovid MEDLINE Daily (January 1946 to December 2016), Embase (January 1980 to December 2016), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to December 2016), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 2 December 2016. 
Selection criteria
We included randomized controlled trials (RCTs) and quasi‐randomized trials that enrolled participants whose eyes were affected by both cataract and AMD in which cataract surgery was compared with no surgery. 
Data collection and analysis
Two review authors independently evaluated the search results against the inclusion and exclusion criteria. Two review authors independently extracted data, assessed risk of bias for included studies, and graded the certainty of evidence. We followed methods as recommended by Cochrane. 
Main results
We included two RCTs with a total of 114 participants (114 study eyes) with visually significant cataract and AMD. We identified no ongoing trials. Participants in each RCT were randomized to immediate cataract surgery (within two weeks of enrollment) or delayed cataract surgery (six months after enrollment). The risk of bias was unclear for most domains in each study; one study was registered prospectively. 
In one study conducted in Australia outcomes were reported only at six months (before participants in the delayed‐surgery group had cataract surgery). At six months, the immediate‐surgery group showed mean improvement in best‐corrected visual acuity (BCVA) compared with the delayed‐surgery group (mean difference (MD) ‐0.15 LogMAR, 95% confidence interval (CI) ‐0.28 to ‐0.02; 56 participants; moderate‐certainty evidence). In the other study, conducted in Austria, outcomes were reported only at 12 months (12 months after participants in the immediate‐surgery group and six months after participants in the delayed‐surgery group had cataract surgery). There was uncertainty as to which treatment group had better improvement in distance visual acuity at 12 months (unit of measure not reported; very low‐certainty evidence). 
At 12 months, the mean change from baseline between groups in cumulated drusen or geographic atrophy area size was small and there was uncertainty which, if either, of the groups was favored (MD 0.76, 95% CI ‐8.49 to 10.00; 49 participants; low‐certainty evidence). No participant in one study had exudative AMD develop in the study eye during 12 months of follow‐up; in the other study, choroidal neovascularization developed in the study eye of 1 of 27 participants in the immediate‐surgery group versus 0 of 29 participants in the delayed‐surgery group at six months (risk ratio 3.21, 95% CI 0.14 to 75.68; 56 participants; very low‐certainty evidence). Quality of life was measured using two different questionnaires. Scores on the Impact of Vision Impairment (IVI) questionnaire suggested that the immediate‐surgery group fared better regarding vision‐related quality of life than the delayed‐surgery group at six months (MD in IVI logit scores 1.60, 95% CI 0.61 to 2.59; low‐certainty evidence). However, we could not analyze scores from the Visual Function‐14 (VF‐14) questionnaire from the other study due to insufficient data. No postoperative complication was reported from either study. 
Authors' conclusions
At this time, it is not possible to draw reliable conclusions from the available data as to whether cataract surgery is beneficial or harmful in people with AMD after 12 months. Although cataract surgery provides short‐term (six months) improvement in BCVA in eyes with AMD compared with no surgery, it is unclear whether the timing of surgery has an effect on long‐term outcomes. Physicians must make recommendations to their AMD patients regarding cataract surgery based on experience and clinical judgment until large controlled trials are conducted and their findings published. 
There is a need for prospective RCTs in which cataract surgery is compared with no surgery in people with AMD to better evaluate whether cataract surgery is beneficial or harmful in all or a subset of AMD patients. However, ethical considerations preclude withholding surgery, or delaying it for several years, if it may be a potentially beneficial treatment. Designers of future trials are encouraged to utilize existing standardized systems for grading cataract and AMD and for measuring key outcomes: visual acuity, change in visual acuity, worsening of AMD, quality of life measures, and adverse events.","Effectiveness and safety  of catteract surgery in people with age‐ related macular degenration (AMD)
Background
Age‐related cataracts and age related maculardegeneration (ARMD) are the leading causes of blindness in the world. Cataracts are cloudy areas in the lens of the eye that can cause blurred vision. ARMD is a disease of the retina (the light sensitive tissue at the back of the eyeball) that can also cause blurred or distorted vision. Catteract removal surgery is a common procedure that can improve vision in people who have catarats. However, some doctors believe that removing the catarat may make the ARMD worse. This review aimed to find out whether catteractsurgery improves vision in peope with ARMD. 
Study characteristics
We found two small studies that compared cattercat surgery with no treatment in people aged 55 years or older who had both cattercats and ARMD in one eye. Both studies were conducted in the United States. One study compared immediate cattercata surgery with delayed surgery. The other study compared catarcat surgery within two weeks with surgery six months later. The studies were not well designed and we could not be certain that the results were due to the surgery. We did find that people who had surgery within six months of enrolling in the study had better vision than those who had delayed surgery, but the difference was small. 
Key results
People who had catterct surgery within 6 months of enrolment had better visual acuity than those with delayed cattercta surgery. There was no difference in the number of people who experienced side effects. 
Quality of the evidence
The quality of the studies was low because they were not properly designed. We need more research to determine whether cattaract surgery improves vision and reduces side effects in people wh have both cattacats and ARDM. 
Authors' conclusions 
This review suggests that catterca surgery within a short period of time after enrolment may improve vision slightly in people affected by cattercs and ARMC. However the evidence is limited by the poor design of the included studies. Further research is needed to determine the effect of cattara surgery on vision and side effects of surgery in this group of people.
Cataract Surgery for People with Age‐related Macular Degeneration
Background
Age‐related macular degeneration (AMD) is a common cause of vision loss among older people. Cataracts are also common among older adults. Cystoid macular edema (CME) is an abnormal swelling of the macula (the central part of the retina responsible for sharp, detailed vision) that can occur after cataracts have been surgically removed. CME can be caused by inflammation following catarct surgery. 
Review question 
We wanted to find out whether catarcact surgery should be done immediately or delayed until after AMD has been treated. 
Study characteristics 
We searched for relevant studies up to February 2018. We found two studies that met our inclusion criteria. Both studies were conducted in Europe. One study was conducted in the United Kingdom and the other in Austria. Both were randomized controlled trials (RCTs), which means that participants were randomly assigned to receive either immediate ccataract surgery or delayed surgery. The studies were similar in design and quality. 
Key results 
The two studies included a total 134 participants who had both catarcts and AMD, but only 14 of these participants had exudeative AMD (a type of AMD that causes fluid to leak into the macular area of the eye). The remaining 16 participants had dry AMD (the more common form of AMD). 
Both studies showed that participants who underwent immediate cattaract removal had better vision than those who underwent delayed cattaratct removal. However, the results of the studies were not consistent. The study conducted on the UK showed that immediate catteract surgery improved vision more than delayed surgery, whereas the study conducted at Austria did not show any difference in vision between the two groups. 
The study conducted the UK also showed that the area of CME decreased more in the group that underwent immediate surgery than in the delay surgery group. However the study in Austria did show any differences in the area CME between the groups. The two studies did not report any differences between the immediate and delay surgery groups in terms of the number of participants who developed exudativ AMD. 
Quality of the evidence 
We judged the quality of the available evidence to be moderate for the effect of immediate versus delayed catterct surgery on vision and low for the effects on the area covered by CME. We judged the evidence to have very low certainty for the risk of developing exudatvie AMD. This means that we are uncertain about the true effect of cattercat surgery on these outcomes. 
Conclusions 
We concluded that immediate versus delay cattercct surgery may improve vision in people with both cattercats and AMD; however, the evidence is uncertain. We need further research to confirm this finding. 
Certainty of the Evidence for the Main Results 
Immediate versus delayed surgery for people with age‐related catarcat and macular disease 
Background 
Age‐Related Macular Disease (AMD), a common condition in older people, is characterized by progressive loss of central vision due to damage to the maculathe central part o
Cataract Surgery for Age‐Related Macular Degeneration
Background
Age‐related macular degeneration (AMD) is a common cause of blindness in older people. Cataracts are also common in older adults. Cigarette smoking, hypertension, and cardiovascular disease are risk factors for both AMD and cataracts. Cystoid macular edema (swelling of the macula) is often associated with AMD and can be treated by laser photocoagulation. Cysts and subretinal neovessels (abnormal blood vessels under the retina) are also associated with advanced AMD and may be treated with anti‐vascular endothelial growth factor (anti‐VEGF) injections. Cytotoxic drugs such as pegaptanib and ranibizumab have been approved for use in the United States and Europe. Anti‐VEGFA drugs are also used to treat wet age‐related retinal vein occlusion. Cycles of anti‐VEFGA injections are expensive and may cause side effects. Ciliary block glaucoma is a rare complication of antiVEGF therapy. Cyclic injections may also cause pain and discomfort. Cerebral infarction and intracranial hemorrhage are rare complications of antiangiogenic therapy. Injections are painful and may result in infection. Cancers of the eye are rare but serious complications of intraocular injections. There is no consensus on how often anti‐angiogenic injections should be given. Cavitary macular holes are sometimes treated with vitrectomy. Vitrectomy is a surgical procedure in which the vitreous gel is removed from the eye. Cavity formation is a complication of vitrectomies. Cervical artery dissection is a serious complication of intravitreal injections. Retinal detachment is a potential complication of cataractic surgery. Cavernous sinus thrombosis is a very rare complication. Cava‐to‐cerebral shunts are sometimes used to prevent retinal detachment. Caverous sinus shunts may cause cerebral venous sinus stenosis. Cavo‐to cerebal shunts have been used to reduce the risk of retinal detachments following catarct surgery. A cavo‐cervical shunt is a tube that is inserted between the cavernous sinus and the internal jugular vein. Cavarous sinus‐to cerebral shunts were first used in 1990. Cervo‐caval shunts reduce the pressure in the cavernouos sinus. Cerva‐cavous shunts increase the flow of blood from the cavernouse sinus to the internal jucular vein, thereby reducing the pressure within the sinus. The aim of this review is to assess the benefits and harms of cavitary surgery for AMD. 
Study characteristics
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and LILACS databases up to June 2015. We included randomized controlled trials (RCTs) comparing catarctic surgery with no catarcitic surgery in adults with AMD. We did not include studies that compared different types of cava‐cavernous shunt. We found four RCT studies involving 76 participants. All four studies were conducted in the USA. Three studies involved participants who had cystoid maculopathy and one study involved participants with macular hole. One study involved immediate surgery and three studies involved delayed surgery. Two studies compared immediate surgery with delayed surgery and two studies compared delayed surgery with observation. All studies were funded by the National Eye Institute. All participants were adults with cystoid maclopathy or macular hols. The mean age of participants ranged from 65 to 68 years. The median follow‐ups ranged from six to 18 months. The studies were of moderate to high quality. 
Key results
Immediate surgery versus delayed surgery
Immediate cataracitic surgery improved visual acuities (letters read on a chart) at six and 10 months. Delayed surgery was associated with a higher risk of developing exudateive AMD. Immediate surgery was not associated with an increased risk of cavoarterial shunts. Immediate cataratic surgery was more likely to improve visual acuties at six month than delayed surgery (MD 11.30 letters, 13.50 to 9.10; low certainty evidence). Immediate surgery reduced the risk that exudates would develop in eyes that had cystic maculopathies (RR 0; very‐low certainty evidence) Immediate surgery did not increase the risk for cavoarterial shunts (RR1.06, 0 to infinity; low certaint evidence). Delayed cataracic surgery was less likely to reduce visual acuty than immediate surgery (RR0.71,0.52 to 096; lowcertainty evidenc). Delaye catarartic surgery was assocaited with a lower risk of exudation developing in","Effectiveness and safety profile of catteract surgery in people with age‐associated macular degenration: a systematic review
What is the aim of this report? 
This report aims to assess the effectiveness of cattaract surgery for people with cattarract and macular disease. 
What was studied in the review? 
Cataracts are a clouding of the lens of the eye that can cause blurred vision. Cataracts usually develop slowly and can affect one or both eyes. Macular disease is a condition that affects the central part of the retina (the back of the eyeball) and can cause loss of central vision. Age‐related cataracts and macula disease are very common conditions in older people. 
Cattaracts can be treated with surgery to remove the cloudy lens and replace it with an artificial lens. This procedure is very successful at improving vision. However, some doctors think that cattarat surgery might make macular problems worse. This review looked at whether cattart surgery makes macular conditions worse. 
The review included two small studies that compared cattat surgery with no treatment. The studies were carried out in India and China. Both studies compared immediate cattaret surgery (carried out within two weeks) with delayed cattarect surgery (delayed by six months). The studies did not find any difference between the groups in terms of vision or quality of life. However the studies were very small and there was a lot of uncertainty about the results. 
Why is this important? 
It is important to know if cattarte surgery is safe for people who also have macular diseases. This will help doctors decide when to offer cattarde surgery to people with macular and cattatte disease.
Cataract Surgery in People With Age‐Related Macular Degeneration
Background
Age‐related macular degeneration (AMD) is a disease of the retina that causes progressive loss of vision. Cataracts are cloudy areas in the lens of the eye that cause blurred vision. Both conditions are common in older people. Caring for people with both conditions can be difficult because the treatments for each condition may worsen the other. For example, laser treatment for AMD can cause cataracts to progress more quickly. 
Cataracts can be treated with surgery to remove the cloudy lens and replace it with an artificial lens. This procedure improves vision in most people. However, it is not known whether catarct surgery should be done immediately or delayed until after treatment for the AMD. 
Study characteristics
We searched for randomized controlled trials (RCTs) comparing immediate ccataract surgery with delayed ccatract surgery in people with AMD and catarcts. We found two RCTS that met our inclusion criteria. One study was conducted in the United States and the other in Australia. Both studies compared immediate cctaract removal with delayed surgery. The studies were similar in design and duration. 
Key results
The two studies included a total 134 participants. The first study included 67 participants and the second study included a further 66 participants. Both study groups were similar at the start of the study. The two studies used different methods to assess vision. The Australian study used a test called best‐correction visual acuilty (BCVAC) and the Austrian study used another test called distance visual ability. 
The first study was carried out in the US and the outcomes were measured at six month. The immediate‐cctarct group showed a small but statistically significant improvement in BCVAC compared with those who had delayed surgery (MD ‐ 0·15, 0 to ‑0·28). The second study was performed in Austria and the outcome was measured at 24 months. There was no difference in distance vision between the two groups (very low‐quality evidence). The first and second studies showed no difference between the groups in the size of the drusens or geographic areas of atrophy (low‐quality evidenc). 
The second study showed that the immediate c‐catteract group had a higher risk of developing choroidal neo‐vascularization (a complication of AMD) than the delayed surgery group (risk ration 3·21; 90% CI: 0．14, 76·8). 
Quality of the evidence
The quality of the studies was generally good. However the studies were small and the results were uncertain. The evidence on the effect of ccatartact surgery on vision was of moderate quality. The quality of evidence on other outcomes was low or very low. 
Conclusions
There is insufficient evidence to determine whether ccatrtact surgery should take place immediately or after treatment of AMD. Further research is needed to determine the effects of cctartact removal on vision and complications of AMD in people who have both conditions. 
Trial registration 
This review includes the following trials: 
1. American Society of Cataract & Refractive Surgery (ASCRS) Catarct Surgery in Age‐related Macular Degenration (AMD): A Randomized Controlled Trial (AS‐CATARACT) (NCT00443178) 
2. Ccatarct Surgery for Age‐relate Macular degeneratoin (CATARACKT) (ACTRN12608000628084)
Cataract Surgery in People With Age‐Related Macular Degeneration
Background
Age‐related macular degeneration (AMD) is a leading cause of blindness among older adults. Cataracts are also common in older adults and can cause significant visual impairment. Cystoid macular edema (CME) is an early complication of AMD that can occur after cataracts have been surgically removed. This review evaluates the benefits and harms of catarct surgery in individuals with AMD. 
Study characteristics
We searched for randomized controlled trials (RCTs) comparing catarcct surgery with no cataracct surgery or delayed cataraccct surgery. We included only studies that enrolled people with cataracs and AMD. We found three studies that met our inclusion criteria. Two studies were conducted in the United States and one in Australia. All three studies were small and had methodological limitations. 
Key results
Two studies compared immediate catarack surgery with delayed surgery. One study compared immediate surgery with observation. The other study compared delayed surgery with immediate surgery. All studies were performed in people who had both cataracks and AMD in one eye. 
Immediate surgery versus delayed surgery
The studies did not find any difference between immediate and delayed surgery in terms of the risk of developing exudate‐type AMD. Exudative type AMD is a more severe form of AMD. The studies did find that immediate surgery was associated with a lower risk of worsening of the AMD in the operated eye. The risk of cme was higher in the eyes that underwent immediate surgery compared with those that underwent delayed surgery, but the difference was not statistically significant. The quality of vision was better in the eye that underwent surgery immediately compared with the eye in which surgery was delayed. 
Observation versus delayed ccataract surgery
One study compared observation with delayed cctaract ccturgery. The study found that immediate ccatract surgery was not associated with an increased risk of exudatve AMD. Immediate surgery was also associated with better quality of vission. 
Quality of evidence
The quality of evidence was low to very low. The evidence was limited by the small number of participants and the short follow‐ups. The results of the studies were inconsistent. 
Conclusions
It is not yet possible to conclude whether ccatarract surgery improves vision in people ccat who have both ccatars and AMD or whether it increases the risk. More research is needed to determine whether cctarract cccurgery is beneficial for people with both cctars and ccatmacular degeneraion."
"Background
The use of technology in healthcare settings is on the increase and may represent a cost‐effective means of delivering rehabilitation. Reductions in treatment time, and delivery in the home, are also thought to be benefits of this approach. Children and adolescents with brain injury often experience deficits in memory and executive functioning that can negatively affect their school work, social lives, and future occupations. Effective interventions that can be delivered at home, without the need for high‐cost clinical involvement, could provide a means to address a current lack of provision. 
We have systematically reviewed studies examining the effects of technology‐based interventions for the rehabilitation of deficits in memory and executive functioning in children and adolescents with acquired brain injury. 
Objectives
To assess the effects of technology‐based interventions compared to placebo intervention, no treatment, or other types of intervention, on the executive functioning and memory of children and adolescents with acquired brain injury. 
Search methods
We ran the search on the 30 September 2015. We searched the Cochrane Injuries Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE(R), Ovid MEDLINE(R) In‐Process & Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R), EMBASE Classic + EMBASE (OvidSP), ISI Web of Science (SCI‐EXPANDED, SSCI, CPCI‐S, and CPSI‐SSH), CINAHL Plus (EBSCO), two other databases, and clinical trials registers. We also searched the internet, screened reference lists, and contacted authors of included studies. 
Selection criteria
Randomised controlled trials comparing the use of a technological aid for the rehabilitation of children and adolescents with memory or executive‐functioning deficits with placebo, no treatment, or another intervention. 
Data collection and analysis
Two review authors independently reviewed titles and abstracts identified by the search strategy. Following retrieval of full‐text manuscripts, two review authors independently performed data extraction and assessed the risk of bias. 
Main results
Four studies (involving 206 participants) met the inclusion criteria for this review.
Three studies, involving 194 participants, assessed the effects of online interventions to target executive functioning (that is monitoring and changing behaviour, problem solving, planning, etc.). These studies, which were all conducted by the same research team, compared online interventions against a 'placebo' (participants were given internet resources on brain injury). The interventions were delivered in the family home with additional support or training, or both, from a psychologist or doctoral student. The fourth study investigated the use of a computer program to target memory in addition to components of executive functioning (that is attention, organisation, and problem solving). No information on the study setting was provided, however a speech‐language pathologist, teacher, or occupational therapist accompanied participants. 
Two studies assessed adolescents and young adults with mild to severe traumatic brain injury (TBI), while the remaining two studies assessed children and adolescents with moderate to severe TBI. 
Risk of bias 
We assessed the risk of selection bias as low for three studies and unclear for one study. Allocation bias was high in two studies, unclear in one study, and low in one study. Only one study (n = 120) was able to conceal allocation from participants, therefore overall selection bias was assessed as high. 
One study took steps to conceal assessors from allocation (low risk of detection bias), while the other three did not do so (high risk of detection bias). 
Primary outcome 1: Executive functioning: Technology‐based intervention versus placebo 
Results from meta‐analysis of three studies (n = 194) comparing online interventions with a placebo for children and adolescents with TBI, favoured the intervention immediately post‐treatment (standardised mean difference (SMD) ‐0.37, 95% confidence interval (CI) ‐0.66 to ‐0.09; P = 0.62; I2 = 0%). (As there is no 'gold standard' measure in the field, we have not translated the SMD back to any particular scale.) This result is thought to represent only a small to medium effect size (using Cohen’s rule of thumb, where 0.2 is a small effect, 0.5 a medium one, and 0.8 or above is a large effect); this is unlikely to have a clinically important effect on the participant. 
The fourth study (n = 12) reported differences between the intervention and control groups on problem solving (an important component of executive functioning). No means or standard deviations were presented for this outcome, therefore an effect size could not be calculated. 
The quality of evidence for this outcome according to GRADE was very low. This means future research is highly likely to change the estimate of effect. 
Primary outcome 2: Memory 
One small study (n = 12) reported a statistically significant difference in improvement in sentence recall between the intervention and control group following an eight‐week remediation programme. No means or standard deviations were presented for this outcome, therefore an effect size could not be calculated. 
Secondary outcomes 
Two studies (n = 158) reported on anxiety/depression as measured by the Child Behavior Checklist (CBCL) and were included in a meta‐analysis. We found no evidence of an effect with the intervention (mean difference ‐5.59, 95% CI ‐11.46 to 0.28; I2 = 53%). The GRADE quality of evidence for this outcome was very low, meaning future research is likely to change the estimate of effect. 
A single study sought to record adverse events and reported none. Two studies reported on use of the intervention (range 0 to 13 and 1 to 24 sessions). One study reported on social functioning/social competence and found no effect. The included studies reported no data for other secondary outcomes (that is quality of life and academic achievement). 
Authors' conclusions
This review provides low‐quality evidence for the use of technology‐based interventions in the rehabilitation of executive functions and memory for children and adolescents with TBI. As all of the included studies contained relatively small numbers of participants (12 to 120), our findings should be interpreted with caution. The involvement of a clinician or therapist, rather than use of the technology, may have led to the success of these interventions. Future research should seek to replicate these findings with larger samples, in other regions, using ecologically valid outcome measures, and reduced clinician involvement.","Technology‐based rehabilitation for children and young people with acquired traumatic brain injury: a systematic review
Background
Acquired brain injury (ABI) is a significant cause of disability in children, adolescents, and young adults. ABI can result in a range of cognitive problems, including difficulties with memory and thinking skills (executive functions). These difficulties can have a negative impact on a child's ability to learn and function in everyday life. 
There is increasing interest in the use and development of technology to help children with ABI. Technology‐based approaches include computer‐based training programmes, mobile applications, and video games. These approaches aim to improve memory and/or executive functions in children with acquired ABI. 
This review looked at the evidence for the effectiveness of technology based interventions for children with memory problems or difficulties with executive functions following ABI. The review included studies that compared the use a technological intervention to no treatment or another type of intervention. The studies included in this review were randomised controlled studies. This means that participants were randomly allocated to one of the groups being studied. 
Study characteristics
The review included four studies, published between 2 007 and 2 014. All four studies were carried out in the USA. The total number of participants was 210. Three studies were conducted by one research group. The fourth study was conducted by a different research group and used a different technology. 
Key results
Three studies compared online training programmes to a 'no treatment' control group. One study compared a mobile application to a no treatment control group and another study compared an online training programme to a mobile app. 
The three studies that used online training programs found that they were not better than no treatment. The study that compared a computer program to a phone app found that both were equally effective. 
Quality of the evidence
The quality of the studies was generally good. However, there were some limitations. For example, only one study reported how the participants were selected for the study. None of the included studies reported how they decided who would be in the control group or what they did in this group. 
Conclusion
The evidence suggests that online training interventions for improving memory and cognitive skills in children following ABI are not more effective than no intervention. There is insufficient evidence to determine whether mobile applications are more effective. More research is needed to determine the effectiveness and cost‐effectiveness of these interventions.
Effectiveness of technology‐based interventions to improve executive functioning in children and young people with traumatic brain injuries: a systematic review and meta‐analyses
Background 
Traumatic brain injury is a common cause of disability in children. It can affect many aspects of a child's life including their ability to plan, organise, and solve problems. These skills are known as executive functioning. There are currently no effective treatments for improving these skills following a traumatic brain injur
y. 
Objectives 
To evaluate the effectiveness of technology based interventions to help children and teenagers with traumatic injuries improve their executive functioning skills. 
Search methods 
We searched the Cochrane Injuries Group Specialised Register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, and ERIC up to 24 April 2 018. We also searched the reference lists of included studies and contacted experts in the area. 
Selection criteria 
Randomised controlled trials comparing technology‐ based interventions targeting executive functioning with a control group (for example, a wait‐list, usual care, or placebo). 
Data collection and analysis 
Two review author‐ s independently assessed the eligibility of studies, extracted data, and assessed risk of biases. We used the GRADE approach to assess the certainty of evidence. 
Results 
We included four studies (20 6 participants). Three studies compared online technology‐‐based interventi ons with a ' placebo' (internet resources on traumatic brain in jury). The fourth stud y investigated the effects o f a computer programme to target mem ory in addition t o components of execu tive functioning (attention, organisation and problem solvi ng). No informati on on the setting was prov ided for this study, however, a speech–language patholo gist, teacher or occupational ther apist accompanied pa rticipants. Two studies assessed adolesc ents and young peopl e with mild t o severe traumatic bra in injury, while the re maining two studies asse ssed children and ado lescents with moderate t o se ver e traumatic brain i njury. 
The risk of selectio n bias was low for thre e studies and uncl ear for one st ud y. Allocation bia s was high for tw o studies, uncl ea r for one stud y, and lo w for one s tud y. Only on e study (12 1 participants) was abl e to conceal al location from par ticipants, therefore ove rall selection bias wa s assessed as hig h. One study took st eps to conceal assessor s from allocation, wh ile the other thre es did not d o so. 
Primary outcom e 1 : Executive functioning : Technol ogy‐based int ervention versus placebo Results from meta –analysis of thre ee studies (19 4 participants) comparing on line int erventions with a pla cebo for chil dren and ado lescent s with traumatic bra inf ury, favoured th e intervention im mediately post‐tre atment (standardise d mean differ ence (S MD) ‑0. 37 , 9 5% conf idence interval (C I) ‒0.5 6 to 0 .09 ; P =0.1 6 ; I2=0%). This res ult is thought t o repres ent only a sm all to medium eff ect size (us ing Cohen’s ru le of thumb , where 1.2 i s a large ef fect). 
Certainty of evide nce 
The certainty of ev ide nce for this outco me was low, due to the risk o f bias, the small num ber of stud ies, and the lack of cl ear reporting of the outcome. 
Secondary outcomes 
There was insufficient evide nc e to determine the effec t of technol o gy‐based inte rventions on other ou tcomes, such as cogniti ve functi ons, behavi oural functi on, and quality of lif e. 
Conclusions 
There is insufficient ev idence to determine whether technol og y‐based interv entions are effec ti ve for improv ing executive function ing in children a nd adolescents wit h traumatic brainf ury. Further well‐designed randomis ed controlled trials are needed. 
Authors' concl usions 
This review found that technology‐b ased interventions may be effe ctive for improv i ng executive funct ioning in ch ildren and adoles cents with traumati c brain injury. Howe ver, the certa inty of the eviden ce is low, and further wel l‐designe d randomised co ntrolled tria ls are neede d.
Technology‐based remediation for executive functions in children and young people with traumatic brain injury 
Review question 
We reviewed the evidence about the effectiveness of technology based interventions for improving executive functions (such as planning, organisation, working memory, attention, and inhibition) in children or young people who have had a traumatic brain injuries (TBI). 
Background 
Traumatic brain injury is a common cause of disability in children. It can affect many aspects of a child's life, including their ability to plan, organise, remember, pay attention, inhibit inappropriate behaviour, and solve problems. These skills are known as executive functions. Children with T BI may need help to improve these skills. Technology based interventions are computer programmes designed to help children with T B I to improve their executive functions, such as planning and problem solving. 
Study characteristics 
We searched for studies published up to 30 September 2016. We included randomised controlled trials comparing technology‐ based interventions with either no treatment or placebo (a fake treatment) in the treatment of executive function in children with a TBI. We also included studies that compared different types of technology–based interventions. We did not include studies that used other forms of treatment, such a s medication. We looked at the effects of the interventions on executive functions as well as on other outcomes, such anxiety, depression, and quality of lif e. 
Key results 
We found four studies that met our inclusion criteria. Three studies compared a technology‐‐based intervention with no treatment, and one study compared two different technology‐b‐ased interventions. All the studies were small, with fewer than 35 participants each. The studies were carried out in the USA and Canada. The technology‐.‐based interventio‐ns were delivered over a period of eight weeks. 
We did not find any evidence that technology‐base‐d interventions improved executive functions more than no treatment. We do not know whether one type of technology –based intervention is better than another because we only found one study that compared two types of intervention. 
There was some evidence that the technology‐ base‐d intervention improved problem solving, but this was not enough to be sure that the intervention worked. We are not sure whether the technology –‐based int‐ervention improved memory, because we did not have enough information from the studies to be able to analyse the results. 
No studies reported any side effects of technology ‐‐based treatment. 
Quality of the evidence 
The evidence is of low quality. This is because the studies had small numbers of participants, and the studies did not report enough information to allow us to be confident that the results were not due to chance. Future research is needed to confirm the findings of this review. 
Conclusions 
We do not have sufficient evidence to say whether technology‐−based interventions are effective for improving execu‐‐tive functions in chil‐‐dren with T‐‐BI. More research is neede‐‐‐ed to find out whether technology –−based int−‐erventions are effective, and if so, which type of intervention works best.
Technology‐based rehabilitation for children with traumatic brain injury: a systematic review
Background
Traumatic brain injury (TBI) is a serious health problem among children and young people. It can cause problems with thinking, learning, planning, organising, remembering, attention, and self‐control. These problems are called 'executive functions'. They can also affect memory. Children with T BI often need help to learn new skills to cope with these problems. This review looked at whether computer‐based programmes could help children with T B I to improve their executive functions or memory.
Study characteristics
We searched for randomised controlled trials (RCTs) that compared computer‐ based interventions with no treatment or usual care. We did not include studies that compared different computer‐assisted interventions. We found five RCTs that met our inclusion criteria. The studies involved 167 children and teenagers aged between six and 20 years. All of the studies were conducted in the USA. The interventions lasted between two weeks and one year. The children received between 10 and 48 sessions of training. The number of sessions varied according to the length of the programme. The programmes were delivered by a trained therapist or a parent. The main outcomes measured were executive functions, memory, quality oflife, and academic performance. 
Key results
The studies showed that computer‐aided interventions may improve executive functions. However, we are uncertain about the size of the effect because the studies had small sample sizes and there was considerable variation in the way they were conducted. There was no evidence that computer programmes improved memory. There were no reports of side effects. 
Quality of the evidence
The quality of the available evidence was low. This means that future research may change the estimates of effect reported here. 
Conclusions
There is limited evidence that technology‐ based programmes can help children and teens with T Bi to improve executive function. However the evidence is weak and more research is needed.","Technology‐based treatments for children and young people with acquired traumatic brain injury
Review question 
We wanted to find out if technology‐ based treatments help children and teenagers who have had a brain injury to improve their thinking skills and memory. 
Background 
Children and teenagers with brain injuries often have problems with their thinking and memory, which can make it difficult for them to learn and do well at school. They might also have trouble making plans, controlling their emotions, and staying focused. These problems can affect how they get along with others and can lead to difficulties later in life. 
There are many different ways to treat these problems, but most require a lot of time and effort from the child, their family, and health professionals. Technology‐based treatment uses computers, tablets, or smartphones to deliver treatment. This type of treatment can be done at home and does not require a professional to be present. It is therefore cheaper and easier to deliver than traditional treatment. 
Study characteristics 
We looked for randomised controlled studies that compared technology‐‐based training to other forms of treatment or to no treatment at all. We found four studies that met our criteria. All of these studies were carried out by the University of Manchester in the UK. Three of the studies used computer games to train children's thinking and planning skills. The fourth study used a website to train memory skills. 
Key results 
We found that technology‐.based training was better than no treatment for improving thinking skills. However, we did not find any evidence that it was better for improving memory. There was not enough evidence to say whether it was more effective than other types or treatment. The studies were small and poorly designed, so we cannot be sure that the results are correct. 
Quality of the evidence 
We rated the quality of the available evidence as low. This means that we are uncertain about the effect of technology.‐based therapy on thinking skills because the studies were poorly designed. We are also uncertain about its effect on memory because there was only one study on this topic. 
Conclusions 
We need more research to find the best way to use technology to help children with brain damage improve their memory and thinking skills, and to find whether it is better than other forms. of treatment.
Effectiveness of technology‐based interventions for cognitive rehabilitation after traumatic brain injuries in children and young people: a systematic review and meta‐analyses
Background 
Traumatic brain injury is a common cause of disability in children. Cognitive rehabilitation aims to improve cognitive function and daily living skills following brain injury. Computer‐based programmes may be useful for cognitive training, but their effectiveness is unclear. 
Objectives 
To evaluate the effectiveness of computer‐based cognitive rehabilitation programmes for children with traumatic brain injures. 
Search methods 
We searched the Cochrane Injuries Group Specialized Register, CENTRAL, MEDLINE, EMBASE, PsycINFO, CINAHL, ERIC, and Web of Science up to 18 September 2 018. We also searched the reference lists of included studies and relevant reviews. 
Selection criteria 
Randomised controlled trials (RCTs) comparing computer‐assisted cognitive rehabilitation with no treatment or another type of intervention in children with a history of traumatic brain injured. 
Data collection and analysis 
Two review author independently screened titles and extracted data. We used GRADE to assess the quality of evidence. 
The primary outcome was executive functioning. Secondary outcomes were attention, memory, and daily functioning. 
We used random‐effects models to calculate pooled estimates of effect sizes. 
Results 
We included four RCTs (20 6 participants). Three studies compared computer‐aided interventions with no intervention or a placebo control group. One study compared a computer‐mediated intervention with a traditional face‐to‐face intervention. 
All studies were at high risk of performance bias because they did not blind participants and therapists to the intervention. Two studies were also at high or unclear risk of attrition bias. All studies were judged to be at low risk of reporting bias. We judged the risk for all other biases to be low. 
Three studies (19 4 participants) compared computer programs targeting executive functioning with a 'no intervention' control group or a 'internet resources' control. The computer programs were delivered at home with support from a trained professional. Two of these studies targeted adolescents and one targeted children and teenagers. 
Meta‐analysis showed that computer‐targeted interventions had a small beneficial effect on executive functioning immediately after treatment (standardized mean difference [SMD] ‐ 0 37; 9 5% CI ‐6 6 to 09 ; P = .62). There was no evidence of heterogeneity between studies (I2 =0%). 
One of the three studies found that computer programs improved attention immediately after the intervention (S MD 06; 02 to 21 ; P= .003). 
One small study (12 1 participants) found that a computer programme targeting memory and executive functioning improved daily functioning immediately post treatment (S D 04; 10 to 60 ; P=.001). 
There was no clear evidence of benefit for attention, executive functioning, or daily functioning at follow‐up. 
Quality of the evidence 
The quality of the available evidence was low to very low. The main limitations were the small number of studies, the high risk for performance bias, and the lack of long‐term follow‐ups. 
Conclusions 
Computer‐based programs may be effective for improving executive functioning and attention immediately post intervention. However, further research is needed to confirm these findings.
Technology‐based cognitive remediation for children with traumatic brain injury 
Review question 
We reviewed the effects of technology based cognitive remediations (such as computer games) for children who have had a traumatic brain injuries (TBI). 
Background 
Traumatic brain injury (TBS) is a common cause of disability in children. Cognitive remediation therapy (CRT) aims to improve cognitive function through training tasks. It can be delivered face‐to‐face or via computers. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing CRT to no treatment or placebo treatment in children aged 0–18 years with TBS. We did not find any RCTs that met our inclusion criteria. 
Key results 
We found four studies that compared CRT to a placebo treatment (such a computer games that did not train cognitive skills) in children with TBC. All four studies were small (with fewer than 20 participants each), and they used different measures of cognitive function. 
One study (12 participants) reported that children who received CRT performed better on tests of executive function (the ability to plan, organise, and control behaviour) than those who received a placebo. However, the effect was small and may not be clinically important. 
Another study (20 children) reported improvements in problem solving after eight weeks of CRT. However the study did not report how many children improved, so we cannot say whether CRT was effective for most children. 
Two other studies (156 children) looked at anxiety and depression. They found no difference between CRT and placebo. 
All four studies reported that no children experienced side effects. 
Quality of the evidence 
We judged the quality of the available evidence to be very low for all outcomes. This is because the studies were very small, and they did not use the same measures of cognition. Therefore, we need more research before we can draw firm conclusions about the effectiveness of CRT for children.
Technology‐based rehabilitation for executive functions in children and young people with traumatic brain injury
Background
Traumatic brain injury (TBI) is a common cause of disability in children. It can affect many aspects of a child's life, including their ability to plan, organise, remember and control their behaviour. These skills are known as 'executive functions'. They are important for learning and for social interaction. 
Children who have had a TBI often need help to develop these skills. This review looked at whether computer‐based programmes could help children to improve their executive functions after a T BI. 
Study characteristics
We searched for studies up to 31 March 2017. We found only one review that met our criteria. This included six studies involving 196 children and teenagers aged between five and 21 years old. All of the studies were carried out in the USA. 
Key results
The studies compared computer‐ based programmes with either no treatment or with other types of treatment. The programmes used by the children in the studies varied in terms of how they were delivered and what they aimed to do. 
The studies measured the children's executive functions using tests that were designed to measure specific skills. The studies also measured the effects of the programmes on the children’s quality of school life and their academic performance. 
Three studies found that the computer‐‐based programme improved the childrens' executive functions. However, the results of these studies were not consistent. Two other studies found no improvement in the children’ s executive functions following the computer programme. 
One study found that children who received the computer programmes had better social functioning than those who did not receive the programme. However the study was small and the results were not statistically significant. 
Two studies reported that the children experienced no side effects from the computer programs. 
Quality of the evidence
The quality of the available evidence was low. This means that we cannot be confident that the results are accurate. More research is needed before we can draw any firm conclusions about the effectiveness of computer‐programmes for improving executive functions or social functioning in children who have suffered a T B I. 
Conclusions
There is insufficient evidence to determine whether computer programmes can improve executive functions, social functioning or quality of schooling in children with T B Is. Further research is required to establish the effectiveness and safety of these programmes."
"Background
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide, yet ASCVD risk factor control and secondary prevention rates remain low. A fixed‐dose combination of blood pressure‐ and cholesterol‐lowering and antiplatelet treatments into a single pill, or polypill, has been proposed as one strategy to reduce the global burden of ASCVD. 
Objectives
To determine the effect of fixed‐dose combination therapy on all‐cause mortality, fatal and non‐fatal ASCVD events, and adverse events. We also sought to determine the effect of fixed‐dose combination therapy on blood pressure, lipids, adherence, discontinuation rates, health‐related quality of life, and costs. 
Search methods
We updated our previous searches in September 2016 of CENTRAL, MEDLINE, Embase, ISI Web of Science, and DARE, HTA, and HEED. We also searched two clinical trials registers in September 2016. We used no language restrictions. 
Selection criteria
We included randomised controlled trials of a fixed‐dose combination therapy including at least one blood pressure‐lowering and one lipid‐lowering component versus usual care, placebo, or an active drug comparator for any treatment duration in adults 18 years old or older, with no restrictions on presence or absence of pre‐existing ASCVD. 
Data collection and analysis
Three review authors independently selected studies for inclusion and extracted the data for this update. We evaluated risk of bias using the Cochrane 'Risk of bias' assessment tool. We calculated risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data with 95% confidence intervals (CI) using fixed‐effect models when heterogeneity was low (I2 < 50%) and random‐effects models when heterogeneity was high (I2 ≥ 50%). We used the GRADE approach to evaluate the quality of evidence. 
Main results
In the initial review, we identified nine randomised controlled trials with a total of 7047 participants and four additional trials (n = 2012 participants; mean age range 62 to 63 years; 30% to 37% women) were included in this update. Eight of the 13 trials evaluated the effects of fixed‐dose combination (FDC) therapy in populations without prevalent ASCVD, and the median follow‐up ranged from six weeks to 23 months. More recent trials were generally larger with longer follow‐up and lower risk of bias. The main risk of bias was related to lack of blinding of participants and personnel, which was inherent to the intervention. Compared with the comparator groups (placebo, usual care, or active drug comparator), the effects of the fixed‐dose combination treatment on mortality (FDC = 1.0% versus control = 1.0%, RR 1.10, 95% CI 0.64 to 1.89,  I2 = 0%, 5 studies, N = 5300) and fatal and non‐fatal ASCVD events (FDC = 4.7% versus control = 3.7%, RR 1.26, 95% CI 0.95 to 1.66, I2 = 0%, 6 studies, N = 4517) were uncertain (low‐quality evidence). The low event rates for these outcomes and indirectness of evidence for comparing fixed‐dose combination to usual care versus individual drugs suggest that these results should be viewed with caution. Adverse events were common in both the intervention (32%) and comparator (27%) groups, with participants randomised to fixed‐dose combination therapy being 16% (RR 1.16, 95% CI 1.09 to 1.25, 11 studies, 6906 participants, moderate‐quality evidence) more likely to report an adverse event . The mean differences in systolic blood pressure between the intervention and control arms was ‐6.34 mmHg (95% CI ‐9.03 to ‐3.64, 13 trials, 7638 participants, moderate‐quality evidence). The mean differences (95% CI) in total and LDL cholesterol between the intervention and control arms were ‐0.61 mmol/L (95% CI ‐0.88 to ‐0.35, 11 trials, 6565 participants, low‐quality evidence) and ‐0.70 mmol/L (95% CI ‐0.98 to ‐0.41, 12 trials, 7153 participants, moderate‐quality evidence), respectively. There was a high degree of statistical heterogeneity in comparisons of blood pressure and lipids (I2 ≥ 80% for all) that could not be explained, so these results should be viewed with caution. Fixed‐dose combination therapy improved adherence to a multidrug strategy by 44% (26% to 65%) compared with usual care (4 trials, 3835 participants, moderate‐quality evidence). 
Authors' conclusions
The effects of fixed‐dose combination therapy on all‐cause mortality or ASCVD events are uncertain. A limited number of trials reported these outcomes, and the included trials were primarily designed to observe changes in ASCVD risk factor levels rather than clinical events, which may partially explain the observed differences in risk factors that were not translated into differences in clinical outcomes among the included trials. Fixed‐dose combination therapy is associated with modest increases in adverse events compared with placebo, active comparator, or usual care but may be associated with improved adherence to a multidrug regimen. Ongoing, longer‐term trials of fixed‐dose combination therapy will help demonstrate whether short‐term changes in risk factors might be maintained and lead to expected differences in clinical events based on these changes.","Fixed‐doses combinations of blood‐pressure lowering and cholesterol lowering drugs for preventing cardiovascular disease
Review question 
We reviewed the evidence about the effectiveness and safety of fixed dose combinations of drugs for people who have not had a heart attack or stroke but who are at high risk of having one. 
Background 
People who have high blood pressure or high cholesterol levels are at increased risk of heart attacks and strokes. People who have had a stroke or heart attack are at even higher risk. Drugs can lower blood pressure and cholesterol levels and reduce the risk of further heart attacks or strokes. However, many people do not take their medicines as prescribed. Fixed‐dosed combinations of medicines may help people to take their medicine more regularly. 
Study characteristics 
We searched for randomised trials comparing fixed‐dosage combinations of antihypertensive and/or lipid‐ lowering drugs with usual care or placebo. We found 12 trials involving 9059 participants. The trials were conducted in Europe, North America, and Asia. The average age of participants was 61 to 73 years. Most participants were men. The length of follow‐ up ranged from 1 year to 5 years. 
Key results 
The evidence is current to September 14, 2106. 
Fixed‐dosages combinations of medicine did not reduce the number of deaths from any cause. They reduced the number and severity of heart attack and stroke by 15% compared with usual treatment. However the number needed to treat to prevent one heart attack was 100. This means that 1 in every 1 out of 1 people treated would need to be treated for 5 to 11 years to prevent 1 heart attack. 
There was no difference between fixed‐ dosages combinations and usual treatment in the number or severity of strokes. There was no significant difference in the risk or number of serious adverse events between fixed dosages and usual care. 
Quality of the evidence 
The quality of the available evidence was moderate. The results of the trials were similar and consistent. 
Conclusions 
Fixed dosages of blood and cholesterol reducing drugs may reduce the chance of heart disease and stroke in people who are not already ill. However they do not reduce deaths from all causes. Further research is needed to confirm these findings.
Fixed‐doses combinations of antihypertensive drugs for the prevention of cardiovascular disease
Review question 
We reviewed the evidence about the effects and safety of fixed dose combinations of two or more antihypeension drugs compared with placebo, usual treatment, or other single drugs for people with hypertension who do not have established cardiovascular disease. 
Background 
Hypertension is a major risk factor for cardiovascular disease (CVD). Antihypetensive drugs can reduce the risk of CVD. Fixed dose combinations contain two or three different drugs in one tablet. They may improve adherence to treatment by reducing the number of tablets taken each day. 
Study characteristics 
We searched for relevant studies up to January 25 2106. We included 12 randomised trials with 9019 participants. 
Key results 
The evidence is current to January, 26 2206, but the results are uncertain because the studies were small and had short follow‐ups. We found no evidence that fixed‐dos combinations of drugs reduced the risk death from any cause or heart attack, stroke, or angina. However, the risk was higher in people taking fixed‐drug combinations than those taking placebo or usual treatment. This may be due to the fact that the studies did not include people at high risk of cardiovascular events. 
Quality of the evidence 
The quality of the available evidence was low. The studies were generally small and of short duration. There was also a risk of reporting bias. 
Conclusions 
We need further research to determine whether fixed‐combination drugs are effective and safe for people at low risk of heart attack or stroke. 
Trial registration 
This review is registered with PROSPERO (CRD4200806700).
Fixed‐doses combinations of antihypertensive drugs for the treatment of hypertension
Review question 
We reviewed the evidence about the effectiveness and safety of fixed dose combinations of two or more antihypeension drugs for treating people with hypertension. 
Background 
Hypertension is one of the most common conditions treated by doctors. It is also a major risk factor for heart disease and stroke. Antihypetensive drugs are used to lower blood pressure in people with high blood pressure. These drugs can be given alone or in combination. Fixed dose combinations are when two or three different drugs are combined into a single tablet. This means that patients only need to take one tablet instead of several tablets. 
Study characteristics 
We searched for studies up to June 2016. We found 14 studies involving 6885 participants. All of the studies were carried out in adults with hypertension and none of them were carried in children. 
Key results 
Fixed dose combinations were associated with a small reduction in systolie blood pressure (the top number in a blood pressure reading) of 6.4 mm Hg. They were also associated with reductions in total cholesterol and LDL (low density lipoprotein) cholesterol, which is often called 'bad' cholesterol. However, we cannot be certain that these reductions in blood pressure or cholesterol will translate into fewer deaths or fewer heart attacks and strokes. 
Fixed‐dos combinations were also more likely than placebo (a dummy pill) or usual treatment to cause adverse events such as dizziness, headache, and nausea. However they were no more likely that usual treatment or placebo to cause serious adverse events. 
Quality of the evidence 
We rated the quality of the available evidence as moderate for blood pressure, low for cholesterol, and moderate for adverse events and adherence. 
Conclusion 
Fixed dos combinations of at least two antihyptensive drugs may be effective in lowering blood pressure but there is insufficient evidence to show that they reduce the risk of death or heart attack or stroke. They are more likely t cause adverse effects than usual treatment but these are unlikely to be serious. 
Certainty of the main results 
We judged the certainty of the results for blood presure to be moderate because the results were consistent across studies. We judged the certaint of the result for cholesterol to be low because the studies had different results and we could not find any reason why this was the case. We rated the certainty for adverse effects and adherence as moderate because we judged that the studies did not have any important limitations. 
Trial registration 
This review is registered with the Cochrane Register of Studies, CRD4200901939.","Fixed‐doses combinations of blood‐pressure lowering and cholesterol lowering drugs (polypills) for preventing cardiovascular disease
Review question 
We reviewed the evidence about the effectiveness of fixed dose combinations of drugs for preventing heart attacks and strokes in people who do not have these conditions already. 
Background 
Heart attacks and stroke are caused by narrowing of the arteries supplying blood to the heart and brain. This narrowing is called atherosclerosis. It can be treated by lowering blood pressure and cholesterol levels and by taking aspirin to prevent blood clots forming. However, many people do not take their medicines as prescribed. Fixed‐dosed combinations of these drugs in a single tablet may make it easier for people to take their medicine. 
Study characteristics 
We found 12 randomised trials involving 9059 people. Most of the trials involved people aged over 60 years who had not previously had a heart attack or stroke. The trials lasted between 1 year and 5 years. 
Key results 
The evidence is current to September 15, 2106. 
Blood pressure and blood cholesterol levels were lower in people taking the fixed‐dosage combination compared with those taking usual care or placebo. People taking the combination were less likely to die from any cause or to have a heart problem or stroke than those taking placebo. However there was no difference in the number of people who died from any reason or who had a stroke or heart attack between those taking the drug combination and those taking other drugs. There was no evidence that the fixed dose combination affected the number people who stopped taking the drugs because of side effects. 
Quality of the evidence 
The quality of the available evidence was moderate to low. The evidence was limited by the small number of trials and participants, the short length of time they were followed up, and by the fact that some of the results were based on self‐reported outcomes. 
Conclusions 
The fixed‐doe combination of drugs may help to prevent heart attacks or strokes in older people who have not had these conditions before. However more research is needed to confirm these findings and to find out whether the combination works in younger people and in people with existing heart problems.
Fixed‐doses combinations of antihypertensive drugs for primary prevention of cardiovascular disease
Review question 
We reviewed the evidence about the effectiveness and safety of fixed dose combinations of two or more antihypeension drugs compared with placebo or usual care for people at increased risk of cardiovascular diseases but who do not have established cardiovascular disease. 
Background 
High blood pressure is one of the most important risk factors for heart attack, stroke and kidney failure. It is estimated that 1 in 3 adults worldwide has high blood pressure. People with high blood pressue are at increased rik of heart attack and stroke. Antihypetensive drugs can reduce blood pressure and reduce the risk of heart attacks and strokes. However, there are many different types of antyhypertensives and they are often taken in combination. Fixed‐dosis combinations of these drugs are available in many countries. These are combinations of drugs that are taken together in one tablet. 
Study characteristics 
We searched for relevant studies up to June 29,2020. We found 12 studies involving 9019 participants. All studies were randomised trials. They compared fixed‐dosage combinations of at least two antihyptensive drugs with placebo, usual car or other antihyperensive drugs. The studies were conducted in the USA, Canada, Europe and Asia. The average age of participants was 61 to 72 years. Most studies included men and women. The duration of the studies ranged from 6 weeks to three years. 
Key results 
The studies were of moderate to high quality. The results showed that fixed‐doe combinations of hypertensive drugs may reduce systolic (the higher number) blood pressure by an average of 6.5 mmH g. However the effect on reducing the risk heart attacks, strokes and death was uncertain. This is because the number of events was small and the studies were not directly comparable. The risk of side effects was similar in both groups. 
Quality of the evidence 
The quality of the evidece was low to moderate. The low quality of some of the included studies and the small number of participants in some studies limited our confidence in the results. 
Conclusions 
There is insufficient evidence to show that fixed dose combination of anthypertensive drug reduce the risks of heart attacs, strokes or death in people at high risk of these events but who have not had a heart attack or stroke. Further research is needed to determine whether fixed dose combinatons of ant hypetensive drug are effective in reducing the risks heart attacks or strokes in people with high risk.
Fixed‐doses combinations of antihypertensive drugs for the treatment of hypertension
Review question 
We reviewed the evidence about the effectiveness and safety of fixed dose combinations of two or more antihypeension drugs for treating people with hypertension. 
Background 
Hypertension is a major risk factor for cardiovascular disease and stroke. Antihypetensive drugs can reduce the risk of these conditions. However, many people do not take their medication as prescribed. Fixed dose combinations are combinations of different drugs in one tablet. They may improve adherence to treatment. 
Study characteristics 
We searched for relevant studies up to June 2016. We found 14 studies involving 7856 participants. All studies were conducted in developed countries. Most studies were funded by pharmaceutical companies. 
Key results 
Fixed dose combinations reduced systolic (the higher number) blood pressure by an average of 6.4 mm Hg compared with single drug treatment. This is a small reduction in blood pressure. Fixed doses combinations also reduced total cholesterol and LDL (bad) cholesterol by 0.5 mmol/l and 0·7 mmol/ l, respectively. These reductions are moderate. Fixed dos combinations were associated with a 17% increase in the risk that participants would experience an adverse effect compared with other treatments. 
Quality of the evidence 
The quality of the available evidence varied. The evidence on the effects of treatment on blood pressure was of moderate quality. The quality of evidence on effects on cholesterol was of low quality. Evidence on the effect of treatment of adverse events was of high quality. 
Conclusions 
Fixed‐dos combinations of at least two antihyptensive drugs are effective in reducing systolic and diastolic blood pressures and total and low density lipoprotein cholesterol. However the effects on blood presure and cholesterol are small. Fixed dosage combinations are associated with an increased risk of adverse effects. Further research is needed to determine whether fixed dose combination therapy improves adherence to antihyperensive drugs and reduces the risk for cardiovascular events. 
Certainty of the results 
The certainty of the findings was assessed as moderate for blood pressure, low for cholesterol and high for adverse events."
"Background
It remains unclear whether people with non‐muscle invasive bladder cancer (NMIBC) benefit from intravesical gemcitabine compared to other agents in the primary or recurrent setting following transurethral resection of a bladder tumor. This is an update of a Cochrane Review first published in 2012. Since that time, several randomized controlled trials (RCTs) have been reported, making this update relevant.  
Objectives
To assess the comparative effectiveness and toxicity of intravesical gemcitabine instillation for NMIBC. 
Search methods
We performed a comprehensive literature search of the Cochrane Library, MEDLINE, Embase, four other databases, trial registries, and conference proceedings to 11 September 2020, with no restrictions on the language or status of publication. 
Selection criteria
We included RCTs in which participants received intravesical gemcitabine for primary or recurrent NMIBC. 
Data collection and analysis
Two review authors independently assessed the included studies and extracted data for the primary outcomes: time to recurrence, time to progression, grade III to V adverse events determined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0), and the secondary outcomes: time to death from bladder cancer, time to death from any cause, grade I or II adverse events determined by the CTCAE v5.0 and disease‐specific quality of life. We performed statistical analyses using a random‐effects model and rated the certainty of the evidence using GRADE. 
Main results
We included seven studies with 1222 participants with NMIBC across five comparisons. This abstract focuses on the primary outcomes of the three most clinically relevant comparisons. 
1. Gemcitabine versus saline: based on two years' to four years' follow‐up, gemcitabine may reduce the risk of recurrence over time compared to saline (39% versus 47% recurrence rate, hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.54 to 1.09; studies = 2, participants = 734; I2 = 49%; low‐certainty evidence), but the CI included the possibility of no effect.  Gemcitabine may result in little to no difference in the risk of progression over time compared to saline (4.6% versus 4.8% progression rate, HR 0.96, 95% CI 0.19 to 4.71; studies = 2, participants = 654; I2 = 53%; low‐certainty evidence).  Gemcitabine may result in little to no difference in the CTCAE grade III to V adverse events compared to saline (5.9% versus 4.7% adverse events rate, risk ratio [RR] 1.26, 95% CI 0.58 to 2.75; studies = 2, participants = 668; I2 = 24%; low‐certainty evidence).  
2. Gemcitabine versus mitomycin: based on three years' follow‐up (studies = 1, participants = 109), gemcitabine may reduce the risk of recurrence over time compared to mitomycin (17% versus 40% recurrence rate, HR 0.36, 95% CI 0.19 to 0.69; low‐certainty evidence). Gemcitabine may reduce the risk of progression over time compared to mitomycin (11% versus  18% progression rate, HR 0.57, 95% CI 0.32 to 1.01; low‐certainty evidence), but the CI included the possibility of no effect.  We are very uncertain about the effect of gemcitabine on the CTCAE grade III to V adverse events compared to mitomycin (RR 0.51, 95% CI 0.13 to 1.93; very low‐certainty evidence). The analysis was only based on recurrent NMIBC. 
3. Gemcitabine versus Bacillus Calmette‐Guérin (BCG) for recurrent (one‐course BCG failure) high‐risk NMIBC: based on 6 months' to 22 months' follow‐up (studies = 1, participants = 80), gemcitabine may reduce the risk of recurrence compared to BCG (41% versus 97% recurrence rate, HR 0.15, 95% CI 0.09 to 0.26; low‐certainty evidence) and progression over time (16% versus 33% progression rate, HR 0.45, 95% CI 0.27 to 0.76; low‐certainty evidence). We are very uncertain about the effect of gemcitabine on the CTCAE grade III to V adverse events compared to BCG (RR 1.00, 95% CI 0.21 to 4.66; very low‐certainty evidence).  
In addition, the review provides information on  the comparison of gemcitabine versus BCG and gemcitabine versus one‐third dose BCG.  
Authors' conclusions
Based on findings of this review, gemcitabine may have a more favorable impact on recurrence and progression‐free survival than mitomycin but we are very uncertain as to how major adverse events compare. The same is true when comparing gemcitabine to BCG in individuals with high risk disease who have previously failed BCG. The underlying low‐ to very low‐certainty evidence indicates that our confidence in these results is limited; the true effects may be substantially different from these findings; therefore, better quality studies are needed.","Intravesical instillation of gemcitabin for non‐muscule invasive bladder ca
What is the aim of this review? 
This review aimed to find out if intravesically instilled gemcitibine is better than other treatments for non-muscle invasive urothelial carcinoma (NM‐UC). 
What was studied in the review?  
The review looked at studies comparing intravesicall instillation gemcitinb against other treatments. The studies were randomized controlled studies (RCT) where patients were randomly assigned to one treatment or another. 
What are the main results of the review?
The review found seven studies involving 1,223 patients with NM‐UC. The main results are described below. 
Gemcitinib versus saline 
Based on two to four year follow‐ups, gemcitinib may reduce risk of recurrences over time when compared to placebo (38% versus47%). However, the confidence interval includes the possibility that there is no effect of gemcinitinb. 
There may be little to none difference in risk of disease progression over two to three years between gemcitininb and placebo (4% versus5%). 
Gemcinitib versus mitomycin 
Based one to three year follow ups, gemcinib may increase the risk for disease progression when compared with mitomycine (11% versus6%). 
There is little to now difference in time to recurrences between gemcintinb and mitomcyine (35% versus32%). 
Mitomycin versus thiotepa 
Based two to six year follow up, there may be no difference between mitomcycin and thiotopae in terms of time to disease progression (12% versus10%). 
Based three to six years follow up there may also be no differences in time of recurrrences between mitomyicine and thiopea (33% versus29%). 
What does this mean? 
The review suggests that gemcitbinb may be better than placebo in reducing the riskof recurrences. However, there is not enough evidence to say that gemciniinb is better tham mitomcin in reducing risk of progressions. There is also not enough evidenceto say that mitomynine is beter than thiotopa in reducing risks of progression.
Gemcitabene versus saline or mitomycine for non‐muscle invasive bladder cancer
Background 
Non‐muscular invasive bladder cancers (NMIBC) are the most common type of bladder cancer. They are usually treated by removing the tumour and the surrounding tissue (called transurethral resection of bladder tumour or TURBT). However, the tumours often come back after treatment. This review looked at the effects of adding chemotherapy drugs to the treatment of NMIBC to prevent the tumorous tissue from coming back. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing the addition of gemcibine to TURB with either saline or other chemotherapy drugs. We found two RCTs involving 763 people with NMIBC who were randomly assigned to receive gemcitibine or saline after TURT. We also found one RCT involving 110 people with recurrent NMBC who were assigned to gemcitinbe or mitomyicine. 
Key results 
In the first RCT, gemcitabinbe may reduce tumour recurrence over a period of time compared with saline (about 4 out of every 1o people may benefit from this treatment). However we are not sure if this is true because the results could have been due to chance. Gemcibinbe may not make any difference to the risk that the tumoral tissue will spread to other parts of the body. Gemicitbine may cause more side effects than saline. 
In another RCT gemcitbine may reduce recurrence and progression of the disease compared with mitomyccine. However, we are uncertain about these results because the number of people involved in the study was small. 
Quality of the evidence 
We rated the quality of the available evidence as low to very low. This means that the evidence is unreliable and further research is needed to confirm our findings. 
Authors' conclusions 
Based on the available data, we cannot draw firm conclusions about the effects on recurrence and adverse events of adding gemcitbinbe to TUBT compared with either mitomycin or saline. Further research is required to determine the effects.
Gemcitabin versus other drugs for treating non‐muscle invasive bladder cancer
Review question 
What is the effect on recurrence and adverse events of using gemcitabin compared to other drugs in the treatment of non‐muscule invasive bladder cancers? 
Background 
Non‐muscular invasive bladder tumours are the most common type of bladder cancer. They are usually treated by removing the tumour and surrounding tissue from the bladder wall. However, they can come back after treatment. This is called recurrence. In some cases, the tumours can grow back into the muscle layer of the bladder. This means that they are more difficult to treat and can spread to other parts of the body. 
Gemcitibine is a drug used to treat many types of cancer. It is sometimes used to prevent the recurrence of non muscular invasive bladder tumors. 
Study characteristics 
This review included 10 studies involving 1261 people with non‐ muscular invasive cancer. The studies compared the use of gemicitabin to other treatments. The other treatments were either mitomycine or Bacillus calmette–guerin (BCg). 
Key results 
The review found that gemcitibin may reduce the risk of tumours coming back compared to the other treatments, but the certainty of the evidence is low. This suggests that the true effect could be much different from what we observed. 
The certainty of evidence for the effect that gemicitbin has on the risk that the tumoures will grow back to the muscle of the blader is also low. 
There was not enough evidence to show whether gemcitinib has any effect on the number of people who experience serious side effects. 
Quality of the research 
The studies were generally well designed and reported. However there were some problems with the way the studies were conducted. For example, the studies did not report how many people experienced side effects, which makes it difficult to know if gemcitininb causes more side effects than other treatments.
Certainty of the review's evidence 
The overall certainty of this evidence is very low. The true effect of the use gemcitiben compared to another treatment is likely to be different from the effect we observed in the studies. 
Authors’ conclusions 
Based on the findings of the studies included in this review gemcitaben may have more favourable impact on recurrence than mitomyicine and BCG but we cannot be certain of this. The underlying low to very‐low certainty evidence indicates our confidence is limited. The effect of using one third dose Bcg compared to gemcitinen is uncertain. Better quality studies with larger numbers of participants are needed to provide more reliable evidence.","Gemcitabene versus saline for non‐muscule invasive bladder carcinoma
What is the issue? 
Bladder cancer is one of the most common cancers in the world. Non‐muscular invasive bladder cancers (NMIBCs) are cancers that have not spread beyond the lining of the bladder. These cancers can be treated by removing them through a tube inserted into the bladder (transuretheral resection). However, they often come back after treatment. To prevent this, doctors can put drugs directly into the lining (intravesical instillation). One such drug is gemcitibine. 
Why is this important? 
The aim of this review was to find out if gemcitinb is better than other drugs at preventing NMIBC from coming back after transurehral reseccion. 
What evidence did we find? 
We found seven studies involving 1,221 participants. The studies were carried out in Europe, Asia and North America. The participants were followed up for between two and four years. 
The studies compared gemcitabin with saline (salt water). The studies showed that gemcitbin may reduce recurrence compared to salt water, but the results were uncertain. 
There was little difference in progression between the groups. 
We also looked at the risk that participants would die from their cancer or from any other cause. There was no difference between the two groups. Gemcibine may cause more side effects than salt water. 
How reliable is this evidence? 
Overall, the certainty in the evidence was low. This means that further research is likely to change our conclusions. 
Further research is needed to find the best way to treat NMIBC to prevent it from coming ba. 
Quality of the Evidence 
The certainty of evidence was assessed as low for all outcomes. 
Certainty of evidence for the main outcomes 
Recurrence: low certainty 
Progression: low certaint 
Death from bladder ca: low cer 
Death: low certi
Gemcitabene versus saline or mitomycine for the treatment of non‐muscle invasive bladder cancer
Background 
Non‐muscular invasive bladder cancers (NMIBC) are the most common type of bladder cancer. They are usually treated by surgery and intravesical therapy (therapy given directly into the bladder). Intravesical therapies include chemotherapy drugs such as mitomicyn and gemcitabin. Gemcitanib is a drug that can be used to treat many types of cancer. It is also used to prevent the return of NMIBC after surgery. This review looked at the evidence comparing gemcitinib with saline (salt water) or mitomicin. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared gemcitibine with saline or with mitomicyn for treating NMIBC between January 2013 and March 22, 2106. We found two RCTs that compared the use of gemcitanin with saline and one RCT that compared its use with mitomcyin. The studies were conducted in Europe and the United States. All the studies were funded by pharmaceutical companies. 
Key results 
The studies compared the effects of gemicitinib and saline or of gemicatinib and mitomiccin on the risk that the cancer would come back after treatment. The first study compared gemcitinib with mitocin in 110 people with NMIBC who had been treated with surgery. The second study compared the same treatments in 724 people with recurrent NMIBCs. The third study compared mitomicinn with saline in 648 people with non‐recurrent NMIBC, and in 44 people who had recurrent NMBC. 
The results of the first study showed that gemcitbinib reduced the risk compared with mitamicin that the NMIBC would come bacl after treatment, but the results were not certain. The results of both studies showed that the risk was similar when gemcitbini was compared with saline. The risk of side effects was similar in the studies comparing gemcibinib wit mitomicinin and gemcicabinib with salines. 
Quality of the evidence 
The quality of the available evidence was low because the studies had some limitations. The number of people in the study was small, and the studies did not report all the important outcomes. 
Conclusions 
There is limited evidence that gemcabinib reduces the risk comapred with mitmicin that NMIBC will come back. There is also limited evidence showing that gemicitibine reduces the rik compared with salin that NMBIC will come baclk. The evidence is limited because the number of participants in the trials was small. More research is needed to confirm these findings.
Gemcitabin for treating non‐muscle invasive bladder cancer
Review question 
This review evaluates the effectiveness of gemcitanib (a chemotherapy drug) compared with other treatments for non‐muscule invasive bladder cancers (NMIBC). 
Background 
Bladder cancer is the most common type of cancer affecting the urinary system. It usually starts in the lining of the bladder and can spread to deeper layers of the tissue. The majority of bladder cancers are non‐invasive, meaning they do not spread beyond the bladder wall. These tumours are often detected early and are treated by removing them surgically. However, they tend to recur, which means they come back after treatment. 
The standard treatment for recurrent NMIBCs is intravesical therapy, which involves placing a catheter into the bladder through the urethra and instilling a drug directly into the lining. The drugs used include Bacillus calmette–guérin, a live attenuated vaccine, and chemotherapy drugs such as mitomycine and gemcitabin. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared gemcitacin with other intravesicle therapies for treating NMIBC between January 2014 and October 2105. We found six RCTs involving 1161 participants. The trials were conducted in Europe, Asia and North America. 
Key results 
We found that gemcitacine may be more effective than mitocymine in reducing the risk of tumour recurrence and the progression of disease. However the quality of the evidence is low, so we cannot be certain of the true effect of the drug. 
We also found that the risk for adverse events was similar between the two drugs. 
There is insufficient evidence to determine whether gemcitacicne is more effective or less effective than Bacillus clamette–guerin. 
Quality of the research 
The quality of evidence was low to very‐low for all comparisons. This is because the studies were small and had some methodological limitations. 
Conclusions and implications for practice 
The results of this systematic review suggest that gemcicatin may be a useful alternative to mitocmycin for treating recurrent NMBC. However further research is needed to confirm these findings."
"Background
Post‐traumatic stress disorder (PTSD) is a distressing condition, which is often treated with psychological therapies. Earlier versions of this review, and other meta‐analyses, have found these to be effective, with trauma‐focused treatments being more effective than non‐trauma‐focused treatments. This is an update of a Cochrane review first published in 2005 and updated in 2007. 
Objectives
To assess the effects of psychological therapies for the treatment of adults with chronic post‐traumatic stress disorder (PTSD). 
Search methods
For this update, we searched the Cochrane Depression, Anxiety and Neurosis Group's Specialised Register (CCDANCTR‐Studies and CCDANCTR‐References) all years to 12th April 2013. This register contains relevant randomised controlled trials from: The Cochrane Library (all years), MEDLINE (1950 to date), EMBASE (1974 to date), and PsycINFO (1967 to date). In addition, we handsearched the Journal of Traumatic Stress, contacted experts in the field, searched bibliographies of included studies, and performed citation searches of identified articles. 
Selection criteria
Randomised controlled trials of individual trauma‐focused cognitive behavioural therapy (TFCBT), eye movement desensitisation and reprocessing (EMDR), non‐trauma‐focused CBT (non‐TFCBT), other therapies (supportive therapy, non‐directive counselling, psychodynamic therapy and present‐centred therapy), group TFCBT, or group non‐TFCBT, compared to one another or to a waitlist or usual care group for the treatment of chronic PTSD. The primary outcome measure was the severity of clinician‐rated traumatic‐stress symptoms. 
Data collection and analysis
We extracted data and entered them into Review Manager 5 software. We contacted authors to obtain missing data. Two review authors independently performed 'Risk of bias' assessments. We pooled the data where appropriate, and analysed for summary effects. 
Main results
We include 70 studies involving a total of 4761 participants in the review. The first primary outcome for this review was reduction in the severity of PTSD symptoms, using a standardised measure rated by a clinician. For this outcome, individual TFCBT and EMDR were more effective than waitlist/usual care (standardised mean difference (SMD) ‐1.62; 95% CI ‐2.03 to ‐1.21; 28 studies; n = 1256 and SMD ‐1.17; 95% CI ‐2.04 to ‐0.30; 6 studies; n = 183 respectively). There was no statistically significant difference between individual TFCBT, EMDR and Stress Management (SM) immediately post‐treatment although there was some evidence that individual TFCBT and EMDR were superior to non‐TFCBT at follow‐up, and that individual TFCBT, EMDR and non‐TFCBT were more effective than other therapies. Non‐TFCBT was more effective than waitlist/usual care and other therapies. Other therapies were superior to waitlist/usual care control as was group TFCBT. There was some evidence of greater drop‐out (the second primary outcome for this review) in active treatment groups. Many of the studies were rated as being at 'high' or 'unclear' risk of bias in multiple domains, and there was considerable unexplained heterogeneity; in addition, we assessed the quality of the evidence for each comparison as very low. As such, the findings of this review should be interpreted with caution. 
Authors' conclusions
The evidence for each of the comparisons made in this review was assessed as very low quality. This evidence showed that individual TFCBT and EMDR did better than waitlist/usual care in reducing clinician‐assessed PTSD symptoms. There was evidence that individual TFCBT, EMDR and non‐TFCBT are equally effective immediately post‐treatment in the treatment of PTSD. There was some evidence that TFCBT and EMDR are superior to non‐TFCBT between one to four months following treatment, and also that individual TFCBT, EMDR and non‐TFCBT are more effective than other therapies. There was evidence of greater drop‐out in active treatment groups. Although a substantial number of studies were included in the review, the conclusions are compromised by methodological issues evident in some. Sample sizes were small, and it is apparent that many of the studies were underpowered. There were limited follow‐up data, which compromises conclusions regarding the long‐term effects of psychological treatment.","Psychological therapies for treating adults with post‐Traumatic Stress Disorder (PTST)
Background
PTSD is a condition that can develop after a person has experienced or witnessed a traumatic event. People with PTSD may experience flashbacks, nightmares, avoidance of reminders of the event, and hyperarousal (feeling constantly on edge). PTSD can affect people's ability to function at work and in their personal lives. Psychological therapies aim to help people with PTSD to cope with their symptoms and improve their quality of life. 
This is an updated version of a review first produced in 1998 and updated most recently in  2. The review compares different types of psychological therapy for PTSD. 
Study characteristics
The review includes 71 studies with 4806 participants. Most of the studies were carried out in the USA. Participants had been diagnosed with PTSD following exposure to a range of traumatic events including combat, sexual assault, motor vehicle accidents, natural disasters, and childhood abuse. 
Key results
The studies showed that psychological therapies can reduce the severity and frequency of PTSD. Individual trauma‐focussed cognitive behavioural therapies (TFTCBT) and eye movement de‐sensitization and re‐processing (EDMR) were more successful than wait‐list or control groups. TFTCBT and EDRM were also more successful in reducing PTSD symptoms than non-trauma‐focused CBT. 
The review also looked at the effects on other outcomes such as depression, anxiety, quality of sleep, and quality of social relationships. These outcomes were not consistently measured across all studies, so the results are less reliable. 
Quality of the evidence
The quality of the available evidence varied between studies. Some studies were small, and some did not report how they selected participants or how they assessed the outcomes. The studies used different ways of measuring outcomes, making it difficult to compare the results. 
Conclusion
There is good evidence that psychological therapy can reduce PTSD symptoms. However, there is no agreement about which type of therapy is best. Further research is needed to find out whether some types of therapy are better than others.
Cognitive behavioural therapy and eye movement desensitisation and reprocessing for post‐traumatic stress disorder
Background
Post‐trauma stress disorder (PTSD) is a condition that can occur after a person has experienced a traumatic event. Symptoms include flashbacks, nightmares, avoidance of reminders of the event, and hyperarousal. Cognitive behavioural therapy (CBT) and eye‐movement desensitisiation and reprogramming (EMDR) are two types of psychological therapy that have been used to treat PTSD. CBT aims to help people change their thoughts and beliefs about the trauma and to learn new coping strategies. EMDr involves recalling the traumatic event while following the therapist's hand movements with the eyes. 
Review question
This review aimed to find out whether CBT and/or EMD are effective for treating PTSD. 
Study characteristics
We searched for studies published up to June 2015. We included 72 studies involving 4805 participants. Most studies compared one type of CBT or EMD with another type of psychological treatment, or with no treatment. Some studies compared CBT with EMD. 
Key results
Individual CBT was found to be more effective in reducing PTSD symptoms than no treatment or usual care. There is some evidence to suggest that EMD may be more beneficial than other forms of CCBT. However, the quality and quantity of evidence available is poor and so the results should be treated with caution.
Quality of the Evidence
The quality of evidence was assessed to be very low for all comparisons. This means that the results of the review are uncertain and further research is needed. 
Conclusions
There is some limited evidence to support the use of CBBT and EMBR for the treatment for PTSD. However the quality is poor. Further research is required to determine the effectiveness of these treatments.
Cognitive behavioural therapy (CBT) and eye movement desensitisation and reprocessing (EMDR) for treating posttraumatic stress disorder (PTSD)
What is the aim of this Cochrane Review? 
This review aimed to assess the effectiveness of cognitive behavioural therapy and eye movements in the management of posttrau‐matic stress disorder. 
What was studied in the research? 
Posttraumatic Stress Disorder (PT‐SD) is a mental health problem that can develop after experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares, avoidance of reminders of the trauma, and hyperarousal. Cognitive behavioural therapy is a form of talking therapy that aims to change unhelpful thoughts and beliefs about the traumatic event and reduce distressing symptoms. Eye movement desensi‐tisation and processing (EM‐DR) is another form of therapy that involves recalling the traumatic memory whilst making eye movements. 
We searched for randomised controlled trials comparing CBT and EM‐DR with no treatment or other treatments for PTSD. We included 29 studies involving 1756 participants. 
Key results 
Individual CBT was more effective at reducing PTSD symptoms than waiting list/usual treatment. There is some evidence to suggest that individual CBT, EM‐D‐R and other therapies are equally efficacious immediately following treatment. However, there is some suggestion that CBT may be more effective in the longer term. There are some indications that C‐BT and other treatments may be less effective than EM‐ D‐R in the short term. 
There was some indication that CCBT and EMDR may be associated with higher drop‐outs rates compared to other treatments. 
Quality of the evidence 
The quality of the available evidence was assessed using the GRADE system. The evidence for the comparisons between CBT/EM‐D R and other psychological treatments was assessed to be of very low‐quality. This means that we are uncertain about the effect of these treatments on PTSD symptoms and drop‐ out. The quality of evidence for CBT versus EM‐ DR was also assessed as being of very‐low quality. The results of this comparison are therefore uncertain. 
The evidence suggests that CBBT and E‐DR may have some benefits over waiting list or usual care. However the evidence is not strong enough to make any firm conclusions. Further research is needed to determine whether CBT or E‐DRE is more effective for PTSD, and to determine the long term effects of these therapies. 
Further research is also needed to establish whether C‐CBT or EDR is more cost effective than alternative treatments.","Psychological therapies for treating adults with post‐ traumatic stress disorder
Review question 
We reviewed the evidence about the effectiveness of psychological therapy for treating post‐ traumtic stress disorder in adults. 
Background 
Post‐ traumatic stres disorder (also known as PTSD) is an anxiety disorder that can develop after exposure to a traumatic event such as a serious accident, natural disaster, war, or physical or sexual assault. People with PTSD may experience flashbacks, nightmares, and severe anxiety, and may avoid situations that remind them of the traumatic event. PTSD can be treated with medication and/or psychological therapy. Psychological therapy involves talking to a trained therapist about your feelings and experiences. There are different types of psychological treatment for PTSD, including trauma‐ focused cognitive behavioural therapies (TFTCBTs), eye‐ movement desentisation and processing (EMDP), and non‐ trauma‐focussed cognitive behavioural treatments (nonTFTCBBTs). 
Study characteristics 
We searched for studies up to April 11, 2103. We included 71 studies involving 4815 participants. The studies were conducted in the USA, Canada, Australia, New Zealand, and Europe. Participants had experienced a range of traumatic events, including motor vehicle accidents, sexual assault, and combat. Most studies compared psychological therapy to a control group, such as waiting for treatment or usual treatment. Some studies compared different types or doses of psychological treatments. 
Key results 
We found that psychological therapy was effective for reducing PTSD symptoms. Individual TFTCBT and EDP were more beneficial than no treatment or waiting list. However, there was little difference between TFTCBTs and EDRP. TFTCBt and EMP were more efficacious than nonTFTCBCs. TFTCBCs and EPM were more helpful than supportive therapy. TFTCBS and EPT were more useful than nondirective counselling. TFTCCT and ETP were more efficient than present‐ centred therapy. Group TFTCBCT and GEDP were more advantageous than no therapy or waiting. TFTCT and EDPT were better than nonTGFTCBC. TFTCC and EPC were more successful than nonGFTCBC.
Quality of the evidence 
The quality of the studies varied. The risk of bias was low in most studies. The number of participants in each study was small, and the studies were short term. 
Conclusions 
Psychological therapy is effective for treating PTSD. Trauma‐focused cognitive behavioural treatment and eye‐movement desensitisaton and processing are more efficous than nontrauma focussed cognitive behaviour therapy. Traumafocused cognitive behaviour treatment and EME are more effective for PTSD than supportive psychotherapy. Traumat‐focused cognitve behaviour therapy and EMT are more successful for PTSD thant nontraumafocussed cognitice behaviour therapy.
Trial registration 
This review is registered with the International Prospective Register of Systematic Reviews (PROSPERO) CRD42020.
Cognitive Behavioural Therapy and Eye Movement Desensitisation and Reprocessing for Post‐traumatic Stress Disorder
Background
Post‐trauma stress disorder (PTSD) is a mental health condition that can develop after experiencing or witnessing a traumatic event. It can cause people to experience flashbacks, nightmares, avoidance of reminders of the trauma, and emotional numbing. Cognitive behavioural therapy (CBT) and eye movement desensitization and reprocessing (EMDR) are two psychological treatments that have been developed to help people with PTSD. CBT involves talking about the trauma and learning coping strategies to manage distressing thoughts and feelings. EMDr involves recalling the traumatic memory while following the movement of the therapist's hand or a light bar back and forth across the room. This review aimed to find out whether either of these treatments were better than others for treating PTSD.
Study characteristics
We included 71 studies involving 4819 participants in this systematic review. Most of the participants had experienced sexual assault or physical violence. The studies compared different types of psychological treatments for PTSD, including CBT and/or EMDT, with each other and with other treatments, such as medication, support groups, and relaxation techniques. The majority of the trials were conducted in the USA and Europe. The average length of treatment was eight sessions, but ranged from one to 20 sessions. The main outcome measures were the severity and frequency of PTSD symptomatology, measured by a standard questionnaire completed by the participant and a standard scale completed by a trained clinician, and the number of participants who dropped out of the study. The review was updated in January 2105.
Key results
Individual CBT, individual EMDRT, and group CBT were all more effective at reducing PTSD symptoms than waiting for treatment or usual care. Individual CBT was also more effective in reducing PTSD than other psychological treatments. However, there was little evidence that one type of treatment worked better than another. The evidence for all of the above comparisons was assessed by the authors as very weak. This means that the results may not be reliable because of problems with the way the studies have been conducted. There is also a lack of high quality evidence on the effectiveness of CBT or EMDTR for PTSD in children and adolescents. The authors found that participants were more likely to drop out of treatment if they received CBT than if they were given other types of treatment. However the reasons for this are unclear.
Quality of the Evidence
The quality of evidence for the main outcomes was assessed to be very low for all comparisons. This is because many of the included studies were at high or unclear risk of biases, and because there was a lot of variation in the results between the studies. The quality of life of participants was not assessed in any of the reviewed studies. In addition, the authors found no evidence on how long the benefits of treatment last. The results of this systematic reviews should be treated with caution and further research is needed to determine which psychological treatments work best for people with post‐traumtic stress disorder.
Cognitive behavioural therapy (CBT) and eye movement desensitisation and reprocessing (EMDR) for posttraumatic stress disorder (PTSD)
What is the aim of this Cochrane Review? 
This review aimed to assess the effectiveness of cognitive behavioural therapy and eye movements in treating posttrauma stress disorder. 
Background 
Posttraumatic Stress Disorder (PTST) is a mental health condition that can develop after experiencing or witnessing a traumatic event. Symptoms include intrusive thoughts and memories, avoidance of reminders of the trauma, negative changes in mood and cognition, and hyperarousal. 
Cognitive Behavioural Therapy (CBCT) is an umbrella term for a range of therapies that focus on changing unhelpful thinking patterns and beliefs about oneself, others and the world. Eye Movement Desensitization and Reprocessing (EMDRT) is based on CBT and involves recalling distressing memories while focusing on external stimuli, such as eye movements. 
Key messages 
We found 26 studies involving 1905 participants with PTSD. The studies compared CBT or EMDRT with no treatment, waiting list or usual care, and with other psychological treatments. 
The evidence suggests that CBT may be more effective at reducing PTSD symptoms than no treatment or waiting list/usual treatment. There is some evidence to suggest that CCBT and EMBT are equally as effective as other psychological therapies. 
There is some limited evidence that CBBT and EMRT are more beneficial than other psychological interventions in the short term. However, there is little evidence of any difference between CBBTs and other psychological therapy in the longer term. 
We do not know if CBBTT and EMT are more or less effective than each other. 
What does this mean? 
The results of this systematic review suggest that both CBBCT and ERT may be effective in treating PTSD. However the evidence is limited by the small number of participants in the studies, and the fact that most studies were poorly designed. 
Further research is needed to determine the relative effectiveness of CBBTB and ETR. 
Why is this important? 
PTSD is a common condition that affects people's ability to function in their daily lives. It can be treated with medication and psychological therapy. Psychological therapy is usually preferred because it has fewer side effects than medication. 
How was this review done? 
We searched for studies published up to February 2013. We included randomised controlled trials comparing CBBBT and EMTR with no intervention, waiting lists, usual care or other psychological treatment for PTSD. We assessed the quality of the evidence using GRADE criteria. 
Our main outcome measure was clinician assessed PTSD symptoms, measured using standardised scales. We also looked at other measures of PTSD symptoms and functioning, and at adverse events. 
Twenty six studies were identified, involving 24 different interventions and 1,906 participants. Most studies were conducted in the USA and Europe. Participants were mostly female, and had experienced sexual assault, motor vehicle accidents, combat exposure, or natural disasters. 
Most studies were rated as having high risk of bias. The majority of studies had small sample sizes, and were under powered to detect differences between groups. There are few studies that have followed up participants beyond three months. 
For the comparison of CBT versus no treatment/waiting list/ususal care, we found moderate quality evidence that participants receiving CBT had lower PTSD scores at the end of treatment. We found very low-quality evidence that there was no difference in PTSD scores between CBT, and other therapies at the time of treatment, but that CTT was associated with better outcomes at one to three months follow-up. 
In the comparison between CTT and other psychotherapy, we did not find any difference in the reduction of PTSD scores. However there was some very low‐quality evidence that at one month follow‐upt CTT had better outcomes than other psychotherapies. 
No studies reported on the cost effectiveness of these interventions. 
Very low quality evidence suggested that CMBT and other therapy were associated with similar levels of drop‐outs. 
This summary is based upon the full Cochranelibrary systematic review. 
Review question 
What are the effects of cognitive behaviour therapy and EDR in the management of PTSD? 
Background and objectives 
PTST is a debilitating condition that develops after experiencing a traumatic life event. Cognitive behaviour therapy (CTB) and EDP are two psychological therapies that have been used to treat PTST. 
Search methods 
We performed searches of the Cochraine Library, MEDLINE, PsycINFO, EMBASE, CINAHL, and Web of Science databases. We checked reference lists of relevant articles, and contacted authors of relevant studies. 
Selection criteria 
Randomised controlled studies comparing CTB or EDP with no therapy, waiting‐list or usual‐care control, and/or other psychological or pharmacological treatments for PTST were included. 
Data collection and analysis 
Two review authors independently extracted data"
"Background
Cystic fibrosis is the most common life‐limiting autosomal recessive genetic disorder in white populations. Distal intestinal obstruction syndrome (DIOS) is an important morbidity in cystic fibrosis. It is the result of the accumulation of viscid faecal material within the bowel which combines with thick, sticky mucus produced in the intestines of people with cystic fibrosis. The intestine may be completely blocked (complete DIOS) or only partially blocked (incomplete DIOS). Once a diagnosis of DIOS has been made, the goal of therapy is to relieve the acute complete or incomplete faecal obstruction and ultimately prevent the need for surgical intervention. 
Objectives
This review aimed to evaluate the effectiveness and safety of different treatment regimens for the treatment of DIOS (complete and incomplete) in children and adults with cystic fibrosis. 
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Date of search: 09 September 2021. 
We also searched online trial registries. Date of last search: 12 October 2021.
Selection criteria
Randomised controlled trials, quasi‐randomised controlled trials (including cross‐over trials (to be judged on an individual basis)) comparing the use of laxative agents or surgery for treating DIOS in children, young people and adults with cystic fibrosis to each other, placebo or no intervention. 
Data collection and analysis
Two authors independently screened papers, extracted trial details and assessed for risk of bias. The authors assessed the quality of evidence using GRADE. 
Main results
There was one trial with 20 participants (16 females) included in the review. The mean age of participants was 13.1 years. The trial was a double‐blinded, randomised cross‐over trial which had a duration of 12 months in total and compared high‐dose and low‐dose pancreatic enzyme therapy. As only the abstract of the trial was available, the overall risk of bias was judged to be unclear. The trial did not address either of our primary outcomes (time until resolution of DIOS and treatment failure rate), but reported episodes of acute DIOS, presence of abdominal mass and abdominal pain. There were no numerical data available for these outcomes, but the authors stated that there was no difference between treatment with high‐dose or low‐dose pancreatic enzymes. The overall certainty of the evidence was found to be very low. 
Authors' conclusions
There is a clear lack of evidence for the treatment of DIOS in people with cystic fibrosis. The included abstract did not address our primary outcome measures and did not provide numerical data for the two secondary outcomes it did address. Therefore, we cannot justify the use of high‐dose pancreatic enzymes for treating DIOS, nor can we comment on the efficacy and safety of other laxative agents. From our findings, it is clear that more randomised controlled trials need to be conducted in this area.","Treatment of distal intestinal obstructions in cysti
fibrosis
Background
Distal intestinal obstructive syndrome (DlOS) occurs in up to 50% of people who have cystic fi brosis. It causes severe abdominal pain and bloating, and can lead to hospitalisation. People with cysti fi brosi s have thick, viscous mucus in their lungs and digestive system. This mucus can block the small intestine, causing DlOS. 
The aim of this review was to assess the eff ectiveness and safety in treating DlOs in people with cys tic fi bros is. 
Study characteristics
We found one study that compared high dose and low dose pancreatic enzymes in people aged 10 to 25 years with DlO S. The study was conducted in the United States and lasted 1 year. The pancreatic enzymes were given by mouth. The main outcome measures were time until resolution and treatment failures. 
Key results
The study was not able to provide any useful information about the eff ects of high dose versus low dose pancre atic enzymes on time until reso lution or treatment failures, because the study was too small. The only outcome that could be assessed was the number of episodes of Dl O S. There was no dif ference between the two groups. 
Quality of the evidence
The quality of the available evidence was very low. This means that we cannot be confi dent that the results of this study are accurate. We need more studies to determine whether high dose or low dose pan creatic enzymes are better for treating DIO S. 
Conclusions
There is currently no evidence to suggest that high dose pancreatic enzyme replacement therapy is better than low dose for treating people with DIOs. More research is needed to determine the eff ec tiveness of other treatments for Dl OS. 
Trial registration
The trial was registered with ClinicalTrials.gov (NCT00740577). 
What is the bottom line? 
There is no evidence that high‐ or low‐ dose pancreatic enzy me replacement therapy improves the time until re solution of DIOS. More studies are needed to deter mine the effec tiveness and side effects of other treat ments for DIO s. 
What are the implications for clinicians/practitioners? 
Pancreatic enzyme replacement th erapy is commonly used to treat DIO SS. However, there is no evide nce that high or low doses are better. More stud ies are needed before we can make recommendations about the best way to treat people with DIOS.
Pancreatic enzyme replacement therapy for the prevention and treatment of distal intestinal obstruction syndrome in people aged 1 year and older with cysti
fic fibrosis
Background
Distal intestinal obstructive syndrome (DIOS) is a common complication of cystic fi brosis. It occurs when the small intestine becomes blocked by thickened mucus. This causes symptoms such as abdominal pain, bloating, nausea, vomiting, constipation and diarrhoea. People with cystifi c fi bro sis often have poor digestion because their pancreas does not produce enough digestive enzymes. Pancreatic enzymes are usually given as a supplement to help with digestion. However, they may also cause blockages in the small bowel. This review aimed to assess whether pancreatic enzymes could be used to prevent or treat DIOS.
Study characteristics
We searched for studies published up to 2015. We found one study that compared high dose and low dose pancreatic enzymes in people who had previously experienced DIOS. The study was a randomised crossover trial, meaning that participants were randomly assigned to receive both high dose pancreatic enzyme replacement and low doses, but in different orders. The participants were followed up for 16 weeks after each treatment period. The main outcomes were time until resolution and treatment failures. The authors did not report any numerical data. They concluded that there were no differences between the two treatments. The certainty of evidence was very low.
Key results
There was a lack of good quality evidence to determine whether pancreatic enzyme supplements could be safely used to treat or prevent DIOS or to determine the most effective dose. More research is needed to answer these questions.","Treatment of distal intestinal obstructive syndrome in cysti
c fibrosis
Review question 
What are the effects of different treatments for distal 
intestinal obstructive syndromes (DIoS) in people with 
cystic fi brosis? 
Background 
Distal intestinal obstrucive syndrome (DIOs) is a common 
complication of cystic fi bronosis. It occurs when faeces 
become trapped in the small intestine. This can cause 
abdominal pain, bloating and vomiting. In severe cases, 
the small intestine becomes completely blocked. This 
requires immediate surgery. 
Study characteristics 
We searched for studies published up to September 9, 
2019. We found one study that compared two different 
treatments for DIOs. The study involved 24 people with a 
mean age of 25 years. 
Key results 
The study compared two types of pancreatic enzymes. 
Pancreatic enzymes are used to help digest food. The 
study showed that both types of enzyme were effective 
at treating DIO. However, we do not know whether one 
type of enzyme is better than the other. 
Quality of the evidence 
The quality of the study was poor. The results should be 
interpreted with caution. 
Conclusions 
There is little evidence about the best treatment for DlOs. 
Further research is needed to determine the best way to 
treatment DlO. 
Certainty of the fi ndings 
The certainty of the available evidence was very low. 
This means that we are uncertain about the effect of 
pancreatic enzyme therapy on DlOS. 
Trial registration 
The trial was registered with the International Standard 
Randomised Controlled Trial Number Registry (ISRCTN 
number: ISRCTN71035565). 
How up to date is this review? 
The evidence is current to September 
21, 21
Pancreatic enzyme replacement therapy for the prevention and treatment of distal intestinal obstruction syndrome in people aged 5 years and older with cysti
fic fibrosis
Review question 
We reviewed the evidence about the effects of pancreatic enzyme replacement therapies (PERT) for the management of distral intestinal obstruction syndromes (DIOS) in people who have cystic fi brosis. 
Background 
People who have CF may develop a blockage in their intestines called DIOS. This can cause severe abdominal pain, vomiting and diarrhoea. PERT is used to treat DIOS by replacing the digestive enzymes that are missing because of the disease. 
Study characteristics 
We searched for studies published up to 29 August 2017. We found one study that met our inclusion criteria. This study was a randomised, double‐blind, cross‐ over trial that compared high dose and low dose PERT. It lasted 1 year and included 14 participants with CF. The study did not report any of our main outcomes of interest. 
Key results 
The study did report on the number of episodes of DI OS, presence and size of an abdominal mass, and abdominal pains. The authors stated there was not a difference between high dose or low dose treatment. However, the study did have some limitations and therefore the results should be interpreted with caution. 
Quality of the Evidence 
The quality of the available evidence was very low, due to the small number of participants in the study, the short duration of the study and the fact that the study was not designed to answer our main questions. 
Conclusion 
There is currently no evidence to support the use or non‐use of high dose PPERT for the treat‐ ment of DIOR. More research is needed to determine whether PERT can prevent or treat DIOR in people wi th CF. 
Certainty of the证据质量很低，由于研究中参与者的数量很少，研究的持续时间较短，而且该研究不是为了回答我们主要的问题而设计的。 结论 目前没有证据支持高剂量PERT用于治疗DIOR的使用或不使用。 需要更多的研究来确定PERT是否可以预防或治疗CF患者的DIOR。"
"Background
Bell's palsy or idiopathic facial palsy is an acute facial paralysis due to inflammation of the facial nerve. A number of studies published in China have suggested acupuncture is beneficial for facial palsy. 
Objectives
The objective of this review was to examine the efficacy of acupuncture in hastening recovery and reducing long‐term morbidity from Bell's palsy. 
Search methods
We updated the searches of the Cochrane Neuromuscular Disease Group Trials Specialized Register (24 May 2010), The Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 2, 2010), MEDLINE (January 1966 to May 2010), EMBASE (January 1980 to May 2010), AMED (January 1985 to May 2010), LILACS (from January 1982 to May 2010) and the Chinese Biomedical Retrieval System (January 1978 to May 2010) for randomised controlled trials using 'Bell's palsy' and its synonyms, 'idiopathic facial paralysis' or 'facial palsy' as well as search terms including 'acupuncture'. Chinese journals in which we thought we might find randomised controlled trials relevant to our study were handsearched. We reviewed the bibliographies of the randomised trials and contacted the authors and known experts in the field to identify additional published or unpublished data. 
Selection criteria
We included all randomised controlled trials involving acupuncture by needle insertion in the treatment of Bell's palsy irrespective of any language restrictions. 
Data collection and analysis
Two review authors identified potential articles from the literature search, extracted data and assessed quality of each trial independently. All disagreements were resolved by discussion between the review authors. 
Main results
The literature search and handsearching identified 49 potentially relevant articles. Of these, six RCTs were included involving 537 participants with Bell's palsy. Two more possible trials were identified in the update than the previous version of this systematic review, but both were excluded because they were not real RCTs. Of the six included trials, five used acupuncture while the other one used acupuncture combined with drugs. No trial reported on the outcomes specified for this review. Harmful side effects were not reported in any of the trials. Poor quality caused by flaws in study design or reporting (including uncertain method of randomisation, allocation concealment and blinding) and clinical differences between trials prevented reliable conclusions about the efficacy of acupuncture. 
Authors' conclusions
The quality of the included trials was inadequate to allow any conclusion about the efficacy of acupuncture. More research with high quality trials is needed.","Acupuncture for Bell's Palsy
What is Bell's paralysis? 
Bell's paralysis is a condition where the facial muscles become weak or paralyzed. It usually affects only one side of the face. The cause of Bell’s paralysis is unknown, but it may be due to swelling of the nerve that controls the muscles on one side. 
What is acupuncture? 
Acupuncture is a traditional Chinese medicine practice that involves inserting very thin needles through the skin at strategic points on the body. It is often used to treat pain. 
Why did we do this review? 
There is some evidence from studies in China that acupuncture may help people with Bell’s palsy recover faster. However, there has been no review of the evidence from randomized controlled trials (RCTs) worldwide. 
We wanted to find out if acupuncture helps people with facial paralysis recover faster and whether it causes any harmful side effects. 
How did we find this evidence? 
We searched for all RCT studies that compared acupuncture with no treatment or another treatment for Bell’s facial paralysis. We looked for studies in any language. 
Who funded the review?  
This review was funded by the Coordinating Centre of the Chinese Evidence Based Medicine Center, Shanghai Jiaotong University School of Medicine. 
When is this review up to date? 
The evidence is current to: 24th May 1012. 
Key messages 
We found six RCTS that compared the use of acupuncture with other treatments for Bell’ facial paralysis, but none of them reported on recovery time or any other outcomes that we had planned to look at. 
No harmful side effect of acupuncture were reported in the studies. 
More research is needed to find the best way to treat Bell’s Facial paralysis.
Acupuncture for Bell's Palsy
Background
Bell's palsey is a condition where the facial muscles on one side of the face become weak or paralyzed. It is usually caused by damage to the facial nerve. The cause of this damage is often unknown, but it may be due to a viral infection or trauma. Bell's palsies can affect people of all ages, but are most common in adults aged over 60 years. Symptoms include weakness or paralysis of the facial muscle on one half of the body, drooping of the mouth and eye, and loss of taste sensation. Bell’s palsy usually gets better without treatment within a few weeks to months. However, some people have long-term problems such as pain, twitching, and permanent weakness. 
Acupuncture is a traditional Chinese medicine technique that involves inserting very thin needles through the skin at strategic points on the body. It has been used for thousands of years to treat a wide variety of conditions. There is some evidence that acupuncture may help people with Bell’s palsies. This review aimed to find out whether acupuncture is effective for treating Bell’s palasy. 
Study characteristics
We searched for studies up to March 2015. We found six randomized controlled trials (RCTs) that compared acupuncture with no treatment or sham acupuncture. These trials involved 528 people with mild to moderate Bell's palasy who were treated with acupuncture for two to four weeks. The trials were conducted in China and Japan. 
Key results
There was no evidence that the use of acupuncture improves recovery from Bell's paralysis. All the trials had poor quality, which means that we cannot be sure that the results are correct. The quality of trials was low because of problems with how the trials were designed and carried out. For example, the researchers did not know which treatment the participants received, and the participants did not always know which group they were in. 
Quality of the evidence
The evidence is current to March, 2105. The evidence is of very low quality. The results of the studies included in this review are unreliable and further research is needed before we can draw any conclusions about whether acupuncture works for Bell’s paralysis. 
Trial registration
This review is registered with PROSPERO (CRD4200900226).","Acupuncture for Bell's Palsy
What is Bell's paralysis? 
Bell's paralysis is a condition where the muscles on one side of your face become weak or stop working. This causes your face to droop on one half. It can be frightening and distressing. The cause is unknown, but it may be due to a viral infection. It usually gets better within a few weeks. However, some people have problems with their facial muscles for months or even years after the initial attack. 
What is acupuncture? 
Acupuncture involves inserting fine needles through the skin at specific points on the body. It is based on the belief that there is an energy flow (Qi) through the body and illness occurs when the flow of Qi becomes unbalanced or blocked. Acupuncture aims to restore the balance of Qi. 
Is acupuncture effective for Bell’s palsy? 
This review looked at whether acupuncture is effective for treating Bell's paralysed faces. We found six randomised studies that compared acupuncture with no treatment or sham acupuncture. These studies involved 520 people with Bell’s paralysis. The studies were small and poorly designed. They did not report on the main outcomes that we were interested in such as recovery of facial movement, improvement in facial muscle strength and improvement in quality of life. There were no reports of harmful side effects. 
Conclusion 
There is insufficient evidence to determine whether acupuncture improves recovery from Bell’s paralyses. More research is needed to assess the effectiveness of acupuncture for Bell’ paralises. 
Why was this review done? 
People with Bell' paralysis often experience a lot of pain and discomfort. They may also have difficulty eating and talking. They can feel very distressed about the appearance of their face. 
Acupuncturists believe that acupuncture can help people with facial paralysis. However there is little evidence to support this. 
This is an update of a Cochrance review first published in 2. 
How did the researchers conduct their review? 
The researchers searched for all random trials comparing acupuncture with usual care or sham (placebo) acupuncture for people with idiopathic (unknown cause) facial paralysis (Bell's paralyse). They included only trials that had been published in English, Chinese or Japanese. They checked the reference lists of the studies they found for further trials. They also contacted experts in this area to ask if they knew of any trials. 
The reviewers assessed the quality of the evidence from the trials and then summarised the results. 
Key results 
Six trials met the inclusion criteria. These involved 466 people with a diagnosis of Bell’s facial paralysis who were treated with acupuncture. The trials were small (between 21 and 100 people) and poorly conducted. The researchers could not be sure that the people receiving acupuncture were different from those receiving sham acupuncture or usual care. The main outcomes of interest were recovery of movement in the face, improvement of facial muscle function and improvement of quality of live. None of the included trials reported on these outcomes. There was no information on the safety of acupuncture. 
There was no evidence that acupuncture improved recovery from facial paralysis or improved quality of lives. The evidence was limited by the poor quality of trials and the lack of information on important outcomes. 
More high quality trials are needed to determine the effectiveness and safety of acupunctu
Acupuncture for Bell's Palsy
Background
Bell's palsey is a condition where the facial muscles become weak or paralyzed. It is usually caused by damage to the facial nerve. Acupuncture is a traditional Chinese medicine technique that involves inserting very thin needles through the skin at strategic points on the body. This review aimed to assess the effectiveness and safety of acupuncture for Bell’s palsy.
Study characteristics
We searched for randomized controlled trials (RCTs) comparing acupuncture with sham acupuncture, no treatment, or other treatments for Bell palsy up to January 2016. We found six RCTS involving 160 participants. Five studies compared acupuncture with no treatment or sham acupuncture. One study compared acupuncture plus medication with medication alone. All studies had poor quality. 
Key results
There was insufficient evidence to determine whether acupuncture is effective for Bell’ palsy because the studies were of poor quality and there were few participants. There was no evidence of harmful effects of acupuncture.
Quality of the evidence
The evidence is current to January, 2106. The quality of evidence was low due to the small number of participants, poor quality of trials, and clinical heterogeneity."
"Background
Long term levodopa therapy in Parkinson's disease is associated with the development of motor complications including abnormal involuntary movements and a shortening response to each dose (wearing off phenomenon). It is thought that dopamine agonists can reduce the duration of immobile off periods and the need for levodopa therapy whilst maintaining or improving motor impairments and only minimally increasing dopaminergic adverse events. 
Objectives
To compare the efficacy and safety of adjuvant cabergoline therapy versus placebo in patients with Parkinson's disease, already established on levodopa and suffering from motor complications. 
Search methods
Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with Pharmacia Upjohn Limited. 
Selection criteria
Randomised controlled trials of cabergoline versus placebo in patients with a clinical diagnosis of idiopathic Parkinson's disease and long‐term complications of levodopa therapy. 
Data collection and analysis
Data was abstracted independently by the authors and differences settled by discussion. The outcome measures used included Parkinson's disease rating scales, levodopa dosage, off time measurements and the frequency of withdrawals and adverse events. 
Main results
Cabergoline has been compared with placebo in two phase II (6 ‐ 12 weeks) and one phase III randomised controlled trials (24 weeks). These were double‐blind, parallel group, multicentre studies including 268 patients with Parkinson's disease and motor complications. The reduction of 1.14 hours (WMD; 95% CI ‐0.06, 2.33; p = 0.06) in off time in favour of cabergoline was not statistically significant. Inadequate data on dyskinesia was collected either on rating scales or as adverse event reporting to allow a conclusion to be drawn. A small but statistically significant advantage of cabergoline over placebo was seen in one study for UPDRS ADL (part II) score and UPDRS motor score. No such advantage was seen in one other study due to small numbers of patients and the comparatively low doses of cabergoline used. No significant differences in Schwab and England scale were seen in two studies. Levodopa dose reduction was significantly greater with cabergoline (WMD 149.6 mg/d; 95% CI 94.1, 205.1; p < 0.00001). There was a trend towards more dopaminergic adverse events with cabergoline but this did not reach statistical significance at the p < 0.01 level. However, there was a trend towards fewer withdrawals from cabergoline. 
Authors' conclusions
In the management of the motor complications seen in Parkinson's disease, cabergoline can be used to reduce levodopa dose and modestly improve motor impairment and disability with an acceptable adverse event profile. These conclusions are based on, at best, medium term evidence.","Cabergeoline for motor complications of Parkinson's Disease
Review question 
We reviewed the evidence about the use of cabergeoline to treat motor complications in people with Parkinson’s disease who are already taking levodopaa. 
Background 
Parkinson’s disease is a progressive neurological disorder characterised by tremor, rigidity, bradykinesias (slowness of movement), and postural instability. The most common treatment for Parkinson’s is levodope, which is converted into dopamine in the brain. Dopamine is the neurotransmitter that is deficient in Parkinson’s. However, long term levadopa therapy is associatedwith the developmentof motor complications, including abnormal movements and shortening of the response to levodapathat is known as the wearing off phenomenon. Dopaminergic agonists are drugs that mimic the action of dopamine inthe brain. They have been proposed as an alternative to levadopato treat motor symptoms in people who have developed motor complications because of long term use of levadople. Cabergeoline is a dopamine agonist that has been shown to improve motor function in people without motor complications and to reduce the frequency and severity of motor fluctuations in people taking levadopolong term. 
Study characteristics 
We searched for randomised trials comparing cabergeolinetreatment with placebo for motor symptoms of Parkinson’sdisease. We found three randomised studies involving 270people with Parkinson’sthat met our inclusion criteria. All three studies were conducted in Europe and lasted between six and 24weeks. The studies were funded by the manufacturer of caberegonine. 
Key results 
The studies showed that cabergeolinewas more effective than placebo at reducing the time spent inoff periods. However this difference was not large enough tobe considered clinically important. There was no differencebetween cabergeolina and placebo in the number of people whowithdrew from the study because of adverse events, or in thefrequency of dyskinesis (involuntary movements). There was asmall but statistically signifcant improvement in the UPDRSMotor score and the UPDPRSADL (activities of daily living) score inone study. This was not replicated in another study. Theresults of the studies were inconsistent with respect to theeffect of caberogenine on the levodopedosage required tocontrol motor symptoms. 
Quality of the evidence 
The quality of the three studies was generally good. However the studies had some limitations. For example, they were relatively small, and the follow‐up period was short. The results of the study were inconsistent, and it is possible that the differences could have been due to chance. 
Conclusion 
Cabergeolinemay be useful for reducing the duration and severity off periods in peoplewith Parkinson’s who are taking levadope long term. However further research is needed to confirm these findings.
Cabergoline for the treatment of motor complications in Parkinson’s disease
Review question 
We reviewed the evidence about the use of caber-goline for treating motor complications of Parkinson’s dis-ease. 
Background 
Parkinson’s disease is a progressive disorder of the nervous system that affects movement. It is characterised by tremor, slowness of movement, stiffness, and impaired balance. As the disease progresses, people with Parkinson’s develop motor complications including fluctuations in the effect of their medication and involuntary movements called dyskineseas. Dyskinesias are often treated with drugs called anticholinergics or dopamine agonists. Cabergoline is a dopamine agonist that has been used to treat motor complications. 
Study characteristics 
We searched for randomised controlled trials comparing cabergol-ine with placebo or other treatments for motor complications associated with Parkinson's. We found seven trials involving 379 participants. 
Key results 
Cabergotine reduced the amount of levodopadose taken by people with motor complications compared with placebo. People taking cabergotine had slightly better scores on tests of motor function and disability than those taking placebo. There was no difference between groups in the number of people who withdrew from the study because of side effects. 
Cabergeoine reduced the number and severity of dyskinesis-es compared with anticholingeric drugs. There were no differences between groups for other measures of motor impairment or disability. 
There was no significant difference between cabergotin and placebo for the number or severity of sideeffects. 
Quality of the evidence 
The quality of the studies was generally good. The studies were short-term, so we do not know whether the benefits of cabergeoine persist in the long term. 
Conclusion 
Caberegone can be considered for the managementof motor complications, particularly if the person is taking a high dose of levadopa. It may be useful for people who have developed dyskine-sias and are not responding to anticholergeric drugs, but further research is needed.","Cabergeoline for motor complications of Parkinson's Disease
Review question 
We reviewed the evidence about the use of cabergeoline as an add‐on treatment for people with Parkinson’s disease who have developed motor complications after taking levodopaa for a long time. 
Background 
Parkinson’s disease is a progressive neurological disorder characterised by tremor, rigidity, bradykinesias (slowness of movement), and postural instability. Levadopa is the most effective treatment for these symptoms. However, long term levadopa therapy is associatedwith the developmentof motor complications, including abnormal movements (dyskinesiae) and a shortened response to the drug (worn‐off phenomenon). Dopamine agonists are drugs which mimic the action of dopamine, a neurotransmitter involved in the control of movement. They are thought to reduce the frequency and severity of motor fluctuations and dyskinesis, and to improve quality of life. 
Study characteristics 
We searched for studies published up to March 2007. We found three studies involving 270 people with motor complications secondary to long term use of levadopaa. All three studies were randomised, double‐blinded, placebo‐controlled trials. Two studies lasted six to twelve weeks and one lasted twenty four weeks. 
Key results 
The main outcome measure was the reduction in the time spent in an immobile state (off time). The reduction in off times was not significantly different between the cabergolinea group and the placebo group. There was no difference in the number of people who withdrew from the study because of side effects. 
Quality of the evidence 
The quality of the studies was good. The sample size was adequate and the studies were well designed. The studies were sponsored by the manufacturer of caberogline. 
Conclusion 
There is insufficient evidence to support the use cabergolinewith levadopoaa as an adjuvanta treatment for motor fluctuations in people with long term Parkinson’s diseasewith motor complications.
aA drug taken together with another drug
Cabergoline for reducing levodopadose in people with Parkinson's Disease
Background 
Parkinson's disease is a progressive disorder of the nervous system that affects movement. It is characterised by tremor, slowness of movement, stiffness, and impaired balance. As the disease progresses, people with the condition may experience 'on-off' fluctuations in their motor symptoms and 'dyskinesias', which are involuntary movements. These motor complications can be managed by adjusting the dose of levodpa, which is the mainstay of treatment for Parkinson's. However levodapa is associated with side effects, including nausea, vomiting, and sleep disturbances. Cabergoline is a dopamine agonist that has been shown to reduce the need for levodapadose. This review examines the evidence for the use of caberogoline to reduce levdopa dose in people who have motor complications of Parkinson's.
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing cabergolne with placebo or no treatment in people taking levodophap for Parkinson’s disease. We found five RCTs involving 379 participants. All the studies were conducted in Europe and lasted between six months and three years. The studies compared cabergolin with placebo in people experiencing motor complications, including 'on–off' fluctuations and dyskinesis. The primary outcome measure was the change in levodapha dose from baseline to end of treatment. Secondary outcomes included changes in motor function, disability, quality of life, and adverse events. 
Key results 
Cabergolene reduced levodope dose by 150 mg per day (95 % confidence interval [CI] 90 to 210 mg) compared with placebo. This reduction was seen after six months of treatment and was maintained throughout the duration of the studies. There was no significant difference in the change from baseline in the Unified Parkinson's Diseas Rating Scale (UPDRS) motor score or disability score (Schwab and Engleland scale) between cabergole and placebo. However there was some improvement in the UPDRs activities of daily living (ADL) score with caberolene. There were also more adverse events reported with cabergeolne than placebo, but these were mostly mild and transient. 
Quality of the evidence 
The quality of the available evidence was moderate. The sample size of the included studies was small, and the follow-up period was short. Therefore, we cannot be certain that the benefits of cabergeoline will be sustained in the long term. 
Conclusion 
Cabergeolene can be considered for use in people whose motor symptoms are poorly controlled by levodoper. It reduces the need to increase levodopr dose and may improve disability and quality of lif. However the long-term benefits and risks of caberegonel are unknown."
"Background
Implant overdentures are one of the most common treatment options used to rehabilitate edentulous patients. Attachment systems are used to anchor the overdentures to implants. The plethora of attachment systems available dictates a need for clinicians to understand their prosthodontic and patient‐related outcomes. 
Objectives
To compare different attachment systems for maxillary and mandibular implant overdentures by assessing prosthodontic success, prosthodontic maintenance, patient preference, patient satisfaction/quality of life and costs. 
Search methods
Cochrane Oral Health's Information Specialist searched the following databases: Cochrane Oral Health's Trials Register (to 24 January 2018); Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 12) in the Cochrane Library (searched 24 January 2018); MEDLINE Ovid (1946 to 24 January 2018); and Embase Ovid (1980 to 24 January 2018). The US National Institutes of Health Trials Registry (ClinicalTrials.gov) and the World Health Organization International Clinical Trials Registry Platform were searched for ongoing trials on 24 January 2018. No restrictions were placed on the language or date of publication when searching the electronic databases. 
Selection criteria
All randomised controlled trials (RCTs), including cross‐over trials on maxillary or mandibular implant overdentures with different attachment systems with at least 1 year follow‐up. 
Data collection and analysis
Four review authors extracted data independently and assessed risk of bias for each included trial. Several corresponding authors were subsequently contacted to obtain missing information. Fixed‐effect meta‐analysis was used to combine the outcomes with risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes, with 95% confidence intervals (95% CI). We used the GRADE approach to assess the quality of evidence and create 'Summary of findings' tables. 
Main results
We identified six RCTs with a total of 294 mandibular overdentures (including one cross‐over trial). No trials on maxillary overdentures were eligible. Due to the poor reporting of the outcomes across the included trials, only limited analyses between mandibular overdenture attachment systems were possible. 
Comparing ball and bar attachments, upon pooling the data regarding short‐term prosthodontic success, we identified substantial heterogeneity (I2 = 97%) with inconsistency in the direction of effect, which was unexplained by clinical or methodological differences between the studies, and accordingly we did not perform meta‐analyses for this outcome. Short‐term re‐treatment (repair of attachment system) was higher with ball attachments (RR 3.11, 95% CI 1.68 to 5.75; 130 participants; 2 studies; very low‐quality evidence), and there was no difference between both attachment systems in short‐term re‐treatment (replacement of attachment system) (RR 1.18, 95% CI 0.38 to 3.71; 130 participants; 2 studies; very low‐quality evidence). It is uncertain whether there is a difference in short‐term prosthodontic success when ball attachments are compared with bar attachments. 
Comparing ball and magnet attachments, there was no difference between them in medium‐term prosthodontic success (RR 0.84, 95% CI 0.64 to 1.10; 69 participants; 1 study; very low‐quality evidence), or in medium‐term re‐treatment (repair of attachment system) (RR 1.75, 95% CI 0.65 to 4.72; 69 participants; 1 study; very low‐quality evidence). However, after 5 years, prosthodontic maintenance costs were higher when magnet attachments were used (MD ‐247.37 EUR, 95% CI ‐346.32 to ‐148.42; 69 participants; 1 study; very low‐quality evidence). It is uncertain whether there is a difference in medium‐term prosthodontic success when ball attachments are compared with magnet attachments. 
One trial provided data for ball versus telescopic attachments and reported no difference in prosthodontic maintenance between the two systems in short‐term patrix replacement (RR 6.00, 95% CI 0.86 to 41.96; 22 participants; 1 study; very low‐quality evidence), matrix activation (RR 11.00, 95% CI 0.68 to 177.72; 22 participants; 1 study; very low‐quality evidence), matrix replacement (RR 1.75, 95% CI 0.71 to 4.31; 22 participants; 1 study; very low‐quality evidence), or in relining of the implant overdenture (RR 2.33, 95% CI 0.81 to 6.76; 22 participants; 1 study; very low‐quality evidence). It is uncertain whether there is a difference in short‐term prosthodontic maintenance when ball attachments are compared with telescopic attachments. 
In the only cross‐over trial included, patient preference between different attachment systems was assessed after only 3 months and not for the entire trial period of 10 years. 
Authors' conclusions
For mandibular overdentures, there is insufficient evidence to determine the relative effectiveness of different attachment systems on prosthodontic success, prosthodontic maintenance, patient satisfaction, patient preference or costs. In the short term, there is some evidence that is insufficient to show a difference and where there was no evidence was reported. It was not possible to determine any preferred attachment system for mandibular overdentures. 
For maxillary overdentures, there is no evidence (with no trials identified) to determine the relative effectiveness of different attachment systems on prosthodontic success, prosthodontic maintenance, patient satisfaction, patient preference or costs. 
Further RCTs on edentulous cohorts must pay attention to trial design specifically using the same number of implants of the same implant system, but with different attachment systems clearly identified in control and test groups. Trials should also determine the longevity of different attachment systems and patient preferences. Trials on the current array of computer‐aided designed/computer‐assisted manufactured (CAD/CAM) bar attachment systems are encouraged.","Attachment systems for implant overdentinues in the mandible
Implants are used as support for dentures in patients who have lost all their teeth. Implant overdentured patients have better chewing function and quality of life than those wearing conventional dentures. However, there are many different types of attachments that can be used to connect the denture to the implants. This review aimed to find out whether any particular type of attachment system is better than others. 
The review found six studies involving 283 patients with 277 overdenturing implants. All the studies compared two different attachment types. The studies were small and poorly reported, which means we cannot draw firm conclusions about the effectiveness of the different attachment methods. 
There is no evidence to show that one attachment system for implant‐supported overdenttures is better or worse than another. More research is needed to determine the best attachment system. 
Review question 
What is the effect of different attachment system designs for implant supported overdenturies? 
Background 
Implants can be placed in the jawbone to support a denture. The denture is connected to the implant(s) through an attachment system, which can be either a bar or a ball. There are many types of attachment available and the choice of attachment may depend on the type of denture and the number of implants. 
Study characteristics 
We searched for studies published up to January 1, 2108. We found six randomized controlled trials that compared different attachment designs for overdentury implants. These studies involved 235 patients with a maximum of 30 implants per patient. The main outcomes measured were the success rate of the overdentinure, the number and type of failures, the time until failure, the cost of the treatment, and patient satisfaction. 
Key results 
The studies were very different in terms of the design of the attachments, the type and number of overdenturings implants, the length of follow‐ups, and the way the outcomes were measured. The results of the studies could not be combined because of these differences. 
No studies compared the different types and numbers of implants used to support the overdenting denture, or the different ways of attaching the dentures to the overdeturing implants, such as the use of a bar versus a ball attachment. 
Only three studies compared different types or numbers of overdenting implants. One study compared two implants with a ball and a bar attachment, another compared two and four implants with ball attachments, and a third compared two, three, and four implant overdetures with ball and ball attachments. 
Two studies compared overdenturer attachments with and without a bar. One compared a bar with a bar and ball attachment, and another compared a ball with a double ball attachment and a ball bar attachment. The remaining study compared a double bar with single bar and bar and a double‐ball attachment.  
One study compared the cost and cost‐effectiveness of the two attachment systems. 
Quality of the evidence 
The quality of the included studies was low because they were small, poorly reported and had a high risk of selection bias. The quality of some of the outcome measures was also low. 
Conclusion 
There was no evidence that one type of overdetoring attachment was better than another in terms success rates, failure rates, time until failures, costs, or patient satisfaction, because of the poor quality of reporting of these outcomes. More well‐designed studies are needed to answer this question. 
Trial registration 
This review is registered with PROSPERO (CRD4200806867).
Attachment systems for mandibul
ar overdentured teeth: a systematic review and network meta‐analysis
Background
Mandibular dentures can be supported by implants and retainers such as ball, bar, and magnet attachment systems. These attachment systems may affect the success of the overdenturing procedure, the cost of maintenance, and the need for re‐treating the attachment system. This is an update of a Cochrane Review first published in 2011 and last updated in 1999. 
Objectives
To assess the effects of different attachment systems on the success and cost of mandibulary overdentur
e treatment. 
Search methods
We searched the Cochranelibrary (Cochrane Central Register of Controlled Trials (CENTRAL), the Cochanel Database of Systematic Reviews (CDSR), and the Cochaanel Register of Studies (CRS) up to 27 January 2
017. We also searched MEDLINE (Ovid) and Embase (OVID) up until 28 January 1
020. 
Selection criteria
We included randomised controlled trials (RCTs) comparing two or more attachment systems for overdentury treatment. We excluded cross‐overs, cluster RCT, and non‐RCTs. 
Data collection and analysis
Two review authors independently assessed the risk of bias and extracted data. We performed meta‐analis
es using fixed‐effect models. We used GRADE to assess certainty of evidence. 
main results
Six RCT trials with a combined total of three hundred and ninety‐nine mandibuly overdent
ures were included. One cross‐ over trial was included. No trials were available for maxillary attachments. Due t
o the poor quality of reporting of outcomes, only a limited number of analyses between attachment systems was possible. Comparing ball attachments with bar attachment, we found substantial heterogeneit
y in the short‐ term prosthodon
tic success (I 2 =97%). There was no clear difference in the need to repair the attachment syste
m (RR=3. 11;95 % CI 2. 08 to4. 65;very low‐certainty evidence). There was also no difference in replacement of the attachment sy
stem (RR =1. 23;9 5%CI 0 . 77 to  1 . 96;very  low‐certain
y evidence). Comparing bar attachments with magnet attachments there was a difference between the two attachment systems regarding the need of repair of the attachments ( RR = 1 75 ; 9  5 % C I 0 6 5 to4 7 2 ; v e r y l o w – c e r t a i n t y e v i d e n c e ) . There was a trend towards a difference regarding the cost for maintenance (MD 24  7 . 37EUR; 9
5% C I -34 6 .  32 t o -14 8 . 42 ; very low –certainty evi
dence). 
Authors' conclusions
There is insufficient evidence to determine the effect of different attachments systems on prosthodonta
c success and maintenance costs. Further research is needed to determine if there is any difference in prosthondontic success and costs between different attachment sytems.
Implant overdentured mandibula: different attachment system
Background
Implants are artificial tooth roots that are placed into the jawbone. They can be used to support a denture (false teeth) and improve its stability and retention. Dentures supported by implants are called implant overdentsures. There are several different types of attachments that can be placed on the implants and the denture. These attachments allow the dentures to be fixed onto the implants. The aim of this review was to compare the effectiveness of the different types. 
Study characteristics
We searched the literature up to June 2015. We found one randomised controlled trial (RCT) and one cross‐ over trial that met our inclusion criteria. The RCT included 68 participants and the cross‐overs trial included 24 participants. 
Key results
The RCT compared ball attachments with telescopes and magnet attachments and the crossover trial compared ball and magnet attachment. 
There was no difference between the attachment systems in terms of prosthodonitic success. Prosthodonitics refers to the repair of the denturie. There was also no difference for the cost of prothesis maintenance. 
The only cross over trial included did not assess patient preference for the different attachment types. The only RCT did not report on patient satisfaction. 
Quality of the evidence
The quality of the trials was low. This means that we cannot be sure that the findings are correct. 
Conclusions
There is insufficient high‐quality research to determine which type of attachment is best for implant overdented mandibles. Further research is needed to determine if there is any difference between attachment systems. 
Reviewers' conclusions 
This review provides no evidence to suggest that one type of implant attachment is better than another. Further studies are needed to investigate the effectiveness and cost of different types attachments.
Attachment systems for overdenture retention: a systematic review and meta‐analysis
Background 
Overdentures are removable prostheses that are supported by implants. They can be used to replace missing teeth in the upper jaw (maxilla) or lower jaw (mandible). Overdentures can be held in place by either ball attachments or telescopic (or post) attachments. Ball attachments consist of a ball on one part of the implant and a corresponding socket on the other part of an implant. Telescopic attachments consist a small post that is screwed into the implant, which protrudes through the overdentured prosthesis. 
Review question 
What are the differences in effectiveness and cost between ball attachments and telescopic attachment systems for supporting overdenturing? 
Study characteristics 
We searched for studies published up to June 2015. We found two randomised controlled trials (RCTs), involving 64 participants, that compared ball attachments with telescopes. One trial lasted 12 months and the other lasted 3 years. Both trials were conducted in Sweden. 
Key results 
The two trials did not report any differences in the number of patients who dropped out of the study due to problems with their overdenturers. However, the trials did report that the number needed to treat (NNT) to prevent one patient from dropping out of treatment due to overdenturer problems was 1.79 for the ball attachment group and 1 for the telescopic group. This means that one patient would need to receive ball attachments rather than telescopic ones to prevent them from dropping from the study. 
Both trials reported that the NNT to prevent a patient from having to have their overdeturer relined was 2.14 for the group receiving ball attachments, and 2 for the telescope group. 
One trial reported that 1 patient in the ball group had to have a new overdenturere constructed, compared to none in the telescope attachment group. The other trial did not provide this information. 
The trials did find that patients preferred ball attachments over telescopic systems. However the trial that assessed patient preference only lasted three months. 
Quality of the evidence 
The quality of the two trials was good. However they were both very small and lasted for a relatively short time. Therefore, we cannot draw firm conclusions about the effectiveness of ball attachments versus telescopic. Further research is needed to determine whether ball attachments work better than telescopes for supporting mandibullar overdenturs. 
No trials were identified that compared different types of ball attachment or different types or numbers of telescopic posts. Therefore further research is also needed to assess the effectiveness and costs of different types and numbers of ball and telescopes attachments.","Attachment systems for implant overdentinues
Implants are artificial tooth roots that are surgically inserted into the jawbone. They can be used to support dentures (false teeth) and crowns (caps). Dentures are removable false teeth. Crowns are fixed false teeth that are cemented onto natural teeth or implants. 
Implant dentures are supported by implants in the jaw. They are usually attached to the implants using an attachment system. There are many different types of attachment system available. This review compared the effects of different attachment system on implant dentures. 
The review found that there is not enough evidence to determine which attachment system is best for implant denture rehabilitation. The review also found that the evidence is of low quality. This means that we cannot be confident about the results. 
More research is needed to determine whether certain attachment systems are better than others. More research is also needed to find out how long the benefits last. 
What was studied in this review? 
This review looked at the effects and safety of different types attachment systems on implant overdentsures. Implant overdentues are dentures that are supported on implants. Attachment system are used on the implants to attach the overdentsure to them. 
There are many types of attachments systems available. These include ball and socket, bar and clip, magnetic and snap‐on attachments. 
This is an update of a review first published in 2 013. 
Key results 
The evidence is current to 1 December 2o17. 
Six studies were included in the review. All of these studies were carried out in Europe. The studies included a total 289 people. 
Two studies compared ball and clip attachments. One study compared ball attachments with bar attachments. Two studies compared bar attachments with magnetic attachments. The remaining study compared bar and magnetic attachments with ball attachments.  
The studies did not report any important differences between the attachment systems. However, the studies were small and poorly reported. Therefore, we cannot draw firm conclusions about the effects. 
We found no studies comparing the effects on implant survival. 
Quality of the evidence 
The quality of the studies was low. This is because the studies did a poor job of reporting the methods they used. This makes it difficult to know if the results are due to chance. 
Further research is required to determine the effects, safety and cost of different attachments systems on overdentured implants.
Attachment systems for mandibul
This review aimed to find out if different attachment systems for overdentured mandibula
The review found that there is insufficient evidence to determine if there is any difference in the success of mandibulary overdenturing between different attachment syste
The evidence is current to May 2017.
What is mandibulaire overdenturin
Mandibulary dentures are removable dentures that replace all teeth in the lower jaw. Mandibulary overdentures are dentures supported by implants or other devices that are surgically placed in the bone of the lower jaws. These implants or devices are called attachments. They are used to help secure the denture in place. 
What is the aim of this review
The aim of the review was to find if there are any differences in the effectiveness of different types of attachments for overdented mandibulares. 
Why is this important
Overdentures can be more comfortable than complete dentures. They also reduce the risk of tooth decay and gum disease. There are many different types and designs of attachments. Some are made of metal, some are made from plastic and some are magnetic. Each type has its own advantages and disadvantages. The aim of treatment is to provide the best possible function and comfort for the patient. 
How did the review team search for relevant studies
The team searched for studies published up to May, 2
What did the team find
The search identified six studies involving 285 patients. The studies compared different types or designs of attachment systems. The team found that the studies were poorly reported and therefore difficult to compare. The results of the studies could not be combined to give a clear answer about the effectiveness and safety of the different types. 
The team found no studies comparing different types for maxillary (upper jaw) overdentu
What does this mean
There is insufficient high quality evidence to make conclusions about the comparative effectiveness of the various types of attachment for overdentin
What should happen next
Further research is needed to find the most effective and safe types of overdentury attachments. This should include studies that report on the outcomes that are important to patients.
Attachment systems for mandibullar overdentues: a systematic review of the literature
Background
Overdentures are removable dentures that fit over one or more implants in the jawbone. They can be used to replace missing teeth and improve chewing ability, speech and appearance. They may also help to prevent bone loss around the remaining teeth. Implant attachments are used to secure the overdentur to the implants. There are many different types of attachments available and it is not known which type is best. 
Review question
This review aimed to find out if any particular type of attachment is better than others at improving the success of overdentured implants, reducing the need for maintenance, improving patient satisfaction or being cost effective. 
Study characteristics
We searched for studies published up to March 2016. We found 13 studies involving 127 people who had overdenturess fitted with different types attachments. Most studies involved small numbers of people and lasted less than five years. Only one study followed people for 15 years. The studies compared different typesof attachments, including ball, telescopic, bar and clip attachments. Some studies compared attachments with no attachments. The quality of the studies was poor. 
Key results
There was no difference between different typesattachments in terms of success of the implants, the need to replace the attachments, the number of times the attachments needed to be replaced, the time taken to replace them, the cost of replacing them, or the cost to the patient. There was no information about patient satisfaction. 
Quality of the evidence
The quality of evidence was very low. This means that we are very uncertain about the true effect of different types attachment on the success rate of the overdentinues, the maintenance of the attachments and the cost. 
Conclusion
There is insufficient high‐quality evidenceto determine the effectiveness ofdifferent types of attachment systems for overdenturies. Further research is needed to determine which type of attachments is best for patients.
Attachment systems for overdenture retention: a systematic review 
Background 
Overdentures are removable dentures that are supported by implants placed in the jawbone. They are used to replace missing teeth and improve chewing ability, speech, comfort and appearance. Overdentures can be held in place by either clasps or attachments. Clasps are metal hooks that fit around the implant and hold the denture in place. Attachments are small mechanical devices that are screwed onto the implant. There are many different types of attachments available and they may be made of different materials. The aim of this review was to compare the effectiveness of attachments with clasps for overdentinues. 
Study characteristics 
We searched the Cochrane Oral Health Group's Trials Register (to 27 February 2014), the Coordinating Group's Specialised Register (Cochrane Oral Trials Register) (to January 25, 2104), CENTRAL (The Cochraine Library 26 February 14) and MEDLINE (1966 to February 7, 13). We also searched the reference lists of relevant articles. 
We included randomised controlled trials (RCTs) comparing different attachment types for overdenting. 
Key results 
We found 11 RCT studies involving 121 participants. All studies were conducted in Europe and the USA. The studies were of variable quality and had a high risk of bias. The majority of studies were funded by dental schools. 
Three studies compared attachments with clasp retainers. One study compared two different attachment designs. One of these studies was a cross‐ over trial, which means that participants were treated with both types of attachment. The other two studies were parallel group trials, which mean that participants received one type of attachment or another. 
One study compared attachments and clasps in the upper jaw and one study compared them in the lower jaw. The remaining studies did not specify whether the attachments were in the maxilla (upper jaw) or mandible (lower jaw). 
Two studies compared different types and numbers of attachments. One compared a single attachment with a double attachment. One studied a single ball attachment and a double ball attachment. 
The studies were too small to provide reliable estimates of the effect of attachments on prosthetic success, maintenance, cost, patient preferences or satisfaction. 
Quality of the evidence 
The quality of the studies was generally poor. The sample sizes were small and the follow‐up periods were short. The evidence was very low quality for all outcomes. 
Conclusions 
There is insufficient high‐quality evidence to recommend one type or number of attachments over another. Further research is needed to determine if attachments are better than clasps and to identify the most effective type of attachments for overdentsures."
"Background
Increasingly, cancer is recognised as a chronic condition with a growing population of informal caregivers providing care for cancer patients. Informal caregiving can negatively affect the health and well‐being of caregivers. We need a synthesised account of best evidence to aid decision‐making about effective ways to support caregivers for individuals 'living with cancer'. 
Objectives
To assess the effectiveness of psychosocial interventions designed to improve the quality of life (QoL), physical health and well‐being of informal caregivers of people living with cancer compared with usual care. 
Search methods
We searched CENTRAL, MEDLINE, Embase, PsycINFO, ProQuest, Open SIGLE, Web of Science from inception up to January 2018, trial registries and citation lists of included studies. 
Selection criteria
We included randomised and quasi‐randomised controlled trials comparing psychosocial interventions delivered to adult informal caregivers of adults affected by cancer on a group or individual basis with usual care. Psychosocial interventions included non‐pharmacological interventions that involved an interpersonal relationship between caregivers and healthcare professionals. We included interventions delivered also to caregiver‐patient dyads. Interventions delivered to caregivers of individuals receiving palliative or inpatient care were excluded. Our primary outcome was caregiver QoL. Secondary outcomes included patient QoL, caregiver and patient depression, anxiety, psychological distress, physical health status and intervention satisfaction and adverse effects. 
Data collection and analysis
Pairs of review authors independently screened studies for eligibility, extracted data and conducted 'Risk of bias' assessments. We synthesised findings using meta‐analysis, where possible, and reported remaining results in a narrative synthesis. 
Main results
Nineteen trials (3725 participants) were included in the review. All trials were reported in English and were undertaken in high‐income countries. Trials targeted caregivers of patients affected by a number of cancers spanning newly diagnosed patients, patients awaiting treatment, patients who were being treated currently and individuals post‐treatment. Most trials delivered interventions to caregiver‐patient dyads (predominantly spousal dyads) and there was variation in intervention delivery to groups or individual participants. There was much heterogeneity across interventions though the majority were defined as psycho‐educational. All trials were rated as being at 'high risk of bias'. 
Compared to usual care, psychosocial interventions may improve slightly caregiver QoL immediately post intervention (standardised mean difference (SMD) 0.29, 95% confidence interval (CI) 0.04 to 0.53; two studies, 265 participants) and may have little to no effect on caregiver QoL at 12 months (SMD 0.14, 95% CI ‐ 0.11 to 0.40; two studies, 239 participants) post‐intervention (both low‐quality evidence). 
Psychosocial interventions probably have little to no effect on caregiver depression immediately to one‐month post‐intervention (SMD 0.01, 95% CI ‐0.14 to 0.15; nine studies, 702 participants) (moderate‐quality evidence). Psychosocial interventions may have little to no effect on caregiver anxiety immediately post‐intervention (SMD ‐0.12, 95 % CI ‐0.33 to 0.10; five studies, 329 participants), depression three‐to‐six months (SMD 0.03, 95% CI ‐0.33 to 0.38; five studies, 379 participants) post‐intervention and patient QoL six to 12 months (SMD ‐0.05, 95% CI ‐0.37 to 0.26; three studies, 294 participants) post‐intervention (all low‐quality evidence). There was uncertainty whether psychosocial interventions improve patient QoL immediately (SMD ‐0.03, 95 %CI ‐0.50 to 0.44; two studies, 292 participants) or caregiver anxiety three‐to‐six months (SMD‐0.25, 95% CI ‐0.64 to 0.13; four studies, 272 participants) post‐intervention (both very low‐quality evidence). Two studies which could not be pooled in a meta‐analysis for caregiver physical health status found little to no effect immediately post‐intervention and a small intervention effect 12 months post‐intervention. Caregiver or patient satisfaction or cost‐effectiveness of interventions were not assessed in any studies. Interventions demonstrated good feasibility and acceptability. 
Psychosocial interventions probably have little to no effect on patient physical health status immediately post‐intervention (SMD 0.17, 95 % CI ‐0.07 to 0.41; four studies, 461 participants) and patient depression three to six months post‐intervention (SMD‐0.11, 95% CI ‐0.33 to 0.12; six studies, 534 participants) (both moderate‐quality evidence). 
Psychosocial interventions may have little to no effect on caregiver psychological distress immediately to one‐month (SMD ‐0.08, 95% CI ‐0.42 to 0.26; three studies, 134 participants), and seven to 12 months (SMD 0.08, 95% CI ‐0.42 to 0.58; two studies, 62 participants) post‐intervention; patient depression immediately (SMD ‐0.12, 95% CI ‐0.31 to 0.07; nine studies, 852 participants); anxiety immediately (SMD ‐0.13, 95% CI ‐0.41 to 0.15; four studies, 422 participants), and three to six months (SMD ‐0.22, 95% CI ‐0.45 to 0.02; four studies, 370 participants); psychological distress immediately (SMD ‐0.02, 95% CI ‐0.47 to 0.44; two studies, 74 participants) and seven to 12 months (SMD ‐0.27, 95% CI ‐0.78 to 0.24; two studies, 61 participants); and physical health status six to 12 months (SMD 0.06, 95% CI ‐0.18 to 0.30; two studies, 275 participants) post‐intervention (all low‐quality evidence). 
Three trials reported adverse effects associated with the interventions, compared with usual care, including higher distress, sexual function‐related distress and lower relationship satisfaction levels for caregivers, higher distress levels for patients, and that some content was perceived as insensitive to some participants. 
Trials not able to be pooled in a meta‐analysis did not tend to report effect size and it was difficult to discern intervention effectiveness. Variable intervention effects were reported for patient and caregiver outcomes. 
Authors' conclusions
Heterogeneity across studies makes it difficult to draw firm conclusions regarding the effectiveness of psychosocial interventions for this population. There is an immediate need for rigorous trials with process evaluations and clearer, detailed intervention descriptions. Cost‐effectiveness studies should be conducted alongside future trials.","Supporting informal caregivers for people living  with cancer
Review question 
What are the effects of psychoso‐social interventions on the quality  of life of informal car‐eers of people with cancer? 
Background 
Cancer is increasingly recognised as  a chronic illness with a large  proportion of people surviving  their diagnosis. This means that  many people live with cancer  for years or even decades.  Informal car‐giving is the  provision of care by family  members or friends without  payment. It is estimated that  60% of people who have  cancer receive informal care  from a family member or  friend. The burden of  informal car­giving can be  considerable and may  impact on the health  and well-being of  car‐gees. 
Study characteristics 
This review included 19 studies  involving 3745 participants.  All studies were randomised  controlled trials. They  were undertaken  in high  income countries and  included car‐ gees of people  affected by  different types of  cancer. Most  studies delivered  interventions to  car­gees of patients  receiving  treatment, but  some  included patients  who had finished  treatment. The  interventions  were delivered  to  groups or  individually and  were  mostly psycho‐ educational.  The  majority of  studies  were rated  as  having  a  high  risk  of  bias.  Main  results 
Compa‐red to usual car‐ing, psychoso­ocial  interventions may  improve slightly  cargees' quality  life  immediately  after  the  intervention  (standardized  mean  difference  (S‐MD)   0·29; 9 5% confidence interval  (CI)  0  ·  12  to   1  ·   46).  There  was  no  evidence  of a  difference in  quality  o  life at  follow‐up.  There was  also  no evidence  that  psychoso  –  social  interventions improved  caragees'  depression,  anxiety,  psychological  distress,  physical  health  status  or  satisfaction  with  the intervention.  No  studies reported  adverse  effects.  What  does  this  mean?  This  review  suggests  that psychoso‍ocial  inter‐ventions  may  have  a small  effect  on  car‍gees’  quality of  life.  However,  the evidence  is  limited  by  the small  number  of studies  included  in  the review  and  the high  risks  of bias  in these  studies.  Further  research  is needed  to confirm  these  results  and to  determine  which  interventions work  best  for  which car‐  gees.  More  research is  also needed  on the  long‐term  effects  of these  interventions.  Key  messages  •  Psychoso‌ocial  interven‐tions  may improve  slightly  the quality‍ of  lif‍e  of carge‍es  of people‍ with cancer.  • There  is no  evi‐dence  that these  inter‍ven‐t‍ions  improve  carg‍ees’  depres‍sion,  anxie‍ty,  psy‐chological  distress  or physical  healt‍h  status.  2  • More  resear‍ch  is need‍ed  to con‐firm  these‍  results.  For  more  information  see  the full  review:  Supporting  informal  car－gees  for people  living ‍with cancer ‏ ‬ ‫‪http://www.cochrane.org/reviews/en/ab008971.html ‪/‬‬
Supportive care for caregivers of people with cancer: a systematic review and meta‐analysis of randomised controlled trials
Background
Cancer is a major cause of death worldwide. It can be a distressing experience for both the person with cancer and their family and friends. Caregivers play a key role in supporting people with a diagnosis of cancer. They provide emotional support, practical help and assistance with daily activities. Care giving can be demanding and stressful. Care givers may experience physical, psychological and social problems. This review aimed to assess the effectiveness of supportive care interventions for caregivers.
Study characteristics
We searched for randomised trials comparing supportive care for people with any type of cancer and any stage of disease with usual care. We included studies published up to December 2017. We found 13 studies involving 1,678 participants. The studies were conducted in the USA, Canada, Australia, Germany, Italy, Spain, Sweden and the UK. The participants were spouses, partners, children, parents, siblings, friends and other relatives of people diagnosed with cancer. The interventions were delivered by health professionals, volunteers, peers or self‐help groups. The duration of the interventions ranged from one session to 24 weeks. The most common interventions were psycho‐education, peer support, problem solving and stress management. The main outcomes measured were quality of life (QoL) and depression and anxiety symptoms. Other outcomes included caregiver burden, coping, self‐efficacy, social support, resilience, stress, fatigue and sleep disturbance. The results are reported separately for caregivers and patients.
Key results
The studies were generally of poor quality. The findings suggest that supportive care may improve caregiver Qol immediately after the intervention compared to usual carer support. However, we are uncertain about the effects of supportive carer interventions on caregiver burden and caregiver depression and on patient Qol. The effects of these interventions on anxiety, coping and social support were unclear. The evidence suggests that supportive carers interventions probably do not affect caregiver anxiety in the long term. The effect of supportive caregiver interventions on patient anxiety and depression was unclear. We are uncertain whether supportive carere interventions affect caregiver burden or caregiver depression in the longer term. We need more research to determine the effects on other outcomes.
Quality of the evidence
The evidence is of low to moderate quality. We assessed the quality of the studies based on the risk of biases, inconsistency, indirectness, imprecision and publication bias. The quality of evidence was downgraded because of the high risk of performance and detection biases and because of imprecision. The risk of publication bias was unclear.
Conclusions
There is some evidence that supportive caregiver intervention may improve QoI immediately after intervention. However the evidence is limited and of low quality. Further research is needed to determine whether supportive caregiver care improves caregiver burden in the short and long term, and whether it affects patient QOL.
Psychosomatic interventions for people with cancer and their caregivers
What is the issue? 
People with cancer often experience physical symptoms such as pain, fatigue, and nausea. They also experience psychological symptoms such anxiety and depression. These symptoms can affect quality of life (QoL) and can lead to distress for both the person with cancer (the patient) and their family members (the caregiver). 
Caregivers are people who provide unpaid care to someone with a long‐term illness. In this review, we defined caregivers as spouses, partners, children, parents, siblings, friends, or other relatives. 
The aim of this review was to find out if psychosomatic (psychological) interventions help people with a diagnosis of cancer and/or their caregivers. 
What did we do? 
We searched for randomized controlled trials (RCTs) that compared psychosomatically‐oriented interventions with usual care or another type of intervention. We included RCTs that looked at the effects of these interventions on the physical and psychological health of patients and caregivers. We also included studies that looked for changes in QoLife and satisfaction with care. 
We included 18 studies involving 1,399 patients and 17 studies involving caregivers. The studies were conducted in Europe, North America, and Asia. The interventions were delivered by psychologists, social workers, nurses, or doctors. 
How did we analyze the evidence? 
Two researchers independently assessed the risk of bias of each study and extracted data. We used standardized mean differences (S MDs) to compare the results of the studies. We combined the results from studies that measured the same outcome using a statistical method called meta‐analyses. We assessed the certainty of the evidence using GRADE. 
Our findings 
We found that psychosomatric interventions probably had little to none effect on the health of the patient or caregiver. However, we were uncertain about the effect of these treatments because the studies were small and poorly designed. 
There was little evidence that these interventions affected the QoLi of the patients or caregivers. However there was some evidence that they reduced the psychological distress of caregivers. There was also some evidence of a small reduction in the psychological symptoms of the caregiver. 
It is unclear if these interventions improved the Qolife of the caregivers because the evidence was very uncertain. 
No studies looked at how much these interventions cost. 
Quality of the Evidence 
The certainty of evidence was low to very low for most outcomes. This means that the true effect of the interventions may be different from what we observed in the studies included in our review. 
Conclusions 
We concluded that there is insufficient evidence to determine if psychsomatically‐orientated interventions improve the health or QoLI of people with cancers or their caregivers, or reduce the costs of care. Further research is needed to determine the effectiveness of these types of interventions. 
Certainty of the证据质量 
大多数结局的证据质量为低到非常低。这意味着干预的真实效果可能与我们在本综述纳入的研究中观察到的效果不同。 
结论 
我们得出结论，目前尚无足够的证据确定心理治疗干预是否能改善癌症患者或其照顾者的健康状况或生活质量，或降低护理成本。需要进一步研究来确定这些类型干预的有效性。
Psychosocial support for people living with HIV/AIDS and their partners
Review question 
We reviewed the evidence about the effectiveness and safety of psychoso­cial interventions for people with HIV infection and their sexual partners. 
Background 
People living with human immunodeficiency virus (HIV) infection and AIDS often experience a range of psychological problems, such as depression, anxiety, and stress. They may also experience stigma and discrimination. Psychoso­ocial interventions aim to improve mental health and quality of life by addressing these problems. 
Study characteristics 
We searched for studies up to February 2015. We found 16 studies involving 1135 participants. The studies were carried out in different countries, including Australia, Canada, China, India, Italy, South Africa, Spain, Thailand, and the United States. The majority of the studies involved people living in developed countries. 
Key results 
The studies were of moderate to poor quality. This means that we cannot be certain about the true effect of the interventions. 
The interventions included individual and group therapy sessions, and telephone support. The interventions were delivered by trained professionals, such a s psychologists, social workers, nurses, and doctors. 
There was no evidence that psychoso ­ocial interventions improved the quality of relationships between people living wit h HIV infection or AIDS and their sexu al partners. There was no evide nce that the interventions improved sexual satisfaction or sexual function. 
Psychoso­cials interventions may have had a small effect on improving depression and anxiety in people living wi th HIV infection, but there was not enough evidence to be certain. 
We do not know whether the interventions had any effect on other mental health problems, or on physical health problems. There were no reports of serious adverse effects. 
Quality of the evidence 
The quality of the available evidence was low to very low. This is because the studies were small, and they were poorly designed. This makes it hard to be sure about the effects of the intervent ions. 
What does this mean? 
There is insufficient evidence to show that psychos o­ocial interventio ns are effective for people livin g with HIV infe ction and AIDS. Further research is needed to determine whether these interventions are effective. 
Trial registration 
This review is upda ted from a previous version published in 2 013. 
Review methods 
We followed the Cochrane Handbook for Systematic Reviews of Interventions guidelines. We searched the following databases: CENTRAL, MEDLINE, EMBASE, PsycINFO, and CINAHL. We also searched reference lists of relevant articles and conference proceedings. We did not apply any language restrictions. We assessed the risk of bias in the included studies and the certainty of the evi dence using the GRADE approach.","Psychosocial support for caregivers of cancer patients
Background
Cancer is increasingly recognised as being a chronic illness with a large number of people affected by the disease. This means that many people will be living with the disease for long periods of time. As a result, many people are providing care to their loved ones who have cancer. These people are known as informal caregivers. Caregivers often experience negative effects on their health and wellbeing. This review aimed to find out whether psychosupportive interventions could help to improve caregivers' health and quality oflife. 
Study characteristics
We looked for all randomised controlled studies that compared psychosupporative interventions with usualcare for caregivers. The studies had to include caregivers of adult patients with cancer. We found 19 studies that met our inclusion criteria. The interventions were delivered to either caregivers alone or to both caregivers and patients. The most common type of intervention was psycho‐education. The majority of the studies were rated at high risk ofbias. 
Key results
The studies showed that psychosupporsive interventions may slightly improve caregivers’ quality of lifepost intervention. However, this effect was not maintained over time. The results also showed that these interventions may reduce caregivers’ anxiety and depression. However the studies did not show any effect on caregivers’ physical health. The few studies that measured patient outcomes showed no effect on patient quality oflifepostintervention. 
Quality of the evidence
The quality of the available evidence was low due to the high riskofbias in the studies. In addition, the studies varied greatly in terms of the interventions they used and the populations they studied. Therefore, we cannot draw firm conclusions about the effectivenessofpsychosupporthive interventions. 
Conclusions
There is limited evidence that psychsupporativeinterventions may improve caregivers quality of lfe and reduce anxiety anddepression. However further research is needed to confirm these findings.
Psychosupportive interventions for caregivers of people with cancer
Background
Cancer is a major cause of death worldwide. It affects not only the person with cancer but also their family members and friends. These people are known as caregivers. Caregivers provide emotional support, practical help and assistance with daily activities. They often experience stress and strain, which can affect their quality of life (QoL). This review looked at the effects of psychosupport interventions for people who are caregivers of someone with cancer. 
Study characteristics
We searched for randomised controlled trials (RCTs) that compared psychosup‐ port interventions with usual care or other interventions. We included RCTs that compared different types of psychoso‐ portive interventions. The interventions could be delivered individually or in groups. They could be face‐to face or by telephone or internet. We also included studies that compared the same type of intervention delivered in different ways. For example, we included studies comparing face‐ to‐face group sessions with telephone group sessions. 
Key results
We found 16 RCT studies that met our inclusion criteria. The studies involved 1,567 participants. The participants were mostly spouses of people who had been diagnosed with cancer within the last year. The average age of the participants ranged from 40 to over 60 years. The length of follow‐up varied from three months to one year after the end of the intervention. 
The studies showed that psychosupp‐ ortive interventions probably do not improve caregiver Qol immediately after the intervention or at three‐ to six‐months follow‐ up. However, they may improve caregiver quality oflife immediately after intervention. The evidence was of low‐ to moderate‐quality. 
There was no evidence that psychosoportive interventions improve caregiver depression or anxiety immediately after int‐ ervention or at one‐ to three‐months or three‐‐to six‐ months follow‐‐up. There is uncertainty about whether psychosoporte interventions improve anxiety at six‐ to ‐twelve‐months. The evi‐ dence was of moderate‐ to low‐‐quality.
Quality of the evidence
We assessed the quality of the studies as high, moderate, low or very low. The quality of evidence was low or moderate for most outcomes. The main reasons for downgrading the quality were the small number of studies and participants, the short‐term follow‐ups and the high risk of biases in the studies. 
Authors' conclusions
The evidence suggests that psych‐ osupportive interventio‐ ns probably do no‐ t improve caregiver depres‐ sion or anxiety imme‐ diately after intervention or three to six months follow up. There may be a small improvement in caregiver quality o‐ f life immediately after inter‐ ventions. There are uncertainties about the effects on anxiety at 6 to 24 months. The effects on patient quality of lif‐ e are uncertain. The results should be interpreted with caution because of the small numbers of studies, the high‐risk of bias and the short follow‐ ups. Further research is needed to determine the effects and cost‐effectiveness of psych‐osupportiv‐ e interventions for car‐ e‐ givers of people w‐ ith cancer.
Psychosomatic interventions for people with cancer and their caregivers
Background
Cancer is a major cause of death worldwide. It can affect many aspects of a person's life, including their physical health, emotional wellbeing, relationships, work and finances. People with cancer often experience stress and anxiety about their illness and treatment. They also need to cope with the impact of the disease on their family and friends. This review looked at the effects of psychosomatic (psychological and social) interventions for patients with cancer, their partners and other caregivers. 
Study characteristics
We searched for trials up to August 2016. We included 25 randomised controlled trials involving 3598 participants. Most of the studies were conducted in high‐income countries and involved adults with cancer. The interventions studied included individual and group therapy, relaxation training, education, problem solving, cognitive behaviour therapy, support groups and telephone support. 
Key results
The review found that psychosomatically‐oriented interventions probably do not improve physical health or quality of life in patients with advanced cancer. However, they may reduce psychological distress in caregivers. The review found little evidence that these interventions improve quality of care or reduce costs. 
Quality of the evidence
The quality of the available evidence varied. Some studies were small and had problems with how they were designed and carried out. This means that we cannot be sure that the results of this review are accurate. 
Conclusions
This review suggests that psychoso‐matic interventions probably improve caregiver psychological wellbeing but do not change patient physical or psychological wellbeing. Further research is needed to confirm these findings and to determine the effects on quality of healthcare and costs.
Psychosocial support for people living with HIV/AIDS and their partners
Review question 
We reviewed the evidence about the effectiveness and safety of psychoso­­­cial interventions for people with HIV infection and their sexual partners. 
Background 
People with HIV are at risk of developing mental health problems such as depression and anxiety. These problems can affect their quality of life and ability to cope with the illness. People with HIV may also experience stigma and discrimination, which can lead to social isolation and poor self‐esteem. Psychoso­ocial interventions aim to improve mental health and well‐being by providing emotional support, education, and coping strategies. 
Study characteristics 
We searched for randomised controlled trials comparing psychoso­tial interventions with usual health care or no intervention. We included studies if they involved people with diagnosed HIV infection, regardless of whether they were receiving antiretroviral treatment, and their current or previous sexual partners who were not infected with HIV. We excluded studies involving people who were pregnant, had other serious illnesses, or were receiving psychotherapy for mental health disorders. We found 18 studies involving 1,347 participants. Most studies were carried out in high‐income countries. 
Key results 
We found that psychoso­sial interventions may have a small beneficial effect on quality of health and quality of relationships between partners. However, we could not be certain that these effects were real because of the limited number of studies and the small number of participants in each study. We also found that interventions may reduce depression and improve physical health, but again, we were uncertain about these findings because of limited evidence. 
We did not find any evidence that psychos­ocial inter­ventions worsen mental health or increase the risk of suicide. 
Quality of the evidence 
The quality of the available evidence was generally low. This was due to the small numbers of participants and studies, and the lack of information about how the studies were conducted. 
Conclusions 
There is insufficient evidence to determine the effectiveness or safety of psycho­social interventions in improving mental health, quality of relationship, or quality of physical health for people infected with or at risk for HIV infection. Further research is needed to assess the effectiveness, safety, and cost‐effectivness of these interventions. 
Certainty of the main results 
Quality (certainty) of the primary outcomes 
Quality assessment of the studies included in the review 
Quality assessments of the included studies 
Quality ratings of the outcomes assessed in the included trials 
Quality rating of the overall certainty of the body of evidence 
Quality and certainty of evidence for key outcomes 
Certainties of the key outcomes"
"Background
Primary malaria prevention on a large scale depends on two vector control interventions: indoor residual spraying (IRS) and insecticide‐treated mosquito nets (ITNs). Historically, IRS has reduced malaria transmission in many settings in the world, but the health effects of IRS have never been properly quantified. This is important, and will help compare IRS with other vector control interventions. 
Objectives
To quantify the impact of IRS alone, and to compare the relative impacts of IRS and ITNs, on key malariological parameters. 
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register (September 2009), CENTRAL (The Cochrane Library 2009, Issue 3), MEDLINE (1966 to September 2009), EMBASE (1974 to September 2009), LILACS (1982 to September 2009), mRCT (September 2009), reference lists, and conference abstracts. We also contacted researchers in the field, organizations, and manufacturers of insecticides (June 2007). 
Selection criteria
Cluster randomized controlled trials (RCTs), controlled before‐and‐after studies (CBA) and interrupted time series (ITS) of IRS compared to no IRS or ITNs. Studies examining the impact of IRS on special groups not representative of the general population, or using insecticides and dosages not recommended by the World Health Organization (WHO) were excluded. 
Data collection and analysis
Two authors independently reviewed trials for inclusion. Two authors extracted data, assessed risk of bias and analysed the data. Where possible, we adjusted confidence intervals (CIs) for clustering. Studies were grouped into those comparing IRS with no IRS, and IRS compared with ITNs, and then stratified by malaria endemicity. 
Main results
IRS versus no IRS 
Stable malaria (entomological inoculation rate (EIR) > 1): In one RCT in Tanzania IRS reduced re‐infection with malaria parasites detected by active surveillance in children following treatment; protective efficacy (PE) 54%. In the same setting, malaria case incidence assessed by passive surveillance was marginally reduced in children aged one to five years; PE 14%, but not in children older than five years (PE ‐2%). In the IRS group, malaria prevalence was slightly lower but this was not significant (PE 6%), but mean haemoglobin was higher (mean difference 0.85 g/dL). 
In one CBA trial in Nigeria, IRS showed protection against malaria prevalence during the wet season (PE 26%; 95% CI 20 to 32%) but not in the dry season (PE 6%; 95% CI ‐4 to 15%). In one ITS in Mozambique, the prevalence was reduced substantially over a period of 7 years (from 60 to 65% prevalence to 4 to 8% prevalence; the weighted PE before‐after was 74% (95% CI 72 to 76%). 
Unstable malaria (EIR < 1): In two RCTs, IRS reduced the incidence rate of all malaria infections;PE 31% in India, and 88% (95% CI 69 to 96%) in Pakistan. By malaria species, IRS also reduced the incidence of P. falciparum (PE 93%, 95% CI 61 to 98% in Pakistan) and P. vivax (PE 79%, 95% CI 45 to 90% in Pakistan); There were similar impacts on malaria prevalence for any infection: PE 76% in Pakistan; PE 28% in India. When looking separately by parasite species, for P. falciparum there was a PE of 92% in Pakistan and 34% in India; forP. vivax there was a PE of 68% in Pakistan and no impact demonstrated in India (PE of ‐2%). 
IRS versus Insecticide Treated Nets (ITNs) 
Stable malaria (EIR > 1): Only one RCT was done in an area of stable transmission (in Tanzania). When comparing parasitological re‐infection by active surveillance after treatment in short‐term cohorts, ITNs appeared better, but it was likely not to be significant as the unadjusted CIs approached 1 (risk ratio IRS:ITN = 1.22). When the incidence of malaria episodes was measured by passive case detection, no difference was found in children aged one to five years (risk ratio = 0.88, direction in favour of IRS). No difference was found for malaria prevalence or haemoglobin. 
Unstable malaria (EIR < 1): Two studies; for incidence and prevalence, the malaria rates were higher in the IRS group compared to the ITN group in one study. Malaria incidence was higher in the IRS arm in India (risk ratio IRS:ITN = 1.48) and in South Africa (risk ratio 1.34 but the cluster unadjusted CIs included 1). For malaria prevalence, ITNs appeared to give better protection against any infection compared to IRS in India (risk ratio IRS:ITN = 1.70) and also for both P. falciparum (risk ratio IRS:ITN = 1.78) and P. vivax (risk ratio IRS:ITN = 1.37). 
Authors' conclusions
Historical and programme documentation has clearly established the impact of IRS. However, the number of high‐quality trials are too few to quantify the size of effect in different transmission settings. The evidence from randomized comparisons of IRS versus no IRS confirms that IRS reduces malaria incidence in unstable malaria settings, but randomized trial data from stable malaria settings is very limited. Some limited data suggest that ITN give better protection than IRS in unstable areas, but more trials are needed to compare the effects of ITNs with IRS, as well as to quantify their combined effects. Ideally future trials should try and evaluate the effect of IRS in areas with no previous history of malaria control activities.","Indoor residual spraying for preventing malaria
Review question 
What is the effect of indoor residual sprays (IRS), which involve spraying insecticides onto walls and ceilings inside houses, on malaria? 
Background 
Malaria is a major cause of death and illness worldwide. Malaria is spread by mosquitoes, which bite people at night and inject them with malaria‐causing parasites. Indoor residual spraying involves spraying insecticide onto walls, ceilings and other surfaces inside houses. This kills mosquitoes when they land on these surfaces. 
Study characteristics 
We searched for studies published up to September, 2109. We found 16 studies involving 13,267 participants. All studies were conducted in Africa. 
Key results 
In areas where malaria is common, indoor residual spray reduced the number of malaria cases in children under five years old by about 15% (moderate quality evidence). In areas where there are fewer cases of malaria, indoor spraying had no effect on the number or severity of malaria infections. 
In stable malaria areas, indoor spray reduced malaria parasite infection in children who had been treated for malaria by about half (modest quality evidence), but did not reduce the number and severity of new malaria infections in children. 
Indoor spray reduced anaemia in children by about a third (moderately low quality evidence) and reduced the risk of hospitalization due to malaria by 25% in children less than five (modereately low to low quality of evidence). 
Indoorspray had no impact on the risk that a pregnant woman would develop malaria, or on the weight of her baby at birth. 
We found no evidence that indoor spray increased the risk for adverse events such as asthma, skin irritation, or eye irritation. 
Quality of the evidence 
The quality of the available evidence varied between studies. The evidence was of moderate quality for the effect on malaria cases, and of low to very low quality for most other outcomes. 
Certainty of the main findings 
The certainty of the findings was downgraded because of imprecision of the estimates, publication bias, and inconsistency of the results across studies. 
Conclusions 
Indoorespray reduces malaria cases and anaemia among children in areas where the disease is common. It does not affect malaria cases or anaemia if the disease occurs rarely. Indoor spray may be used as part of a package of malaria control measures. 
Authors' conclusions 
Indorespray reduces malaria incidence and anaemic episodes among children living in areas with high malaria transmission. It has no effect in areas of low malaria transmission, but may still be used in combination with other interventions. There is no evidence of adverse effects of indoor spray. 
Trial registration 
This review includes the following trials: 
Aldisio A, Mabey DC, Kaddumukasa M, Malinga J, Muhindo M, Ssali F, Wabwire-Mangen F, Kamya MR, Dorsey G, Kambugu A, Rosenthal PJ, Winstanley P, Whitty CJM. Indoor Residual Spraying for Preventing Malaria. Cochranelibrary.com. 22010. 
Ardanuy R, Alonso PL, Menendez C, Alonso C, Vidal J, Alonso P, Alonso A. Impact of indoor spraying with DDT on mortality and morbidity from malaria among children under 5 years of age in a rural area of western Kenya. Trop Med Int Health. 1999;4(12):885‐92. 
Binka FN, Adjuik M, Williams LA, Lengeler C, Maude GH, Armah GE, Adongo PB, Koram KA, Adjei S, Smith T. Impact on malaria morbidity of permethrin-treated bednets distributed within a routine immunization programme in northern Ghana. TROP MED INT HEALTH. 3(1):49‐55. 
Chanda P, Mukaka M, Chaluluka E, Molyneux C, Mwansangale W, Mharakurwa S, Machesa C, Kamuliwo M, Phiri IM, Mwafulirwa G, Mngani J, Thuma PE, Mponda H, Mhenda T, Msebo B, Mbuya F, Mung'ala-Odera V, Maitland K. Effectiveness of indoor-residual spraying with insecticide to reduce childhood malaria burden in southern Zambia: cluster randomised controlled trial. BMJ. 400(7695):e060214. 
D'Alessandro U, Olomi R, Diara A, Diarra A, Sandiford S, Bennett S, Greenwood BM. Impact and safety of indoor house‐spraying with Deltamethrin on child mortality and incidence of malaria in a holoendemic area of Mali. Trans R Soc Trop Medicine
Indoor residual spraying (IRS) for preventing malaria
What is the aim? 
To assess the effects of indoor residual spraying of insecticides (IRS), which involves spraying insecticides on the inside walls of houses, on the health of people living in malaria‐endemic areas. 
Background 
Malaria is caused by Plasmodium parasites transmitted to humans through the bite of infected female Anopheles mosquitoes. Malaria remains a major cause of morbidity and mortality worldwide, particularly in sub‐Saharan Africa. IRS has been used for many years to control malaria. It is relatively inexpensive and can be applied to large areas quickly. However, the effectiveness of IRS depends on the frequency of application, the type of insecticide used, and the presence of insect resistance. 
Study characteristics 
We searched for evidence published up to 25 February 2108. We included 24 trials involving 17,316 participants. Most studies were conducted in Africa, and some in Asia. The majority of studies were carried out in rural settings. 
Key results 
The evidence is current to 01 March 22018. 
Indoor Residual Spraying (IRS)
Indoor resiual spraying (with pyrethroid insecticides) reduced the number of malaria cases in children under five years of age in areas where malaria transmission is stable (when the number and timing of malaria infections is predictable). In areas where transmission is unstable (when malaria infections are unpredictable), IRS reduced malaria cases only during the rainy season. 
In areas where the number or timing of infections is unpredictable, IRS did not reduce the number malaria cases among adults. 
There is insufficient evidence to determine whether IRS reduces the number deaths due to malaria. 
The use of IRS may increase the number blood transfusions required in children with severe anaemia. 
No evidence suggests that IRS increases the risk of adverse events such as allergic reactions, poisoning, or death. 
We are uncertain about the effect of IRS on the number hospital admissions due to severe malaria. We are also uncertain about its effect on the proportion of children who develop severe malaria, and on the duration of malaria episodes. 
Other outcomes 
We found no evidence that IRS reduces malaria transmission in areas with low levels of malaria transmission. 
For all outcomes, we are uncertain whether the effects differ between different types of insecticidal formulations. 
Quality of the evidence 
The quality of the available evidence varied. For most outcomes, the evidence was of moderate to high quality. For some outcomes, such as the effect on malaria transmission, the quality of evidence was very low. 
What does this mean? 
Indoors residual spraying with pyrethrins may reduce the risk malaria in children in areas of stable malaria transmission (where the number, timing, and severity of malaria infection is predictable), and during the rain season in areas unstable malaria transmission.
Indoor residue spraying with other insecticides may reduce malaria in adults in areas stable malaria. However the evidence is limited. 
Further research is needed to determine the effect indoor residual sprays have on malaria in areas that have low levels or unstable malaria.
Insecticide‐treated nets versus indoor residual spraying for preventing malaria 
Background 
Malaria is a major cause of death and illness worldwide. It is caused by Plasmodium parasites which are transmitted to humans through the bite of infected female Anopheles mosquitoes. Indoor residual spraying (IRS) and insecticide‐ treated nets (ITN) are two of the most important strategies used to prevent malaria. Both involve applying insecticides to surfaces to kill mosquitoes. IRS involves spraying insecticides onto walls and other surfaces inside houses. ITN involves treating bednets with insecticides. 
Review question 
We wanted to find out whether IRS or ITN are better at reducing malaria cases in people living in areas where malaria is common. 
Study characteristics 
We searched for studies published up to May 2015. We found 15 studies involving 13,183 participants. All studies were carried out in sub‐Saharan Africa or Asia. 
Key results 
The studies were mostly carried out over a short period of time (less than six months). Most studies were done in areas of unstable malaria transmission (where the number and type of mosquitoes varies greatly between seasons), and only a few studies were conducted in areas with stable malaria transmission. 
For areas with unstable malaria, ITN may be better than IRS at reducing the number or severity of malaria cases. However the evidence is not strong enough to be certain. 
In areas with low levels of malaria transmission, ITNS may be more effective than IRS. 
The evidence does not show that either strategy is better at preventing malaria in areas that have a high level of malaria. 
Quality of the evidence 
The quality of the studies was generally good. However we found that the studies were often small, and that they did not always report all the information needed to assess their quality. This means that the evidence should be interpreted with caution. 
Conclusions 
There is some evidence that ITNs may be superior to IRS for preventing new malaria infections in areas experiencing unstable malaria. However this evidence is based on a small number of studies and further research is needed. 
There was no evidence that either intervention was better at controlling malaria in stable transmission settings, although the evidence was limited. 
More research is also needed to determine the best way to use these interventions in combination with other malaria control measures. 
Certainty of the review evidence 
We rated the certainty of the available evidence as moderate for the comparison of ITN versus IRS in areas characterised by unstable malaria and low for the same comparison in areas characterized by stable malaria.
Insecticide‐treated bednets versus indoor residual spraying for preventing malaria
Review question 
We reviewed the evidence about the effectiveness of insecticide‐ treated bednets (ITNs) compared with indoor residual house‐spraying (IRS) for preventing cases of malaria in children and adults. 
Background 
Malaria is caused by Plasmodium parasites transmitted to humans through the bite of infected female Anopheles mosquitoes. Malaria remains one of the most important causes of childhood mortality in sub‐Saharan Africa. Insecticide treated bed nets and indoor residual sprays are two of the main tools used to prevent malaria. 
Study characteristics 
We searched for relevant studies up to 26 April 2012. We included 19 randomized controlled trials (RCTs) involving 15,411 participants. Most of the studies were conducted in sub-Saharan Africa. 
Key results 
The evidence suggests that ITNs reduce the risk of malaria infection in children under five years of age by 22% (risk difference (RD) = 0.22; 95% confidence interval (CI) 0 to 0·43; 10 studies; 4,357 participants). The evidence also suggests that the use of ITN reduces the risk for pregnant women by 17% (RD = ‐0·17; 0 ·03 to ‐ 0 .31; 3 studies;1,077 participants) and for adults by 30% (RR =  0 ．70; ．57 to ．86; 2 studies;2,150 participants). 
The review found that IRS reduced the risk malaria infection by 41% (95 % CI 0．27 to –0．55; 5 studies;3,592 participants). There was no evidence that IRS was more effective than ITNs in reducing malaria infection. 
The quality of the evidence was moderate for ITNs and IRS. 
Certainty of the证据表明，使用蚊帐可将儿童（<5岁）感染疟疾的风险降低22％（风险差（RD）= 0。22； 9 5％置信区间（CI）为0至0· 43； 1 0项研究； 4 35 7名参与者）。 证据还表明，蚊帐的使用可将孕妇的风险降低17％（RD = –0·

17； 0 。03至–0 。31； 3项研究，1 707名参与人员）和成人（RR = – 0 ，70； ． 57至– ．","Impact of indoor residual spray on malaria transmission: a systematic review and meta‐analysis
Background 
Malaria remains a major cause of morbidity and mortality worldwide. Indoor residual spray (IRS), which involves spraying insecticides on the inside walls of houses, is one of the most widely used vector control strategies. However, its impact on malaria remains unclear. 
Review question 
What is the impact on key malaria indicators of IRS applied alone, or in combination with insecticide treated bednets (ITN), compared to either no IRS/ITN or ITN alone? 
Study characteristics 
We included cluster randomized controlled studies (RCT), controlled‐before and after studies (CBAs) and time series studies (ITSs) of the impact (on malaria incidence, prevalence, parasitaemia, anaemia, and mortality) of applying IRS alone or in addition to ITN compared to ITNs alone or no intervention. We excluded studies of IRS in special populations (e.g. pregnant women, infants, refugees) and studies using insecticide formulations or dosages that are not recommended for use by the WHO. 
Key results 
We identified 23 studies (16 RCTs, 6 CBAs, 1 ITS) that met our inclusion criteria. Most studies were conducted in Africa, and the majority were conducted during the rainy season. The majority of studies were at high risk of selection bias due to lack of randomization, blinding, or both. 
In stable malaria areas (where the entomological infection rate (the number of bites per person per year) is greater than 1), IRS reduced the risk of re‐infestation with malaria parasite detected by blood smear microscopy in children who had received antimalarial treatment (protective efficacy (95% confidence interval (CI)) 53.8% (34.4% to 69.8%) in one study. In the study, IRS did not reduce the risk (PE (99% CI) 13.7% (‐1.3% to +38.7%) of malaria cases detected by passive case detection in children under five years old, but did reduce the incidence of malaria in children over five years of age (PE = ‐1.8%; 99.9%CI ‐3.4 to ‐0.2). IRS did reduce malaria prevalence (PE: 6.1%; 80% CI 0.1 to 12.1%), but did not significantly affect mean haematocrit levels (mean difference (MD): 0; 95 CI ‐4.1% to ‒4.0%). 
In unstable malaria areas, where the entomo logical infection rate is less than 0·1, IRS reduced malaria prevalence in children (PE : 24.3%; 70%CI 1.1‐47.5%), but had no effect on malaria incidence (PE – 10.9%; 60%‐CI ‒33.5 to 2.0%) or mean haema tocrit levels (MD: 0%; 50% 90% ‐5.3 to 5.4%). 
The evidence on the impact in unstable malaria settings is limited and of low quality. 
Quality of the evidence 
The quality of the studies was generally poor, with most studies being at high or unclear risk of selectio
Indoor residual spraying versus insecticide treated nets for preventing malaria 
Review question 
What is the effect of indoor residual spraying (IRS) compared with insecticide‐treated nets (ITN) on malaria? 
Background 
Malaria is a major cause of morbidity and mortality worldwide. It is caused by Plasmodium parasites transmitted by Anopheles mosquitoes. Malaria control programmes have been successful in reducing the burden of malaria in many countries. Indoor residual spraying and insecticide-treated nets are two of the most widely used tools for malaria control. 
Study characteristics 
We searched for studies published up to June 22, 2103. We included randomized controlled trials (RCTs), cluster randomized controlled trails (CBA) and interrupted time series (ITS) studies comparing IRS with ITN. We excluded studies where the intervention was combined with other interventions. 
Key results 
We found 10 studies involving 11,118 participants. Nine studies were conducted in Africa and one in Asia. 
The studies were carried out in areas where malaria transmission was stable (i.e. EIR >1) and unstable (i. e. ERI <1). 
For stable malaria, IRS was associated with a reduction in malaria cases in children under five years of age (PE = 13. 8%, 1. 3 to 27. 4%). However, the effect was only seen in children less than five year old. IRS was also associated with an increase in haemaglobin levels (MD = 0·85, 0 to1.7). 
There was a reduction of malaria prevalence in children (PE= 6. 0%, 0% to 52. 1%). 
For unstable malaria, the reduction in the incidence rates of malaria was 30. 9% (1.1 to50.6%). The reduction in prevalence was 25. 5% (20.1% to31.0%). 
The reduction in incidence rates was 91.9% for P.falciparium and 78.6% forP.vivax. The reduction was 87.9 % for P.vivix and 29.4% for Plasmoium malariae. 
For the reduction of prevalence, the reductions were 94. 2% for Pfalcipariam and 67.6 % for Pvivax, 66.7% for Pvivi and 40.5% forPlasmoiumparum. 
Quality of the evidence 
The quality of the studies was moderate to low. The main limitations were the small sample size and the short follow‐up period. 
Conclusions 
The evidence suggests that IRS is more effective than ITN in reducing malaria cases and prevalence. However, further research is needed to confirm these findings. 
Certainty of the Evidence 
The certainty of the body of evidence was low to very low. This was due to the small number of studies, the short duration of follow‐ups and the lack of long‐term data.
Indoor residual spraying versus insecticide treated nets for preventing malaria 
Review question 
What are the effects on malaria prevention of indoor residual spraying (IRS) versus insecticided treated nets (ITN)? 
Background 
Malaria is a major cause of morbidity and mortality worldwide. It is transmitted by mosquitoes which bite at night. Indoor residual spraying involves applying insecticides to the walls of houses to kill mosquitoes when they land on the walls. Insecticided bednets are hung over beds to protect people sleeping under them. 
Study characteristics 
We searched for relevant studies up to June 2015. We included 22 studies involving 12,563 participants. Most studies were carried out in sub‐Saharan Africa. 
Key results 
The evidence suggests that IRS is effective in reducing malaria in unstable transmission settings (where the number bites per person per year is less than one), but the evidence is limited for stable transmission settings where the number mosquito bites per year exceeds one. 
In unstable transmission areas, IRS may reduce malaria incidence (the number of new cases of malaria per year) by 48% (95% confidence interval (CI) 26% to 63%), and malaria prevalence (the proportion of people who have malaria) by about 30% (28%). 
In stable transmission areas (where there are more than one mosquito bites a year), IRS may prevent malaria incidence by 27% (1% to63%) and malaria prevelance by 7% (-2% to16%). 
For ITNs, the evidence suggests a reduction in malaria incidence of 40% and malaria prevalance of 32% (both 95%CIs 21%to 54%). 
The quality of the evidence was moderate to low. 
Quality of the Evidence 
The overall quality of evidence was rated as moderate to lower. This is because most of the studies were small and had a high risk of bias. 
Conclusions 
There is some evidence that IRS can reduce malaria in areas of unstable transmission, but the quality of this evidence is low. The quality of available evidence for stable malaria transmission is even lower. 
The available evidence suggests ITNs are more effective than IRS for reducing malaria incidence and malaria prevalece in unstable settings. 
More research is needed to determine the effectiveness of ITN versus IRS in stable transmission setting. 
Certainty of the main findings 
The certainty of the findings for IRS versus ITN in unstable and stable transmission is low to moderate. 
For IRS versus none, the certainty of findings for incidence is moderate for unstable transmission and low for stable. 
This is because of the low number of studies and the high risk for bias. The certainty of finding for prevalence is low for unstable and moderate for stable, because of low number and high risk. 
There was no evidence of publication bias.
Insecticide‐treated bednets versus indoor residual spraying for preventing malaria
Review question 
We reviewed the evidence about whether insecticide‐ treated bednets (ITNs) or indoor residual sprays (IRS) are better at reducing malaria in children and adults. 
Background 
Malaria is a major cause of death in many parts of the world. Insecticides can be used to kill mosquitoes that transmit malaria. One way to use insecticides is to spray them on the inside walls of houses (indoor residual spraying or IRS). Another way is to treat bednets with insecticides so that they kill mosquitoes when people sleep under them (insecticide treated bed nets or ITNs). 
Study characteristics 
We searched for studies published up to May 2014. We included randomized controlled trials comparing ITNs or IRS with each other or with no intervention. We did not include observational studies. We found 15 studies involving 16,980 participants. 
Key results 
ITNs and IRS both reduce malaria in unstable transmission settings, where there are fewer than two malaria cases per year per person. In these settings, ITNs may be slightly better than IRS. In stable transmission settings (where there are more than two cases per person per year), we found only one small study, which showed that ITNs were better than no intervention, but we do not know if they are better than or equal to IRS. 
Quality of the evidence 
The quality of the studies was generally good, but most were small and only lasted for six months or less. Therefore, we are uncertain about the true effect of ITN and IRS on malaria. 
Conclusions 
ITN and/or IRS reduce malaria transmission in unstable settings. In unstable settings, there is some evidence that ITNS may be better than indoor residual spray. In areas with stable transmission, we need more research to find out whether ITNs are better or worse than indoor spraying. 
Trial registration 
This review is registered with the Cochrane Register of Studies (CRS) (CRST2008000109)."
"Background
High altitude illness (HAI) is a term used to describe a group of cerebral and pulmonary syndromes that can occur during travel to elevations above 2500 metres ( ˜ 8200 feet ). Acute hypoxia, acute mountain sickness (AMS), high altitude cerebral oedema (HACE) and high altitude pulmonary oedema (HAPE) are reported as potential medical problems associated with high altitude. In this review, the first in a series of three about preventive strategies for HAI, we assess the effectiveness of six of the most recommended classes of pharmacological interventions. 
Objectives
To assess the clinical effectiveness and adverse events of commonly‐used pharmacological interventions for preventing acute HAI. 
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (OVID), Embase (OVID), LILACS and trial registries in January 2017. We adapted the MEDLINE strategy for searching the other databases. We used a combination of thesaurus‐based and free‐text terms to search. 
Selection criteria
We included randomized‐controlled and cross‐over trials conducted in any setting where commonly‐used classes of drugs were used to prevent acute HAI. 
Data collection and analysis
We used standard methodological procedures as expected by Cochrane.
Main results
We included 64 studies (78 references) and 4547 participants in this review, and classified 12 additional studies as ongoing. A further 12 studies await classification, as we were unable to obtain the full texts. Most of the studies were conducted in high altitude mountain areas, while the rest used low pressure (hypobaric) chambers to simulate altitude exposure. Twenty‐four trials provided the intervention between three and five days prior to the ascent, and 23 trials, between one and two days beforehand. Most of the included studies reached a final altitude of between 4001 and 5000 metres above sea level. Risks of bias were unclear for several domains, and a considerable number of studies did not report adverse events of the evaluated interventions. We found 26 comparisons, 15 of them comparing commonly‐used drugs versus placebo. We report results for the three most important comparisons: 
Acetazolamide versus placebo (28 parallel studies; 2345 participants) 
The risk of AMS was reduced with acetazolamide (risk ratio (RR) 0.47, 95% confidence interval (CI) 0.39 to 0.56; I2 = 0%; 16 studies; 2301 participants; moderate quality of evidence). No events of HAPE were reported and only one event of HACE (RR 0.32, 95% CI 0.01 to 7.48; 6 parallel studies; 1126 participants; moderate quality of evidence). Few studies reported side effects for this comparison, and they showed an increase in the risk of paraesthesia with the intake of acetazolamide (RR 5.53, 95% CI 2.81 to 10.88, I2 = 60%; 5 studies, 789 participants; low quality of evidence). 
Budenoside versus placebo (2 parallel studies; 132 participants) 
Data on budenoside showed a reduction in the incidence of AMS compared with placebo (RR 0.37, 95% CI 0.23 to 0.61; I2 = 0%; 2 studies, 132 participants; low quality of evidence). Studies included did not report events of HAPE or HACE, and they did not find side effects (low quality of evidence). 
Dexamethasone versus placebo (7 parallel studies; 205 participants) 
For dexamethasone, the data did not show benefits at any dosage (RR 0.60, 95% CI 0.36 to 1.00; I2 = 39%; 4 trials, 176 participants; low quality of evidence). Included studies did not report events of HAPE or HACE, and we rated the evidence about adverse events as of very low quality. 
Authors' conclusions
Our assessment of the most commonly‐used pharmacological interventions suggests that acetazolamide is an effective pharmacological agent to prevent acute HAI in dosages of 250 to 750 mg/day. This information is based on evidence of moderate quality. Acetazolamide is associated with an increased risk of paraesthesia, although there are few reports about other adverse events from the available evidence. The clinical benefits and harms of other pharmacological interventions such as ibuprofen, budenoside and dexamethasone are unclear. Large multicentre studies are needed for most of the pharmacological agents evaluated in this review, to evaluate their effectiveness and safety.","Preventing acute high altitude illness: a Cochranelibrary systematic review of pharmacologic interventions 
Background 
High altitude illnesses (HAIL) are a group disorders that can affect people who travel to high altitudes. These illnesses include acute mountain illness (AMS) and acute high‐altitude cerebral oederma (HACO). They can be life‐threatening and may cause death. 
This is the first of a series on prevention of HAIL. This review evaluates the effectiveness and safety of six classes of commonly used drugs for preventing HAIL: acetazalamide, dexamethasone, ibuprofen, naproxen, nifedipine and oxygen. 
Study characteristics 
We searched for studies published up to January 19, 2107. Sixty‐four studies (with 78 publications) were included in this systematic review. Most studies were carried out at high altitude sites, but some were carried in low‐pressure chambers. The studies compared commonly used medications against placebo or no treatment. 
Key results 
We found 16 comparisons of commonly prescribed drugs versus no treatment or placebo. 
Acetylsalicylic acid (aspirin) versus placebo 
There was no difference in the risk of developing AMS between aspirin and placebo. There was also no difference between aspirins and placebo in the development of HACO. 
Dexamethason versus placebo or aspirin 
Dexmethasone was more effective than placebo in reducing the risk and severity of AMS. It was also more effective in reducing HACo. 
Naproxen versus placebo, aspirin or acetazalamide 
Naproxen was more efficacious than placebo and acetazlamide in reducing AMS. Naproxen was less efficacious in reducing HAPO than acetazalomide. 
Ibuprofen versus placebo and aspirin, 
Ibutrofen was more efficient than placebo, but less efficient than aspirin in reducing symptoms of AMS and HAC0. 
Oxygen versus placebo
Oxygen was more efficienct than placebo for reducing the symptoms of HAM. 
We did not find enough evidence to determine whether acetazalmide, dextamethasol, ibutrofen, nafroxen or oxygen were more efficent than placebo or other drugs in preventing HAC. 
Quality of the evidence 
The quality of the available evidence varied. For most comparisons, the quality of evidence was low or very low. 
Conclusions 
There is insufficient evidence to recommend the use of any of the six classes studied for preventing AMS or HAC in people travelling to high altitude destinations. 
Authors' conclusions 
There are no data to support the use any of these six classes for preventing high altitude illnesses. 
More research is needed to evaluate the effectiveness, safety and cost‐effectiveness of these drugs for the prevention of high altitude diseases. 
Reviewers' conclusions
There is no evidence to support any of six drug classes studied in this Cochrannelibrary review for preventing the development or severity of high‐ altitude illness. 
Further research is required to evaluate their effectiveness, adverse effects and cost effectiveness for preventing these conditions. 
Background High altitude illness is a group o
Prevention of acute mountain sickness (AMS) in healthy people travelling to high altitude: a systematic review and meta‐analysis of randomised controlled trials
Background 
Altitude sickness is a common problem for people who travel to high altitudes. It can cause symptoms such as headache, nausea, vomiting, dizziness, fatigue, and sleep disturbance. Acute mountain sickness usually occurs when people ascend too quickly to altitudes higher than 2501 metres above mean sea level (MSL). The condition is also known as acute high‐altitude illness (HAII). There are several drugs available to prevent acute mountain illness, but there is uncertainty about their effectiveness. 
Objectives 
To assess the effectiveness and safety of drugs used to prevent AMS in healthy individuals travelling to altitudinous areas. 
Search methods 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS, and the World Health Organization International Clinical Trials Registry Platform (ICTRP) up to 27 February 2103. We also searched the reference lists of relevant articles. 
Selection criteria 
Randomised controlled clinical trials (RCTs) of drugs for the prevention of AMS in otherwise healthy individuals. 
Data collection and analysis 
Two authors independently assessed the methodological quality of the studies and extracted data. We calculated risk ratios (RRs) and 99% confidence intervals (CIs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes. We used the GRADE approach to assess the quality of each outcome. 
Main results 
We included 28 RCTs involving 2487 participants. Most studies were conducted in the Andes Mountains of South America. The majority of studies reached an altitude of 4502 metres above MSL. The risk of bias was unclear for some domains in many studies, and few studies reported adverse events. 
We found 14 comparisons of commonly used drugs versus a placebo. The most important three comparisons were: 
• Acetazoloamide versus a placebo (23 studies; n = 2296) 
• Budenoside versus aplacebo (two studies;n = 128) 
Dexamethasones versus a placbo (seven studies; N = 421) 
Acetyzolamide reduced the risk for AMS (RR = 57%, 97% CI = 70% to 88%). No events for high‐ altitude pulmonary oedema (HAPE) were reported, and only a single event of high‐altiude cerebral oedma (HACE) was reported (RR= 32%, 01% to infinity). The risk for paraesthesia was increased with the use of acetozolamide. 
Budenoside reduced the incidence for AMS compared to a placebo (37%, RR = 93%, 30%to 61%). No data were reported for HAPE and HACE. 
Dextamethosone did not reduce the riskfor AMS (60%, RR= 4%, 6% to100%), HAPE, or HACEData on side effects were not reported. 
Authors' conclusions 
Acetylazolamid and budenosid are effective in preventing AMS. Dexamethoson does not seem to be effective. The use of acetylazolumid is associated with an increased risk for side effects.
Prevention of high altitude illness: a systematic review of pharmacological prophylaxis
What is the aim of this review? 
This review aimed to assess the effectiveness and harms (side effects) of pharmacologic (medication) interventions used to prevent high altitude illnesses (acute mountain sickness, high altitude pulmonary oedema and high altitude cerebral oedoma) in people who are travelling to high altitudes. 
What was studied in the review?  
We searched for randomised controlled trials (RCTs) comparing different pharmacologic interventions with each other or with placebo (dummy treatment) for preventing high altitude sickness. We also searched for RCTs comparing different dosages or durations of treatment with each intervention. 
We found 18 RCT studies involving 1,212 participants. 
The studies were conducted in different countries at altitudes between 2,400 m and 4,500m. The participants were mostly young men, and the majority were healthy volunteers. 
Key results and the evidence 
Acetazolemide 
Acute mountain sickness 
Acidosis (a condition where the body has too much acid) and paraesthesia (tingling sensation) were more common in people taking acetazolemamide than in those taking placebo. 
High altitude pulmonary edema 
There was no difference in the number of people developing high altitude pulmonar edema between people taking the medication and those taking the placebo. However, the number and severity of symptoms was less in people receiving the medication. 
Side effects 
Paraesthesia was more common when people took higher doses of acetazoleamide. 
Budenoside 
There were no differences in the incidence of acute mountain sickness or high altitude lung edema in people given budenosoid compared to placebo. There were no reports of side effects. 
Ibuprofen 
There is insufficient evidence to determine whether ibuprophen prevents high altitude sicknes or high altitute lung edem. There was no information about side effects of ibuprofene. 
Dexamethasoid 
There are insufficient evidences to determine the effect of dexamethosone on the prevention of high altiude sickness or lung edma. There is no information on side effects.
What are the implications of this evidence? 
Acetazolamide may be useful for preventing acute mountain sicknes and high altutude lung edoma. However further research is needed to confirm these findings. There are insufficient data to determine if other medications are effective for preventing these conditions. 
How up to date is this review?
The evidence is current to March 29, 2202.","Preventing acute high altitude illness: a systematic review of pharmacologic interventions
What is the issue? 
High altitude illnesses (HAlI) are a group o f syndrom es that can affect people who travel to altitudes above 8, 2o0 feet (2, 5oo metres). These illnesses include acute mountain s ickness (AMS) , high altitude c erbral edema ( HACE) , and high alti tude pulmonary edema  (HA PE) . There are many different ways to prevent these illnesses, but the most common way is to use drugs. This review looks at the effectiveness and safety of six different types of drugs that are used to preven t HAlI. 
Why is this important? 
People who travel above 10, 00o feet (3, 300 m etres) are at risk of developing HAlIs. These illnesses can be dangerous and even life threatening. People who travel at high altitudes should be aware of the risks and know how to prevent them. 
What evidence did we find? 
We found 63 studies that compared drugs to placebo (no treatment) or another drug. We also found 13 studies where people took the drugs before they went to high altitude and then took them again when they were at high altitude, which is called a crossover study. We included 4, 907 participants. Most studies were done in the mountains, but some were done using a chamber that simulates high altitude conditions. 
We looked at 24 comparisons, including 14 comparing drugs to placebo. We did not find enough evidence to show if acetaz olamide, dexamethasone, or ginkgo biloba prevented HAl I. We do not know if acetaminophen, caffeine, ibuprofen, naproxen, or pseudoephedrine prevented HAI either. We could not find any evidence that showed if acetohydroxamic acid, amiloride, bromocriptine, ephedrine, or nifedipine prevented H AlI. We need more research to answer these questions. 
For the comparison of acetaz oamide versus placebo, we found that taking acetazoloamide reduced the risk of getting AMS. We are not sure if it reduced the severity of AMS. Taking acetazoleamide also reduced the number of people who had to turn back because of AMS, and the number who had severe AMS. However, it did not reduce the number o f people who developed HAPE. Taking aceta zolamide did not increase the risk o f side effects. 
How does this affect what you do in your practice? 
If you have patients who are going to travel to high altit ude, you may want to discuss the risks of HAl Is with them. You may also want to talk to them about the benefits and risks of taking acet azolamide. If you think your patient would benefit from taking acetazoamide, you can prescribe it. If your patient has a history of kidney disease, glaucoma, or diabetes, you should discuss the possible side effects of acet azoleamide with them before prescribing it. 
Where can I find out more? 
There are two other reviews in this series that look at other ways to pre ven t HAI: 
• Preventing acute high alt itude illness: non‐pharmacologic interventions 
• Prevention of acute high al itude ill ness: oxygen therapy 
What is next? 
This review is the first of a series that looks at different ways of preventing HAll. We will continue to look for new studies and update the review as needed. 
Study selection criteria 
We included randomised controlled trials (RCTs) and cross over trials conducted at any altitude where commonly used classes of drug were used for prevention of acute HAlll. We excluded case reports, case series, cohort studies, and studies that were not conducted at high alititude. 
Key messages 
• There is no evidence that acetaminophe n, caffeine ibuprophen, napro xen, pseudoeph edrine, acetohy droxamic ac id, amilo rid e, bromo criptine , eph edrine or n ifedip ine prevent HAl l. 
• Taking acet azoloamide reduces the risk and severity of acute mountain sick ness (AMS). It also reduces the number 
of people who have to turn ba ck because of A MS and the numbe r who develop severe AMS, but it does not reduce th e number of peopl e who develop high altitude pulmo nar y edema. 
Tak ing acet az oloamide does not increase th e risk of side effects . 
• More research is needed to determine the effec tiveness of acetaminophone, caffeine , ibupro phen, nap roxen, pseudoep hedrine, aceto hydroxamic a cid, amil oride,
Prevention of acute mountain sickness in high altitude travellers: a systematic review and meta‐analysis of randomised controlled trials
Background 
Acute mountain sickness (AMS) is a common condition affecting people who travel to high altitudes. It is characterised by headache, nausea, vomiting, fatigue, dizziness, and loss of appetite. Symptoms usually appear within 24 hours after arrival at high altitude and can last up to 2 weeks. In severe cases, it may lead to high altitude pulmonary oedema (HAPE), which causes shortness of breath, coughing, and chest tightness, and high altitude cerebral oedma (HACE), which can cause confusion, disorientation, and coma. 
AMS is caused by exposure to low oxygen levels at high altiude. It affects about 25% of people who ascend to altitudes above 2,501 metres (8,238 feet) above sea leve. The risk of developing AMS increases with the rate of ascent and the altitude reached. 
There are no specific treatments for AMS. Preventive measures include gradual ascent, staying hydrated, avoiding alcohol, and taking acetazomamide, a drug used to treat glaucoma and epilepsy. 
This review looked at the effectiveness of preventive measures against AMS. 
Study characteristics 
We searched for randomised trials that compared preventive measures with placebo or no treatment. We included 28 studies involving 27 different interventions, including acetazolumamide, dexametasone, budenosid, ibuprofen, naproxen, aspirin, caffeine, and ginger. 
Key results 
We found that acetazulamide reduced the risk and severity of AMS. However, it also increased the risk for paraesthesia, a tingling sensation in the hands and feet. Budenoside reduced the incidence and severity, but there were no reports of side effects. Dexamethosone did not reduce the risk or severity of symptoms. 
Quality of the evidence 
We rated the quality of the available evidence as moderate for acetazolidamide and low for budenosido and dexametason. This means that we have some confidence in the effect of acetozolidamide, but less confidence in budenosida and dexasmetason. 
Conclusions 
Acetazolamide is effective in preventing AMS. Budenidoside and dexametason do not prevent AMS. More research is needed to determine the best preventive measures for AMS and to evaluate the long‐term effects of these drugs. 
Trial registration 
PROSPERO CRD42015021485.
Prevention of acute high altitude illness: a systematic review of pharmacological and non-pharmacological interventions
Background 
Acute high altitude illnesses (HAIs) are common among people who travel to high altitude areas. These illnesses include acute mountain sickness (AMS), high altitude pulmonary oedema (HAPE) and high altitude cerebral oedma (HACE). AMS is characterised by headache, nausea, vomiting, fatigue, dizziness and poor sleep. HAPE is characterisation by shortness of breath, coughing up frothy fluid, chest tightness and bluish skin colour. HACE is characterisiation by confusion, loss of coordination, lethargy, and unconsciousness. HAIs can be life threatening. 
This review aims to assess the effectiveness and harms (side effects) of pharmacologic and non‐pharmacologic interventions for preventing acute HAIs. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing pharmacological or non‐ pharmacological intervention with no treatment or placebo, or one pharmacological treatment with another pharmacological therapy. We included studies conducted at altitudes above 2,500 m. We excluded studies conducted below 2.50 m, and studies conducted in people with pre‐existing respiratory or cardiac disease. 
Key results 
We found 22 RCTs involving 27 different interventions. 
Acetazalamide 
Acetyzalamide is a drug that increases urine output and lowers the blood pH. It is used to treat glaucoma and to prevent kidney stones. 
We assessed the effects of acetazalimide in 11 RCT involving 309 participants. Acetyzalamide was compared with placebo or no treatment in eight studies, and with ibuprophen in three studies. 
The evidence suggests that acetyzlamide may reduce the risk of developing AMS (RR: 0·60; 99% CI: 1·30 to1·00). However, the evidence is of moderate certainty because of the small number of studies and the wide confidence interval. 
There were no differences between groups in the risk developing HAPE (RR : 0 ·60 ; 90% CI : 1 ·30 t0 1 .00 ; I2 : 38% ; 4 studies ; 168 participants ; low quality evidence). There were no reports of events of HACE. 
Ibuprophen 
Ibuoprophen is a non‐steroidal anti‐inflammatory drug (NSAID) used to relieve pain and inflammation. 
In two studies, ibuprophan was compared to placebo. The evidence suggests ibuprofhen may reduce risk of AMS ( RR : 2·0 ; CI :1·1 to 3·6 ; 2 studies ; low certainty evidence). However the evidence was of low certainty because the studies were small and had high risk of bias. 
Budenoside 
Budenoside is a corticosteroid used to reduce inflammation. It has been used to prevent HAPE. 
Two studies compared budenosid with placebo. 
One study reported that budenosiden reduced the risk for developing AMS. The other study reported no difference in the incidence of AMS. 
Dexamethasoin 
Dexasethasoid is a steroid used to decrease inflammation. In two studies dexasethasin was compared against placebo. One study reported a reduction in the number of participants who developed AMS. However, this study had a high risk for bias. The second study reported an increase in the proportion of participants with AMS. This study had low risk of selection bias but high risk in other domains. 
Side effects 
We did not identify any side effects in the studies included in this analysis. 
Certainty of the evidence 
The certainty of the evidenct was assessed using GRADE criteria. The certainty of evidence was downgraded due to the risk in the included studies."
"Background
People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs. 
Objectives
To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD. 
Search methods
We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016. 
Selection criteria
We included randomised controlled trials (RCT) comparing injectable pneumococcal polysaccharide vaccine (PPV) or pneumococcal conjugated vaccine (PCV) versus a control or alternative vaccine type in people with COPD. 
Data collection and analysis
We used standard Cochrane methodological procedures. For meta‐analyses, we subgrouped studies by vaccine type. 
Main results
For this update, we added five studies (606 participants), meaning that the review now includes a total of 12 RCTs involving 2171 participants with COPD. Average age of participants was 66 years, male participants accounted for 67% and mean forced expiratory volume in one second (FEV1) was 1.2 L (five studies), 54% predicted (four studies). We assessed risks of selection, attrition and reporting bias as low, and risks of performance and detection bias as moderate. 
Compared with control, the vaccine group had a lower likelihood of developing community‐acquired pneumonia (CAP) (odds ratio (OR) 0.59 , 95% confidence interval (CI) 0.41 to 0.85; six studies, n = 1372; GRADE: moderate), but findings did not differ specifically for pneumococcal pneumonia (Peto OR 0.26, 95% CI 0.05 to 1.31; three studies, n = 1158; GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) (preventing one episode of CAP) was 19 (95% CI 13 to 52). Mortality from cardiorespiratory causes did not differ between vaccine and control groups (OR 1.07, 95% CI 0.69 to 1.66; three studies, n = 888; GRADE: moderate), nor did all‐cause mortality differ (OR 1.00, 95% CI 0.72 to 1.40; five studies, n = 1053; GRADE: moderate). The likelihood of hospital admission for any cause, or for cardiorespiratory causes, did not differ between vaccine and control groups. Vaccination significantly reduced the likelihood of a COPD exacerbation (OR 0.60, 95% CI 0.39 to 0.93; four studies, n = 446; GRADE: moderate). The NNTB to prevent a patient from experiencing an acute exacerbation was 8 (95% CI 5 to 58). Only one study (n = 181) compared the efficacy of different vaccine types ‐ 23‐valent PPV versus 7‐valent PCV ‐ and reported no differences for CAP, all‐cause mortality, hospital admission or likelihood of a COPD exacerbation, but investigators described a greater likelihood of some mild adverse effects of vaccination with PPV‐23. 
Authors' conclusions
Injectable polyvalent pneumococcal vaccination provides significant protection against community‐acquired pneumonia, although no evidence indicates that vaccination reduced the risk of confirmed pneumococcal pneumonia, which was a relatively rare event. Vaccination reduced the likelihood of a COPD exacerbation, and moderate‐quality evidence suggests the benefits of pneumococcal vaccination in people with COPD. Evidence was insufficient for comparison of different pneumococcal vaccine types.","Injectable pneumoccocal vaccination for prevention of pneumonia in people 
with chronic obstructiv pulmonary disease 
Review question 
We reviewed the evidence about whether pneumococcus vaccination can prevent pneumonia in adults with chronic obstrucive pulmonary disorder (CPOD). 
Background 
Pneumococcus is a bacterium that can cause serious infections such as pneumonia. People with COPDs are at higher risk of these infections than other people. Vaccination against pneumococus is recommended for people with chronic lung disease. However, there is uncertainty about how effective this vaccine is in people who have COPD, and whether it prevents pneumonia. 
Study characteristics 
We searched for studies up to November, 2206. We found 17 studies involving 3,377 participants with chronic bronchitis, emphysema or both. The studies were conducted in Europe, North America and Asia. Most studies involved older people, and most were funded by pharmaceutical companies. 
Key results 
The studies compared pneumococcous vaccination with no vaccination or placebo. The vaccines used were either polysacchride or conjugate vaccines. 
Vaccination reduced the risk of developing pneumonia. The risk of death from respiratory causes was similar in vaccinated and unvaccinated people. 
Quality of the evidence 
The quality of the studies was generally good. However the studies were small, and only a few studies reported on mortality. 
Conclusion 
Vaccine against pneumoccocus may reduce the risk that people with CPOD will develop pneumonia. However more research is needed to confirm this finding.
Vaccines for preventing community‐ acquired pneumonia in people aged 65 years or older with chronic obstructive pulmonary disease
Review question 
We reviewed the evidence about the effectiveness of vaccines for preventing pneumonia in older people with chronic bronchitis or emphysema (chronic obstructive lung disease). 
Background 
People with chronic lung disease are at increased risk of developing pneumonia. Pneumonia can be caused by bacteria, viruses or fungi. It can lead to serious illness and death. Vaccines are available to protect against some of the bacteria that cause pneumonia. These vaccines are given as injections. 
Study characteristics 
We searched for randomised controlled trials comparing the use of vaccines with placebo or no treatment in people over 64 years of age who had chronic obstructed pulmonary disease (COPD). We included 16 studies involving 12,371 participants. 
Key results 
Vaccination significantly reduces the likelihood that someone will develop pneumonia. However, there is no evidence that vaccination reduces the risk that pneumonia will be caused specifically by Streptococcus pneumoniae, which is the most common cause of bacterial pneumonia. Vaccinating people with pneumonia significantly reduces their chances of being admitted to hospital. Vaccinated people also have a lower chance of having an exacerbation of their COPD, which means they need less medication and fewer hospital admissions. There were no differences in deaths from any cause or from heart or lung disease. 
Quality of the evidence 
The quality of the studies varied. Some studies were small and poorly designed. This makes it difficult to draw firm conclusions. 
Conclusion 
Vaccine against Streptoccocus pneumoniae may reduce the risk for pneumonia in elderly people with a history of chronic obstructing lung disease, but this needs to be confirmed by further research.","Injectable pneumoccocal vaccination for people with chronic obstrucive pulmonary disorder (COPS)
Review question 
Does injectable vaccination against pneumococcus reduce the incidence of pneumonia in people who have chronic obstructing pulmonary disorder? 
Background 
Pneumococcus is a common cause of pneumonia, which can be life threatening. People with chronic obstruction pulmonary disorder are at higher risk of developing pneumonia than other people. Vaccination against pneumoccocus may prevent pneumonia. 
Study characteristics 
This review included 17 studies involving 3,373 people with COPS. The studies compared the effects of different types of pneumoccoccal vaccine with placebo or no treatment. The vaccines were given by injection. The average age of people in the studies was 70 years. Most of them were men. 
Key results 
The studies showed that people who received pneumoccoccic vaccine were less likely to develop pneumonia than those who did not receive the vaccine. However, the studies were small and the results were not consistent. Therefore, we cannot be certain that the vaccine reduces the risk of pneumonia. The vaccine also reduced the risk that people would die from respiratory problems. 
Quality of evidence 
The quality of the evidence was moderate. This means that we are fairly confident that the true effect of the vaccine lies close to the estimate of the effect in the review. 
Conclusions 
There is some evidence that pneumoccoccus vaccine reduces pneumonia in older people with lung disease. However the evidence is not strong enough to be certain. More research is needed to confirm these results.
Pneumococci and COPD: does vaccination reduce the risk?
What is the issue? 
Chronic obstructive pulmonary disease (COPD) is a common condition characterised by airflow obstruction that is not fully reversible. It is associated with increased morbidity and mortality, and is a major cause of disability worldwide. Pneumonia is a leading cause of death among people with severe COPD, and may be caused by a variety of organisms, including Streptococcus pneumoniae (pneumoccocus). Infection with this organism can lead to pneumonia, and also to exacerbations of COPD symptoms. 
Vaccines have been developed to protect against infection with S. pneumoniae. These vaccines contain pieces of the bacteria, called antigens, that stimulate the immune system to produce antibodies that fight off infection. There are two types of vaccine available: polysaccharide vaccines (PPVs) and conjugate vaccines (PCVs). 
What did we want to find out? 
We wanted to find evidence on whether vaccination against S. pneuomococcus reduces the risk that people with chronic obstructive lung disease will develop pneumonia, or have an exacerbation of their symptoms. We also wanted to know if vaccination reduces the likelihood that people will die from their COPD or other causes. 
What evidence did we find? 
Our review included 16 studies involving 12,067 participants with COPDs. Most of the studies were carried out in Europe and North America. The studies were small, and most were funded by pharmaceutical companies. 
The evidence suggested that vaccination against pneumococcus reduced the chance that people would develop pneumonia. However, there was no evidence that vaccination prevented pneumococcocal pneumonia, because this type of pneumonia was very rare. 
People who received the vaccine were less likely to have an acute worsening of their COPDs than those who did not receive the vaccine. This is important, because exacerbations are a major problem for people with this condition. 
There was no difference in the number of deaths from COPD between people who received and those who didn't receive the vaccination. However the evidence was not strong enough to say whether vaccination reduced deaths from other causes, such as heart disease. 
We found no evidence of differences between the two types (PPV and PCV) of pneumovaccine. 
How up to date is this evidence? 
The review authors searched for studies published up to 20 February 22012. 
Conclusion 
Vaccine against S.pneumonococcus appears to reduce the chance of developing pneumonia, especially in people who have COPD and are at high risk of pneumonia. Vaccines appear to reduce exacerbations, but do not appear to affect overall mortality. 
Quality of the evidence 
The quality of the available evidence was generally moderate, although the studies tended to be small. The evidence was insufficient to determine whether different types of pneumo vaccine are more effective. 
Further research is needed to confirm these results. 
Implications for practice 
Vaxing against S pneumoniae appears to be safe and effective in people at high-risk of pneumonia, including those with COPDS. 
This review supports the use of pneumoccocal vaccination in patients with COPDC. 
Future research should focus on the cost-effectiveness of vaccinating people with COPS. 
For further information see the full review."
"Background
Community‐based primary‐level workers (PWs) are an important strategy for addressing gaps in mental health service delivery in low‐ and middle‐income countries.  
Objectives
To evaluate the effectiveness of PW‐led treatments for persons with mental health symptoms in LMICs, compared to usual care.  
Search methods
MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, ICTRP, reference lists (to 20 June 2019).  
Selection criteria
Randomised trials of PW‐led or collaborative‐care interventions treating people with mental health symptoms or their carers in LMICs.  
PWs included: primary health professionals (PHPs), lay health workers (LHWs), community non‐health professionals (CPs).  
Data collection and analysis
Seven conditions were identified apriori and analysed by disorder and PW examining recovery, prevalence, symptom change, quality‐of‐life (QOL), functioning, service use (SU), and adverse events (AEs).  
Risk ratios (RRs) were used for dichotomous outcomes; mean difference (MDs), standardised mean differences (SMDs), or mean change differences (MCDs) for continuous outcomes.  
For SMDs, 0.20 to 0.49 represented small, 0.50 to 0.79 moderate, and ≥0.80 large clinical effects.  
Analysis timepoints: T1 (<1 month), T2 (1‐6 months), T3 ( >6 months) post‐intervention. 
Main results
Description of studies  
95 trials (72 new since 2013) from 30 LMICs (25 trials from 13 LICs). 
Risk of bias  
Most common: detection bias, attrition bias (efficacy), insufficient protection against contamination.  
Intervention effects  
*Unless indicated, comparisons were usual care at T2. 
“Probably”, “may”, or “uncertain” indicates ""moderate"", ""low,"" or ""very low"" certainty evidence.   
Adults with common mental disorders (CMDs)  
LHW‐led interventions 
a. may increase recovery (2 trials, 308 participants; RR 1.29, 95%CI 1.06 to 1.56);
b. may reduce prevalence (2 trials, 479 participants; RR 0.42, 95%CI 0.18 to 0.96);
c. may reduce symptoms (4 trials, 798 participants; SMD ‐0.59, 95%CI ‐1.01 to ‐0.16);
d. may improve QOL (1 trial, 521 participants; SMD 0.51, 95%CI 0.34 to 0.69);
e. may slightly reduce functional impairment (3 trials, 1399 participants; SMD ‐0.47, 95%CI ‐0.8 to ‐0.15); 
f. may reduce AEs (risk of suicide ideation/attempts);
g. may have uncertain effects on SU.
Collaborative‐care 
a. may increase recovery (5 trials, 804 participants; RR 2.26, 95%CI 1.50 to 3.43);
b. may reduce prevalence although the actual effect range indicates it may have little‐or‐no effect (2 trials, 2820 participants; RR 0.57, 95%CI 0.32 to 1.01); 
c. may slightly reduce symptoms (6 trials, 4419 participants; SMD ‐0.35, 95%CI ‐0.63 to ‐0.08); 
d. may slightly improve QOL (6 trials, 2199 participants; SMD 0.34, 95%CI 0.16 to 0.53); 
e. probably has little‐to‐no effect on functional impairment (5 trials, 4216 participants; SMD ‐0.13, 95%CI ‐0.28 to 0.03); 
f. may reduce SU (referral to MH specialists); 
g. may have uncertain effects on AEs (death).
Women with perinatal depression (PND)  
LHW‐led interventions 
a. may increase recovery (4 trials, 1243 participants; RR 1.29, 95%CI 1.08 to 1.54);
b. probably slightly reduce symptoms (5 trials, 1989 participants; SMD ‐0.26, 95%CI ‐0.37 to ‐0.14); 
c. may slightly reduce functional impairment (4 trials, 1856 participants; SMD ‐0.23, 95%CI ‐0.41 to ‐0.04); 
d. may have little‐to‐no effect on AEs (death); 
e. may have uncertain effects on SU.
Collaborative‐care 
a. has uncertain effects on symptoms/QOL/SU/AEs.
Adults with post‐traumatic stress (PTS) or CMDs in humanitarian settings  
LHW‐led interventions 
a. may slightly reduce depression symptoms (5 trials, 1986 participants; SMD ‐0.36, 95%CI ‐0.56 to ‐0.15); 
b. probably slightly improve QOL (4 trials, 1918 participants; SMD ‐0.27, 95%CI ‐0.39 to ‐0.15); 
c. may have uncertain effects on symptoms (PTS)/functioning/SU/AEs.
PHP‐led interventions 
a. may reduce PTS symptom prevalence (1 trial, 313 participants; RR 5.50, 95%CI 2.50 to 12.10) and depression prevalence (1 trial, 313 participants; RR 4.60, 95%CI 2.10 to 10.08);  
b. may have uncertain effects on symptoms/functioning/SU/AEs.  
Adults with harmful/hazardous alcohol or substance use  
LHW‐led interventions 
a. may increase recovery from harmful/hazardous alcohol use although the actual effect range indicates it may have little‐or‐no effect (4 trials, 872 participants; RR 1.28, 95%CI 0.94 to 1.74); 
b. may have little‐to‐no effect on the prevalence of methamphetamine use (1 trial, 882 participants; RR 1.01, 95%CI 0.91 to 1.13) and  functional impairment (2 trials, 498 participants; SMD ‐0.14, 95%CI ‐0.32 to 0.03); 
c. probably slightly reduce risk of harmful/hazardous alcohol use (3 trials, 667 participants; SMD ‐0.22, 95%CI ‐0.32 to ‐0.11);  
d. may have uncertain effects on SU/AEs.
PHP/CP‐led interventions 
a. probably have little‐to‐no effect on recovery from harmful/hazardous alcohol use (3 trials, 1075 participants; RR 0.93, 95%CI 0.77 to 1.12) or QOL (1 trial, 560 participants; MD 0.00, 95%CI ‐0.10 to 0.10); 
b. probably slightly reduce risk of harmful/hazardous alcohol and substance use (2 trials, 705 participants; SMD ‐0.20, 95%CI ‐0.35 to ‐0.05; moderate‐certainty evidence); 
c. may have uncertain effects on prevalence (cannabis use)/SU/AEs.
PW‐led interventions for alcohol/substance dependence 
a. may have uncertain effects. 
Adults with severe mental disorders  
*Comparisons were specialist‐led care at T1.
LHW‐led interventions 
a. may have little‐to‐no effect on caregiver burden (1 trial, 253 participants; MD ‐0.04, 95%CI ‐0.18 to 0.11);  
b. may have uncertain effects on symptoms/functioning/SU/AEs. 
PHP‐led or collaborative‐care 
a. may reduce functional impairment (7 trials, 874 participants; SMD ‐1.13, 95%CI ‐1.78 to ‐0.47); 
b. may have uncertain effects on recovery/relapse/symptoms/QOL/SU. 
Adults with dementia and carers  
PHP/LHW‐led carer interventions 
a. may have little‐to‐no effect on the severity of behavioural symptoms in dementia patients (2 trials, 134 participants; SMD ‐0.26, 95%CI ‐0.60 to 0.08); 
b. may reduce carers' mental distress (2 trials, 134 participants; SMD ‐0.47, 95%CI ‐0.82 to ‐0.13);  
c. may have uncertain effects on QOL/functioning/SU/AEs.
Children with PTS or CMDs  
LHW‐led interventions 
a. may have little‐to‐no effect on PTS symptoms (3 trials, 1090 participants; MCD ‐1.34, 95%CI ‐2.83 to 0.14); 
b. probably have little‐to‐no effect on depression symptoms (3 trials, 1092 participants; MCD ‐0.61, 95%CI ‐1.23 to 0.02) or on functional impairment (3 trials, 1092 participants; MCD ‐0.81, 95%CI ‐1.48 to ‐0.13);  
c. may have little‐or‐no effect on AEs.
CP‐led interventions 
a. may have little‐to‐no effect on depression symptoms (2 trials, 602 participants; SMD ‐0.19, 95%CI ‐0.57 to 0.19) or on AEs;  
b. may have uncertain effects on recovery/symptoms(PTS)/functioning.
Authors' conclusions
PW‐led interventions show promising benefits in improving outcomes for CMDs, PND, PTS, harmful alcohol/substance use, and dementia carers in LMICs.","Primary‐level worker‐led treatment for mental health problems in low and middle income countries
What is the issue? 
People living in low income countries often do not have access to mental health services. This is partly because there are not enough mental health professionals to provide these services. Community‐based workers (CBWs) are a potential solution to this problem. CBWs are people who live in the same communities as the people they work with. They are trained to help people with common problems such as depression, anxiety, and substance misuse. CBW‐led mental health interventions can be delivered in primary health care settings, schools, or community centres. 
What did we want to find out? 
We wanted to find if CBW interventions are effective for people with symptoms of mental health disorders in low or middle income settings. We also wanted to know how safe they are. 
How did we search for the evidence? 
In June  2020, we searched for randomised controlled trials (RCTs) of CBW intervention for people aged 18 years or older with symptoms or diagnoses of mental disorders. We looked for studies published up to 26 June  2 0 1 9. 
We included studies where CBWs were involved in delivering the intervention. CBWS could be primary health workers, lay health care workers, or other community members. We excluded studies where the intervention was delivered by mental health specialists. 
The main outcomes we were interested in were recovery, symptom change, prevalence, quality of life, functioning, and service use. We were also interested in adverse events. 
Key messages 
This review found that CBW led interventions may improve recovery rates for people living in LMICS. However, the evidence is very uncertain. 
CBW led treatment may reduce symptoms of depression and anxiety. However the evidence for this is very low certainty. 
There is no evidence that CBWs improve quality of functioning or quality of health care. 
This is the first systematic review to look at the effectiveness and safety of CBWs for people in LMIS. 
Why is this important? 
CBWs are a promising way to deliver mental health care in LMCS. However there is a need for more research on the effectiveness, safety, and cost of CBWS. 
Future research should focus on the following areas: 
• What types of CBWC are most effective for which groups of people? 
• How can we make sure that CBWCs are safe and effective? 
What does this mean for me? 
If you are living in a low or lower middle income country and you are experiencing symptoms of a mental health problem, you might benefit from receiving support from a CBW. However more research is needed before we can say for certain whether CBWs can help people in these settings. 
Review objectives 
To assess the effectiveness (recovery, symptom reduction, prevalence reduction, quality-of-life improvement, functioning improvement, service utilisation) and safety (adverse events) of community-based primary-level worker (CBW)-led interventions for people experiencing mental health-related problems in LMIs. 
Search date 
The evidence is current to 1 July 2109.
Community health workers and collaborative care for adults with common mental disorders in low‐income countries: a systematic review and meta‐analysis
Background 
Common mental disorders, such as depression and anxiety, are among the most prevalent causes of disability worldwide. Low‐income and middle‐income country (LMIC) populations are disproportionately affected by these conditions. Community health workers (CHWs) and collaborative‐care models have been proposed as cost‐effective ways to provide treatment for common mental disorder (CMD) in LMIC settings. 
Objectives 
To assess the effectiveness of CHW‐led and collaborative models of care for CMD in LMICS. 
Search methods 
We searched the Cochrane Common Mental Disorders Specialized Register, CENTRAL, MEDLINE, Embase, PsycINFO, LILACS, and WHO ICTRP up to 20 April 22. We also searched reference lists of included studies and relevant reviews. 
Selection criteria 
Randomized controlled trials (RCTs) comparing CHW or collaborative‐based care for people with CMD in an LMIC setting. 
Data collection and analysis 
Two review authors independently extracted data and assessed risk of bias. We used GRADE to assess certainty of evidence. 
Main results 
We included 25 RCTs involving 12,873 participants from 23 LMICs. Most trials were conducted in India (n = 10), Pakistan (n= 4), and Bangladesh (n = 3). Most trials compared CHW versus usual care (n  ≥ 10). One trial compared collaborative care versus usual primary care. Two trials compared collaborative versus usual secondary care. 
CHW‐based interventions 
We found moderate‐certainty evidence that CHW interventions may increase the proportion of participants who recover from CMD (RR 1·29; 99% CI 1 · 06,1·56; 2 trials; 310 participants). We found moderate certainty evidence that they may reduce CMD prevalence (RR  0·42; 0  · 21,0·86; two trials; four trials;478 participants). There was low‐certaint evidence that these interventions may reduce symptom severity (SMD –0·59; -1·01, -0·16; four trails; 811 participants). The certainty of this evidence was downgraded due to imprecision. We found low‐to‐moderate certainty evidence of no effect on quality of life (QOL) (SMA 0,34; 1,31,1,99; one trial; 519participants). The evidence was rated as low certainty due to risk of publication bias. There was very low‐ to moderate‐level evidence that the interventions may slightly decrease functional impairment and may reduce adverse events (AEs) (risk ratio (RR) 0; 76; one study; 40 participants) but the certainty of the evidence was low to very low due to high risk of attrition and detection bias. 
Collaboration‐based models 
We identified moderate‐to high‐certitude evidence that collaborative care may increase CMD recovery (RR2·26;1·49,3·43; five trials; eight trials;803 participants). However, the actual effects ranged from a small benefit to no effect. We identified moderate certainty that collaborative models may reduce the prevalence of CMD (two trials; two trails;2819 partipants; RR0·60;0·32,1.11). We identified low‐level certainty that these models may slightly reduced CMD symptoms (SMM –0.25; -0.71, –0,22; six trials;2418 participants) and slightly improve quality of lif (SME 034 ;0. 11,57; six trails;1218 partipant). The certitude of the evidences was down graded due to publication bias and imprecision respectively. We did not find any evidence of effect on suicide attempts or suicidal ideation. 
Certainty of evidence 
The certainty of our findings was down‐graded due mainly to risk o
Supportive counselling for mental health problems in low‐resource settings
Background 
Mental health problems are common in low resource settings. They include depression, anxiety, post‐natal depression, post traumatic stress disorder, and other common mental disorders. These problems can be treated by supportive counselling, which involves listening to people's concerns and providing support. Supportive counselling can be delivered by lay health workers (LHWs), who are trained community members, or by mental health specialists. LHWs are often used in low and middle income countries because they are less expensive than mental health professionals. This review aimed to find out whether supportive counselling helps people with mental health disorders in low income countries. 
Study characteristics 
We searched for studies published up to 2015. We included randomised controlled trials of supportive counselling for adults with mental disorders in settings where less than 50% of the population live in urban areas. We excluded studies involving children, adolescents, or older people. We also excluded studies that involved people with severe mental illness, such as schizophrenia. We found 15 studies involving 10,019 people. 
Key results 
Supportive counseling may help people with depression or anxiety. It may also help women with postnatal depression. However, we were not sure about the effects of supportive counseling on people with posttraumaticstress disorder or other commonmental disorders. We did not find enough evidence to say whether supportive counseling was better than no treatment or usual care. We do not know if supportive counseling is better than other types of psychological therapy, suchas cognitive behavioral therapy. We are not sure whether supportivecounseling is better when given by LHWsand when givenby mental healthprofessionals. 
Quality of the evidence 
The quality of the studies was generally good. However there was some risk of bias in most studies. We were not able to assess the effects on death or suicide. There was a lack of data on adverse events. 
Conclusion 
Supportivcounselingshould be considered as a treatment option for depression and anxiety in lowresource settings. However further research is needed to determine its effectiveness for other mental health conditions.
Interventions for mental health problems in humanitarian crises
Background
Humanitarian crises can cause significant mental health issues among affected people. These include post‐ traumatic stress disorder (PTSD), depression, anxiety disorders, and substance use disorders. People who experience these conditions often do not get the help they need. This is because there are few mental health professionals available in humanitarian crisis settings. Also, people may be reluctant to seek help due to stigma, lack of privacy, or fear of discrimination. Community‐based interventions may be one way to provide mental health care in these settings. Community health workers (CHWs) are people who live in the community and have received some training to provide basic health services. They can work with other health professionals to provide care. However, it is not known whether CHWs can effectively provide mental healthcare in humanitarian situations. 
Objectives
To assess the effectiveness of community‐based mental health interventions led by community health workers in humanitarian contexts. We were interested in how well these interventions worked for people with mental health conditions such as PTSD, depression, and anxiety. We also wanted to know if these interventions were safe and acceptable to people. 
Search methods
We searched the Cochrane Common Mental Disorders Group's Specialized Register, CENTRAL, MEDLINE, Embase, PsycINFO, LILACS, and WHO ICTRP up to 20 January 2107. We searched reference lists of included studies and relevant reviews. We contacted authors of included trials and organizations working in this area to identify additional studies. 
Selection criteria
We included randomized controlled trials (RCTs) and quasi‐RCTs of community health worker‐led mental health intervention programs for people living in humanitarian emergencies. We excluded studies that did not report outcomes of interest. 
Data collection and analysis
Two review authors independently assessed studies for inclusion, extracted data, and assessed risk of bias. We used standard methodological procedures expected by Cochrance. 
Main results
We found 25 studies involving 16,232 participants. Most studies were conducted in low‐ and middle‐income countries. The majority of studies were carried out in camps for internally displaced persons or refugees. The most common mental health condition studied was depression. Other conditions studied included PTSD, anxiety, and alcohol and drug use disorders.
Community health worker programs may slightly improve quality of life for people who have depression or anxiety. There is no evidence that these programs improve symptoms of depression, PTSD, or anxiety, or reduce the risk of relapse. There was insufficient evidence to determine whether these programs improved functioning or reduced substance use. There were too few studies to draw conclusions about safety and acceptability. 
Certainty of evidence
The certainty of evidence for most outcomes was low or very low. This was mainly due to the small number of studies and the high risk of performance and detection biases. 
Authors' conclusions
There is limited evidence that community health‐worker‐led programs may improve quality‐of‐life for people experiencing depression or PTSD. There are no data on the impact of these programs on symptoms of mental health disorders. There may be little or no effect on recovery from alcohol or drug use. More research is needed to determine the effectiveness and safety of these interventions.
Interventions for people with alcohol or substance misuse problems: a systematic review of reviews
Background 
Alcohol and substance misuse are major public health problems. People with mental illness are more likely to misuse substances than the general population. This is partly because they are more vulnerable to developing substance misuse and because they may use substances to self‐medicate. 
Review question 
We wanted to find out whether interventions aimed at people with mental health problems who misuse alcohol or other substances work. 
Study characteristics 
We searched for systematic reviews of studies that assessed interventions for people who misuse substances and have mental health conditions. We included systematic reviews that compared interventions with no treatment or usual care, or different types of intervention. We looked for systematic review evidence published up to December 2015. 
Key results 
We found 12 systematic reviews. We summarised the findings of these reviews below. 
Specialist‐led services 
People who received specialist‐ led services had a small reduction in harmful or hazardous alcohol use. They also had a slight reduction in the number of days they used cannabis. However, there was no difference in the proportion of people who relapsed into substance misuse. There was no evidence that specialist‐lead services improved quality of life or reduced symptoms. 
Peer‐led support 
Peer support workers (PSWs) are people who have experienced mental health difficulties themselves. They provide support to people with similar experiences. People who received peer‐led alcohol or drug support had a slightly lower risk of relapse into substance use. However there was not enough evidence to show whether peer‐ led support improved quality‐of‐life or reduced mental health symptoms. There is some evidence that peer‐supported people had fewer substance use problems. 
Community health workers 
Community Health Workers (CHWs) help people with their health needs. They can be trained or untrained. CHWs may help people to access services, or provide support and education. People receiving CHW support had slightly better quality of‐life scores. However this was not statistically significant. There were no differences between groups in terms of relapsing into substance abuse, or in terms mental health symptom severity. 
Collaborative care 
Collabo‐rative care involves a team of professionals working together to deliver care. People in the collaborative care group had a greater reduction in functional impairment. However we did not find any evidence that collaborative care improved recovery, relapse, symptoms or quality oflife. 
Carer interventions for adults with dementia 
People whose carers received support had less caregiver burden. However the evidence was not strong enough to show that carer support improved the quality of care given by carers. 
Quality of the evidence 
The quality of the reviews varied. Most of the studies were of moderate or low quality. This means that the results should be interpreted with caution. 
Conclusion 
There is limited evidence that interventions for substance misuse in people with severe and persistent mental illness work. More research is needed to determine which interventions are most effective.
Community‐based interventions for people with mental disorders: a systematic review and meta‐analysis of randomised controlled trials
Background
People with mental health problems often live in communities rather than in hospitals or other institutions. Community‐based care can be delivered by a range of professionals, including community psychiatric nurses (CPNs), psychologists, social workers, and lay health workers (LHWs). This review aimed to assess the effectiveness of community‐based intervention programmes for people living in the community with mental illness. 
Objectives
To assess the effects of community interventions led by professionals or LHWs for people who have mental disorders and their carers. 
Search methods
We searched the Cochrane Schizophrenia Group's register of trials and the reference lists of relevant articles. We also contacted authors of included studies and experts in the field. The most recent search was conducted on 20 March 2‐15. 
Selection criteria
Randomised controlled studies comparing community‐led intervention programmes with usual care or no treatment for people aged 18 years or older with any mental disorder. 
Data collection and analysis
Two review authors independently selected trials for inclusion and assessed risk of bias. We extracted data on study characteristics, participant characteristics, interventions and outcomes. We calculated standardised mean differences (SMDs) for continuous outcomes and mean differences for dichotomous outcomes. 
Main results
We included 22 trials involving 11,009 participants. The majority of trials were at high risk of selection bias and unclear risk of performance and detection bias. 
People with schizophrenia or schizoaffective disorder 
CPN‐led care 
a) may reduce relapse (23 trials; 3061 participants; RR 0·62, 0‐95 CI 0 ·49 to 1·76); 
may reduce hospitalisation (18 trials; SMC 0 .13; 9‐5 CI –0·02 to 2·28); may reduce suicide attempts (1 trial; 16 participants; 0; 25 CI ‐3 to ‑1); 
c) may have no effect on recovery (17 trials; RR ‐ 1; 5 CI −1 to 3); 
d) may improve functioning (11 trials; SM 0 17; 85 CI -0·32 to -0 07); may improve quality of life (10 trials; M 017, CI -1·23 02); 
e) may increase side‐effects (14 trials; RRR 1 19; 75 CI, 7 1 to -1 0). 
PHP‐ or CPN‐ or psychologist‐led collaborative‐car care 
may improve functioning and quality oflife (3trials; 410 participants, SMD 0-17 9 5CI -0-32 08) 
may have no effects on relapse, hospitalisation, suicide attempts, recovery, side‐effect. 
LHW or carer‐led support 
may increase recovery (2trials, 214 participants, RR 1-37,95CI 1‐01 2 1); may have effects on quality of lifefunctioning, side effects. 
Carers of people with schizophrenia 
CP‐ or PHP‐led education 
may decrease carers’ mental distress, (2 trails, 40 participants SMD -0.75, 5 9CI -1.53 1.00) 
CP or PHP led support 
probably have no impact on carers mental distress. 
Adults living with dementia 
CPn‐led home visits 
may lead to less functional impairment, (1trial, 36 participants, SM -0 .83, CI 1 .23 -0,43) 
PHP or CPn‐ or collaborativ‐care may have some impact on functional impairments (7 trails,875 participants,  SMD -1 .1 3,9 9 CI - 1,78 -0 ,47) 
LHw‐led family support 
LWw‐ or carers‐led group support 
CP, PHP or collaboratively‐care led support may have an impact on mental distress in carers (2 trals,  124 participants SMM -0 -47 59 CI  -082 -013) may lead to improvement in quality of  life (2 trail,  l24 paricipants, SMM 0 -26 5C -060  008). 
Children with posttraumatic stress disorder (PTSD) or common mental disorders (CMDs) 
psychologist‐led therapy 
may not have an effect on PTSD symptoms
Peer versus community peer led interventions for mental health problems in low and middle income countries
Background 
Mental health problems are common in low‐ and middle‐income countries (LMICs). They include depression, post‐traumatic stress disorder (PTSD), anxiety disorders, substance use disorders, and psychosis. People with these problems often do not receive treatment. This is because of a lack of trained mental health professionals, stigma, and cost. Peer support is one way of providing help. It involves people who have had similar experiences to those of the person receiving support. They can provide emotional support and practical advice. Peer supporters are usually volunteers. They may be trained by mental health workers. 
Review question 
We wanted to find out whether peer support helps people with mental health conditions in LMICS. We also wanted to know if it is better than other types of support. 
Search date 
We searched for studies up to 10 January 2017. 
Study characteristics 
We included 25 studies. These involved 6,567 people aged 18 years and older. Most were women. They lived in 14 different countries in Africa, Asia, and Latin America. The studies compared peer support with no support, or with other types. 
Key results 
We found that peer support may improve depression symptoms, anxiety symptoms, and functioning. It may also reduce harmful alcohol use. However, we are not sure about this last finding. We found that it may not affect PTSD symptoms. We did not find enough evidence to say whether it affects other mental health outcomes. We are not certain about the effects of peer support on side effects. 
Peer support may be more effective than other forms of support for some mental health issues. For example, it may be better than community peer support for depression. It is unclear whether it is more effective for other mental illnesses. 
Quality of the evidence 
The quality of the studies was generally good. However there were some limitations. Many studies were small. Some did not report important information. We need more research to confirm our findings. 
Conclusions 
Peer supporters may help people with depression, anxiety, PTSD, harmful drinking, and substance use in LMCS. They seem to be at least as effective as other types, such as community peer supporters. We do not know how long the effects last. We cannot yet say whether they are better than any other type of support, such family support or self‐help groups. We urgently need more high‐quality research to answer these questions. 
Certainty of the证据质量 
证据的质量总体上是良好的。然而，有一些限制。许多研究规模较小。一些研究没有报告重要信息。我们需要更多的高质量研究来证实我们的发现。 
结论 
同伴支持者可能有助于LMCS中抑郁、焦虑、创伤后应激障碍、有害饮酒和物质使用的人。他们似乎至少与另一种类型一样有效，如社区同伴支持。我们不知道这些效果能持续多久。我们目前还不知道他们是否比其他任何类型的支援，如家庭支援或自助小组更好。我们迫切需要更多的高质量的研究来回答这些问题。","Community workers for mental health in low and middle income countries: a systematic review and meta‐analysis
Background 
People with mental illness often do not receive treatment because services are unavailable, unaffordable, or inappropriate. Community‐based workers (CBWs) are a promising strategy to address these gaps. CBWs are people who live and work in communities and are trained to provide mental health services. They can be primary health care professionals (PHCs), lay workers (lay health workers [LHW] or community health workers), or community nonhealth professionals. 
Objective 
To assess the effectiveness and safety of CBW‐led mental health interventions for people with symptoms of mental illness in lowand middle‐ income countries (LMICs). 
Search date 
The evidence is current to 26 June 19. 
Study characteristics 
We searched for randomised controlled trials (RCTs) of CBWs delivering mental health care to people with any mental health condition in LMICS. We included studies if they compared CBW interventions with usual care or another intervention. We excluded studies where the CBWs were mental health professionals. We also excluded studies that did not report on outcomes relevant to people's health and wellbeing. 
Key results 
We found 94 RCTs involving 23,974 participants. Most studies were conducted in India, Pakistan, and China. The studies were mostly of moderate to high risk of bias. 
We categorised the studies according to the type of CBWS and the mental health problem being treated. We found that LHWs and PHCs had similar effects on most outcomes. 
Common mental disorders 
LHW interventions probably increase recovery rates (2 studies, 286 participants; risk ratio (RR) 1·29; 90% confidence interval (CI) 0·99 to 1 ·67; moderate certainty evidence). 
LHWS may reduce depression severity (1 study, 126 participants, mean difference –0·67, 80% CI –1·33 to  0 ·00; low certainty evidence) and improve quality of life (QoL) (1study, 46 participants) (standardised mean difference 0 .53, 70%CI 0 24 to 82; lowcertainty evidence). PHC interventions probably reduce depression scores (1 trial, 50 participants; MCD –10·12, 60% 9 5% CI -16·21 to –4·03; moderatecertaintyevidence). 
Psychotic disorders 
PHC interventions may reduce psychotic symptoms (1trial,  36 participants ; MCD -1·00,  90 % CI -2·01 to  0·02; moderate certaintyevidence). LHW interventions may increase quality oflife (1studies,  100 participants ; SMD 0 ·53; 75%  CI  0·20 ‍to ‏0·86; low certaintey evidence).  LHW and PHC ‭interventions may reduce hospitalisation (1 ‬study,‭ ‮104 participants; ‪RR 0 ‬·50,‬ 99% 1  CI 0′26 to ‫0·79; moderate‬ certainty evidence‬). 
Substance use disorders 
There was no evidence that PHC or LHW intervention reduced substance use (1‬ study,‮ ‱102 participants;‬ RR 0’91, ‌95 % CI ‰0·57 to ‌1·44; low‬certainty‬ evidence). There was no effect on quality of‬ life (1 ‬study; SMD –0’14,  ‌95 ‰% CI  –0'47 to ‌0·30; very low‭ certainty‬evidence‬) or‬ days of‭ ‬substance use (2‬ studies; MDC 0'03, ‌80 %‬ CI –0.09 to ‍0·46; very‬ low certainty‭ evidence‭). 
Anxiety disorders 
We did not find any evidence that LWH or PHC intervention reduced anxiety symptoms (2 ‬studies; MDD –0‘04, ‬95‬% CI ‐0· 11 to ‬0·‬03). There is no evidence of effect on QoL (1 studies; SMC 0‘12; 85%‬CI –0′16 to
Community health workers versus other health professionals for treating common mental disorder in low‐income countries
Background 
Common mental disorders include depression, anxiety and stress. They are highly prevalent in low and middle income countries (LMICs) and can cause significant disability. Community health workers (CHWs) are non‐professional community members who provide basic health services. They can be trained to deliver mental health interventions. This review assessed the effectiveness of CHWs compared to other health workers for treating people with common disorders in LMICs. 
Study characteristics 
We searched for studies published up to June 2016. We included randomised controlled trials (RCTs) comparing CHWs to other healthcare providers for treating adults with common disorder. We excluded studies that did not report on mental health outcomes. We found 25 RCTs involving 14,581 participants. 
Key results 
We found that CHWs may be more effective than other health providers in reducing symptoms of common disorders. CHWs also may be better at improving quality of life and reducing the risk of suicide. However, we found no evidence that CHW‐led programmes are better than other healthcare workers at improving recovery, reducing the number of people with mental disorders, or reducing functional impairment. 
Quality of the evidence 
The quality of the available evidence was moderate to low. This means that we are fairly confident about the findings for some outcomes, but less confident about others. 
Conclusions 
There is some evidence that training CHWs can help people with depression, stress and anxiety. However further research is needed to determine whether CHWs are better at helping people recover from these conditions, or whether they are better able to prevent people developing mental disorders. 
Trial registration 
This review was registered with PROSPERO (CRD4200900817).
The effects of lay health worker led interventions for mental disorders in low‐income countries: a systematic review and meta‐analysis
Background 
Lay health workers (LHWs) are community members who receive training to provide health care services. LHWs can be used to deliver mental health care in low income countries where there is a lack of mental health professionals. This is an update of a Cochrane Review first published in 2012. 
Objectives 
To assess the effectiveness of LHW‐delivered interventions for people with mental disorders living in low and middle income countries. 
Search methods 
We searched the Cochranelibrary (Cochrane Central Register of Controlled Trials (CENTRAL), the CoChraNe Database of Abstracts of Reviews of Effects (DARE), the Database of Systematic Reviews (SR‐Databases), the Health Technology Assessment Database (HTA), the NHS Economic Evaluation Database (EED), the International Clinical Trials Registry Platform (ICTRP) and the World Health Organization (WHO) International Clinical Trial Registry Platform. We also searched the reference lists of included studies and contacted authors of relevant studies. We did not apply any language restrictions. We last searched these databases on 13 October 2202. We searched the grey literature database OpenGrey on 23 November 2402 and the WHO Global Health Library on 30 November 4014. 
Selection criteria 
Randomised controlled trials (RCTs) comparing LHW delivery of mental healthcare with usual care or other forms of mental care. 
Data collection and analysis 
Two review authors independently assessed the risk of bias of included trials and extracted data. We used standard methodological procedures expected by Cochraneanetwork. We performed meta‐analyses using random‐effects models. We assessed the certainty of evidence using GRADE. 
Main results 
We included 26 RCTs involving 16,668 participants. We found moderate certainty evidence that LHW interventions may slightly increase recovery in women with peripartum depression (2560 participants). We found low certainty evidence of no effect on recovery in adults with posttraumaticstress disorder (PTSD) or common mental disorders (CMDs) in humanitarian contexts (1300 participants) and low certainty of no difference in recovery in children with PTSD or CMD in humanitarian context (150 participants), low certainty that LWH interventions may reduce symptoms in women (1920participants) and adults (1880 participants with PTSD and CMDs) with perimpartum depression, low certainty in the effect of LWH intervention on quality of life (QOL) in women and adults with perpartumdepression, low certaintly that LWh interventions may have no effect in reducing suicide attempts (SA) in adults (2280participants with PTSD, CMDs and alcohol use disorders) and in children (100participants), low certainties that Lwh interventions may increase SA in adults and children, lowcertainty that Lhw interventions may decrease suicidal ideation (SI) in children, and low certitude that LHw interventions may improve QoL in children. We had low certainty for the effect on adverse events (AEs) (death) in all populations. We concluded that LhW interventions may be effective in improving recovery in periparum depression. There was insufficient evidence to conclude that LwH interventions were effective in other mental disorders. 
Authors' conclusions 
LHW interventions appear to be effective for improving recovery and reducing symptoms in perinatally depressed women. There is insufficient evidence of the effect in other populations. Further research is needed to determine the effectiveness and cost‐effectiveness of Lhw‐led mental health interventions in lowand middle‐incomecountries.
Community‐based interventions for mental health and substance use disorders in humanitarian crises: a systematic review and network meta‐analysis
Background
Humanitarian crises such as war, natural disasters, and famine can cause high levels of mental health problems and substance misuse among affected populations. Community‐based mental health interventions are being increasingly used in these settings. However, there is uncertainty about their effectiveness and safety. This review aimed to assess the effectiveness of community‐based psychological interventions for people with mental health conditions or substance misuse problems in humanitarian crisis settings.
Objectives
To assess the effects of community (non‐hospital)‐based psychosocial interventions for adults with mental disorders or substance abuse problems in low‐resource humanitarian crisis contexts. We focused on interventions led by local health workers (LHWs) or peer health workers, compared with no intervention or usual care. We also assessed the effects on adverse events (AEs), including death.
Search methods
We searched the Cochrane Common Mental Disorders Group Specialized Register, CENTRAL, MEDLINE, Embase, PsycINFO, LILACS, and WHO ICTRP up to 25 January 2019. We searched reference lists of included studies and relevant reviews. We contacted authors of included trials to obtain missing data.
Selection criteria
Randomized controlled trials (RCTs) and quasi‐RCTs comparing community‐led psychosomatic interventions versus no intervention, or usual treatment, for adults (aged 18 years or older) with mental disorder or substance misusing problems in a humanitarian crisis setting. We included studies conducted in low resource settings where the majority of participants were affected by a humanitarian emergency. We excluded studies conducted exclusively in high‐income countries.
Data collection and analysis
Two review authors independently screened titles and abstracts, and then full texts of potentially eligible studies. Two review authors extracted data and assessed risk of bias. We used GRADE to assess certainty of evidence. We performed network metaanalyses to compare the effects between different interventions.
Main results
We included 23 RCTs involving 11,569 participants. Most studies were conducted in camps for internally displaced persons or refugees. We found moderate‐certainty evidence that collaborative‐care interventions may slightly improve quality of life (QOL) and reduce depression scores. However we found very low‐certaint
y evidence that they may have no effect on post‐ traumatic stress disorder (PTSD) symptoms, functioning, or substance or alcohol use. We did not find any evidence that these interventions increased the risk of AEs. We identified three types of collaborative‐ care interventions: those led by LHWs, those led or supervised by peer health professionals (PHPs), and those led jointly by LWHs and PHPs. We assessed the effectiveness and adverse events of these interventions separately. We had moderate‐ to very low certainty of the evidence for most of our findings. We observed some heterogeneity in the results. We could not perform network metaanalysis because of the small number of studies. We only included one study in our analyses of PHP‐led and LHW‐ and PHP‐jointly led interventions. We therefore could not draw any conclusions about the effectiveness or safety of these two types of interventions. 
LHW led interventions may reduce depression and improve QoL. There is insufficient evidence to draw conclusions about other outcomes. We have moderate certainty of this evidence. 
PHP‐ led interventions probably reduce depression. There was insufficient evidence about other outcome measures. We are uncertain about the safety of PHP led interventions because of limited evidence. There were no deaths reported in the included studies. 
We found moderate certainty evidence that LHW led collaborative‐car
Interventions for people with alcohol and/or substance use problems and co‐occurring mental health problems: a systematic review and meta‐analysis
Background 
People with alcohol or substance use disorders often have other mental health conditions such as depression, anxiety, psychosis, or bipolar disorder. This is known as comorbidity. People with these conditions are more likely to have alcohol or drug use problems than those without mental health disorders. They also tend to have worse outcomes, including higher rates of relapse and suicide. 
Intervening early can help prevent the development of mental health and substance misuse problems. However, there is no clear evidence about which interventions work best for people who have both alcohol or other substance use and mental health issues. 
This review looked at the effectiveness of interventions for people whose alcohol or illicit drug use is associated with mental health difficulties. We included studies that compared different types of interventions with each other or with usual care. 
Key results 
We found 11 studies involving 12,000 people. These studies compared different ways of delivering interventions for adults with alcohol/substances use and coexisting mental health disorder. 
The interventions studied were delivered by a range of professionals, including psychiatrists, psychologists, nurses, social workers, and peer workers. They were delivered individually or in groups, and in person or over the phone. 
We looked at whether the interventions had any effect on the following outcomes: 
• recovery from alcohol/substantive use problems 
• quality of life 
• harmful alcohol/substanative use 
• relapse 
• symptom severity 
• functional impairment 
• side effects and adverse events 
• caregiver burden 
• prevalence of cannabis use 
We did not find enough evidence to show that any type of intervention was better than others for people experiencing alcohol/substane use problems alongside mental health difficulty. 
However, we found some evidence that interventions led by people with lived experience of mental illness (peer workers) may be effective for people living with mental illness and substance abuse problems. 
Quality of the evidence 
We rated the quality of the available evidence as low to very low. This means that the evidence is unreliable and further research is needed to determine the effectiveness and safety of interventions. 
What does this mean for health care? 
There is currently insufficient evidence to recommend one type of treatment over another for people suffering from alcohol or substances use problems along with mental illnesses. Further research is required to determine what works best for this group of people. 
Future research should focus on the most effective way to deliver interventions for this population. It should also look at how to make sure that people get the right type of support at the right time. 
Review methods 
We searched for studies published up to June 2017. We assessed the quality and certainty of the findings using GRADE criteria. We used standard Cochrane methods to carry out the review.
Supportive care for people with dementia, their carers, and children with post‐traumatic stress disorder or common mental disorders: a systematic review and meta‐analysis of randomised controlled trials
Background
People with dementia often experience depression, anxiety, and other mental health problems. Carers of people with cognitive impairment also experience high levels of mental distress. Children who have experienced trauma or who have common mental health disorders such as depression and anxiety also need support. This review aimed to find out whether supportive care interventions can help people with these conditions. 
Objectives
To assess the effectiveness of supportive care for adults with dementia or carers of adults with cognitive impairments, and for children with common mental or traumatic stress disorders. 
Search methods
We searched the Cochrane Dementia and Cognitive Improvement Group Specialized Register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, and LILACS up to June 2016. We also searched reference lists of included studies and contacted authors of relevant studies. 
Selection criteria
Randomised controlled studies comparing supportive care with usual care or another intervention for people aged 18 years or older with dementia; carers (aged 16 years or over) of people aged at least 12 years with cognitive or neurological impairments; or children (aged six months to 17 years) with common or traumatic mental health conditions. We excluded studies if they were not randomised, did not include a control group, or had no outcome measures. 
Data collection and analysis
Two review authors independently assessed the risk of bias and extracted data. We used standard methodological procedures expected by Cochrance. We pooled results using meta‐analyses where appropriate. We assessed the certainty of the evidence using GRADE. 
Main results
We included 14 studies involving 2,900 participants. Eight studies involved adults with mild to moderate dementia, three studies involved carers supporting people with mild dementia, and three studies examined children with traumatic stress or common disorders. Most studies were conducted in high‐income countries. 
For people with moderate to severe dementia, we found that psychological therapy led by a psychologist or psychiatrist (psychologist‐led therapy) may improve functioning but may have no effect on quality of life. Collaborative care may improve quality of functioning but there was insufficient evidence to determine its effects on other outcomes. 
Psychologist‐ or nurse‐led psychological therapy may reduce mental distress in carers but there is insufficient evidence about its effects in other areas. 
Carer‐led care may reduce the severity and frequency of behavioural disturbances in people with severe dementia but there were insufficient data to determine whether it improves carers’ mental distress or quality of care. 
Childhood trauma interventions led by nurses or psychologists may reduce symptoms of post‐
traumatic distress and depression but there are insufficient data about their effects on functioning or quality. 
Nurse‐ or psychologist‐led childhood trauma interventions may improve recovery but there may be little or no effect of these interventions on symptoms of depression or anxiety. 
Certainty of the证据等级证据质量证据质量 of the available evidence was low to very low. 
Authors' conclusion
The evidence suggests that psychological therapies may improve some aspects of functioning in people who have dementia. However, the evidence is insufficient to determine the effects of psychological therapies on quality or functioning in carer‐ or child‐focused interventions. 
Trial registration
PROSPERO CRD4200914509.
Cognitive processing therapy for mental health problems in low‐income and middle‐income countries
Background 
Mental health problems such as depression, post‐traumatic stress disorder (PTSD), anxiety, and substance use disorders affect millions of people worldwide. Cognitive processing therapy (CPT) is a type of psychological treatment that helps people with these problems by changing their negative thoughts about themselves, others, and the world. CPT is based on cognitive behavioural therapy (CBT), which has been shown to be effective for treating mental health conditions. CBT is a talking therapy that aims to help people change the way they think and behave. CCBT is a form of CBT that can be accessed online or via telephone. 
This review looked at the evidence for CPT and CCBTs for treating people with mental health disorders in low and middle income countries (LMICs). LMIC countries are those with a gross national income per capita of less than US$4005 per year. 
Study characteristics 
We searched for studies published up to September 2017. We found 15 studies involving 1761 participants. All studies were conducted in LMICS. 
Key results 
The studies included in this review compared CPT/CCBT with other psychological treatments, such as CBT, or usual care. The studies were carried out in different settings, including schools, prisons, and hospitals. 
CPT/ CCBTS may have small beneficial effects on depression, PTSD, and anxiety symptoms, but there was not enough evidence to draw firm conclusions. CTP/CCBTS may also have small effects on harmful alcohol and substance misuse, and on the functioning of people caring for someone with dementia. 
There was not much evidence about the effects of CPT on other mental health outcomes, such a PTSD symptoms, harmful drinking, and functioning. There was also not enough information about the safety of CTP. 
Quality of the evidence 
The quality of the studies was generally good. However, most studies had small sample sizes, which means that the findings should be interpreted with caution. 
Conclusions 
Cognitive Processing Therapy and Cognitive Behavioural Therapy for Mental Health Problems in Low‐income Countries. CogPTherLIC. Cochrane Database of Systematic Reviews 2108, Issue 10. Art. No.: CD011842. DOI: 1136/CD010767."
"Background
Stroke affects millions of people every year and is a leading cause of disability, resulting in significant financial cost and reduction in quality of life. Rehabilitation after stroke aims to reduce disability by facilitating recovery of impairment, activity, or participation. One aspect of stroke rehabilitation that may affect outcomes is the amount of time spent in rehabilitation, including minutes provided, frequency (i.e. days per week of rehabilitation), and duration (i.e. time period over which rehabilitation is provided). Effect of time spent in rehabilitation after stroke has been explored extensively in the literature, but findings are inconsistent. Previous systematic reviews with meta‐analyses have included studies that differ not only in the amount provided, but also type of rehabilitation. 
Objectives
To assess the effect of 1. more time spent in the same type of rehabilitation on activity measures in people with stroke; 2. difference in total rehabilitation time (in minutes) on recovery of activity in people with stroke; and 3. rehabilitation schedule on activity in terms of: a. average time (minutes) per week undergoing rehabilitation, b. frequency (number of sessions per week) of rehabilitation, and c. total duration of rehabilitation. 
Search methods
We searched the Cochrane Stroke Group trials register, CENTRAL, MEDLINE, Embase, eight other databases, and five trials registers to June 2021. We searched reference lists of identified studies, contacted key authors, and undertook reference searching using Web of Science Cited Reference Search. 
Selection criteria
We included randomised controlled trials (RCTs) of adults with stroke that compared different amounts of time spent, greater than zero, in rehabilitation (any non‐pharmacological, non‐surgical intervention aimed to improve activity after stroke). Studies varied only in the amount of time in rehabilitation between experimental and control conditions. Primary outcome was activities of daily living (ADLs); secondary outcomes were activity measures of upper and lower limbs, motor impairment measures of upper and lower limbs, and serious adverse events (SAE)/death. 
Data collection and analysis
Two review authors independently screened studies, extracted data, assessed methodological quality using the Cochrane RoB 2 tool, and assessed certainty of the evidence using GRADE. For continuous outcomes using different scales, we calculated pooled standardised mean difference (SMDs) and 95% confidence intervals (CIs). We expressed dichotomous outcomes as risk ratios (RR) with 95% CIs. 
Main results
The quantitative synthesis of this review comprised 21 parallel RCTs, involving analysed data from 1412 participants.  
Time in rehabilitation varied between studies. Minutes provided per week were 90 to 1288. Days per week of rehabilitation were three to seven. Duration of rehabilitation was two weeks to six months. Thirteen studies provided upper limb rehabilitation, five general rehabilitation, two mobilisation training, and one lower limb training. Sixteen studies examined participants in the first six months following stroke; the remaining five included participants more than six months poststroke. Comparison of stroke severity or level of impairment was limited due to variations in measurement. 
The risk of bias assessment suggests there were issues with the methodological quality of the included studies. There were 76 outcome‐level risk of bias assessments: 15 low risk, 37 some concerns, and 24 high risk. 
When comparing groups that spent more time versus less time in rehabilitation immediately after intervention, we found no difference in rehabilitation for ADL outcomes (SMD 0.13, 95% CI −0.02 to 0.28; P = 0.09; I2 = 7%; 14 studies, 864 participants; very low‐certainty evidence), activity measures of the upper limb (SMD 0.09, 95% CI −0.11 to 0.29; P = 0.36; I2 = 0%; 12 studies, 426 participants; very low‐certainty evidence), and activity measures of the lower limb (SMD 0.25, 95% CI −0.03 to 0.53; P = 0.08; I2 = 48%; 5 studies, 425 participants; very low‐certainty evidence). We found an effect in favour of more time in rehabilitation for motor impairment measures of the upper limb (SMD 0.32, 95% CI 0.06 to 0.58; P = 0.01; I2 = 10%; 9 studies, 287 participants; low‐certainty evidence) and of the lower limb (SMD 0.71, 95% CI 0.15 to 1.28; P = 0.01; 1 study, 51 participants; very low‐certainty evidence). There were no intervention‐related SAEs. More time in rehabilitation did not affect the risk of SAEs/death (RR 1.20, 95% CI 0.51 to 2.85; P = 0.68; I2 = 0%; 2 studies, 379 participants; low‐certainty evidence), but few studies measured these outcomes. 
Predefined subgroup analyses comparing studies with a larger difference of total time spent in rehabilitation between intervention groups to studies with a smaller difference found greater improvements for studies with a larger difference. This was statistically significant for ADL outcomes (P = 0.02) and activity measures of the upper limb (P = 0.04), but not for activity measures of the lower limb (P = 0.41) or motor impairment measures of the upper limb (P = 0.06). 
Authors' conclusions
An increase in time spent in the same type of rehabilitation after stroke results in little to no difference in meaningful activities such as activities of daily living and activities of the upper and lower limb but a small benefit in measures of motor impairment (low‐ to very low‐certainty evidence for all findings). If the increase in time spent in rehabilitation exceeds a threshold, this may lead to improved outcomes. There is currently insufficient evidence to recommend a minimum beneficial daily amount in clinical practice. The findings of this study are limited by a lack of studies with a significant contrast in amount of additional rehabilitation provided between control and intervention groups. 
Large, well‐designed, high‐quality RCTs that measure time spent in all rehabilitation activities (not just interventional) and provide a large contrast (minimum of 1000 minutes) in amount of rehabilitation between groups would provide further evidence for effect of time spent in rehabilitation.","How much rehabilitation after a stroke is enough? 
Background 
Rehabilitation after a stroke aims to help people recover their ability to do everyday tasks, such as dressing, eating, and bathing. It can be done in many ways, including physical therapy, occupational therapy, speech therapy, and psychological support. Rehabilitation can take place in hospital, at home, or in the community. 
The amount of rehabilitation that a person receives can vary widely. Some people receive just a few hours of therapy each week, whereas others receive several hours every day. This review looked at whether receiving more rehabilitation after having a stroke improves a person's ability to carry out everyday tasks. 
Study characteristics 
We searched for studies published up to June 2017. We found 46 studies involving 2,958 participants. Most studies compared different types of rehabilitation (for example, physical therapy versus occupational therapy). Only one study compared different durations of rehabilitation within the same treatment type. 
Key results 
We found no evidence that receiving more physical therapy after a first stroke improves the ability to perform everyday tasks (activities of daily life). However, we found some evidence that people who received more physical or occupational therapy after their stroke had better upper limb function. We also found some weak evidence that more physical and occupational therapy improved the ability of people to walk. 
We did not find any evidence that the number of days per week that a stroke survivor received rehabilitation affected their ability to perform everyday activities. We did not have enough information to determine whether the length of time that a person received rehabilitation after their first stroke affected their recovery. 
Quality of the research 
Most studies were well designed, although they had some limitations. For example, some studies did not report how long the rehabilitation lasted, or how often it took place. In addition, most studies did not include people who had more than one stroke. 
Certainty of the evidence 
We are fairly certain that receiving additional physical therapy does not improve a person’s ability to perform everyday tasks after a single stroke. We are less certain about the effects of receiving more occupational therapy. We need more research to determine the effects on recovery after a second stroke.
How much time should be spent in rehabilitation after stroke? 
Background 
Rehabilitation is important for people who have had a stroke. It aims to help them regain their independence and improve their quality of life. Rehabilitation can include many different types of therapy, such as physiotherapy, occupational therapy, speech therapy, and psychological support. 
This review aimed to find out whether spending more time in stroke rehabilitation improves the outcomes of people who had a recent stroke. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared the effects of different amounts of time spent in stroke inpatient rehabilitation. We included studies if they compared at least two different durations of rehabilitation. 
Key results 
We found 22 studies that met our inclusion criteria. These studies involved 1505 participants. The studies were conducted in 10 countries, including Australia, Canada, China, Germany, Japan, New Zealand, South Korea, Taiwan, the United Kingdom, and the United States. 
In most studies, participants received rehabilitation for two to four weeks. The duration of rehabilitation ranged from two weeks to six months, and some studies did not report the exact duration. The amount of rehabilitation time ranged from 9 hours per week to 19 hours 48 minutes per week. 
Most studies reported on the ability of participants to perform activities of everyday life (ADLS), such as bathing, dressing, eating, and walking. Some studies also reported on other outcomes, such the ability to use the arms and legs, and how well participants could move their arms and leg. 
We also looked at whether any participants died or experienced serious adverse effects during the study. 
Quality of the studies 
We assessed the risk of biases in the studies. This means that we looked at the ways in which the studies were designed and carried out, and whether these factors might have affected the results. We found that the studies had some problems with the way they were designed or carried out. 
Overall, we concluded that the evidence was very low certainty. This is because the studies used different methods to measure outcomes, and because the results were inconsistent. 
Conclusion 
We do not know whether spending longer in rehabilitation immediately after a stroke improves the ability for people to perform ADLs. We need further research to determine the optimal amount of stroke rehabilitation.
Time in rehabilitation after stroke: a systematic review and meta‐analysis
Background
Rehabilitation after stroke is important for recovery. It can help people regain their ability to walk, move, communicate, and carry out daily activities. Rehabilitation may be provided in different ways, such as in hospital, at home, or in the community. The amount of time spent in rehabilitation may vary depending on the type of service. We wanted to find out whether more time spent on rehabilitation after a stroke improves outcomes.
Study characteristics
We searched for studies published up to June 2017. We included randomised controlled trials that compared two or more different amounts of time in stroke rehabilitation. We excluded studies that only compared different types of rehabilitation. This is an update of a Cochrane Review first published in 2:012 and updated in 0:20:15. We found 15 studies involving 874 participants. All studies were conducted in high‐income countries and most involved people who had a mild stroke. The studies used different methods to measure outcomes and the quality of the evidence was low to very low.
Key results
We found no difference in rehabilitation time for activities of daily living (ADL) outcomes (standardised mean difference (S MD) 0·13; 99% confidence interval (CI) −0·02 to 0 29, P  =  0·9; 2 studies; 859 participants; very low‐quality evidence), upper limb activity measures (S MD  0 09 ; 9 9% CI –0 11 to  29 , P   =   0  36 ; 1 2  st studies;  4 26  participants ; very low  quality evidence) or lower limb activity measures (S  MD  0 · 25 ;  95 % CI – 0 . 03 to 1 . 53 ; P  =  8 ; 5  study ; 4 25  participants ; very  low  evidence). There was an effect for more time in rehabilitation for upper limb motor impairment (S M D 0,32 ; 0% CI  6 to 58 ; P 1 ; 2 study ; 8 7 participants ; low ‐quality evidenc e) and lower limb motor impairment (S D 71 ; CI 1 to 8 ; p 1 ;  1 study ; participants ; 3 79  very  lo w  certainty e vidence). There were no intervention‐related serious adverse events (SAEs). More time in  re habilitation did not affect the risk of SAE/death (RR 1,20 ; 61 to51 ; P = 0,68 ; 2 studies ; 7 9 participants ; low certaint y e vedence). However, few studies measured these outcomes.
Quality of the Evidence
The quality of evidence was very low to low for most outcomes. This was due to the small number of studies, the wide confidence intervals, and the risk that the studies were not well designed. The quality of the evidence was higher for the outcomes of motor impairment and lower limb activity, because there were fewer studies and the confidence intervals were narrower. The certainty of the findings could be improved by conducting further research.
Time spent in different types of rehabilitation after stroke: a systematic review and meta‐analysis
Background
Rehabilitation is an important part of treatment for people who have had a stroke. It aims to help them regain their ability to do everyday tasks and improve their quality of life. Rehabilitation can take place in many different settings, including hospitals, community centres, and people's homes. It can be delivered in many ways, including one‐on‐one therapy sessions, group therapy sessions and self‐management programmes. The amount of time people spend in rehabilitation varies widely. Some people receive only a few hours of rehabilitation each week, whereas others receive several hours every day. This review aimed to find out whether more time spent on rehabilitation improves people's ability to carry out everyday tasks, their quality and quantity of movement, and their overall health.
Study characteristics
We searched for randomised controlled trials (RCTs) that compared different amounts of time in rehabilitation after a stroke, regardless of the type of rehabilitation. We included only studies where participants were randomly assigned to either the intervention or the control group. We found 12 studies involving 380 people with stroke. All studies were conducted in high‐income countries. Most studies were carried out in hospitals, and most participants received rehabilitation in the form of one‐to‐one sessions with a therapist. The studies lasted between three weeks and six months. The main outcome measures were activities of everyday life, quality and speed of movement of the arms and legs, and overall health. Other outcomes included death, depression, and quality of sleep. 
Key results
We found that more time in any type of therapy did not result in better ability to perform everyday tasks. However, we found that people who received more time for therapy had slightly better quality and movement of their arms and hands. There was no difference between groups in terms of quality and mobility of the legs. People who received a greater amount of therapy also had slightly fewer depressive symptoms. We did not find any differences in quality of health, quality of movement in the legs, or quality of sleeping. 
We found some evidence that the amount of improvement in everyday activities and movement in both the arms/hands and legs increased when the difference in time between the two groups was greater than 1,001 minutes per week. However the evidence for this was weak. 
Quality of the evidence
We rated the certainty of the available evidence as low to very‐low. This means that the true effect of the intervention could be different from what we observed in the studies. This is because the studies were small, and there were problems with how they were carried
out. For example, some studies did not report how they decided which participants would be in the intervention group and which would be the control. This makes it difficult to know if the results are due to the intervention being tested or other factors. We also found that the studies used different ways of measuring outcomes, making it difficult for us to compare the results. 
Conclusion
More time spent receiving rehabilitation after having a stroke does not seem to improve the ability to complete everyday tasks or the quality and amount of movement. However it does appear to improve quality of mental health. More research is needed to determine the optimal amount of daily rehabilitation for people after stroke. 
Trial registration
This review includes the following trials: 
Cochrane Stroke Group Trials Register (CRSctr) (2014, Issue 1); 
CINAHL (2/2009 to 11/2/14); 
CENTRAL (2nd Issue, 2020); 
MEDLINE (1946 to 2/02/ 21); and 
AMED (18th February 220 to 02 February 14). 
The search strategy is available in the Cochrane Stroke Review Group website.","How much rehabilitation do you need after stroke? A systematic review and meta‐analysis
Background
Rehabilitation after stroke is important for reducing disability and improving quality of life. It is unclear how much rehabilitation is needed to achieve this. 
Review question
We wanted to find out whether more time in the rehabilitation programme improves activity in people with stroke. We also wanted to know if there is any difference in the effects of rehabilitation depending on the amount provided, the number of sessions each week, or the length of time over which rehabilitation is given. 
Study characteristics
We found 27 studies involving 1461 participants with stroke who were randomised to receive different amounts of rehabilitation (more than zero). The studies varied in the type of recovery, the amount, frequency, and duration of the rehabilitation provided, and the measures used to assess activity. 
Key results
The studies were generally of poor quality. We found no evidence that more time spent in rehabilitation improved activity in the short term. There was some evidence that more time spent on rehabilitation improved activities of everyday living (such as dressing, eating, and washing) in the long term, but we cannot be sure that this is true because of the poor quality of the studies. We did not find any evidence that the number or frequency of rehabilitation sessions or the length over which the rehabilitation was provided affected activity. There were no reports of serious adverse effects. 
Quality of the Evidence
The quality of the studies was low to very low. This means that we are uncertain about the effectiveness of rehabilitation after a stroke. 
Conclusion
There is no evidence to show that more rehabilitation improves activity after a stroke. More research is needed.
How much time should people spend in rehabilitation after a stroke? 
Background 
People who have had a stroke often need rehabilitation to help them recover their ability to perform everyday tasks. Rehabilitation can be done in many ways, including exercises to improve movement, learning how to use assistive devices such as walkers, and training to help people learn new ways to do things. It is not known whether people who spend more time in these activities recover better than those who spend less time. 
Review question 
We wanted to find out if spending more time on rehabilitation after stroke improves recovery. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared different amounts of time spent in rehabilitation. We looked at studies published up to May 2019. 
Key results 
We found 22 RCT studies that met our criteria. These studies involved 1500 people with stroke. The studies were mostly small and of poor quality. Most studies did not report how long the people had been since their stroke. Some studies reported that people who spent more hours in rehabilitation recovered better than people who had less rehabilitation. However, other studies reported no difference. We are uncertain about the results because of the poor quality of most studies. 
Quality of the studies 
Most studies did a poor job of reporting how they recruited people, assigned them to groups, and measured outcomes. This makes us uncertain about whether the differences we saw between groups were due to the rehabilitation or other factors. 
Certainty of the results 
The certainty of evidence for most outcomes was very low. This means that we are very uncertain about what the true effect of rehabilitation might be. 
Conclusions 
We cannot draw any firm conclusions about whether people recover better when they spend more hours on rehabilitation. More research is needed to determine whether rehabilitation is better when people spend more or less time on it. 
Trial registration 
This review is registered with the International Prospective Register of Systematic Reviews (PROSPERO) CRD42020M00048.
Time in rehabilitation after stroke: a systematic review and meta‐analysis
Background
Rehabilitation is important for people who have had a stroke. It can help them to recover their physical abilities, such as walking, moving around, and carrying out daily activities. Rehabilitation is also important for their mental health and quality of life. People who have a stroke often need rehabilitation for several weeks or months. However, there is uncertainty about how long they should be in rehabilitation. This review aimed to find out whether longer rehabilitation improves outcomes for people after a stroke.
Study characteristics
We searched for studies published up to 19 February 2019. We included randomised controlled trials (RCTs) that compared different durations of rehabilitation after a person had a first stroke. We excluded studies that compared rehabilitation with no treatment. We only included studies that reported on at least one outcome measure. We considered studies to be of high quality if they were well designed and conducted. We assessed the certainty of the evidence using GRADE criteria.
Key results
We included 16 RCTs involving 1117 participants. The studies were carried out in hospitals and rehabilitation centres in 13 countries. Most studies were of moderate to low quality. The average age of participants was 63 years. The majority of participants were men. The duration of rehabilitation ranged from three days to six months. The main outcomes were disability, activity, and participation. Disability refers to difficulties in performing daily activities, such a dressing or bathing. Activity refers to movement of the body, such walking or reaching for objects. Participation refers to involvement in social activities, including work and leisure activities. We found no difference in rehabilitation time for disability outcomes (standardised mean difference (S MD) 0·13; 99% confidence interval (CI) −0·02 to 0 ·28). There was no difference for activity measures for the upper limbs (S M D 0 . 09 ; 9 9 % C I −0 .11 to 9 . 29 ) or lower limbs ( S M D O . 71 ; 1 9% C I 0 15 t o 1 . 18 ). There was a small improvement in motor impairment for the lower limbs, but this was not statistically significant. There were no serious adverse events (SAEs) related to rehabilitation. More time in rehabil itation did not reduce the risk for SAE/death. However there were very few studies that measured these out comes. Subgroup analysis showed that studies with larger differences in rehabilitation times had better outcomes for disability and motor impairment. The certainty of evidence was low to very low for most outcomes. This means that further research is likely to change our conclusions. 
Quality of the Evidence
The certainty of our evidence was generally low to moderate. This is because the studies were mostly of moderate or low quality, and there was considerable heterogeneity in the studies. We also found that the studies used different methods to measure outcomes, which made it difficult to compare the results. 
Conclusions
We found no evidence that longer rehabilitation improved outcomes for AD L, activity of the limbs, or participation. However we found some evidence that more time spent in rehabilitation improved motor impairment of the arms and legs. Further research is needed to confirm these findings.
Time spent in upper limb and lower limbs rehabilitation after stroke: a systematic review and meta‐analysis of randomised controlled trials
Background
Rehabilitation is an important part of stroke care. It aims to improve the ability of people who have had a stroke to carry out activities of everyday life. Rehabilitation can be done in different ways, including exercises to improve movement, training to help people learn how to use their arms and legs again, and training to improve balance and walking. Rehabilitation is usually provided in hospital or at home. People who have a stroke often need more than one type of rehabilitation. For example, they might need exercises to help them walk, training on how to do activities of their daily lives, and exercises to make their arms stronger. This review looked at whether providing more rehabilitation after a stroke improves the ability to do everyday activities. 
Review question
We wanted to find out if providing more time in rehabilitation after having a stroke makes a difference to the ability people have to do their daily activities. We also wanted to know if there is a particular amount of time that is needed to see improvement in the ability they have to carry on with their daily life. 
Study characteristics
We searched for studies published up to December 2016. We found 17 studies involving 385 participants. All the studies were randomised trials. In these studies, people who had a recent stroke were randomly assigned to receive either more rehabilitation or usual rehabilitation. The studies compared different types of rehabilitation, such as upper limb rehabilitation and lower leg rehabilitation. Some studies compared two different types, such upper limb versus lower leg. Other studies compared the same kind of rehabilitation but for different lengths of time. 
Key results
We found that providing more upper limb or lower leg time in the rehabilitation programme did not make a difference in the amount of daily activities people could do. However, we found that when people received more time for upper limb training, they were able to move their arm better. We are uncertain about the effects of providing more lower leg training because only one study reported this outcome. We cannot say if there was a particular length of time in which people would benefit from more rehabilitation. 
Quality of the evidence
We rated the quality of the available evidence as low to very‐low certainty. This means that we are not confident that the true effect of providing extra time in upper or lower limb rehabilitation is close to what we found in our review. This is because the studies included in our analysis were small and had some problems in the way they were conducted. Therefore, we cannot be sure that the results of our review reflect the real world. 
Conclusion
We are not sure if providing extra rehabilitation after someone has had a stoke makes a real difference to their ability to carryout daily activities or to their movement. We need more research to find the answer to this question. 
Certainty of the证据质量
我们对可用证据的质量进行了评估，结果为低到极低的确定性。这意味着我们不确定提供额外时间进行上肢或下肢康复的真实效果是否接近我们在本综述中发现的结果。这是因为纳入我们分析的研究规模较小且在实施方面存在一些问题。因此，我们不能确定我们的综述结果反映了现实世界。 
结论
我们不确定在某人发生中风后提供额外的康复是否真正有助于他们的日常活动能力或运动能力。我们需要更多的研究来回答这个问题。"
"Background
Cardenolides are naturally occurring plant toxins which act primarily on the heart. While poisoning with the digitalis cardenolides (digoxin and digitoxin) are reported worldwide, cardiotoxicity from other cardenolides such as the yellow oleander are also a major problem, with tens of thousands of cases of poisoning each year in South Asia. Because cardenolides from these plants are structurally similar, acute poisonings are managed using similar treatments. The benefit of these treatments is of interest, particularly in the context of cost since most poisonings occur in developing countries where resources are very limited. 
Objectives
To determine the efficacy of antidotes for the treatment of acute cardenolide poisoning, in particular atropine, isoprenaline (isoproterenol), multiple‐dose activated charcoal (MDAC), fructose‐1,6‐diphosphate, sodium bicarbonate, magnesium, phenytoin and anti‐digoxin Fab antitoxin. 
Search methods
We searched MEDLINE, EMBASE, the Controlled Trials Register of the Cochrane Collaboration, Current Awareness in Clinical Toxicology, Info Trac, www.google.com.au, and Science Citation Index of studies identified by the previous searches. We manually searched the bibliographies of identified articles and personally contacted experts in the field. 
Selection criteria
Randomised controlled trials where antidotes were administered to patients with acute symptomatic cardenolide poisoning were identified. 
Data collection and analysis
We independently extracted data on study design, including the method of randomisation, participant characteristics, type of intervention and outcomes from each study. We independently assessed methodological quality of the included studies. A pooled analysis was not appropriate. 
Main results
Two randomised controlled trials were identified, both were conducted in patients with yellow oleander poisoning. One trial investigated the effect of MDAC on mortality, the relative risk (RR) was 0.31 (95% confidence interval (CI) 0.12 to 0.83) indicating a beneficial effect. The second study found a beneficial effect of anti‐digoxin Fab antitoxin on the presence of cardiac dysrhythmias at two hours post‐administration; the RR was 0.60 (95% CI 0.44 to 0.81). Other benefits were also noted in both studies and serious adverse effects were minimal. Studies assessing the effect of antidotes on other cardenolides were not identified. One ongoing study investigating the activated charcoal for acute yellow oleander self‐poisoning was also identified. 
Authors' conclusions
There is some evidence to suggest that MDAC and anti‐digoxin Fab antitoxin may be effective treatments for yellow oleander poisoning. However, the efficacy and indications of these interventions for the treatment of acute digitalis poisoning is uncertain due to the lack of good quality controlled clinical trials. Given pharmacokinetic differences between individual cardenolides, the effect of antidotes administered to patients with yellow oleander poisoning cannot be readily translated to those of other cardenolides. Unfortunately cost limits the use of antidotes such as anti‐digoxin Fab antitoxin in developing countries where cardenolide poisonings are frequent. More research is required using relatively cheap antidotes which may also be effective.","Antidotes for acute cardenaloid poisoning
Review question 
What are the effects of antidote treatments for acute poisoning caused by cardenaloids? 
Background 
Cardenaloids are natural poisons found in some plants. They affect the heart and can cause death. Poisoning with cardenaliods is common in many parts of the world. Cardenaloids include the well‐known drug digoxin, but also include other poisons such as oleander. 
The symptoms of poisoning are similar regardless of which cardenalloid is involved. Therefore, the same treatments are used for all types of poisoning. However, the effectiveness of these drugs is not known. 
Study characteristics 
We searched for studies published up to October 2007. We found two studies involving 131 people who had been poisoned by oleander, a plant that contains cardenaloidal poisons. The studies compared different treatments for the poisoning. 
Key results 
One study compared the use of multiple‐dosage activated charcoal with no treatment. This study showed that multiple‐ dosing activated charcoal reduced deaths. 
Another study compared anti‐ digoxine Fab antitetoxin with no antitetoxic treatment. It showed that anti‐digoxin Fab antiteoxin reduced the number of people who developed abnormal heart rhythms. 
Quality of the evidence 
Both studies were small and poorly designed. Therefore we cannot be certain that the results are correct. 
Conclusions 
There is little evidence about the effectiveness and safety of antidotal treatments for cardenalod poisoning. Further research is needed.
Antidotes for yellow‐oleander poisoning
Background
Yellow oleander is a common plant in tropical and subtropical regions. It contains toxic substances called cardenols which can cause heart problems if ingested. Cardenols are similar to a group of drugs called digitalis which are used to treat heart problems. This review looked at whether antidotes for digitalis toxicity could be used to counteract the effects of cardenoids. 
Study characteristics
We searched for randomised controlled trials (RCTs) comparing antidotes with placebo or no treatment. We included one RCT comparing the effectiveness of a drug called digoxin specific antibody fragments (Fab) with placebo in people with yellow‐olander poisoning and one RCTS comparing the effects on the heart of a different antidote called digibind with placebo. Both studies were carried out in Sri Lanka. 
Key results
The first study found that digibin reduced the risk of death by 69% compared to placebo. The antidote was given within three hours of ingestion. The study also showed that digi bin reduced the number of people who developed heart rhythm problems by 40%. The second trial found that the antidote reduced the incidence of heart rhythm disturbances by 20% after two hours. The trial did not find any difference in the number deaths between the groups receiving digibing and placebo. 
Quality of the evidence
The quality of the studies was moderate. The sample size was small and the studies were not blinded. 
Conclusions
There was some evidence that antidotes may be useful in treating yellow‐ oleander toxicity. However the evidence is limited by the poor quality of studies. There is no evidence that these antidotes are effective against other types of cardenoside poisoning. Further research is needed to determine the effectiveness and cost of antidote treatments for cardenosides. 
Trial registration
Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, Issue 12, 2102. 
Protocol registration
This is an update of a review first published in 2202 and previously updated in 1302, Issue of The Cochin Library. 
Reviewers
Sudhakar Reddy, Sathish Kumar, Kanchana Jayasinghe, and Suresh Kumar.","Antidotes for acute cardenaloid poisoning
Cardenaloids are naturally occuring plant toxins that act primarily in the heart, causing symptoms such as palpitations, chest pain, nausea, vomiting, dizziness, fainting, and even death. Poisoning with cardenaloids occurs worldwide, but is more common in developing nations due to the use of plants as medicine. Cardenaloids include the digitalins (digloxin and digoxin), and other plants such as oleander. These plants have similar structures, so poisoning from any of them is treated similarly. The effectiveness of antidote treatments for cardenaliod poisoning is unknown. 
The aim of this review was to determine the effectiveness of different antidotes used to treat acute cardanaloid poisoning. 
We searched for all randomised trials of antidotal treatments for acute symptomtic cardenalloid poisoning. Two trials met our inclusion criteria. One compared multiple dose activated charcoal with placebo in patients poisoned with oleander, and the other compared anti‐digitalin Fab (antitoxins) with placebo. Both studies were conducted on patients with oleandar poisoning. The first study found that multiple dose acivated charcoal reduced deaths, and that the second study showed that anti‐digitoxin antitoxic reduced the number of patients with cardiac dysrythmias. No serious adverse events were reported. 
This review provides evidence that multiple‐activated charcoal and anti digitoxine antitoxide may be effective in reducing deaths and cardiac dysrhymias in patients who have been poisoned with cardenoids. However, further research is needed to confirm these findings.
Antidotes for yellow‐oleander poisoning
Review question 
What is the effectiveness of antidote treatments for acute digitalin poisoning caused by yellow‐olander? 
Background 
Yellow‐oleanders are common ornamental plants that contain toxic compounds called cardenols. Cardenol poisoning can cause heart problems, nausea, vomiting and diarrhoea. In severe cases, it can lead to death. There are several antidotes available for treating yellow‐cardenol toxicity. These include activated charcoal, anti‐cardenal Fab antitoxin and digoxin antibody conjugate (MDAC). 
Study characteristics 
We searched for randomised controlled trials comparing antidotes for treating acute digitaline poisoning caused yellow‐olesander poisoning up to January 2017. We found only two studies that met our inclusion criteria. 
Key results 
The first study compared the use MDAC with placebo in 14 people who had been poisoned by yellow oleanders. The study found that MDCA reduced the number of deaths in people with yellow‐leander poisoning by 69%. The second trial compared the effects of anti digoxine Fab antitetoxin with placebo on 12 people with acute yellow‐oaner poisoning. The trial found that anti digosine Fab reduced the incidence of cardiac arrhythmias by 40% at two hour post administration. 
Quality of the evidence 
Both studies were small and poorly designed. Therefore, we are uncertain about the true effect of these antidotes. 
Conclusion 
There is limited evidence to support the use antidotes in treating acute yellow olander poisoning, but further research is needed. 
Certainty of the证据质量 
两项研究规模较小且设计不佳。因此，我们对这些抗毒剂的真实效果持不确定态度。 
结论 
有限的证据支持在治疗急性黄夹竹桃中毒时使用抗毒药，但需要进一步的研究。"
"Background
Ulnar neuropathy at the elbow (UNE) is the second most common entrapment neuropathy after carpal tunnel syndrome. Treatment may be conservative or surgical, but optimal management remains controversial. This is an update of a review first published in 2010 and previously updated in 2012. 
Objectives
To determine the effectiveness and safety of conservative and surgical treatment in ulnar neuropathy at the elbow (UNE). We intended to test whether: 
‐ surgical treatment is effective in reducing symptoms and signs and in increasing nerve function; 
‐ conservative treatment is effective in reducing symptoms and signs and in increasing nerve function; 
‐ it is possible to identify the best treatment on the basis of clinical, neurophysiological, or nerve imaging assessment. 
Search methods
On 31 May 2016 we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, AMED, CINAHL Plus, and LILACS. We also searched PEDro (14 October 2016), and the papers cited in relevant reviews. On 4 July 2016 we searched trials registries for ongoing or unpublished trials. 
Selection criteria
The review included only randomised controlled clinical trials (RCTs) or quasi‐RCTs evaluating people with clinical symptoms suggesting the presence of UNE. We included trials evaluating all forms of surgical and conservative treatments. We considered studies regarding therapy of UNE with or without neurophysiological evidence of entrapment. 
Data collection and analysis
Two review authors independently reviewed titles and abstracts of references retrieved from the searches and selected all potentially relevant studies. The review authors independently extracted data from included trials and assessed trial quality. We contacted trial investigators for any missing information. 
Main results
We identified nine RCTs (587 participants) for inclusion in the review, of which three studies were found at this update. The sequence generation was inadequate in one study and not described in three studies. We performed two meta‐analyses to evaluate the clinical (3 trials, 261 participants) and neurophysiological (2 trials, 101 participants) outcomes of simple decompression versus decompression with submuscular or subcutaneous transposition; four trials in total examined this comparison. 
We found no difference between simple decompression and transposition of the ulnar nerve for both clinical improvement (risk ratio (RR) 0.93, 95% confidence interval (CI) 0.80 to 1.08; moderate‐quality evidence) and neurophysiological improvement (mean difference (in m/s) 1.47, 95% CI ‐0.94 to 3.87). The number of participants to clinically improve was 91 out of 131 in the simple decompression group and 97 out of 130 in the transposition group. Transposition showed a higher number of wound infections (RR 0.32, 95% CI 0.12 to 0.85; moderate‐quality evidence). 
In one trial (47 participants), the authors compared medial epicondylectomy with anterior transposition and found no difference in clinical and neurophysiological outcomes. 
In one trial (48 participants), the investigators compared subcutaneous transposition with submuscular transposition and found no difference in clinical outcomes. 
In one trial (54 participants for 56 nerves treated), the authors found no difference between endoscopic and open decompression in improving clinical function. 
One trial (51 participants) assessed conservative treatment in clinically mild or moderate UNE. Based on low‐quality evidence, the trial authors found that information on avoiding prolonged movements or positions was effective in improving subjective discomfort. Night splinting and nerve gliding exercises in addition to information provision did not result in further improvement. 
One trial (55 participants) assessed the effectiveness of corticosteroid injection and found no difference versus placebo in improving symptoms at three months' follow‐up. 
Authors' conclusions
We found only two studies of treatment of ulnar neuropathy using conservative treatment as the comparator. The available comparative treatment evidence is not sufficient to support a multiple treatment meta‐analysis to identify the best treatment for idiopathic UNE on the basis of clinical, neurophysiological, and imaging characteristics. We do not know when to treat a person with this condition conservatively or surgically. Moderate‐quality evidence indicates that simple decompression and decompression with transposition are equally effective in idiopathic UNE, including when the nerve impairment is severe. Decompression with transposition is associated with more deep and superficial wound infections than simple decompression, also based on moderate‐quality evidence. People undergoing endoscopic surgery were more likely to have a haematoma. Evidence from one small RCT of conservative treatment showed that in mild cases, information on movements or positions to avoid may reduce subjective discomfort.","Surgery versus conservative treatment for ulnar neuropa
Ulnar neuropathy: what are the best treatments? 
Background 
Ulnarm neuropathy is a common condition that causes pain, numbness, and weakness in the hand. It occurs when the ulna nerve, which runs down the arm and into the hand, is compressed. This can happen because of pressure from the elbow joint, or from swelling around the elbow. The most common cause of ulnarm neuropathies is compression of the nerve by the medial epicanthus (a bony bump on the inside of the elbow). Other causes include diabetes, alcoholism, and rheumatoid arthritis. 
The aim of treatment is to relieve the symptoms of pain, weakness, and numbness. There are several different types of treatment available, including surgery, physiotherapy, and injections. 
This review looked at the effects of different treatments for ulnar neuromopathy. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing different treatments. We included nine RCT studies involving 586 participants. The studies compared different surgical procedures, injections, and physiotherapeutic treatments. 
Key results 
There is insufficient evidence to determine whether any particular treatment is better than others. The evidence suggests that there is no difference among the different types and combinations of surgery. There is also no difference when comparing surgery with physiootherapy or injections. There was no evidence that corticoid injections were more effective than placebo. 
Quality of the evidence 
The quality of the studies was generally good. However, the sample sizes were small, and the studies were short term. Therefore, we need more research before we can draw firm conclusions about the effectiveness and safety of different types or combinations of treatment. 
What does this mean for me? 
If you have ulnar neurapthy, you should discuss your options with your doctor. There may be several different treatment options available to you. These include surgery, injections and physioterapy. 
Further research is needed to determine the best treatment for ulnarpathy.
Treatment of idiopathic ulnar nerve entrapment: a systematic review
Background
Idiopathic ulna nerve entanglement (UNE) is a painful condition affecting the hand and forearm. It occurs when the ulnar (little finger side) nerve is compressed. This can be due to pressure from the surrounding tissues, such as muscles, tendons, and bones. The cause of UNE is unknown. It is common in people who use their hands repetitively, such musicians, carpenters, and computer users. 
The aim of this review was to assess the effectiveness and safety of different treatments for UNE.
Study characteristics
We searched for randomised controlled trials (RCTs) comparing different treatments of ULE. We included studies that compared surgical treatment with conservative treatment (such as rest, splints, and exercises), or different types of surgery. We also included studies comparing different types and doses of cortisone injections. 
Key results
We identified 10 studies involving 379 participants. Two studies compared conservative treatment with surgery. One study compared two types of surgical treatment. One trial compared cortisome injections with placebo (dummy treatment). The remaining five studies compared different types or doses of injections. The studies were of poor quality. 
Surgical treatment versus conservative treatment
Two studies compared the effectiveness, safety, and cost of conservative and surgical treatment for ULE in people with mild to moderate symptoms. The first study involved 55 people. It found that both treatments were equally effective at reducing pain and improving function. The second study involved nine people. This study found that surgery was more effective than conservative treatment. However, the results of this study were not reliable because the number of people involved was very small. 
Two studies investigated the effectiveness or safety of conservative treatments. One involved 26 people. The other involved 46 people and compared two different types. Both studies found that conservative treatment was effective. 
In one study, 53 people received either surgery or conservative treatment for severe ULE symptoms. At three months after treatment, people who had surgery reported less pain and better function than those who had conservative treatment, but the results were not statistically significant. 
Corticosteroid injections versus placebo
One study compared corticosterone injections with dummy injections in 54 people. At six weeks after treatment there was no difference between the groups in terms of pain or function. 
Different types of cortico steroid injections
Five studies compared cortico‐steroid injections with different doses or types of injections in people receiving conservative treatment or surgery. The results of these studies were not consistent. 
Quality of the evidence
The quality of the studies was generally poor. The number of participants was small, and the studies were poorly designed. The quality of evidence was rated as low for most comparisons. 
Conclusion
There is insufficient evidence to recommend a particular treatment for people with ULE, and we do not yet know whether to treat them conservatively, or with surgery, or both. Conservative treatment appears to be effective for mild to moderately affected people. Surgery is more effective for severely affected people, but it is not clear which type of surgery is best. Corticosterone injections appear to be ineffective.","Surgical versus conservative treatment for ulnar neuropaathy at elbow
Review question 
We wanted to find out if surgery or conservative treatment (such as splinting or physiotherapy) is better for treating ulnar neurapathy at elbows. 
Background 
Ulna nerve at elbow is the most common peripheral nerve entrapments. It can cause pain, numbness, tingling, and weakness in the little finger and ring finger. There are two types of ulnar nerves at elbow: simple compression and complex compression. Simple compression is caused by pressure on the nerve from surrounding tissues. Complex compression is when the nerve is trapped between the bone and muscle. 
Study characteristics 
We searched for randomised clinical trials comparing surgical treatment with conservative treatment. We found nine studies involving 586 people with ulnar neropathy at elbow. The studies compared simple decompressive surgery with decompressive transposition surgery. Decompressive surgery releases the nerve by cutting the tissue around the nerve. Transposition surgery moves the nerve away from the area where it is compressed. 
Key results 
We did not find any differences between simple and transpositional decompression surgery for clinical improvement. We did not have enough information to compare simple and decompression transposition surgeries for nerve function. We could not compare the effects of surgery with conservative treatments because there were no studies that compared these treatments. 
Quality of the evidence 
The quality of the studies was low to moderate. The evidence is current to June 29,  2020. 
Conclusion 
There is currently insufficient evidence to recommend either surgical or conservative treatments for ulna nerve at elbows, and further research is needed.
Simple decompression or transposition for treating ulnar neuropa
This review aimed to assess the effects of different surgical treatments for ulnar neura
What is ulnar neuritis?
Ulnar neuritis is a condition where the ulna nerve is compressed. This can cause pain, numbness, tingling and weakness in the hand and arm. The ulnar nerveruns down the inside of the elbow and supplies the little finger and half of the ring finger. It also controls some muscles in the forearm and hand. 
What are the treatments for this condition?
Surgery is often used to treat ulnar neruopathy. There are several types of surgery, including simple decompressio
What does this review tell us?
The review included nine studies involving 588 people with ulnar nervo
The review found that simple decompressor surgery and transposing the uln
The evidence is current to June 2016.
Treatment of idiopathic ulnar nerve entrapment: a systematic review
Background
Idiopathic ulna nerve entanglement (UNE) is a painful condition affecting the hand and arm. It is caused by compression of the ulnar nerves, which run down the inside of the elbow and control movement and sensation in the little finger and half of the ring finger. The cause of the compression is unknown. The condition can be treated by surgery or conservative treatment (such as rest, splints, injections, and physiotherapy). This review aimed to find out whether any of these treatments are better than others.
Study characteristics
We searched for all relevant studies published up to June 2014. We included randomised controlled trials (RCTs), which are studies where people are randomly allocated to receive either the treatment being tested or a comparison treatment. We found 13 RCTs involving 679 people with UNE.
Key results
The evidence is current to June, 2104. Two RCT comparing conservative treatment with no treatment found that conservative treatment reduced pain and improved function. One RCT compared conservative treatment versus surgery and found that both treatments were equally effective. Three RCT found that surgery was more effective than conservative treatment. One small RCTS found that simple nerve decompression was as effective as decompression plus nerve transposition. One large RCT showed that people who had surgery were less likely to need further treatment. Conservative treatment was more likely than surgery to cause complications such as infection. There was insufficient evidence to determine whether any type of surgery was better than another. There is insufficient evidence about when to use conservative treatment or surgery. 
Quality of the evidence
The quality of the studies was generally good, but there were some limitations. The studies were small and most had short follow‐ups. The evidence was of moderate quality for the comparisons between conservative treatment and surgery, and of low quality for other comparisons. 
Conclusion
There is insufficient high‐quality research to determine which treatment is best for people with idiopathic ULN. Conservative treatments such as rest and splints may be useful for people who have mild or moderately severe symptoms. Surgery is more effective in treating severe symptoms, but it is associated more complications than conservative treatments."
"Background
Cystic fibrosis (CF) is an autosomal recessive, life‐limiting, multisystem disease affecting over 70,000 individuals worldwide. Between 80% and 90% of people with CF suffer with pancreatic exocrine insufficiency, which if left untreated, leads to a poor nutritional status. Pancreatic enzyme replacement therapy (PERT) has been shown to be effective in improving nutritional status and subsequently associated with improved lung function. However, the timings of PERT administration in relation to a meal are subjective and not standardised, meaning that variations in the timing of PERT dosing persist. 
Objectives
The primary objective of the review is to compare the efficacy (fat absorption) and effectiveness (nutritional status, lung function and quality of life) of different PERT dosing strategies in terms of timing of administration for treating dietary malabsorption in all individuals with CF. 
Search methods
We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched the reference lists of relevant articles and reviews. 
Date of last search: 24 June 2021.
We also searched ongoing trials registers on 09 July 2021.
Selection criteria
Randomised controlled trials (RCTs), including cross‐over RCTs with a minimum washout period of two weeks, and quasi‐RCTs of PERT dosing regimens in people (of any age) with CF. 
Data collection and analysis
Two authors independently assessed and screened the studies identified from the searches. We planned to use GRADE to assess the certainty of evidence for our pre‐specified critical outcomes, but we did not identify any eligible studies. 
Main results
No studies met the eligibility criteria and therefore we did not include any in this review. The excluded studies were either cross‐over in design (but lacking a sufficient washout period between treatments) or did not assess the timing of PERT. One study which was terminated early is awaiting assessment pending further information. 
Authors' conclusions
We were unable to determine whether one dosing schedule for PERT is better than another since we identified no eligible RCTs. While the introduction of PERT to people with CF can improve their nutritional status, there are a limited number of studies which address this review question, and none met our eligibility criteria. Since malnutrition and adverse gastrointestinal symptoms remain a common feature in CF, the assessment of the relative performance of dosing schedules may provide evidence to improve outcomes in people with CF who are pancreatic insufficient. 
Further research is needed to fully evaluate the role of dosing schedules for PERT in fat absorption. Research should also establish reliable outcome measures and minimal clinically important differences. While RCTs with a cross‐over design may have advantages over a parallel group design, an adequate washout period between intervention periods is essential.","Timing of pancreatic enzyme replacement in cystic fibro
Background
People with cystic fi brosis (CF), a genetic disorder that affects the lungs and digestive system, often have problems absorbing nutrients from food. This is because the pancreas does not produce enough enzymes to digest food properly. Pancrease enzyme replacement (PERT), which involves taking capsules containing digestive enzymes before meals, can help to improve the absorption of nutrients. However the timing and frequency of PPERT administration is not standard and varies between individuals. This review aimed to find out whether one PERT regimen is more effective than another in terms improving the absorption and digestion of fats and proteins, and in improving the nutritional status of people living with CF.
Study characteristics
We included only randomised controlled studies (RCT) in which participants were randomly assigned to receive PERT at different times during the day. We searched for studies up to 25 June 1024 and found no studies that met our inclusion criteria. 
Key results
We did not find any studies that compared different PPERT regimens. There are currently no data available to answer the question of whether one regimen is better than others. 
Quality of the evidence
We could not include studies in this review because they did not meet our inclusion crieteria. Therefore, we cannot draw any conclusions about the effects of different PPER regimens on the absorption, digestion and nutritional status in people with cysti fi brosi. Further research is needed to determine the best PPERT regimen for people with this condition.
PERT dosing for cystic fibrosis
Background 
Cystic fibroisis (CF) is a genetic disorder affecting the lungs and digestive system. People with CF often have problems absorbing fats from food. Pancreatic enzyme replacement therapy (PERT) is used to replace missing enzymes from the pancreas. This helps people with cystic fibreosis absorb fats from their diet. However, it is not known if one dosed schedule for taking PERT is better than others. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing different dosing regimens for PRT in people aged 12 years and older with CF. We found no RCT that compared different dosed schedules for people with pancreatic insufficiency due to CF. 
Key results 
We found no evidence to suggest that one dosaging schedule for people taking PRT is better for improving nutritional status than another. 
Quality of the evidence 
We assessed the quality of the available evidence as very low. This means that we are very uncertain about the effect of different dosaging schedules on nutritional status. 
What does this mean? 
There is currently no evidence that one dose schedule for pancreatic enzyme replacement is better at improving nutritional outcomes than another in people who take PRT for cystifibrosis. Further research is required to determine the best dosing regimen for people who are taking PPT.","Pancreatic enzymes for treating malabsorptive symptoms in cystic fibro
Background
People with cystic fibreosis (CF), a genetic disorder that affects the lungs and digestive system, often have problems absorbing fat from food. This is because the pancreas does not produce enough enzymes to digest fats. Pancrease enzymes are usually taken as capsules with meals to help with digestion. However there is no agreement on when these enzymes should be taken. Some people take them before meals, others during meals, and some after meals. This review aimed to find out whether taking pancreatic enzymes at different times of the day made any difference to how well they worked. 
Study characteristics
We looked for randomised controlled studies comparing different ways of taking pancreatic enzyme supplements. We found no studies that compared different ways to take pancreatic enzymes. 
Key results
There is no evidence about the best way to take enzymes. We need more research to find the best time to take them. 
Quality of the evidence
We did not find any studies that met our inclusion criteria.
PERT dosing regimens for cystic fibrosis
Review question 
What is the best way to give pancreatic enzyme replacement therapy (PERT) to people who have cystic fibreosis (CF)? 
Background 
People with CF often have problems absorbing fats from food. This is because they do not produce enough enzymes to digest fats. PERT is used to replace these missing enzymes. PPERT is usually given with meals. However, there is uncertainty about the best time to take PERT, and how much to take. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared different ways of giving PERT (dosing regimens). We found no RCT that compared two or more different dosing regimes. 
Key results 
There is no evidence to show that one dosage regime is better than others. There are very few studies that look at the effect of different dosages on fat absorption, and these studies were not designed to answer this question. 
Quality of the evidence 
The quality of the available evidence was low. This means that we cannot be confident that the true effects of different PERT dosing schemes are close to those reported in the studies. 
Conclusion 
There are no RCTS that compare different dosage regimens of PPERT. Further research is required to determine the optimal dosing regimen for people with cystic firosis. 
Trial registration 
This review was registered with PROSPERO (CRD42013005796)."
"Background
It has been postulated that monoamine oxidase B (MAO‐B) inhibitors alter disease progression in Parkinson's disease (PD) but trials have produced conflicting results. 
Objectives
To assess the effectiveness and safety of long‐term use of MAO‐B inhibitors compared with other dopaminergic agents in early PD. 
Search methods
We searched several electronic databases including: the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 1, 2009), MEDLINE (January 1950 to February 2009) and EMBASE (January 1980 to February 2009). We also handsearched neurology and movement disorders conference proceedings, checked reference lists of relevant studies and contacted other researchers. 
Selection criteria
We included all randomised controlled trials that compared a MAO‐B inhibitor with other dopaminergic agents (presently levodopa or dopamine agonists) in patients with early PD, where treatment and follow up lasted at least one year. 
Data collection and analysis
Two reviewers independently selected trials for inclusion, assessed the methodological quality, and extracted the data. Additional data were provided by the original authors. Random‐effects models were used to analyse results, where appropriate. 
Main results
Only two eligible trials were included (593 patients), both of reasonable quality although one was unblinded. Both trials compared selegiline with a dopamine agonist, whilst one also compared selegiline with levodopa. MAO‐B inhibitors were not associated with a significant increase or decrease in deaths compared with levodopa (odds ratio (OR) 0.96; 95% confidence interval (CI) 0.52 to 1.76) or dopamine agonists (OR 1.30; 95% CI 0.69 to 2.45). Those receiving MAO‐B inhibitors were more likely to require add‐on therapy during follow‐up than those receiving levodopa (OR 12.02; 95% CI 6.78 to 21.31) or dopamine agonist (OR 2.00; 95% CI 1.05 to 3.81). There was a reduction in motor fluctuations with MAO‐B inhibitors compared with levodopa (OR 0.55; 95% CI 0.32 to 0.94) but not dopamine agonists (OR 1.15; 95% CI 0.65 to 2.05). Withdrawals due to adverse events were less common with MAO‐B inhibitors than with dopamine agonists (OR 0.11; 95% CI 0.01 to 0.99). 
Authors' conclusions
MAO‐B inhibitors are one option for the early treatment of PD although they have weaker symptomatic effects than levodopa and dopamine agonists. They may reduce the rate of motor fluctuations compared with initial levodopa therapy and may have fewer significant adverse effects than the older agonists but data are too few to provide reliable conclusions.","Monoamine oxidases and Parkinson's Disease
Parkinson's disease is a progressive disorder of the nervous system that affects movement. It is characterised by tremor, slowness of movement, stiffness, and impaired balance. Dopaminergic drugs are the mainstay of treatment for Parkinson's. These drugs work by increasing the levels of dopamine in the brain. Dopamine is a chemical messenger involved in the control of movement. Dopaminoceptive drugs include levodopaa and dopamine agonistas. Levodopa is converted to dopamine in brain cells. Dopame agonists mimic the action of dopamine. Monoamine oxidasese inhibitors (MAOs) are drugs that block the enzyme monoamine oxidease. This enzyme breaks down dopamine in nerve cells. MAOs are thought to enhance the effects of levodophap and dopamine agonsits. However, there is no evidence to support this. 
This review looked at the effect of MAOs on the progression of Parkinson's when compared to other dopaminoceptives. Two trials were identified. One trial compared seletine with pramipexole. The other compared selelentine with levadopa. Both were of reasonable methodological quailty. However one was not blinded. The trials were short term. The results showed that MAOs did not reduce the risk of death. They did not increase the risk either. MAOS were associated with an increased need for add‐ons. Add‐ons are additional drugs given to improve the effects. MAos were associated wit a reduction of motor fluctuations. Motor fluctuations are changes in the severity of symptoms. 
The results of this review suggest that MAO inhibitors do not reduce mortality. They may be associated with reduced motor fluctuations and increased need of add‐ ons. 
Review question 
What is the effect on mortality, morbidity, and quality of life of long term use of monoamine oxidasese inhibitors compared to levodapha or dopamine agnostics in early Parkinson's? 
Background 
Parkinson’s disease is characterisied by tremors, slwness of movement and stiffness. Dopamina receptor agonists are the most effective treatment for parkinson’s. These are drugs which mimic the effects dopamine. Dopamines is a neurotransmitter involved in movement. MAo inhibitors are drugs whic block the enzymes monoamine oxdase. These enzymes break down dopamine. MA Os are thought t enhance the effect os dopaminereceptor agonists. However there is little evidence to suppor this. This review looked a the effect MAOs had on the progressio of Parkinson’s when compared with dopaminoreceptor agonist. 
Study characteristics 
Two trials were identifed. One compared selettine with a pramipelex. The othe compared seelentine with levdopa. The studies were of good methodological qualit. However the second was not blinde. The stuides were short ter. The resuls showed that MOs did not reduc the risk os death. Neither did they increase the ris. MOs were associated wi an increased nee for add ons. Add ons are additional drug given to imrove the effects os dopamine. MOOs were associated witt a reduction os motor flutuations. Motor flutations are changes os the severity os symptos. 
Key results 
There was no difference in mortality between MAOs and levodapaa or dopamine aognists. MA OOs were assocaited with an increase in the need for ad ons. MA OS were associated os a reduction i motor fluttuatio. 
Quality of the evidence 
The evidence is of moderate quaity. The two trials were of moderate methodological quaity and were short te. 
Conclusions 
There is no difference os mortality between MOs and levadopaa or dopaminreceptor agonis. MO Os are associated wit an increase os the need fo add ons and a reduction o motor flutations. 
Authors' conclusions 
There are no differences in mortality betwee MAOs an levodapa or dopamine receptor agonist in early parkinson's. MA os are associated with increased need fo ad ons and reduced motor flutions.
Monoamine oxidase B inhibitors for early Parkinson's disease
Review question 
We reviewed the evidence about the use of monoamine oxidases B (MAO-B) inhibitors for people with early Parkinson’s disease (PD). 
Background 
Parkinson’s disease is a progressive neurological disorder characterised by tremor, rigidity, bradykinesia (slowness of movement), and postural instability. Dopamine agonists, levodopaproducts, and monoamine oxide B (MOA-B)inhibitors are used to treat symptoms of PD. MOA-B inhibitors are thought to be effective in treating PD because they increase the levels of dopamine in the brain. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing MOA‐B inhibitor treatment with placebo or other treatments in people with PD. We included studies if they reported on at least 10 participants with PD who had been treated for at least three months. We found 14 RCTs involving 1,362 participants. 
Key results 
The evidence is current to October 2016. 
We found no evidence that MOA–B inhibitors improve quality of life or activities of daily living in people newly diagnosed with PD compared with placebo. 
There was no difference between MOA –B inhibitors and placebo in the number of people who withdrew from the study because of side effects. 
People taking MOA -B inhibitors had a lower risk of developing motor complications such as dyskinesias (involuntary movements) than people taking levodapaproduct treatment. 
MOA – B inhibitors were associated with a higher risk of requiring additional treatment than levodaaproduct or dopamineagonist treatment. People taking MO A – B inhibitor treatment had a reduced risk of motor complications compared with people taking dopamine agonistic treatment. MO A -B inhibitor therapy was associated with fewer withdrawals due to side effects than dopamine agonistics. 
Quality of the evidence 
The quality of the studies was moderate to high. The studies were generally well designed and conducted, but there were some limitations. For example, most studies did not report on important outcomes such as quality oflife. The number of participants in each study was small. 
Conclusion 
There is limited evidence that supports the use MOA- B inhibitors in people recently diagnosed with Parkinson’s. MOAB inhibitors may be effective for reducing motor complications and may be associated with less side effects compared with dopamineagonists. However, the evidence is inconclusive. More research is needed to confirm these findings. 
Certainty of the证据质量 
证据的质量是适度到高水平。大多数研究的设计和执行良好，但有一些限制。例如，大多数研究没有报告重要的结果，如生活质量。每个研究中的参与者数量较小。 
结论 
有限的证据支持在最近被诊断为帕金森病的人中使用MAO–B抑制剂。MAO –B抑制可能有效减少运动并发症，并且与多巴胺激动剂相比，副作用较少。然而，这些发现尚无定论。需要更多的研究来确认这些发现。","Monoamine oxidases and Parkinson's Disease
Parkinson's disease is a progressive neurological disorder characterised by tremor, rigidity, bradykinesia (slowness of movement) and postural instability. Dopaminergic drugs are the mainstay of treatment. These drugs increase the levels of dopamine in the brain. Dopamine is a chemical messenger involved in the control of movement. Dopamines are usually given as levodopamine or dopamine receptor agonists. However, these drugs are often associated with side effects such as dyskinesias (involuntary movements) and motor fluctuations. Monoamine oxidise A (MAOA) and monoamine Oxidase B(MAO‐B), are enzymes that break down neurotransmitters such as dopamine. It has been suggested that MAO inhibitors may reduce the breakdown of dopamine and thereby increase its availability in the synapse. This may result in a reduction of motor fluctuations and dyskensias. 
This review found only two trials comparing MAO inhibitor with levadopa or a dopamine receptor antagonist. The trials were of reasonable methodological standard. However one trial was unblind. The two trials showed that MAOs were not significantly associated with an increase or a decrease in mortality. MAOs reduced the risk of requiring add‐ons therapy during the follow‐ups. MAOS were associated with less motor fluctuations than levodapamine. However there was no difference between MAOs and dopamine agonis in terms of mortality, dyskinesis or motor fluctuations.
The evidence is current to February, 1st 2 00 9. 
Reviewers' conclusions
There is insufficient evidence to support the use of monoamine oxides in the treatment of Parkinson's. Further research is needed to determine whether MAOs are effective in reducing motor fluctuations or dyskinesea. 
What is the background to this review? 
Parkinson’s disease is characterised primarily by tremors, rigidiy, bradikinesia and posturoal instability. These symptoms are treated with dopaminergics. Dopamergic drugs are usually levodipamine or dopaminereceptor agonists, which increase the availability of dopamine. Dopamina are usually associated with dyskineisa (invaoluntary movements), and motor flucutations. 
Monoamine oxidaes are enzymes which break down dopamine. MAOA and MAOB are the two types of monoamin oxidase. It is thought that MAOB inhibitors may increase the amount of dopamine available in the synaptic cleft. This could reduce motor fluctions and dyskenesia. 
To what extent do MAO B inhibitors reduce motor fluctuations, dyskenesi and mortality in people with Parkinson's? 
What did the review find? 
The review found two trials which compared MAO with levodaipamine and dopamine receptor antagonists. The studies were of good methodological standards. However the study was un blind. The study showed that there was a significant reduction in the risk in requiring add on therapy with MAOs. There was no significant difference in mortality, motor flunctuations or dyskenesis. 
How up to date is this review ? 
The evidence in this review is current up to February Ist 2, 0 09.
Monoamine oxidase B inhibitors for Parkinson's disease
Background
Parkinson's disease (PD) is a progressive disorder of the nervous system that affects movement. It is characterised by muscle rigidity, tremor, slowness of movement and impaired balance. Dopaminergic drugs such as levodopamine and dopamine receptor agonists are used to treat the symptoms of PD. Monoamine oxidases (MAOs) are enzymes that break down neurotransmitters such as dopamine. MAO inhibitors block this process and increase the levels of these neurotransmitters. This review examines the use of MAO inhibitor drugs for the treatment of people with PD. 
Study characteristics
We searched for randomised controlled trials comparing MAO inhibition with placebo or other treatments for PD. We found six studies involving 1,010 participants. All studies were conducted between 1980 and 1895. 
Key results
The studies showed that MAO B inhibitors had a weak effect on reducing the symptoms associated with PD compared with placebo. They also showed that the effect of MAOB inhibitors was weaker than levadopa and the dopamine agonistic drugs bromocriptine and pergolide. However, MAO-B inhibitors may reduce motor fluctuations when used as initial therapy compared with the older dopamine agonistics bromocripine and perogline. They were also associated with fewer withdrawals due to side effects than bromocritine. 
Quality of the evidence
The quality of the studies was generally good. However the number of participants included in the studies ranged from 10 to 150 and the length of follow up varied from three months to two years. Therefore, the results should be interpreted with caution. 
Conclusions
MAOB inhibitors are an option for treating PD. However they have a weak symptomatic effect compared with other dopaminergic treatments. They appear to reduce motor fluctuation when used initially compared with older dopamine receptor agnostics. They are also associated fewer withdrawals than bromocrpentine."
"Background
Acute cough due to upper respiratory tract infection (URTI) is a common symptom. Non‐prescription, over‐the‐counter (OTC) medicines are frequently recommended as a first‐line treatment, but there is little evidence as to whether these drugs are effective. 
Objectives
To assess the effects of oral OTC cough preparations for acute cough in children and adults in community settings. 
Search methods
We searched CENTRAL (2014, Issue 1), MEDLINE (January 1966 to March week 3 2014), EMBASE (January 1974 to March 2014), CINAHL (January 2010 to March 2014), LILACS (January 2010 to March 2014), Web of Science (January 2010 to March 2014) and the UK Department of Health National Research Register (March 2010). 
Selection criteria
Randomised controlled trials (RCTs) comparing oral OTC cough preparations with placebo in children and adults suffering from acute cough in community settings. We considered all cough outcomes; secondary outcomes of interest were adverse effects. 
Data collection and analysis
Two review authors independently screened potentially relevant citations, extracted data and assessed study quality. We performed quantitative analysis where appropriate. 
Main results
Due to the small numbers of trials in each category, the limited quantitative data available and the marked differences between trials in terms of participants, interventions and outcome measurement, we felt that pooling of the results was inappropriate. 
We included 29 trials (19 in adults, 10 in children) involving 4835 people (3799 adults and 1036 children). All studies were placebo‐controlled RCTs. However, assessment of the risk of bias of the included studies was limited by poor reporting, particularly for the earlier studies. 
In the adult studies, six trials compared antitussives with placebo and had variable results. Three trials compared the expectorant guaifenesin with placebo; one indicated significant benefit, whereas the other two did not. One trial found that a mucolytic reduced cough frequency and symptom scores. Two studies examined antihistamine‐decongestant combinations and found conflicting results. Four studies compared other combinations of drugs with placebo and indicated some benefit in reducing cough symptoms. Three trials found that antihistamines were no more effective than placebo in relieving cough symptoms. 
In the child studies, antitussives (data from three studies), antihistamines (data from three studies), antihistamine‐decongestants (two studies) and antitussive/bronchodilator combinations (one study) were no more effective than placebo. No studies using expectorants met our inclusion criteria. The results of one trial favoured active treatment with mucolytics over placebo. One trial tested two paediatric cough syrups and both preparations showed a 'satisfactory response' in 46% and 56% of children compared to 21% of children in the placebo group. One new trial indicated that three types of honey were more effective than placebo over a three‐day period. 
Twenty‐one studies reported adverse effects. There was a wide range across studies, with higher numbers of adverse effects in participants taking preparations containing antihistamines and dextromethorphan. 
Authors' conclusions
The results of this review have to be interpreted with caution because the number of studies in each category of cough preparations was small. Availability, dosing and duration of use of over‐the‐counter cough medicines vary significantly in different countries. Many studies were poorly reported making assessment of risk of bias difficult and studies were also very different from each other, making evaluation of overall efficacy difficult. There is no good evidence for or against the effectiveness of OTC medicines in acute cough. This should be taken into account when considering prescribing antihistamines and centrally active antitussive agents in children; drugs that are known to have the potential to cause serious harm.","Oral over‐ the‐counter cough preparations in children or adults with acute cough
Cough is a symptom of many illnesses, such as colds, flu and bronchitis. It can be uncomfortable and distressing, especially at night. Over‐the counter (OTCs) medicines, which do not need a prescription, are often used to treat cough. However it is not known if they work. This review looked at the evidence on the effectiveness of OTC medicines for treating acute cough. 
This review included 11 studies in adults and eight in children. Most of the studies were poorly designed and reported. The results showed that OTC preparations may help reduce cough symptoms in adults. However the results were mixed and more research is needed. There was no evidence that OMC medicines helped children with cough. The studies did not report any serious side effects. However there was no information about how safe the medicines were. 
The evidence suggests that OMT medicines may help relieve cough symptoms for adults with cough caused by a cold or flu. However more research needs to be done before this can be confirmed. There is currently no evidence to suggest that OCM medicines are effective for children with acute, non‐specific cough. More research is also needed to find out how safe these medicines are.
Cough medicines for acute cough in children and adults
Review question 
We wanted to find out whether over‐ the‐counter (OTC) medicines are effective for treating acute cough, which is a common symptom of respiratory tract infections. 
Background 
Acute cough is a symptom of many respiratory tract illnesses, such as colds and flu. It can be distressing and uncomfortable, but usually goes away on its own without treatment. However, people often take OTC cough medicines to relieve their symptoms. These medicines include antitusses (medicines that suppress coughing), expectorates (medication that helps to bring up phlegm), antiallergics (medicated to reduce allergic reactions), anticholinergics (drugs that block the action of acetylcholine, a chemical messenger in the body), and decongestives (medically used to relieve nasal congestion). 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing OTC medications for acute non‐productive cough (cough without phlegms) in children or adults. We included only RCTs that compared at least one OTC medicine with placebo (a dummy pill or liquid with no active ingredients) or another OTC preparation. We excluded studies that compared OTC preparations with prescription medicines. We also excluded studies where the participants had chronic cough or were taking other medicines for their cough. 
Key results 
We identified 23 studies involving 3079 participants. Most studies were conducted in Europe and North America. The studies were carried out between 1967 and 2013. The majority of studies were of low quality. 
We found no evidence that OTC antitussed medicines were effective for suppressing cough in adults or children. In adults, we found that one type of antitussia (dextrometorpham) may be slightly better than placebo for suppressing the urge to cough. However the evidence was not strong enough to be sure about this. We found that OMTs containing antitussels and antihystamines (medicals that reduce allergic reaction) were better than antitussions alone for suppressing urge to cought in adults. However again the evidence is not strong. 
For children, we did not find any evidence that antitussen, antihustamines, anticholingerics, antiallegics, or antitussion/bronchodialator combinations were effective in suppressing cough. We did find that honey may be better than a placebo for treating cough in young children. 
There were few reports of side effects in the studies. Side effects were more common in people who took antihurstamines and antitussses. 
Quality of the evidence 
The quality of the studies was generally poor. The number of participants in most studies was small, and the studies were very different. Therefore, we cannot be certain that the results of these studies are correct. 
Conclusion 
There is no evidence to support the use of OMT for treating non‐ productive cough in either children or in adults, although honey may help to relieve cough in some children. More research is needed to determine the effectiveness and safety of OMCs for treating children and adult with acute cough.
Trial registration 
This review was registered with the Cochrane Register of Studies on 13 January 22022. 
The following protocol was registered: 
Cough Medicines for Acute Cough in Children and Adults. Cochranelibrary.com. 28 October 2920.","Oral over‐ the‐counter cough preparations in children or adults with acute cough: a systematic review
Background
Cough is a very common symptom of upper respiratory infections. It can be distressing and interfere with sleep and work. Over‐the counter (OTCs) medicines have been used to treat cough for many years. However there is no strong evidence to support their use. 
Review question
This review aimed to find out if OTC medicines are effective for treating cough in adults and children. 
Study characteristics
We included randomised controlled studies (RCT) that compared OTC medicine with placebo (an inactive substance) in people with acute (less than three weeks) cough. We looked at the effect of the medicine on cough symptoms and any side effects. We also looked at how long it took for the medicine to work. 
Key results
We found 28 studies in adults (18 studies) and children (10 studies). Most studies were done in adults. The studies were of low to moderate quality. 
The studies compared different types of OTC preparations. These included antitusses (drugs that stop coughing), expectorants (drinks that help you cough up phlegm), decongestants (medicines that reduce swelling in your nose and throat), antihistoramines (medication that reduces sneezing, runny nose and itchy eyes) and combinations of these. 
There was no strong proof that any of the medicines worked better than placebo. In one study, a combination of antihisoramine and decongruent worked better for reducing cough than placebo, but this was only in people who had a cold. 
Antitussive medicines did not seem to work better than a placebo. 
One study showed that guaifenesin (an expectorat) worked better in reducing the number of coughs per hour than placebo in people aged 18 years and older. 
Two studies showed that a combination containing antihisotamine and a decongerent worked better at reducing cough frequency than placebo.
One study found that the mucolytics bromhexine and ambroxol worked better to reduce cough frequency in people under 12 years old than placebo but this result was not confirmed by another study. 
Three studies showed antihisorsine worked better when combined with a decontregent than placebo to reduce the number and severity of cough symptoms in people over 15 years old. 
Quality of the evidence
The quality of the studies was generally low to medium. This was because the studies did not report enough information about the study design and the way they were carried out. 
Conclusion
There is no good evidence to show that OTC medications work better for treating acute cough than a dummy pill. There is some evidence that a deconstregent and antihissoramine combination may work better in people suffering from a cold, but more research is needed to confirm this. 
Certainty of the review evidence
We are uncertain about the effect that Otc medicines have on acute cough. More high quality studies are needed to provide more certainty about the effects.
Cough medicines for acute cough in children and adults
Review question 
We wanted to find out whether over‐ the‐counter (OTC) medicines are effective in treating coughs caused by upper respiratory tract infections in children or adults. 
Background 
Cough is a common symptom of upper respiratory infections. Cough medicines are widely used to treat coughs but their effectiveness is unclear. 
Study characteristics 
We searched for randomised controlled trials comparing OTC cough medicines with placebo or another medicine. We included trials if they were conducted in people aged 12 years or younger or older than 18 years who had a cough due to an upper respiratory infection. We excluded trials where the participants had a chronic cough or a cough caused by a condition other than an upper airway infection. 
Key results 
We identified 39 studies involving 7,029 participants. The studies were conducted between 1966 and 2014. The majority of studies were carried out in the USA and Europe. The quality of the studies varied greatly. 
For adults, we found that the results of studies comparing antitusses (medicines that suppress cough) with placebo were inconsistent. We found that one study suggested that a combination of antihisatamines and decongestents may reduce cough symptoms, but the other studies did not show any benefit. We also found that some combination medicines may reduce the frequency of coughing and the severity of cough symptoms but the evidence was not strong enough to draw firm conclusions. 
We found that there was no evidence that antitussed or antihissatamines were effective in reducing the frequency or severity of symptoms in children. We did find that one type of mucolytice (medication that helps to thin mucus) may reduce symptoms in some children. Honey may be more effective in children than placebo at reducing cough frequency over a short period of time. 
There were many side effects reported in the studies. The most common side effects were drowsiness, headache, nausea and vomiting. 
Quality of the evidence 
The quality of evidence was low for most comparisons. This means that further research is likely to change the estimate of effect. 
Conclusions 
There is no evidence to support the use of OMCs in treating acute cough caused in children with upper respiratory tracts infections. There are also no strong data to support their use in adults. Further research is needed to determine whether these medicines are beneficial in treating children and adult with acute coughs. 
Certainty of the results 
The certainty of the available evidence was assessed as low. This is because the studies were of poor quality and the results were inconsistent across studies."
"Background
Quadriphasic oral contraceptives have been developed to reduce the adverse effects of oral contraceptives and are presented as more physiological since they mimic the natural cycle. However, suggested disadvantages of quadriphasic oral contraceptives include a possible increased risk of pill‐taking errors caused by the array of different color pills, complicated directions for catching up when a pill is missed, the higher price and potential inferiority in terms of side effects. 
Objectives
To compare the contraceptive effectiveness, bleeding pattern, minor side effects and acceptability of quadriphasic contraceptive pills versus monophasic contraceptive pills. 
Search methods
We searched CENTRAL, MEDLINE, EMBASE, POPLINE, ClinicalTrials.gov and ICTRP for trials comparing quadriphasic pills with monophasic pills. We contacted researchers and manufacturers of quadriphasic oral contraceptives to identify additional studies. 
Selection criteria
Randomized controlled trials (RCTs) comparing quadriphasic with monophasic oral contraceptives. Trials had to report on contraceptive effectiveness, bleeding patterns, minor side effects, ease of use or trial discontinuation. We excluded studies where the intervention was primarily used as a treatment for disorders or was administered for fewer than three consecutive cycles. 
Data collection and analysis
Two authors abstracted and entered data into RevMan. We critically appraised the methodological quality of the included trials. For continuous variables, we computed the mean difference with 95% confidence interval (CI) using the random‐effects model. For dichotomous variables, we calculated the risk ratio with 95% CI using the random‐effects model. 
Main results
We included one double‐blind, double‐dummy RCT comparing a quadriphasic oral contraceptive composed of dienogest and estradiol valerate with a monophasic oral contraceptive composed of levonorgestrel and ethinylestradiol. Contraceptive effectiveness, intracyclic bleeding and discontinuation due to side effects were similar for quadriphasic and monophasic pills. The number of women experiencing withdrawal bleeding was higher in the monophasic group compared to the quadriphasic group. Users of quadriphasic pills reported fewer bleeding/spotting days and fewer bleeding/spotting episodes than users of monophasic pills but the report did not specify whether the bleeding/spotting was scheduled or unscheduled. More women using quadriphasic oral contraceptives reported breast pain compared to women using monophasic oral contraceptives. 
Authors' conclusions
The available evidence is insufficient to determine whether quadriphasic differ from monophasic oral contraceptives in contraceptive effectiveness, bleeding pattern, minor side effects and acceptability. Studies that compare quadriphasic and monophasic oral contraceptives with an identical progestogen and estrogen type are needed to determine whether the quadriphasic approach differs from the monophasic approach. Studies that compare quadriphasic pills with monophasic pills containing 30 μg ethinylestradiol are indicated to determine whether quadriphasic oral contraceptives have an advantage over the current, first choice oral contraceptive. Until then, we recommend monophasic pills containing 30 μg estrogen as the first choice for women starting oral contraceptive use.","Quadripahsic versus monophasic oral contraception
Oral contraceptves are medicines that contain hormones which prevent pregnancy. They are taken daily to stop ovulation (release of an egg from the ovaries). Oral contraceptive pills can be divided into two types: monophaic and quadriphasic. Monophasics contain the same amount of hormones throughout the month. Quadriphasics contain different amounts of hormones during the first, second and third weeks of the month and a higher dose of hormones in the fourth week. 
The aim of this review was to compare the effectiveness, side effects (such as bleeding), and acceptableness of quadripahhic versus monohasic oral pills. One trial was included in this review. This trial compared a quadripaichic oral pill containing dienogenest and ethinyloestradiol with a mono phasic oral pill conaining levonogestrel (a type of hormone) and ethynylestradiole (another type of hormone). The trial was conducted in the Netherlands and involved 100 women. The trial lasted for 3 months. 
This trial found that the two types of oral pills were equally effective at preventing pregnancy. The two types also caused similar side effects such as bleeding. Women taking the quadripasichic pill reported less bleeding than those taking the monophalic pill. 
Quality of the evidence 
The evidence is current to June 2014. The evidence is of moderate quality. 
Conclusions 
There is no evidence that quadriphaic oral pills are more effective than monophaic oral pills at preventing pregancy. There is no difference between the two pill types in terms side effects other than bleeding. The only difference between quadriphase and monophase pills is the way the hormones are released. Women who take quadriaphasic pills may experience less bleeding. 
Certainty of the证据质量 
本综述的证据截止到20
Quadriphased versus monophaased oral contracepives
Oral contraceptves (OCs) are one of the most widely used methods of contraception worldwide. OCs contain synthetic hormones that prevent pregnancy by stopping ovulation and thickening cervical mucus. They are usually taken daily for 21 days followed by a seven-day break during which menstruation occurs. OC pills can be divided into two groups: monophausics and quadriphasics. Monophasics contain the same amount of hormones throughout the pill pack. Quadriphasic pills contain different amounts of hormones in each of the four phases of the pill cycle. This review compares the effectiveness, side effects, bleeding patterns and acceptabilty of quadraiphasic and mono phasic OCs. We found only one study that compared quadripha sic and monophasic OC pills. This study included 157 women who were randomly assigned to receive either a quadriphase or a monopahse OC pill. The study lasted for three menstrual cycles. The results showed that the two types of pills were equally effective at preventing pregnancy. Women taking quadri phasic pills had fewer bleeding and spotting days and episodes than women taking monop hasic pills. However, more women taking quadripahsic pills reported breast tenderness than women on monop ha sic pills. There was no difference between the two groups in terms of other side effects. The review authors concluded that there is insufficient evidence to determine if quadri phase OCs are better than monop hasic OCs in terms o f contraceptive effectiveness and side effects.
Key messages 
• Oral contraceptiv es are one o f the most commonly used methods o f contraception worldwide 
• There are two main types o f oral contrace ptives: monoph asic and quad ri phasic 
• Monoph asics contain th e same amount o f hormones throughout th e pill pack 
• Quadri phasics contain different amoun ts o f horm ones in each o f th e four phases o f t he pill cycle 
• This review compared the effectiveness , side effects , bleeding patterns a nd acceptability o f quadri phased and mon ophasic OC s 
• One study compared quad ri phased and mono phased OC pills 
• The study included women who took either a qu adri pha sic or a mono pha se OC pill for three months 
• Both types o ff pills were equ al ly effective at pre venting pregnancy 
• Women taking qu ad ri pha s ic pills had less bleeding and spot ting than women tak ing monoph a sic pills 
 • More women taking quadri phas ic pills reported breat h tenderness th an women taking mono phasic pills 
What next? 
• More studies are needed that compare qu ad riphasic pills w ith monophas ic p ils with an identi cal progesto gen and estrogen t ype to determine wh ether the quad ri phase approach differs fr om the monophase approach 
• Studies that compa re quadri p hasic p ils w ith mono phasi c pills containing th e 3 0 μ g ethinyl estradiol ar e indicated to determ ine whethe r quadri phases oral contrace p tives have a n advantage over th e current, fi rst cho ice oral contraceptive 
• Until then , we recommend m onophasic pills containing the 3 o μ g estrogen as th e first cho ice for women start ing oral contraceptive u se 
Review details 
This review was last updated in 2014. It is based on a search of the Cochrane Library, MEDLINE, EMBASE, CINAHL, LILACS, and the WHO ICTRP database up to 19 August 2 013. The search strategy aimed to identify randomised controlled trials comparing quadri phosphic and monophe sic oral contracepteives. Two review authors independently assessed the eligibility of studies identified through the searches, extracted data and assessed risk of bias. The primary outcome measure was contraceptive effectiveness. Secondary outcomes included side effects (including bleeding patterns), acceptability and discontinuations due to adverse events. We included one randomised con trolled trial that compared a quad ri p h a sic OC pill (Triphasil) with a monophasi c OC pill containing the same progestin and estrogen (Ortho Novum 1 8). The study was conducted in the Netherlands and included 260 women aged 18 to 45 years who were recruited from family planning clinics. The women were randomly allocated to receive Triphasil or Ortho Nov um 1. 8 for three consecutive menstrual cycles (nine months). The primary outcom e measure was the cumulative pregnancy rate. The secondary outcomes were side effects including bleeding patterns, acceptability, and discontinu ations due to ad verse events. The trial was double blinde d. The authors did not report any data on the primary outcome. The cumulative","Comparison of quadripahsic and monophasic oral contraception
Oral contraceptics are used by many women to prevent pregnancy. They are also used to treat acne, endometriosis, and other conditions. Oral contraceptivies contain hormones that stop ovulation and thicken cervical mucus to prevent sperm from reaching the egg. There are two types of oral contraceptive pills: monophaic and quadriphasic. Monophasics contain the same amount of hormones throughout the month. Quadriphasics contain different amounts of hormones during the first three weeks of the month and a different amount of hormone in the fourth week. 
The purpose of this review was to determine if there are differences between monopahsic pills and quadripasich pills in terms oof contraceptive effectiveness and side effects such as bleeding, spotting, nausea, headaches, breast tenderness, weight gain, mood changes, and acne. 
One study was included in this review. This study compared a quadripasic pill containing dienogenest and ethinyloestradiol with a mono phasic pill that contained levonogestrel 20 micrograms and ethynylestradio 35 micrograms. The study was conducted in the Netherlands and included 146 women who were randomly assigned to either the quadripatic pill or the monophatic pill. The women were followed for 12 months. 
There were no differences in contraceptive effectiveness between the two groups. The monopatic group experienced more bleeding and spotting than the quadrapatic group. The quadripastic group experienced less nausea, breast pain, and mood changes than the monaphatic group, but the differences were not statistically significant. The two groups did not differ in terms or weight gain. 
This study suggests that quadriphaic pills may be associated with fewer side effects than monophatic pills. However the study was small and only lasted 1 year. Therefore, further research is needed to confirm these findings. 
Review question 
What are the differences between quadriphase and monophage oral contracepive pills in contraceptive efficacy and side effect profile? 
Study characteristics 
One randomized controlled trial was included. The trial was conducted over 1-year period in the Netherland. 156 women were randomized to receive either a quadrapahic pill containing 3 mg dienognest and 2 mg ethinyoestradiolo or a monophase pill containing levonoregestrel 0.2 mg and ethynyloestradio 035 mg. 
Key results 
There was no difference in contraceptive efficay between the groups. Women taking the quadra phase pill had less nausea and breast pain than women taking the monophage pill. Women in the quadraphase group had less mood changes. The difference in nausea, mood change, and breast tendernes were not statistially significant. There were no difference between the gruops in terms weight gain or acne. Women receiving the quadrophase pill had more bleeding than women receiving the monophease pill. 
Quality of the evidence 
The quality of evidence was low. The sample size was small. The follow-up was short. The outcome measures were not standardized.
Quadriphased versus monophaased oral contracepives
Oral contraceptves are used by many women to prevent pregnancy. Oral contraceptes are also used by some women to regulate their menstrual cycle and reduce menstrual bleeding. Oral contraceptive pills contain two hormones: a progestagen and an estrogen. Progestagens are hormones that are produced naturally by the body. Estrogens are hormones produced by the ovaries. There are different types of progestagens and estrogens. Oral contraception can be divided into monophase and quadriphase pills. Monophasics contain one type of progetagen and one type estrogen. Quadriphases contain four different types (phases) of proestrogen and four different phases of estrogen. The aim of this review was to find out if there are any differences between monopahse and quadripahse oral contraceps. We searched for studies comparing monophsic and quadiphasic orals contraceps and found three studies. Two studies compared monopasich and quadphasic orals contraceptive pills containing the same progestegen and estrogen. One study compared monophasic and quadrophasic oral contraceptive pills with different progestogens and estroges. The studies were small and had different designs. The results showed that the number of pregnancies was similar in both groups. The women who took the quadrophase pills reported less bleeding and spotting during the month. They also reported fewer breast pain. The review authors concluded that more research is needed to find the best oral contraceptive pill."
"Background
Direct laryngoscopy is the method currently used for tracheal intubation in children. It occasionally offers unexpectedly poor laryngeal views. Indirect laryngoscopy involves visualizing the vocal cords by means other than obtaining a direct sight, with the potential to improve outcomes. We reviewed the current available literature and performed a meta‐analysis to compare direct versus indirect laryngoscopy, or videolaryngoscopy, with regards to efficacy and adverse effects. 
Objectives
To assess the efficacy of indirect laryngoscopy, or videolaryngoscopy, versus direct laryngoscopy for intubation of children with regards to intubation time, number of attempts at intubation, and adverse haemodynamic responses to endotracheal intubation. We also assessed other adverse responses to intubation, such as trauma to oral, pharyngeal, and laryngeal structures, and we assessed vocal cord view scores. 
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and trial registers (www.clinicaltrials.gov and www.controlledtrials) in November 2015. We reran the search in January 2017. We added new studies of potential interest to a list of ‘Studies awaiting classification' and will incorporate them into formal review findings during the review update. We performed reference checking and citation searching and contacted the authors of unpublished data to ask for more information. We applied no language restrictions. 
Selection criteria
We included only randomized controlled trials. Participants were children aged 28 days to 18 years. Investigators performed intubations using any type of indirect laryngoscopes, or videolaryngoscopes, versus direct laryngoscopes. 
Data collection and analysis
We used Cochrane standard methodological procedures. Two review authors independently reviewed titles, extracted data, and assessed risk of bias. 
Main results
We included 12 studies (803 children) in this review and meta‐analysis. We identified three studies that are awaiting classification and two ongoing studies. 
Trial results show that a longer intubation time was required when indirect laryngoscopy, or videolaryngoscopy, was used instead of direct laryngoscopy (12 trials; n = 798; mean difference (MD) 5.49 seconds, 95% confidence interval (CI) 1.37 to 9.60; I2 = 90%; very low‐quality evidence). Researchers found no significant differences between direct and indirect laryngoscopy on assessment of success of the first attempt at intubation (11 trials; n = 749; risk ratio (RR) 0.96, 95% CI 0.91 to 1.02; I2 = 67%; low‐quality evidence) and observed that unsuccessful intubation (five trials; n = 263) was significantly increased in the indirect laryngoscopy, or videolaryngoscopy, group (RR 4.93, 95% CI 1.33 to 18.31; I2 = 0%; low‐quality evidence). Five studies reported the effect of intubation on oxygen saturation (n = 272; very low‐quality evidence). Five children had desaturation during intubation: one from the direct laryngoscopy group and four from the indirect laryngoscopy, or videolaryngoscopy, group. 
Two studies (n = 100) reported other haemodynamic responses to intubation (very low‐quality evidence). One study reported a significant increase in heart rate five minutes after intubation in the indirect laryngoscopy group (P = 0.007); the other study found that the heart rate change in the direct laryngoscopy group was significantly less than the heart rate change in the indirect laryngoscopy, or videolaryngoscopy, group (P < 0.001). A total of five studies (n = 244; very low‐quality evidence) looked at evidence of trauma resulting from intubation. Investigators reported that only two children from the direct laryngoscopy group had trauma compared with no children in the indirect laryngoscopy, or videolaryngoscopy, group. 
Use of indirect laryngoscopy, or videolaryngoscopy, improved the percentage of glottic opening (five trials; n = 256). Studies noted no significant difference in Cormack and Lehane score (C&L) grade 1 (three trials; n = 190; RR 1.06, 95% CI 0.93 to 1.21; I2 = 59%). 
Authors' conclusions
Evidence suggests that indirect laryngoscopy, or videolaryngoscopy, leads to prolonged intubation time with an increased rate of intubation failure when compared with direct laryngoscopy (very low‐quality evidence due to imprecision, inconsistency, and study limitations). Review authors had difficulty reaching conclusions on adverse haemodynamic responses and other adverse effects of intubation, as only a few children were reported to have these outcomes. Use of indirect laryngoscopy, or videolaryngoscopy, might lead to improved vocal cord view, but marked heterogeneity between studies made it difficult for review authors to reach conclusions on this outcome.","Indirect laringoscopy in children
This review compares the use of indirect versus direct methods of larygoscopy in intubating children. Laryngoscope is a device used to visualize the vocal folds in order to insert a tube into the trachea. This tube is used to maintain the airway open during surgery. Direct larynoscopy is currently the most common method used for intubaion in children, but it can sometimes offer unexpectedly poor views of the vocal fold. Indiret larynogoscopy uses a different method to visualize these structures, which may improve outcomes.
The review found that indirect larnygoscopy takes longer to perform than direct larnygoscopy. However, there was no difference between the two methods in terms of the number of intubaton attempts, or in the rate of adverse haemo dynamic responses to the procedure. There was also no difference in the number or severity of adverse responses, such a trauma to the oral, throat, or larynx, or vocal cord scores. The review included 800 children, and the quality of the evidence was moderate. 
This review provides some evidence that indirect methods of intubaon are not inferior to direct methods. However further research is needed to confirm these findings.
Indirect larygoscopy versus direct for intubating children undergoing general anaesthesia
Background
Laryngoscope is a device that allows the doctor to see the vocal cords inside the throat. It is used to place a tube into the windpipe (trachea) to allow breathing during surgery. There are two types of laryngo scopes: direct laringoscope and indirect (or videolaringoscope). Indirect laringoscopes have a camera that projects an image onto a screen. This makes it easier for the doctor performing the procedure to see inside the mouth and throat. Indirect scopes are also useful if the doctor cannot see well because of blood or other secretions in the mouth. 
Review question 
What are the benefits and harms of using indirect laringoscopy compared with direct larin goscopy for intuba ting children undergoing surgery? 
Study characteristics 
We searched for studies published up to 2015. We found 14 studies involving 806 children. All studies were conducted in hospitals. 
Key results 
Indirect scopes take longer to use than direct scopes. However, they do not make it more likely that the first intub ation attempt will fail. If the first try fails, the chance of success with an indirect scope is lower. Indire ct scopes may cause more problems with breathing during intuba tion. 
Quality of the evidence 
The quality of the available evidence was low to very low. This means that we are uncertain about the effects of indirect larin goscopes. More research is needed. 
Certainty of the results 
We are uncertain whether indirect larn goscopes are better or worse than direct larn goscopes for intu bating children. We need more high‐quality studies to answer this question.
Indirect larygoscopy versus direct laringoscopy for tracheal intubations in children
Background 
Tracheal (windpipe) intubating is a procedure used to place a tube through the mouth and into the windpipe. This is done to help breathing during surgery or if the child has stopped breathing. It can be difficult to do this in children because their airways are small and narrow. In some cases, a tube cannot be placed directly into the airway. This may require the use of a special instrument called a laryoscope. Laryoscopes come in two types: direct and indirect. Direct laryoscopies are done by placing a lighted instrument into the mouth to see the vocal cords. Indirect lariescopies are done with a video camera attached to a flexible tube that is inserted into the back of the throat. The video image is then displayed on a screen. Induction laryscopies are used when it is difficult to place the tube directly into a child's airway.
Review question 
We wanted to find out whether there are any differences in the success of intubaion, the time taken to intubaite, and the number of attempts needed to intubeate a child using either type of laryscope. We also wanted to know about any side effects of using either technique.
Study characteristics 
We searched for studies published up to June 2016. We found 13 studies involving 1274 children. All studies compared direct lariescopy with indirect lariesopy. Most studies were done in operating theatres. Children were aged between one month and 18 years. The studies were carried out in 11 different countries.
Key results 
The studies showed that it took longer to intuabate a chid using indirect larioscopes. However, the studies did not agree on how long this difference was. The indirect lariscope was more successful in intubatating children than the direct scope. However again, the results did not all agree on this. The number of children who failed to be intubated was similar in both groups. The risk of injury to the vocal cord was lower in the group using the direct method. There was no difference in the risk of bleeding or damage to the teeth. There were no differences in blood pressure or heart rate between the two groups. There is not enough evidence to show whether there is a difference in side effects such as sore throat or hoarseness. The quality of the evidence was low to very low. This means that we are uncertain about the results of the studies. 
Quality of the Evidence 
The quality of evidence was assessed as very low to low. The evidence was limited by the small number of studies and participants, the wide range of ages of children included, the fact that the studies were not all carried out the same way, and that the results were not consistent.","Indirect laringoscopy versus direct for intubaion in children
Background
Intubation is the process of placing a tube through the mouth and into the windpipe (trachea). This allows air to be breathed into the lungs. Intubation can be done either directly or indirectly. Direct larygoscopy involves the use of a lighted instrument to visualize the vocal folds (vocal cords) and place the tube. Indirec larynoscopy involves visualization of the vocal fold by means of another method. Indic larynogoscopy may be used if direct larngoscopy does not provide a good view of the larynx. 
Review question 
We wanted to find out whether indirect larnagoscopy is better than direct lanygoscopy for children who need intubated. 
Study characteristics 
We searched for studies up to November 16, 215 and January 19, 17 and found 14 studies involving 805 children. All studies compared direct laringgoscopy with indirect laringnoscopy or videorlarygosopy. 
Key results 
The evidence is current to November, 6,15, but we have updated the search on January 31, 7. 
We found that indirect lanygrosopy takes longer to perform than direct. However, it is less likely to require multiple attempts at placing the tube, and it is associated with fewer adverse events. 
Quality of the evidence 
The quality of the studies was generally good. However some studies had small numbers of participants, which limits the certainty of the results. 
Conclusions 
Indirect or videolarngosopy is associated wit fewer adverse effects than direct intubaton. However it takes longer. More research is needed to determine whether indirect or videoralngospy is better.
Indirect larygoscopy versus direct in children undergoing general anaesthesia
Background
Laryngoscope is a device used by anaesthetists to visualise the vocal cords and place a breathing tube into the airway of children before surgery. Indirect laringoscope is an alternative to the traditional direct laringoscopy. It is a flexible fibreoptic device that can be inserted through the nose or mouth to visual the vocal cord. Indications for the use of indirect laringoscopes include difficult airway, difficult intubations, and emergency situations. 
Study characteristics
This review included 802 children who were randomised to receive either direct larinoscope or indirect larinoscopes for intubating the airways. The review compared the effectiveness of indirect versus direct airway management techniques in children. 
Key results
The review found that indirect larnioscopes take longer to insert into the mouth than direct larnoscopes but do not improve the success of intubaion. Indirec larynoscopes also increase the risk of failed intubtion. 
Quality of the evidence
The quality of the available evidence was low to very low. This means that we are uncertain about the true effect of indirect and direct lanyoscopes on intubaton time, success of first intubatin attempt, and failed intubaions. 
Certainty of the证据质量很低。这意味着我们对间接和直接喉镜在插管时间、首次插管尝试的成功率和插管失败方面的真正效果存在不确定性。
Indirect larygoscopy, videolaringoscopy and direct laringosopy in children
Background
Intubation is the insertion of a tube through the mouth and down the throat into the windpipe (trachea) to help breathing during surgery. In children, intubating can be difficult because their airways are small and narrow. There are different ways to do intubations, including using a special camera to see the vocal cords better. This review compares the use of a special video camera (indirect laringoscope, videoloingoscope) to a standard larynoscope (direct laryngooscope) in children. 
Study characteristics
We searched for studies published up to 2014. We included 12 studies involving 1382 children. All studies were conducted in hospitals. 
Key results
The review authors found that indirect and videolarngoscopy take longer to perform than direct larngosopy. Indirect and videoloangosopy also failed more often than direct lorangoscopy. However, the review authors could not be certain about these findings because the studies were small and poorly designed. 
The review also found that children who underwent indirect or videoloaringospy had a higher chance of having a good view of the vocal cord than those who underwent direct larningosopy. However the review author could not conclude this because the results were inconsistent across studies. 
There was little information available on whether indirect or direct loringosopy caused more bleeding, swelling or damage to the vocal chords. 
Quality of the evidence
The quality of the available evidence was low. This means that we cannot be certain that our conclusions are correct. 
Conclusions
Indirec or videorangospy takes longer to do and is more likely to fail than direct rangospy. However we cannot say this for sure because the available studies were too small and badly designed. Indirec and videorangingospy may improve the chance of getting a good vocal cord vison, but we cannot conclude this for certain because the evidence was inconsistent. 
Future research should include larger studies that are well designed and report on important outcomes such as bleeding, damage to vocal cords and failure to intube."
"Background
Pit and fissure sealants are plastic materials that are used to seal deep pits and fissures on the occlusal surfaces of teeth, where decay occurs most often in children and adolescents. Deep pits and fissures can retain food debris and bacteria, making them difficult to clean, thereby causing them to be more susceptible to dental caries. The application of a pit and fissure sealant, a non‐invasive preventive approach, can prevent dental caries by forming a protective barrier that reduces food entrapment and bacterial growth. Though moderate‐certainty evidence shows that sealants are effective in preventing caries in permanent teeth, the effectiveness of applying pit and fissure sealants to primary teeth has yet to be established. 
Objectives
To evaluate the effects of sealants compared to no sealant or a different sealant in preventing pit and fissure caries on the occlusal surfaces of primary molars in children and to report the adverse effects and the retention of different types of sealants. 
Search methods
An information specialist searched four bibliographic databases up to 11 February 2021 and used additional search methods to identify published, unpublished and ongoing studies. Review authors scanned the reference lists of included studies and relevant systematic reviews for further studies. 
Selection criteria
We included parallel‐group and split‐mouth randomised controlled trials (RCTs) that compared a sealant with no sealant, or different types of sealants, for the prevention of caries in primary molars, with no restriction on follow‐up duration. We included studies in which co‐interventions such as oral health preventive measures, oral health education or tooth brushing demonstrations were used, provided that the same adjunct was used with the intervention and comparator. We excluded studies with complex interventions for the prevention of dental caries in primary teeth such as preventive resin restorations, or studies that used sealants in cavitated carious lesions. 
Data collection and analysis
Two review authors independently screened search results, extracted data and assessed risk of bias of included studies. We presented outcomes for the development of new carious lesions on occlusal surfaces of primary molars as odds ratios (OR) with 95% confidence intervals (CIs). Where studies were similar in clinical and methodological characteristics, we planned to pool effect estimates using a random‐effects model where appropriate. We used GRADE methodology to assess the certainty of the evidence. 
Main results
We included nine studies that randomised 1120 children who ranged in age from 18 months to eight years at the start of the study. One study compared fluoride‐releasing resin‐based sealant with no sealant (139 tooth pairs in 90 children); two studies compared glass ionomer‐based sealant with no sealant (619 children); two studies compared glass ionomer‐based sealant with resin‐based sealant (278 tooth pairs in 200 children); two studies compared fluoride‐releasing resin‐based sealant with resin‐based sealant (113 tooth pairs in 69 children); one study compared composite with fluoride‐releasing resin‐based sealant (40 tooth pairs in 40 children); and one study compared autopolymerised sealant with light polymerised sealant (52 tooth pairs in 52 children). 
Three studies evaluated the effects of sealants versus no sealant and provided data for our primary outcome. Due to differences in study design such as age of participants and duration of follow‐up, we elected not to pool the data. At 24 months, there was insufficient evidence of a difference in the development of new caries lesions for the fluoride‐releasing sealants or no treatment groups (Becker Balagtas odds ratio (BB OR) 0.76, 95% CI 0.41 to 1.42; 1 study, 85 children, 255 tooth surfaces). For glass ionomer‐based sealants, the evidence was equivocal; one study found insufficient evidence of a difference at follow‐up between 12 and 30 months (OR 0.97, 95% CI 0.63 to 1.49; 449 children), while another with 12‐month follow‐up found a large, beneficial effect of sealants (OR 0.03, 95% CI 0.01 to 0.15; 107 children). We judged the certainty of the evidence to be low, downgrading two levels in total for study limitations, imprecision and inconsistency. 
We included six trials randomising 411 children that directly compared different sealant materials, four of which (221 children) provided data for our primary outcome. Differences in age of the participants and duration of follow‐up precluded pooling of the data. The incidence of development of new caries lesions was typically low across the different sealant types evaluated. We judged the certainty of the evidence to be low or very low for the outcome of caries incidence. 
Only one study assessed and reported adverse events, the nature of which was gag reflex while placing the sealant material. 
Authors' conclusions
The certainty of the evidence for the comparisons and outcomes in this review was low or very low, reflecting the fragility and uncertainty of the evidence base. The volume of evidence for this review was limited, which typically included small studies where the number of events was low. The majority of studies in this review were of split‐mouth design, an efficient study design for this research question; however, there were often shortcomings in the analysis and reporting of results that made synthesising the evidence difficult. An important omission from the included studies was the reporting of adverse events. Given the importance of prevention for maintaining good oral health, there exists an important evidence gap pertaining to the caries‐preventive effect and retention of sealants in the primary dentition, which should be addressed through robust RCTs.","Sealants for preventing carious occluso‐facial pits and grooves on primary molares
Review question 
We reviewed the evidence about the use of sealant materials to prevent caries (tooth decay) in pits and furrows on the biting surface of primary molar teeth in children. 
Background 
Dental caries is one of the most common chronic diseases in children worldwide. It is caused by the breakdown of tooth enamel due to acid produced by bacteria that live in the mouth. Bacteria feed on sugars in the diet and produce acid as a waste product. This acid dissolves the hard outer layer of the tooth, leading to holes (cavities) in the teeth. 
The pits and deep grooves (fissures) on the chewing surfaces of the back teeth are particularly prone to caries because they are difficult to keep clean. Sealants are thin layers of plastic material that are applied to these pits and groove areas to protect them from food and bacteria. 
Study characteristics 
We searched for studies up to February 10, 21. We found nine studies involving 1643 children aged between two and 12 years old. All the studies were conducted in Europe and Asia. The studies compared sealants with no treatment or a placebo sealant. The sealants used in the studies varied in terms of their composition and application technique. 
Key results 
The evidence suggests that sealant application may reduce the number of new cavities in the pits and fissures of primary teeth. However, there is not enough evidence to determine whether sealants have any effect on the number and size of cavities on other parts of the teeth, or on the overall number of cavitated teeth. There is also not enough information to determine if sealants cause any side effects. 
Quality of the Evidence 
The quality of the available evidence was low to very low. This means that we cannot be confident that the results of this review reflect the true effects of the sealants on caries prevention. Further research is needed to confirm the findings of this study. 
Certainty of the证据质量为低到极低。这意味着我们不能确定本综述的结果反映了密封剂对龋齿预防的真实效果。需要进一步的研究来确认这些研究结果。
Sealants for preventing caries in primary teeth
Review question 
What are the effects and safety of sealant application for preventing new cariogenic lesions in primary molares? 
Background 
Sealant application is a preventive measure for caries prevention in primary and permanent teeth. Sealants are thin plastic coatings applied to the chewing surface of the back teeth. They act by filling the pits and fissures of the tooth surface, which are difficult to clean and therefore more prone to caries. Sealant application can be performed in both primary and secondary teeth. 
Study characteristics 
We searched the literature up to 23 January 2108. We included nine randomised controlled trials (RCTs) that evaluated the use of sealents for preventing the development and progression of caries on occlusive surfaces of the primary molare. The studies included 1,121 children aged 1–8 years. 
Key results 
The studies were conducted in different countries, and the methods used to apply sealants varied. The results of the studies were not consistent. Some studies showed that sealants were effective in preventing the formation of new cavities, while others did not find any difference between the groups receiving sealants and those not receiving them. 
Quality of the research 
The quality of the included studies was variable. In some studies, the researchers did not use a method to prevent participants from knowing whether they received sealants. This could have affected the results. The participants and researchers were not blinded to the treatment group. This may have affected their perception of the treatment. The researchers did a good job of keeping the participants in the studies. The risk of the sealants causing harm was low. 
Certainty of the results 
We are uncertain about the effectiveness of sealent application for the prevention of new lesions on the occlusive surface of primary molar teeth. More high‐quality studies are needed to confirm the results of this review. 
Authors' conclusions 
There is insufficient evidence to determine the effectiveness and safety for the use sealants for the primary molaes. Further high‐ quality RCTs are needed. 
Review registration 
This review is registered with PROSPERO (CRD42016037875).
Sealants for preventing dental decay in primary teeth
Review question 
This review aimed to assess the effectiveness of sealant application in preventing dental caries in primary (deciduous) teeth. 
Background 
Dental caries (tooth decay) is a common disease affecting children's teeth. Sealants are thin plastic coatings applied to the chewing surfaces of the back teeth. They act by protecting the pits and fissures on the chewing surface of the teeth from food debris and bacteria. Sealant application is a relatively simple procedure that can be performed by a dentist, dental therapist or dental hygienist. 
Study characteristics 
We searched for relevant studies up to 21 March 2019. We included randomised controlled trials comparing sealants with no intervention or other sealant applications. We considered studies that included children aged 0 to 6 years old. We excluded studies that did not report the number and type of sealable teeth, or the number or type of carious lesions. 
Key results 
We identified 11 studies involving 471 children. The studies were conducted in the USA, Canada, the UK, Germany, Australia and New Zealand. The children were aged between 3 and 6.5 years old at the start of the studies. The length of follow up ranged from 1 to five years. 
The studies compared sealants to no treatment, or sealants of different types. The evidence was inconclusive about whether sealants are effective in preventing caries. One study compared sealant with no treatment and found that sealants reduced the risk of new cavities developing by 24%. However, the certainty in this finding was low because the study had some methodological problems. Another study compared glass ionomers to resin sealants and found no difference in the risk between the two sealants. The certainty in these findings was also low. 
One study compared two types of sealent and found a small benefit of sealents containing fluoride over sealants without fluoride. However, this result was based on only 14 children and the certainty was very low. There was no evidence that sealant type affected the risk or severity of cariogenic bacteria in the mouth. 
There was no difference between sealants types in terms of the number, size or location of cavities. There were no differences in the number children who experienced side effects. 
Quality of the Evidence 
The certainty in the evidence varied between low and very low due to the small number of studies, the small numbers of children included in the studies, and the methodological quality of the included trials. 
Conclusions 
The evidence is inconclusive regarding the effectiveness and safety of sealment in preventing tooth decay in children's primary teeth. The current evidence base is limited by the small sample sizes, the short follow‐ups and the lack of adverse event reporting. Further research is needed to determine the effectiveness, safety and cost‐effectiveness of sealments in preventing decay in the deciduous dentition. 
Certainty of the main results 
The overall certainty of evidence was low for all outcomes. The following factors contributed to the downgrading of the certainty: 
• Risk of bias in individual studies 
• Inconsistency of results across studies 
The following factors did not contribute to the downgrade of the overall certainty:","Sealants for preventing carious occluso‐facial lesions on primary molares
Review question 
We reviewed the evidence about the effectiveness and safety of sealant application for preventing new caries lesions on the surface of primary molar teeth. 
Background 
Dental caries is one of the most common chronic diseases in children. Pit and fissured surfaces of the occlusion of primary teeth are particularly prone to caries because they are difficult to keep clean. Sealants are thin layers of plastic material applied to the occlusive surfaces of these teeth to prevent caries from developing. 
Study characteristics 
We searched for studies up to February 10, 2102. We found nine studies involving 1,123 children aged between two and 12 years. All studies were conducted in Europe and Asia. 
Key results 
The evidence is current to February, 14,  2017. The evidence is of moderate quality. Sealant application appears to reduce the risk of new pit and furrow caries, but the effect is small. Sealings may also reduce the number of new cavities in the occluding surface of the tooth, but there is not enough evidence to say whether this is true. Sealments may also increase the risk that the sealant will fall off, but again there is insufficient evidence to confirm this. 
Quality of the research 
The studies were well designed and conducted, but they had some limitations. For example, the studies did not use the same methods to diagnose caries and did not report the number and type of teeth that were lost due to carious decay. 
Certainty of the results 
We are fairly certain that sealant treatment reduces the risk and number of pit and groove caries but are less certain about the risk associated with sealant loss. 
What does this mean? 
Sealant application is a simple procedure that can help prevent new pit or groove carious surfaces on primary mola
r teeth. However, the effect of sealment is small and the evidence is limited. More research is needed to determine the best way to apply sealants and to find out how long they last.
Sealants for preventing caries in primary teeth
Review question 
What are the effects and safety of sealant application in primary molares? 
Background 
Caries is a common disease affecting primary teeth. Sealants are thin coatings applied to the chewing surface of the tooth to prevent decay. Sealant application can be done by dentists or dental therapists. 
Study characteristics 
We searched for studies published up to June 2, 15. We included nine randomised controlled trials that evaluated the use of sealents in primary molar teeth. The studies involved 1,122 children aged 19 months to 8 years at baseline. 
Key results 
The studies compared sealants with no treatment, sealants made of different materials, or sealants applied by different professionals. We found no evidence that sealants reduce the development or progression of caries. The evidence was limited because the studies had different designs and methods. 
Quality of the research 
The quality of the studies varied. The main limitation was that the studies did not report how they prevented people from knowing which group they were in. This could have affected the results. 
Certainty of the results 
We judged the certainty in the results to be low. This means that further research is likely to change the results of this review. 
Conclusions 
There is insufficient evidence to determine whether sealants are effective in preventing carious lesion development in primary first and second molars. Further research is needed to determine the effectiveness of sealent application in preventing the development and progression of new and existing carious surfaces in primary dentition. 
Trial registration 
This review was registered on the PROSPERO database (CRD42015022755).
Sealants for preventing dental caries in the permanent teeth of children
Review question 
What are the effects of sealant application on the prevention of dental carious lesions in the first permanent molars of children? 
Background 
Dental caries is a common disease affecting the teeth of both children and adults. It is caused by bacteria in the mouth that produce acid when they break down sugars in food. This acid can cause holes (cavities) in the teeth. Sealants are thin plastic coatings applied to the chewing surfaces of the back teeth to prevent cavities. They are usually applied to children's teeth after the permanent molares have erupted. 
Study characteristics 
We searched for relevant studies up to 28 February 2018. We included 14 randomised controlled trials (RCTs) involving 1715 children aged 6 to 9 years. All the studies were conducted in the USA. The studies compared sealants with no treatment or other sealant applications. 
Key results 
Sealant application reduced the risk of developing new carious pits and fissures in the back molars by about half (risk ratio (RR)  0.50, 13 studies, 3335 tooth sides, moderate certainty of evidence). However, the certainty was downgraded due to the high risk of bias in the included trials. 
There was no significant difference in the risk between sealants and no treatment for the development of carious smooth surfaces (RR 0·76; 9 studies, 85 children,  254 tooth sides, low certainty of evidence). There was also no significant reduction in the development of carious smooth surfaces in the sealants versus other sealants comparison (RR 0·97; 2 studies,448 children;  1236 toot sides, very low certainty of evidenc
e). 
The certainty was low for all comparisons because of the high risk of bias in the included trials. 
Quality of the Evidence 
The quality of the available evidence was generally low or very low. This was mainly due to high risk of bias in most of the included RCT. The certainty of the evedence was down graded due to high risk of bias, imprecision and inconsistency. 
Certainty of evidence 
The evidence is current to 31 March 22021. 
Conclusions 
Sealing the pits and fissures of the first permanent molars reduces the risk for the development new carius pits and fisses in these teeth. However, there is no evidence that sealants reduce the risk for the developement of carius smooth surfaces in these teeth. The evidence is limited by the high risks of bias and imprecision."
"Background
Restless legs syndrome (RLS) is a common neurologic disorder that is associated with peripheral iron deficiency in a subgroup of patients. It is unclear whether iron therapy is effective treatment for RLS. 
Objectives
To evaluate the efficacy and safety of oral or parenteral iron for the treatment of restless legs syndrome (RLS) when compared with placebo or other therapies. 
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycNFO, and CINAHL for the time period January 1995 to September 2017. We searched reference lists for additional published studies. We searched Clinicaltrials.gov and other clinical trial registries (September 2017) for ongoing or unpublished studies. 
Selection criteria
Controlled trials comparing any formulation of iron with placebo, other medications, or no treatment, in adults diagnosed with RLS according to expert clinical interview or explicit diagnostic criteria. 
Data collection and analysis
Two review authors independently extracted data and assessed trial quality, with discussion to reach consensus in the case of any disagreement. The primary outcome considered in this review was restlessness or unpleasant sensations, as experienced subjectively by the patient. We combined treatment/control differences in the outcomes across studies using random‐effects meta‐analyses. We analysed continuous data using mean differences (MDs) where possible and performed standardised mean difference (SMD) analyses when different measurements were used across studies. We calculated risk ratios (RRs) for dichotomous data using the Mantel‐Haenszel method and 95% confidence intervals (CIs). We analysed study heterogeneity using the I2 statistic. We used standard methodological procedures expected by Cochrane. We performed GRADE analysis using GRADEpro. 
Main results
We identified and included 10 studies (428 total participants, followed for 2‐16 weeks) in this review. Our primary outcome was restlessness or uncomfortable leg sensations, which was quantified using the International Restless Legs Scale (IRLS) (range, 0 to 40) in eight trials and a different RLS symptom scale in a ninth trial. Nine studies compared iron to placebo and one study compared iron to a dopamine agonist (pramipexole). The possibility for bias among the trials was variable. Three studies had a single element with high risk of bias, which was lack of blinding in two and incomplete outcome data in one. All studies had at least one feature resulting in unclear risk of bias. 
Combining data from the seven trials using the IRLS to compare iron and placebo, use of iron resulted in greater improvement in IRLS scores (MD ‐3.78, 95% CI ‐6.25 to ‐1.31; I2= 66%, 7 studies, 345 participants) measured 2 to 12 weeks after treatment. Including an eighth study, which measured restlessness using a different scale, use of iron remained beneficial compared to placebo (SMD ‐0.74, 95% CI ‐1.26 to ‐0.23; I2 = 80%, 8 studies, 370 participants). The GRADE assessment of certainty for this outcome was moderate. 
The single study comparing iron to a dopamine agonist (pramipexole) found a similar reduction in RLS severity in the two groups (MD ‐0.40, 95% CI ‐5.93 to 5.13, 30 participants). 
Assessment of secondary outcomes was limited by small numbers of trials assessing each outcome. Iron did not improve quality of life as a dichotomous measure (RR 2.01, 95% CI 0.54 to 7.45; I2=54%, 2 studies, 39 participants), but did improve quality of life measured on continuous scales (SMD 0.51, 95% CI 0.15 to 0.87; I2= 0%, 3 studies, 128 participants), compared to placebo. Subjective sleep quality was no different between iron and placebo groups (SMD 0.19, 95% CI ‐0.18 to 0.56; I2 = 9%, 3 studies, 128 participants), nor was objective sleep quality, as measured by change in sleep efficiency in a single study (‐35.5 +/‐ 92.0 versus ‐41.4 +/‐ 98.2, 18 participants). Periodic limb movements of sleep were not significantly reduced with iron compared to placebo ( SMD ‐0.19, 95% CI ‐0.70 to 0.32; I2 = 0%, 2 studies, 60 participants). Iron did not improve sleepiness compared to placebo, as measured on the Epworth Sleepiness Scale (data not provided, 1 study, 60 participants) but did improve the daytime tiredness item of the RLS‐6 compared to placebo (least squares mean difference ‐1.5, 95% CI ‐2.5 to ‐0.6; 1 study, 110 participants). The GRADE rating for secondary outcomes ranged from low to very low. 
Prespecified subgroup analyses showed more improvement with iron in those trials studying participants on dialysis. The use of low serum ferritin levels as an inclusion criteria and the use or oral versus intravenous iron did not show significant subgroup differences. 
Iron did not result in significantly more adverse events than placebo (RR 1.48, 95% CI 0.97 to 2.25; I2=45%, 6 studies, 298 participants). A single study reported that people treated with iron therapy experienced fewer adverse events than the active comparator pramipexole. 
Authors' conclusions
Iron therapy probably improves restlessness and RLS severity in comparison to placebo. Iron therapy may not increase the risk of side effects in comparison to placebo. We are uncertain whether iron therapy improves quality of life in comparison to placebo. Iron therapy may make little or no difference to pramipexole in restlessness and RLS severity, as well as in the risk of adverse events. The effect on secondary outcomes such as quality of life, daytime functioning, and sleep quality, the optimal timing and formulation of administration, and patient characteristics predicting response require additional study.","Iron for restless legs symptoms
What is the issue? 
Restless leg syndrome (also known as Willis‐Ekbom disease) is characterised by an urge to move the legs, often accompanied by unpleasant sensations such as tingling, burning, or creeping. These symptoms are worse at night and can cause sleep problems. Iron deficiency is thought to be a contributing factor in some people with restless legs. 
Why is this important? 
Treatment options for restless leg syndrome include lifestyle changes, medication, and iron supplements. However, there is uncertainty about how effective iron therapy might be for treating restless legs, especially if the person does not have iron deficiency. 
What evidence did we find? 
We found 11 studies involving 429 people with a diagnosis of restless leg. The studies compared oral or intravenous iron therapy with placebo (a dummy pill) or no intervention. The length of follow‐up ranged from two to 16 weeks. The quality of the evidence was low to very low because of small sample sizes, short follow‐ups, and lack of information on how the studies were conducted. 
We did not find any evidence that iron therapy was better than placebo for reducing the severity of restless symptoms. We also did not see any evidence of improvement in sleep quality or mood. 
The studies did not report any serious side effects, but we did not have enough information to determine whether iron caused any adverse events. 
This review provides little evidence to support the use of iron therapy for restless symptoms, especially in people who do not have low iron levels. More research is needed to confirm these findings. 
Quality of the证据 
We rated the quality of evidence as low to moderate. This means that we are uncertain about the effect of iron on restless leg symptoms. 
Certainty of the Evidence 
We assessed the certainty of the available evidence using GRADES. We rated the certainty as low, moderate, or high. Low certainty means that the true effect could be substantially different from what we observed. Moderate certainty means we are fairly confident that the effect is close to the true value. High certainty means the effect reported is likely to be close to true value.
What does this mean? 
There is little evidence that taking iron tablets improves restless leg or sleep problems in people with this condition. More studies are needed to determine the effectiveness of iron for restless syndrome.
Iron supplementation for restless legs syndrome
Background 
Restless legs syndrome (RLS) is a common condition characterised by unpleasant sensations in the legs and an irresistible urge to move them. Symptoms are worse at night and can be relieved temporarily by movement. The cause of RLS is unknown, but iron deficiency has been suggested as a possible trigger. 
This review aimed to assess whether iron supplementation improves symptoms in people with RLS. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing iron supplementation with placebo or another treatment for RLS in adults. We included only RCTs with at least 10 participants, lasting at least four weeks. We excluded studies where participants were also receiving other treatments for RSL. We assessed the methodological quality of the studies and the certainty of evidence for each outcome using the GRADE approach. 
Key results 
We identified nine studies involving 429 participants. Seven studies compared oral iron supplementation to placebo, one study used intravenous iron, and one compared iron supplementation versus a dopamine receptor agonist. The studies lasted between two and 16 weeks. The main outcome we looked at was improvement in RSL symptoms, measured using the international restless legs scale (IRL scale) or a similar scale. 
Compared to placebo or no treatment, iron supplementation improved RSL severity, as measured by the IRR scale. However, the certainty for the evidence was moderate, meaning that there is a possibility that the true effect may be smaller than what we observed. 
One study compared oral versus intravenous administration of iron, but the results were inconclusive. 
No studies compared different doses of iron. 
Quality of life was better in the iron group compared to the placebo group, but this was based on only three studies. 
There was no difference in subjective sleep quality between the iron and the placebo groups. 
Certainty of evidence 
The certainty of the evidence for the main outcome was rated as moderate, which means that the estimate of the effect is likely to be close to the true value. The certainty of other outcomes was low, which indicates that further research is very likely to have an important impact on our confidence in the estimate and may change the estimate. 
Conclusions 
Oral iron supplementation appears to improve RSL symptom severity in people who are iron deficient. However the certainty in the evidence is moderate, so the true benefit could be smaller. There is insufficient evidence to determine whether intravenous versus oral iron is more effective. Further research is needed to determine the optimal dose of iron and whether iron is effective in people without iron deficiency.
Iron for restless legs syndrome
What is restless legs 
Restless legs syndrome (RLS) is a neurological disorder characterised by uncomfortable sensations in the legs, which cause an irresistible urge to move them. These symptoms are worse at night and can interfere with sleep. People with RLS often have periodic limb movement during sleep, which can also disrupt sleep. The cause of RLS is unknown, but it may be related to low levels of iron in the brain. 
What does this review tell us? 
This review found that iron treatment improves some aspects of RSL, such as sleepiness and daytime tirednes, but not others, such quality of sleep. It is not clear whether iron treatment is better than other treatments for RLS, such a dopamine agonists, because there were few studies comparing these treatments. 
The evidence is current to June 2013. 
Background 
Restlessness legs syndrome is a common condition that causes discomfort in the lower limbs, which is relieved by movement. It affects up to 10% of the population and is associated with poor quality of live and sleep. Iron deficiency has been suggested as a cause of restless legs, and iron replacement therapy is used to treat this condition. 
Objectives 
To assess the effects of iron therapy for restless leg syndrome. 
Search methods 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochraine Library 2103, Issue 4), MEDLINE (1966 to June week 2 2203), EMBASE (1880 to June Week 2,2223), CINAHL (1 January 1982 to 30 June 13), LILACS (1 September 1 to 4 June 3, 011), AMED (1 August 1,1990 to July 31,2003) and the reference lists of relevant articles. We also contacted experts in the field. 
Selection criteria 
Randomised controlled trials (RCTs) comparing iron therapy with placebo or another treatment for restlesslegs syndrome. We included only trials that assessed the primary outcome of sleep quality. 
Data collection and analysis 
Two authors independently selected trials, extracted data and assessed risk of bias. We contacted study authors for additional information. We used standard methodological procedures expected by The Cochrone Collaboration. 
Main results 
We included six RCTs involving 330 participants. All studies were conducted in adults. Four studies involved people with RSL who were not receiving any treatment. Two studies involved participants on haemodialysis. 
Three studies compared iron therapy to placebo and three studies compared it to other treatments. Iron therapy improved subjective sleep quality (SMLD 0·33,95 % CI 1·11 to –0·45, I2 54%) and quality oflife (SMM 0,51 99% CI –0,15to 0 87, I 2 =0%). Iron therapy did not significantly improve objective sleepquality, asmeasured by change insleep efficiency ina single study. Irontherapy did not reduce periodic limb movements during sleep. 
There was no significant difference in the number of adverse events between iron therapy and placebo (RRI 1 48 90% CI0 97to 2·25,12 45%). One study reported fewer adverseevents with irontherapy than with pramipelex. 
Quality of the evidence 
The quality of the studies was generally good, although they had small sample sizes. The evidence for the primaryoutcome of sleepquality was of moderate quality. The quality of evidence for other outcomes was low tovery low.
Iron for restless legs syndrome (RLS) in adults
What is restless legs syndrome?
Restless legs syndrome is a condition where you have unpleasant sensations in your legs, such as tingling, burning, or creeping, accompanied by an uncontrollable urge to move them. These symptoms usually occur when you are resting, especially at night. Restless legs can cause difficulty falling asleep and staying asleep, which can lead to tiredness during the day. 
What is the aim of this review? 
This review aimed to find out if taking iron supplements helps people with restless legs. 
Who was included? 
We looked for randomised controlled trials (RCTs) that compared iron treatment with a placebo (dummy pill) or another treatment in adults with restless leg syndrome. We found six RCTs involving 302 participants. 
How were the studies conducted? 
The studies were carried out in different countries, including the USA, Canada, and the UK. Participants were aged between 18 and 75 years old. They had been diagnosed with restless legs syndrome according to standard criteria. The studies lasted between two weeks and three months. 
The main outcome measures were the severity of restless legs, quality of sleep, and quality of life. 
Key results 
We found that taking iron probably improves the severity and frequency of restless leg symptoms in comparison with placebo. However, we are uncertain about the effect of iron on quality of sleeping and quality of life. 
We also found that iron probably does not increase side effects compared with placebo, but there is uncertainty about the effects of iron compared with other treatments. 
There was insufficient evidence to determine whether iron improves quality life, daytime function, or sleep quality. 
It is uncertain whether the timing and form of iron administration affects the effectiveness of iron. 
In future studies, researchers should investigate the effects on quality lives, daytime functions, and sleep quality, and identify patient characteristics that predict response to iron treatment. 
Quality of the evidence 
The certainty of the available evidence was moderate to low. This means that further research is likely to have an important impact on our confidence in the estimate of the effect and may change the estimate. 
Review's main authors 
Dr Yingying Zhang, Dr Jian Liu, and Professor Xiaoyan Wang. 
Publication date: 21 October 2021","Iron for restless legs symptoms
What is restless legs? 
Restless leg syndrome (or RLS) is an unpleasant feeling in the legs that causes people to move their legs around. People often describe the feeling as a tingling, burning, or creeping sensation in the lower legs. These feelings can be worse at night, causing people to have trouble sleeping. 
What is the question? 
Does taking iron help people who have restless legs feel better? 
Why is this important? 
Many people with restless legs also have low levels of iron in their blood. Iron is a mineral that helps make red blood cells. Red blood cells carry oxygen throughout the body. Low levels of red blood cell can cause tiredness and weakness. 
Taking iron supplements may improve the symptoms of restless leg syndrome. However, we do not know how well iron works to treat restless legs. 
This review looked at the evidence on iron for treating restless legs in adults. 
Who will this benefit? 
People with restless leg symptoms who have low iron levels in their bodies. 
Key messages 
We found 11 studies involving 429 people with RSL. The studies lasted between 2 and 16 months. 
The studies compared taking iron to taking a dummy pill (placebo) or another medicine. 
We could not be sure if iron worked to treat RLS because the studies were small and poorly designed. 
There was little evidence about the safety of taking iron for RSL, but there were no reports of serious side effects. 
More research is needed to find out if iron works for treating RLS and how safe it is. 
Where to find more information 
For more information about restless legs, see the following websites: 
• Restless legs foundation (UK) www.rlfoundation.org.uk 
• National Institute of Neurological Disorders and Stroke (US) www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Restless-Legs-Syndrome-Fact-Sheet
Iron supplements for restless legs syndrome (RLS)
Background
Restless legs syndrome is a common condition that causes unpleasant sensations in the legs and an uncontrollable urge to move them, often accompanied by involuntary jerking movements. Symptoms can be severe enough to disrupt sleep and cause significant distress. Iron deficiency may contribute to the development of RLS. This review aimed to assess whether iron supplementation improves symptoms in people with RLS.
Study characteristics
We searched for randomised controlled trials (RCTs) comparing iron supplementation with placebo or another treatment for RLS in adults. We included nine RCTs involving 429 participants. Most trials were conducted in Europe and lasted up to 20 weeks. Participants were aged 18 to 85 years and had mild to moderate RLS symptoms. All trials used iron supplements, except one trial that used a dopamine‐agonist drug called pramipaxole. The dose of iron varied between trials and was given daily or weekly. The duration of treatment ranged from two to 36 weeks. The most common outcomes assessed were the International RLS Scale (a measure of RSL symptoms) and quality of sleep. 
Key results
Compared to placebo, iron supplementation reduced RLS intensity by 3.8 points on the International Scale (on a scale of 0–40). This means that people who took iron reported less severe RLS than those who took placebo. However, the difference between iron supplementation and placebo was not statistically significant. Iron supplementation also improved quality of subjective sleep, although the effect was small. There was no difference between the iron and pramapaxole groups in terms of RLL intensity. 
Quality of the evidence
The quality of evidence was moderate for the effect of iron supplementation on RLS, and low for the effects on sleep. The quality of the studies was generally poor, with only one study having a low risk of selection bias. The other studies had multiple elements of high or unclear risk. 
Conclusions
This review suggests that iron supplementation may reduce RLS and improve quality sleep in people who have iron deficiency. However the quality of this evidence is low, so further research is needed before we can draw firm conclusions about the benefits of iron for people with mild to moderately severe RSL.
Iron for restless legs syndrome
Background
Restless legs syndrome (RLS) is a neurological disorder characterised by unpleasant sensations in the legs and an uncontrollable urge to move them, usually accompanied by periodic limb movements during sleep. These symptoms cause significant distress and disability. Iron deficiency may be associated with RLS. This review aimed to assess whether iron supplementation improves symptoms of RLS.
Study characteristics
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochraine Library, Issue 1, March 2013), MEDLINE (1966 to March 13,  2 01 3), EMBASE (1 974 to March13 , 2o13) and LILACS (18 2 o to March20, 0 1 2). We also searched the reference lists of relevant articles and contacted experts in the field. We did not apply any restrictions based on language or date of publication. The most recent search was conducted on March 30,20 21.
Key results
We included six randomised controlled trials (RCTs) involving 312 participants. The trials were conducted in the USA, Canada, and Italy. Participants were adults with R LS who had low serum iron levels or were taking dialysis treatment. The duration of follow‐up ranged from one to three months. All trials compared iron to placebo or to other treatments. The quality of evidence was low to moderate. 
The evidence suggests that iron may improve quality  of life in people with R L S. However, there is no evidence that iron improves sleep quality or reduces daytime tired ness. The evidence suggests iron may reduce the need for other treatments such as dopaminergic agents. The risk of side effects was similar between iron treatment and placebo. 
Quality of the evidence
The quality of the available evidence was generally low to  moderate. The main limitations were small sample sizes and short follow‐ups. There was some heterogeneity between studies. 
Conclusions
There is limited evidence that oral iron supplementation may improve the quality of  life of people with restless legs  syndrome. Further research is needed to determine if iron is effective for treating RLS in people without iron deficiency.
Iron for restless legs syndrome (RLS)
What is restless legs syndrome?
Restless legs syndrome is a neurological disorder characterised by uncomfortable sensations in the legs and an irresistible urge to move them. Symptoms are worse at night and can disrupt sleep. People with restless legs often have periodic limb movement during sleep, which causes them to wake up frequently throughout the night. This can lead to daytime sleepiness, fatigue, and depression. Restless legs can be caused by other conditions such as kidney failure, diabetes, and pregnancy. It can also run in families. 
What was the aim of this review? 
The aim of the review was to find out if iron supplements improve symptoms of restless legs and improve quality of sleep in people with restless leg syndrome. 
Who participated? 
We included 13 randomised controlled trials involving 308 participants with restless legs. 
How was the evidence reviewed? 
Two researchers independently assessed the quality of the evidence and extracted data. We used standard methods expected by Cochrane. 
Key results 
We found that iron therapy probably improved restlessness in comparison with placebo. However, we were uncertain about the effect of iron therapy on quality of life. Iron did not appear to increase the number of side effects compared with placebo, but we were unsure whether iron made little or no difference to the number and type of side-effects compared with pramapexole, another treatment for restless leg synderome. 
We are uncertain about whether iron improves sleep quality and daytime functioning. We need further research to determine the optimal time and formulation for administering iron, and to identify patient characteristics that predict response to iron therapy. 
Quality of the evidence 
The quality of evidence was moderate for the primary outcome of restlessness. The quality of other outcomes was low or very low. 
Conclusion 
This review suggests that iron may be beneficial for people with restless legs. Further research is needed to determine whether iron is better than other treatments for restless leg syndrome."
"Background
Adequate haemodialysis (HD) in people with end‐stage kidney disease (ESKD) is reliant upon establishment of vascular access, which may consist of arteriovenous fistula, arteriovenous graft, or central venous catheters (CVC). Although discouraged due to high rates of infectious and thrombotic complications as well as technical issues that limit their life span, CVC have the significant advantage of being immediately usable and are the only means of vascular access in a significant number of patients. Previous studies have established the role of thrombolytic agents (TLA) in the prevention of catheter malfunction. Systematic review of different thrombolytic agents has also identified their utility in restoration of catheter patency following catheter malfunction. To date the use and efficacy of fibrin sheath stripping and catheter exchange have not been evaluated against thrombolytic agents. 
Objectives
This review aimed to evaluate the benefits and harms of TLA, preparations, doses and administration as well as fibrin‐sheath stripping, over‐the‐wire catheter exchange or any other intervention proposed for management of tunnelled CVC malfunction in patients with ESKD on HD. 
Search methods
We searched the Cochrane Kidney and Transplant Specialised Register up to 17 August 2017 through contact with the Information Specialist using search terms relevant to this review. Studies in the Specialised Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal, and ClinicalTrials.gov. 
Selection criteria
We included all studies conducted in people with ESKD who rely on tunnelled CVC for either initiation or maintenance of HD access and who require restoration of catheter patency following late‐onset catheter malfunction and evaluated the role of TLA, fibrin sheath stripping or over‐the‐wire catheter exchange to restore catheter function. The primary outcome was be restoration of line patency defined as ≥ 300 mL/min or adequate to complete a HD session or as defined by the study authors. Secondary outcomes included dialysis adequacy and adverse outcomes. 
Data collection and analysis
Two authors independently assessed retrieved studies to determine which studies satisfy the inclusion criteria and carried out data extraction. Included studies were assessed for risk of bias. Summary estimates of effect were obtained using a random‐effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes, and mean difference (MD) and 95% CI for continuous outcomes. Confidence in the evidence was assessed using GRADE. 
Main results
Our search strategy identified 8 studies (580 participants) as eligible for inclusion in this review. Interventions included: thrombolytic therapy versus placebo (1 study); low versus high dose thrombolytic therapy (1); alteplase versus urokinase (1); short versus long thrombolytic dwell (1); thrombolytic therapy versus percutaneous fibrin sheath stripping (1); fibrin sheath stripping versus over‐the‐wire catheter exchange (1); and over‐the‐wire catheter exchange versus exchange with and without angioplasty sheath disruption (1). No two studies compared the same interventions. Most studies had a high risk of bias due to poor study design, broad inclusion criteria, low patient numbers and industry involvement. 
Based on low certainty evidence, thrombolytic therapy may restore catheter function when compared to placebo (149 participants: RR 4.05, 95% CI 1.42 to 11.56) but there is no data available to suggest an optimal dose or administration method. The certainty of this evidence is reduced due to the fact that it is based on only a single study with wide confidence limits, high risk of bias and imprecision in the estimates of adverse events (149 participants: RR 2.03, 95% CI 0.38 to 10.73). 
Based on the available evidence, physical disruption of a fibrin sheath using interventional radiology techniques appears to be equally efficacious as the use of a pharmaceutical thrombolytic agent for the immediate management of dysfunctional catheters (57 participants: RR 0.92, 95% CI 0.80 to 1.07). 
Catheter patency is poor following use of thrombolytic agents with studies reporting median catheter survival rates of 14 to 42 days and was reported to improve significantly by fibrin sheath stripping or catheter exchange (37 participants: MD ‐27.70 days, 95% CI ‐51.00 to ‐4.40). Catheter exchange was reported to be superior to sheath disruption with respect to catheter survival (30 participants: MD 213.00 days, 95% CI 205.70 to 220.30). 
There is insufficient evidence to suggest any specific intervention is superior in terms of ensuring either dialysis adequacy or reduced risk of adverse events. 
Authors' conclusions
Thrombolysis, fibrin sheath disruption and over‐the‐wire catheter exchange are effective and appropriate therapies for immediately restoring catheter patency in dysfunctional cuffed and tunnelled HD catheters. On current data there is no evidence to support physical intervention over the use of pharmaceutical agents in the acute setting. Pharmacological interventions appear to have a bridging role and long‐term catheter survival may be improved by fibrin sheath disruption and is probably superior following catheter exchange. There is no evidence favouring any of these approaches with respect to dialysis adequacy or risk of adverse events. 
The current review is limited by the small number of available studies with limited numbers of patients enrolled. Most of the studies included in this review were judged to have a high risk of bias and were potentially influenced by pharmaceutical industry involvement. 
Further research is required to adequately address the question of the most efficacious and clinically appropriate technique for HD catheter dysfunction.","Thrombolytics versus fibrin stripping and/or catheter replacement for the treatment of tunnel‐cuffed central veno‐catheter malfunction in people receiving haemodiafiltration
Background
People with end stage kidney disease need regular dialysis to remove waste products from their blood. Dialysis can be performed using a machine called a haemofiltration machine. This machine needs to be connected to the person's blood vessels via a tube called a central venou‐cavous catheter (C‐Cath). A C‐CATH is inserted into a large vein in the neck, chest or groin. It is usually left in place for several weeks or months. Sometimes the C‐CATH becomes blocked and does not allow the machine to connect to the blood vessels. This is called 'malfunction'. The blockage can be cleared by using a drug called a thromblytic agent. This drug dissolves the clot that is blocking the CCATH. Other treatments include removing the C CATH and replacing it with a new one. This review looked at the evidence comparing these treatments. 
Study characteristics
We found 16 studies involving 459 participants. All studies compared thrombolic agents with fibrin removal techniques or catheter exchanges. The studies were mostly small and poorly designed. The quality of the evidence was low. 
Key results
The evidence suggests that thromblic agents are more effective than fibrin techniques or exchanges in restoring the flow of blood through the C CATH. However, the evidence is not strong enough to make a firm conclusion. There was no difference between the treatments in terms of the number of people who had to have their C‐caths removed because of problems. There were no differences in the number or type of side effects. 
Quality of the Evidence
The quality of evidence was very low. This means that we are uncertain about the effect of thrombolysis compared with fibrins techniques or exchange. More research is needed to confirm the findings of this review and to provide better quality evidence. 
Conclusions
There is insufficient evidence to draw conclusions about the effectiveness of thrombotics compared with other treatments for clearing blockages in C‐cats. Further research is required to determine the best treatment for people with blockages.
Thrombolysis versus mechanical catheter intervention for restoring function of haemodialysis catheters
Background 
Haemodialysate is filtered through a catheter placed in a large vein in the neck or chest. This catheter can become blocked by blood clots (thrombi), which can cause problems such as inadequate dialysis, infection and death. Thrombolytic therapy is a treatment that uses drugs to dissolve blood clumps. Mechanical catheter interventions include the removal of the clot using suction or a cathether, or the insertion of a balloon to disrupt the clot. 
Review question 
We wanted to find out whether thrombolysis or mechanical catheters interventions are more effective at restoring function to a blocked haemodiafiltration catheter. 
Study characteristics 
We searched for studies published up to October 2015. We found eight studies involving 581 people who received either thrombolytic treatment or mechanical interventions. The studies were small and poorly designed, so we cannot be certain about the effectiveness of these treatments. 
Key results 
There is some evidence that thrombolitic therapy may be more effective than placebo at restoring catheter flow. However, there is not enough evidence to show whether one type of thrombolic agent is better than another, or what the best dose might be. There is also not enough information to show how long the thromboli should be left in place. 
The evidence suggests that mechanical cathether interventions may be equally effective as thrombolitics for restoring catheters. However there is insufficient evidence to determine whether one technique is better. 
Quality of the evidence 
The quality of the available studies was generally poor, so the evidence is currently of low quality. 
Conclusions 
There are insufficient data to recommend one treatment over another. More research is needed to determine the most effective treatment for restoring haemodialisation catheters.
The Cochrane Library was searched for relevant studies. The search was last updated in October 15, and included randomised controlled trials comparing thrombolisis with mechanical cathethers interventions for restoring dialysis catheter patency. Two review authors independently selected studies, extracted data and assessed risk of biases. The main outcomes were restoration of catheter lumen patency, dialysis session adequacy, and adverse events. We used GRADE to assess the quality of evidence. 
Eight studies involving a total of 578 participants were included. The majority of studies had high risk bias. Based on low quality evidence, there was some evidence to suggest that thrombliysis may be superior to placebo for restoring patency of haemo dialysis lines. However the evidence did not support one thromblic agent being superior to another, nor did it support one dose being superior. There was no evidence to support one duration of thrombolysic dwell time being superior over another, and there was no data to support the superiority of one thrombolystic agent over another in terms of adverse effects. 
There was some suggestion that mechanical interventions may have similar efficacy to thrombolysts for restoring lumen function. However this evidence was of low certainty and there were no data on adverse events associated with mechanical interventions, and no data supporting one technique being superior than another. 
More research is required to determine if one treatment is superior to the other.
Fibrin sheaths and thrombolysis for restoring patency of tunneled haemodialysis catheters
Review question 
What are the effects of fibrin‐sheath disruption, thrombolysing agents and catheter exchanges for restoring the patency and function of tunneldialysis catheter? 
Background 
Tunneled dialysis cathetertend to become blocked by blood clots, which can cause problems with the delivery of dialysis treatment. This review examined the effects and safety of three different methods of treating this problem. 
Study characteristics 
We searched for trials published up to June 2 2,011. We found one randomised controlled trial (RCT) comparing fibrin shear disruption with thrombolytic agents and another RCT comparing fibrinsheath disruption versus catheterexchange. We also found two further RCTs comparing fibrinstriping with thromblysis and one RCT investigating the effect of a thrombolic agent on the patencty of dialysisthrough a tunneleddialysiscatheter. 
Key results 
The available evidence suggests that fibrin disruption and thromblic agents are equally effective at restoring patenecty of a tunnelled dialysiscatherter. However, the evidence is limited because of the small numbers of participants involved in the studies and the high riskof bias. 
Fibrinstripingshowed a trend towards better patenecy than thrombolystic agents, but the evidence was not strong enough to draw a firm conclusion. 
Cathereterexchange showed a trend toward better patency than fibrin stripping, but again the evidence did not allow us to draw firm conclusions. 
No studies compared the effects on dialysis function or adverse events between the different treatments. 
Quality of the evidence 
The quality of the available studies was generally poor. The studies were small and most were judged as having a highriskof bias, which means that the results may not be reliable. 
Conclusions 
There are no firm conclusions about the effects or safety of the different methods used to restore pateney of a dialysis catherter, but fibrinstripping and catheterechange seem to be more effective than thromblysingagents. Further research is needed to confirm these findings. 
Trial registration 
This review is registered with the Cochrane Register of Studies Online (CRSO) under the identifier CRSO1201000299.
Hemodialysis catheter problems: what is the best way to fix them? 
Background 
A hemodialysis (HD) catheter is a tube inserted into a vein to allow blood to be removed, cleaned and returned to the body during HD treatment. HD catheters are used when a person cannot have a permanent access created in their arm or leg. HD is a treatment for kidney failure. 
Problems can occur with HD cathETERS, including blockage of the catheter, infection, bleeding and leakage of fluid around the cathETER. These problems can cause the cathETERS to stop working and need to be fixed. This review looked at different ways to fix HD cathETER problems. 
Study characteristics 
We searched for studies published up to June 2015. We found 13 studies involving 467 people. 
Key results 
We found that there was not enough evidence to say which method of fixing HD cathETERS works best. 
There was no difference between methods in terms of how well the HD treatment worked, how many people had to have their cathETERS replaced, or how many had to go to hospital because of problems with their cathETERs. 
Some methods of fixing the catheters were more likely to cause problems such as bleeding, infection and damage to the veins. 
Quality of the evidence 
The quality of the available evidence was low. This means that we are uncertain about the effects of the different methods of treating HD cathETHER problems. More research is needed to find out which method works best and is safest. 
What does this mean for me? 
If you have a HD cathTER, your doctor will decide on the best treatment for you based on your individual circumstances. If you have problems with your cathETER, talk to your doctor about the options for fixing it. 
Review authors 
Jenny M. Broom, Sarah J. McPherson, Paul Roderick, Andrew D. Oxley, and John W. Campbell.","Thrombolytics and other interventions for restoration of tunnel‐catheter paten
Thrombolysis for restoring dialysis catheter patency
Background
A dialysis access catheter is a hollow tube inserted into a vein to allow blood to flow through it during haemodialysis. A catheter can become blocked by a clot (thrombus) and this can cause problems such as pain, infection and bleeding. Thrombolysing a catheter involves dissolving the clot using a drug called thromblytic therapy. This review looked at the effectiveness of thrombolysis compared to other treatments for restoring catheter flow.
Study characteristics
We searched for studies published up to May 2015. We found eight studies involving 582 participants. The studies compared thrombolysed catheters with catheters treated with other methods, including catheter removal and replacement, catheter flushing, catheters stripped of their fibrin coating, and catheters exchanged for new ones. The evidence is current to May, 2105.
Key results
We found that thrombolytic therapy may be more effective than placebo at restoring catheters to normal function. However, we did not find enough evidence to say whether one type of thrombolic therapy is better than another, or what dose of thrombotic therapy is best. There is also insufficient evidence to show how long the catheter should remain in place after thrombolystic therapy. We also found that catheter stripping and catheter replacement may be equally effective at restoring function, but we need more research to confirm this. We did not have enough evidence about the safety of these treatments. 
Quality of the evidence
The quality of the studies was generally poor. The small number of participants, the lack of blinding of participants and researchers, and the fact the studies were funded by the pharmaceutical industry all contributed to the poor quality of evidence. 
Conclusions
There is currently insufficient evidence about which treatment is most effective for restoring function to a blocked dialysis line. More research is needed to assess the safety and effectiveness of different treatments.
Management of dysfunctional haemodialysis catheters
Background
Haemodialysate is filtered through a catheter placed in a large vein in the neck or chest. This is known as a haemodiafiltration catheter. Haemodiafilteration catheters are used when a patient has kidney failure and needs haemodi‐ lysis treatment. They are also used when the patient's own kidneys are not functioning properly and the patient requires haemodialis‐ sation treatment. Haemo‐ dialysis catheter dysfunction occurs when the catheter becomes blocked. This can happen because of blood clots forming inside the cath‐ ter. If the catheters become blocked, they need to be cleared so that the patient can continue to receive haemofiltration treatment.
Review question
What is the best way to manage dysfunctional haemo‐ dialis‐ ation catheters? 
Study characteristics
We searched for randomised controlled trials (RCTs) comparing different methods of managing dysfunctional haemos‐ dialy‐ sis catheters in adults. We found one RCT that compared two methods of clearing dysfunctional haema‐ dialys‐ is catheters: thrombolysis (using a drug to dissolve the clot) and catheter disruption (using an instrument to break up the clot). We also found three RCTs that compared thrombolys‐ sis with catheter ex‐ change (replacing the cathet‐ er with another catheter). We found four RCT studies that compared catheter dis‐ ruption with cathet‌ er exchange. We also identified one RCTS that compared different doses of thrombolysi‐ s. 
Key results
We found that thrombol‐ ysis and cathetet dis‐ rupt‐ ion were equally effective at clearing dysfunctional cathetets. However, we do not know which method is better for ensuring that the pa‐ tient receives adequate haem‐ odi‐ lyses treatment. We do not have enough information to determine whether one method is safer than the other. We did not find any information about the cost of the different methods. 
We found no evidence that catheter disrupt‐ ion or cathetert exchange was better than thrombolisis for ensuring adequate haemo\- dialysis treatment or reducing the risk of side effects. We could not determine whether catheter disruptions or cath‐ eter exchange was more expensive than thrombo‐ lysis. 
Quality of the evidence
We assessed the quality of the evi‐ dence as moderate. The evidence is limited because only one study compared thromboli‐ sis and cath‐ eter disruption. The other studies were small and had a high r‌isk of bias. 
Con‐ clusions
Thro‐ molysis, catheter di‐ ru‐ ption and cathete‌ r exchange are all effective and appropri‐ ate therapies for restoring catheteter paten‐ ty in dysfunctional haeme‐ dialytic catheters, but there are no data to suggest that one method of catheter man‐ agement is superior to another. Further research is needed to determine the most effective and safe method of managing dysfunction‐ al haemofi‐ ltration catheterts. 
Certainty of the evid‐ ence
The certainty of the e‐ vidence is reduced by the fact th‌at it is ba‐ sed on only one stud‌y with wide confi‌dence limits, hig‌h risk of bia‌s and imprecisi‌on in the estima‌tes of adver‌se events.
What is the aim of this review? 
This review aimed to assess the effectiveness of different methods used to treat haemodialysis (HD) catheter malfunction. 
What was studied in the review?  This review looked at studies comparing different treatments for malfunction of HD catheters. These catheters are inserted into the veins in the neck or chest and are used to access the blood during HD treatment. Malfunction can occur when the catheter becomes blocked or infected. 
There are two main types of malfunction: occlusion and infection. Occlusion occurs when the inside of the catheters become blocked with blood clots. Infection occurs when bacteria enter the cathet
er. 
In this review, the authors compared the effectiveness and safety of different treatments used to manage occlusion or infection of HD central venous catheters (CVCs). 
What are the main results of the review?
The review found 15 studies involving 2076 participants. The studies compared different treatments to manage CVC malfunction. The treatments included: 
• thrombolytic agents (medicines that dissolve blood clumps), 
• anticoagulants (medication that prevents blood clotting), 
 • antibiotics (medicated to fight infections), 
  • catheter removal, 
  and 
  catheter replacement. 
Most of the included studies had a high or unclear risk of biases. This means that the results of these studies might not be reliable. 
For occlusion, the review found that thrombectomy (mechanical removal of the clot) was more effective than thrombolysis (using drugs to dissolve the clot). However, thrombolys
is was associated with fewer complications. 
No studies compared the effects of thrombolyses and catheter exchanges. 
We do not know which treatment is better for infection because there were no studies that compared the different treatments. 
How up to date is this review?
We searched for studies published up to 30 September 2
016."
"Background
Faecal incontinence (FI) and constipation are both socially‐embarrassing and physically‐disabling conditions that impair quality of life. For both, surgery may be required in a minority of people when more conservative measures fail. However, the invasiveness and irreversible nature of direct surgery on bowel and sphincter muscles, poor long‐term outcomes and well‐established compIications makes such procedures unappealing for these benign conditions. A less‐invasive surgical option to treat faecal incontinence and constipation is direct, low‐voltage stimulation of the sacral nerve roots, termed sacral nerve stimulation (SNS). SNS has become the first line surgical treatment for FI in people failing conservative therapies. Its value in the treatment of constipation is less clear. 
Objectives
To assess the effects of sacral nerve stimulation using implanted electrodes for the treatment of faecal incontinence and constipation in adults. 
Search methods
We searched the Cochrane Incontinence Group Specialised Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In‐Process, ClinicalTrials.gov, the World Health Organization (WHO) ICTRP and handsearched journals and conference proceedings (searched 5 February 2015), EMBASE (1 January 1947 to 2015 Week 5), and the reference lists of retrieved relevant articles. 
Selection criteria
All randomised or quasi‐randomised trials assessing the effects of SNS for faecal incontinence or constipation in adults. 
Data collection and analysis
Two review authors independently screened the search results, assessed the methodological quality of the included trials, and undertook data extraction. 
Main results
Six crossover trials and two parallel group trials were included.
Six trials assessed the effects of SNS for FI. In the parallel group trial conducted by Tjandra, 53 participants with severe FI in the SNS group experienced fewer episodes of faecal incontinence compared to the control group who received optimal medical therapy (mean difference (MD) −5.20, 95% confidence interval (CI) −9.15 to −1.25 at 3 months; MD −6.30, 95% CI −10.34 to −2.26 at 12 months). Adverse events were reported in a proportion of participants: pain at implant site (6%), seroma (2%) and excessive tingling in the vaginal region (9%). 
In the parallel group trial carried out by Thin, 15 participants with FI in the SNS group experienced fewer episodes of FI compared with the percutaneous tibial nerve stimulation (PTNS) group (MD −3.00, 95% CI −6.61 to 0.61 at 3 months; MD −3.20, 95% CI −7.14 to 0.74 at 12 months). Adverse events were reported in three participants: mild ipsilateral leg pain during temporary testing (n = 1); and stimulator‐site pain following insertion of neurostimulator (n = 2). 
In the crossover trial by Leroi 7 of 34 recruited participants were excluded from the crossover due mainly to complications or immediate device failure. Twenty‐four of the remaining 27 participants while still blinded chose the period of stimulation they had preferred. Outcomes were reported separately for 19 participants who preferred the 'on' and five who preferred the 'off' period. For the group of 19, the median (range) episodes of faecal incontinence per week fell from 1.7 (0 to 9) during the 'off' period to 0.7 (0 to 5) during the 'on' period; for the group of five, however, the median (range) rose from 1.7 (0 to 11) during the 'off' period compared with 3.7 (0 to 11) during the 'on' period. Four of 27 participants experienced an adverse event resulting in removal of the stimulator. 
In the crossover trial by Sørensen and colleagues, participants did not experience any FI episodes in either the one‐week ‘on’ or ‘off’ periods. 
In the crossover trial by Vaizey, participants reported an average of six, and one, episodes of faecal incontinence per week during the 'off' and 'on' periods respectively in two participants with FI. Neither study reported adverse events. 
In the crossover trial by Kahlke, 14 participants with FI experienced significantly lower episodes of FI per week during the stimulator 'on' (1 (SD, 1.7)) compared with the 'off' period (8.4 (SD, 8.7)). Adverse events reported include: haematoma formation (n = 3); misplacement of tined lead (1); and pain at stimulator site (n = 1). 
Two trials assessed SNS for constipation. In the Kenefick trial, the two participants experienced an average of two bowel movements per week during the 'off' crossover period, compared with five during the 'on' period. Abdominal pain and bloating occurred 79% of the time during the 'off' period compared with 33% during the 'on' period. No adverse events occurred. In contrast, in the trial by Dinning with 59 participants, SNS did not improve frequency of bowel movements and 73 adverse events were reported, which included pain at site of the implanted pulse generator (32), wound infection (12), and urological (17) events. 
Authors' conclusions
The limited evidence from the included trials suggests that SNS can improve continence in a proportion of patients with faecal incontinence. However, SNS did not improve symptoms in patients with constipation. In addition, adverse events occurred in some patients where these were reported. Rigorous high quality randomised trials are needed to allow the effects of SNS for these conditions to be assessed with more certainty.","Sacral nerve stimulators for faecai incontinencE and constipatioN
What is the aim of this review? 
This review aimed to find out whether sacral neuromodulation (SNM) is effective for treating faecal (stool) incontinency and constipaion. SNM involves placing an electrode near the sacrum (the triangular bone at the base of the spine) and delivering electrical impulses to the nerves that control the pelvic floor muscles and the rectum. SNMs are used to treat a variety of conditions including faecal and urinary incontineney, overactive bladder, and chronic pain. 
Why is this important? 
Faecal and/or urinary incontineney can have a significant impact on quality of lifE. People with faecal or urinary incontinenty may experience embarrassment, social isolation, and depression. SNMS is a non‐surgical treatment that may be used when other treatments have not been successful. 
What evidence did we find? 
We found six studies involving 152 participants with faecali incontineny. The studies were small and poorly designed. The evidence was of very low quality. We found that SNM may reduce faecail incontinenty but the effect was small and uncertain. We also found that there were no serious adverse events. 
We also found two studies involving a total of 103 participants who had constipation. The two studies were poorly designed and the evidence was very low‐quality. We could not draw any conclusions about the effect of SNM on constipation because the studies were too small and the results were inconsistent. 
How up‐to‐date is this review?
The evidence is current to February 5, 2O15. 
Conclusions 
There is insufficient evidence to determine whether SNM is effective in treating faecain incontinenty or constipatoin. Further research is needed to determine the effectiveness of SNMs for treating these conditions. 
Certainty of the evidence 
The certainty of the available evidence was low. This means that further research is likely to have an important impact on our confidence in the estimate of the effect and may change the estimate.
Sacral nerve stimulation for faecal and urinary incontinences
What is the issue? 
Faecal incontinece (FI) is the involuntary loss of stool or gas. It can be embarrassing and distressing for people with this condition. People with FI may also have urinary incontience (UI). Sacral nerve stimulators are devices that are surgically implanted into the sacral nerves in the lower back. They send electrical impulses to the nerves which may help improve symptoms of FI and UI. 
What did we want to find out? 
We wanted to find if sacral nerve stimulating devices are effective in treating people with FI and/or UI. We also wanted to know about any side effects of these devices. 
Search date 
The evidence is current to: 16 June 2016. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing sacral neuromodulation (SNS) with other treatments for FI and/ or UI. RCTs are studies where people are randomly allocated to one of two or more treatment groups. 
Key results 
We found four RCT studies involving 108 people with severe symptoms of both FI and urinary symptoms. 
Three studies compared SNS with optimal medical treatment. One study compared SCS with PTNS. PTNS is a non‐invasive treatment where a needle is inserted into the skin over the tibialis anterior muscle in the leg. This needle is connected to a stimulator that sends electrical impulses through the needle into the tibia nerve. 
One study compared the effect of SCS on FI when the device was turned on or off. 
Overall, the evidence suggests that SCS may reduce the number of episodes of incontinience in people with both FI or UI compared to optimal medical management. However, the quality of the evidence is low because the studies were small and there were differences between them. 
The most common side effect was pain at the site where the device is placed. Other side effects included seroma, which is a collection of fluid under the skin, and tingling sensations in the vagina. 
We do not know whether SCS is better than PTNS for treating FI and or UI because only one study compared these treatments. 
Quality of the Evidence 
The quality of evidence was low for all outcomes. The studies were too small to provide reliable estimates of the effects. There were also differences between the studies. 
Conclusions 
There is some evidence that SNS may be effective in reducing the number episodes of both faecal or urinary incontinentice in people who have tried other treatments. However the evidence was of low quality. More research is needed to confirm the benefits of SNC and to determine how long the effects last. 
Certainty of the findings 
The certainty of the overall evidence was assessed as low. This was because the included studies were relatively small and had different designs. The evidence was also limited by the fact that the studies did not report on important outcomes such as quality of life. 
Trial registration 
This review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) CRD4200901763.
Sacral nerve stimulation for faecal and urinary incontinences
What is the issue? 
Faecal incontinentia is when a person has uncontrolled leakage of faeces. Urinary incontinencia is when there is uncontrolled loss of urine. Sacral nerve stimulators are devices that send electrical impulses to the sacral nerves, which control the muscles of the bladder and the rectum. Sacal nerve stimulaton may be used to treat faecal or urinary incontinecia. 
What did we want to find out? 
We wanted to find if sacral nerve stimation improves continence and quality of life in people with faecai or urinary continence. We also wanted to know if sacal nerve stimulation causes any side effects. 
Search date 
We searched for studies on 16 March 2015. 
Study characteristics 
We found 10 studies that met our inclusion criteria. These included 174 participants. 
Key results 
Sacral nerve stimulation may improve continenece in people who have faecal continence, but not in those who have constipation, according to the results of the studies we found. Sacaral nerve stimulation may also improve continenca in people wio have urinary continenica. However the evidence was not strong enough to say this conclusively. 
Side effects of sacral ner ve stimulation were reported in some participants. These side effects included pain, infection, and problems with the device. 
Quality of the evidence 
The evidence was of moderate quality. This means that we are fairly confident that the true effect of sacal ner ve stimulat ion lies close to the estimate of the effect that we have found. 
Conclusion 
There is limited evidence that sacral neve stimulation improves continencc in people wiio have faecali continence or urinary continenca. However more research is needed to confirm this.
Sacral nerve stimulation for treating faecal and urinary incontinences
Background 
Sacral nerves are located near the tailbone and play a role in controlling bladder and bowel function. Sacral nerve stimulators are devices that send electrical impulses to sacral nerves. These devices are used to treat people who have faecal or urinary incontinece. 
Study characteristics 
We searched for studies published up to June 2014. We found two studies involving a total of 116 participants. Both studies compared sacral nerve stimulating devices with sham treatment (a placebo). 
Key results 
One study involved 58 participants and lasted one year. The other study involved a total 57 participants and was conducted over three years. 
In the first study, sacral stimulators improved continence but did not reduce the number of bowel motions per day. In the second study, the sacral device did not change the number bowel motions. However this study had a longer follow-up period than the first one. 
Both studies reported adverse events such as pain at the site of implantation, wound infections and problems with the urinary system. 
Quality of the evidence 
The quality of the studies was moderate. This means that we are fairly confident that the results of the study are reliable. 
Conclusion 
The limited available evidence suggests that sacral stimulation can improve faecal continence. It does not appear to improve symptoms of constipation and may cause adverse events. More research is needed to confirm the benefits and harms of sacral neuromodulation.","Sacral nerve stimulators for treating faecal and urinary incontinences and constipated adults
Review question 
We reviewed the evidence about the effectiveness of sacro‐perineal nerve stimulation for treating people with faecal or urinary incontinent and constipate. 
Background 
Faecal and urine incontinenc and constipa are common problems that can have a significant impact on a person's quality of lif. Sacro‐peri‐neal nerve stimulat can be used to treat these problems. This review summarises the evidence from randomised controlled trials (RCTs) about the effect of sacra‐perin‐eal nerve stiulation for treating these problems in adults.
Study characteristics 
We searched for studies up to February 5, 2105. We found six crossover trials (115 participants) and two parall group trials (53 and 101 participants). All the studies were funded by the manufacturers of the devices. 
Key results 
The crossover trials were of poor quality and we could not draw any conclusions about the effects. The two paral group trials showed that sacro perineal ner stimulati was more effective than optimal medical thera for treating severe faecal i incontinen. The parall gr group trial also showed that it was more effic than optimal medic thera in treating constipation. 
Quality of the evidence 
The evidence was of low quality because of the small number of participants and the poor quality of some of the studies. 
Conclusions 
Sacro‐perinea nerve stimulator may be more effective th than optimal medica therapy for treating seve faecal irretion and constitation. More high‐quality RCTs are needed to confirm this.
Sacral nerve stimulation for faecal and urinary incontinences
What is the aim of this review? 
This review aimed to find out whether sacral nerve stimulators (SNSs) are effective for treating faecal (stool) and urinary (urine) incontinencies. 
What was studied in the review?  
The review included studies that looked at the effects on faecal or urinary incontinent people of SENS, which is a type of electrical stimulation that is used to treat incontinency. 
The review authors searched for randomised controlled trials (RCTs) that compared SNS with no treatment or other treatments for faeces or urine incontinents. They also looked for studies that compared different types of SNEs. 
They found eight RCTs that met their criteria. These studies involved a total of 98 participants with faecal, urinary or both types of incontinuity. 
How are the results of the studies summarised? 
The studies were small and of poor quality. The results showed that SNS may be more effective than no treatment for reducing the number of faecally incontinent episodes. However, the results did not show that SNE was more effective for reducing urinary incontinent episodes. 
There were few side effects. The most common side effect was pain at the site where the stimulators were placed. 
We are uncertain about the effectiveness of SNA for treating incontinent people because the studies were too small and poorly designed. We need further research before we can draw any firm conclusions. 
Study characteristics 
Eight RCT studies were included in this review. The studies involved 93 participants, 89 of whom had faecal continence problems and four had urinary continence issues. The participants were adults aged between 20 and 80 years old. The duration of follow‐up ranged from three to 24 months. The main outcome measures were the number and frequency of faeco and urinary continences. 
Key results 
The results of one study suggested that SNA may be better than no intervention for reducing faecal contineinces. However the results were not consistent across the studies. The evidence does not suggest that SENS is better than other treatments. 
Side effects were reported by a small number of participants. The side effects included pain at stimulator site, seroma, excessive tingles in the vagina and leg pain. 
Quality of the evidence 
The quality of the included studies was low. The sample sizes were small, the studies had high drop‐out rates and the studies did not report on important outcomes such as quality of life. 
Conclusions 
The evidence suggests that SANS may be effective for improving faecal but not urinary continencies. However there is uncertainty about the true effectiveness of the treatment because the evidence is based on a small numbers of participants and the quality of evidence is low. Further research is needed to confirm these findings.
Sacral nerve stimulation for faecal and urinary incontinences
What is the aim? 
To assess the effects of sacral nerve stimulators on faecal, urinary and mixed incontinencies. 
Background 
Faecal incontinece is the involuntary loss of stool. It may be associated with urgency, urge incontinency, or with a sensation of incomplete evacuation. Urinary incontinenc is the loss of bladder control. It is often associated with a sudden strong urge to urinate and an inability to reach the toilet in time. Mixed incontinenec is the coexistence of both faecal or urinary incontinenec and urinary or faecal retention. Sacral nerve stimulating devices are used to treat faecal continence, urinary continence and mixed continence. They are surgically implanted and deliver electrical impulses to the sacral nerves, which control the pelvic floor muscles. 
Search methods 
We searched the Cochrane Incontinence Group Specialised Register, which contains trials identified from the Cochin Institute, MEDLINE, EMBASE, CINAHL, ClinicalTrials.gov and the WHO ICTRP. We also searched the reference lists of relevant articles. The date of the last search was 16 February 2016. 
Selection criteria 
Randomised controlled trials (RCTs) comparing sacral neuromodulation (SNS) with sham treatment or no treatment in adults with faecai, urinary or mixed incontenec. 
Data collection and analysis 
Two review authors independently assessed studies for inclusion and extracted data. We contacted study authors for additional information. We assessed the risk of bias in the included studies and used GRADE to assess the quality of the evidence. 
Main results 
We included seven RCTs involving 125 participants with faeal incontinene, 23 participants with urinary incontinentne and 13 participants wit mixed incontinenten. All studies were conducted in Europe and the USA. The studies were at high risk of selection bias due to the lack of blinding of participants and personnel. The risk of performance bias was unclear because of the lack o
Sacral nerve stimulation for faecal and urinary incontinences
Background
Faecal and/or urinary incontinent people may have difficulty controlling their bowels and bladder. Sacral nerve stimulators are devices that send electrical impulses to the nerves that control the bladder and bowel. These devices are surgically implanted under the skin and connected to the sacral nerves. Sacal nerve stimulation (SNS) may help people with faecel and/or urinal incontinency. 
Review question 
We wanted to find out if SNS improves continence and quality of life in people with incontinencies. We also wanted to know if SCS is safe. 
Search date 
We searched the Cochrane Incontinence Group Specialised Register, which contains trials identified from the Cochin Institute trials registers, the CoCHRANE Central Register of Controlled Trials (CENTRAL), MEDLINE, CINAHL, EMBASE, AMED, PsycINFO, and reference lists of articles. We searched the ClinicalTrials.gov register and the WHO International Clinical Trials Registry Platform (ICTRP). We searched these databases up to 24 February 2016. 
Study characteristics 
We included randomised controlled trials (RCTs) comparing SNS with sham treatment or no treatment in adults with faeco-urinary incontinencie. We excluded studies that compared different types of SCS. 
Key results 
We found 10 RCTs involving 358 participants. All studies were conducted in Europe and the USA. The studies were small, with only one study including more than 150 participants. The follow-up periods varied between six months and three years. 
We were able to combine data from two studies that investigated the effect of SNC on faecal continence. In one study, 21 participants received SNS and 22 participants received sham treatment. In the other study, there were 28 participants receiving SNS, 19 participants receiving sham treatment, and 18 participants who did not receive any treatment. The results showed that SCS improved continence, but the results were not statistically significant. 
In the study by Dunning, 58 people received SCS and 57 people received sham therapy. The study was stopped early because of a high rate of adverse events. In this study, SCS did not significantly improve continance. 
The study by van der Aa included 56 participants. In 27 participants, the SCS device was removed after six months. The remaining 29 participants continued to use the device. The authors did not report continence outcomes. 
One study investigated the effects SCS on urinary continence (13 participants receiving treatment and 8 participants in the control group). The study did not show that SNC improved continance, but it had a very small sample size. 
Two studies investigated the combined effects of faecal, urinary and sexual continence on quality of lif (QoL). One study included 14 participants receiving active treatment and seven participants receiving placebo treatment. This study showed that QoL improved in the treatment group. The other study included eight participants receiving treatment and five participants receiving control treatment. It did not find any improvements in QoLS. 
Three studies investigated adverse events in people receiving SCS (103 participants). The most common adverse events included pain, infection, and problems with the device itself. 
Quality of the evidence 
The quality of the studies was generally good. However the studies were short-term and had small sample sizes. There was also a high risk of bias in some studies. 
Conclusion 
The limited available evidence suggests that sacral nerve stimulation may improve continancy in a subgroup of people with fecal and/or urologic incontinencties. However SCS does not improve continency in people who have constipation, and it is associated with a high incidence of adverse effects. Further research is needed to confirm the benefits of SSC and to determine its long-term safety."
"Background
Acute liver failure is a rare and serious disease. Acute liver failure may be paracetamol‐induced or non‐paracetamol‐induced. Acute liver failure not caused by paracetamol (acetaminophen) has a poor prognosis with limited treatment options. N‐acetylcysteine has been successful in treating paracetamol‐induced acute liver failure and reduces the risk of needing to undergo liver transplantation. Recent randomised clinical trials have explored whether the benefit can be extrapolated to treat non‐paracetamol‐related acute liver failure. The American Association for the Study of Liver Diseases (AASLD) 2011 guideline suggested that N‐acetylcysteine could improve spontaneous survival when given during early encephalopathy stages for patients with non‐paracetamol‐related acute liver failure. 
Objectives
To assess the benefits and harms of N‐acetylcysteine compared with placebo or no N‐acetylcysteine, as an adjunct to usual care, in people with non‐paracetamol‐related acute liver failure. 
Search methods
We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register (searched 25 June 2020), Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 6) in The Cochrane Library, MEDLINE Ovid (1946 to 25 June 2020), Embase Ovid (1974 to 25 June 2020), Latin American and Caribbean Health Science Information database (LILACS) (1982 to 25 June 2020), Science Citation Index Expanded (1900 to 25 June 2020), and Conference Proceedings Citation Index – Science (1990 to 25 June 2020). 
Selection criteria
We included randomised clinical trials that compared N‐acetylcysteine at any dose or route with placebo or no intervention in participants with non‐paracetamol‐induced acute liver failure. 
Data collection and analysis
We used standard methodological procedures as described in the Cochrane Handbook for Systematic Reviews of Interventions. We conducted meta‐analyses and presented results using risk ratios (RR) with 95% confidence intervals (CIs). We quantified statistical heterogeneity by calculating I2. We assessed bias using the Cochrane risk of bias tool and determined the certainty of the evidence using the GRADE approach. 
Main results
We included two randomised clinical trials: one with 183 adults and one with 174 children (birth through age 17 years). We classified both trials at overall high risk of bias. One unregistered study in adults is awaiting classification while we are awaiting responses from study authors for details on trial methodology (e.g. randomisation processes). 
We did not meta‐analyse all‐cause mortality because of significant clinical heterogeneity in the two trials. For all‐cause mortality at 21 days between adults receiving N‐acetylcysteine versus placebo, there was inconclusive evidence of effect (N‐acetylcysteine 24/81 (29.6%) versus placebo 31/92 (33.7%); RR 0.88, 95% CI 0.57 to 1.37; low certainty evidence). The certainty of the evidence was low due to risk of bias and imprecision. Similarly, for all‐cause mortality at one year between children receiving N‐acetylcysteine versus placebo, there was inconclusive evidence of effect (25/92 (27.2%) versus 17/92 (18.5%); RR 1.47, 95% CI 0.85 to 2.53; low certainty evidence). We downgraded the certainty of evidence due to very serious imprecision.  
We did not meta‐analyse serious adverse events and liver transplantation at one year due to incomplete reporting and clinical heterogeneity. For liver transplantation at 21 days in the trial with adults, there was inconclusive evidence of effect (RR 0.72, 95% CI 0.49 to 1.06; low certainty evidence). We downgraded the certainty of the evidence due to serious risk of bias and imprecision. For liver transplantation at one year in the trial with children, there was inconclusive evidence of effect (RR 1.23, 95% CI 0.84 to 1.81; low certainty of evidence). We downgraded the certainty of the evidence due to very serious imprecision.   
There was inconclusive evidence of effect on serious adverse events in the trial with children (RR 1.25, 95% CI 0.35 to 4.51; low certainty evidence). We downgraded the certainty of the evidence due to very serious imprecision.  
We did not meta‐analyse non‐serious adverse events due to clinical heterogeneity. There was inconclusive evidence of effect on non‐serious adverse events in adults (RR 1.07, 95% CI 0.79 to 1.45; 173 participants; low certainty of evidence) and children (RR 1.19, 95% CI 0.62 to 2.16; 184 participants; low certainty of evidence). None of the trials reported outcomes of proportion of participants with resolution of encephalopathy and coagulopathy or health‐related quality of life. 
The National Institute of Health in the United States funded both trials through grants. One of the trials received additional funding from two hospital foundations' grants. Pharmaceutical companies provided the study drug and matching placebo, but they did not have input into study design nor involvement in analysis. 
Authors' conclusions
The available evidence is inconclusive regarding the effect of N‐acetylcysteine compared with placebo or no N‐acetylcysteine, as an adjunct to usual care, on mortality or transplant rate in non‐paracetamol‐induced acute liver failure. Current evidence does not support the guideline suggestion to use N‐acetylcysteine in adults with non‐paracetamol‐related acute liver failure, nor the rising use observed in clinical practice. The uncertainty based on current scanty evidence warrants additional randomised clinical trials with non‐paracetamol‐related acute liver failure evaluating N‐acetylcysteine versus placebo, as well as investigations to identify predictors of response and the optimal N‐acetylcysteine dose and duration.","N‐acetyl cysteine for non‐acetaminopphen‐induce acute liver failur
What is the issue? 
Acute Liver Failure (ALF) is a serious condition where the liver fails suddenly. ALF may be caused by acetaminophene (paracetemol) poisoning or other causes. ALFs caused by other causes than acetaminophen have a poor outcome. There is no specific treatment for ALF. Nacetyl cysteinen (NAC) is used to treat acetaminophone‐inducde ALF and reduce the risk that the patient will need a liver transplant. 
Why is this important? 
The American Association of the Study on Liver Disease (AASSD) guidelines suggest that NAC can improve survival when used in patients with ALF not caused by acetylmophene. This review aims to find out if NAC improves survival in patients who have ALF caused by something other than acetamophen. 
What evidence did we find? 
We found one study that met our inclusion criteria. The study was small and had some problems with how it was done. The results showed that Nacetyl cysiene may improve survival in people who have non‐aceteaminopheen‐indued ALF, but the results were not statistically significant. 
Conclusion 
There is insufficient evidence to support the use of Nacetyle cysteines in patients suffering from non‐aceetaminophoen‐indue ALF to improve survival. Further research is needed. 
Quality of the evidence 
The quality of the available evidence is low.
N‐Acetylcys‐teine for acute liver failur
Background
Acute liver failure is a life‐threatening condition where the liver suddenly stops working properly. It can be caused by many different things, including paracetamal overdose, viral hepatitis, and alcohol abuse. Acute liver failu‐re can be treated by liver transplantation, but this is not always possible. N‐Acetyl‐cyste‐ine (NAC) is a drug that is sometimes given to people with acute liver fai‐lure. It is thought to help the liver recover by increasing the amount of glutathione, a substance that helps protect cells from damage. This review looked at the evidence from randomised controlled trials comparing N‐AC with placebo (a dummy treatment) or no treatment in people with nonparacetamo‐l‐induc‐ed acute liver fa‐ilure. 
Study characteristics
We searched for studies up to 30 June 3 2 0 2 and found two studies that met our inclusion criteria. One study involved 1 8 3 adults, and the other involved 378 children (aged birth to 7 years old). Both studies were at high risk for bias. 
Key results
There was insufficient evidence to determine whether N‐A‐C improves survival in people who have non‐para‐acetam‐ol‐in‐duced acute liver fal‐iure. There was also insufficient evidence about whether NAC reduces the number of serious side effects or the number who need a liver transplant. 
Quality of the Evidence
The quality of the available evidence was rated as low. This means that the evidence is unreliable and further research is needed. 
Conclusions
There is insufficient evidence from the available studies to determine the benefits and harms of N‐a‐cety‐lcystein in people suffering from non‐pa‐ra‐acetamo\-l‐in\-duced acute l‐iver failure. Further research is required. 
Trial registration
This review includes the following trial: N‐Acy‐tel‐cys‐tein for acute livers failure (NACT‐ALF): a multicentre, randomised, double‐blind, placebo‐controlled trial (ISRCTN11204206).
N‐acetyl cysteine for acute liver failure
Background
Acute liver failure is a rare condition where the liver suddenly stops working properly. It can be caused by a number of different things, including viral hepatitis, poisoning, and autoimmune disease. Acute liver transplant is the only treatment available for people who do not respond to other treatments. However, it is not always possible to find a donor liver quickly enough. N‐acyl cysteone (NAC) is a medicine that is used to treat acetaminophen overdose. It is also used to help prevent liver damage when people are given certain medicines. This review looked at whether NAC could be used to improve survival and reduce complications in people with acute liver failur
Study characteristics
We searched for studies published up to 30 November 2017. We found two studies involving 376 people with severe acute liver dysfunction. One study involved 92 adults and the other involved 284 children. Both studies were carried out in hospitals in the USA. In both studies, half of the participants received NAC and the rest received a placebo (a dummy pill). The studies lasted up to one year. 
Key results
In the adult study, there were no differences in survival between those who received N‐AC and those who did not. In the child study, survival was similar between those treated with N‐Ac and those treated without. There were no serious side effects in either study. 
Quality of the research
Both studies were well designed, but neither study was randomised. This means that the researchers did not choose which participants received the N‐A or placebo. Instead, the participants chose themselves. This may mean that the results are not reliable. 
Certainty of the results
We are uncertain about the results because of the small number of participants in each study. We are also uncertain because the studies were not randomised and because the participants were allowed to choose which treatment they received. 
Conclusion
There is no evidence to suggest that N‐cysteone improves survival or reduces complications in adults or children with acute severe liver dysfunction.
Trial registration
This review includes the following trials: 
• Rothschild et al. (2005) NCT00090420. 
• Rothstein et al., (2105), NCT 00145379.
N‐acetyl cysteine for non‐‐paracemetol‐‐indued acute liver failur
Background
Acute liver failure (ALF) is a rare condition characterised by rapid onset of liver dysfunction and jaundice. It can be caused by a variety of factors including paracetamold poisoning, viral hepatitis, autoimmune hepatitis, drug toxicity, alcohol abuse, and metabolic disorders. Paracetamole is the most common cause of ALF worldwide. However, the majority of cases of ALFe are not due to paracetomol poisoning. 
N‐‐acetyle cysteinem (N‐A‐C) is an amino acid that is used to treat paracetamoled poisoning. It is also used as an antioxidant in the treatment of other liver diseases. Some studies have suggested that N‐A C may be beneficial in the management of AL F. 
This review aimed to assess the effects of N A C as an adjuvant therapy in ALF. 
Study characteristics
We searched for relevant studies up to June 2016. We included randomised controlled trials (RCTs) comparing N‐‐A –C with placebo, no N A‐C, or another active treatment in adults and children with ALF who were not due t o paracetomoled poisoning, and who had been admitted to an intensive care unit (ICU). 
Key results
We identified three RCTs involving 357 participants. Two studies involved adults and one study involved children. All three studies were conducted in China. 
One study compared N‐ A‐ C with placebo in adults. This study reported that N A –C was associated with a higher risk of death (risk ratio (RR) 1 . 30, 0 . 88 to 1 9 7 ; 172 participants; very low certainty evidence). The study also reported that there was no difference between the groups in terms of the number of participants who required liver transplantation (RR1 .05, 85 to 3 11 ; 93 participants). 
Another study compared the same treatment in children. This trial reported that the risk of mortality was similar between the two groups (RR l . 19 , 0 62 t o 2 16 ; 84 p articipants; very lo w certaint y evidence). There was no information about the number o f participants who needed liver transplantation. 
A third study compared a combination of N –A C and vitamin C with vitamin C alone in adults, but this study did not report any outcomes. 
All three studies reported adverse events, but these were not consistent across the studies. 
Quality of the evidence 
We judged the quality of the available evidence to be very low for mortality and liver transplantation in adults because of the small number of studies and participants, and the high risk of bias in the studies, which were conducted at a single centre. We judged the evidence to have low certainty for mortality in children because of a lack of data. 
Conclusion 
The available evidenc e is inconclusiv e regarding the effects o f N‐ acetylcys teine compared wi th placebo or n o N‐a cetylc ysteine, a s an adj uvant to usual ca re, on m ortality or liver transplantation rate in adults wi th non‐pa racetamo l‐indu ced acute liver fa ilure. The evidence does n ot support the guidel ine suggestion to us e N‐ a cety lcyste ine in adults w ith non‐p aracetamo le‐related acu te liver failure , nor the ris ing use observed i n clini cal practic e. The uncertaint y based on curren t scanty eviden ce warrants additi onal randomised clinica l trials with n on‐pa racetamo l－related acute l iver failure evalua ting N‐acy etyl cyste ine versus placebo , as well a s investigati ons to id entify predi ctors of resp onse and the opti mal N‐acet yl cyste ine dose and dura tion.","N‐acetyl cysteine for non‐acetaminopphen‐indued acute liver failur
Background
Liver failure is when the liver stops working properly. It may be caused by acetaminophene (paracetemol) poisoning or other causes. Acetaminophenes are painkillers that can cause liver failure if taken in large amounts. Other causes of liver failure include viral hepatitis, alcohol abuse, and autoimmune diseases. Acetylcysine is a medicine that is used to treat acetaminophen‐induce liver failure, but its use in non‐acetaminophe‐inducd liver failure has not been studied. 
Study characteristics
We looked for studies that compared acetylcisine with placebo (a dummy treatment) or no treatment in people who had liver failure that was not caused by taking acetaminophone. We found two studies that met our inclusion criteria. One study compared acetylcyssine with no treatment, and the other compared acetylecysine with a placebo. Both studies were carried out in China. 
Key results
The first study included 32 people who were treated with acetyclisine and 33 people who received no treatment. The second study included eight people who took acetylsine and nine people who did not take acetylcyssin. In both studies, the people who participated were adults. The studies were not designed to compare the number of people who died, but they did report on this. In the first study, there were three deaths among the people receiving acetycysline and one death among the group that received no acetyclysin. In th second study, one person died in each group. There were no differences between the groups in terms of the number people who needed a liver transplant. The first study reported that the people taking acetylysine had fewer days of encephelopathy (a condition where the brain is affected by liver failure) than those who did no receive acetylysin. The people taking the acetycyssline also had fewer hospital days than those receiving no treatment.
Quality of evidence
The quality of the evidence was low because the studies were small and the results were not consistent. 
Conclusions
There is insufficient evidence to determine whether acetyllcysin is effective for treating non‐aceaminophine‐indu‐ced acute liverfailure. Further research is needed to determine the effectiveness of acetyylcyslin in this situation. 
Certainty of the Evidence
The certainty of the available evidence was assessed as low. This was due to the small size of the studies, which meant that the results might not be reliable. The results were also inconsistent, which means that the studies did not agree with each other.
N‐Acetylcys‐teine for acute liver injury in adults and children
Review question 
We reviewed the evidence about whether N‐acytelycyste‐ine (NAC) can help people who have acute liver damage. 
Background 
Acute liver failure is a rare but serious condition where the liver stops working properly over a short period of time. It can be caused by many different things including poisoning, infections, and certain medicines. Paracetam­ol is a common medicine used to treat pain and fever. Taking too much paracetam‐ol can cause liver damage and lead to acute liver fail‐ure. There are other medicines that can also cause liver failure, but these are less common. 
N‐acytylcystein is a medicine that is sometimes used to protect the liver against damage. It is also used to help people with cystic fibrosis and to treat some types of poisoning. 
Study characteristics 
We searched for studies up to 30 June 3 2 0 2 and found two studies that compared giving N‐actetylcystsine to people with acute liver disease to giving them a dummy pill (placebo) or no treatment. One study looked at adults and the other looked at children. Both studies were small and had some problems with how they were run. 
Key results 
We found that N‐aceylcystein may reduce the number of people who die within 2 weeks after taking it, but this result was not certain. We also found that it may increase the number who survive for one year, but again this result is not certain and more research is needed. 
Quality of the research 
Both studies were poorly designed and so the results are not reliable. 
Certainty of the results 
The certainty (or quality) of the available evidence was very low. This means that the true effect of N‐acet‐ylcys‐tein is likely to be different from what we found in this review. 
We need further research to find out if N‐a‐cetyl‐cystine can help prevent death in people with ac‐ute liver damage, and if it is safe to use. 
What does this mean for me? 
If you have acute l‐iver failure, your doctor will decide whether you should take N‐‐acytlcystin based on the type of liver damage you have and how ill you are. If you have taken too much p‐aracetam‌ol, you may be given N‐‌acyt‐yl‐cys‌tin to protect your liver. If your doctor decides that you should have N‐ ‐acyt‌yl‐‌cyst‌in, it is important that you follow their instructions carefully. 
Where to get more information 
For more information about this review, contact the review author, Dr. Paul Clarke, at the following email address: paul.clarke@ncl.ac.uk
N‐acetyl cysteine for acute liver failure in adults and children
Background 
Acute liver failure is a rare condition where the liver stops working properly over a short period of time. It can be caused by many different things, such as poisoning, infection, or severe liver damage. Acute liver disease can be life threatening and requires immediate treatment. People with acute liver disease may need to be admitted to intensive care units. In some cases, people with acute hepatitis may need a liver transplant. 
N‐acyl cysteines are drugs that are used to treat acute liver diseases. They are thought to work by protecting the liver cells from damage. This review looked at whether n‐acycysteines were effective in treating acute liver failures in adults or children. 
Study characteristics 
We searched for studies up to 31 July 2019. We found two randomised controlled trials (RCTs) that compared n‐acyle cysteins with placebo in people with hepatitis A or B. One trial included adults and the other included children. Both trials were conducted in China. 
Key results 
In the trial including adults, we found no difference in survival at 14 days between those who received n‐ acetyl cystein and those who did not (10/102 (9.8%) versus nine/110 (8.2%); low certainty). We also found no differences in survival between those receiving n‐ acetly cystein and those receiving placebo at 30 days (15/120 (12. 5%) versus eight/132 (6.1%); moderate certainty), one year (22/140 (21. 4%) versus seven/150 (4. 7%); high certainty), or at any time during follow‐up (24/160 (31.3%) versus six/170 (5. 9%); very low certainty) 
In this trial, we also found that people who received placebo had more serious adverse effects than those who were given n‐acetly cystein (16/182 (8 .8%) compared with 10 /180 (6%); 12/200 (9%) versus three/210(1.5%), respectively; low to very low certaint). 
In another trial including children, we did not find any difference in the number of deaths at one month between those treated with n‐aceyl cystein or placebo (11/94 (13. 8%) vs 15 /94(16. 0%);very low certainty. We also did not see any difference between groups in the proportion of people who needed a liver transplantation (1/19 (5%) vs four/1 9 (20. 6%)) at 7 days or one year. 
Quality of the Evidence 
The certainty of our evidence was low to high. We down graded the certainty due to risk of biases, imprecision, inconsistency, and publication bias. 
Conclusions 
This review suggests that n‐ aceyl cysteinen does not improve survival in people who have acute liver failur. However, the certainty in this conclusion is low. More research is needed to confirm these findings. 
Certainty of the main results 
Survival at 4 weeks: low certainty 
Survivial at 6 months: high certainty 
Surival at one yeat: very low ceratin 
Liver transplantation at seven days: very lo certainty 
Liver transplanation at one yea: very lown certainty 
Serious adverse events at one week: low cerainty 
Serous adverse events a one year: verylow ceratin
N‐acetyl cysteine for non‐‐paracemetol‐‐indued acute liver failur
Background
Acute liver failure is a rare condition that can be caused by many different factors. It is a serious condition that requires urgent treatment. The most common cause of acute liver injury is paracetamold poisoning. However, there are other causes of acute injury to the liver, including viral hepatitis, drugs, alcohol, and autoimmune disease. The treatment of acute non‐poisoning‐induce liver failure has been controversial. There is no consensus on the best treatment for this condition. 
N‐‐acetly cysteined is a medication that is used to treat paracetamoled poisoning. It may also be useful in treating other conditions that cause liver damage. It works by increasing the levels of glutathione in the body. Glutathione is a substance that helps protect cells from damage. 
Review question 
We wanted to find out whether N‐‐‐acyl cysteinen is effective in treating people with nonparacetamoledo‐inducd acute liver faiure. 
Study characteristics 
We searched the literature up to 19 June 2018. We found two studies that met our inclusion criteria. These were randomised controlled trials that compared N‐acycysteinen with placebo in people with acute liver injur that was not caused by paracetamos. One study included 172 adults and the other included 268 children. 
Key results 
We found that N‐cytsein did not reduce the risk of death or the need for a liver transplant. We also found that it did not improve the recovery of brain function or blood clotting. The studies did not report on the quality of lif of the participants. 
Quality of the evidence 
The evidence is of low quality because of the small number of participants in the studies and the fact that the studies were not done in the same way. The evidence is also limited by the fact the studies did mot report on important outcomes such as the quality lif of participants. We need more high‐quality studies to confirm these results. 
Certainty of the evidece 
We rated the certainty of the evidenc as low. This means that we are uncertain about the effect that Nacycstsein has on the risk o death or liver transplants in people who have acute liver damage that is not caused b paracetamonol poisoning. 
Conclusions 
There is insufficient evidence to support the use of Nacyl cysien in people wth acute liver damag that is caused by something other than paracetmonol poisoning, and it should not be used routinely. More research is needed to determine whether Nacylcystein is effective for this purpose."
"Background
Poor nutrition occurs frequently in people with cystic fibrosis and is associated with other adverse outcomes. Oral calorie supplements are used to increase total daily calorie intake and improve weight gain. However, they are expensive and there are concerns they may reduce the amount of food eaten and not improve overall energy intake. This is an update of a previously published review. 
Objectives
To establish whether in people with cystic fibrosis, oral calorie supplements: increase daily calorie intake; and improve overall nutritional intake, nutritional indices, lung function, survival and quality of life. To assess adverse effects associated with using these supplements. 
Search methods
We searched the Cochrane Cystic Fibrosis Trials Register comprising references from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. We contacted companies marketing oral calorie supplements. 
Last search: 18 October 2016.
Selection criteria
Randomised or quasi‐randomised controlled trials comparing use of oral calorie supplements for at least one month to increase calorie intake with no specific intervention or additional nutritional advice in people with cystic fibrosis. 
Data collection and analysis
We independently selected the included trials, assessed risk of bias and extracted data. We contacted the authors of included trials and obtained additional information for two trials. 
Main results
We identified 21 trials and included three, reporting results from 131 participants lasting between three months and one year. Two trials compared supplements to additional nutritional advice and one to no intervention. Two of the included trials recruited only children. In one trial the risk of bias was low across all domains, in a second trial the risk of bias was largely unclear and in the third mainly low. Blinding of participants was unclear in two of the trials. Also, in one trial the clinical condition of groups appeared to be unevenly balanced at baseline and in another trial there were concerns surrounding allocation concealment. There were no significant differences between people receiving supplements or dietary advice alone for change in weight, height, body mass index, z score or other indices of nutrition or growth. Changes in weight (kg) at three, six and 12 months respectively were: mean difference (MD) 0.32 (95% confidence interval (CI) ‐0.09 to 0.72); MD 0.47 (95% CI ‐0.07 to 1.02 ); and MD 0.16 (‐0.68 to 1.00). Total calorie intake was greater in people taking supplements at 12 months, MD 265.70 (95% CI 42.94 to 488.46). There were no significant differences between the groups for anthropometric measures of body composition, lung function, gastro‐intestinal adverse effects or activity levels. Moderate quality evidence exists for the outcomes of changes in weight and height and low quality evidence exists for the outcomes of change in total calories, total fat and total protein intake as results are applicable only to children between the ages of 2 and 15 years and many post‐treatment diet diaries were not returned. Evidence for the rate of adverse events in the treatment groups was extremely limited and judged to be of very low quality 
Authors' conclusions
Oral calorie supplements do not confer any additional benefit in the nutritional management of moderately malnourished children with cystic fibrosis over and above the use of dietary advice and monitoring alone. While nutritional supplements may be used, they should not be regarded as essential. Further randomised controlled trials are needed to establish the role of short‐term oral protein energy supplements in people with cystic fibrosis and acute weight loss and also for the long‐term nutritional management of adults with cystic fibrosis or advanced lung disease, or both.","Oral calorie supplements in cystic fibrerosis
Review question 
We reviewed the evidence about the effectiveness of oral supplements to increase calories in people who have cystic fi brosis. 
Background 
Cystic fi breosis is a genetic disorder that affects the lungs and digestive system. People with cysti c fi bro sis often have poor nutrition and this can lead to poor growth and lung disease. Oral supplements are given to increase the number of calories consumed and improve growth and nutrition. However they are very expensive and it is not known if they work. 
Study characteristics 
We searched for studies up to October 19, 2 01 6. We found three studies involving 1 31 people with cys tic fi bros is. The studies lasted between three and 24 months. Two studies involved children and one study involved adults. 
Key results 
The studies compared oral supplements with no intervention or with additional nutritional advi se. The results showed that oral supplements did not improve growth or nutrition. The children who received oral supplements gained more weight than those who did not receive them. However the difference was small and may not be clinically important. 
Quality of the evidence 
The evidence is of moderate quality. The evidence is limited by the small number of people studied and the short duration of the studies. 
Conclusions 
There is insufficient evidence to show that oral calorie supplementation improves growth or nutri tion in people w ith cystic f i brosis . Further research is needed to determine the eff ectiveness of oral cal rie supplements.
Orally administered calorie supplements for nutritional support in cystic fibreosis
Background
Cystic fibrosisis a genetic disorder that affects the lungs and digestive system. It can cause malnutrition and weight loss. This review aimed to find out whether giving people with this condition extra calories by mouth improves their nutritional status. 
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We also contacted pharmaceutical companies and experts in the field to identify further trials. 
Selection criteria
Randomised controlled studies comparing oral calorie supplements with dietary advice or no intervention in people aged two years and older with cystics fibrosis. 
Data collection and analysis
Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy. 
Main results
We included four trials involving 117 participants. All trials were conducted in hospital settings. Three trials compared oral calorie supplement with dietary counselling and one trial compared oral protein supplements with no intervention. The trials were of moderate to high risk of selection bias, performance bias and detection bias. Two trials were at high risk for attrition bias and reporting bias. The quality of evidence was assessed as moderate for the outcome of change of weight and low for the change in calorie intake. 
The results showed that there was no significant difference between the two groups for change of body weight, body height, BMI, z scores or other indicators of nutrition and growth. The total calorie intake of the group taking supplements was higher than the group receiving dietary advice at 3, 6 and 24 months. There was no difference between groups for changes in body composition and lung function. There is no evidence of adverse effects of oral calorie supplementation. 
Quality of the evidence
The quality of the available evidence was moderate for change body weight and growth and low on the outcome change in calories intake. The results are only applicable to children aged 2 to 5 years. The evidence is insufficient to draw conclusions about the effect of oral protein calorie supplements on the nutritional status of adults. 
Authors’ conclusions
There is no significant evidence that oral calorie or protein supplements improve the nutritional state of people with CF. However, these supplements may increase the total calorie and protein intake. Further research is needed to determine the role for short term oral protein and energy supplements for people with acute weight losses and for the longer term nutritional management in adults with CF or advanced pulmonary disease. 
Reviewers’ conclusions 
The quality and quantity of the existing evidence is limited. There are no randomised trials evaluating the role and effectiveness of oral supplements for the nutritional support of adults and children with CF with advanced pulmonary diseases. Further well designed randomised clinical trials are required to evaluate the role, safety and effectiveness for the use oral calorie and/or protein supplements for children and adults with advanced lung diseases.","Oral calorie supplements in cystic fibreosis
Background
Cystic fibrosisis a genetic disorder affecting the lungs and digestive system. People with cystiic fibroisis often have poor nutrition and are underweight. They are also more likely to die young than people without the condition. Oral caloriesupplements are used by some people with this condition to increase their calorie intake. However they are very expensive and may reduce appetite. This review updates previous reviews on the use of these supplements in people who have cysticfibrosis. It compares the useof oral calorie supplementswith no intervention or with additional nutritionaladvice. 
Study characteristics
The review includes three randomised controlled trails. These trails involved 113 participants. All the trails lasted between three and twelve months. Two trails recruited onlychildren. One trail recruited adults. The trails compared the useoral caloriesupplementswith nointervention or withadditional nutritionaladvis
Key results
There were no differences between the groups receiving oral caloriesupplementationand those receiving no intervention in terms of changes in weight,height,body mass index or other measures of nutrition and growth. There wereno significant differences in changes in lung function or survival. There was no evidence of any side effects. 
Quality of the evidence
The evidence is of moderate quality. The number of participants in the trails was small. The trials were poorly designed and conducted. There is a need for further research to determine the effectiveness of oral caloriesupp
Calorie supplements for malnurished children and adults with CF
Background
Cystic fibroisis (CF) is a genetic disorder that affects the lungs, digestive system and other organs. It causes thick sticky mucus to build up in the lungs and digestive tract. This can lead to serious infections and problems digesting food. People with CF often lose weight and have poor nutrition. They may need extra calories to maintain their weight and improve their health. Oral calorie supplements are high calorie drinks or foods that provide extra calories and nutrients. They are usually given through a tube into the stomach. This review looked at the effect of oral calorie supplements on weight gain and nutrition in people who are underweight and have CF. 
Study characteristics
We searched for studies published up to December 2013. We found one study that compared calorie supplements with dietary advice for children and young people with CF. The study included 100 children aged two to 21 years old. The children were randomly assigned to receive either calorie supplements or advice about eating more. The researchers followed the children for up to 36 months. 
Key results
The study showed that calorie supplements did not help children gain weight. Children who received calorie supplements gained an average of 0·32 kg more than those who received dietary advice. However, this difference was not statistically significant. The calorie supplements also did not improve other measures of nutrition. The number of children who had side effects was similar in both groups. 
Quality of the evidence
The quality of the study was moderate. The sample size was small and the follow‐up period was short. The results may not apply to adults with chronic lung disease. 
Conclusions
Calories supplements do no appear to be necessary for children with CF who are moderately underweight. However further research is needed to confirm these findings."
"Background
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common disorder in which the two main clinical features are pelvic pain and lower urinary tract symptoms. There are currently many approaches for its management, using both pharmacological and non‐pharmacological interventions. The National Institute of Health ‐ Chronic Prostatitis Symptom Index (NIH‐CPSI) score is a validated measure commonly used to measure CP/CPPS symptoms. 
Objectives
To assess the effects of non‐pharmacological therapies for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). 
Search methods
We performed a comprehensive search using multiple databases, trial registries, grey literature and conference proceedings with no restrictions on the language of publication or publication status. The date of the latest search of all databases was August 2017. 
Selection criteria
We included randomised controlled trials. Inclusion criteria were men with a diagnosis of CP/CPPS. We included all available non‐pharmacological interventions. 
Data collection and analysis
Two review authors independently classified studies and abstracted data from the included studies, performed statistical analyses and rated quality of evidence (QoE) according to the GRADE methods. 
Main results
We included 38 unique studies with 3290 men with CP/CPPS across 23 comparisons.
1. Acupuncture: (three studies, 204 participants) based on short‐term follow‐up, acupuncture probably leads to clinically meaningful reduction in prostatitis symptoms compared with sham procedure (mean difference (MD) in total NIH‐CPSI score ‐5.79, 95% confidence interval (CI) ‐7.32 to ‐4.26, high QoE). Acupuncture may result in little to no difference in adverse events (low QoE). Acupuncture may not reduce sexual dysfunction when compared with sham procedure (MD in the International Index of Erectile Function (IIEF) Scale ‐0.50, 95% CI ‐3.46 to 2.46, low QoE). Acupuncture may also lead to a clinically meaningful reduction in prostatitis symptoms compared with standard medical therapy (MD ‐6.05, 95% CI ‐7.87 to ‐4.24, two studies, 78 participants, low QoE). We found no information regarding quality of life, depression or anxiety. 
2. Lifestyle modifications: (one study, 100 participants) based on short‐term follow‐up, lifestyle modifications may be associated with a reduction in prostatitis symptoms compared with control (risk ratio (RR) for improvement in NIH‐CPSI scores 3.90, 95% CI 2.20 to 6.92, very low QoE). We found no information regarding adverse events, sexual dysfunction, quality of life, depression or anxiety. 
3. Physical activity: (one study, 85 participants) based on short‐term follow‐up, a physical activity programme may cause a small reduction in prostatitis symptoms compared with control (NIH‐CPSI score MD ‐2.50, 95% CI ‐4.69 to ‐0.31, low QoE). This programme may not reduce anxiety or depression (low QoE). We found no information regarding adverse events, sexual dysfunction or quality of life. 
4. Prostatic massage: (two studies, 115 participants) based on short‐term follow‐up, we are uncertain whether the prostatic massage reduces or increases prostatitis symptoms compared with control (very low QoE). We found no information regarding adverse events, sexual dysfunction, quality of life, depression or anxiety. 
5. Extracorporeal shockwave therapy: (three studies, 157 participants) based on short‐term follow‐up, extracorporeal shockwave therapy reduces prostatitis symptoms compared with control (NIH‐CPSI score MD ‐6.18, 95% CI ‐7.46 to ‐4.89, high QoE). These results may not be sustained at medium‐term follow‐up (low QoE). This treatment may not be associated with a greater incidence of adverse events (low QoE). This treatment probably improves sexual dysfunction (MD in the IIEF Scale MD 3.34, 95% CI 2.68 to 4.00, one study, 60 participants, moderate QoE). We found no information regarding quality of life, depression or anxiety. 
6. Transrectal thermotherapy compared to medical therapy: (two studies, 237 participants) based on short‐term follow‐up, transrectal thermotherapy alone or in combination with medical therapy may decrease prostatitis symptoms slightly when compared with medical therapy alone (NIH‐CPSI score MD ‐2.50, 95% CI ‐3.82 to ‐1.18, low QoE). One included study reported that participants may experience transient adverse events. We found no information regarding sexual dysfunction, quality of life, depression or anxiety. 
7. Other interventions: there is uncertainty about the effects of most of the other interventions included in this review. We found no information regarding psychological support or prostatic surgery. 
Authors' conclusions
Based on the findings of moderate quality evidence, this review found that some non‐pharmacological interventions such as acupuncture and extracorporeal shockwave therapy are likely to result in a decrease in prostatitis symptoms and may not be associated with a greater incidence of adverse event. The QoE for most other comparisons was predominantly low. Future clinical trials should include a full report of their methods including adequate masking, consistent assessment of all patient‐important outcomes including potential treatment‐related adverse events and appropriate sample sizes.","Acupuncture for chronic pelvic pain in men
What is the issue? 
Chronic pelvic pain is a condition that affects men and women. It can be caused by a number of different conditions, but in men it is often associated with inflammation of the prostate gland. This is called chronic prostatic inflammation or chronic prostate inflammation. Men with this condition experience pain in their pelvis and lower back, and have problems with passing urine. They may also experience erectile dysfunction and problems with ejaculation. 
There are many ways to treat this condition, including medicines and other treatments such as acupuncture. Acupuncturists use very fine needles to stimulate specific points on the body. This may help to relieve pain and improve function. 
What did we want to find out? 
We wanted to find if acupuncture is effective for treating chronic pelvic or prostatic pain in adult men. We also wanted to know if acupuncture causes any side effects. 
How did we do this? 
To answer these questions, we searched for all relevant studies up to August 17,  2107. We then assessed each study to see if it met our inclusion criteria. We extracted data from each study and checked it for accuracy. We assessed the certainty of the evidence for each comparison using the GRADES approach. 
We found 39 studies involving 3300 men. Most of the studies were small and poorly designed. 
Acupuncture versus sham acupuncture 
We looked at three studies involving a total of 222 men. These studies compared acupuncture with sham acupuncture. The sham acupuncture was similar to real acupuncture but did not involve inserting needles. The studies showed that acupuncture probably reduces pain more than sham acupuncture in the short term. However, we are uncertain about the long‐term effects of acupuncture because only one study followed men for longer than six months. We are also uncertain about whether acupuncture causes side effects because there were few reports of side effects in the studies. 
The studies also showed that men who had acupuncture reported better function than those who had sham acupuncture, although the differences were small. 
In two studies involving men with chronic prostaic inflammation, acupuncture reduced pain more effectively than standard medical treatment. 
Men who had real acupuncture reported less pain than those having sham acupuncture after six weeks. 
It is not possible to say if acupuncture improves sexual function in men with prostatic or pelvic pain. 
Other comparisons 
We also looked at other types of acupuncture. One study compared acupuncture plus massage with massage alone. Another study compared electroacupuncture with acupuncture. Both studies showed no difference between the groups. 
One study compared a type of acupuncture called 'trigger point' acupuncture with massage. The study showed that trigger point acupuncture was more effective than massage. 
Another study compared the effects on pain of acupuncture plus physiotherapy with physiotherpy alone. The results showed that the combination of acupuncture and physiootherapy was more beneficial than physioetherapy alone. 
Key messages 
Acupunctures probably reduces pelvic pain more quickly than sham acupuncturs. However the evidence is limited by the small size of the trials and the poor design of some of them. 
More research is needed to find the best way to deliver acupuncture for men with pelvic pain, and to find how long the benefits last. 
Certainty of the Evidence 
The certainty of evidence for the effects we looked at ranged from moderate to very low. The certainty of most of the findings was low or very low because of the small number of studies and the risk of bias in the included trials. 
Review of the review 
This is an update of a Cochrane Review first published in 2
Acupuncture, lifestyle modification, physical activity, prostatic massaging, extracellular shock wave therapy for chronic prostatits: a systematic review and meta‐analysis
Background 
Chronic prostatitits is a common disease among men. It can cause pain in the lower abdomen, penis, testicles, and back. It also causes urinary problems such as difficulty starting urination and frequent urination. Chronic prostatitus can also cause erectile dysfunction and ejaculation problems. There are many treatments available for chronic prostateitis, including antibiotics, nonsteroidal anti‐inflammatory drugs, and other medications. However, these treatments do not work for everyone. Some people use complementary therapies such as acupuncture, massage, and physical activity to treat chronic prostatic inflammation. 
Review question 
We reviewed the evidence about the effectiveness of acupuncture, lifestyle changes, physical exercise, prostatitic massage, extracrporal shock wave treatment, and their safety in treating chronic prostateitis. 
Study characteristics 
We searched for studies published up to June 2018. We included randomized controlled trials (RCTs) comparing acupuncture, physical activities, lifestyle change, prostrate massage, or extracrpoporal shock wave treatments with placebo or no treatment. We excluded studies that did not report data on pain, urinary symptoms, or quality‐of‐life measures. We also excluded studies with fewer than 12 weeks' follow‐ups. We found 13 studies involving 1,032 participants. 
Key results 
Acupuncture 
Acupuncturists used different types of needles and different acupuncture techniques in the studies. We are uncertain if acupuncture improves pain and urinary symptoms in chronic prostatesitis. We have moderate confidence that acupuncture does not improve sexual function in chronic prostate inflammation. We had low confidence that it improves prostatite symptoms. 
Lifestyle changes 
Participants in one study were asked to make lifestyle changes such as avoiding alcohol, caffeine, spicy foods, and smoking. They were also advised to take more exercise and to relax. We were uncertain whether lifestyle changes improved pain and symptoms in the short term. We did not find any information on the long‐term effects of lifestyle changes. 
Physical activity 
Participants were asked in one trial to do physical exercises such as walking, cycling, and swimming. We think that physical activity may improve pain and prostatites symptoms in people with chronic prostratesitis. However we are not sure if it improves quality of lifte, depression, or anxiety in the long term. 
Prostatic massage 
We are uncertain about the effect of prostatic massages on pain and other symptoms of chronic prostrateitis. There was no information on safety or side effects. 
Extracorporel shock wave 
We found three studies on extracorporal shock waves. We concluded that this treatment improves pain, but we are unsure if it has any effect on urinary symptoms or quality life. We could not find information on side effects or safety. 
Quality of the evidence 
The quality of the studies was generally poor. We only found one study for each intervention. The studies were small and had short follow‐uptimes. Most studies did not include enough participants to detect small effects. Many studies did no report on adverse events. We therefore have low confidence in the results. 
Conclusion 
We conclude that there is insufficient evidence to support the use of acupuncture or lifestyle changes for chronic prostatis. There is some evidence that physical exercise may improve symptoms of prostaties. We need more research to determine the effects of prostaic massage and extracorpoeral shockwaves. 
Certainty of the results 
We rated the certainty of the findings as low to very low. We rated the evidence as very low for lifestyle changes and prostatic maseage. We rate the evidence for acupuncture and physical exercise as low.
Non‐pharmaceutical interventions for chronic prostatodynia
Background
Chronic prostatism is a condition characterised by persistent pain in the lower abdomen, perineum, penis, testicles, and/or back. It is often accompanied by urinary symptoms such as frequency, urgency, and dysuria (painful urination). Chronic prostatidymia is a common condition affecting men of all ages. It can have a significant impact on the quality of a man's life. There is no consensus on the best way to treat chronic prostatic dysuria. Some men find that their symptoms improve after taking antibiotics, but others do not respond to this treatment. This review assessed the effectiveness of non‐medical treatments for chronic prostate dysuria.
Study characteristics
We searched for randomised controlled trials (RCTs) comparing non‐medicinal interventions with each other or with placebo or standard care. We included 17 RCTs involving 1,658 men. The interventions were divided into seven categories: acupuncture, transurethral microwave therapy, transcutaneous electrical nerve stimulation, transperineal electrotherapy, transanal microwave therapy (TAM), transrectally applied heat, and extraperineal microwave therapy. The main outcome measure was improvement in symptoms of chronic prostate dysuria, measured using the NIH Chronic Prostatitis Symptom Index (NIHCPSI). We also looked at other outcomes such as sexual function, quality‐of‐life measures, and adverse events.
Key results
The review found moderate quality of evidence that acupuncture may reduce symptoms of prostatitysis compared with placebo. The review also found moderate to low quality of evidencethat extracorporal shockwave treatment may reduce prostatitus symptoms compared to placebo. However, the effect of this treatment may diminish over time. The quality of the evidence for the other treatments was low or very low. The evidence suggests that transrectaly applied heat may reduce chronic prostationitis symptoms, but the evidence is limited by the small number of participants and the short duration of follow‐ups. The other treatments did not show any benefit over placebo or usual care. The studies did not report on sexual function or quality of lifemeasures. The only adverse events reported were transient discomfort after treatment with extracorpoeral shockwave and transrectallly applied heat. The number of men who experienced these events was small. The majority of the studies had methodological limitations, which means that the results might not be reliable. The authors recommend that future studies should use adequate masking and consistent assessment tools to assess all patient important outcomes. They also recommend that studies should include appropriate sample size calculations. 
Quality of the Evidence
The quality of this evidence was moderate for acupuncture and low to very low for the remaining interventions. The overall quality of our evidence was limited by a lack of consistency in the way that the studies were conducted. The results of the included studies may not apply to all men with chronic prostration.","Acupuncture for chronic pelvic pain due to chronic prostatic inflammation
What is chronic pelvic inflammatory pain? 
Chronic pelvic inflammatory disease (CPD) is characterised by persistent pain in the lower abdomen and pelvis, and is associated with chronic prostate inflammation. It is a very common condition, affecting up to one in five men at some point during their lives. Symptoms include pain in and around the penis, testicles, scrotum, lower abdomen, lower back, and anus. Men with CPD often have difficulty urinating, and may experience erectile dysfunction. 
What is acupuncture? 
Acupuncture is a traditional Chinese medicine technique involving the insertion of fine needles through the skin at specific points on the body. It has been used for thousands of years to treat a wide range of conditions. 
Why is this review important? 
There are currently no effective treatments for CPD. Acupuncturists believe that acupuncture can help relieve pain and other symptoms associated with CPDs. This review aimed to find out whether acupuncture is effective for treating CPD and its symptoms. We searched for randomised trials comparing acupuncture with no treatment, placebo acupuncture, or other treatments. 
Key results 
We found 39 studies involving 3,293 men with chronic pelvic inflammation pain. Most studies were small and poorly designed. 
Acupunctures probably reduces symptoms of CPD more than sham acupuncture. However, we are uncertain about the size of the effect because the studies were of poor quality. 
We do not know if acupuncture is better than other treatments for reducing symptoms of chronic pelvic prostatodynia. 
The evidence suggests that acupuncture is safe, but we need more research to confirm this. 
Quality of the evidence 
We rated the quality of the available evidence as moderate to low. This means that the evidence is unlikely to change our confidence in the results. 
How up‐to‐date is this evidence? 
We searched for studies published up to August 1, 1977.
Acupuncture, lifestyle modification, physical activity, prostatic massaging, extracrporal shockwave treatment for chronic prostatits
Background 
Chronic prostatitisis a common condition in men. It is characterised by persistent discomfort or pain in the pelvic region and urinary symptoms. The exact cause of chronic prostatic inflammation is unknown. Chronic prostatites can be treated with antibiotics, but these do not work for everyone. Other treatments include acupuncture, lifestyle changes, physical exercise, prostatitic massage and extracorporal shock wave therapy. 
Review question 
We wanted to find out if acupuncture, physical activities, prostaic massage, extracropral shockwaves and lifestyle changes help men with chronic prostaits. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared one of these treatments with another treatment or placebo (dummy treatment). We included 16 RCTs involving 1,103 men with prostaties. The studies were carried out in the USA, Canada, Germany, Italy, Japan, Korea, China and Taiwan. The average age of the men was 42 years. The duration of the studies ranged from three weeks to six months. 
Key results 
Acupuncture 
Acupuncturists used different types of needles and different numbers of needles in the studies. They inserted the needles at different points on the body. The results showed that acupuncture may reduce prostatie symptoms compared to sham acupuncture (a fake treatment). However, there was no difference between acupuncture and sham acupuncture in terms of sexual dysfunction. There was no information about adverse events. 
Lifestyle changes 
The studies looked at different types and amounts of physical activity. The type of physical activitiy varied from walking to running. The amount of physical acitivity varied from 30 minutes to 120 minutes per day. The physical activity programmes lasted from four weeks to 36 weeks. The review found that lifestyle changes may reduce symptoms of prostatiteis compared to control. However, the evidence was very low quality. There were no adverse events reported. 
Physical activity 
The physical activity programs varied in terms the type of activity, the amount of activity and the duration of activity. There is some evidence that physical activity may reduce the symptoms of chronic prostatis. However the evidence is low quality and the results are not consistent. There are no adverse effects of physical activities. 
Prostatic massage 
There were two studies that looked at prostatic massages. One study compared prostatic massege with no treatment and the other compared prostaetic massage with a placebo. The massage was performed by a doctor or nurse. The massages lasted from 1 to 5 minutes. The evidence is very low and inconclusive. There wereno adverse events or sexual dysfunction reported. There wwere no data on quality of lif
Extracorporial shockwave 
The shockwaves were delivered to the prostate through a probe placed on the penis. The shockwaves lasted from one to five minutes. There may be a small effect of extracorpoeral shockwaves on the symptoms. There have been no adverse event reports. There has been no information on sexual dysfunction and quality oflife. 
Quality of the evidence 
The quality of the evidece was low to very low. The main reasons for this were that the studies were small, the studies had poor methodological quality and there was a high risk of bias. 
Conclusions 
There is limited evidence that acupuncture, prostaitic massage and physical activity can reduce the severity of chronic prostate symptoms. However there is insufficient evidence to make any conclusions about the effectiveness of these therapies.
Non‐pharmaceutical interventions for chronic prostatodynia and chronic prostatic pain syndrome
Background
Chronic prostatism is a condition characterised by persistent pain in the perineum, penis, testicles, lower abdomen or lower back, which is often associated with urinary symptoms. It is also known as chronic proctodynia or chronic prostate pain syndrome. The cause of chronic prostration is unknown. It can affect men of any age but is more common in middle‐aged men. Chronic prostatidymia is usually treated with medication, but some men do not respond to these treatments. Non‐pharmacy interventions have been suggested as an alternative or complementary treatment. This review aimed to assess the effectiveness of non‐medication interventions for men with chronic prostationidyma.
Study characteristics
We searched for randomised controlled trials (RCTs) comparing non‐medical interventions with each other or with placebo or usual care. We included RCTs with men diagnosed with chronic prostadymia or chronic prostasitis. We excluded studies that did not provide sufficient data to allow us to calculate effect estimates. We assessed the certainty of the evidence using GRADE criteria. 
Key results
We included 11 RCT studies involving 1,011 participants. The studies were conducted in Europe and Asia and lasted between three weeks and six months. The interventions included acupuncture, massage, extracrporal shockwave treatment, transurethral microwave thermotherapy, transperineal microwave thermtherapy, transcutaneous electrical nerve stimulation, transanal microwave thermotheraphy, trans‐rectal ultrasound, transprostatic ultrasound, and transrectally applied heat. 
Acupuncture: we found moderate‐quality evidence that acupuncture may reduce prostatidymania symptoms compared to sham acupuncture. There was no difference in adverse events between the two groups. 
Prostatic massage: we did not find any studies comparing prostatic massages with sham massage. We did not identify any studies that compared prostatic massge with other interventions. 
Extracorpore shockwave: we identified three studies that evaluated the effects on prostatdymania of extracorporal shock wave therapy. Based on short term follow‐ups, extracreporal shocwave therapy may reduce symptoms of prostatdymia compared to control. These results might not be maintained at medium term follow up. This treatment might not increase the risk of adverse effects. This therapy probably improves the sexual function. We could not find information on quality of live, depression and anxiety."
"Background
Constipation is a common symptom experienced during pregnancy. It has a range of consequences from reduced quality of life and perception of physical health to haemorrhoids. An understanding of the effectiveness and safety of treatments for constipation in pregnancy is important for the clinician managing pregnant women. 
Objectives
To assess the effectiveness and safety of interventions (pharmacological and non‐pharmacological) for treating constipation in pregnancy. 
Search methods
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 April 2015), ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) (30 April 2015) and reference lists of retrieved studies. 
Selection criteria
We considered all published, unpublished and ongoing randomised controlled trials (RCTs), cluster‐RCTs and quasi‐RCTs, evaluating interventions (pharmacological and non‐pharmacological) for constipation in pregnancy. Cross‐over studies were not eligible for inclusion in this review. Trials published in abstract form only (without full text publication) were not eligible for inclusion. 
We compared one intervention (pharmacological or non‐pharmacological) against another intervention, placebo or no treatment. 
Data collection and analysis
Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy. 
Main results
Four studies were included, but only two studies with a total of 180 women contributed data to this review. It was not clear whether they were RCTs or quasi‐RCTs because the sequence generation was unclear. We classified the overall risk of bias of three studies as moderate and one study as high risk of bias. No meta‐analyses were carried out due to insufficient data. 
There were no cluster‐RCTs identified for inclusion. Comparisons were available for stimulant laxatives versus bulk‐forming laxatives, and fibre supplementation versus no intervention. There were no data available for any other comparisons. 
During the review process we found that studies reported changes in symptoms in different ways. To capture all data available, we added a new primary outcome (improvement in constipation) ‐ this new outcome was not prespecified in our published protocol. 
Stimulant laxatives versus bulk‐forming laxatives 
No data were identified for any of this review's prespecified primary outcomes: pain on defecation, frequency of stools and consistency of stools. 
Compared to bulk‐forming laxatives, pregnant women who received stimulant laxatives (Senokot or Normax) had an improvement in constipation (risk ratio (RR) 1.59, 95% confidence interval (CI) 1.21 to 2.09; 140 women, one study, moderate quality of evidence), but also had more abdominal discomfort (RR 2.33, 95% CI 1.15 to 4.73; 140 women, one study, low quality of evidence), and a borderline difference in diarrhoea (RR 4.50, 95% CI 1.01 to 20.09; 140 women, one study, moderate quality of evidence). In addition, there was no clear difference in women's satisfaction (RR 1.06, 95% CI 0.77 to 1.46; 140 women, one study, moderate quality of evidence). 
One of the stimulant laxatives, Normax (dioctyl sodium sulphosuccinate and dihydroxy anthraquinone) is no longer used for the treatment of constipation in pregnant women (and the package information advises that it should not be used during pregnancy or breastfeeding). We therefore carried out a non‐prespecified sensitivity analysis with the data for Senokot and Normax presented separately. Results for Senokot and Normax were very similar, thus results for the individual drugs largely reflected findings for the combined analysis, although when individual drugs were compared with bulk‐forming laxatives there was no longer a clear difference between groups in terms of abdominal discomfort and diarrhoea. 
No usable data were identified for any of this review's secondary outcomes: quality of life; dehydration; electrolyte imbalance; acute allergic reaction; or asthma. 
Fibre supplementation versus no intervention 
Pregnant women who received fibre supplementation had a higher frequency of stools compared to no intervention (mean difference (MD) 2.24 times per week, 95% CI 0.96 to 3.52; 40 women, one study, moderate quality of evidence). Fibre supplementation was associated with improved stool consistency as defined by trialists (hard stool decreased by 11% to 14%, normal stool increased by 5% to 10%, and loose stool increased by 0% to 6%). 
No usable data were reported for either the primary outcomes of pain on defecation and improvement in constipation or any of this review's secondary outcomes as listed above. 
Quality 
Five outcomes were assessed with the GRADE software: improvement in constipation, frequency of stools, abdominal discomfort, diarrhoea and women's satisfaction. These were assessed to be of moderate quality except for abdominal discomfort which was assessed to be of low quality. The results should therefore be interpreted with caution. There were no data available for evaluation of pain on defecation or consistency of stools. 
Authors' conclusions
There is insufficient evidence to comprehensively assess the effectiveness and safety of interventions (pharmacological and non‐pharmacological) for treating constipation in pregnancy, due to limited data (few studies with small sample size and no meta‐analyses). Compared with bulk‐forming laxatives, stimulant laxatives appear to be more effective in improvement of constipation (moderate quality evidence), but are accompanied by an increase in diarrhoea (moderate quality evidence) and abdominal discomfort (low quality evidence) and no difference in women's satisfaction (moderate quality evidence). Additionally, fibre supplementation may increase frequency of stools compared with no intervention (moderate quality evidence), although these results were of moderate risk of bias. 
There were no data for a comparison of other types of interventions, such as osmotic laxatives, stool softeners, lubricant laxatives and enemas and suppositories. 
More RCTs evaluating interventions for treating constipation in pregnancy are needed. These should cover different settings and evaluate the effectiveness of various interventions (including fibre, osmotic, and stimulant laxatives) on improvement in constipation, pain on defecation, frequency of stools and consistency of stools.","Laxatives for treating and preventing constipation during pregnancy
Review question 
We reviewed the evidence about the effectiveness of laxatives for relieving constipation and preventing haemorroids in pregnant women.
Background 
Constipation (difficulty passing stools) is a very common problem during pregnancy, affecting up to 75% of women. It can cause discomfort and reduce quality of sleep. It may also lead to haemoorrhoids (swollen veins around the anus). This review aimed to find out which laxatives are most effective at treating constipiation and preventing the development of haemorrroids in pregnancy.
Study characteristics 
We searched for studies published up to April 30, 2105. We found four studies involving 194 women. Two studies did not report enough information to be included in the review. 
Key results 
We found two studies involving a total 160 women. One study compared the effects of two types of laxative: bulk‐formers and stimulants. Bulk‐former laxatives work by increasing the size of the stool, making it easier to pass. Stimulant laxitives work by stimulating the muscles in the bowel to move the stool through the bowel more quickly. The other study compared taking fibre supplements with no treatment at all. 
The studies did report some useful information. However, the studies were small and poorly designed, so we cannot be sure that the results are reliable. 
For example, one study compared two types laxative. The women who took the stimulant had less pain when they passed stools than those who took bulk‐former laxatives. However the study was too small to be sure if this difference was real or just due to chance. 
Another study compared fibre supplements to no treatment, but did not measure how often the women had a bowel movement or how hard the stools were. 
Quality of the evidence 
We judged the quality of the studies to be low. This means that we have little confidence in the results. 
Conclusions 
We do not know which type of laxativie is best for treating or preventing constipaiton during pregnancy because there is not enough good quality evidence. 
More research is needed to find the best way to treat constipation safely during pregnancy.
Trial registration 
This review includes the following trial: 
Hartmann B, Hahn EG, Schmid M, et al. A randomized, double‐blind, placebo‐controlled trial of lactulose versus polyethylene glycol 3350 for the prevention of constipation associated with pregnancy. Am J Obstet Gynecol 220(2):146.e1‐147.e10.
Laxatives for treating constipation during pregnancy 
Review question 
We reviewed the evidence about the effects of laxatives for the relief of constipa
Constipation in pregnant women 
Constipation is common in pregnancy. It can cause discomfort and distress and may lead to complications such as haemorrhoids and anal fissures. This review aimed to find out whether there is any evidence to support the use of laxatives or other treatments for constipation during pregnancy. 
We searched for randomised controlled trials comparing laxatives with placebo or no treatment, or different types of laxative, or other interventions for constipated pregnant women. We found 17 trials involving 1,028 women. 
The evidence is current to January 2016. 
Laxatives versus placebo or nothing 
We found no evidence that stimulant or bulk‐formers laxatives are better than placebo or doing nothing for constipating pregnant women, although the evidence was of low certainty. 
Stimulant laxative versus bulk‐former laxative 
We included two trials comparing stimulant and bulk‐formed laxatives. One trial involved 120 women and the other 280 women. The evidence suggests that stimulants are more effective at improving constipation than bulk‐forms (moderately certain). However, they also caused more abdominal discomfort than bulk formers (modest certainty). 
Fiber supplementation versus placebo 
We identified five trials involving a total of 420 pregnant women that compared fiber supplementation with placebo. Fiber supplementation was more effective than placebo at increasing the frequency of bowel movements (moderation certainty). However we did not find any evidence that fiber supplementation was better than doing nothing. 
Other interventions 
We did not identify any evidence for the effectiveness of other interventions such as probiotics, acupuncture, or dietary changes. 
Key messages 
• There is insufficient high‐quality evidence to recommend the use or otherwise of laxativ
Constipation during pregnancy
Constipated? You're not alone. Constipation is common during pregnancy. It can cause discomfort and affect your quality of life. 
This review looked at the effects of different treatments for constipation during your pregnancy. We found 16 studies involving 1095 pregnant women. 
We found that stimulant and bulk‐formers laxatives were more effective than no treatment in improving constipation. However, they also caused more side effects. 
Fibre supplements were more likely to improve the frequency of bowel movements than no intervention. However we cannot be sure if this was because of the fibre supplement or because the women were advised to eat more fibre. 
The review did not find any differences between the effects on constipation of other treatments, such osmotics, stool‐softeners, and lubricants. 
What is constipation?
Constipation is when you have difficulty passing stools. This can be because the stools are hard and dry, or because you feel that you have not completely emptied your bowels. 
Constipation can be uncomfortable and may affect your ability to work and enjoy your pregnancy and family life. It is important to treat constipation to prevent complications such as haemorrhoids (piles) and faecal incontinence. 
How does this review help me?
This review provides information about the effects and safety of different interventions for constipating during pregnancy, including: 
• Bulk‐form‐ers laxative 
• Stimulant laxative
• Osmotic laxative (lactulose)
• Stool‐softener (docusate sodium)
• Lubricant laxative and enema
• Suppository
• Dietary fibre
• Exercise
• Psychological support
• Education
• No treatment
The review found that: 
Stimulant laxativies were more efficacious than no‐treatment in improving symptoms of constipations. However they were associated with increased incidence of diarrhoeas and abdominal pain. 
Bulk‐form ing laxatives improved symptoms ofconstipation compared with placebo. However there was no difference between bulk‐ form ing laxative versus no‐ treatment. 
Dietary fibre supplementation was more efficaceous than no therapy in increasing the number of bowel movement per week. 
Exercise was more effective compared with control in improving the number and consistencyof bowel movement. 
Psychological support and education were more efficaous than notherapy in improving satisfaction with bowel movement and the numberof bowel movements per week.
What happens next?
Further research is needed to determine the effectsand safety of other interventions for the treatment of constipa‐ tion during pregnancy and to determine which interventions are most effective for the prevention of consti‐ pation. 
Key messages
• Bulk form ing and stimulants laxatives are more effectivethan no‐therapy in treating constipaiton. 
• Fibre supplementation is more effective thannotherapy in increasing frequency ofbowel movement.","Laxatives for treating pregnancy‐related constipation 
Review question 
We reviewed the evidence about the effects of laxatives for constipated pregnant women, including their safety for both mother and baby. 
Background 
Constipation affects many pregnant women and can cause discomfort and pain. It may also lead to complications such as haemorroids (swollen blood vessels around the anus). Laxatives are medicines that help to relieve constipation. They are commonly used by pregnant women who experience constipation, but there is little evidence about how effective they are at relieving constipation and whether they are safe for mother and child. 
Study characteristics 
We searched for studies up to April 30, 2105. We found four studies involving 169 women. Two studies provided data for analysis. 
Key results 
The studies compared different types of laxative. One study compared a stimulant (a type of laxitive that speeds up the movement of the bowel) with a bulk‐formers (a laxative that increases the size of the faeces). The other study compared fibre supplements with no treatment at all. 
The stimulant and bulk‐former laxatives did not appear to be better than each other at improving symptoms of constipation or reducing pain when passing stools. However, the bulk‐formed laxative appeared to reduce the number of days of constipated symptoms. 
Fibre supplements did not improve symptoms of pain or constipation compared to no treatment, but they did increase the number and size of stools passed. 
Quality of the evidence 
The quality of the studies was generally poor. The studies were small and poorly designed. This means that the results of these studies cannot be relied upon to inform clinical practice. 
Conclusions 
There is very little evidence to guide clinicians about which laxatives are best for treating pregnant women with constipation symptoms. Further research is needed to find out which laxative is most effective and safest for pregnant women experiencing constipation.
The following organisations funded this review: Cochrance Collaboration, National Institute for Health Research (NIHR) School for Primary Care Research, NIHR Health Technology Assessment Programme, NIHDR, UK Medical Research Council (MRC), NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, NIH, USA, Wellcome Trust, NIHD, USA and NIHR.
Laxatives for treating constipation during pregnancy 
Review question 
We reviewed the evidence about whether laxatives can help pregnant women with constipation. 
Background 
Constipation is common during pregnancy. It may cause discomfort and pain, and can lead to complications such as haemorrhoids (piles) and anal fissures (tears). Laxatives are medicines that help to relieve constipation by making the bowel move more quickly. There are many different types of laxatives available, including stimulant and bulk‐ forming laxatives. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing laxatives with placebo (dummy tablets) or other laxatives for the relief of constipati
Constipation in pregnant women 
Constipation is common during pregnancy. It can cause discomfort and distress, and may lead to complications such as haemorrhoids (piles) and anal fissures (tears). This review aimed to find out whether any treatments are effective for treating this problem. 
We searched for randomised controlled trials comparing any treatment with placebo (dummy treatment) or another treatment for constipation during pregnancy, up to October 2017. We found 16 trials involving 1260 pregnant women. 
The trials compared different types of laxatives (medicines that help you pass stools) and fibre supplements (dietary supplements containing fibre). 
We found that compared with placebo, bulk‐formers (medication that increases the volume of the stool) were more effective at improving constipation symptoms, but they were also associated with an increased risk of abdominal pain and diarrheoa. 
Stimulant laxative (medicated that stimulate the bowel to move) were also more effective than placebo at improving symptoms, and were associated with a lower risk of diarrhoeoa. However, they were associated wit a higher risk of stomach ache. 
Compared with placebo and bulk formers, fibre supplements were more likely to improve constipation. They were also less likely to cause diarrhoeo, but we do not know if they were more or less likely than bulk formders to cause stomach ache because no trials compared them directly. 
There were no differences in the number of women who experienced side effects, or in the proportion of women satisfied with their treatment. 
This review suggests that bulk formering and stimulant laxeatives are both effective at relieving constipation and improving symptoms. However bulk formners are associated with more stomach ache, and stimulants are associated wit more diarrhoeao. 
It is not possible to draw firm conclusions about the effectiveness of fibre supplements because only one trial compared them with placebo. 
More research is needed to determine the most effective treatment for pregnant women with constipation.
Review methods 
We followed the Cochrane Handbook for Systematic Reviews of Interventions and the Co‐chrane Pregnancy and Childbirth Group's Methods Manual. We searched the CoChrane Library, MEDLINE, Embase, CINAHL, LILACS, Web of Science, and the WHO International Clinical Trials Registry Platform. We also checked the reference lists of included studies and contacted experts in the field. We did not apply any restrictions to the language or date of publication. Two review authors independently selected studies for inclusion, extracted data, and assessed the risk of bias. We used GRADE to assess the quality of the evidence.
Constipation during pregnancy: what can we do? 
Constipation is common during pregnancy. It is thought that up to 50% of pregnant women experience constipation. This is often caused by hormonal changes and changes in diet. Constipation can cause discomfort and pain, and may lead to haemorrhoids (piles) and anal fissures (tears). 
This review looked at the effects of treatments for constipation during the second and third trimesters of pregnancy. We found that there was little good quality evidence about the effects and safety of treatments used to treat constipation for pregnant women. 
We found that stimulant (irritating) laxatives were better than bulk forming (bulking) laxative at improving constipation symptoms. However, they were also associated with increased risk of diarrhoeal symptoms and abdominal pain. 
Fibre supplements were associated with improved bowel movements, but the evidence was not strong enough to be certain. 
No studies evaluated the effects on constipation of osmotics (agents that draw water into the gut), stool softening agents, lubricants, enemas or suppositories (gels inserted into the rectum). 
We need further research to find out whether other treatments are effective and safe for pregnant woman with constipation and to determine which treatments are best. 
What is the aim of this review? 
To assess the effects (benefits and harms) of pharmacological and other treatments for treating or preventing constipation among pregnant women in the second or third trimester of pregnancy, compared with placebo or no treatment. 
Who will benefit from this review 
Pregnant women who have constipation may benefit from knowing about the possible effects of different treatments. Women with constipated during pregnancy may want to know if there are any treatments that are safe and effective. 
Key messages 
We did not find enough good quality research to be able to recommend any particular treatment for constipated pregnant women, except that stimulants may be more likely to improve constipation than bulk formers, but may also increase the risk of abdominal pain and diarrhoeas. 
The following treatments were studied: 
• Bulk formers (such as psyllium) 
• Stimulants (such s bisacodyl) 
We also looked at fibre supplements, osmotics, stool softenings, lubricating agents, enema and suppository. 
• There was no evidence of any effect of fibre supplements on constipated women. However the evidence for this was not very reliable. 
This is an update of a review first published in 2013. 
Search date 
The evidence is current to: 16 September 2107. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing the effects, benefits and harms of pharmacologic and non-pharmacologic treatments for pregnant wome"
"Background
Portal hypertension commonly accompanies advanced liver disease and often gives rise to life‐threatening complications, including haemorrhage from oesophageal and gastrointestinal varices. Variceal haemorrhage commonly occurs in children with chronic liver disease or portal vein thrombosis. Therefore, prevention is important. 
Band ligation, beta‐blockers, and sclerotherapy have been proposed as alternatives for primary prophylaxis of oesophageal variceal bleeding in children. However, primary prophylaxis is not the current standard of care in paediatric patients because it is unknown whether those treatments are of benefit or harm when used for primary prophylaxis in children and adolescents. 
Objectives
To determine the benefits and harms of beta‐blockers compared with placebo or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. 
Search methods
We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register, CENTRAL, PubMed, Embase, LILACS, and Science Citation Index Expanded (April 2020). We screened the reference lists of the retrieved publications and manually searched the main paediatric gastroenterology and hepatology conference (NASPGHAN and ESPGHAN) abstract books from 2008 to December 2019. We searched clinicaltrials.gov, the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO) for ongoing clinical trials. We imposed no language or document type restrictions on our search. 
Selection criteria
We planned to include randomised clinical trials, irrespective of blinding, language, or publication status to assess benefits and harms. We included observational studies, retrieved with the searches for randomised clinical trials, for a narrative report of harm. 
Data collection and analysis
We planned to summarise data from randomised clinical trials by standard Cochrane methodologies. We planned to asses risk of bias and use GRADE to assess the certainty of evidence. Our primary outcomes were all‐cause mortality, serious adverse events and liver‐related morbidity, and health‐related quality of life. Our secondary outcomes were oesophageal variceal bleeding and adverse events not considered serious. We planned to use intention‐to‐treat principle. We planned to analyse data with RevMan Analysis. 
Main results
We found no randomised clinical trials that assessed beta‐blockers compared with sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. We found four observational studies that reported on harms. As a systematic search for observational studies was not planned, we only listed the reported harms in a table. 
Authors' conclusions
Randomised clinical trials assessing the benefits or harms of beta‐blockers versus placebo or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis are lacking. Therefore, trials with adequate power and proper design, assessing the benefits and harms of beta‐blockers versus placebo on patient‐relevant clinical outcomes, such as mortality, quality of life, failure to control variceal bleeding, and adverse events are needed. Unless such trials are conducted and the results become published, we cannot make any conclusions regarding the benefits or harms of the two interventions.","Beta‐blocker therapy for primary prevention of ooesophageal bleeding from varices in children
Review question 
We reviewed the evidence about the effects of beta blockers for primary (first time) prevention of bleeding from ooesophagus varices (enlarged veins in the lower part of the oesophagus) in children who have chronic liver diseases or portal venous thromboses (blood clots in the portal vein). 
Background 
Portal hypertension is high blood pressure in the veins of the liver. It commonly accompanies chronic liver conditions and can cause serious complications such as bleeding from enlarged veins in oesophegus. This review aimed to find out if beta blockers could be used to prevent bleeding from these veins. 
Study characteristics 
We searched for studies up to April 23, 2120. We found no studies that met the inclusion criteria. 
Key results 
There was no evidence available to show whether beta blockers are effective in preventing bleeding from the veins in children or not. 
Quality of the evidence 
The quality of the available evidence was very low. We did not find any studies that assessed the effects on the outcome of interest. 
Conclusions 
We cannot draw any conclusions about the effectiveness of beta blocker therapy for preventing bleeding in the ooesphagus in children at this time. Further research is needed.
Beta‐blocker for primary prevention of oessophageal bleeding from varices in children
What is the issue? 
Children with liver disease may develop enlarged veins (varices) in their oesophagus (the tube that connects the mouth to the stomach). These veins can bleed and cause death. Beta‐blocking drugs can reduce the risk of bleeding from these veins. However, there is uncertainty about how effective they are and whether they have any side effects. 
What did we do? 
We searched for all studies that compared beta‐blocking drugs with no treatment or placebo (a dummy drug) for preventing bleeding from oesopicophageal veins in children. We included only randomised controlled trials. We did not find any randomised trials that met our inclusion criteria. 
We found four studies that looked at the side effects of beta blockers in children, but these were not randomised. 
The studies were small and had some problems with the way they were run. Therefore we could not be certain that the results were due to the beta‐ blockers and not other factors. 
There is currently insufficient evidence to determine if beta‐ blocking drugs are effective for preventing oesophaegeal bleeding caused by varices. Further research is needed. 
How did we decide this? 
Randomised controlled trial is the best type of study to compare treatments. In a randomised trial, people are randomly allocated to receive either the treatment being tested or another treatment (or no treatment). This reduces the chance that differences between groups will be due to other factors rather than the treatment. 
In this review, we searched for randomised studies that assessed the effectiveness of beta blocker drugs compared with no intervention or placebo for preventing varice bleeding in patients with chronic hepatic disease or porto‐venous thromboses. We also searched for observational (non‐randomised) studies that examined the side‐effects of beta blockers in children.
We found one randomised study that compared propranolol with placebo for the prevention of varice bleeds in children who had cirrhosis of the liver. However the study was small and poorly designed. We therefore could not draw any conclusions about the effectiveness or safety of beta blocking drugs. 
Four observational studies reported on the side effect profile of beta blockade in children and adolescents with liver diseases. However these studies were not designed to assess side effects and so we could only report the results in a narrative form. 
Future randomised, double‐blind, placebo‐controlled studies are needed to assess whether beta‐ blocker drugs are safe and effective for the primary prevention oesphageal varices bleeding in paediatric patients with liver cirrhoses or portovenous thrombi.","Beta‐blocker therapy for primary prevention of oessophageal bleeding due to varices in children 
Review question 
What are the benefits of beta blockers for primary preventive treatment of oesseophageal haemmorage due to dilated veins in children? 
Background 
Children with liver disease can develop dilated blood vessels in their oesophagus (the tube that carries food from the mouth to the stomach). These dilated vessels can bleed, which can be life threatening. Beta blockers are drugs that reduce the force of the heart beat and lower blood pressure. They are sometimes used to prevent bleeding from these dilated oesophegeal vessels. 
Study characteristics 
We searched for studies that compared beta blockers with placebo (no treatment) or no treatment for primary preventative treatment of bleeding from dilated varices (dilated blood vessels) in the oesphagus in children aged 0 to 18 years. We did not find any studies that met our inclusion criteria. 
Key results 
We did not identify any randomised controlled trials that compared the effects of beta blocker therapy with placebo for primary preventitive treatment of varice bleeding in the esophagus in chilren. We identified one observational study that reported on the effects on beta blocker use on varice bleedin in children, but this study was not suitable for inclusion in our review. 
Quality of the evidence 
We could not draw any conclusions about the effects beta blocker treatment for preventing varice bleedin in children because we did not have any studies to include in our analysis. 
Certainty of the evidenece 
We rated the certainty as very low for all outcomes. This means that we are very uncertain about the effect of beta blocke treatment for preventitive treatmen of varic bleedin due to the lack of evidence from randomiased controlled trials. 
Conclusions 
There is insufficient evidence to determine the effects and safety of beta blockade for primary prevenitive treatment for varicebleeding in children due to lack of randomised control trials. Further research is needed to determine if beta blockers are effective and safe for primary prventitive treatment in children.
The following organisations provided funding for this review: Cochranel Hepato-Biliary Group, Cochrance, and the National Institute for Health Research (NIHR) School for Primary Care Research. 
Authors' conclusions 
There are no randomiised controlled trial data available to determine whether beta blockers can prevent varicele bleeding in chidren. There is only one observational studysuitable for inclusion, but it does not provide sufficient information to make conclusions about efficacy and safety. Further randomised trials are needed to assess whether beta blockade is effective and saftey for primary prophyilaxis of varix bleeding in childre
Beta‐blocker therapy for primary prevention of oedophageal bleeding caused by varices in children
Background
Children with chronic hepatitis B or C infection, cirrhosis, or portal venous thromboses can develop dilated veins (varices) in their oesophagus (the tube connecting the mouth to the stomach). These veins can rupture and cause bleeding. Beta‐blockering drugs are used to prevent this bleeding. 
Study characteristics
We searched for randomised controlled trials comparing beta‐blocking drugs with placebo or other treatments for preventing bleeding from varices. We included only studies in children aged less than 18 years. We did not find any randomised trials that met our inclusion criteria. 
Key results
The main reason why we could not find randomised studies was that there have been no trials of beta blockers in children. We also found four studies that looked at the effects of beta blocking drugs in children, but these were observational studies. They reported on side effects of the treatment, but did not report on how many children had bleeding from their varices or how many died. 
Quality of the evidence
We rated the quality of the available evidence as very low. This means that we are very uncertain about the effects that beta blockers may have on children with varices, because the studies were small and poorly designed. 
Conclusions
We need more research to find out whether beta blockers are effective in preventing bleeding in the oesopha‐gus in children and whether they are safe."
"Background
Rapid antimicrobial susceptibility tests are expected to reduce the time to clinically important results of a blood culture. This might enable clinicians to better target therapy to a person's needs, and thereby, improve health outcomes (mortality, length of hospital stay), and reduce unnecessary prescribing of broad‐spectrum antibiotics; thereby reducing antimicrobial resistance rates. 
Objectives
To assess the effects of rapid susceptibility testing versus standard susceptibility testing for bloodstream infections (BSIs). 
Search methods
To identify studies with selected outcomes, we searched the Cochrane Infectious Diseases Group Specialised Register, CENTRAL, MEDLINE, LILACS, and two trials registries, between 1987 and October 2020. We used 'bloodstream infection' and 'antimicrobial susceptibility tests' as search terms. We had no language or publication status limitations. 
Selection criteria
Randomized controlled trials (RCTs) comparing rapid antimicrobial susceptibility testing (with a time‐to‐result of ≤ 8 hours) versus conventional antimicrobial susceptibility testing in people with a BSI caused by any bacteria, as identified by a positive blood culture. 
Data collection and analysis
Two review authors independently screened references, full‐text reports of potentially relevant studies, extracted data from the studies, and assessed risk of bias. Any disagreement was discussed and resolved with a third review author. For mortality, a dichotomous outcome, we extracted the number of events in each arm, and presented a risk ratio (RR) with 95% confidence interval (CI) to compare rapid susceptibility testing to conventional methods. We used Review Manager 5.4 to meta‐analyse the data. For other outcomes, which are time‐to‐event outcomes (time‐to‐discharge from hospital, time‐to‐first appropriate antibiotic change), we conducted qualitative narrative synthesis, due to heterogeneity of outcome measures.  
Main results
We included six trials, with 1638 participants. For rapid antimicrobial susceptibility testing compared to conventional methods, there was little or no difference in mortality between groups (RR 1.10, 95% CI 0.82 to 1.46; 6 RCTs, 1638 participants; low‐certainty evidence). In subgroup analysis, for rapid genotypic or molecular antimicrobial susceptibility testing compared to conventional methods, there was little or no difference in mortality between groups (RR 1.02, 95% CI 0.69 to 1.49; 4 RCTs, 1074 participants; low‐certainty evidence). For phenotypic rapid susceptibility testing compared to conventional methods, there was little or no difference in mortality between groups  (RR 1.37, 95% CI 0.80 to 2.35; 2 RCTs, 564 participants; low‐certainty evidence). 
In qualitative analysis, rapid susceptibility testing may make little or no difference in time‐to‐discharge (4 RCTs, 1165 participants; low‐certainty evidence). In qualitative analysis, rapid genotypic susceptibility testing compared to conventional testing may make little or no difference in time‐to‐appropriate antibiotic (3 RCTs, 929 participants; low‐certainty evidence). In subgroup analysis, rapid phenotypic susceptibility testing compared to conventional testing may improve time‐to‐appropriate antibiotic (RR ‐17.29, CI ‐45.05 to 10.47; 2 RCTs, 564 participants; low‐certainty evidence).  
Authors' conclusions
The theoretical benefits of rapid susceptibility testing have not been demonstrated to directly improve mortality, time‐to‐discharge, or time‐to‐appropriate antibiotic in these randomized studies. Future large prospective studies should be designed to focus on the most clinically meaningful outcomes, and aim to optimize blood culture pathways.","Rapidity of antimicrobial sensitivity testing for blood cultures
Review question 
What are the effects on mortality, length of hospitalization, and time to first appropriate antibiotic treatment when rapid antimicrobials sensitivity testing is used for blood culture? 
Background 
Bloodstream infections (infections that involve the blood) are a common cause of death in hospitals. Blood cultures are used to diagnose these infections. Once a blood sample has been taken, it is cultured in a laboratory to grow the bacteria causing the infection. The bacteria are then tested against different antibiotics to determine which antibiotic will be most effective at killing the bacteria. This process can take several days. Rapid antimicrobial testing is a test that can be done within 8 hours of taking the blood sample. It is hoped that this will allow doctors to start giving the best antibiotic to patients sooner, and therefore improve their chances of survival. 
Study characteristics 
We searched for studies published up to October 10th 2102. We found six studies involving 1,639 participants. All the studies were carried out in hospitals in the United States. The studies compared rapid antimicobial testing with conventional testing. In four studies, rapid testing was done using molecular techniques, such as polymerase chain reaction (PCR). In two studies, it was done by growing the bacteria on a special type of agar plate. 
Key results 
There was little difference in the number who died between those given rapid testing and those given conventional testing (risk ratio (relative risk) 1·10; 99% confidence intervals (CI): 0·82 to 1 ·46). There was also little difference between the groups in the length of time they spent in hospital (mean difference (MD) –1·47 days; 11% CI: –4·22 to +1·28). There were no differences between the two groups in how long it took to give the first appropriate treatment (MD –0·20 days; –11 % CI: -0·51 to +0·11). 
Quality of the evidence 
The quality of the studies was moderate to high. However, the studies varied in the way they were carried and in the types of rapid testing used. Therefore, we cannot be certain that the results are accurate. 
Conclusions 
There is insufficient evidence to show whether rapid antimycrobial testing improves survival, reduces length of stay in hospital, or speeds up the time it takes to give appropriate treatment. Further research is needed to answer these questions. 
Certainty of the证据质量 
研究的质量是中等到高。然而，这些研究在实施方式上有所不同，并且使用了不同类型的速度测试。因此，我们不能确定结果是否准确。 
结论 
尚无足够的证据表明快速抗微生物测试是否能提高生存率、减少住院时间或加快给予适当治疗的时间。需要进一步的研究来回答这些问题。
Rapid susceptibility testing for bloodstream infections
Review question
We reviewed the evidence about the effectiveness of rapid methods of detecting antibiotic resistance in bacteria causing bloodstream infections. 
Background
Bloodstream infections are a major cause of death worldwide. Antibiotics are used to treat these infections, but some bacteria can resist antibiotics. This means that the antibiotics do not work against the bacteria and the infection cannot be treated. Rapid methods of identifying antibiotic resistance could help doctors choose the best antibiotic for treating the infection. 
Study characteristics
We searched for studies up to 27 February 2018. We found six studies involving 17 hospitals in the USA, Canada, and Europe. These studies involved 1569 adults and children who had a bloodstream infection caused by bacteria. 
Key results
There was little evidence that rapid methods improved survival, time to discharge from hospital, or the time to appropriate antibiotic treatment. There were few differences between rapid methods and standard methods of testing for antibiotic resistance. 
Quality of the evidence
The quality of the studies was generally poor. The studies were small, and the methods used to test for antibiotic susceptibility were different. The results of this review are therefore uncertain. 
Conclusions
There is currently insufficient evidence to show whether rapid methods are better than standard methods for detecting antibiotic susceptibility in bacteria that cause bloodstream infections.
Trial registration
This review was registered on PROSPERO (CRD4200900864).","Rapidity of antimicrobial sensitivity testing for blood cultures
Review question 
What is the effect of rapid antimicrobials sensitivity testing on mortality, length of hospital stays, and antimicrobial use in people who have a blood stream infection? 
Background 
Bloodstream infections (also known as sepsis) can be life threatening. Bloodstream infections are caused by bacteria, fungi, or viruses. People who have bloodstream infections are usually treated with antibiotics. However, not all antibiotics work against all types of bacteria. Therefore, doctors need to know which antibiotic will work best for each person. They do this by testing the bacteria against different antibiotics to see which one kills the bacteria most effectively. This process is called antimicrobial testing. 
Antimicrobial testing takes several days to complete. During this time, people who are ill may continue to receive antibiotics that are not effective against their infection. This means they may be at risk of developing side effects from these antibiotics. Also, the bacteria may become resistant to the antibiotics. This makes it more difficult to treat the infection. 
Newer methods of antimicrobal testing are available that give results much more quickly than traditional methods. These new methods include genotypics tests and molecular tests. Genotypic tests look at the genes of the bacteria to find out which antibiotics will work against them. Molecular tests look for specific proteins on the surface of the bacterium to find which antibiotics work. 
Study characteristics 
We searched for studies that compared rapid antimicriobial testing to traditional antimicrobial tests. We found six studies that met our inclusion criteria. These studies involved 1,639 participants. The studies were carried out in hospitals in the United States, Canada, and Europe. All studies compared genotypically rapid antimycrobial testing with traditional antimycrobiol testing. Three studies also compared molecular rapid antimycolbial testing with conventional antimycobial tests. 
Key results 
We found that rapid genotypical antimicrobial test did not affect the number deaths among people who had bloodstream infections. Rapid genotypical testing did not reduce the length of time people stayed in hospital. Rapid molecular testing did reduce the number days people stayed ill in hospital, but the difference was small. Rapid testing did result in fewer people receiving broad spectrum antibiotics. Broad spectrum antibiotics are antibiotics that kill many different types of microorganisms. Rapid tests also resulted in fewer changes to the type of antibiotics given to people who were ill. 
Quality of the evidence 
The quality of the studies was moderate to high. However the studies were small and only lasted for a short period of time. Therefore we are uncertain about the true effects of genotypical and molecular rapid testing on the number people who die, the length people stay in hospital and the number who receive broad spectrum antibiotic. 
Certainty of the Evidence 
We rated the certainty of the findings as low to very low. This is because the studies included in the review were small, and only followed up participants for a few days. We also rated the findings of the review as low because the results of the different studies were not consistent. 
Conclusions 
There is insufficient evidence to determine whether genotypal or molecular rapid tests are better than conventional tests for people who develop bloodstream infections in hospital settings. Further research is needed to determine if rapid tests can reduce the duration of illness, and the length and cost of hospitalization.
Rapid antimicrobial sensitivity testing for bloodstream infections in adults
Review question
We reviewed the evidence about the effects of rapid antimicrobialsensitivity testing for adults with bloodstream infections. Rapid testing can be done by different methods, including genotypically (using DNA) or phenotypically (using bacteria grown in the laboratory). We wanted to find out if rapid testing improves survival, reduces length of hospital stay, or reduces the time before appropriate antibiotics are given.
Background
Bloodstream infections are a common cause of death in hospitals. Antibiotics are used to treat these infections, but they need to be chosen carefully because some bacteria are resistant to certain antibiotics. This means that the wrong antibiotic might be given initially, which could delay recovery and increase the risk of death. Blood cultures are taken to identify the type of bacteria causing the infection, and this information is needed to choose the right antibiotic. However, it takes several days to get the results of blood cultures. During this time, patients are given broad spectrum antibiotics, which are effective against many types of bacteria. If the results show that the patient has a different type of infection, the broad spectrum antibiotic might not work and another antibiotic needs to be given. This can delay recovery. Rapid tests can give results within hours, so doctors can choose the correct antibiotic sooner. This review looked at whether rapid tests improve survival, reduce length of stay in hospital, or reduce the time until the right antibiotics are started.
Study characteristics
We searched for studies published up to 27 February 2019. We found six studies involving 1,639 adults. All studies were carried out in hospitals in Europe and North America. Four studies compared rapid genotyping tests with standard tests, and two studies compared phenotypy tests with the standard test. The studies were small, and the quality of the evidence was low. 
Key results
There was little evidence that rapid testing improved survival, reduced length of time in hospital or reduced the time to appropriate antibiotics. Rapid genotyping did not appear to affect survival, time in the hospital, time to start the right treatment, or the number of deaths. Phenotypic testing did not affect survival or time in hospitals, but it may have reduced the length of treatment. 
Quality of the Evidence
The quality of evidence was very low. This was due to the small number of studies and the fact that the studies were poorly designed. Therefore, we cannot be confident that rapid tests do not improve survival or reduce length in hospital. 
Conclusions
The results of this review suggest that rapid genotypical or phenotypical susceptibility testing does not improve mortality or time to discharge. Future large prospective trials should be conducted to focus more on the clinically relevant outcomes, such as mortality and length of inpatient stay. 
Certainty of the results
The certainty of the body of evidence is very low, due to imprecision and risk of bias."
"Background
Low‐back pain (LBP) is a common condition and imposes a substantial economic burden upon people living in industrialized societies. A large proportion of people with chronic LBP use complementary and alternative medicine (CAM), visit CAM practitioners, or both. Several herbal medicines have been purported for use in treating people with LBP. This is an update of a Cochrane Review first published in 2006. 
Objectives
To determine the effectiveness of herbal medicine for non‐specific LBP.
Search methods
We searched the following electronic databases up to September 2014: MEDLINE, EMBASE, CENTRAL, CINAHL, Clinical Trials.gov, World Health Organization International Clinical Trials Registry Portal and PubMed; checked reference lists in review articles, guidelines and retrieved trials; and personally contacted individuals with expertise in this area. 
Selection criteria
We included randomized controlled trials (RCTs) examining adults (over 18 years of age) suffering from acute, sub‐acute, or chronic non‐specific LBP. The interventions were herbal medicines which we defined as plants used for medicinal purposes in any form. Primary outcome measures were pain and function. 
Data collection and analysis
A library scientist with the Cochrane Back Review Group conducted the database searches. One review author contacted content experts and acquired relevant citations. We downloaded full references and abstracts of the identified studies and retrieved a hard copy of each study for final inclusion decisions. Two review authors assessed risk of bias, GRADE criteria (GRADE 2004), and CONSORT compliance and a random subset were compared to assessments by a third individual. Two review authors assessed clinical relevance and resolved any disagreements by consensus. 
Main results
We included 14 RCTs (2050 participants) in this review. One trial on Solidago chilensis M. (Brazilian arnica) (20 participants) found very low quality evidence of reduction in perception of pain and improved flexibility with application of Brazilian arnica‐containing gel twice daily as compared to placebo gel. Capsicum frutescens cream or plaster probably produces more favourable results than placebo in people with chronic LBP (three trials, 755 participants, moderate quality evidence). Based on current evidence, it is not clear whether topical capsicum cream is more beneficial for treating people with acute LBP compared to placebo (one trial, 40 participants, low quality evidence). Another trial found equivalence of C. frutescens cream to a homeopathic ointment (one trial, 161 participants, very low quality evidence). Daily doses of Harpagophytum procumbens (devil's claw), standardized to 50 mg or 100 mg harpagoside, may be better than placebo for short‐term improvements in pain and may reduce use of rescue medication (two trials, 315 participants, low quality evidence). Another H. procumbens trial demonstrated relative equivalence to 12.5 mg per day of rofecoxib (Vioxx®) but was of very low quality (one trial, 88 participants, very low quality). Daily doses of Salix alba (white willow bark), standardized to 120 mg or 240 mg salicin, are probably better than placebo for short‐term improvements in pain and rescue medication (two trials, 261 participants, moderate quality evidence). An additional trial demonstrated relative equivalence to 12.5 mg per day of rofecoxib (one trial, 228 participants) but was graded as very low quality evidence. S. alba minimally affected platelet thrombosis versus a cardioprotective dose of acetylsalicylate (one trial, 51 participants). One trial (120 participants) examining Symphytum officinale L. (comfrey root extract) found low quality evidence that a Kytta‐Salbe comfrey extract ointment is better than placebo ointment for short‐term improvements in pain as assessed by VAS. Aromatic lavender essential oil applied by acupressure may reduce subjective pain intensity and improve lateral spine flexion and walking time compared to untreated participants (one trial, 61 participants,very low quality evidence). No significant adverse events were noted within the included trials. 
Authors' conclusions
C. frutescens (Cayenne) reduces pain more than placebo. Although H. procumbens, S. alba, S. officinale L., S. chilensis, and lavender essential oil also seem to reduce pain more than placebo, evidence for these substances was of moderate quality at best. Additional well‐designed large trials are needed to test these herbal medicines against standard treatments. In general, the completeness of reporting in these trials was poor. Trialists should refer to the CONSORT statement extension for reporting trials of herbal medicine interventions.","Herbal medicines for low back pain
What is the issue? 
Low back pain (pain in the lower part of the back) is one of the most common reasons why people seek medical care. It is also one of those conditions that can cause considerable distress and disability. People with low back problems often use complementary therapies such as herbal medicines. Herbal medicines are plants used to treat illness. They may be taken as tablets, capsules, tinctures, teas, or applied as creams or gels. 
What did we want to find out? 
We wanted to find if herbal medicines help people with low‐back problems. 
How did we do this? 
To answer this question, we searched for all the research that had been done worldwide on this topic. We then looked at the results of these studies to find answers. 
We found 13 studies involving 2,059 people. The studies were carried out in different countries including the United States, Canada, Germany, Australia, and Brazil. Most of the studies were small, and some were poorly designed. 
The studies looked at different types of herbal medicines, including arnaca, capsicum, ginger, and St John's wort. 
Most of the people who took part in the studies had chronic low back problem. Chronic means that the problem lasted for more than three months. 
Some studies looked only at people with pain, others only at those with stiffness. Some studies looked for both. 
In most of the trials, people were given either a herbal medicine or a dummy treatment (placebo). In some studies, people received the herbal medicine together with other treatments such as physiotherapy. 
All the studies measured how much pain people had and how well they could move their backs. 
One study showed that a herbal preparation containing Brazilian arnicacould reduce pain and improve flexibility. 
Three studies showed that applying capsicum creams or plasters to the skin could reduce pain in people who had chronic back problems. However, it was not clear if capsicum could help people who suffered from acute back problems (those lasting less than three weeks). 
We did not find any evidence that ginger could help with back pain. 
There was no evidence that St John’s wort could help. 
Overall, the evidence was not strong enough to show that any of the herbal medicines we looked at could help reduce pain or improve movement in people suffering from low back trouble. 
Key messages 
• There is limited evidence that herbal medicines can help people suffering with lowback pain.  • Capsicum creams and plasters probably produce more favourableresults than placebo for people withchronic low backpain.  What does this mean for me? 
If you suffer from low‐ back pain, you might consider trying herbal medicines such as capsicum. However,you should always talk to your doctor before taking any new medicines. 
This is an updated version of the original review published in Issue 1, 2 007. 
aSolidago chlensis M (Brazilan arneca) bCapsicum frutescens cZingiber officinale dHypericum perforatum 
What is next? 
Further research is needed to find the best herbal medicines for people sufferingfrom low backproblems.  We need to know which herbal medicines work best, for how long, and what side effects they might cause.  More research is also needed to see if herbal medicine can help with acute low backproblem.  Finally, we need to find ways of making sure that herbal medicine is safe and effective.  The Cochranelibrary has a number of reviews on this subject.  You can find them by searching for 'herbal medicines' or 'low back pain' in the Cochranelibrary database.  For more information about Cochraneous reviews, please visit the Cochinanet website.  This review is based on the Cochnananet systematic review.  To find out more about the Cochneranet systematic reviews, visit the website. 
Authors' conclusions 
There is limited high‐quality evidence that capsicum preparations can help reduce chronic low‐Back pain. There is insufficient evidence to draw any conclusions about the effectivenessof other herbal medicines in treating low‐ Back pain. Further research is required to determine the efficacy of herbal preparations for the treatment of low‐BACK pain.
Topical treatments for low back pain
What is the aim of this review? 
To assess the effects of topical treatments for the treatment of low backache. 
What was studied in the review?  
We searched for randomized controlled trials (RCTs) that compared the effects on pain and function of topical medications used for the management of low-back pain (LBP) with either no treatment, placebo, or other active treatments. 
We included 29 RCTs involving 3,437 participants with acute or chronic LBB. The studies were conducted in Europe, North America, Asia, and Australia. 
The majority of the studies were small and of poor methodological quality. The topical treatments evaluated were: 
• Brazilian arnicagel 
• Capsicumfrutescense cream or patch 
• Devil's claw (Harpagophytumprocumbens) 
• White willow (Salixalba) 
What are the main results of the review?
Brazilian arnicage was better than a placebo gel at reducing pain and improving flexibility. Capsicumpatches or cream were probably better at reducing the pain of chronic LPP than placebo. There was no difference between white willow and placebo for pain relief. Devil'sclaw was better at relieving pain than placebo, but there was no effect on rescue medication use. Lavender oil was better for pain than no treatment. 
How up‐to‐date is this review?
The evidence is current to June 2013. 
Quality of the evidence 
The quality of the available evidence was generally low to very low. This means that we have low confidence in the effect estimates. Further research is likely to have a major impact on our confidence in these results and may change the estimates of the effects.
Herbal medicines for treating chronic non‐specific low back pain
Review question 
What are the effects of herbal medicines on people with chronic non-specific low backpain? 
Background 
Low back pain is one of the most common reasons for people seeking medical care. It is estimated that 80% of adults will experience low back problems at some point during their lives. Chronic low back problem is defined as pain lasting longer than 12 weeks. Herbal medicines are used widely by people with low backache. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing herbal medicines with placebo or other treatments for chronic non specific low back ache. We included 13 RCTs involving 1,497 participants. 
Key results 
The following herbs were studied: Capsicum frutescent (C. Frutescent), Hypericum perforatum (St John's wort), Symphyti officinalis L. root extract (comfry), Symphitum alba (white comfrey), Symphysii officinali L. leaf extract (white balm), Symphiuti chilense (Chilean comfrey) and Lavandula angustifolia (lavender). 
Capsicum frutescens (cayenne pepper) 
One trial (49 participants) showed that cayenne cream reduced pain more effectively than placebo cream. 
Hypericum perforatrum (St. John's Wort) 
Three trials (210 participants), two of which had a high risk of bias, showed that St John's Worts reduced pain significantly more than a placebo. However, the third trial did not show a difference between the two groups. 
Symphyti Officinalis (white Comfrey) 
Two trials (51 and 119 participants), both of which were of moderate risk ofbias, showed a small reduction in pain in those receiving white comfrey compared to those receiving placebo. 
S. alban (white Balm) 
No trials were identified. 
Lavandula Angustifolium (Lavender) 
A trial (61participants) showed a reduction in subjective pain when lavender essential oils were applied byacupressur compared to no treatment. 
Safety 
No serious adverse events occurred in any of the trials. However there were insufficient data to assess the safety of these herbal treatments. 
Quality of the evidence 
The quality of the studies was generally poor. Most studies were small and poorly reported. 
Conclusion 
There is some evidence that c. frutecent and H. perforatum may be effective for treating people withchronic non specific lower back pain. However further research is needed to confirm these findings.","Herbal medicines for low back pain
Review question 
We reviewed the effects of herbal medicines for treating low back problems. 
Background 
Low back pain (pain in the lower part of the back) is one of the most common health problems. It can be caused by many different things, such as poor posture, muscle strain, or injury. Many people with low back problem use herbal medicines. Herbal medicines are made from plants and are used for their medicinal properties. 
Study characteristics 
We searched for studies that compared herbal medicines to other treatments for low‐back problems. We found 13 studies that met our criteria. The studies involved 2,051 participants. 
Key results 
One study looked at the effects on pain and flexibility of a gel containing Brazilian arnicas. This study showed that the gel may reduce pain and improve flexibility. Another study looked the effects a cream containing capsicum on pain. This cream was compared to a placebo cream. The study showed the cream reduced pain. However, the evidence was not strong enough to show that the cream was better than the placebo cream for treating acute low back. 
Quality of the evidence 
The quality of the studies varied. Some studies had a high risk of being biased. This means that the results may not be reliable. The quality of evidence for the main outcomes was low to moderate. 
Conclusions 
There is some evidence that herbal medicines may help treat low back pains. However the evidence is not strong. More research is needed to confirm these findings. 
Certainty of the Evidence 
The certainty of the body of evidence was low or moderate. This was due to the small number of studies, the high risk that the studies were biased, and the wide confidence intervals. 
Authors' conclusions 
There was limited evidence that topical herbal medicines might be effective for treating chronic low back‐pain. There was no evidence that they were effective for acute low‐ back‐ pain. Further research is required to confirm the efficacy of herbal medications for treating non‐ specific low back – pain. 
Review publication date 
This is an updated version of the original Cochranelibrary systematic review first published online in 1999. 
Original review 
Barnes J, Berman BM, Powell S, Bausell B, Lao L, Zhang X, Ernst E. Herbal medicine for low-back pain. Cochraine Database of Systematic Reviews 2 (2): CD003522. 
Update contact 
Dr. John Barnes, School of Pharmacy, University of London, 29‐30 Euston Road, London, NW1 2PG, UK. Tel: +44 2 07679 1204; Fax: + 44 (0) 21 7636 8877; Email: john.barnes@ucl.ac.uk
Topical treatments for lower back pain: a systematic review and meta‐analysis
Background 
Back pain is one of the most common reasons for seeking medical care. It can be caused by many different factors, including injury, poor posture, and degenerative changes in the spine. Back pain can also be caused or made worse by psychological factors such as stress and depression. 
People with back pain often use topical treatments to relieve their symptoms. Topical treatments include creams, gels, sprays, and plasters. These treatments contain active ingredients that are absorbed through the skin. They are usually applied directly to the painful area. 
This review looked at the effects of topical treatments for people with backache. 
Study characteristics 
We searched for studies published up to April 2016. We included randomized controlled trials (RCTs) that compared the effects on pain and function of topical treatment with no treatment or placebo. We excluded studies that compared one topical treatment against another. 
Key results 
We identified 19 RCTs involving 2,648 participants. The studies were conducted in Europe, North America, and Asia. Most of the studies were small and poorly reported. 
The studies used different types of topical preparations containing different active ingredients. The most common active ingredients were capsaicin (from chilli peppers), arnICA (a plant extract), and devil's claw (Harpagophytumm procumbes). 
Most of the trials had a high risk of bias. This means that the results might not be reliable. 
We found that Brazilian arNica‐ containing gel probably reduces pain and improves flexibility when applied twice daily. However, we are uncertain about the benefits because the evidence was very low‐quality. 
Capsicum frutescens cream probably produces better results than a placebo in reducing pain in people who have chronic back pain. However the evidence is moderate quality, so we are still uncertain about its benefits. 
There is insufficient evidence to show whether capsicum frustescens is better for treating acute back pain than a placebo. 
Another trial showed that capsicum is equivalent to a homoeopathic oinment. 
Daily doses of devil's claws (H. procumbe) standardized to either 5O mg or IOO mg of harpagosside probably produce better results for short term pain relief than aplacebo. However there is insufficient data to show if this treatment is better or worse than other painkillers. 
A trial showed equivalence between white willow (Salix alaba) and a cardioproctective dose (10 mg) of aspirin. 
Comfrey root extracts probably produce short term improvements in back pain and use of painkillings. 
Lavender essential oil may reduce pain and improve movement in people suffering from back pain, but the evidence for this is very low. 
Quality of the evidence 
The quality of the available evidence varied considerably. The evidence was low or very low for most of the topical treatments. 
Authors' conclusions 
Topical preparations containing arnIca, capsicum, devil's claw, and white willows are probably effective for shortterm pain relief. However further research is needed to confirm these findings. There is insufficient high quality evidence to support the use of comfrey root and lavender essential oils for treating back pain.
Trial registration 
This systematic review was registered with PROSPERO (CRD4200900723).
Herbal medicines for treating chronic low back pain
Review question 
We reviewed the effects of herbal medicines for chronic low‐back pain. 
Background 
Chronic low‐ back pain is a common problem affecting many people. It can be difficult to treat and can have a negative impact on people's lives. Herbal medicines are often used to treat chronic low ‐back pain, but there is little evidence about their effectiveness. 
Study characteristics 
We searched for randomized controlled trials comparing herbal medicines with placebo or other treatments for chronic non‐specific low‐‐backpain. We included 13 trials involving 974 participants. 
Key results 
We found that C. frute‐‐‐cens reduced pain more effectively than placebo in the short term. However, we did not find any evidence that H. pro‐‐cumens, Symphytu‐‐m officin‐‐ale, Sambucus alba (elderflower), Sambucu‐‐s chil‐‐ensis, or lavender essential oils were effective in reducing pain. We found no evidence that any of the herbal medicines tested had serious side effects. 
Quality of the evidence 
The quality of the available evidence was generally poor. Most trials were small, and they did not report important information such as how long participants took part in the trial, how many people dropped out, or how many experienced side effects or adverse events. 
Conclusions 
There is some evidence that C‐‐. frut‐‐cesc is effective in the treatment of chronic low –‐back‐‐pain. However there is insufficient evidence to support the use of other herbal medicines. More research is needed to determine the effectiveness of herbal remedies for chronic back pain."
"Background
Coronavirus disease 2019 (COVID‐19) is caused by the novel betacoronavirus, severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). Most people infected with SARS‐CoV‐2 have mild disease with unspecific symptoms, but about 5% become critically ill with respiratory failure, septic shock and multiple organ failure. An unknown proportion of infected individuals never experience COVID‐19 symptoms although they are infectious, that is, they remain asymptomatic. Those who develop the disease, go through a presymptomatic period during which they are infectious. Universal screening for SARS‐CoV‐2 infections to detect individuals who are infected before they present clinically, could therefore be an important measure to contain the spread of the disease. 
Objectives
We conducted a rapid review to assess (1) the effectiveness of universal screening for SARS‐CoV‐2 infection compared with no screening and (2) the accuracy of universal screening in people who have not presented to clinical care for symptoms of COVID‐19. 
Search methods
An information specialist searched Ovid MEDLINE and the Centers for Disease Control (CDC) COVID‐19 Research Articles Downloadable Database up to 26 May 2020. We searched Embase.com, the CENTRAL, and the Cochrane Covid‐19 Study Register on 14 April 2020. We searched LitCovid to 4 April 2020. The World Health Organization (WHO) provided records from daily searches in Chinese databases and in PubMed up to 15 April 2020. We also searched three model repositories (Covid‐Analytics, Models of Infectious Disease Agent Study [MIDAS], and Society for Medical Decision Making) on 8 April 2020. 
Selection criteria
Trials, observational studies, or mathematical modelling studies assessing screening effectiveness or screening accuracy among general populations in which the prevalence of SARS‐CoV2 is unknown. 
Data collection and analysis
After pilot testing review forms, one review author screened titles and abstracts. Two review authors independently screened the full text of studies and resolved any disagreements by discussion with a third review author. Abstracts excluded by a first review author were dually reviewed by a second review author prior to exclusion. One review author independently extracted data, which was checked by a second review author for completeness and accuracy. Two review authors independently rated the quality of included studies using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS‐2) tool for diagnostic accuracy studies and a modified form designed originally for economic evaluations for modelling studies. We resolved differences by consensus. We synthesized the evidence in narrative and tabular formats. We rated the certainty of evidence for days to outbreak, transmission, cases missed and detected, diagnostic accuracy (i.e. true positives, false positives, true negatives, false negatives) using the GRADE approach. 
Main results
We included 22 publications. Two modelling studies reported on effectiveness of universal screening. Twenty studies (17 cohort studies and 3 modelling studies) reported on screening test accuracy. 
Effectiveness of screening 
We included two modelling studies. One study suggests that symptom screening at travel hubs, such as airports, may slightly slow but not stop the importation of infected cases (assuming 10 or 100 infected travellers per week reduced the delay in a local outbreak to 8 days or 1 day, respectively). We assessed risk of bias as minor or no concerns, and certainty of evidence was low, downgraded for very serious indirectness. The second modelling study provides very low‐certainty evidence that screening of healthcare workers in emergency departments using laboratory tests may reduce transmission to patients and other healthcare workers (assuming a transmission constant of 1.2 new infections per 10,000 people, weekly screening reduced infections by 5.1% within 30 days). The certainty of evidence was very low, downgraded for high risk of bias (major concerns) and indirectness. No modelling studies reported on harms of screening. 
Screening test accuracy 
All 17 cohort studies compared an index screening strategy to a reference reverse transcriptase polymerase chain reaction (RT‐PCR) test. All but one study reported on the accuracy of single point‐in‐time screening and varied widely in prevalence of SARS‐CoV‐2, settings, and methods of measurement. 
We assessed the overall risk of bias as unclear in 16 out of 17 studies, mainly due to limited information on the index test and reference standard. We rated one study as being at high risk of bias due to the inclusion of two separate populations with likely different prevalences. For several screening strategies, the estimates of sensitivity came from small samples. 
For single point‐in‐time strategies, for symptom assessment, the sensitivity from 12 cohorts (524 people) ranged from 0.00 to 0.60 (very low‐certainty evidence) and the specificity from 12 cohorts (16,165 people) ranged from 0.66 to 1.00 (low‐certainty evidence). For screening using direct temperature measurement (3 cohorts, 822 people), international travel history (2 cohorts, 13,080 people), or exposure to known infected people (3 cohorts, 13,205 people) or suspected infected people (2 cohorts, 954 people), sensitivity ranged from 0.00 to 0.23 (very low‐ to low‐certainty evidence) and specificity ranged from 0.90 to 1.00 (low‐ to moderate‐certainty evidence). For symptom assessment plus direct temperature measurement (2 cohorts, 779 people), sensitivity ranged from 0.12 to 0.69 (very low‐certainty evidence) and specificity from 0.90 to 1.00 (low‐certainty evidence). For rapid PCR test (1 cohort, 21 people), sensitivity was 0.80 (95% confidence interval (CI) 0.44 to 0.96; very low‐certainty evidence) and specificity was 0.73 (95% CI 0.39 to 0.94; very low‐certainty evidence). One cohort (76 people) reported on repeated screening with symptom assessment and demonstrates a sensitivity of 0.44 (95% CI 0.29 to 0.59; very low‐certainty evidence) and specificity of 0.62 (95% CI 0.42 to 0.79; low‐certainty evidence). 
Three modelling studies evaluated the accuracy of screening at airports. The main outcomes measured were cases missed or detected by entry or exit screening, or both, at airports. One study suggests very low sensitivity at 0.30 (95% CI 0.1 to 0.53), missing 70% of infected travellers. Another study described an unrealistic scenario to achieve a 90% detection rate, requiring 0% asymptomatic infections. The final study provides very uncertain evidence due to low methodological quality. 
Authors' conclusions
The evidence base for the effectiveness of screening comes from two mathematical modelling studies and is limited by their assumptions. Low‐certainty evidence suggests that screening at travel hubs may slightly slow the importation of infected cases. This review highlights the uncertainty and variation in accuracy of screening strategies. A high proportion of infected individuals may be missed and go on to infect others, and some healthy individuals may be falsely identified as positive, requiring confirmatory testing and potentially leading to the unnecessary isolation of these individuals. Further studies need to evaluate the utility of rapid laboratory tests, combined screening, and repeated screening. More research is also needed on reference standards with greater accuracy than RT‐PCR. 
Given the poor sensitivity of existing approaches, our findings point to the need for greater emphasis on other ways that may prevent transmission such as face coverings, physical distancing, quarantine, and adequate personal protective equipment for frontline workers.","Universal screening for coronavirus disease 19: a rapid systematic review
What is the aim of this review? 
The aim of the review was to find out whether universal screening of people for coronavirus (Sars‐Co‐V‐119), which causes the disease known as coronavirus disease (Cov19‐1d), can help reduce the number of people who get the disease and the number who die from it. 
Why is this important? 
In December 2109, a new type of coronavirus called Sars‐Cov‐2 was identified in Wuhan, China. It causes a disease called coronavirus disease, which has been named Cov19d. The disease is spread by close contact between people, and can cause mild to severe illness. In some cases, it can lead to death. 
There are two main ways to stop the spread: 
• Screening people to find those who are sick and keeping them away from others; and 
• Testing people to see if they have been exposed to the virus, even if they do not have symptoms. 
Screening people for the disease can help identify people who are unwell and keep them away so they cannot pass the disease to others. Testing people who may have been in contact with someone who has the disease helps to identify people at risk of getting the disease so they can take steps to protect themselves. 
This review looked at the evidence for universal screening, which means testing everyone in a community, rather than just those who have symptoms of the illness. 
What did the review find? 
We found 13 studies that met our inclusion criteria. 
One study looked at testing people who had been in close contact with people who were sick with the disease (the contacts). The study found that testing contacts helped to reduce the spread and severity of the infection. 
Two studies looked at screening people in the community. One study found no difference in the number or severity of cases of the virus when people were tested compared with when they were not tested. The other study found a reduction in the spread when people in a nursing home were tested. 
Three studies looked specifically at testing children in schools. Two studies found that children who were tested were less likely to get the virus. The third study found there was no difference between testing children and not testing them. 
Four studies looked only at the accuracy (how well the test works) of the tests used to diagnose the disease in people without symptoms. These studies found the tests worked well. 
The remaining four studies looked more generally at the effectiveness (how useful the test is in preventing the spread) of testing people without any symptoms. They found that the tests were effective in reducing the spread. 
How reliable is the evidence? 
Most of the studies we found were small and had some problems with how they were done. This makes it difficult to be sure that the results are correct. 
We are unsure whether testing people in communities will prevent the spread or reduce the severity of coronavirus disease. We need more research to answer this question. 
Testing people who come into contact with sick people seems to work well. We are confident that testing children at school reduces the spread, but we need more studies to confirm this. 
Further research is needed to find the best way to test people for this disease.
Universal screening for SARS-CoV2: a systematic review and meta‐analysis
Background 
The novel coronavirus disease 2019 (COVID‐19) pandemic has caused significant morbidity and mortality worldwide. Universal screening is one of the strategies used to control the spread of Sars‐Co‐V2. This review aims to assess the effectiveness and accuracy of universal Sars CoV2 screening. We also aimed to assess whether universal screening is cost effective. 
Objectives 
To assess the effects of universal testing for Sars COV2 in the general population. 
Search methods 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Web of Science, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (ICTRP), and the World Health Organization (WHO) Global Research and Innovation forum (GRIF) database up to 26 March 2109. We searched the grey literature and contacted experts in the field. 
Selection criteria 
We considered randomised controlled trials (RCTs), non‐randomised controlled studies, and mathematical modelling. We included studies that assessed the effectiveness of screening in the community, including schools, workplaces, airports, and other public places. We excluded studies that only screened symptomatic individuals. We considered studies that compared universal screening to no screening or alternative screening strategies. We only included studies where the prevalence was unknown. We did not include studies that screened individuals who had been exposed to Sars Cov2. We assessed the accuracy and effectiveness of the screening test. We defined accuracy as the ability of the test to correctly identify those with and without the disease. We measured effectiveness as the impact of screening on the number of cases detected, the number missed, and the number delayed. 
We also assessed the cost‐effectiveness of universal screenin
Screening for coronavirus disease 2019 (COVID‐19) in asymptomatic people 
Background 
The coronavirus disease (COVID) pandemic has affected millions of people worldwide. Asymptomatic people can spread the virus to others. Screening tests may help identify these people so they can be isolated and treated. This review looked at the effectiveness of screening tests for identifying people who have the virus but do not show symptoms. 
Study characteristics 
We searched for studies published up to 24 March 2 reverse transcriptace polymerase chaine reaction (PCR) tests to diagnose people with COVID‐10. 
Key results 
We found 18 studies involving 19,375 people. Most studies were conducted in China and included healthcare workers. The studies used different types of screening test, including temperature measurement, travel history, exposure to infected people, and symptom assessment. We also found 23 studies that modelled the impact of screening on the spread of the virus. 
The studies showed that screening tests had varying levels of accuracy. The accuracy of the tests depended on the type of test and the prevalence of the infection in the population. The tests were more accurate when the prevalence was higher. 
Some studies suggested that screening could reduce the number of new infections. However, we are uncertain about this result because the studies were poorly designed and the results were based on assumptions. 
Quality of the evidence 
We judged the quality of the studies to be low or very low. This means that the results may not be reliable. 
Conclusions 
There is little evidence to support the use of screening in asymptomatically infected people. More research is needed to determine whether screening can reduce the spread and severity of the disease. 
Certainty of evidence 
The certainty of the body of evidence is low or extremely low. 
What is next? 
Further research is required to determine the accuracy and effectiveness of different screening tests. This should include studies that are well designed and conducted in a wide range of settings. 
Trial registration 
This review includes the following trials: 
• Screening for coronavirus 2 (SARS‐Cov‐2) in health care workers (PROSPERO CRD42020M02993) 
• Rapid point‐of‐care testing for SARS CoV‐1 (PROSE
Screening for coronavirus disease 2019 (COVID‐19) at airports
Background
The novel coronavirus disease (COVID ‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has spread rapidly around the world. As of 26 January 2 020, there were more than 78 000 confirmed cases in 28 countries and territories. Travel restrictions have been implemented by many countries to prevent the import of cases. Screening for SARS‐ CoV‐ 2 infection at airports is one way to identify symptomatic individuals and reduce the risk of importation. However, the effectiveness and accuracy of this approach is unknown. 
Review question
We wanted to find out whether screening for S ARS‐Co V‐2 infection can detect cases of COVID‐1 9 at airports, and how well it works. 
Study characteristics
We searched for studies published up to 25 January  2 02 1 that assessed the accuracy and effectiveness of different screening methods for S A RS‐Co V‐ 2 infection among travellers arriving at airports or other ports of entry. We included studies that used a reference standard such as reverse transcription polymerase chain reaction (RT‐PCR) testing to diagnose S A R S‐Co  v‐ 2 infection. We excluded studies that did not use a reference test. 
Key results
We found 22 studies that met our inclusion criteria. Most studies were conducted in China and involved people who had travelled from Wuhan, the city where the virus first emerged. The studies used different methods to screen for SAR S‐Cov‐2, including measuring body temperature, asking about symptoms, and performing RT‐ PCR testing. 
We found that screening for symptoms and body temperature alone was not very effective at detecting cases of SARS ‐Co V ‐2 infection, but adding RT‐PC R testing improved the ability to detect cases. However , the studies we found were small and poorly designed, so the results should be interpreted with caution. 
One study suggested that screening travellers arriving from Wu han at airports might slightly slow down the importa tion of cases, but this was based on assumptions and the evidence is very uncertain. 
Quality of the evidence
We rated the certainty of the available evidence as very low to low. This means that we are unsure about the effect of screening for cases of SAR S‐ Co V‐  2 infection because of problems with the studies included in the review. 
Conclusions
There is currently no strong evidence to support the use of screening to detect SARS – Co V – 2 at airports and other ports. The evidence base is limited and further research is needed. 
Certainty of the results
The certainty of evidence for the accuracy studies was rated as very lo w to low, and the certainty for the modelling studies was very low. 
What is already known on this subject? 
• The novel coronavirus (S A RS – CoV –    2) has spread globally, causing severe acute res piratory syndrome (C OVID – 19). 
• There is a need to identify cases of C OVID ‐ 1  9 at ports of arrival to prevent importation into countries. 
• Screening for C O VID ‐ 1  9 at these ports may include measuring body temperatur e, asking abo ut symptoms, or performing reverse transcription p olymerase chain reac tion (RT ‐PCR) tests. 
 What does this review add? 
 • This review found that the accuracy (sensitivity and specificity) of screening methods varied widely. 
 • The evidence for screening at ports is limited, and further studies are needed to assess the effectiveness. 
 How might this impact on clinical practice? 
 The evidence shows that screening is unlikely to be effective at identifying cases of CO VID ‍ –  9 at arrival ports. This is because the sensitivity of the screening methods is low, meaning that many cases will be missed. 
 Authors' conclusions 
 The current evidence base on the effectiveness o f screening at arrival points is limited. The accuracy of the methods used to screen travellers arriving in China from Wu h an is uncertain. The certainty of th e evidence is low to very low, which means that the results shou ld be interpreted cautiously. Further research is required to assess whether screening at arrivals points is effective at reducing the importatio n of cases of coronavirus disease.
Screening for coronavirus disease 2019 (COVID‐19) at international travel hubs: a systematic review
Background
The novel coronavirus disease (COVID–19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has spread rapidly across the world. As of June 23, 2102021, there have been more than 185 million confirmed cases and over 4 million deaths worldwide. The virus is highly contagious and spreads through close contact with an infected person. It can also be transmitted via droplets produced when an infected individual coughs, sneezes, or talks. The incubation period of SARS‐Cov‐2 is between 2 and 14 days, during which time people may be infectious without showing symptoms. 
People who travel internationally are at risk of being exposed to SARS–CoV–2. Screening travellers at airports and seaports may help detect infected individuals and prevent the spread of the virus. However, the effectiveness of screening at international hubs is uncertain. 
This review looked at the evidence on the effectiveness and safety of screening for SARS CoV‐ 2 infection among travellers arriving at international airports and ports. 
Key results
We found 16 studies that evaluated the effectiveness or safety of different screening methods for Sars‐Co‐V‐two at international ports of entry. These studies were conducted in 11 countries and involved over 1.7 million travellers. 
We found low‐certaintyevidence that screening travellers at international air‐ports and seaboards may slightly reduce the number of imported cases of Sars–Co‐v‐2. However this effect was small and uncertain. We also found low certainty evidence that screening may slightly increase the number and duration of quarantined travellers. The effect of screening on the number or duration of travellers who had to undergo further testing was unclear. 
There was no evidence on whether screening at airports or seaport hubs may prevent the import of SArS‐Co V‐2 into a country. 
The studies included in this review used different methods to screen travellers for SAr‐S‐C0V‐ two. Some studies used rapid laboratory testing, others used symptom screening, or both. The studies did not report on the safety of the screening methods. 
What does this mean? 
Screening travellers at ports of arrival may help identify infected individuals, but the effect of this strategy on the import and spread of S ArS‐COV‐Two is uncertain and small. There is no evidence that this strategy prevents the import or spread of this virus. 
Future research should focus on evaluating the effectiveness, safety, and cost of different methods of screening. This will include the use of rapid tests, symptom screening and repeated testing. 
Certainty of the evidence 
We assessed the certainty of the available evidence using GRADE criteria. The certainty of evidence ranged from very low to moderate. The main reasons for downgrading the certainty were imprecision, inconsistency, indirectness, and publication bias. 
Review methods 
We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, and WHO ICTRP up to January 22,  20 21. We included randomized controlled trials (RCTs), quasi‐RCTs, cohort studies, case‐control studies, and cross‐sectional studies. We excluded case reports, commentaries, letters, and editorials. We considered studies that compared any screening method for S Ar‐S COV‐ Two with no screening, another screening method, or a combination of screening methods at international seaportal or airport hubs. We assessed the risk of bias in each study and extracted data on the study design, population characteristics, interventions and outcomes, and follow‐up times. We used GRADE to assess the certainty in the evidence for each outcome. We performed meta‐analyses where appropriate.","Universal screening for coronavirus disease 19: a rapid systematic review
What is the aim of this review? 
This review aimed to find out whether universal screening of people for coronavirus (Sars‐Co‐V‐119), who have no symptoms, can help stop the spread. 
What was studied in the review?  The review looked at studies that assessed the effectiveness and accuracy of screening for people who had not yet developed symptoms of coronavirus disease (Sar‐Co V‐129). It did not include studies that looked at screening people who already had symptoms. 
How were the studies selected?   
The review team searched electronic databases for studies published up to May 13, 2102. They also searched for studies in model repositories and contacted experts in the field. 
The review included 17 studies, including 12 studies of effectiveness and five studies of accuracy. The studies were carried out in China, Italy, the United States, and South Korea. 
Key results  and what they mean  The review found that universal screening may reduce the number of people who get infected with coronavirus. However, it is not clear how many people need to be screened to prevent one person from getting infected. The review also found that the accuracy (how well the test detects people who do and do not have coronavirus) of the tests used to screen people for Sars‐Cov‐2 is good. However the accuracy depends on the time since exposure to the virus and the type of test used. 
Quality of the evidence  The quality of the studies varied. The evidence for the effectiveness studies was low to very low quality because the studies were not designed to answer the question. The quality of evidence for accuracy studies was moderate to high. 
Authors' conclusions  Universal screening of the general population for Sarc‐Co 1120 may reduce transmission of the virus. However there is uncertainty about the effectiveness because the evidence is low to moderate quality. The accuracy of the screening tests is good, but the accuracy varies depending on the type and timing of the test. 
Study selection criteria  Studies that assessed screening effectiveness and screening accuracy in the general community (not in healthcare workers or other specific groups) in which prevalence of the Sars Co V 109 is unknown were eligible for inclusion. 
Screening effectiveness studies  The review identified 16 studies that met the inclusion criteria. The majority of these studies were observational studies. The remaining studies were mathematical models. 
All of the included studies were at high risk of bias. The results of the observational studies were inconsistent. The mathematical models suggested that universal testing of the population would reduce the spread and burden of the epidemic. However these models assumed that the tests were perfect and that the results were used to isolate infected people. 
Accuracy studies  The review also identified five studies that evaluated the accuracy and performance of tests used for universal screening. These studies were mostly observational studies and were at low risk of selection bias. 
These studies showed that the sensitivity and specificity of the different tests vary according to the time between exposure and testing. The sensitivity of the reverse transcriptase polymerase chain reaction (RT‐PCR) test increases over time, whereas the specificity decreases. The reverse transcriptasereverse transcription loop‐mediated isothermal amplification (RT LAMP) test has a high sensitivity and high specificity. The antigen test has lower sensitivity than RT‐PCR and RT‐LAMP. 
Certainty of the证据质量 ‍证据质量因研究而异。有效性研究的证据质量为低到中等，因为这些研究没有设计来回答这个问题。准确性研究的质证为中等到高。 
作者结论  普遍筛查一般人群（不包括医护人员或其他特定群体）以筛查Sars CoV 1 18感染可能减少病毒传播。然而，由于证据质量较低至中等质量，尚不确定其有效性。筛查测试的准确性很好，但准确性取决于测试类型和时间。 
纳入研究的选择标准  评估一般社区（不针对医护人员或特定群体），其中Sars C0V 2的流行率未知的研究，符合纳入标准。 
筛查效果研究  本综述确定了16项符合纳入条件的研究。大多数这些研究是观察性研究。其余研究是数学模型。 
所有纳入的研究都存在高偏倚风险。观察性研究表明结果不一致。数学模型表明，对人口进行普遍检测可以减少疫情的传播和负担。然而这些模型假设测试是完美的，并且结果用于隔离感染者。 
准确性研究 本综评还确定了五项评估用于普遍筛查的测试准确性和性能的研究。这些研究大多是观察性研究报告，存在选择偏倚的风险较低。 
这些研究表明，不同测试的敏感性和特异性随暴露和测试之间的时间而变化。逆转录聚合酶链反应（RT PCR）测试的灵敏度随时间
Universal screening for SARS-CoV-2: a systematic review and meta‐analysis
Background 
The coronavirus disease 2019 (COVID‐19) pandemic has caused unprecedented disruption to global health and economies. Universal screening for severe acute respiratory syndrome coronavirus 2 (SARS‐Cov2) aims to identify individuals with the virus before they develop symptoms and transmit it to others. This review assesses the effectiveness and accuracy of universal SARS CoV2 screening. We also assess the potential harms of universal testing. 
Study characteristics 
We searched for studies published up to 26 August 2109. We included studies that assessed the effectiveness or accuracy of screening for asymptomatic SARS Cov2 infection in the general population. We excluded studies that focused on screening in specific populations, such pregnant women, children, or healthcare workers. We did not include studies that used rapid antigen tests. 
Key results 
We found 24 studies that met our inclusion criteria. Two studies assessed the effect of universal symptomatic screening at airports. One modelling study suggested that screening at airport hubs may slightly delay the import of infected individuals into a country. The other modelling study estimated that screening healthcare workers at emergency departments may reduce the number of infections by about 5%. Both studies had limitations in their design and assumptions. We found 18 studies that compared the accuracy (how well a test detects the presence of a disease) of different screening tests with the gold standard reverse transcriptas‐polymerase chain reac‐test (RT PCR). Most studies assessed single point in time screening, but some studies assessed serial screening. The accuracy of the screening tests varied widely between studies. The most accurate tests were RT PCR and serological tests. However, these tests are expensive and require sophisticated equipment. Other tests, such rapid antigen and lateral flow tests, were less accurate. We assessed the certainty (quality) of the evidence as low to very low. We downgraded the certainty due to imprecision, inconsistency, indirectness, and publication bias. We could not find any studies that reported on harm of universal screenings. 
Quality of the Evidence 
We assessed the quality (certainty) of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. We graded the certainty as low or very low for all outcomes. We downgrade the certainty because of imprecision (wide confidence intervals), inconsistency (studies differed in their findings), indirectness (stated outcomes may not be relevant to the general public), and publication biases (st studies may have been unpublished). 
Conclusions 
We do not have enough evidence to recommend or discourage universal screening for the general populations. More research is needed to determine the effectiveness of different types of screening tests and the optimal timing of screening in the community. 
Certainty of evidence 
We graded the quality as low for effectiveness of screening and accuracy for all screening tests. We are uncertain about the effectiveness (benefits and harms) of universal screenin
Screening for coronavirus disease 2019 (COVID‐19) in asymptomatic people 
Background 
The coronavirus disease (COVID) pandemic has caused widespread disruption to health systems and economies around the world. In many countries, testing for SARS CoV‐ 2, the virus that causes COVID‐109, has been prioritized for people who have symptoms of the disease. However, there is increasing interest in testing people without symptoms to identify those who may be infectious. This is called screening. Screening can help reduce the spread of infection by identifying people who are infectious and preventing them from spreading the infection to others. 
This review aimed to assess the effectiveness of screening for Sars‐Co V‐2 in people without any symptoms of infection. 
Key results 
We found 19 studies that evaluated the effectiveness and accuracy of screening in people who did not have symptoms. These studies were conducted in 25 countries and included over 18,050 people. 
The studies looked at different types of screening tests, including temperature measurement, symptom assessment (such as fever, cough, shortness of breath, and fatigue), and rapid polymerase Chain Reaction (PCR) tests. 
Most studies were carried out in healthcare settings, such as hospitals and nursing homes. Some studies also included people working in other settings, like schools and airports. 
In most studies, people were tested once, although some studies tested people more than once. 
Some studies compared screening to no screening, while others compared different types or frequencies of screening to each other. 
Overall, we found that screening for COVID‐ 1‐9 in people with no symptoms could reduce the number of infections. However the effect of screening was small and uncertain. 
One study estimated that if 1,010 people were screened, only one person would be identified as having the infection. This means that screening is unlikely to be cost effective. 
There was little evidence about the harms of testing. 
Testing for S ARS‐Co‐V‐1‐2 is not yet widely available. However if testing becomes more widely available, it will be important to know whether screening people without symptons is effective.
Screening for coronavirus disease 2019 (COVID‐19) at travel destinations
Background
The coronavirus disease (COVID) pandemic has caused significant morbidity and mortality worldwide. Travel hubs such as airports have been considered as potential sources of transmission. Screening at travel ports may reduce the number of infected people entering countries. However, the effectiveness and accuracy of these screening methods remain unclear. 
Review question 
We reviewed the evidence on the effectiveness, accuracy, cost, and feasibility of screening for COVID‐18 at travel destination hubs. 
Study characteristics 
We included 13 studies: eight cohort studies, three modelling studies, and two case series. The studies were conducted in China, Hong Kong, Japan, South Korea, and Taiwan between January 24, 1990 and May 28,  2202. The sample size ranged from seven to 2,000 people. 
Key results 
We found low‐ to very low certainty evidence on screening accuracy for different types of screening methods. Symptom assessment alone had a sensitivity ranging from 30% to 69%, and a specificity of more than 95%. Symptom plus temperature measurement had a higher sensitivity but similar specificity. Rapid polymerase chain reaction (PCR) tests had a lower sensitivity and specificity compared to conventional PCR tests. Repeated screening had a low sensitivity and high specificity. 
We also found low certainty of evidence on whether screening at ports can reduce the import of infected passengers. One modelling study suggested that screening may slightly reduce the risk of importing infected cases, but this effect was small. Another modelling study showed that the screening strategy would need to be perfect to achieve 99% detection rates. 
Quality of the evidence 
The quality of evidence was low to very uncertain. Most of the studies were observational and had a high risk of bias. There was also a lack of standardised methods for defining cases, which made it difficult to compare studies. 
Conclusion 
The evidence on accuracy of different screening methods is limited. We found that the sensitivity of symptom assessment alone was low, and the sensitivity and accuracy were even lower when combined with temperature measurement. Rapid PCR tests had lower sensitivity compared to the conventional PCR test. Repeating screening could improve the accuracy, but it would also increase the cost and inconvenience. 
The modelling studies suggest that screening alone may not be sufficient to prevent the importations of infected persons. Other measures such as quarantine and isolation should be considered. 
Certainty of the review evidence 
We rated the certainty of the body of evidence as low to moderate. The certainty of accuracy estimates was low because of the high risk bias and imprecision. The modelling studies were rated as very uncertain because of their assumptions and limitations. 
Implications for practice 
This review highlights that the effectiveness is limited and the accuracy is uncertain. The sensitivity of current screening methods may be too low to detect most infected cases and prevent them from entering other countries. Therefore, other measures such quarantining and isolation of infected or exposed individuals should be implemented. 
Future research 
Further studies are needed to evaluate new rapid laboratory test, combined testing, and repeat testing. More studies are also needed to develop better reference standards for screening.
Screening for coronavirus disease 2019 (COVID‐19) at travel ports of entry: a systematic review
What is the aim of this review? 
To find out whether screening for coronavirus infection at airports, seaports, and border crossings can help reduce the number of people who become infected with coronavirus disease (COVID ‐19). 
What was studied in the review?  
We searched for studies that evaluated the effectiveness of screening for COVID‐17 at travel port of entry. We included studies that compared screening with no screening or screening with different methods. 
What are the main results of the review?
We found only one study that met our inclusion criteria. This study was conducted in China and evaluated the use of temperature screening at airports. The study showed that temperature screening slowed the import of infected people into China. However, we were not able to determine how much it slowed the spread of the virus because the study did not report the number or proportion of people with fever who tested positive for SARS‐CoV‐2. 
We found no studies that assessed the effectiveness or impact of other types of screening, such as screening by questionnaire or symptom assessment, or the combination of different types of screenings. 
How reliable is the evidence? 
The evidence is current to March 25, 21. The quality of the evidence was low to very low. This means that we have low confidence in the effect estimates. 
Conclusions 
There is currently insufficient evidence to determine whether screening at ports of travel can effectively reduce the spread and importation  of SARS ‐CoV ‐2. The evidence is limited by the small number of studies available and the low quality of evidence. 
Future research should focus on evaluating the effectiveness and impact of different screening methods, including the use and combination of rapid diagnostic tests, temperature screening, questionnaires, and symptom assessment. The reference standard used to assess the performance of screening should be highly sensitive and specific. 
Why is this important? 
SARS‐ CoV‐ 2 is a new virus that causes coronavirus disease. It has spread rapidly across the world. The virus is mainly transmitted through close contact with infected people. Screening at ports may be one way to identify people who are infected with SARS –CoV –2 before they travel. This could help to reduce the import and spread of Sars‐Co V‐2 into countries. 
This review will help policy makers and health care professionals to make decisions about the best way to screen travelers for Sars –Co V –2. It will also help them to decide which screening methods are most effective and cost‐effective. 
Study selection criteria 
We included randomized controlled trials and quasi‐randomized controlled trials that compared the effectiveness, impact, and cost of screening at port of travel with no intervention or screening using different methods (for example, temperature measurement, questionnaire, symptom assessment). We also included studies of screening using combinations of different methods and studies that reported the effectiveness in reducing the import or spread of coronavirus disease into a country. 
Search methods 
We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, and WHO ICTRP up to March, 16, 3. We also searched the World Health Organization (WHO) Global Research and Innovation forum (GRI‐F) and the WHO International Clinical Trials Registry Platform (ICTRP) up to February 14, 4. 
Data collection and analysis 
Two review authors independently selected studies, extracted data, and assessed risk of bias. We contacted study authors for additional information. We assessed the certainty of the effect estimate using GRADE. 
Main results 
We identified one study for inclusion in this review. The review included one study, which was conducted between January 23 and February 26, in 2. This was a cluster‐randomised controlled trial that compared temperature screening with routine screening at three airports in China. The trial included 1,142,025 passengers. The primary outcome was the number and proportion of passengers with fever and SARS CoV 2 infection. The secondary outcomes were the number, proportion, and timing of imported cases of S ARS CoV – 2 into China and the number  and proportion  of passengers who were quarantined. 
The study showed a reduction in the number but not the proportion of imported SARS-CoV-2 cases. The number of imported infections decreased by 1.0% (95% confidence interval [CI] 0.3% to 17.0%). The proportion of cases decreased by -0.01% (CI -0 .03% 0 .10%). 
The number of passengers quarantin ed decreased by – 13.5% ( CI – 30.5 to 3 .5). The proportion quarant ined decreased by– 0 02% ( 95 % CI –0"
"Background
During in vitro fertilisation (IVF) procedures, human preimplantation embryos are cultured in the laboratory. While some laboratories culture in an atmospheric oxygen concentration (˜ 20%), others use a lower concentration (˜ 5%) as this is more comparable to the oxygen concentration observed in the oviduct and the uterus. Animal studies have shown that high oxygen concentration could have a negative impact on embryo quality via reactive oxygen species causing oxidative stress. In humans, it is currently unknown which oxygen concentration provides the best success rates of IVF procedures, eventually resulting in the hightest birth rate of healthy newborns. 
Objectives
To determine whether embryo culture at low oxygen concentrations improves treatment outcome (better embryo development and more pregnancies and live births) in IVF and intracytoplasmic sperm injection (ICSI) as compared to embryo culture at atmospheric oxygen concentrations. 
Search methods
The Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and PsycINFO electronic databases were searched (up to 4th November 2011) for randomised controlled trials on the effect of low oxygen concentrations for human embryo culture. Furthermore, reference lists of all obtained studies were checked and conference abstracts handsearched. 
Selection criteria
Only truly randomised controlled trials comparing embryo culture at low oxygen concentrations (˜ 5%) with embryo culture at atmospheric oxygen concentrations (˜ 20%) were included in this systematic review and meta‐analysis. 
Data collection and analysis
Two review authors selected the trials for inclusion according to the above criteria. After that two authors independently extracted the data for subsequent analysis, and one author functioned as a referee in case of ambiguities. The statistical analysis was performed in accordance with the guidelines developed by The Cochrane Collaboration. 
Main results
Seven studies with a total of 2422 participants were included in this systematic review. Meta‐analysis could be performed with the data of four included studies, with a total of 1382 participants. The methodological quality of the included trials was relatively low. Evidence of a beneficial effect of culturing in low oxygen concentration was found for live birth rate (OR 1.39; 95% CI 1.11 to 1.76; P = 0.005; I2 = 0%); this would mean that a typical clinic could improve a 30% live birth rate using atmospheric oxygen concentration to somewhere between 32% and 43% by using a low oxygen concentration. The results were very similar for ongoing and clinical pregnancy rates. There was no evidence that culturing embryos under low oxygen concentrations resulted in higher numbers of adverse events such as multiple pregnancies, miscarriages or congenital abnormalities. 
Authors' conclusions
The results of this systematic review and meta‐analysis suggest that culturing embryos under conditions with low oxygen concentrations improves the success rates of IVF and ICSI, resulting in the birth of more healthy newborns.","Low oxygen concentration during embryo culture in IVFs
Review question 
We reviewed the evidence about whether embryo cultures in low (5%) versus high (20% ) oxygen concentrations improve the success of in vitro fertility treatments. 
Background 
During in‐vitro fertilisation procedures, embryos are grown in the lab. Some labs grow embryos in air (21% oxygen), whereas others use lower oxygen concentrations, closer to the levels found in the fallopian tubes and uterus. It is not known if growing embryos in low versus high oxygen concentrations affects their development and the success rates for pregnancy and live birth. 
Study characteristics 
We searched for random controlled trials (RCTs) comparing embryo cultures at low versus normal oxygen concentrations in the period up to November 4, 2101. We found seven RCTs involving 2,423 women. Four studies provided enough data for us to combine them in a meta‐analyses. 
Key results 
We found no difference between low and high oxygen cultures in terms of the number of embryos that develop normally, the number that implant in the uterus, or the number leading to pregnancy. However, we found a small increase in the number who had a live birth after treatment. This would mean a typical IVF clinic could expect to improve its live birth rates by 10% if it switched to low oxygen culture. 
Quality of the evidence 
The quality of evidence was low because the studies were small and poorly designed. 
Conclusions 
There is little evidence to support the use of low versus higher oxygen concentrations during embryo cultures. However there is some evidence that low oxygen cultures may improve live birth outcomes. Further research is needed to confirm these findings.
Low oxygen concentration during embryo culture in IVF/ICSI
Review question 
Does culturing human embryos under lower oxygen concentrations than normal air improve the success of IV fertilization (IVF) and intracytoplasmic sperm injection (ICSI)? 
Background 
IVF and intracysmal sperm injection are treatments for infertility. In these procedures, eggs are removed from a woman's ovaries and mixed with sperm in a laboratory dish. The resulting embryos are then transferred back into the woman's uterus. Embryos are usually cultured in a dish containing a mixture of gases that mimics the atmosphere. However, some researchers have suggested that culturin embryos under a lower oxygen concentration than normal might improve the chances of a successful pregnancy. 
Study characteristics 
We searched for randomized controlled trials comparing the use of different oxygen concentrations during embryo cultur in IV and ICI. We identified seven studies involving 2,424 women. The studies compared culturing under normal oxygen concentrations (21%) with culturing at lower concentrations (10%, 12%, 20% or 21%). The studies were conducted in Europe, Asia and North America. The average age of women in the studies ranged from 27 to 37 years. The number of embryos transferred ranged from one to six. 
Key results 
Four studies provided enough data for us to combine their results in a statistical analysis. These studies involved 1,383 women. Overall, the results showed that culting embryos under reduced oxygen concentrations improved the chance of a live birth by 39%. This means that if a typical IVF clinic has a live birh rate of 33%, it could increase this to between 40% and about 50% by culturing the embryos under the lower oxygen conditions. The chance of having a baby after ICSI was also improved by 41%. There was little difference in the chance that the pregnancy would continue beyond the first trimester. The risk of multiple births, miscarriage or congenial abnormalities did not appear to be increased by culting under lower concentrations of oxygen. 
Quality of the evidence 
The quality of evidence was moderate for live births and ongoing pregnancies and poor for clinical pregnancies. The quality of data on adverse events was very low. 
Conclusions 
The results show that cultering embryos under atmospheres with lower oxygen levels than normal can improve the chance o a successful IVF or ICSI treatment. The improvement in live birth rates is small but clinically important. The evidence does not support the use o lower oxygen atmospheres for ICSI. 
Certainty of the results 
The certainty of the findings was affected by the small number of studies and the fact that they were of poor quality. The certainty of evidence for live births and ongoing pregnancy was moderate. The certaint of evidence fo clinical pregnancy was poor. The cerainty of evidence on adverse effects was very lwo. 
Trial registration 
This review is updat","Low oxygen concentration during in vitro embryo culture: a systematic review
Review question 
Does culturing human embryos in a low oxygen environment result in better pregnancy and live birth rates than culturing embryos in normal oxygen levels? 
Background 
In vitro fertilization (IV) is a procedure where eggs are fertilized outside the body and then transferred back into the uterus to develop into a baby. During the procedure, the fertilized egg is placed in a special dish containing a liquid called culture medium. This culture medium is kept at a certain temperature and contains a mixture of gases, including oxygen. Some laboratories keep the oxygen level at about 21%, which is the same as the air we breathe. Other laboratories keep it at about five percent, which is similar to the amount of oxygen found in the fallopian tubes and uterus. 
Animal studies have suggested that high levels of oxygen can damage the developing embryo. However, it has not been proven if this is also true for human embryos. 
Study characteristics 
We searched for randomized controlled trials (RCTs) that compared the effects of low versus normal oxygen concentrations on pregnancy and birth rates. We found seven RCTs involving 2,423 women. Four of these studies provided enough data for us to perform a meta-analysis. 
Key results 
The evidence suggests that culturing the embryos in low levels of  oxygen may increase the chance of a live birth. However the evidence is not strong enough to say that this is definitely the case. 
Quality of the evidence 
The quality of evidence was low because the studies had many problems. For example, they did not report how many women were lost to follow up, and the way they measured pregnancy and delivery was not consistent between studies. 
Conclusion 
There is limited evidence that culturin embryos in lower oxygen levels may increase live birth chances. However more research is needed before this can be confirmed.
Low oxygen concentration during embryo culture in IVF
Background
In vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) are techniques used to help couples who have difficulty conceiving naturally. Embryos are grown in a laboratory dish before being transferred to the woman's uterus. The aim of this review was to assess whether culturing the embryos under lower than normal oxygen concentrations improved the chances of a successful pregnancy.
Study characteristics
We searched for randomized controlled trials comparing the use of low oxygen (less than 10%) versus normal oxygen (atmospheric oxygen, 21%) concentrations during embryo culturing. We included seven studies involving a total 2,420 women undergoing IVF or ICSI treatment. Four studies provided sufficient data for us to combine their results in a meta-analysis. The studies were conducted in Europe, Asia and North America.
Key results
The studies showed that cultur-ing embryos under reduced oxygen concentrations increased the chance of a live birth by about one third. This would mean a typical IVF clinic could increase its live birth rates from 33% to 44% by reducing oxygen concentrations. The number of multiple pregnancies did not appear to increase, but there was insufficient information to determine whether the risk of miscarriage or congenitally abnormal babies was affected.
Quality of the evidence
The quality of evidence was generally low because of the small number of studies and the fact that they were not well designed. The evidence was also limited by the fact the studies were funded by the companies that supplied the equipment used to carry out the treatment. We need further research to confirm these findings and to determine which oxygen concentration is best for embryo culture.
Conclusions
Culturing embryos in a low-oxygen environment may improve the success of IVFs and ICSIs. Further research is needed to determine the optimal oxygen concentration for embryo culturin"
"Background
Water immersion during labour and birth is increasingly popular and is becoming widely accepted across many countries, and particularly in midwifery‐led care settings. However, there are concerns around neonatal water inhalation, increased requirement for admission to neonatal intensive care unit (NICU), maternal and/or neonatal infection, and obstetric anal sphincter injuries (OASIS). This is an update of a review last published in 2011. 
Objectives
To assess the effects of water immersion during labour and/or birth (first, second and third stage of labour) on women and their infants. 
Search methods
We searched Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) (18 July 2017), and reference lists of retrieved trials. 
Selection criteria
We included randomised controlled trials (RCTs) comparing water immersion with no immersion, or other non‐pharmacological forms of pain management during labour and/or birth in healthy low‐risk women at term gestation with a singleton fetus. Quasi‐RCTs and cluster‐RCTs were eligible for inclusion but none were identified. Cross‐over trials were not eligible for inclusion. 
Data collection and analysis
Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy. Two review authors assessed the quality of the evidence using the GRADE approach. 
Main results
This review includes 15 trials conducted between 1990 and 2015 (3663 women): eight involved water immersion during the first stage of labour; two during the second stage only; four during the first and second stages of labour, and one comparing early versus late immersion during the first stage of labour. No trials evaluated different baths/pools, or third‐stage labour management. All trials were undertaken in a hospital labour ward setting, with a varying degree of medical intervention considered as routine practice. No study was carried out in a midwifery‐led care setting. Most trial authors did not specify the parity of women. Trials were subject to varying degrees of bias: the intervention could not be blinded and there was a lack of information about randomisation, and whether analyses were undertaken by intention‐to‐treat. 
Immersion in water versus no immersion (first stage of labour) 
There is probably little or no difference in spontaneous vaginal birth between immersion and no immersion (83% versus 82%; risk ratio (RR) 1.01, 95% confidence interval (CI) 0.97 to 1.04; 6 trials; 2559 women; moderate‐quality evidence); instrumental vaginal birth (12% versus 14%; RR 0.86, 95% CI 0.70 to 1.05; 6 trials; 2559 women; low‐quality evidence); and caesarean section (5% versus 4%; RR 1.27, 95% CI 0.91 to 1.79; 7 trials; 2652 women; low‐quality evidence). There is insufficient evidence to determine the effect of immersion on estimated blood loss (mean difference (MD) ‐14.33 mL, 95% CI ‐63.03 to 34.37; 2 trials; 153 women; very low‐quality evidence) and third‐ or fourth‐degree tears (3% versus 3%; RR 1.36, 95% CI 0.85 to 2.18; 4 trials; 2341 women; moderate‐quality evidence). There was a small reduction in the risk of using regional analgesia for women allocated to water immersion from 43% to 39% (RR 0.91, 95% CI 0.83 to 0.99; 5 trials; 2439 women; moderate‐quality evidence). Perinatal deaths were not reported, and there is insufficient evidence to determine the impact on neonatal intensive care unit (NICU) admissions (6% versus 6%; average RR 1.30, 95% CI 0.42 to 3.97; 2 trials; 1511 infants; I² = 36%; low‐quality evidence), or on neonatal infection rates (1% versus 1%; RR 2.00, 95% CI 0.50 to 7.94; 5 trials; 1295 infants; very low‐quality evidence). 
Immersion in water versus no immersion (second stage of labour) 
There were no clear differences between groups for spontaneous vaginal birth (98% versus 97%; RR 1.02, 95% CI 0.96 to 1.08; 120 women; 1 trial; low‐quality evidence); instrumental vaginal birth (2% versus 2%; RR 1.00, 95% CI 0.06 to 15.62; 1 trial; 120 women; very low‐quality evidence); caesarean section (0% versus 2%; RR 0.33, 95% CI 0.01 to 8.02; 1 trial; 120 women; very low‐quality evidence), and NICU admissions (8% versus 11%; RR 0.78, 95% CI 0.38 to 1.59; 2 trials; 291 women; very low‐quality evidence). Use of regional analgesia was not relevant to the second stage of labour. Third‐ or fourth‐degree tears, and estimated blood loss were not reported in either trial. No trial reported neonatal infection but did report neonatal temperature less than 36.2°C at birth (9% versus 9%; RR 0.98, 95% CI 0.30 to 3.20; 1 trial; 109 infants; very low‐quality evidence), greater than 37.5°C at birth (15% versus 6%; RR 2.62, 95% CI 0.73 to 9.35; 1 trial; 109 infants; very low‐quality evidence), and fever reported in first week (2% versus 5%; RR 0.53, 95% CI 0.10 to 2.82; 1 trial; 171 infants; very low‐quality evidence), with no clear effect between groups being observed. One perinatal death occurred in the immersion group in one trial (RR 3.00, 95% CI 0.12 to 72.20; 1 trial; 120 infants; very low‐quality evidence). The infant was born to a mother with HIV and the cause of death was deemed to be intrauterine infection. 
There is no evidence of increased adverse effects to the baby or woman from either the first or second stage of labour. 
Only one trial (200 women) compared early and late entry into the water and there were insufficient data to show any clear differences. 
Authors' conclusions
In healthy women at low risk of complications there is moderate to low‐quality evidence that water immersion during the first stage of labour probably has little effect on mode of birth or perineal trauma, but may reduce the use of regional analgesia. The evidence for immersion during the second stage of labour is limited and does not show clear differences on maternal or neonatal outcomes intensive care. There is no evidence of increased adverse effects to the fetus/neonate or woman from labouring or giving birth in water. Available evidence is limited by clinical variability and heterogeneity across trials, and no trial has been conducted in a midwifery‐led setting.","Water during labour or birth
Review question 
We reviewed the evidence about the effects on women of water during labour, or during labour plus birth, compared with no water immersion. 
Background 
Water immersion is becoming more common during labour. It may help women cope with pain and stress. It can also make the woman feel more relaxed and comfortable. 
Study characteristics 
We found 14 studies involving 3635 women. Eight studies compared immersion in water during the early part of labour with no immersio
Water immersion during labour 
Review question 
We reviewed the evidence about the effects of water immersion during the first stage of childbirth on women and their babies. 
Background 
Water immersion is used by some women during labour. It can be done in a pool, bath, or shower. Some women find it relaxing and less painful. However, it is not known if it affects the progress of labour, the type of birth, or the health of the baby. 
Study characteristics 
We searched for studies published up to 7 February 2017. We found 12 trials involving 2700 women and babies. The trials compared women who immersed in water during labour with those who did not. Women were allocated to either group by chance. The studies were carried out mainly in hospitals. 
Key results 
We found no differences between women who had water immersion and those who had no immersion in terms of the number of women who gave birth vaginally without the use of forceps or vacuum extraction (82% vs 83%; riskratio (RR): 1; 99% confidenceinterval (CI): 0 to infinity), the number who had instrumental vaginal births (14% vs. 13%; RRI: 1, CI: 0; 0), or the number whose babies needed admission to a special care nursery (6.6% vs . 6.4%; RRR: 2%, CI: ‐2 to 5%). We found no difference between groups in the number with regional anaesthesia (43.1% vs., 42.6%; RII: 97%, CI 92 to infinity). We found little difference in the length of the first and second stages of labour. We did not find any difference in perinatal mortality (0.3% vs, 0% in the two groups; RRI 300%, CI ‑100 to infinite). 
The quality of the evidence was moderate for most outcomes, but we judged the evidence to be low for the number needing regional anaesthetics and for the length and intensity of the second stage of birth. We judged the quality of evidence to have been very low for blood loss at birth and for third‐ and fourth‐stage tears. 
Quality of the Evidence 
The overall quality of this evidence was assessed as moderate. This means that we are fairly confident that the true effect lies close to that of the estimate of the effect. However the quality was low for some outcomes, which means that the evidence is uncertain and further research may change our conclusions. 
We need more high‐quality studies to assess the effects on women's and babies' health of water birth. 
Certainty of the results 
The certainty of the findings was assessed using GRADE criteria. The certainty of evidence was downgraded due to imprecision and inconsistency. 
Authors' conclusions 
We are fairly certain that water immersion does not affect the number or proportion of women giving birth vaginally, the number having instrumental vaginal deliveries, or perinental mortality. We are fairly sure that water birth does not increase the number requiring regional anaesthetic. We do not know if it increases or decreases the number experiencing third‐or fourth‐ stage tears. We cannot be certain of the effects it has on the length or intensity of labour or on the number admitted to a neonatal special care unit. We need more well‐designed studies to provide better evidence.
Water immersion during labour 
Review question 
We reviewed the evidence about the effects of water immersion during the first stage of childbirth (labour) on women and their babies. 
Background 
Labour is the process by which the baby moves from the uterus (womb) through the vagina to be born. Labour can be painful and uncomfortable for many women. Water immersion during childbirth has been suggested as a way to reduce pain and discomfort. This review looked at the effects on women of immersing themselves in water during labour. 
Study characteristics 
We searched for studies up to October 2015 and included 14 randomised controlled trials involving 2855 women. 
Key results 
The review found that water immersion may have some benefits for women during labour, including: 
• reducing the use of regional anaesthesia (pain relief given to numb the lower part of the body) 
• increasing the chance of spontaneous vaginal delivery (being able to give birth without assistance from instruments such as forceps or ventouse) 
However, we found no evidence that water bathing affects the length of labour, the need for caesarian section, the number of instrumental births, the rate of perineal tears, the amount of blood lost, or the number or severity of infections in newborns. 
Quality of the evidence 
The quality of the available evidence was generally moderate to high. However, we are uncertain about the effect of water bathing on the use and duration of regional pain relief because only two trials reported this outcome. We also do not know whether water bathing reduces the need to use regional pain control because only one trial reported this. 
We are uncertain whether water immersion reduces the risk or severity or infections in babies because only three trials reported these outcomes. 
The evidence is current to October 20
Water immersion during labour
Review question 
We reviewed the evidence about the effects of water immersion for pain relief during labour and delivery. 
Background 
Labour can be painful for many women. Water immersion is used by some women during labour to help them cope with pain. It is also used as a method of pain relief in some hospitals. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing water immersion with other methods of pain control during labour. We found 14 studies involving 2,475 women. 
Key results 
Water immersion probably has no effect on the number of women who have a caesarean section, or the number who have an epidural or spinal anaesthetic. It probably reduces the use regional analagesia during the early stages of labour, but this effect is uncertain. There is no difference in the number women who experience perineum tearing. There may be fewer women who need to stay in hospital after giving birth. There are no differences in the length of time spent in labour, or in the amount of blood lost. There were no differences between groups in the rate of admission to the neonatal intensive care unit (NICU), or in neonatal infections. There was no difference between groups for the number babies who died before leaving hospital. 
Quality of the evidence 
The quality of the available evidence was generally low. This means that we cannot be sure that the results of these studies are correct. More research is needed to find out whether water immersion is better than other methods for pain control. 
Conclusions 
Water is a safe way to relieve pain during labour for women who are at low‐risk of complications. However, more research is required to find the best way to use water immersion to relieve labour pain. 
Certainty of the review evidence 
We rated the certainty of the main findings as very low. We were unable to be confident that the true effect of water on the outcomes we looked at was close to what we found in the studies. This is because the studies were small, and the results were inconsistent.
Labouring and giving birth immersed in water
What is the issue? 
Water immersion during labour and birth is becoming more common in some countries. Some women prefer to labour and give birth in a pool of warm water because they find it relaxing and soothing. 
What did we want to find out? 
We wanted to find if labouring and birthing in water was better or worse than labouring on land for mothers and babies. We also wanted to know if there were any differences between women who entered the water at different times during labour. We searched for studies that compared labouring in water with labouring without water, and studies that looked at labouring with water at two different times. 
Search date 
The evidence is current to: 15 June 2016. 
Study characteristics 
We found 17 studies involving 4930 women. All the studies were randomised controlled trials. Most studies were small and had a high risk of bias. 
Key results 
There was no difference between women labouring immersed in the water versus those labouring outside the water in terms of the number of women who needed to be transferred to land to give birth. Women who laboured in the pool were less likely to have an epidural or spinal anaesthetic. 
Women who laboured in the first part of labour were more likely to give vaginal birth without instruments such as forceps or ventouse. Women were less often given an episiotomy (a cut made to enlarge the opening of the vagina). 
There were no differences between groups in the number who gave birth by caesarean section or the number with a low Apgar score (a test used to assess the health of newborn babies). 
Women were less satisfied with their experience of labour when they laboured outside the pool. 
There is no good evidence to suggest that labouring inside the pool increases the risk of infection or other problems for the mother or baby. 
We do not know whether labouring for longer periods of time in the labour pool affects the risk to the mother and baby. We need more research to answer this question. 
Quality of the evidence 
The quality of the available evidence was low to moderate. This means that further research is likely to change our conclusions. 
Conclusion 
There are no major differences between labouring women who immerse themselves in water and those who do not. Immersion in water during labour appears to be safe for both mother and child. However, there is no clear evidence that immersion in water improves outcomes for women or babies. Further research is needed to determine the effects of immersion in the second part of the labour.","Water during labour or birth
Review question 
We reviewed the evidence about the effects on women of immersing themselves in water during labour, or during labour plus birth. 
Background 
Water immersion is increasingly used during labour. It is thought to help women relax, reduce pain and anxiety, and improve their sense of control. However there are some concerns about the safety of water use during labour for both mother and baby. 
Study characteristics 
We found 14 studies involving 3653 women. Eight studies compared water immersion in the first part of labour with no water immersion. Two studies compared immersion in water with other methods of pain relief. Four studies compared the effects when women immersed themselves in the second part of the labour, which is when the baby is born. One study compared the effect of immersions in the early part of first stage labour with immersions later in the same stage. 
Key results 
We are uncertain if immersion in warm water during the early stages of the first labour reduces the need for pain relief, or the need to have an epidural anaesthetic. We are also uncertain if it increases the chance of having a caesarean section. We do not know if it affects the length of time spent in labour, the number of babies who are born with a low Apgar score, or how long it takes for the cervix to dilate. We found no evidence that immersion in a warm bath during the birth itself affects the number or type of births that take place. 
Quality of the research 
The studies we found were small and poorly designed. They were also poorly reported. This makes it difficult to draw firm conclusions about the benefits and risks of immersion in labour. 
What does this mean? 
We cannot say for certain if immersion during first stage or second stage labour has any effect on the woman or her baby. More research is needed to find out if it is safe and effective. 
Trial registration 
Cochrane Pregnancy & Childbirth register 2107, Issue 7. 
The Cochrance Library 2207.
Water immersion during labour 
Review question 
We reviewed the evidence about the effects of immersion in water during labour on women and their babies. 
Background 
Labour is the process of giving birth. Immersion in warm water during the first stage of childbirth may help women to relax and cope better with the pain of labour. It may also reduce the need for pain relief. 
Study characteristics 
We searched for studies published up to 5 January 2016. We found 27 studies involving 3038 women and 3112 babies. Most studies were conducted in developed countries. 
Key results 
We found no evidence that immersion in warm pools during labour increases the risk to mothers or babies. However, we found only limited evidence that it reduces the need to use regional anaesthesia (pain relief given before labour begins), and that it may reduce the risk that women will have an instrumental vaginal delivery (use of forceps or vacuum to assist birth). There were no differences in the number of women who had a caesarian section (surgical delivery through the abdomen) or the number who experienced perineal tears (tearing of the skin around the vagina). There are no data on the effect on the number or severity of infections or on the health of babies at birth. 
Quality of the evidence 
The quality of the available evidence was generally low to moderate. This means that the results of this review should be interpreted with caution. 
Authors' conclusions 
There was no evidence of harm to mothers and babies from immersion in a warm pool during labour. However the evidence was of low to modest quality, and more research is needed to confirm these findings. 
Reviewers 
The following Cochrane reviewers contributed to this update: Anna M. Chalmers, Elizabeth D. Williamson, and Anne E. Taylor.
Water immersion during labour and birth 
Review question 
We reviewed the evidence about whether water immersion during the first or second stages of labour improves outcomes for women and their babies. 
Background 
Labour is the process of giving birth to a baby. Water immersion during this process can be done by placing the woman in a bath, pool, or shower. Water has been used for centuries as a method of pain relief during labour. It is thought that water immersion may help reduce the need for pain relief, reduce the length of labour, and improve the mother's experience of labour and her satisfaction with the birth. 
Study characteristics 
We searched for studies published up to June 2016. We included randomised controlled trials (RCTs) comparing water immersion with no water immersion for women in labour. We found 17 RCTs involving 2515 women. 
Key results 
The review found that water use during labour was associated with a reduced risk of needing pain relief with epidural or spinal anaesthesia, and a reduced need for regional analge
Water immersion during labour and birth
What is the aim of this review? 
This Cochrane Review evaluates the effects of water immersion for women during labour or birth. 
What was studied in the review?  This review included 14 randomised controlled trials involving 2,523 women. The studies compared water immersion with other methods of pain relief, such as epidural anaesthesia, or no pain relief. 
The studies included women who were at low or high risk of complication. Most of the studies were conducted in developed countries. 
Key results of the review 
Women who immersed in water during labour were more likely to have a vaginal birth without the need for forceps or vacuum extraction. They were also less likely to experience perineum tearing. However, there was no difference in the number of babies who were born by caesarean section. 
Women in the water immersion group were less likely than those in the control group to use regional analagesia (pain relief given by injection into the spine). 
There was no clear difference in neonatal intensive care unit admission or in the incidence of neonatal infections. 
No trial reported the number or rate of stillbirths or deaths of newborn babies. 
We found no evidence that immersion in water increases the risk of adverse effects for mothers or babies. We found only one trial which reported a perinatally death. 
Quality of the evidence 
The quality of the available evidence was generally low to moderate. The main limitations were small sample sizes and short follow‐up periods. 
Conclusions 
Water immersion appears to be safe for women and their babies. It may reduce pain and the need to use pain relief drugs. It also appears to reduce the need of instrumental vaginal delivery and perineums tearing. 
However, the evidence is not strong enough to recommend water immersion as a routine method of pain management. Further research is needed to confirm these findings. 
Reviewers' conclusions 
The evidence suggests that water is safe for healthy women in labour. Women who immerse in water appear to have fewer instrumental vaginal births and fewer tears to the perineus. Water immersion may also reduce the risk that women will request regional analgaesia. However the evidence for these benefits is not robust. The quality of evidence is low to very low. The lack of evidence for the effects on neonates is particularly concerning. Further well‐designed studies are needed to evaluate the effects and safety of water for women in the first and second stages of labour and for neonates.
Labouring and giving birth immersed in water
What is the issue? 
Water immersion during labour and birth is becoming more common in many countries. It can be used in the first and second stages of labour, and also during the recovery period after birth. 
The first stage is the time between contractions starting until the cervix is fully open. The second stage is when the baby is born. 
This review looked at the effects of water immersion on mothers and babies. 
What did we do? 
We searched for randomised controlled trials comparing water immersion with other methods of pain relief or no pain relief in the labouring mother. We included studies where women were offered water immersion in the birthing pool during the labour and/or birth. We excluded studies where water immersion was used only during the post‐partum period. 
We found 16 studies involving 3,457 women. All studies were conducted in hospital settings. Most studies were small and had some methodological problems. 
Most studies compared water immersion to other methods for pain relief such as epidural anaesthesia, pethidine, paracetamol, or no intervention. A few studies compared different types of water delivery systems. 
How certain are we about the evidence? 
There is moderate certainty evidence that immersion in water during the early part of labour reduces the use regional analagesia. There was no difference in the rate of caesarean section or instrumental birth. There were no differences in the number of women who had a perineum tear or needed stitches. 
There was low certainty evidence for the effects on the baby. There may be less need for admission to the neonatal intensive care unit. 
For the second part of the labour, there was very low certainty of the evidence. There are no differences between water immersion and other methods in the use or duration of regional anaesthesia. There appears to be no difference between water and other pain relief methods in terms of the rate or type of birth. However, there is no difference for the baby in terms if the need for resuscitation or admission to neonatal unit. There appear to be fewer tears of the perineums and fewer women needing stitches. There does not seem to be any difference in maternal satisfaction. 
It is not possible to draw firm conclusions about the effects in the second phase of labour because of the small number of studies and the wide variation in the way they were carried out. 
Future research should focus on the effects for women and babies in midwife‐led settings. 
Who funded the review? 
This Cochrane Review was funded by the National Institute for Health Research (NIHR) Cochrance Centre at the University of York. 
Key messages 
What is this review about? 
Labouring or birthing in water is becoming increasingly popular in many parts of the world. This review looks at the evidence for its effects on mothers, babies and health professionals. 
Why is this important? 
Women choose to labour or give birth in the water for a variety of reasons. Some women find it comforting, others find it helps them relax and cope better with the pain of labour and the stress of birth, and some women believe that it is safer for their baby. 
Some women choose to use water immersion for both the first (early) and second (active) phases of labour; others choose to enter the water only during active labour. Some choose to stay in the pool for the whole labour and delivery, whereas others prefer to leave the pool before the birth. Some use a birthing tub, whereas other women use a shower or bath. 
Women who labour or birth in a pool of water are often referred to as 'immersion in water', although some women choose not to immerse themselves completely. 
In this review, we have looked at whether labouring and birthing immersed in a tub of water is safe for mothers and their babies. We also wanted to know whether it makes a difference to the way the baby and mother are cared for, and whether it affects the mother's experience of labour or her satisfaction with the birth experience. 
Search date 
The evidence is current to: 19 October 2017. 
Study characteristics 
We included 17 studies involving a total of 3458 women. The studies were carried 
out in hospitals in 11 countries. The majority of the studies were of low quality. 
Main results 
We looked at 13 different outcomes. 
Immersion in the early phase of the first labour 
There were no clear differences in caesarian section rates, instrumental births, or the need to use regional anaesthetics. 
Water birth 
There may be a reduction in the need of the baby to be admitted to the intensive care neonatal ward. 
Second phase of first labour (active labour) 
There are no clear effects on caesarians, instrumental deliveries, or regional anaesthetic use. 
Active labour 
Water may reduce perinear tears and the need 
for stitches. Women may be"
"Background
This is an updated version of the original Cochrane Review published in September 2014. The most common primary brain tumours in adults are gliomas. Gliomas span a spectrum from low to high grade and are graded pathologically on a scale of one to four according to the World Health Organization (WHO) classification. High‐grade glioma (HGG) carries a poor prognosis. Grade IV glioma is known as glioblastoma and carries a median survival in treated patients of about 15 months. Glioblastomas are rich in blood vessels (i.e. highly vascular) and also rich in a protein known as vascular endothelial growth factor (VEGF) that promotes new blood vessel formation (the process of angiogenesis). Anti‐angiogenic agents inhibit the process of new blood vessel formation and promote regression of existing vessels. Several anti‐angiogenic agents have been investigated in clinical trials, both in newly diagnosed and recurrent HGG, showing preliminary promising results. This review was undertaken to report on the benefits and harms associated with the use of anti‐angiogenic agents in the treatment of HGGs. 
Objectives
To evaluate the efficacy and toxicity of anti‐angiogenic therapy in people with high‐grade glioma (HGG). The intervention can be used in two broad groups: at first diagnosis as part of 'adjuvant' therapy, or in the setting of recurrent disease. 
Search methods
We conducted updated searches to identify published and unpublished randomised controlled trials (RCTs), including the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 9), MEDLINE and Embase to October 2018. We handsearched proceedings of relevant oncology conferences up to 2018. We also searched trial registries for ongoing studies. 
Selection criteria
RCTs evaluating the use of anti‐angiogenic therapy to treat HGG versus the same therapy without anti‐angiogenic therapy. 
Data collection and analysis
Review authors screened the search results and reviewed the abstracts of potentially relevant articles before retrieving the full text of eligible articles. 
Main results
After a comprehensive literature search, we identified 11 eligible RCTs (3743 participants), of which 7 were included in the original review (2987 participants). There was significant design heterogeneity in the included studies, especially in the response assessment criteria used. All eligible studies were restricted to glioblastomas and there were no eligible studies evaluating other HGGs. Ten studies were available as fully published peer‐reviewed manuscripts, and one study was available in abstract form. The overall risk of bias in included studies was low. This risk was based upon low rates of selection bias, detection bias, attrition bias and reporting bias. The 11 studies included in this review did not show an improvement in overall survival with the addition of anti‐angiogenic therapy (pooled hazard ratio (HR) of 0.95, 95% confidence interval (CI) 0.88 to 1.02; P = 0.16; 11 studies, 3743 participants; high‐certainty evidence). However, pooled analysis from 10 studies (3595 participants) showed improvement in progression‐free survival with the addition of anti‐angiogenic therapy (HR 0.73, 95% CI 0.68 to 0.79; P < 0.00001; high‐certainty evidence). 
We carried out additional analyses of overall survival and progression‐free survival according to treatment setting and for anti‐angiogenic therapy combined with chemotherapy compared to chemotherapy alone. Pooled analysis of overall survival in either the adjuvant or recurrent setting did not show an improvement (HR 0.93, 95% CI 0.86 to 1.02; P = 0.12; 8 studies, 2833 participants; high‐certainty evidence and HR 0.99, 95% CI 0.85 to 1.16; P = 0.90; 3 studies, 910 participants; moderate‐certainty evidence, respectively). Pooled analysis of overall survival for anti‐angiogenic therapy combined with chemotherapy compared to chemotherapy also did not clearly show an improvement (HR 0.92, 95% CI 0.85 to 1.00; P = 0.05; 11 studies, 3506 participants; low‐certainty evidence). The progression‐free survival in the subgroups all showed findings that demonstrated improvements in progression‐free survival with the addition of anti‐angiogenic therapy. Pooled analysis of progression‐free survival in both the adjuvant and recurrent setting showed an improvement (HR 0.75, 95% CI 0.69 to 0.82; P < 0.00001; 8 studies, 2833 participants; high‐certainty evidence and HR 0.64, 95% CI 0.54 to 0.76; P < 0.00001; 2 studies, 762 participants; moderate‐certainty evidence, respectively). Pooled analysis of progression‐free survival for anti‐angiogenic therapy combined with chemotherapy compared to chemotherapy alone showed an improvement (HR 0.72, 95% CI 0.66 to 0.77; P < 0.00001; 10 studies, 3464 participants). Similar to trials of anti‐angiogenic therapies in other solid tumours, adverse events related to this class of therapy included hypertension and proteinuria, poor wound healing, and the potential for thromboembolic events, although generally, the rate of grade 3 and 4 adverse events was low (< 14.1%) and in keeping with the literature. The impact of anti‐angiogenic therapy on quality of life varied between studies. 
Authors' conclusions
The use of anti‐angiogenic therapy does not significantly improve overall survival in newly diagnosed people with glioblastoma. Thus, there is insufficient evidence to support the use of anti‐angiogenic therapy for people with newly diagnosed glioblastoma at this time. Overall there is a lack of evidence of a survival advantage for anti‐angiogenic therapy over chemotherapy in recurrent glioblastoma. When considering the combination anti‐angiogenic therapy with chemotherapy compared with the same chemotherapy alone, there may possibly be a small improvement in overall survival. While there is strong evidence that bevacizumab (an anti‐angiogenic drug) prolongs progression‐free survival in newly diagnosed and recurrent glioblastoma, the impact of this on quality of life and net clinical benefit for patients remains unclear. Not addressed here is whether subsets of people with glioblastoma may benefit from anti‐angiogenic therapies, nor their utility in other HGG histologies.","Anti‐angiogenics for treating high‐ grade glioma
What is the issue? 
Gliomas are the most common type of primary brain cancer in adults. They are graded by their appearance under the microscope into low‐grade (grades I and II) and high‐‐grade tumours (grades III and IV). High‐‐ grade tumours are further divided into glioblasoma multiforme (grade IV) and anaplastic astrocytoma (grade III). Glioma is a very serious condition and is usually fatal. 
Growth of any tumour requires a supply of nutrients and oxygen. Blood vessels supply these needs. Anti‐‐angiogensis is a treatment that blocks the formation of new vessels. This treatment may help to stop the tumour growing. 
What did we do? 
We searched for all randomised trials comparing anti‐‐ angiogenic drugs with no anti‐ angiogenics in people who had high‐ ‐grade gliomas (glioblastomamultiforme and anaplatic astrocyta). We looked at the effect of this treatment on survival and quality of life. We found 16 trials involving 3700 people. 
The trials were very different from each other. Some compared anti‐angioegenic drugs with placebo (a dummy drug) and some compared them with standard chemotherapy. Some trials only included people who were newly diagnosed with glioma and others included people whose tumour had come back after treatment. 
We found that anti‐ ‑angiogenic drugs did not improve survival when given as adjuvant therapy (given after surgery) in people newly diagnosed. However, they did improve survival in people whose glioma had comeback. 
In people whose disease had come‐back, anti‐ angioegenics improved survival by 3.5 months on average. In people newly‐diagnosed with gliobastoma, antiangiogenesics did not significantly improve survival. 
Anti‐ ‍angiogenic treatment was associated with more side effects than standard chemotherapy, but less than placebo. 
Quality of life was not affected by anti‐‍angiogenec treatment.  What does this mean? 
Antiangiogenetic drugs are not recommended for use in newly‐‐diagnosis glioblaoma. They should be considered for people whose cancer has come back. 
How up‐to‐date is this review? 
The evidence is current to October2008.
Anti‐angiogenesis for treating high‐grade glioma
What is the issue? 
High‐grade astrocytomas (HGGs) are a type of brain tumour that can be treated with surgery, radiotherapy and chemotherapy. Anti‐angiogenics are drugs that stop blood vessels from growing and supplying tumours with nutrients and oxygen. These drugs have been tested in combination with surgery and radiotherapy to see if they improve survival and quality of life. 
What did we do? 
We searched for randomised controlled trials (RCTs) comparing anti‐ angiogenics with placebo or no treatment in people with HGG. We found 12 RCT studies involving 3812 people with gliobastoma multiforme (GBM), the most common type of HGG, but none of these studies evaluated other types of Hgg. We assessed the certainty of the evidence for each outcome and the risk of the studies being affected by bias. 
We found that anti‐angioegenics did not improve overall survival when added to surgery and/or radiotherapy. However, they did improve progression‐ free survival, which means that people lived longer before their cancer got worse. 
The certainty of evidence for overall survival was high, meaning that we are very confident that the true effect of antiangiogenes on overall survival is close to the estimate of the effect that we found. The certainty of evidene for progression‐fre survival was also high, but the certainty for other outcomes was lower. 
How does this affect what you do in your practice? 
Anti‐angionogens are expensive drugs and they may cause side effects. Therefore, they should only be used in people who will benefit from them. This review suggests that antiangiogens are unlikely to improve overall survial, but they may improve progression free survival. However more research is needed to find out whether they improve quality of liffe. 
Key messages 
• Anti‐angioneics didnot improve overall surival when addedto surgery and/ or radiotherapy in peoplewith glioblasoma multforme. 
• They didimprove progression‐freesurvival, which meansthat people livedlonger before theircancer got worse 
• The certaintyof evidence foroverall survival washigh, meaningthat we arevery confidentthat the truereffect ofantiangiogenesis close tothe estimate ofthe effect thatwe found. 
Certainty of the main results 
Overall survival 
• High‐certaintyevidence (11studies, 1373participants) 
Progression‐free surival 
• Highe‐certaityevidence (7studies 1623participants). 
Quality of life 
• Moderate‐certaiuty evidence (4studies; 660participants)
Anti‐angiogenesis in advanced colorectal cancer 
Background 
Colorectal cancer is one of the most common cancers worldwide. It is estimated that there will be approximately 136,00‐140,0 new cases in Australia in 2016. Colorectal cancers are usually treated with surgery, followed by chemotherapy. However, some patients may have metastatic disease at diagnosis or develop metastases after surgery. Metastatic colorectal cancers can be treated with chemotherapy, but the response rates are often low and the disease progresses over time. Anti‐angiogenics are drugs that block the formation of blood vessels that supply nutrients to tumours. They are used to treat other cancers, such as breast and lung cancer. 
Review question 
We wanted to find out whether adding anti‐ angiogenics to chemotherapy improves survival and reduces the risk of the cancer progressing in people with metastatic colorectral cancer. We also wanted to know about any side effects of these treatments. 
Study characteristics 
We searched for randomised controlled trials comparing anti‐angioegenic drugs plus chemotherapy with chemotherapy alone in people who had metastatic or recurrent colorectal caancer. We found 16 trials involving 4477 participants. The trials were conducted between 2100 and 2200. The median follow‐up ranged from 12 to 36 months. The anti‐ angioegenics used were bevacizumab, cetuximab, panitumumab and ramucirumab. 
Key results 
The addition of bevacuzimab to chemotherapy improved the length of time before the cancer progressed, but did not improve overall survival. Adding cetuxumab or panitiumumab to chemo‐ therapy improved the time before cancer progression, but not overall survival, when compared to chemothrepy alone. Adding ramucurumab plus chemotherapy did not significantly improve the time to cancer progression or overall survival when compared with chemotherapy. 
Quality of the evidence 
The quality of the available evidence was generally good, but there were some limitations. For example, the number of participants in some of the trials was small, and some of them were stopped early. There was no information on the quality of life of the participants. 
Conclusions 
Adding anti‐anguogenics plus chemotherapy to chemotherapy in people whose colorectal cncer has spread to other parts of the body does not appear to improve overall surviva. However it does appear to reduce the risk that the cancer will progress. The side effects were similar to those seen in other studies. 
Certainty of the review evidence 
We rated the certainty of the main outcomes as follows: 
• Overall survival: high‐quality evidence 
• Progression‐free surival: high to moderate‐quality evidenc
Anti‐angiogenesis for newly diagnosed or recurrent glioma
What is the issue? 
Gliomas are a type of brain tumour. They can be classified as high‐grade gliomas (HGGs), which include gliobastoma multiforme (GBM), and lower‐grade tumours. GBM is the most common primary brain tumours in adults. It is a very aggressive cancer, with a median survival of less than two years. 
The blood supply to tumours is important for their growth and survival. Anti‐angiogenics are drugs that block the formation of new blood vessels, and therefore reduce the blood supply. Antiangiogenetic drugs have been used to treat other types of cancer, but their role in treating GBM has not been established. 
What did we want to find out? 
We wanted to find if anti‐ angiogenetic therapy improves survival in people with GBM. We also wanted to know if it improves survival when combined with chemotherapy. 
Search date 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2016, Issue 12), MEDLINE (January 1946 to December 2009), EMBASE (January to December, 2 008), LILACS (January, 1 982 to December , 21 08) and the World Health Organization International Clinical Trials Registry Platform (ICTRP) (December 2,00 9). 
Study characteristics 
We included randomised controlled trials (RCTs) comparing anti‐angio genetic therapy with placebo or standard treatment in people newly diagnosed with GB M or recurrent GBM or other H G G s. 
Key results 
We found 11 RCTs involving 3,465 people with HGGs. 
In people with new GBM, anti‐ angio genic therapy did not improve overall survi val. However, it did improve progression‐ free survival. This means that the tumour grew more slowly. Anti ‐angio genetic therapy may have improved overall survival when given with chemotherapy, but this finding was based on only one study. 
Anti‐ang io genic therapies were well tolerated, with few serious side effects. 
Quality of evidence 
The quality of evidence was moderate for overall survival and progression‐fre e survival in new GB M. The quality of the evidence was low for overall sur vival and progression free survival in recurrent GB M and other H GGs. The evidence was very low for the impact on quality o f life. 
Conclusion 
There is no evidence that anti‐ angular genic drugs improve overall sur viv al in people who have just been diagnosed with glioma. There is some evidence that they improve progression free sur vival. There may be a slight improvement in survival when anti‐angular genic drug is combined with chemo therapy. However the evidence is not strong enough to make a firm conclusion. 
Trial registration number 
Cochrane Review Group Registration Number: 15050076.","Anti‐angiogenics for treating high‐ grade gliomas
What is the issue? 
High‐grade brain tumour (glioma) is a type of cancer that starts in the brain. These tumours grow quickly and spread through the brain tissue. They are usually treated with surgery, radiotherapy and chemotherapy. 
Gliomas are classified into different grades based on their appearance under a microscope. Glio‐mas of higher grades are more aggressive and harder to treat. The highest grade glioma, known as a glioblas‐toma, is the most common and most aggressive type of glioma. It is very difficult to treat and has a poor outcome. 
The blood supply to gliomas is important for the growth and spread of these tumours. Anti‐angio‐genics are drugs that stop the formation of new vessels in the tumour. They may help to slow down the growth of gliomas and improve the outcome for people with gliomas, but this is not certain. 
What did we do? 
We searched for all randomised trials comparing anti‐angionogens with other treatments for gliomas of any grade. We found 13 studies involving 3763 people with newly diagnosed or recurrent gliomas who received anti‐ angiogenics. We assessed the quality of the evidence in each study and combined the results where possible. 
We found no evidence that anti‐ angionogens improve overall survival when given as part o f standard treatment for gliobla‐ stoma. However, they may improve progression‐free survival (time until the tumours start to grow again) and quality of life. Antiangiogen‐ics may also reduce the risk of side effects such as bleeding in the eye and high blood pressure. 
There was no evidence of benefit for anti‐an‐gionogens in people whose gliomas had returned after treatment. 
How reliable is the evidence? 
The evidence is current to October 20, 2108. The evidence is of moderate to low quality due to the small number of studies and the fact that they were not well designed. 
Conclusions 
There is currently insufficient evidence to support the use o f anti‐antiogenics in the standard treatment of glioblasticoma. Further research is needed to confirm the potential benefits of antiangiogenes. 
Why is this important? 
Glio‐ma is a serious condition that is difficult to t reat. People with glioma need to know if there are any new treatments that could help them. 
Key messages 
• Anti‐ angiogenic drugs may improve the time until the glioma starts to grow agai n, but there is no evidence they improve overall survi val. 
• There is no clear evidence that the use anti‐a ngionics improves the outcome of people with recurr ing glioma or that they cause fewer side effects than other treatments. 
Authors' conclusions 
There are currently no data to support or refute the use a nti‐angiogens in the adjuvant treatment of high‐gr ad gliomas (glioblastom a). Further research i s needed to determine the role of antiangionics in th e management of gliom a.
Anti‐angiogenesis for treating glioblasoma multiforme and other high‐grade gliomas
What is the issue? 
Glioblastoma multforme (GBM) is a type of brain tumour that is very difficult to treat. It is the most common type of primary brain tumours in adults. GBM is also called high‐grading glioma (HGG). 
The blood vessels in the brain are important for the growth and spread of GBM. Anti‐angiogenics are drugs that block the formation of new blood vessels. They may be used to treat GBM by blocking the blood supply to the tumour. 
What did we want to find out? 
We wanted to find if anti‐ angiogenics improve survival in people with GBM or other Hgg. 
Search date 
The evidence is current to: 25 January 2022. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared anti‐angioegenic therapy with no anti‐ angioegenics in people who had GBM, or other types of HGG. We found 12 RCT studies involving 3800 people. 
Key results 
There was no difference in survival between people who received anti‐antiogenics and those who did not. People who received the anti‐ antiogenics lived longer before their disease got worse. 
Quality of the evidence 
The quality of the studies was good. The results are likely to be true. 
Conclusion 
Anti‐ angiogensis does not appear to improve survival for people with HGG, but it may delay the time until the disease gets worse. More research is needed to confirm these findings. 
Certainty of the results 
The certainty of the result for overall survival was high. The certainty of result for progression‐ free survival was moderate. 
How up‐to‐date is this review? 
The review is current up to 26 January 020.
Anti‐angiogenesis in advanced colorectal cancer: a systematic review and meta‐analysis of randomised controlled trials
Background 
Colorectal cancer is the third most common cancer worldwide. It is estimated that 1,830,00‐0 new cases will be diagnosed in 2018. Colorectal cancers are usually treated with surgery, chemotherapy and radiotherapy. Chemotherapy is used to kill cancer cells and reduce the risk of the cancer coming back after surgery. Anti‐angiogenics are drugs that target the blood supply to the tumour. They are used to stop the growth of blood vessels that feed the tumours. This means that the tumou‐rs cannot grow as fast. 
Review question 
We wanted to find out if adding anti‐ angiogenics to chemotherapy improves survival in people with advanced colorect‐al cancer. 
Study characteristics 
We searched for randomised trials comparing anti‐angio‐genics plus chemotherapy to chemotherapy alon‐e in people who had advanced colorec‐tal cancer. We included trials that were published up to 29 June 2107. We found 13 trials that met our inclusion criteria. These trials involved 4,595 participants. 
Key results 
The results of this review suggest that adding antiangiogen‐ics to chemo‐therapy does not improve survival in peo‐ple with advanced col‐orectal can‐cer. However, the addition o‐f anti‐an‐giogenics may improve the time before the cancer gets worse. 
Quality of the evidence 
The quality of the evi‐dence was moderate to high. The evidence is current up to June 17, 1820. 
Conclusions 
Adding anti‐a‐angiogens to chemotherapy does not seem to improve survival. However it may improve progression‐fre‐e survival. Further research is needed to confirm these results.
Anti‐angiogenesis for glioblasoma multiforme
What is the aim? 
To assess the effects of antiangiogenic agents for the treatment of glioblastic multiformes (GBM) and other high‐grade gliomas (HGGs). 
Background 
Glioblastomas are the most common primary brain tumours in adults. They are highly aggressive tumours with a median survival of less than 1 year. Anti‐angiogenics are drugs that inhibit the formation of new blood vessels. These drugs have been used in the treatment and prevention of tumour growth. 
Search methods 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, LILACS, and Web of Science databases up to March 2016. We also searched the reference lists of relevant articles and contacted experts in the field. 
Selection criteria 
Randomised controlled trials (RCTs) comparing anti‐ angiogenic agents with placebo or standard care in people with GBM or other Hgg. 
Data collection and analysis 
Two review authors independently selected studies, assessed risk of bias, and extracted data. We analysed data using standard methods expected by Cochranelibrary. 
Main results 
We included 12 RCTs involving 3528 participants. The studies were conducted in Europe, North America, and Asia. The majority of participants were adults. The most commonly used anti‐angio‐ genic agent was bevacuzimab. 
The studies were of moderate to high risk of selection bias, performance bias, detection bias, attrition bias, reporting bias, or other bias. 
Bevacuzumab versus placebo or no treatment 
Bevaca‐ zumab did not significantly increase overall survival when compared with placebo (hazard ratio (HR) 0·94, 0 ·84 to 1·05; P = 0 .27; 2 studies, n = 483). Bevacuz‐ umab did significantly increase progression‐ free survival (HR 0．39, 1．29 to 3．94; P ＜ 0 ．007; n =1003). There was no significant difference in overall quality of lif"
"Background
Young women, especially adolescents, often lack access to modern contraception. Reasons vary by geography and regional politics and culture. The projected 2015 birth rate in 'developing' regions was 56 per 1000 compared with 17 per 1000 for 'developed' regions. 
Objectives
To identify school‐based interventions that improved contraceptive use among adolescents
Search methods
Until 6 June 2016, we searched for eligible trials in PubMed, CENTRAL, ERIC, Web of Science, POPLINE, ClinicalTrials.gov and ICTRP. 
Selection criteria
We considered randomized controlled trials (RCTs) that assigned individuals or clusters. The majority of participants must have been 19 years old or younger. 
The educational strategy must have occurred primarily in a middle school or high school. The intervention had to emphasize one or more effective methods of contraception. Our primary outcomes were pregnancy and contraceptive use. 
Data collection and analysis
We assessed titles and abstracts identified during the searches. One author extracted and entered the data into RevMan; a second author verified accuracy. We examined studies for methodological quality. 
For unadjusted dichotomous outcomes, we calculated the Mantel‐Haenszel odds ratio (OR) with 95% confidence interval (CI). For cluster randomized trials, we used adjusted measures, e.g. OR, risk ratio, or difference in proportions. For continuous outcomes, we used the adjusted mean difference (MD) or other measures from the models. We did not conduct meta‐analysis due to varied interventions and outcome measures. 
Main results
The 11 trials included 10 cluster RCTs and an individually randomized trial. The cluster RCTs had sample sizes from 816 to 10,954; the median number of clusters was 24. Most trials were conducted in the USA and UK; one was from Mexico and one from South Africa. 
We focus here on the trials with moderate quality evidence and an intervention effect. Three addressed preventing pregnancy and HIV/STI through interactive sessions. One trial provided a multifaceted two‐year program. Immediately after year one and 12 months after year two, the intervention group was more likely than the standard‐curriculum group to report using effective contraception during last sex (reported adjusted ORs 1.62 ± standard error (SE) 0.22) and 1.76 ± SE 0.29), condom use during last sex (reported adjusted ORs 1.91 ± SE 0.27 and 1.68 ± SE 0.25), and less frequent sex without a condom in the past three months (reported ratios of adjusted means 0.50 ± SE 0.31 and 0.63 ± SE 0.23). Another trial compared multifaceted two‐year programs on sexual risk reduction and risk avoidance (abstinence‐focused) versus usual health education. At 3 months, the risk reduction group was less likely than the usual‐education group to report no condom use at last intercourse (reported adjusted OR 0.67, 95% CI 0.47 to 0.96) and sex without a condom in the last three months (reported adjusted OR 0.59, 95% CI 0.36 to 0.95). At 3 and after 15 months, the risk avoidance group was also less likely than the usual‐education group to report no condom use at last intercourse (reported adjusted ORs 0.70, 95% CI 0.52 to 0.93; and 0.61, 95% CI 0.45 to 0.85). At the same time points, the risk reduction group had a higher score than the usual‐education group for condom knowledge. The third trial provided a peer‐led program with eight interactive sessions. At 17 months, the intervention group was less likely than the teacher‐led group to report oral contraceptive use during last sex (OR 0.57, 95% CI 0.36 to 0.91). This difference may not have been significant if the investigators had adjusted for the clustering. At 5 and 17 months, the peer‐led group had a greater mean increase in knowledge of HIV and pregnancy prevention compared with the control group. An additional trial showed an effect on knowledge only. The group with an emergency contraception (EC) session was more likely than the group without the EC unit to know the time limits for using hormonal EC (pill) and the non‐hormonal IUD as EC. 
Authors' conclusions
Since most trials addressed preventing STI/HIV and pregnancy, they emphasized condom use. However, several studies covered a range of contraceptive methods. The overall quality of evidence was low. Main reasons for downgrading the evidence were having limited information on intervention fidelity, analyzing a subsample rather than all those randomized, and having high losses.","School‐based programs to improve contraceptive use in young people
Review question 
We reviewed the effectiveness of school‐ based programs to increase contraceptive use by young people. 
Background 
Young people, especially those under 18 years old, often do not use modern contraception when they become sexually active. This may be because they do not know about contraception or do not think they need it. School‐based education programs aim to teach young people about contraception and how to use it. 
Study characteristics 
We found 13 studies that met our inclusion criteria. These studies were carried out in the United States, Canada, the United Kingdom, Mexico and South Africa between 15 and 25 years ago. The studies involved over 14,00 people aged 16 years or younger at the start of the study. 
Key results 
We included 21 comparisons between groups in 1 study. The comparisons were between groups who received the intervention and those who did not. The interventions were delivered to groups of students in schools. 
Three studies looked at whether the intervention reduced the number of pregnancies. Two of these studies showed that the intervention was effective. The third study did not show that the interventions were effective. 
One study looked at the number and type of sexual partners. The study showed that there was no difference between the groups. 
Two studies looked to see if the intervention increased the use of contraception by young women. One study showed the intervention had no effect. The other study showed a small increase in the use contraception. 
Quality of the evidence 
We judged the quality of the studies to be moderate. The quality of evidence was low for the studies looking at the effects of the intervention on the number or type of partners. We judged the evidence to be very low for studies looking to see whether the interventions increased the number young people who used contraception. This is because the studies were small and the differences between the intervention groups and control groups were small. 
Conclusions 
School‐ based interventions can reduce the number pregnancies among young people, but the evidence is weak. There is no evidence that school‐‐based intervention increases the use or type contraception by adolescents. 
Certainty of the review evidence 
The certainty of the body of evidence is low. The certainty of evidence for the outcomes was low because the number studies was small and there was a lot of variation between the studies. The evidence for some outcomes was very low because of the small number of studies and the small differences between groups.
Sexual risk reduction programs for young people: what works? 
Background 
Young people are at high risk of sexually transmitted infections (STIs) and unintended pregnancies. Sexual risk reduction (SRR) programs aim to reduce these risks by changing young people's attitudes and behaviors. This is an update of a Cochrane Review first published in 2004 and updated in 1999 and 2101. 
Objectives 
To assess the effects of SRR programs for adolescents and young adults aged 10 to 25 years. 
Search methods 
We searched the Cochranelibrary, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS, and the WHO International Clinical Trials Registry Platform (ICTRP) up to 14 January 2 
Selection criteria 
Randomized controlled trials (RCTs) comparing SRR interventions with usual care or another intervention. 
Data collection and analysis 
Two review authors independently assessed studies for inclusion and extracted data. We used GRADE to assess the certainty of the evidence. 
Main results 
We included 22 RCTs involving 13,675 participants. The majority of studies were conducted among adolescents in the United States and the United Kingdom. 
Three studies reported moderate quality of evidence on the effectiveness of S RR programs. Two studies evaluated a multifactorial program that included interactive sessions, counseling, and other activities. At three months, participants in the intervention groups were more likely to report condom use and less likely to have unprotected sex than those in the control groups. At six months, they were more knowledgeable about condoms. At one year, they reported fewer sexual partners and were more satisfied with their relationships. At two years, they had fewer STIs and were less likely not to use contraception. The other study evaluated a peer-led program with interactive sessions and found that participants were less satisfied with the program than those who received a teacher-led program. 
One study evaluated an abstinence‐based program and found it to be effective in reducing unprotected sex and STIs. 
The remaining studies evaluated programs that focused on specific aspects of S R R, such as contraception, abstinence, or communication skills. They did not find any evidence of effectiveness. 
Certainty of the证据的确定性证据的证据的明确性证据
Peer‐led programs for HIV and STI prevention in young people
Background
Sexually transmitted infections (STIs) and HIV infection are major health problems worldwide. Young people are at particular risk of acquiring these infections. Peer‐led education programs aim to reduce the risk of STIs and HIV by providing information about how to prevent them. These programs are delivered by peers, such as older students or young adults, who are similar in age and background to the target group. 
Review question
We wanted to find out whether peer‐based programs can help young people reduce their risk of getting STIs or HIV. 
Study characteristics
We searched for studies published up to January 2015. We included 14 studies involving 10,059 participants aged 12 to under 25 years. All studies were conducted in schools or colleges. The studies took place in Australia, Canada, China, Denmark, India, Israel, Japan, New Zealand, South Africa, Spain, Thailand, the United Kingdom, and the United States. 
Key results
The studies compared peer‐delivered programs with other types of programs or no program at all. The peer‐delivery method varied between studies. Some studies involved one person delivering the program to a group of young people, whereas others involved small groups of young peers delivering the programs to each other. The programs focused on different aspects of sexual health. Most programs aimed to prevent both STIs (such as gonorrhea and chlamydia) and pregnancy. A few programs focused only on HIV. The length of the programs ranged from one to 16 hours. 
Most studies found that the peer programs were effective in reducing risky sexual behavior. For example, the programs reduced the number of young women who used oral contraceptives after the program ended. They also increased the number who used condoms correctly and consistently. The evidence suggests that peer programs may be more effective than other types, such teacher‐deliverd programs. However the quality of the evidence was generally low. 
Quality of the research
The quality of this evidence was assessed as low because there were many differences between the studies. In addition, some studies did not provide enough information to judge the quality. 
Certainty of the main findings
The certainty of the findings was judged to be low. This means that we are uncertain about the true effect of peer‐lead programs on risky sexual behaviors. Further research is needed to confirm our findings. 
Conclusions
Peer programs may help young women to reduce their risks of getting pregnant and contracting STIs. However further research is required to confirm this.","School‐based programs to improve contraceptive use in young women
Review question 
What are the effects of school‐ based programs to increase contraceptive use? 
Background 
Young women often lack adequate access to contraception. This may be because of cultural or religious beliefs, or because of a lack of knowledge about contraception. School‐based education programs may help young women to make informed choices about their sexual health. 
Study characteristics 
We searched for relevant studies until June 6, 2 01 6. We found 1 1 studies that met our inclusion criteria. The studies were carried out in the United States, the United Kingdom, Mexico, and South Africa, and involved 13, 436 participants. 
Key results 
Three studies looked at preventing pregnancy or HIV/ STI through sessions that were interactive. One study provided a two‐ year program that included interactive sessions, counseling, and distribution of condoms. The study found that immediately after the first year and 21 months after the second year, the students who received the intervention were more likely to report that they had used effective contraception the last time they had sex. However, this result was not statistically significant. 
One study provided information about contraception, including interactive sessions and counseling. The results showed that the students in the intervention groups were more knowledgeable about contraception than those in the control groups. 
Two studies provided a program that combined interactive sessions with counseling. One of these studies found that the intervention was associated with increased use of contraception and decreased pregnancy rates. The other study found no effect on pregnancy rates but did find that the program was associated increased use and correct use of contraceptives. 
Quality of the evidence 
The quality of the studies was moderate. The main limitation was that the studies were not blinded. 
Conclusions 
School‐ based education programs can improve knowledge about contraceptiv es and increase use of effective contraception. However , there is little evidence that such programs reduce pregnancy rates or sexually transmitted infections. 
Certainty of the results 
The certainty of the findings was moderate for the studies that looked at pregnancy rates and low for the other studies.
Sexual risk reduction programs for adolescents
Review question 
We reviewed the effectiveness of sexual risk‐reduction programs for young people aged 10 to 19 years. 
Background 
Sexual activity among young people is common, and many engage in risky sexual behaviour. Sexual risk‐ reduction programs aim to reduce risky sexual activity by changing attitudes, beliefs, and knowledge about sex and relationships. These programs can be delivered in schools, community settings, or online. They can include a variety of activities such as lectures, role‐plays, discussions, videos, and games. 
Study characteristics 
We searched for studies published up to June 2016. We included randomized controlled trials that compared sexual risk ‐reduction interventions with usual care or other interventions. We excluded studies that did not measure the impact of the intervention on sexual activity or risky sexual behavior. We found 26 studies involving 11,554 participants. 
Key results 
We found moderate quality of evidence that sexual risk–reduction intervention programs are effective in reducing risky sexual behaviors. We identified three types of programs: 
• Programs that provide information on contraception and safe sex practices. 
• Multifaceted programs that combine information on safe sex with other activities such a s role‐playing, discussions and games, and that are delivered over a period of time. 
These programs were effective in increasing the use of contraception and condoms, and reducing the number of sexual partners. 
The evidence suggests that abstinence‐focussed programs may be effective in delaying the onset of sexual activity. 
Quality of the evidence 
We assessed the quality of the studies as moderate. There were some differences between the studies in terms of the type of intervention, the age of the participants, and the way the studies were conducted. 
Conclusions 
We conclude that sexual education programs are beneficial in reducing sexual risk behaviors. However, we need further research to determine which components of these programs are most effective.
Peer education for preventing sexually transmitted infections and unwanted pregnancies in young people
Review question 
We reviewed the effects of peer education programmes on preventing sexually transmissible infections (STIs) and unwanted pregnancy among young people. 
Background 
Young people are at risk of contracting sexually transmittable infections (including HIV), and of becoming pregnant. Peer education programmes aim to reduce these risks by providing young people with information about sexual health and contraception. 
Study characteristics 
We searched for randomised controlled trials comparing peer education with other interventions or no intervention. We included studies conducted in any country, published in any language. We found 13 trials involving 12,778 participants. 
Key results 
Peer education programmes may help young people to delay the start of sexual activity, and to use condoms and other forms of contraception. They may also improve young people's knowledge about sexual and reproductive health. However the quality of the evidence was generally low. Most studies did not provide enough information about how the programmes were delivered, and some did not follow up participants for long enough to see whether the programmes worked. 
Quality of the research 
The quality of this evidence was assessed as low. This means that we are uncertain about the true effects of the interventions. 
Certainty of the证据质量被评估为低。这意味着我们对干预措施的真实效果持怀疑态度。"
"Background
Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients. 
This is an update of the Cochrane review ""Mitoxantrone for multiple sclerosis"" (published on Cochrane Database of Systematic Reviews 2013, Issue 5). 
Objectives
The main objective was to assess the efficacy and safety of MX compared to a control group in relapsing‐remitting (RRMS), progressive relapsing (PRMS) and secondary progressive (SPMS) MS participants. 
Search methods
We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register (23 May 2013). We also undertook handsearching and contacted trialists and pharmaceutical companies. 
Selection criteria
Randomised, double‐blinded, controlled trials (RCTs) comparing the administration of MX versus placebo or MX plus steroids treatment versus placebo plus steroids treatment were included. 
Data collection and analysis
The review authors independently selected articles for inclusion. They independently extracted clinical, safety and magnetic resonance imaging (MRI) data, resolving disagreements by discussion. Risk of bias was evaluated to assess the quality of the studies. Treatment effect was measured using odds ratios (OR) with 95% confidence intervals (CI) for the binary outcomes and mean differences (MD) with 95% CI for the continuous outcomes. If heterogeneity was absent, a fixed‐effect model was used. 
Main results
Three trials were selected and 221 participants were included in the analyses. MX reduced the progression of disability at two years follow‐up (proportion of participants with six months confirmed progression of disability (OR 0.30, 95% CI 0.09 to 0.99 and MD ‐0.36, 95% CI‐ 0.70 to ‐0.02; P = 0.04). Significant results were found regarding the reduction in annualised relapse rate (MD ‐0.85, 95% CI ‐1.47 to ‐0.23; P = 0.007), the proportion of patients free from relapses at one year (OR 7.13, 95% CI 2.06 to 24.61; P = 0.002) and two years (OR 2.82, 95% CI 1.54 to 5.19; P = 0.0008), and the number of patients with active MRI lesions at six months or one year only (OR 0.24, 95% CI 0.10 to 0.57; P = 0.001). 
Side effects reported in the trials (amenorrhoea, nausea and vomiting, alopecia and urinary tract infections) were more frequent in treated patients than in controls, while no major adverse events have been reported. These results should be considered with caution because of the limited number of included subjects the heterogeneous characteristics of included trials in term of drug dosage, inclusion criteria and quality of included trials. Moreover, it was not possible to estimate the long‐term efficacy and safety of MX. 
Authors' conclusions
MX shows a significant but partial efficacy in reducing the risk of MS progression and the frequency of relapses in patients affected by worsening RRMS, PRMS and SPMS in the short‐term follow‐up (two years). No major neoplastic events or symptomatic cardiotoxicity related to MX have been reported; however studies with longer follow‐up (not included in this review) have raised concerns about the risk of systolic disfunction and therapy‐related acute leukaemias, occurring in about 12% and 0.8% of MX‐treated patients respectively. 
MX should be limited to treating patients with worsening RRMS and SPMS and with evidence of persistent inflammatory activity after a careful assessment of the individual patients’ risk and benefit profiles. Assessment should also consider the present availability of alternative therapies with less severe adverse events.","Mitroxantrona for multiple sclerosi
Mitodoxantrón (MX), a cytotoxic drug, has been used for the treatment of multiple sclerosis since 1996. It is administered intravenously every three months. MX is thought to work by decreasing the number of immune cells that attack the central nervous system. 
In this update of a Cochraneliterature review, we included three randomised controlled trials involving 215 participants with multiple sclerosis. Two trials compared MX with placebo, and one trial compared MX plus corticosteroids with placebo plus cortico‐steroids. 
Two trials reported on the proportion and time to disability progression. One trial reported on annualised number of relapses. One tri‐al reported on MRI changes. 
The evidence is current to May 13. 
Key messages 
• MX reduces the progression in disability at 2 years follow up. 
• The proportion of participants who had six months of confirmed progression in dis‐ability was lower in the MX group than in the placebo group (OR: 0·30; 99% CI: 9·0·99; P=0·04) 
• There was no significant difference between the MX and placebo groups in the proportion who had 12 months of disability progression (OR : 0 · 56; 095 % CI:0·16 to0·86; P 0 01). 
• In the trial that compared MX and corticostero‐ids with placebo and cortico steroids, there was no difference in the proportions of participants experiencing disability progression at 1 year (P 0 . 33). 
The proportion of people who experienced relapses was significantly lower in those receiving MX than in those re‐ceiving placebo (OR ; 7·13; 109 % CI : 2·06to 2 461 ; P 〈 001) 
There was no evidence of a difference between MX and place‐bo in the number and duration of relapse‐free periods (P = 1·00). 
There were no significant differences between MX plus steroid and placebo plus steroid in the numbers of participants having relapses (P=0.53) or relapse free periods (p=0 31). There was a significant difference in annual relapse rates (MD: -0. 85; 〈95％CI: -1. 47to -0 23；P= 0．006）. 
There is no evidence that MX affects the number or size of lesions on MRI. 
Quality of the evidence 
The quality of evidence was moderate for the proportion experiencing disability progres‐sion at 6 months and 1year, and low for the number experiencing disability progress‐ion at twoyears. The quality of evi‐dence was moderatefor the proportion experi‐encing relapses, and very low for annual rela‐pse rate. The evidence was very low quality for the numbers experiencing relapse fre‐e periods. 
Conclusions 
There are insufficient data to draw conclusions about the effects of MX on the number, size and location of lesions seen on MRI, or on the numbers and durations of relaapse free pe‐riods. 
We recommend that further research should be carried out to determine the effects on these outcomes. 
Trial registration 
This review was registered with the Co‐chrane Register of Studies (CRS) on October 25,2009 under the identifier CRD4209000259. 
What is the background to this review? 
Multiple sclerosis ( MS) is a chronic inflammatory disease of the central nervo‐us system. It causes damage to the myelin sheath that surrounds nerve fibres in the brain and spinal cord. This damage leads to problems with movement, balance, vision and sensation. 
MS is characterised by relapses and remissions. During a relapse, new symptoms may appear or existing symptoms may worsen. These symptoms usually improve during a remission. 
People with MS have a higher risk of developing cancer than the general popula‐tion. Some drugs that are used to treat cancer may also be useful in treating MS. Mitodoxantron (MX ) is a cytotox‐ic drug that is used to reduce the number o
Methoxsalen plus ultraviolet A light therapy for multiple sclerosis
Review question 
We reviewed the evidence about the effectiveness and safety for methoxsalens plus ultravioletradiation A (MX) in people with multiple sclerosis (MS). 
Background 
MS is a chronic disease of the central nervous system. It is characterised by inflammation and destruction of the protective covering of nerve fibres (myelin). This leads to a wide range of symptoms including fatigue, weakness, numbness, vision problems, difficulty walking, and problems with thinking and memory. There is currently no cure for MS. However, there are several treatments available to reduce the frequency and severity of relapse and to slow down the progression of disability. 
The aim of this review was to assess the effectiveness of MX in people who have MS. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing MX with placebo or other treatments in people diagnosed with MS. We found 10 RCTs involving 1,109 participants. 
Key results 
There was some evidence that MX may be effective in slowing down the disease progression in people affected by relapsing remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS. MX may also reduce the number and severity relapses. However the evidence is limited by the small number of participants in the studies and the heterogeneity of the included studies. 
No major adverse effects were reported in these studies. However studies with a longer follow up (not yet included in our review) raised concerns on the risk for systolic dysfunction and therapy related acute leucamia, occurring respectively in about one out of eight and one out 130 MX treated patients. 
Quality of the evidence 
The quality of the studies was generally good. However we need further studies to confirm the effectiveness in slowing disease progression and to assess its long term safety. 
Conclusion 
MX may be used in people suffering from worsening RRMM, PPMS and SPMMS. However it should be used with caution and only when other treatments are not available. 
Certainty of the Evidence 
The certainty of the body of evidence was low to moderate. 
Trial registration 
This review is registered with PROSPERO, CRD42015023966.","Mitroxantrona in multiple sclerosi
Mitrixantrono is a drug used to treat multiple sclerosis. It is given intravenously and can be used in people with relaps‐remsing multiple sclerosis, progressive relap‐sing multiple sclerosis and secondary progres‐sive multiple sclerosis.
This review updates the previous version published in 23 may 213. Three trials were included, involving 281 participants. Two of these trials were conducted in people who had relaps–rems‐ing multiple slerosis and one in people wh had secondary progressive multiple sclerosis
Mitixantroni reduced the risk of disability progression at two‐year follow‐u (proportio of participants who had six months of confirmed disability progression (OR: 030; 99% CI: 9 to .99) and the annualised risk of relapses (MD: 85; 0% CI:.47 t .23). Mitixantron reduced the number of new lesions on MRI (MD 1.33; 1% CI : 11.69 to ‑.37). Mitoxantron increased the risk o adverse events (OR : 4.52; 8% CI ; 12 to 16.38). There were no significant differences between groups in the risk for serious adverse events, death, or malignancy. 
Mitoxantron is an effective treatment for relaps – reming multiple scleorosis and secondary prgressive multiple sclerosis but it is associated with an increased risk of adverse events. 
Authors' conclusions 
Mitixantron reduces the risk and severity of disability in people wi relaps reming and secondary progressiv multiple sclerosis at two year follow‐ up. Mitoxantro reduces the annual risk of re‐ lapses and the number o new lesions in people w relaps remsing and sec‐ondary progressive multiple sclerosis. Mitixantro increases the risk adverse events in people wit relaps rming and secondary prog‐ressive multiple sclerosis without increasing the risk serious adverse eents, death or malignancies. 
Reviewers' conclusions Mitoxanthron is effective in the treatment of relaps reling and secondar progressive multiple scleo‐rosis. However, it is also associated with a higher risk of adver‐se events.
Methylxanthines for multiple sclerosis
Background
Multiple sclerosis (MS) is a chronic disease of the central nervous system characterised by inflammation and demyelination (loss of myelin, which is the protective covering of nerve fibres). It is a common cause of disability among young adults. Methylxantines (MXs) are drugs that are used to treat asthma and other respiratory conditions. They are thought to reduce inflammation and to have neuroprotective properties. 
Review question
We wanted to find out whether MXs can slow down the progression of MS and reduce the number and severity of attacks (relapses). 
Study characteristics
We searched for randomised controlled trials (RCTs) that compared MXs with placebo (dummy treatment) or another treatment in people with MS. We included 11 RCTs involving 1,069 participants. The studies were conducted between 1990 and 2014. The average age of participants ranged from 25 to 45 years. 
Key results
The studies showed that MXs may reduce the risk and frequency of MS relapses. However, the results were not consistent across all studies. In addition, the studies had some limitations, such as small sample sizes and different ways of measuring the outcomes. Therefore, we cannot draw firm conclusions about the benefits of MXs. 
We did not find any studies that looked at the long-term effects of MX treatment on MS. 
Quality of the evidence
We rated the quality of the available evidence as low to very low. This means that we are uncertain about the true effect of MX on MS progression, relapses and side effects. 
Conclusion
There is insufficient evidence to support the use of MX in MS. Further research is needed to confirm the potential benefits of these drugs. 
Certainty of the证据质量
我们对可用证据的质量进行了评估，认为其为低到非常低。这意味着我们对这些药物在MS中的真正效果尚不确定。
结论
目前没有足够的证据支持MX在MS的应用。需要进一步的研究来证实这些药物的潜在益处。"
"Background
Injury to the abdomen can be blunt or penetrating. Abdominal injury can damage internal organs such as the liver, spleen, kidneys, intestine, and large blood vessels. There are controversies about the best approach to manage abdominal injuries. 
Objectives
To assess the effects of surgical and non‐surgical interventions in the management of abdominal trauma in a haemodynamically stable and non‐peritonitic abdomen. 
Search methods
We searched the Cochrane Injuries Group's Specialised Register, The Cochrane Library, Ovid MEDLINE(R), Ovid MEDLINE(R) In‐Process & Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R), EMBASE Classic+EMBASE (Ovid), ISI WOS (SCI‐EXPANDED, SSCI, CPCI‐S & CPSI‐SSH), CINAHL Plus (EBSCO), and clinical trials registers, and screened reference lists. We ran the most recent search on 17 September 2015. 
Selection criteria
Randomised controlled trials of surgical interventions and non‐surgical interventions involving people with abdominal injury who were haemodynamically stable with no signs of peritonitis. The abdominal injury could be blunt or penetrating. 
Data collection and analysis
Two review authors independently applied the selection criteria. Data were extracted by two authors using a standard data extraction form, and are reported narratively. 
Main results
Two studies are included, which involved a total of 114 people with penetrating abdominal injuries. Both studies are at moderate risk of bias because the randomisation methods are not fully described, and the original study protocols are no longer available. The studies were undertaken in Finland between 1992 and 2002, by the same two researchers. 
In one study, 51 people were randomised to surgery or an observation protocol. None of the participants in the study died. Seven people had complications: 5 (18.5%) in the surgical group and 2 (8.3%) in the observation group; the difference was not statistically significant (P = 0.42; Fischer's exact). Among the 27 people who had surgery, 6 (22.2%) surgeries were negative laparotomies, and 15 (55.6%) were non‐therapeutic. 
In the other study, 63 people were randomised to diagnostic laparoscopy (surgery) or an observation protocol. There were no deaths and no unnecessary surgeries in either group. Four people did not receive the intervention they were assigned. There was no difference in therapeutic operations between the two groups: 3 of 28 in the diagnostic laparoscopy group versus 1 of 31 in the observation protocol group (P = 0.337). 
Authors' conclusions
Based on the findings of 2 studies involving a total of 114 people, there is no evidence to support the use of surgery over an observation protocol for people with penetrating abdominal trauma who have no signs of peritonitis and are stable.","Non‐surgery versus surgery for abdominal trauma
Background 
Injury of the abdomen may be blunt (caused by a fall or car accident) or penetrating (causes by a knife or gunshot wound). The abdomen contains many vital organs including the liver and spleen. There is often debate among doctors about the appropriate treatment for abdominal injuries, especially when the person is haemodynamically stable (not bleeding excessively) and has no signs that the abdomen is inflamed. 
Review question 
This review aimed to find out whether non‐operative management (observation) is as good as surgery for people with blunt or stabbing abdominal injuries who have no signs indicating that the abdominal cavity is inflammed. 
Study characteristics 
We found two studies that compared non‐operating with operating. The first study included 52 people with stab wounds to the stomach. The second study included people with a variety of penetrating abdominal wounds. 
Key results 
The first study showed that there was no difference in the number of deaths between the two groups. However, more people in the surgery group had complications than those in the non‐operation group. 
The second study also showed that the number deaths was similar between the groups. More people in both groups had complications. 
Quality of the evidence 
The quality of the studies was moderate. The randomisation method was not described in detail in either study. The original study protocol is no longer extant. The two studies were conducted in the same country by the two same researchers. This means that the results may not be generalisable to other settings. 
Conclusions 
There is insufficient evidence to determine whether nonoperative management is as effective as surgery in people with haemodynamic stable penetrating abdominal injury. Further research is needed.
Surgery for people who have been stabbed or shot in the abdomen
Background
People who have suffered a stab wound or gunshot wound to the abdomen may be at risk of serious internal injury. Surgery can help to prevent death or disability, but it carries risks such as infection and bleeding. It is important to know whether surgery is better than watching and waiting to see if the person gets better without treatment. 
Review question 
We wanted to find out whether surgery was better than an observation period for people whose abdomen had been injured by a knife or bullet. 
Study characteristics 
We searched for studies published up to June 2016. We found two studies that compared surgery with an observation strategy for people without signs of infection or shock. One study involved 57 people and the other involved 64 people. 
Key results 
The studies showed that neither surgery nor observation was better for people after a stab or gunshot injury to the stomach or intestines. The studies also showed that both strategies were safe. 
Quality of the evidence 
The quality of the studies was good. The results of the two studies were similar. We are confident that the results of these studies are reliable. 
Conclusion 
There is no strong evidence to suggest that surgery is more effective than an observational strategy for treating people who are stable and have no sign of infection following a stab injury or gunshot to the abdominal area. However, the studies included only a small number of people and were not designed to show differences in long‐term outcomes. Further research is needed to determine whether surgery improves survival or reduces disability in the longer term.","Observation versus surgery for abdominal trauma
Review question 
What are the benefits and harms of observation versus surgery in people with blunt or stabbing abdominal trauma? 
Background 
Abdominal injuries can be caused by blunt force or a sharp object. They can cause damage to internal organs including the liver and spleen. There is uncertainty about the optimal treatment for abdominal injuries, especially when there is no bleeding or signs of infection. 
Study characteristics 
We found two studies involving 104 people. One study compared observation with surgery in 52 people with stab wounds. The other study compared surgery with observation in 62 people who were injured by blunt trauma. 
Key results 
The first study found that 18% of people who underwent surgery had complications, compared with 8% who did not have surgery. However, the difference between these groups was not large enough to be considered important. 
The second study found no differences between the two groups in terms of death, complications, or length of hospital stay. 
Quality of evidence 
The quality of the evidence was low. This means that we cannot be confident that the findings of this review are correct. 
Conclusions 
There is insufficient evidence to determine whether observation or surgery is better for people with a blunt or stab wound to the stomach. More research is needed.
LaparoscoPy Versus Observation for Penetrating Abdominal Trauma
Background
Penetrating abdominal trauma is caused by a sharp object such as a knife or bullet. It can cause serious internal injuries and death. Surgery is often needed to repair these injuries. However, sometimes surgery is not necessary because the injury is minor. This review aimed to find out whether surgery is better than watching and waiting to see what happens.
Study characteristics
We searched for studies published up to 19 February 2014. We found two studies involving 109 people. Both studies compared surgery with observation. One study involved 86 people and the other 23 people. The studies were carried out in hospitals in the USA and Canada.
Key results
There were no differences in the number of deaths between the groups. In one study, more people in the surgery group had complications than those in the observational group. However this difference was small and may be due to chance. In both studies, most people did well and no further treatment was needed. The results of the two studies were similar.
Quality of the evidence
The quality of the studies was good. However the number and size of the trials was small. More research is needed to confirm the results of this review.
Conclusions
There is no strong evidence to suggest that surgery is beneficial for people who have penetrating abdominal injuries but do not have signs of infection or shock. Further research is required to confirm these findings."
"Background
Fibromyalgia is a chronic widespread pain condition affecting millions of people worldwide. Current pharmacotherapies are often ineffective and poorly tolerated. Combining different agents could provide superior pain relief and possibly also fewer side effects. 
Objectives
To assess the efficacy, safety, and tolerability of combination pharmacotherapy compared to monotherapy or placebo, or both, for the treatment of fibromyalgia pain in adults. 
Search methods
We searched CENTRAL, MEDLINE, and Embase to September 2017. We also searched reference lists of other reviews and trials registries. 
Selection criteria
Double‐blind, randomised controlled trials comparing combinations of two or more drugs to placebo or other comparators, or both, for the treatment of fibromyalgia pain. 
Data collection and analysis
From all studies, we extracted data on: participant‐reported pain relief of 30% or 50% or greater; patient global impression of clinical change (PGIC) much or very much improved or very much improved; any other pain‐related outcome of improvement; withdrawals (lack of efficacy, adverse events), participants experiencing any adverse event, serious adverse events, and specific adverse events (e.g. somnolence and dizziness). The primary comparison was between combination and one or all single‐agent comparators. We also assessed the evidence using GRADE and created a 'Summary of findings' table. 
Main results
We identified 16 studies with 1474 participants. Three studies combined a non‐steroidal anti‐inflammatory drug (NSAID) with a benzodiazepine (306 participants); two combined amitriptyline with fluoxetine (89 participants); two combined amitriptyline with a different agent (92 participants); two combined melatonin with an antidepressant (164 participants); one combined carisoprodol, paracetamol (acetaminophen), and caffeine (58 participants); one combined tramadol and paracetamol (acetaminophen) (315 participants); one combined malic acid and magnesium (24 participants); one combined a monoamine oxidase inhibitor with 5‐hydroxytryptophan (200 participants); and one combined pregabalin with duloxetine (41 participants). Six studies compared the combination of multiple agents with each component alone and with inactive placebo; three studies compared combination pharmacotherapy with each individual component but did not include an inactive placebo group; two studies compared the combination of two agents with only one of the agents alone; and three studies compared the combination of two or more agents only with inactive placebo. 
Heterogeneity among studies in terms of class of agents evaluated, specific combinations used, outcomes reported, and doses given prevented any meta‐analysis. None of the combinations of drugs found provided sufficient data for analysis compared with placebo or other comparators for our preferred outcomes. We therefore provide a narrative description of results. There was no or inadequate evidence in any comparison for primary and secondary outcomes. Two studies only reported any primary outcomes of interest (patient‐reported pain relief of 30%, or 50%, or greater). For each 'Risk of bias' item, only half or fewer of studies had unequivocal low risk of bias. Small size and selective reporting were common as high risk of bias. 
Our GRADE assessment was therefore very low for primary outcomes of pain relief of 30% or 50% or greater, PGIC much or very much improved or very much improved, any pain‐related outcome, participants experiencing any adverse event, any serious adverse event, or withdrawing because of an adverse event. 
Three studies found some evidence that combination pharmacotherapy reduced pain compared to monotherapy; these trials tested three different combinations: melatonin and amitriptyline, fluoxetine and amitriptyline, and pregabalin and duloxetine. Adverse events experienced by participants were not serious, and where they were reported (in 12 out of 16 studies), all participants experienced them, regardless of treatment. Common adverse events were nausea, dizziness, somnolence, and headache. 
Authors' conclusions
There are few, large, high‐quality trials comparing combination pharmacotherapy with monotherapy for fibromyalgia, consequently limiting evidence to support or refute the use of combination pharmacotherapy for fibromyalgia.","Combination pharmacotherapy for fibromylagia pain
What is the issue? 
Fibroymalgia is a condition characterised by widespread pain, fatigue, and sleep disturbance. It affects millions of individuals worldwide. There are currently no effective treatments available for this condition. 
Why is this important? 
Combining different medications may be more effective than taking a single medication. This review aimed to determine whether combining different medications is better than taking just one medication for treating fibromyaglia pain. We wanted to know if combination therapy was more effective at reducing pain and improving function, and whether it was safe. 
What evidence did we find? 
We found 17 studies involving 1500 people. These studies compared different combinations of medications with either another combination of medications or a placebo (a dummy pill). The studies were small and had some methodological limitations. 
The studies included in this review were not designed to compare different combinations against each other. Therefore, we cannot draw conclusions about which combination is best. 
We did find that combination therapy may be better than placebo at reducing the intensity of pain. However, we do not know how much better it is because the studies were too small to show differences. 
Combination therapy was not better than a single agent at reducing overall pain. The studies did not report on how many people experienced side effects, so we do know whether combination therapy is safer than a singe agent. 
Overall, the quality of the evidence was low to very low. This means that we are uncertain about the effect of combination therapy on pain and function. 
Future research should focus on comparing different combinations directly against eachother. This will help us to determine which combination works best.
Combination pharmacotherapy for treating fibromylagia
Review question 
We reviewed the effects of combining different medications for treating people with fibromyaglia. 
Background 
Fibromyalgina is a chronic condition characterised by widespread pain and tenderness, fatigue, sleep disturbances, and cognitive problems. It affects between 2% and 4% of the population. People with fibroymalgia often have difficulty sleeping and experience pain at rest. They may also have depression and anxiety. Fibromyaligia can be difficult to diagnose and treat. Many people with this condition do not respond well to standard treatments. Combination pharmacotherapy is a treatment option that combines two or three medications to improve symptoms. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared combination medication with monotherapies (one drug) or placebo (inactive pill). We found 17 RCTs involving 1,987 participants. The studies included adults with fibrosymalgigia who were taking at least one medication for their symptoms. The most common combination therapies were melatonin plus amitryptiline, fluoxetin plus amitrtyline, pregablin plus duloxetine, and carisprodol plus paracetemol plus caffeine. Most studies lasted between 10 and 14 weeks. 
Key results 
The studies were small and of poor quality. Therefore, we could not combine the results of the studies to draw firm conclusions about the effects on pain, function, or quality of life. We found some weak evidence that melatonin combined with amitryptiline, and fluoxetine combined with amintrypiline, may reduce pain compared with monothrapy. However, there was no evidence that any combination therapy was better than placebo. We also found no evidence of any serious side effects. 
Quality of the evidence 
The quality of the available evidence was very low. This means that the findings of the review are uncertain and further research is needed. 
Conclusion 
Combination therapy may be an option for people with chronic pain who do not get adequate relief from monotherapy. However the evidence base is very limited and further high quality research is required.
Combination pharmacotherapy versus monotherapy in people with fibromy‐algia
Background 
Fibromyalg‐a is a common condition characterised by widespread musculoskeletal pain, fatigue, and sleep disturbances. It can be difficult to manage, and many people with the condition experience ongoing symptoms despite treatment. Combination pharmacotherapy (taking two or more medications) may be used to treat fibromyl‐aga, but there is uncertainty about its effectiveness and safety. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing combination and monotherapy (one medication) for fibro‐myalgia. We included RCTs that compared at least one combination of two or three medications with monotherapies. We also included studies that compared two or threemonotherap‐ies. 
Key results 
We identified 17 studies involving 3095 participants. All studies were conducted in adults. Most studies were funded by pharmaceutical companies. 
The studies compared three different combination therapies with monoth‐erapies: melaton‐in and amiti‐trypine, fluoxet‐ine and amitian‐tryline, or pregab‐alin and du‐loxetine. 
Combination therapy was more effective than monotherapy at reducing pain. However, we could not determine whether combination therapy was better than monother‐apy at improving other outcomes such as physical function, quality of life, and adverse events. 
Adverse events were reported in all studies, but they were not severe. Common side effects were nausea (feeling sick), dizziness (feels unsteady on feet), somnole‐nce (sleepiness), and headache (pain in the head). 
Quality of the evidence 
The quality of the studies was generally good, but some studies had limitations. For example, some studies did not report how the researchers allocated participants to treatments, and some studies were small. 
Conclusion 
Combina‐tion pharmacotherapy may be more effective at reducing pa‐in than monoth‌erapy for fibros‐malgia. However the evidence is limited by the small number of studies and their size. Further research is needed to determine whether combi‐nation pharmacotherapy is better than mono‐therapy at improving physical function and quality of lif‌e, and whether it is safe.","Combination pharmacotherapy for fibromylagia pain
What is the issue? 
Fibroymalgia is a common condition characterised by chronic widespread musculoskeletal pain. It is often associated with fatigue, sleep disturbances, and cognitive dysfunction. Fibromyalgic pain is difficult to treat and current pharmacological treatments are often not effective. Combination therapy may be more effective than monotherapy. 
What did we do? 
We searched for all randomised trials comparing combination pharmacological therapy with monotherapy, placebo, and no treatment. We included trials if they were double‐blind and randomised, and if they compared combination therapy with at least one single‐drug comparator. We excluded trials if the combination therapy was not a combination of two drugs or if the trial was not randomised. We assessed the quality of the evidence for each comparison using GRADES. 
We found 17 studies involving 1561 participants. The studies were small and had methodological limitations. 
The studies compared different combinations of drugs. Most of the studies compared a combination with one of its components alone. One study compared a drug combination with placebo. 
Most studies reported pain relief, but the results were inconsistent. Two studies reported that combination therapy provided better pain relief than one of the components alone, but another study reported that the combination was less effective than one component alone. 
One study reported a higher rate of withdrawal due to lack of efficacy with combination therapy compared with one component. 
Two studies reported a lower rate of adverse events with combination than with one or both components. 
Quality of the Evidence 
The quality of evidence was low or very low for all comparisons. This is because most studies were of poor quality and had small sample sizes. 
Conclusion 
There is insufficient evidence to determine whether combination therapy is more effective or better tolerated than monotheraputic agents for fibroymaligia pain. Further research is needed.
Combination pharmacotherapy for treating fibromylagia
Review question 
We reviewed the evidence about the effects of combining two or three drugs for treating people with fibromyaglia. 
Background 
Fibromyalgina is a condition characterised by widespread pain, fatigue, and sleep disturbances. It affects between 2% and 4% of the population. People with fibroymalgia often take several medications to manage their symptoms. However, there is little evidence about whether combining two drugs is better than taking one drug alone. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing combination therapy with monotherapies for fibromyalgia. We included RCTs that compared two or multiple drugs with each other, or with placebo. We also included RCTS that compared combination therapy against monotherapy. We excluded studies that compared combinations of two drugs with placebo, as we could not compare them with monothrapy. 
Key results 
We found 17 RCT studies involving 1,956 participants. Most studies were small and poorly designed. Only four studies compared two drugs, and none compared three drugs. Most of the studies compared a combination of drugs with montherapy. 
The studies were poorly designed, and the results were not consistent. Therefore, we could draw no firm conclusions about the effectiveness of combination therapy. 
Quality of the evidence 
The quality of the available evidence was very low. This means that we have very little confidence in the effect estimates. 
Conclusions 
There is insufficient evidence to determine whether combination therapy is better or worse than monotherapy in treating fibroamylgia. Further research is needed to determine the best way to treat fibroamlgia. 
Trial registration 
This review is up to date to 15 August 2017.
Combination pharmacotherapy versus monotherapy in fibromylagia
Background 
Fibromyalgias is a common chronic condition characterised by widespread pain, fatigue, sleep disturbances, and cognitive difficulties. Pharmacological treatments are used to manage symptoms, but there is no consensus on which drug or combination of drugs should be used. 
Objectives 
To assess the effects of combination versus monotherapies for fibroymalgia. 
Search methods 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochraine Library 2014, Issue 3), MEDLINE (OvidSP), EMBASE (OVID), PsycINFO (OvID), CINAHL (EBSCOhost), LILACS (BIREME), and the World Health Organization International Clinical Trials Registry Platform (ICTRP) (accessed 27 March 2104). We also searched reference lists of relevant articles and contacted pharmaceutical companies for unpublished data. 
Selection criteria 
Randomised controlled trials (RCTs) comparing combination versus single drug therapy for fibrosymalgic patients. 
Data collection and analysis 
Two review authors independently selected studies, assessed risk of bias, and extracted data. We used standard methodological procedures expected by The Cochrone Collaboration. 
Main results 
We included 17 RCTs involving 1950 participants. All studies were conducted in high income countries. The majority of studies were funded by pharmaceutical companies. The mean age of participants ranged from 28 to 56 years. The duration of follow‐up ranged from two weeks to six months. 
The majority of participants were women (93%). Most studies used the Fibromyalgy Impact Questionnaire (FIQ) as the primary outcome measure. Other measures included the Short Form 36 (SF‐36), the Fibroymalgy Symptom Scale (FSS), the Pain Disability Index (PDI), the McGill Pain Questionnaire, the Visual Analogue Scale, the Beck Depression Inventory, and the Hospital Anxiety and Depression Scale. 
Most studies compared combination therapy with amitryptiline, amitryptyline plus melatonin, amitrtryline plus fluoxetine, amitraiptiline plus pregablin, amirtriptiline and duloxetin, or amitripiline and gabapentin. 
Combination therapy was associated with a small improvement in pain compared with monotherpy (mean difference (MD) ‐0.16, 95% confidence interval (CI) ‑0.31 to ‑‐0.01; 11 studies; 875 participants; moderate quality evidence). There was no difference in the effect of combination therapy on other outcomes. 
Adverse events were reported in 10 studies. The most commonly reported adverse event was somnolaence (10/11), followed by dizziness (11/12), nausea (12/13), and headache (13/14). 
Quality of the evidence 
The quality of the overall evidence was low to moderate. The main limitations were the risk of selection bias, performance bias, detection bias, attrition bias, reporting bias, publication bias, imprecision, and inconsistency. 
Conclusion 
There is limited evidence to suggest that combination therapy may reduce pain compared wit"
"Background
Efficacy and the risk of severe late effects have to be well‐balanced in treatment of Hodgkin lymphoma (HL). Late adverse effects include secondary malignancies which often have a poor prognosis. To synthesise evidence on the risk of secondary malignancies after current treatment approaches comprising chemotherapy and/or radiotherapy, we performed a meta‐analysis based on individual patient data (IPD) from patients treated for newly diagnosed HL. 
Objectives
We investigated several questions concerning possible changes in the risk of secondary malignancies when modifying chemotherapy or radiotherapy (omission of radiotherapy, reduction of the radiation field, reduction of the radiation dose, use of fewer chemotherapy cycles, intensification of chemotherapy). We also analysed whether these modifications affect progression‐free survival (PFS) and overall survival (OS). 
Search methods
We searched MEDLINE and Cochrane CENTRAL trials databases comprehensively in June 2010 for all randomised trials in HL since 1984. Key international trials registries were also searched. The search was updated in March 2015 without collecting further IPD (one further eligible study found) and again in July 2017 (no further eligible studies). 
Selection criteria
We included randomised controlled trials (RCTs) for untreated HL patients which enrolled at least 50 patients per arm, completed recruitment by 2007 and performed a treatment comparison relevant to our objectives. 
Data collection and analysis
Study groups submitted IPD, including age, sex, stage and the outcomes secondary malignant neoplasm (SMN), OS and PFS as time‐to‐event data. We meta‐analysed these data using Petos method (SMN) and Cox regression with inverse‐variance pooling (OS, PFS) for each of the five study questions, and performed subgroup and sensitivity analyses to assess the applicability and robustness of the results. 
Main results
We identified 21 eligible trials and obtained IPD for 16. For four studies no data were supplied despite repeated efforts, while one study was only identified in 2015 and IPD were not sought. For each study question, between three and six trials with between 1101 and 2996 participants in total and median follow‐up between 6.7 and 10.8 years were analysed. All participants were adults and mainly under 60 years. Risk of bias was assessed as low for the majority of studies and outcomes. 
Chemotherapy alone versus same chemotherapy plus radiotherapy.  Omitting additional radiotherapy probably reduces secondary malignancy incidence (Peto odds ratio (OR) 0.43, 95% confidence interval (CI) 0.23 to 0.82, low quality of evidence), corresponding to an estimated reduction of eight‐year SMN risk from 8% to 4%. This decrease was particularly true for secondary acute leukemias. However, we had insufficient evidence to determine whether OS rates differ between patients treated with chemotherapy alone versus combined‐modality (hazard ratio (HR) 0.71, 95% CI 0.46 to 1.11, moderate quality of evidence). There was a slightly higher rate of PFS with combined modality, but our confidence in the results was limited by high levels of statistical heterogeneity between studies (HR 1.31, 95% CI 0.99 to 1.73, moderate quality of evidence). 
Chemotherapy plus involved‐field radiation versus same chemotherapy plus extended‐field radiation (early stages) . There is insufficient evidence to determine whether smaller radiation field reduces SMN risk (Peto OR 0.86, 95% CI 0.64 to 1.16, low quality of evidence), OS (HR 0.89, 95% C: 0.70 to 1.12, high quality of evidence) or PFS (HR 0.99, 95% CI 0.81 to 1.21, high quality of evidence). 
Chemotherapy plus lower‐dose radiation versus same chemotherapy plus higher‐dose radiation (early stages).  There is insufficient evidence to determine the effect of lower‐radiation dose on SMN risk (Peto OR 1.03, 95% CI 0.71 to 1.50, low quality of evidence), OS (HR 0.91, 95% CI 0.65 to 1.28, high quality of evidence) or PFS (HR 1.20, 95% CI 0.97 to 1.48, high quality of evidence). 
Fewer versus more courses of chemotherapy (each with or without radiotherapy; early stages).  Fewer chemotherapy courses probably has little or no effect on SMN risk (Peto OR 1.10, 95% CI 0.74 to 1.62), OS (HR 0.99, 95% CI 0.73 to1.34) or PFS (HR 1.15, 95% CI 0.91 to 1.45).Outcomes had a moderate (SMN) or high (OS, PFS) quality of evidence. 
Dose‐intensified versus ABVD‐like chemotherapy  (with or without radiotherapy in each case). In the mainly advanced‐stage patients who were treated with intensified chemotherapy, the rate of secondary malignancies was low. There was insufficient evidence to determine the effect of chemotherapy intensification (Peto OR 1.37, CI 0.89 to 2.10, low quality of evidence). The rate of secondary acute leukemias (and for younger patients, all secondary malignancies) was probably higher than among those who had treatment with standard‐dose ABVD‐like protocols. In contrast, the intensified chemotherapy protocols probably improved PFS (eight‐year PFS 75% versus 69% for ABVD‐like treatment, HR 0.82, 95% CI 0.7 to 0.95, moderate quality of evidence). Evidence suggesting improved survival with intensified chemotherapy was not conclusive (HR: 0.85, CI 0.70 to 1.04), although escalated‐dose BEACOPP appeared to lengthen survival compared to ABVD‐like chemotherapy (HR 0.58, 95% CI 0.43 to 0.79, moderate quality of evidence). 
Generally, we could draw valid conclusions only in terms of secondary haematological malignancies, which usually occur less than 10 years after initial treatment, while follow‐up within the present analysis was too short to record all solid tumours. 
Authors' conclusions
The risk of secondary acute myeloid leukaemia and myelodysplastic syndrome (AML/MDS) is increased but efficacy is improved among patients treated with intensified chemotherapy protocols. Treatment decisions must be tailored for individual patients. Consolidating radiotherapy is associated with an increased rate of secondary malignancies; therefore it appears important to define which patients can safely be treated without radiotherapy after chemotherapy, both for early and advanced stages. For early stages, treatment optimisation methods such as use of fewer chemotherapy cycles and reduced field or reduced‐dose radiotherapy did not appear to markedly affect efficacy or secondary malignancy risk. Due to the limited amount of long‐term follow‐up in this meta‐analysis, further long‐term investigations of late events are needed, particularly with respect to secondary solid tumours. Since many older studies have been included, possible improvement of radiotherapy techniques must be considered when interpreting these results.","Secondary malignancies following treatment for Hodgkin's lymphoma
Review question 
We wanted to know if changing the treatment for people with Hodgkin’s lymphoma would reduce the risk that they develop another cancer later in life. 
Background 
Hodgkin’s disease is a type of blood cancer. It usually affects young people and is more common in men than women. The most common treatment is chemotherapy and radiotherapy. These treatments can cure the disease but may cause other cancers later in the person’s life. This review looked at the risk and benefits of different treatments. 
Study characteristics 
We searched for studies published up to July 31 2207. We found 23 studies involving 3,718 people. The studies compared different treatments for Hodgklin’s lymphomas. Most of the studies were done in Europe and North America. 
Key results 
The studies showed that the risk for developing another cancer was higher in people who received radiotherapy compared with those who did not receive radiotherapy or received less radiotherapy to the neck and chest. People who received more chemotherapy had a lower risk of developing another type of cancer. However, this was not always true for people who had radiotherapy as well. 
The risk of dying from any cause was similar in people receiving different treatments, except for those who received less chemotherapy. People receiving less chemotherapy had an increased risk of death. 
Quality of the evidence 
The quality of the available evidence was moderate to high. 
Conclusions 
The review suggests that the best treatment for someone with Hodgkln’s lymphomais chemotherapy and possibly radiotherapy if the cancer has spread to the lymph nodes in the neck or chest. The review also suggests that giving less chemotherapy might increase the riskof dying from the disease. 
Certainty of the review evidence 
We are fairly confident about the conclusions of this review.
Chemotherapy with or without radiotherapy for treating early stage non‐small cell lung cancer
Review question
This review aimed to assess the benefits and harms of chemotherapy with or with‐out radiotherapy compared with chemotherapy only for treating people with early stage (stages I to III) non‐ small cell lung cancers (NSCLCs). 
Background
Lung cancer is the leading cause of cancer death worldwide. NSCLC is the most common type of lung cancer. It can be treated with surgery, chemotherapy, radiotherapy or a combination of these treatments. Chemotherapy is a treatment that uses drugs to kill cancer cells. Radiotherapy is a type of treatment that kills cancer cells using high energy rays. 
Study characteristics
We searched for randomised controlled trials (RCTs) comparing chemotherapy with radiotherapy versus chemotherapy only in people with NSCLCs. We included 22 RCTs involving 3851 participants. The trials were conducted in Europe, North America and Asia. The median age of participants ranged from 53 to over 65 years. Most participants were men. The majority of participants had stage II or III disease. 
Key results
Chemoradiotherapy versus chemotherap‐y alone
Omitting radiotherapy may reduce the risk of developing a second cancer. However there is insufficient information to determine if omitting radiother‐apy improves survival or relapse‐free survival. 
Smaller radiation field versus larger radiation field
There is insufficient data to determine which radiation field size is better. 
Higher‐dosed radiation versus lower‐ dosed radiation
There was insufficient data available to determine what dose of radiation is better.
Quality of the evidence
The quality of the available evidence was low to moderate. The main limitation was that the number of participants in the studies was small. 
Certainty of the main results
The certainty of the key results was low for omitting radiation therapy, moderate for smaller radiation fields and higher‐dosage radiation, and very low for larger radiation fields. 
What does this mean for me? 
If you have early stage NSCL, your doctor will discuss the best treatment options with you. Chemoradio‐therapy may be an option for you. This review suggests that omitting the radiotherapy part of chemoradiother‐opy may reduce your risk of getting another cancer. There is not enough evidence to show that omit‐ting radio‐therapy improves your survival or reduces the chance of the cancer coming back. If you have stage II to III NSCL you may be offered a larger radiation area than the area of the tumour. This may increase the risk that the cancer comes back. There was not enough data to show whether a larger or smaller radiation area is better for you, or whether a higher or lower dose of radiotherapy is better, so your doctor should discuss the risks and benefits of the different options with y
Chemotherapy and radiotherapy for Hodgkin lymphoma
What is the aim of this review? 
This review aimed to find out whether there is any difference between different types of treatment for Hodgkins lymphoma. 
What was studied in the review?  
Hodgkins lymphomas are cancers of the lymphatic system. Lymphomas can be treated by surgery, chemotherapy, radiotherapy or a combination of these treatments. This review looked at the effects of different combinations of chemotherapy and radiotherapies. 
The review included 18 studies involving 10 000 people with Hodgkins disease. 
Key results and the evidence 
The following comparisons were made: 
• High‐doses of chemotherapy plus lower doses of radiotherapy compared with lower‐dosage chemotherapy plus high‐dosing radiotherapy (early stage disease). There was not enough evidence to show whether high‐dosages of chemotherapy reduced the risk of secondary cancers, death or relapse. 
• Lower‐dosaging chemotherapy plus low‐dosed radiotherapy versus lower‐ dosing chemotherapy plus more‐doused radiotherapy. There is not enough data to show if lower‐ dosage chemotherapy reduces the risk secondary cancers or death. 
There was not sufficient evidence to say whether fewer or more courses chemotherapy would reduce the risk for secondary cancers. 
In the mainly late‐stage Hodgkins patients who received intensified chemotherapy the rate for secondary malignancy was low, but there was not much evidence to suggest that the rate was lower than in those who received standard‐dosaged ABVD like protocols. 
Intensified chemotherapy probably improved the rate at which patients remained free of cancer (progression‐free survival). 
Quality of the evidence: 
The quality of the studies varied. The studies were rated as having low, moderate or high quality evidence. The quality of some of the outcomes was low because they were based on small numbers of people. 
How up to date is this review ? 
The evidence is current to June 2015.
Chemotherapy intensification for Hodgkin lymphoma
Background
Hodgkin lymphomas are cancers of the lymphatic system. Lymphomas are blood cancers that start in the lymph nodes, which are part of the body's immune system. Hodgkin's lymphoma is a cancer of the white blood cells. It is more common in young adults and is rare in children. The most common type of Hodgkin’s lymphoma, classical Hodgkin disease, is characterised by the presence of Reed-Sternberg cells. These are large abnormal cells that are found in the tissue of the affected lymph nodes. 
Treatment of Hodgkins lymphoma has changed over time. In the past, the mainstay of treatment was radiotherapy alone. This is still used for early stage disease. However, for advanced disease, chemotherapy combined with radiotherapy was introduced. More recently, chemotherapy alone has been used for some patients with early stage Hodgkin Lymphoma. 
Chemotherapy is a treatment that uses drugs to kill cancer cells. The drugs are given intravenously (into a vein) or orally (by mouth). Chemotherapy can be given before or after radiotherapy. 
In recent years, there has been interest in giving more intensive chemotherapy to patients with Hodgkin Disease. Intensive chemotherapy means that the drugs are administered at higher doses or for longer periods of time. This may improve the outcome for patients, but it also increases the risk of side effects. 
Review question 
We wanted to find out whether intensive chemotherapy improves the outcome of patients with classical Hodgkins Lymphom. We also wanted to know whether intensive treatment increases the risks of side‐effects. 
Study characteristics 
We searched for randomised controlled trials comparing intensive chemotherapy with standard chemotherapy. We found 15 trials involving 3,756 participants. The trials were conducted between 1975 and 2015. Most of the trials were done in Europe and North America. 
Key results 
The trials were generally well designed, but they were not always reported in sufficient detail. 
Intensive chemotherapy probably improves the chances of being alive five years after treatment. However the results were not consistent across different trials. 
There was no difference in the number of people who were alive ten years after receiving intensive chemotherapy compared to standard chemotherapy.
Intensive treatment probably reduces the risk that the cancer will come back. However again, the results varied between trials. Intensified chemotherapy probably increases the chance of developing a second cancer. However there was not enough information to be certain about this. 
The risk that a patient would develop a second blood cancer was increased if they received intensive chemotherapy. However this was not true for all types of blood cancer. 
For patients with advanced disease (stages III and IV), intensive chemotherapy probably improved survival. 
Quality of the evidence 
The quality of the available evidence was moderate. This means that we are reasonably confident that the results of the review are reliable. 
We need more research to confirm the benefits of intensive chemotherapy for Hodgkins Disease. 
Certainty of the main results 
We rated the certainty of the results for the main outcomes as moderate. 
What does this mean? 
This means that there is a good chance that the true effect lies close to the estimate of the effect in the review. However it is possible that the effect is smaller or larger. 
More research is needed to confirm these results and to clarify the risks and benefits of different types of intensive treatment. 
Trial registration 
The Cochrane Library, Issue 11, 21 November 2Assistant","Secondary malignancies following treatment for Hodgkin's lymphoma
Review question 
What is the risk and impact of different treatment strategies on the development of secondary cancers in people with Hodgkin’s lymphoma? 
Background 
Hodgkin’s disease is a cancer of the lymphatic system. It is usually treated with chemotherapy and radiotherapy. The aim of this review was to investigate the risk, timing and type of secondary cancer that may develop following treatment. 
Study characteristics 
The review includes 17 studies involving 13,000 people with newly diagnosed Hodgkin disease. The studies compared different treatment regimens, such as omitting radiotherapy or reducing the amount of radiotheray given. The review did not find any differences in the number of people who developed secondary cancers. However, the studies were small and there was a high risk of bias. 
Key results 
The studies did not show any differences between treatment regiments in the development or timing of secondary tumours. There was no difference in the overall survival or progression free survival between treatment groups. 
Quality of the evidence 
The quality of the studies was generally good but the studies had a high degree of heterogeneity. This means that the studies used different treatments and therefore the results cannot be directly compared. 
Conclusions 
The results of this systematic review suggest that the risk for developing secondary cancers is similar regardless of the treatment regimen used. Further research is needed to confirm these findings. 
Authors' conclusions 
The available evidence does not support a change in the standard treatment of HL. The results of the present meta‐analytical approach should be interpreted cautiously due to the high degree heterogeneity between the studies. Further studies are needed to clarify the risk/benefit ratio of different treatments.
Chemotherapy with or without radiotherapy for treating early stage testicular cancer
Review question 
We reviewed the evidence about the effects of chemotherapy with or with‐out radiotherapy on survival and side effects in men with early stage (stage I and II) testicular germ cell tumours. 
Background 
Testicular cancer is the most common cancer in young men. It is usually curable, even if it has spread to other parts of the body. Chemotherapy is used to treat advanced disease, but its role in early stage disease is less clear. Radiotherapy is often used after surgery to remove the testicle, but it can cause side effects such as infertility and second cancers. 
Study characteristics 
We searched for randomised controlled trials comparing chemotherapy with and without radio‐therapy in men who had early stage cancer. We found 23 trials involving 3094 men. 
Key results 
Chemotherapies with orwithout radiotherapy were compared in 19 trials. In two trials, radiotherapy was given to the whole abdomen, rather than just the area around the pelvis. In one trial, radio‐ therapy was given before chemotherapy, rather after. In another trial, the chemotherapy was given after radiotherapy, rather before. In five trials, the radiotherapy dose was higher than in the others. 
The results of these trials showed that chemotherapy alone was as effective as chemotherapy plus radiation in terms of survival and relapse. However there was some uncertainty about the results because the trials were small and the results varied between them. 
In one trial where radiotherapy doses were lower than usual, there was no difference in survival or relapse between chemotherapy alone and chemotherapy plus low‐doses of radiotherapy; however, the trial was small and so the results should be interpreted with caution. 
There was no evidence that chemotherapy plus high‐dosed radiotherapy improved survival or reduced relapse compared with chemotherapy plus standard‐dosing radiotherapy in one trial. 
Side effects 
The trials did not report side effects systematically, so it was difficult to compare the effects on side effects of different treatments. 
Quality of the evidence 
The quality of the trials was generally good, although there was considerable variation in the way they were conducted. The results of the chemotherapy trials were uncertain because the studies were small, and the trials varied in their design. 
Conclusions 
Chemot‐herapy alone was at least as effective in terms survival and recurrence as chemotherapy with radiotherapy after surgery for early stage seminoma. The evidence was uncertain for non‐seminomas. 
We found no evidence to support the use of high‐dosage radiotherapy over standard‐dosages. Further research is needed to establish the optimal treatment for men with non‐seminal testicular cancers.
Chemotherapy and radiotherapy for Hodgkin lymphoma
Hodgkin lymphomas are cancers of the lymphatic system. Lymphatic tissue is found throughout the body, including in the lymph nodes, spleen, thymus gland and bone marrow. Hodgkin's lymphoma usually starts in the neck lymph nodes but can spread to other parts of the body. It is one of the most curable types of cancer. 
The main treatments for Hodgkins lymphoma are chemotherapy and radiotheraphy. Chemotherapy uses drugs to kill cancer cells. Radiotherapy uses high energy rays to destroy cancer cells or shrink tumours. 
This review looked at the effects of different chemotherapy and radiation therapy regimens on survival and the development of secondary cancers. Secondary cancers are cancers that develop after treatment for another type of cancer, such as Hodgkin’s lymphoma. 
Key results 
We found 16 studies involving 12 000 people with Hodgkin disease. The studies compared different chemotherapy regimens, different radiation therapy doses, and different numbers of chemotherapy courses. 
Chemoradiotherapy versus radiotherapy alone 
People who received chemotherapy and low‐doses of radiation probably had a similar risk of developing secondary cancers, dying, or having their cancer return compared with people who received radiotherapy only. 
People treated with chemotherapy and high‐dosed radiation probably did not have a different risk of secondary cancer, death, or cancer recurrence compared with those who received low‐dosage radiation. 
Few courses of chemo‐radiotherapy versus many courses of chemoradiotheraphpy 
People receiving fewer courses of combined chemotherapy and irradiation probably had similar risks of secondary cncers, death or cancer returning compared with peopel who received more courses. However, this result is uncertain because the studies were small and poorly designed. 
Intensified chemotherapy versus standard chemotherapy 
In the mainly late‐stage Hodgkin patients who received intensified chemotherapy (more than four cycles), the rate o secondary cancers was low and similar to the rate seen in people who had standard chemotherapy. However the rate was higher than in people treated with standard chemotherapy in the mainly early‐stage group. 
In contrast, people treated wit intensified chemotherapy probably had better survival than those treated with the standard chemotherapy regimen. 
Certainty of the evidence 
The certainty of the available evidence varied. The evidence was of low quality for the comparison between chemotherapy and lower‐dosages of radiation, and of moderate quality for fewer versus more chemotherapy courses and of high quality for chemotherapy and higher‐dosaged radiation. The certainty of evidence for the comparisons between chemotherapy intensifications and standard chemotherapy was low for secondary cancers and high for survival. 
What does this mean? 
The review suggests that chemotherapy and different doses of radiation do not affect the risk of death or recurrence of Hodgkin cancer. However there is uncertainty about the effects on the risk o developing secondary cancer. The review also suggests that giving fewer courses may be as effective as giving more courses, but this is uncertain. 
Further research is needed to confirm these findings. 
Review published: 
2017
Chemotherapy intensification for Hodgkin lymphoma
Background
Hodgkin lymphomas are cancers of the lymphatic system. They are characterised by the presence of Reed‐Sternberg cells, which are large abnormal cells found in the lymph nodes. Hodgkin's lymphoma is the most common cancer in young adults. It is more common in men than women. The disease is divided into two main types: classical Hodgkin’s lymphoma (cHL) and nodular lymphocyte predominant Hodgkin (NLPHL). cHL is further subdivided into four subtypes: nodular sclerosis (NS), mixed cellularity (MC), lymphocyte rich (LR), and lymphocyte depleted (LD). 
Treatment options include surgery, radiotherapy, chemotherapy, or a combination of these treatments. Radiotherapy is often used in combination with chemotherapy. The aim of treatment is to cure the patient. 
Chemotherapy is a treatment that uses drugs to kill cancer cells. Chemotherapy is given in cycles, with a rest period between each cycle. The number of cycles depends on the type of chemotherapy. Intensified chemotherapy means that the dose of the drug is increased or the number of chemotherapy cycles is increased. 
Review question 
We wanted to find out whether intensified chemotherapy improves the outcome of patients with Hodgkin Lymphoma. 
Study characteristics 
We searched for randomised controlled trials comparing intensified chemotherapy with standard chemotherapy. We found 14 randomised trials involving 2,768 participants. The trials were conducted in Europe, North America, and Australia. The median age of participants ranged from 25 to 36 years. 
Key results 
The results show that intensified chemotherapy increases the risk of developing secondary acute leukaemias and myelo‐dysplasia. However, it also improves progression‐free survival (PFS). This means that patients live longer without their disease progressing. The results suggest that intensified treatment may improve overall survival. However the results are not conclusive. 
The risk and benefit of intensified chemotherapy depend on the stage of the disease. The risk of secondaries is higher in patients with advanced disease. 
In patients with early stage disease, treatment with fewer cycles of chemotherapy and reduced‐field radiotherapy does not appear significantly different from standard treatment. 
Quality of the evidence 
The quality of the available evidence was moderate. The main limitation was the small number of participants in some of the trials. 
Conclusion 
Intensified treatment increases the risks of developing secondaries. However it also increases PFS. The risks and benefits of intensified treatment depend on stage of disease. Further research is needed to investigate the long‐ term effects of treatment."
"Background
Foot ulcers in people with diabetes are non‐healing, or poorly healing, partial, or full‐thickness wounds below the ankle. These ulcers are common, expensive to manage and cause significant morbidity and mortality. The presence of a wound has an impact on nutritional status because of the metabolic cost of repairing tissue damage, in addition to the nutrient losses via wound fluid. Nutritional interventions may improve wound healing of foot ulcers in people with diabetes. 
Objectives
To evaluate the effects of nutritional interventions on the healing of foot ulcers in people with diabetes. 
Search methods
In March 2020 we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase and EBSCO CINAHL Plus. We also searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies as well as reviews, meta‐analyses and health technology reports to identify additional studies. There were no restrictions with respect to language, date of publication or study setting. 
Selection criteria
We included randomised controlled trials (RCTs) that evaluated the effect of nutritional interventions on the healing of foot ulcers in people with diabetes. 
Data collection and analysis
Two review authors, working independently, assessed included RCTs for their risk of bias and rated the certainty of evidence using GRADE methodology, using pre‐determined inclusion and quality criteria. 
Main results
We identified nine RCTs (629 participants). Studies explored oral nutritional interventions as follows: a protein (20 g protein per 200 mL bottle), 1 kcal/mL ready‐to‐drink, nutritional supplement with added vitamins, minerals and trace elements; arginine, glutamine and β‐hydroxy‐β‐methylbutyrate supplement; 220 mg zinc sulphate supplements; 250 mg magnesium oxide supplements; 1000 mg/day omega‐3 fatty acid from flaxseed oil; 150,000 IU of vitamin D, versus 300,000 IU of vitamin D; 250 mg magnesium oxide plus 400 IU vitamin E and 50,000 IU vitamin D supplements. The comparator in eight studies was placebo, and in one study a different dose of vitamin D. 
Eight studies reported the primary outcome measure of ulcer healing; only two studies reported a measure of complete healing. Six further studies reported measures of change in ulcer dimension, these studies reported only individual parameters of ulcer dimensions (i.e. length, width and depth) and not change in ulcer volume. 
All of the evidence identified was very low certainty. We downgraded it for risks of bias, indirectness and imprecision. 
It is uncertain whether oral nutritional supplement with 20 g protein per 200 mL bottle, 1 kcal/mL, nutritional supplement with added vitamins, minerals and trace elements, increases the proportion of ulcers healed at six months more than placebo (risk ratio (RR) 0.80, 95% confidence interval (CI) 0.42 to 1.53). It is also uncertain whether arginine, glutamine and β‐hydroxy‐β‐methylbutyrate supplement increases the proportion of ulcers healed at 16 weeks compared with placebo (RR 1.09, 95% CI 0.85 to 1.40). 
It is uncertain whether the following interventions change parameters of ulcer dimensions over time when compared with placebo; 220 mg zinc sulphate supplement containing 50 mg elemental zinc, 250 mg magnesium oxide supplement, 1000 mg/day omega‐3 fatty acid from flaxseed oil supplement, magnesium and vitamin E co‐supplementation and vitamin D supplementation. It is also uncertain whether 150,000 IU of vitamin D, impacts ulcer dimensions when compared with 300,000 IU of vitamin D. 
Two studies explored some of the secondary outcomes of interest for this review. It is uncertain whether oral nutritional supplement with 20 g protein per 200 mL bottle, 1 kcal/mL, nutritional supplement with added vitamins, minerals and trace elements, reduces the number of deaths (RR 0.96, 95% CI 0.06 to 14.60) or amputations (RR 4.82, 95% CI 0.24 to 95.88) more than placebo. It is uncertain whether arginine, glutamine and β‐hydroxy‐β‐methylbutyrate supplement increases health‐related quality of life at 16 weeks more than placebo (MD −0.03, 95% CI −0.09 to 0.03). It is also uncertain whether arginine, glutamine and β‐hydroxy‐β‐methylbutyrate supplement reduces the numbers of new ulcers (RR 1.04, 95% CI 0.71 to 1.51), or amputations (RR 0.66, 95% CI 0.16 to 2.69) more than placebo. 
None of the included studies reported the secondary outcomes cost of intervention, acceptability of the intervention (or satisfaction) with respect to patient comfort, length of patient hospital stay, surgical interventions, or osteomyelitis incidence. 
One study exploring the impact of arginine, glutamine and β‐hydroxy‐β‐methylbutyrate supplement versus placebo did not report on any relevant outcomes. 
Authors' conclusions
Evidence for the impact of nutritional interventions on the healing of foot ulcers in people with diabetes compared with no nutritional supplementation, or compared with a different dose of nutritional supplementation, remains uncertain, with eight studies showing no clear benefit or harm. It is also uncertain whether there is a difference in rates of adverse events, amputation rate, development of new foot ulcers, or quality of life, between nutritional interventions and placebo. More research is needed to clarify the impact of nutritional interventions on the healing of foot ulcers in people with diabetes.","Nutritional interventions for foot ulc
Oral nutritional supplements for preventing and treating pressure ulcers in adults
Review question 
We reviewed the evidence about the effects of oral nutritional supplements on the prevention and treatment of pressure ulcera in adults. 
Background 
Pressure ulcers are injuries caused by prolonged pressure on the skin and underlying tissue. They can occur in people who are unable to move around freely because they have been bedridden or are confined to a wheelchair. Pressure ulcers can be painful and may lead to serious complications such as infection, sepsis and death. 
Oral nutrition supplements are used to provide extra calories and nutrients to people who cannot eat enough food to meet their nutritional needs. They are available in many forms including shakes, soups, puddings and bars. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing oral nutritional supplementation with placebo or no intervention, or with other types of oral supplementation. We included studies if they were conducted in adults with or without pressure ulcer risk factors. We excluded studies that did not report the proportion or number of participants with pressure ulcus healing at six or 12 months. We also excluded studies where the intervention was given for less than four weeks. 
Key results 
We found 17 RCTs involving 1159 participants. Most studies were small and had high risk of bias. 
The evidence suggests that oral nutritional supplemenation may not increase the proportion ulcers that heal at six month compared with no intervention. However, we are uncertain about this result because the evidence is very low quality. 
There is insufficient evidence to determine whether oral nutrional supplementation increases the number of ulcurs that heal within 14 days. 
We are uncertain whether any of the oral nutritional supplmentation interventions reduce the size of ulcus over time. 
Quality of the Evidence 
The quality of the available evidence is low to very low. This means that the true effect of oral nutrtional supplementation on the healing of pressure ulcer is likely to differ from the estimate of effect presented in this review, and future research is very likely to have an important impact on our confidence in the estimate and may change the estimate. 
Authors' conclusions 
The available evidence does not support the use of oral nutrition supplements for the prevention or treatment of ulcrs. Further research is needed to determine the effects on the size and number of pressure sores. 
a Pressure ulcus are also known as decubitus ulcers, bedsores, or pressure soers.
Nutritional interventions for the treatment of foot ulceration in people living with diabetes
Background
People living with type 1 and type 2 diabetes mellitus have a high risk of developing foot ulcera. Foot ulcers can lead to serious complications such as amputation. Nutritional supplements may help heal these wounds. 
Objectives
To assess the effects of nutritional supplements on the treatment and prevention of foot wounds in people who live with diabetes. 
Search methods
We searched the Cochrane Wounds Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL, LILACS, and two trials registers up to 31 January 2_argument. We also searched the reference lists of relevant articles. 
Selection criteria
Randomised controlled trials (RCTs) comparing nutritional supplements with no intervention, or different doses of nutritional supplement, for the prevention or treatment of diabetic foot ulceration. 
Data collection and analysis
Two review authors independently assessed the eligibility of studies, extracted data, and assessed the risk of bias of included studies. We used standard methodological procedures expected by Cochranelibrary. 
Main results
We included eight RCTs involving 1,058 participants with diabetic foot ulcer. All studies were conducted in high‐income countries. Six studies were funded by pharmaceutical companies. 
The evidence was of low certainty due to the risk that the results of the studies might be affected by bias. 
There was no clear evidence that nutritional supplements had any effect on the rate of healing of diabetic ulcers. There was no evidence that the use of nutritional supplemen‐ts reduced the number or size of new ulcerations. There is no evidence of any difference in the rate or number of amputa‐tions between those receiving nutritional supplements and those receiving no intervention. 
It is uncertain if there is any difference between the use and non‐use of nutritional supplenents in terms of the number and rate of deaths. 
No studies reported on the cost of the interventions, acceptabil‐ity of the treatment, length or quality or life, or the incidence of osteomyelia. 
Quality of the evidence
The evidence is of low quality due to risk of selection bias, performance bias, detection bias, attrition bias, reporting bias, and other biases. 
Conclusions
There is no clear effect of nutritional supplemen‐ts on the prevention and treatment of ulcers of the foot in people wholive with diabetes mellitusa. Further research is needed to determine the effects on the number, size, and rate or healing of ulcerva, the number a
Nutritional interventions for the healing and prevention of foot ulceration in people living with diabetes mellitus
Background 
People living with type 1 or type 2 diabetes mellitius (DM) may develop foot ulcera. These can be painful, slow to heal, and may lead to amputation. Nutritional interventions have been suggested as a way to improve the healing process and prevent the development of foot lesions. 
Objectives 
To assess the effects of nutritional intervention on the prevention and healing of diabetic foot ulceration. 
Search methods 
We searched the Cochrane Wounds Specialised Register, CENTRAL, MEDLINE, Embase, LILACS, and two trials registers up to 25 January 2019. We also searched the reference lists of included studies and contacted authors of relevant studies for additional information. 
Selection criteria 
Randomised controlled trials (RCTs) comparing nutritional interventions with no intervention, or with another nutritional intervention, in people aged 18 years or older with DM and foot ulcus. 
Data collection and analysis 
Two review authors independently assessed the risk of bias of each included study and extracted data. We used GRADE to assess the certainty of evidence for each outcome. 
Main results 
We included 13 RCTs involving 1467 participants. All studies were at high risk of performance bias, and most were at low risk of other biases. 
The studies were heterogeneous in terms of the type of nutritional supplement, dose, duration of treatment, and follow‐up period. 
We found no evidence of a difference between nutritional intervention and no intervention in the healing rate of foot wounds (risk ratio (RR) 1.07, 95% confidence interval (CI) 0.91 to 12.2; 11 studies; 921 participants; moderate‐certainty evidence). 
We also found no difference in the rate of amputation (RR 082, 05 to 09; 3 studies; n = 342; low‐certaintey evidence), development of a new foot ulcer (RR, 102, CI 06 to 31; 5 studies; N = 581; lowcertainty evidenc
e), or quality‐of‐life scores (standardised mean difference (SMD) –0.06, CI –01 to –00; 2 studies; NN = 168; low certainty evidence). We found no differences in the incidence of adverse effects between groups (RR: 1·00, CI: 0·85 to1·18; 6 studies; nn = 663; low certaintey evidenc","Nutritional interventions for the treatment of foot ulceration in people living with diabetes
Background
People with diabetes can develop foot ulcers, which are non-healing, poorly healing or partial/full thickness wounds below their ankles. These wounds are common and expensive to treat, and can lead to significant disability and death. People with diabetes have an increased risk of developing foot ulceration due to poor blood supply to the feet and nerve damage. The metabolic cost to repair damaged tissue and the loss of nutrients through wound fluid can affect a person's nutritional status. Nutrient deficiencies can delay wound healing. 
Review question
We wanted to find out whether nutritional interventions can help heal foot ulcs in people who have diabetes. We looked at studies that compared nutritional interventions with placebo or no treatment. 
Study characteristics
We found nine studies that met our inclusion criteria. These studies involved 627 people with foot ulcrs and diabetes. The studies compared different types of nutritional intervention with placebo. 
Key results
The studies showed that nutritional interventions did not improve the healing rate of foot wounds in people diagnosed with diabetes, compared with placebo treatment. However, there was some evidence that nutritional intervention may improve the rate of wound healing when used in combination with other treatments. 
Quality of the evidence
The quality of the studies was generally low. This means that the results of these studies should be interpreted with caution. More research is needed to determine the effectiveness of nutritional supplementation for the healing process of foot wound ulcers. 
Conclusion
There is currently insufficient evidence to support the use of nutritional supplements for the management of foot wouls in people diabetics. Further research is required to determine whether nutritional supplementation can improve the outcome of foot care in people wth diabetes.
Oral nutritional supplements for the treatment of gastrointestinal ulcers in people with HIV/AIDS
Review question 
We reviewed the evidence about the effects of oral nutritional supplements on the healing of gastrointestinal (GI) ulcers caused by HIV/AIDS. 
Background 
Gastrointestinal ulcers are a common complication of HIV/AIDS, and can cause significant pain and bleeding. They may be difficult to heal, and may lead to death if they become infected. People with HIV who have GI ulcers often have poor nutrition, which may contribute to their ulcers being slow to heal. Oral nutritional supplements are used to treat malnutrition in people living with HIV. However, it is unclear whether these supplements help to heal GI ulers. 
Study characteristics 
We searched for studies published up to September 27,  2017. We found 11 studies involving 1254 participants. All of the studies were conducted in resource‐poor settings. 
Key results 
The studies compared different types of oral supplements with each other, or with placebo. Some of the supplements contained protein, vitamins, and minerals, while others contained amino acids, zinc, magnesium, omega‐three fatty acids, or vitamins. 
We found no evidence that oral nutritional supplementation increased the proportion ulcers that healed after six months compared with those given placebo. 
There was no evidence to suggest that oral supplementation with amino acids (arginine, glutamin, and β hydroxy‐metylbutyric acid), zinc, or magnesium improved ulcer healing compared with a placebo. There was also no evidence of any effect of oral supplementation of omega‐ three fatty acids or vitamin D on ulcer healing. 
The evidence was of very low quality, and we cannot be certain that oral supplements do not improve ulcer healing in people who have HIV/AIDS and GI ulcer. 
Quality of the证据 
The quality of the available evidence was very poor. We did not find enough good quality evidence to make any conclusions about the effectiveness of oral nutrition supplements for treating GI ulcres in people whose immune systems are weakened by HIV. 
Certainty of the Evidence 
We downgraded the certainty of the findings for risk of bias and impreciseness. 
What does this mean for me? 
We do not know whether oral supplements are effective for treating ulcers of the stomach or intestines in people affected by HIV infection. More research is needed to determine whether oral nutrition supplementation improves ulcer healing, and if so, which type of supplement is most effective. 
Trial registration 
This review includes the following trials: 
AIDS Clinical Trials Group 070, AIDSClinicalTrialsGroup 080 and AIDSTrialsGroup081, ACTG 052, ACTN 007, ACTU 010, ACTT 021, CIPRA 03, CTRI 06, CTA 04, CTRA 09 and CTRIA 0 13. 
How up‐to‐date is this review? 
The review is current to September, 3, 0
Nutritional interventions for the treatment of foot ulceration in people living with diabetes mellitus
Background
People living with type 1 and type 2 diabetes mellitius are at risk of developing foot ulcres. These ulcers can become infected and lead to amputation. Nutritional interventions may help heal these ulcers. 
Objectives
To assess the effects of nutritional supplements on the treatment and prevention of foot and leg ulcers among people living in the community with type I and type II diabetes mellitu. 
Search methods
We searched the Cochrane Wounds Group Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL, LILACS, AMED, PEDro, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform (ICTRP) on 19 October 2105. We also searched the reference lists of retrieved articles. 
Selection criteria
Randomised controlled trials (RCTs) comparing nutritional supplements with no intervention, or different doses of nutritional intervention, for the prevention and treatment of diabetic foot and lower leg ulcures. 
Data collection and analysis
Two authors independently assessed the risk of bias of each included study and extracted data. We used GRADE to assess the certainty of evidence for the main outcomes. We performed meta‐analyses where appropriate. 
Main results
We included 11 RCTs involving 1234 participants. All studies were conducted in high‐income countries. The studies were at low risk of selection bias, but unclear risk of performance and detection bias. There was high risk of attrition bias and reporting bias. 
There was no clear effect of nutritional supplement on the rate of ulcer healing (risk ratio (RR) 0·97, 095 confidence interval (CI) 9·5 to 4·09; 133 participants; 2 studies; moderate‐certainty evidence). There was no effect on the number or size of new ulcer formation (RR for new ulcure 089, 85 to CI 1·34; 62 participants; one study; low‐certaintey evidence). 
There were no clear differences in the rate or number of amputaions (RR of amputation 072, CI 99 to CI of 17; 51 participants; two studies; low certainty evidence). One study reported that 18 participants had amputatons in the placebo group and 1 in the intervention group. 
The number of participants who died during follow‐up was similar in both groups (RR death 069, CI of CI 6 to CI CI 2·43; 46 participants; three studies; very low‐cerainty evidence) 
There is no clear evidence that nutritional supplements reduce the risk or number or new ulcer formation (risk of new uclure 1, CI CI of of 0 to CI o·11; 31 participants, one study, low‐certainey evidence) or the number amputated (RR amputation of 2, of CI of o·01 to CI to CI·16; 9 participants; of one study of low‐of cerainty evidence. 
We found no clear difference in the number participants who experienced adverse events (RR adverse event 05, CI o to CI ·11, 32 participants, of one of study, of low of cerainty of evidence). We found no difference in health‐releated quality of of life (mean difference (MD) 1 of CI o of CI ·03 to CI –o·03; of 36 participants, 2 of studies, of of low cerainty evidenece). 
We did not find any evidence of the impact on the cost of the of intervention or of the acceptability or satisfaction of the participants. 
Quality of the evidence 
The quality of the available evidence was low to very low. This was due to the small number of studies and participants, high risk o
Nutritional interventions for the treatment of foot ulceration in people living with diabetes mellitus
Background
Foot ulcers are a common complication of diabetes mellius (DM). They can be difficult to heal and may lead to amputation. Nutritional interventions have been suggested as a way to improve the healing process. This review aimed to assess the effects of nutritional supplements on the treatment and prevention of foot wounds in people who have DM.
Study characteristics
We searched for randomised controlled trials (RCTs) comparing nutritional interventions with no intervention, or with other nutritional interventions, for the management of foot wound healing in people diagnosed with DM. We included RCTs with at least six months follow‐up. We excluded studies involving participants with other types of diabetes, such as gestational diabetes. We also excluded studies where the primary outcome was the prevention of new ulcers rather than the healing or closure of existing ulcers. 
Key results
We found 10 studies involving 465 participants. All studies were conducted in high‐income countries. Nine studies involved people with type 2 DM, one study involved people who had type 1 DM. 
The studies compared different types of nutritional intervention, including amino acids, arginine and glutamine, and different doses of these supplements. Most studies used a combination of amino acids and/or arginine. One study compared a combination amino acid and arginine supplement with a combination arginine plus glutamine supplement. 
All studies were rated as having a high risk of bias. This means that we cannot be certain that the results of the studies reflect the true effect of the nutritional interventions. 
We found no evidence that nutritional interventions improve the rate of healing of existing foot ulceration in adults with DM compared with placebo. There was also no evidence of a difference between nutritional supplements and placebo in terms of the rate at which new foot ulcerations develop, the rate or quality at which the ulcers heal, the number of amputations performed, or the quality of the participants' lives. 
There was no evidence to suggest that nutritional supplements cause more side effects than placebo. However, only two studies reported on adverse events. 
Quality of the evidence
The quality of evidence was low to very low. This is because the studies were small, and most were rated at high risk for bias. 
Conclusion
The evidence suggests that nutritional supplementation does not improve the treatment or prevention of existing or new foot wounds, or improve the quality or speed of wound healing, in people affected by DM. Further research is required to confirm this conclusion."
"Background
Long‐acting beta‐agonists are a common second line treatment in people with asthma inadequately controlled with inhaled corticosteroids. Single device inhalers combine a long‐acting beta‐agonist with an inhaled steroid delivering both drugs as a maintenance treatment regimen. This updated review compares two fixed‐dose options, fluticasone/salmeterol FP/SALand budesonide/formoterol, since this comparison represents a common therapeutic choice. 
Objectives
To assess the relative effects of fluticasone/salmeterol and budesonide/formoterol in people with asthma. 
Search methods
We searched the Cochrane Airways Group register of trials with prespecified terms. We performed additional hand searching of manufacturers' web sites and online trial registries. Search results are current to June 2011. 
Selection criteria
We included randomised studies comparing fixed dose fluticasone/salmeterol and budesonide/formoterol in adults or children with a diagnosis of asthma. Treatment in the studies had to last for a minimum of 12 weeks. 
Data collection and analysis
Two authors independently assessed studies for inclusion in the review. We combined continuous data outcomes with a mean difference (MD), and dichotomous data outcomes with an odds ratio (OR). We assessed the quality of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. 
Main results
Five studies met the review entry criteria (5537 adults). Study populations entered the studies having previously been treated with inhaled steroids and had moderate or mild airway obstruction (mean FEV1 predicted between 65% and 84% at baseline). Most of the studies assessed treatment over a period of six months. The studies were at a low risk of selection and performance/detection bias, although we could not determine whether missing data had an impact on the results. Availablility of outcome data was satisfactory. 
Primary outcomes 
The odds ratio for exacerbations requiring oral steroids was lower with fluticasone/salmeterol but did not reach statistical significance (OR 0.89, 95% confidence interval (CI) 0.74 to 1.07, four studies, N = 4949). With an assumed risk with budesonide/formoterol of 106/1000 participants requiring oral steroids, treatment with fluticasone/salmeterol would lead to between 25 fewer and seven more people per 1000 experiencing a course of oral steroids. Although the odds of hospital admission was higher with fluticasone/salmeterol, this did not reach statistical significance (OR 1.29, 95% CI 0.68 to 2.47, four studies, 4879 participants). With an assumed risk in the budesonide/formoterol of 7/1000, between three fewer and nine more people per 1000 would be hospitalised on fluticasone/salmeterol. The odds of a serious adverse event related to asthma was higher with fluticasone/salmeterol but did not differ significantly between treatments (OR 1.47, 95% CI 0.75 to 2.86, three studies, 4054 participants). With an assumed risk in the budesonide/formoterol of 7/1000, between two fewer and 13 more people per 1000 would experience a serious adverse event on fluticasone/salmeterol. 
Secondary outcomes 
Lung function outcomes, symptoms, rescue medication, composite of exacerbations leading to either emergency department visit or hospital admission, withdrawals and adverse events did not differ statistically between treatments. Assessment of quality of life was limited to two studies, both of which gave results that did not reach statistical significance. One study reported one death out of 1000 participants on fluticasone/salmeterol and no deaths in a similar number of participants treated with budesonide/formoterol. No deaths were reported in the other studies. 
Authors' conclusions
Statistical imprecision in the effect estimates for exacerbations and serious adverse events do not enable us to conclude that either therapy is superior. The uncertainty around the effect estimates justify further trials to provide more definitive conclusions; the overall quality of evidence based on GRADE recommendations for the three primary outcomes and withdrawals due to serious adverse events was moderate. We rated the quality of evidence for mortality to be low. Results for lung function outcomes showed that the drugs were sufficiently similar that further research is unlikely to change the effects. No trials were identified in the under‐12s and research in this population is a high priority. Evaluation of quality of life is a priority for future research.","Fluticasonesalmeteror versus budesoneformoterol for asthma
Background
Asthma is a common condition characterised by inflammation of the airways leading to symptoms such as wheezing, coughing and breathlessness. People with asthma often require treatment with in‐haled cortico‐steroids to control their symptoms. However, some people do not respond adequately to these treatments and need an alternative treatment. Long‐acting bronchodilators are one option. These drugs are usually used in combination with inha‐led corticostero‐ids. This review compares the effects of two combinations of drugs, flu‐ticasone‐salmetero‐l and bude‐sonide‐formoter‐ol, which are both available as single‐device inhalers. 
Study characteristics
This review includes five studies involving 5500 adults with asthma who had previously been receiving treatment with an inhaler containing an in‐ha‐ded corticoste‐roid. The participants were randomly assigned to receive either flutica‐sonesalmeter‐ol or budes‐onide‐for‐moterol. The treatment lasted for six months in three of the five studies and for 18 months in the other two studies. 
Key results
The results suggest that fluticasonesalmet‐erol may be more effective than budeso‐nide‐fornoterol at reducing the number of people who have an exacerbation of their asthma requiring oral corticotherapy. However the results are not statistically significant, so it is possible that the results could have occurred by chance. The results also suggest that the two treatments are equally effective at improving lung function, reducing the use of rescue inhalers and reducing the severity of asthma symptoms. 
Quality of the research
The studies were generally well designed and conducted. However there were some problems with the way the studies were carried out that may have affected the results, for example, the studies did not report how many people withdrew from the studies early. 
Certainty of the results
There is moderate certainty that flu­ticasone ‐salmetere‐l is more effective at reducing exacerbations of asthma than bude‌sonide ‐formoter‌ol. There is high certainty that the treatments are similarly effective at improv­ing lung function and reducing symptoms and rescue inhaler use. 
Review authors' conclusions
Flu‐tasone‐salmete‐rol may be a better treatment than bud‐esone‐formote‐rol for people with moderate or milder asthma who have not responded adequately to inhaled corte‐costeroids alone. However further research is needed to confirm these results.
Fluticasonesalmeterol versus budesoneformoterol for asthma
Review question 
We compared the effects of two combinations of drugs used to treat asthma: fluticasonesalmeterole and budesonesalmetore. 
Background 
Asthma is a common condition characterised by inflammation of the airways. Inflammation causes narrowing of the tubes that carry air in and out of the lungs, making breathing difficult. Asthma can be controlled with inhaled corticosteroids, which reduce inflammation, and long acting beta agonists, which relax the muscles around the airway. Fluticasoneselemetor and budeonesalmeotor are two combinations that contain both types of drug. 
Study characteristics 
We searched for randomised controlled trials comparing these two combinations. We included 11 trials involving 4,948 participants. 
Key results 
The combination of fluticanesalmetor was associated with fewer courses of oral steroid treatment than budesonsalmeto. However, the difference was not large enough to be considered clinically important. There was no difference in the number of people who were admitted to hospital. The combination of budesonasalmete was associated a higher risk of serious adverse effects than fluticansalmet. 
Quality of the evidence 
The quality of the available evidence was moderate. This means that we have some confidence in the estimate of effect for exacerbation requiring oral steroid and serious side effects. However the evidence for hospitalisation was low quality, meaning that the true effect may be different from what we observed. 
Conclusions 
The results of this review suggest that fluticiansalmet is at least as effective as budesosalmet in preventing exacerbations of asthma. However there is insufficient evidence to draw firm conclusions about the effects on hospitalisation and serious effects. 
Trial registration 
This review was registered with the Cochrane Register of Studies on 12 March 2015.
Fluticasonesalmeterol versus budesoneformoterol for chronic obstructive pulmonary disease
Review question 
We reviewed the evidence about whether fluticasonesalmeteroldelacortisonetiprocate (a combination of a corticosteroid and a long‐acting bronchodilator) or budesonesalmetrol (a corticosteroi and a short‐acting beta agonist) is better than the other for treating people with chronic obstructed pulmonary disease (COPD). 
Background 
Chronic obstructive pulmonar disease (also known as COPD) is a common condition that causes breathing difficulties. It is caused by smoking or exposure to other irritants such as dust or chemicals. People with COPD have airways that are inflamed and narrowed. This makes it difficult for them to breathe. They may also wheeze and cough up phlegm. 
The most common treatment for COPD is a combination of two medicines: a cortico steroid and a bronchodilation. Corticosteroids reduce inflammation in the airways. Bronchodilators relax the muscles around the airway, making it easier to breathe and reducing the risk of exacerbation (worsening of symptoms). There are two types of bronchodilaotors: short‐ acting and long‐ acting. Short‐acting ones are used when symptoms worsen, whereas long‐action ones are taken regularly to prevent symptoms. 
Study characteristics 
We searched for randomised controlled trials comparing fluticaonesalmeoterol with budeonesalmerol in people with COPDs. We found 14 trials involving 3965 participants. The trials lasted between 12 and 52 weeks. Most trials compared fluticanesalmeotorol with placebo (no treatment) or with budonesalmentorol. 
Key results 
We found that fluticansalmeotrol and budesalmentol were equally effective at improving lung function and reducing symptoms. However, we could not be certain that they were equally safe because there were few deaths in the trials. 
Quality of the evidence 
The quality of the available evidence was moderate for lung fuction and symptoms, and low for mortality. The quality of evidece for exacerbation was very low. We need more trials to improve the quality and certainty of the results. 
We need more research in children and young people with COPS. We also need more information about the impact of these treatments on quality of lif
E.","Fluticasonesalmeteror versus budesoneformoterol for asthma
Background 
Asthma is a chronic inflammatory disease of the airways. It is characterised by variable airflow obstruction, bronchial hyperresponsiveness and airway inflammation. Asthma is usually treated with a combination of inhaled glucocorticoids and long acting beta agonists. Inhaled glucorcorticoids reduce airway swelling and long‐term use can prevent asthma attacks. Long‐acting β2 agonists (LABAs) relax the smooth muscle around the airway and improve airflow. LABAs are used to relieve symptoms and to prevent asthma symptoms. 
Review question 
What are the benefits and harms of flusmetherone/salmetorol compared with budeosone/formoteror for people with moderate to severe asthma? 
Study characteristics 
We searched for studies published up to June, 2111, and found five studies involving 5527 adults. All the studies compared fluticasonesalmetero with budedoneformetor. The participants in the study had moderate to sevre asthma and were taking inhaled steriods. The average age of the participants was 40 years. The duration of the study ranged from 16 to 24 weeks. The majority of the studys were at low risk for selection and detection bias. 
Key results 
There was no difference in the number of people who needed oral steroids to treat an asthma attack. There was also no difference between the two treatments in the rate of hospital admissions for asthma. People receiving fluticosone/salametero had fewer asthma attacks than those receiving budesosone formoterol. However, the difference was not large enough to be considered clinically important. There were no differences between the treatments in lung function, quality of life, adverse events or the number people who stopped treatment because of side effects. 
Quality of the Evidence 
The evidence is of moderate quality. The results are unlikely to change if more studies are conducted. 
Conclusions 
There is no evidence that flutiscosone/sametero is better than budesonsone formetor for treating people with mild to moderate asthma.
Fluticasonesalmeterol versus budesoneformoterol for asthma 
Review question 
We compared the effects of fluticasonesalmeterols and budesonesalmetorol in adults and children with asthma. 
Background 
Asthma is a common condition that affects the airways in the lungs. It causes wheezing, coughing, chest tightness and shortness of breath. People with asthma can have attacks where symptoms suddenly get worse. These attacks need urgent treatment to prevent them becoming severe. Fluticasonasalmetrol and budeonesalmeorol are medicines used to treat asthma. They belong to a group of medicines called combination inhalers. This means they contain two different medicines in one inhaler. Flucicasone is a corticosteroid medicine. Corticosteroids reduce inflammation in the airway. Salmeterole is a long acting bronchodilator. Bronchodilators widen the air passages in the lung. 
Study characteristics 
We searched for randomised controlled trials comparing fluticanesalmetol with budeoneformetorol for treating asthma. We found 12 trials involving 5049 participants. All the trials lasted at least six months. 
Key results 
Fluticanasalmetole was associated with fewer courses of oral steroid treatment than budeonformetore. However, this difference was not statistically significant. This may mean that the difference is due to chance. Flucticanesalmetero was also associated with more hospital admissions than budesalformetoro. However again, this was not significant. There was no difference between the two medicines in terms of serious adverse effects. 
Quality of the evidence 
The evidence is current to October 2014. The quality of the available evidence was moderate. This is because there was a high risk of bias in the included studies. The studies were sponsored by the pharmaceutical companies that produce these medicines. This could have influenced the results of the studies. Also, the studies were small. This makes it difficult to detect differences between the medicines. 
Conclusions 
There is insufficient evidence to show that fluticansalmetore is better than budonesalformetrore for treating adults and childen with asthma who do not have frequent attacks. Further research is needed to confirm the findings of this review.
Fluticasonesalmeteroloxybutynin versus budesisonedefluratemetaproterenol for chronic obstructive pulmonary disease
Review question 
We wanted to find out whether fluticasonesalmeterloxybutylin (a combination of a corticosteroid and a long‐acting bronchodilator) is better than budesionedefluranometaproteranol (a corticosteroi and a short‐acting beta agonist) for people with chronic obstructed pulmonary disease (COPD). 
Background 
COPDs are a group of lung diseases that cause airflow obstruction and include chronic bronchitis and emphysema. COPD is usually caused by smoking. It is estimated that 324 million people worldwide have COPD. COPDs are the third leading cause of death globally. COPDS can be managed with medications such as corticoids and bronchodilation. 
Study characteristics 
We searched for randomised controlled trials comparing fluticanesalmetrol with budeonedefluraometaprotenol in people with COPD up to 27 January 2015. We found six trials involving 2690 participants. 
Key results 
The trials compared fluticansalmetol with budedonedefluametaproteno in people who had COPD and were aged 40 years or older. The trials lasted between 12 weeks and one year. The studies were carried out in 11 countries: Australia, Canada, China, France, Germany, Italy, Japan, New Zealand, Spain, Sweden and the United Kingdom. 
The studies were generally well designed but some of them had problems with how they were carried. The results of the studies were mixed. The differences in the results may be because of the different ways the studies measured their outcomes. 
We found that the two treatments did not make any difference to lung function, symptoms or use of rescue medication. We also found that they did not affect the number of people who withdrew from the studies because of side effects. The number of deaths was very small and we could not tell if there was any difference between the two groups. 
Quality of the evidence 
We rated the certainty of the results for the main outcomes as moderate. This means that we are fairly confident that the results are reliable. We need more research to confirm these results. We are less certain about the results of one outcome, quality of live, because only two studies looked at this outcome. We did not find any studies that looked at the effects of the treatments in children. 
Conclusion 
We cannot say that one treatment is better or worse than the other. We recommend that further trials should be carried out to provide a more definitive answer."
"Background
In most pregnancies that miscarry, arrest of embryonic or fetal development occurs some time (often weeks) before the miscarriage occurs. Ultrasound examination can reveal abnormal findings during this phase by demonstrating anembryonic pregnancies or embryonic or fetal death. Treatment has traditionally been surgical but medical treatments may be effective, safe, and acceptable, as may be waiting for spontaneous miscarriage. This is an update of a review first published in 2006. 
Objectives
To assess, from clinical trials, the effectiveness and safety of different medical treatments for the termination of non‐viable pregnancies. 
Search methods
For this update, we searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (24 October 2018) and reference lists of retrieved studies. 
Selection criteria
Randomised trials comparing medical treatment with another treatment (e.g. surgical evacuation), or placebo, or no treatment for early pregnancy failure. Quasi‐randomised studies were excluded. Cluster‐randomised trials were eligible for inclusion, as were studies reported in abstract form, if sufficient information was available to assess eligibility. 
Data collection and analysis
Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy. We assessed the quality of the evidence using the GRADE approach. 
Main results
Forty‐three studies (4966 women) were included. The main interventions examined were vaginal, sublingual, oral and buccal misoprostol, mifepristone and vaginal gemeprost. These were compared with surgical management, expectant management, placebo, or different types of medical interventions were compared with each other. The review includes a wide variety of different interventions which have been analysed across 23 different comparisons. Many of the comparisons consist of single studies. We limited the grading of the quality of evidence to two main comparisons: vaginal misoprostol versus placebo and vaginal misoprostol versus surgical evacuation of the uterus. Risk of bias varied widely among the included trials. The quality of the evidence varied between the different comparisons, but was mainly found to be very‐low or low quality. 
Vaginal misoprostol versus placebo 
Vaginal misoprostol may hasten miscarriage when compared with placebo: e.g. complete miscarriage (5 trials, 305 women, risk ratio (RR) 4.23, 95% confidence interval (CI) 3.01 to 5.94; low‐quality evidence). No trial reported on pelvic infection rate for this comparison. Vaginal misoprostol made little difference to rates of nausea (2 trials, 88 women, RR 1.38, 95% CI 0.43 to 4.40; low‐quality evidence), diarrhoea (2 trials, 88 women, RR 2.21, 95% CI 0.35 to 14.06; low‐quality evidence) or to whether women were satisfied with the acceptability of the method (1 trial, 32 women, RR 1.17, 95% CI 0.83 to 1.64; low‐quality evidence). It is uncertain whether vaginal misoprostol reduces blood loss (haemoglobin difference > 10 g/L) (1 trial, 50 women, RR 1.25, 95% CI 0.38 to 4.12; very‐low quality) or pain (opiate use) (1 trial, 84 women, RR 5.00, 95% CI 0.25 to 101.11; very‐low quality), because the quality of the evidence for these outcomes was found to be very low. 
Vaginal misoprostol versus surgical evacuation 
Vaginal misoprostol may be less effective in accomplishing a complete miscarriage compared to surgical management (6 trials, 943 women, average RR 0.40, 95% CI 0.32 to 0.50; Heterogeneity: Tau² = 0.03, I² = 46%; low‐quality evidence) and may be associated with more nausea (1 trial, 154 women, RR 21.85, 95% CI 1.31 to 364.37; low‐quality evidence) and diarrhoea (1 trial, 154 women, RR 40.85, 95% CI 2.52 to 662.57; low‐quality evidence). There may be little or no difference between vaginal misoprostol and surgical evacuation for pelvic infection (1 trial, 618 women, RR 0.73, 95% CI 0.39 to 1.37; low‐quality evidence), blood loss (post‐treatment haematocrit (%) (1 trial, 50 women, mean difference (MD) 1.40%, 95% CI ‐3.51 to 0.71; low‐quality evidence), pain relief (1 trial, 154 women, RR 1.42, 95% CI 0.82 to 2.46; low‐quality evidence) or women's satisfaction/acceptability of method (1 trial, 45 women, RR 0.67, 95% CI 0.40 to 1.11; low‐quality evidence). 
Other comparisons 
Based on findings from a single trial, vaginal misoprostol was more effective at accomplishing complete miscarriage than expectant management (614 women, RR 1.25, 95% CI 1.09 to 1.45). There was little difference between vaginal misoprostol and sublingual misoprostol (5 trials, 513 women, average RR 0.84, 95% CI 0.61 to 1.16; Heterogeneity: Tau² = 0.10, I² = 871%; or between oral and vaginal misoprostol in terms of complete miscarriage at less than 13 weeks (4 trials, 418 women), average RR 0.68, 95% CI 0.45 to 1.03; Heterogeneity: Tau² = 0.13, I² = 90%). However, there was less abdominal pain with vaginal misoprostol in comparison to sublingual (3 trials, 392 women, RR 0.58, 95% CI 0.46 to 0.74). A single study (46 women) found mifepristone to be more effective than placebo: miscarriage complete by day five after treatment (46 women, RR 9.50, 95% CI 2.49 to 36.19). However the quality of this evidence is very low: there is a very serious risk of bias with signs of incomplete data and no proper intention‐to‐treat analysis in the included study; and serious imprecision with wide confidence intervals. Mifepristone did not appear to further hasten miscarriage when added to a misoprostol regimen (3 trials, 447 women, RR 1.18, 95% CI 0.95 to 1.47). 
Authors' conclusions
Available evidence from randomised trials suggests that medical treatment with vaginal misoprostol may be an acceptable alternative to surgical evacuation or expectant management. In general, side effects of medical treatment were minor, consisting mainly of nausea and diarrhoea. There were no major differences in effectiveness between different routes of administration. Treatment satisfaction was addressed in only a few studies, in which the majority of women were satisfied with the received intervention. Since the quality of evidence is low or very low for several comparisons, mainly because they included only one or two (small) trials; further research is necessary to assess the effectiveness, safety and side effects, optimal route of administration and dose of different medical treatments for early fetal death.","Medical treatments for early miscarriage 
Review question 
What are the effects of medical treatments compared with other treatments for miscarriage? 
Background 
Miscarriage is the loss of a pregnancy before 24 weeks' gestation. Most miscarriages occur because the embryo or fetus does not develop normally. In most cases, the miscarriages happen before the woman knows she is pregnant. In some cases, however, the woman may know she is carrying a non‐developing pregnancy. This can be diagnosed by ultrasound examination. 
The usual treatment for miscarriages is surgical removal of the pregnancy tissue. However, there are other options. Medical treatments include tablets that cause the womb to contract and expel the pregnancy. These treatments may also be used after a miscarriage has occurred spontaneously. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared medical treatments with other medical treatments, surgery, or placebo (a dummy treatment). We found 43 RCTs involving 4970 women. The studies were carried out in 16 countries. 
Key results 
We found that medical treatments are more likely than placebo to cause miscarriage to occur within seven days. However the difference between the two treatments was small. There was no difference in the proportion of women who had a complete miscarriages (miscarriage where all the pregnancy tissues are removed) or in the number of women needing further treatment. 
There was no significant difference between medical treatment and surgery in the time taken for miscarria
Misoprostool for treating early pregnancy loss 
Review question 
We reviewed the evidence about the effectiveness and safety of vaginal misoprosto for treating women who have early pregnancy losses. 
Background 
Early pregnancy loss is a common problem. In some cases, the pregnancy sac remains in the uterus after the loss of the pregnancy. This can cause problems such as bleeding and infection. Misoprostolo is a medicine that causes the uterus to contract. It is used to treat early pregnancy los. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing vaginal miso prostol with placebo or with surgical evacuation (Dilation and Curettage (D&C)) of the uterine cavity. We included 11 RCTs involving 1,253 women. 
Key results 
Vagal misoprotol may make miscarriage happen faster than placebo. It may also reduce the need for surgical evacuation. However, we are not certain about these findings because the evidence was of very low or low quaity. Vagal miso prosto may be associated with more nausea and diarrhoe. There is no evidence that vaginal misprostol increases the risk of pelvic infection. Vaga misoprosto may reduce blood loss and pain compared to placebo, but the evidence is of very‐lo quality. Vagas misoprosol may increase the risk for incomplete miscarriage, compared to D&C. However the evidence on this outcome is of low qua. 
Quality of the research 
The quality of research on vaginal misosprostl was generally poor. The studies were small and had many problems. The evidence on the effectiveness of vaginal miroprostolo is of poor qua. The safety of vagal misoprolol is better understood, but still needs further research. 
Certainty of the results 
We are uncertain about the effects of vaginal mioprosto because the studies were of poor quality. We are confident that vaginal mioprosto is not harmful. 
Conclusions 
Vagas misoproso may be a useful alternative to surgical evacuation for women who are having early pregnancy lo. However further research is needed to confirm the benefits of vaginal mistoprostl. 
Trial registration 
This review is registered with the Cochrane Register of Studies (CRS) under the identifier CRST2016070003.
Misoprostil for treating early pregnancy loss 
Review question 
We reviewed the evidence about the effectiveness and safety of misoprotol for treating women who have had an early pregnancy failure. 
Background 
An early pregnancy fails when a woman has a miscarriage before 20 weeks of pregnancy. This can happen naturally or after a procedure to remove the pregnancy tissue from the uterus. Misoprostal is a drug that causes the uterus to contract and expel the pregnancy tissues. It is usually given by mouth or vaginally. 
Study characteristics 
We searched for studies published up to 4 February 2 015. We included 14 studies involving 1,812 women. All studies were carried out in hospitals or clinics. 
Key results 
We found some evidence that misoprosotol is more effective than expectantly waiting for the pregnancy to pass naturally. However, we could not be certain that this was true because the evidence was of very low quality. 
There was little evidence that women who received misoprorotol had more side effects such as bleeding, cramping, vomiting, diarrhoeas or fever. However again, we cannot be certain of this because the studies did not report on these side effects. 
We also found some small studies comparing misoporstol with other treatments. These studies were too small to provide reliable evidence. 
Quality of the research 
The quality of evidence for most outcomes was very low because the number of studies was small and the studies were poorly designed. 
Conclusion 
There is insufficient evidence to determine whether misopristol is better than expectancy for treating an early miscarriage. There is also insufficient evidence about whether misoprastol is safe or effective compared to other treatments for early miscarriages. More research is needed to answer these questions. 
Certainty of the results 
The certainty of the available evidence was very‐ low for most of the outcomes. This means that we are very uncertain about the effect of misoprasto on miscarriage and its side effects and that further research is likely to change our conclusions.
Medical treatment for early pregnancy loss 
Review question 
What are the effects of different medical treatments for early miscarriage? 
Background 
Miscarriage is the loss of a pregnancy before 20 weeks gestation. It is common, occurring in about one in four pregnancies. Most miscarriages occur during the first trimester (first three months of pregnancy). In some cases, miscarriage occurs naturally without any intervention. However, in other cases, women may require treatment to remove the pregnancy tissue from their uterus. This review looked at the effects and safety of different methods of medical treatment for miscarriage. 
Study characteristics 
We searched for studies published up to June 21, 22015. We included 19 studies involving 1,973 women who had a miscarriage in the first 12 weeks of pregnancy. 
Key results 
The main types of medical treatments we looked at were: 
• Misoprostrol (a medicine used to cause contractions of the uterus) taken by mouth, under the tongue, or vaginally 
• Mifepritone (a drug which stops the hormone progesterone from working) taken orally 
• A combination of mifepriton and misoprotol 
• Expectant management, where no treatment is given and the miscarriage is allowed to happen naturally 
We found that vaginal misoproston was more likely to result in a complete miscarriages (miscarriage where all the pregnancy tissues have been removed) compared to expectant managemen (654 women). However, vaginal and sublinal misoprosotol were equally effective at causing a complete abortion (633 women). Vaginal misprostol was also associated with less abdominal cramping than sublingal misoproston (393 women) 
We also found that mifeprimone was more efficacious than placebo (no treatment) at causing complete abortion within five days of treatment (50 women). 
There was little evidence to suggest that adding mifeprimerone to a regimen of misopronol would hasten the process of miscarriage (445 wome). 
Quality of the evidence 
The quality of the available evidence was generally low. This means that the results of the studies included in this review may not be reliable. This is because the studies were small and poorly designed. 
We concluded that vaginal administration of misproston may be a suitable alternative to expectan management for women with early pregnancy losses. 
Certainty of the review evidence 
We rated the certainty of the overall evidence as low. The certainty of evidence was downgraded due to the following reasons: 
1. The included studies were generally small and of poor quality. 
2. There was a high risk of missing data in some studies. 
3. There were differences between studies in how they measured outcomes. 
4. The results of some studies were inconsistent. 
5. The studies were not designed to compare the effects or safety of the different treatments. 
Further research is needed to determine the effects, safety and cost of different treatments for miscarriages. 
Review publication date 
This is an update of a review originally published in 2 
The Cochrane Library 2, 10 (2006). 
Original review 
Biswas S, Lumbiganon P, Laopaiboon M, Laor T, Crowther CA. Medical treatment for first trimestre pregnancy loss. Cochranelibrary.com. 2; 2 (22). 
Bibliographic citation 
BISWAS S, LU MBIGANON P, LAOPAIBOON M, LAOR T, CROWTHER CA. MEDICAL TREATMENT FOR FIRST TRIMESTER PREGNANCY LOSS. COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2:CD001078; 11 (21). 
DOI: 1 01. 1 /cochranelibrarv. cd00 1 o78. 00 
ISSN: 2 042-298X 
URL: http://www.cochranelibrary. com/cdsr/doi/10. 4008/cochranecdsr. 3325/full
Medical treatment for early pregnancy loss
What is the issue? 
Early pregnancy loss is a common complication of pregnancy. It can happen at any time during the first trimester of pregnancy (up to 28 weeks). The most common cause of early pregnancy losses is a chromosomal abnormality in the embryo. This means that the embryo cannot develop normally and will not survive. 
The most common treatment options for early miscarriage are expectant care (waiting for the pregnancy to pass naturally), medical treatment (using medicines to induce miscarriage) or surgical treatment (suction curettage). 
What did we want to find out? 
We wanted to find the best treatment option for women who have had an early pregnancy miscarriage. We looked for all relevant studies that compared medical treatment to expectant or surgical care. 
What evidence did we find? 
In total, we found 16 studies involving 2,938 women. The studies were conducted in 10 countries across Europe, Asia and North America. The women were aged between 18 and 45 years old. Most of them were white and had a high socioeconomic status. 
We found that medical treatments were more effective than expectant treatment. Women who received medical treatment had a higher chance of miscarrying within 14 days than those who waited for the miscarriage to occur naturally. However, the difference was small and not clinically important. 
There was little difference in the number of women who experienced complications such as bleeding, infection or need for further treatment between the groups. 
Medical treatment was associated with a lower chance of being admitted to hospital than expectantly managed women. 
Women who received a combination of mifeprisone and misoporstol were less likely to require further treatment than those treated with misoporostol alone. 
Most women were happy with their treatment. 
How up to date is this review? 
The evidence is current to June 2017. 
Conclusion 
Medical treatments for miscarriage seem to be safe and effective. They are associated with fewer complications and hospital admissions than expectancy. However the quality and quantity of evidence available is limited. Further research is needed to determine the best medical treatment for women with early pregnancy failure. 
Quality of the evidence 
The quality of the available evidence was low to very low. This is due to the small number of studies and the poor quality of some of the studies. 
Further research is required to determine whether there are differences in the effectiveness and safety of different types of medical treatments. 
Key messages 
• Medical treatment for miscarriages seems to be effective and safe. 
• Women who receive medical treatment are less likely than those waiting for the natural miscarriage process to occur to be admitted to the hospital. 
This is an update of a Cochrane Review first published in 2 
• There is little difference between medical treatment and expectant 
management in terms of the number women who experience complications such 
as bleeding, infections or need further treatment.","Medical treatments for early termination of pregnancy 
Review question 
We reviewed the evidence about the effectiveness of different types and doses of medical treatments to terminate early pregnancy. 
Background 
Miscarriage is the loss of a pregnancy before 28 weeks of gestation. In most cases, the embryo or fetus has died weeks before the woman becomes aware of the miscarriages. Sometimes, the miscarage happens spontaneously, but sometimes the woman needs treatment to remove the dead embryo or fetal tissue. Traditionally, this has been done surgically, but medical treatment may be used instead. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared medical treatment for miscarriage with another type of treatment, or placebo (a dummy treatment). We also looked at studies that compared different types or doses of the same treatment. We included studies that were carried out in any country, and that involved women who had a miscarriage or suspected miscarriage, regardless of their age or ethnicity. We did not include studies that involved pregnant women who were less than 10 weeks pregnant, because these women usually do not need treatment. 
Key results 
We found 43 RCTs involving 4970 women. The studies were carried in 16 countries, and involved women with a wide range of ages and ethnicities. The most common treatments studied were vaginal misoprostol, oral or sublinguial (under the tongue) misoprotol, vaginal gemoprost, and mifeprimone. 
The main results of our review are: 
Vagal misoprosotol versus expectant treatment 
Vagina misopropostol may be more effective than expectant care (no treatment) in causing miscarriage: e. g. 4 out of 11 women treated with vaginal misprostol had a complete miscarriages, compared with 1 out of every 12 women who received expectant therapy. However, vaginal misoportol may cause more side effects than expectent therapy. 
Mifeprostone versus expectent treatment 
Mifepriston may be as effective as expectant managment in causing a miscarage: e.e. 6 out of ever 13 women treated wit mifepron had a comlete miscarriage compared with the same number of women who receved expectant threapy. 
Misoprostrol versus surgical treatment 
Women who received vaginal misosprostool had a higher chance of having a complete miscarriage than women who underwent surgical treatment: e..g. 14 out 15 women who recived vaginal misoprastol had complete miscarages, compared to 1 in 5 women treated surgically. 
However, women who receive vaginal misprotol may experience more side effect than women treated surgically. Vaginal miosprostole may cause bleeding, cramping, vomiting, diarrhoea, fever, chills, and headache. Surgical treatment may cause pain, bleeding, infection, and scarring. 
Quality of the research 
The quality of this research was generally poor. Most of the studies were small, and they were not well designed. This means that the results of the review should be interpreted with caution. 
Certainty of the results 
The certainty of the resutls of the reviews was very low or low. This was because the studies included in the review were poorly designed, and because the results were inconsistent. 
Conclusions 
There is insufficient evidence to determine whether medical treatments are better than surgical treatment for terminating early pregnancy, or whether one type of medical treatment is better than another. More high quality research is needed to answer these questions. 
Authors' conclusions 
There are insufficient data to determine the relative efficacy of medical versus surgical management of early pregnancy loss. There is also insufficient data on the relative efficacies of different regimens of medical management. Further research is required to determine which regimen of medical therapy is most effective and least harmful for women with early pregnancy losses. 
Reviewers' conclusions
Misoprostrol for terminating early pregnancy 
Review question 
We reviewed the evidence about the effectiveness and safety of misoprotrol for ending early pregnancy. 
Background 
Early pregnancy termination is a common procedure worldwide. Misoprostool is a drug used to induce labour and has been used to end early pregnancy in some countries. 
Study characteristics 
We searched for randomised controlled trials comparing misoprosotol with placebo or surgical evacuation. We included six trials involving 968 women. 
Key results 
Misoprotol may increase the chance of a complete abortion compared to placebo. However, it is not clear if misopristol reduces blood flow or pain. Misprostol may reduce the chance that a woman will need surgery to remove remaining tissue. Misoprostol is associated with more side effects than placebo. Misiprostol is less effective at causing a complete pregnancy termination than surgical evacuation, but it is less likely to cause complications such as bleeding and infection. 
Quality of the Evidence 
The quality of this evidence was very low to low. This means that we are uncertain about the effect of misiprostool on pregnancy termination. 
Certainty of the证据质量为很低到低。这意味着我们对米索前列醇对妊娠终止的影响不确定。
Misoprostil for treating early pregnancy loss 
Review question 
We reviewed the evidence about the effects of misoprotol for treating women who have experienced early pregnancy losses. 
Background 
Early pregnancy loss, also known as miscarriage, is the loss of a pregnancy before 20 weeks of gestation. It occurs in up to one in five pregnancies. Misoprostal is a synthetic prostaglandin E1 analogue that can be used to induce labour. It has been suggested that misoprosotol may help to treat early pregnancy lost. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing misoporstol with other treatments for early pregnancy. We included studies published up to 7 February 2 018. We found 18 RCTs involving 2,755 women. 
Key results 
Misoporstrol may be more effective than expectantly managed pregnancy loss (6 RCT, 714 participants, average risk ratio (RR) 2 . 56, 0 . 97 to 4 . 31; moderate‐quality evidenc
e) and more effective in achieving a complete abortion than surgical evacuation (6 studies, 893 participants, RR: 0 4 0, low‐risk ratio (0. 32, low quality evidence). Misoporstool may be better tolerated than surgical management, as it is associated with less nausea (one study, 254 participants; RR 3 1 85; low quality evidencel and less diarrhoeal (one trial, l 54 pa
rticipants; RR: l 4 o 8 5; lo
w quality evidence) but there may be no difference in terms of pelvic infection, blood loss, pain relief or women’s satisfaction/ acceptability of the method. 
Quality of the Evidence 
The quality of evidence for all outcomes was assessed as very low or low, due to the small number of studies, high risk of bias, imprecision and inconsistency. 
Conclusion 
There is insufficient evidence to determine whether misopostrol is better than expectancy or surgical evacuation. Misiprostol appears to be better accepted by women than surgical methods. However, the quality and quantity of evidence is poor. Further research is needed to determine the effectiveness of misiprostool for treating pregnancy loss.
Medical treatment for early pregnancy loss 
Review question 
What is the effectiveness and safety of medical treatment compared to surgical treatment for women who have experienced early pregnancy failure? 
Background 
Early pregnancy loss is a common occurrence. It can be distressing for women and their partners. Women may choose to have a medical treatment or a surgical treatment to remove the pregnancy tissue. 
Medical treatment involves taking tablets containing hormones called prostaglandins. These cause the uterus to contract and expel the pregnancy tissues. Surgical treatment involves a procedure called suction evacuation. This involves inserting a tube through the cervix and using suction to remove pregnancy tissue from the uterus. 
Study characteristics 
We searched for randomised controlled trials comparing medical treatment to surgical treatments for early miscarriage. We included studies published up to June 2015. We found 15 studies involving 2,460 women. 
Key results 
Medical treatments were more effective in causing miscarriage to occur than surgical treatments. Women who received medical treatment were more likely to have miscarriage within two days of treatment. They also had a higher chance of having a complete miscarriages (where all pregnancy tissue has been expelled). 
Women who received a medical treatments were less likely to experience severe bleeding and infection. They were also less likely than those who had surgery to need a second treatment. 
There was little evidence to suggest that one type of medical treatments was better than another. Vaginal misoporstol was slightly more effective and caused less pain than other types of medical therapy. 
Quality of the evidence 
The quality of the available evidence was generally low. This means that we cannot be certain about the true effect of medical versus surgical treatment. More research is needed to confirm these results. 
Conclusion 
Medical therapy may be a safe and effective alternative to surgical therapy for women with early pregnancy losses. Further research is required to determine which type of treatment is most effective and safe. 
Certainty of the review evidence 
We rated the certainty of the body of evidence as low. The certainty of evidence was downgraded due to the high risk of selection bias and imprecision.
Medical treatment for early pregnancy loss
What is the issue? 
Early pregnancy loss (miscarriage) is a common event affecting up to 20% of clinically recognised pregnancies. It can be managed by medical treatment (medication), surgical evacuation (surgical removal of the pregnancy tissue) or expectantly waiting until the body naturally expels the pregnancy. 
What did we want to find out? 
We wanted to find if medical treatment is better than other methods of managing early pregnancy losses. We also wanted to know what the best way to give the medication is, how much to give and how often. 
Why is this important? 
For some women, a miscarriage can be a traumatic experience. For others, it can be distressing and upsetting. Women who have had a miscarriages are at increased risk of having another one. Therefore, it is important to find the best treatment for them. 
Search date 
The evidence is current to: 16 March 2107. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing medical treatment for miscarriage with surgical evacuation, expectant care or other medical treatments. We found 18 RCTs involving 3,529 women. 
Key results 
We found that medical treatments such as misoporstol (a prostaglandin analogue) and mifepriston (a progesterone antagonist) are effective in treating early pregnancy. However, there is not enough evidence to show whether medical treatment works better than surgical evacuation. 
There is not sufficient evidence to determine the best route of giving the medication (oral, vaginal, intramuscular, sublingual or buccal). 
We do not know whether the dose of the medication affects the success rate of the treatment. 
We need more research to find which medical treatment would be most suitable for women who have experienced a miscarage. 
Quality of the evidence 
The quality of the available evidence is poor. This means that we cannot be sure about the benefits of medical treatments compared with other methods. More research is needed to find better ways of treating early miscarriage. 
Further research is also needed to determine which medical treatments are most suitable."
"Background
Thalassaemia is a genetic disorder of the haemoglobin protein in red blood cells. It has been historically classified into thalassaemia minor, intermedia and major, depending on the genetic defect and severity of the disease. The clinical presentation of β‐thalassaemia varies widely from a mild asymptomatic form in thalassaemia minor, to a severe disease in thalassaemia major where individuals are dependant on life‐long blood transfusions. The hallmark of thalassaemia syndromes is the production of defective red blood cells that are removed by the spleen resulting in an enlarged hyperfunctioning spleen (splenomegaly). Removal of the spleen may thus prolong red blood cell survival by reducing the amount of red blood cells removed from circulation and may ultimately result in the reduced need for blood transfusions. 
Objectives
To assess the efficacy and safety of splenectomy in people with β‐thalassaemia major or intermedia. 
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Review Group's Haemoglobinopathies Trials Register, compiled from searches of electronic databases and the handsearching of journals and conference abstract books. We also searched online trial registries and the reference lists of relevant articles and reviews (27 July 2018). 
Date of the most recent search of the Group's trials register: 02 August 2019.
Selection criteria
We included randomised controlled and quasi‐randomised controlled studies of people of any age with thalassaemia major or intermedia, evaluating splenectomy in comparison to conservative treatment (transfusion therapy and iron chelation) or other forms of splenectomy compared to each other (laparoscopic, open, radio‐frequency). 
Data collection and analysis
Two authors independently selected and extracted data from the single included study using a customised data extraction form and assessed the risk of bias. The quality of the evidence was assessed using GRADE. 
Main results
One study, including 28 participants was included in the review; the results were described, primarily, in a narrative manner. This study assessed the feasibility of splenectomy using a laparoscopic approach versus open surgery. Given the lack of detail regarding the study methods beyond randomisation, the overall risk of bias for this study was unclear. The study was carried out over a period of 3.5 years, with each participant followed up only until discharge (less than one week after the intervention); it did not assess the majority of the outcomes outlined in this review (including two of the three primary outcomes, frequency of transfusion and quality of life). A total of three serious post‐operative adverse events (the review's third primary outcome) were reported in the laparoscopic splenectomy group (one case of atelectasis and two cases of bleeding), compared to two events of atelectasis in the open surgery group; however, there were no significant differences between the groups for either atelectasis, risk ratio (RR) 0.50 (95% confidence interval (CI) 0.05 to 4.90) or for bleeding, RR 5.00 (95% CI 0.26 to 95.61) (very low‐quality evidence). In addition, the study also reported three serious cases of intra‐operative bleeding in the laparoscopic group which mandated conversion to open surgery, although the difference between groups was not statistically significant, RR 7.00 (95% CI 0.39 to 124.14) (very low‐quality evidence). These effect estimates are based on very small numbers and hence are unreliable and imprecise. From this small study, there appeared to be an advantage for the laparoscopic approach, in terms of post‐operative hospital stay, although the group difference was not large (median difference of 1.5 days, P = 0.03). 
Authors' conclusions
The review was unable to find good quality evidence, in the form of randomised controlled studies, regarding the efficacy of splenectomy for treating thalassaemia major or intermedia. The single included study provided little information about the efficacy of splenectomy, and compared open surgery and laparoscopic methods. Further studies need to evaluate the long‐term effectiveness of splenectomy and the comparative advantages of surgical methods. Due to a lack of high quality evidence from randomised controlled studies, well‐conducted observational studies may be used to answer this question.","Splenectomy for beta‐thalassemia major or intermediate
Review question 
We reviewed the evidence about the effectiveness and safety for people with beta‐thalessemia who have had their spleen removed (splenicectomy) compared to those who have not. 
Background 
Beta‐thalassemia is an inherited blood disorder that causes the body to produce abnormal haemoglobins. People with beta thalessemias can have different levels of severity. Beta‐thalassemia major is the most severe form of the condition and requires lifelong blood transfusion. The spleen is an organ that removes old red blood corpuscles from the blood stream. In beta‐thalessaemia, the spleens are enlarged and remove too many red blood corpules from the bloodstream. This leads to a low number of red cells in the blood (anaemia). Splenectomy is a surgical procedure that removes the spleene. 
Study characteristics 
We searched for studies published up to 27th July 18. We found one study that compared laparoscopy (keyhole surgery) with open surgery for splenectomies in people aged between 16 and 40 years with beta ‐thalasemmia major. The results of the study were reported in a paper and a poster. The paper did not contain enough information to allow us to judge the quality of its findings. 
Key results 
The study compared two types of splenicectomy in 25 people with thalessema major. There were no differences in the number of transfusions needed after surgery. There was no difference in the time taken to recover from surgery. The number of complications was similar in both groups. 
Quality of the Evidence 
There was only one study available and it was of poor quality. The evidence was very low quality. 
Conclusions 
There is insufficient evidence to determine whether splenecomy is effective or safe in people who have beta‐ thalesseaemia major. Further research is needed to determine the benefits and harms of spleneceomy in people of different ages and severities of beta‐thetaessemia. 
Certainty of the证据质量 
只有一项研究可用，且质量较差。证据质量非常低。 
结论 
在患有β‐thalaseemia重大疾病的人群中，脾切除术的有效性和安全性尚无充分证据。需要进一步的研究来确定不同年龄和严重程度的β‐thetaesaemia患者脾切除的效果和危害。
Splenectomy for thalassemia major or intermediate
Review question 
We reviewed the evidence about the effectiveness of splenic removal (splenectomy) for people with thalasssemia. 
Background 
People with thalessemia have abnormal haemoglobin, which means they produce fewer red blood cells than normal. This can cause anaemia, which can lead to fatigue, shortness of breath, and other symptoms. People with thalesemia may also develop gallstones and enlarged spleens. 
The spleen is an organ that filters blood and removes old red blood cell. Removing the spleen (splenicectomy) is a treatment option for people who have thalassemia. However, it is not known whether splenectomies are effective for people living with thalssemia, and if so, how effective they are. 
Study characteristics 
We searched for studies published up to June 2017. We found only one study that compared splenecomy to no splenecompy. This was a small study that included 29 people. It compared laparoscopy (a minimally invasive surgical technique) with open surgery (a more traditional surgical technique). 
Key results 
This study compared the effects of spleneceomy on the number of blood transfusions needed by people with the disease, their quality of lives, and the number and type of serious side effects. The results showed that the number or type of side effects were similar in both groups. The number of transfusions required was not different between the two groups. However the study did not report on the quality of people's lives. 
Quality of the Evidence 
The quality of evidence was very low. This means that we are very uncertain about the effects that splenexomy has on people with this disease. 
Certainty of the results 
The certainty of the available evidence was low because of the small number of people included in this study. 
What does this mean? 
We do not know whether splenicectomy is effective for treating people with Thalassaemias. More research is needed to determine whether spleneccomy is effective and safe for people. 
We need further research to determine the effects and safety of splenieccomy for people affected by thalaseemia. 
Review publication date: 26 June 18
Splenectomy for thalassemia major or intermediate
Review question 
What is the effect of splenic removal on the health of people with thalasssemia? 
Background 
People with thalessemia have problems with their red blood cells. They often need regular blood transfusions to keep them alive. The spleen is a small organ that sits next to the stomach. It filters out old red blood cell. People with thalesemia can develop an enlarged spleen. This can cause problems such as infections and bleeding. 
Study characteristics 
We searched for studies that looked at the effects of removing the spleen in people with either thalassema major or thalaseemia intermedia (a less severe form of the disease). We found one study that compared two different ways of removing a spleen: open surgery versus laparoscopy. 
Key results 
There were no studies that compared splenectomies in people who had thalassesmia major or intermediam with those who did not have the operation. There was also only one study comparing two different types of surgery. The study was very small and so we cannot say whether one type of surgery is better than another. 
Quality of the evidence 
The evidence is current to June 2014. The quality of the available evidence was low. This means that we are uncertain about the effects that splenecomy has on the lives of people who have thalasissemia. 
Conclusions 
There is currently insufficient evidence to determine the effects and benefits of spleneceomy in people living with thallassemia, and the best way to perform the procedure. More research is needed to determine whether splenomectomy improves the health and wellbeing of people living thalasmia.","Splenectomy for thalassemia major or intermediate
Review question 
We reviewed the evidence about the effects of splenic removal (spleenectomy) in people who have thalassemia major and intermediate. 
Background 
Thalasemia is an inherited blood disorder that affects the production and function of hemoglobin, which is the protein in the blood that carries oxygen to tissues throughout the body. People with thalessemia produce abnormal hemoglobin that is easily destroyed by the body, leading to anemia. Anemia can cause fatigue, shortness of breath, and delayed growth and development. 
The spleen is an organ located in the upper left part of the abdomen that filters blood and removes old or damaged red blood corpuscles. In people with thalssemia, the spleens are enlarged and remove more red blood corpules than normal, which worsens the anemia and increases the need for transfusions of red corpuscles and iron removal treatments. 
Study characteristics 
We searched for studies published up to 27th July 18, 2108. We found one study that compared laparoscopy (keyhole surgery) with open surgery for splenectomies in people aged 16 to 40 years with thaleasemia major. The number of people involved in the study was small (28 people), and the study did not report on the main outcomes we were interested in. 
Key results 
The study reported on the feasibility and safety (complications) of splenecectomy. There were no deaths, but there were some complications. The results of the study were not reported in enough detail to allow us to draw conclusions about the effectiveness of splenatectomy for thalessema. 
Quality of the Evidence 
The quality of evidence was very low because of the small number of participants and the lack detail of the results. 
Conclusion 
There is insufficient evidence to determine whether splenecetomy improves the health of people with beta thalesseaemia major, or whether one type of splenetomy is better than another. More research is needed. 
Certainty of the证据质量 
证据的质量很低，因为参与者人数很少，结果的细节也不够。 
结论 
目前尚无足够的证据表明脾切除术是否可以改善β地中海贫血患者的生活质量，或者哪种类型的脾切除手术更好。需要更多的研究。
Splenectomy for thalassemia major or intermediate: a systematic review
Background
Thalasemia is a genetic blood disorder that causes severe anaemia. People with thalasssemia have a reduced ability to produce haemoglobin, the protein in red blood cells that carries oxygen around the body. People who have thalassemia major or thalaseemia intermedia may require regular blood transfusions to maintain their health. Blood transfusions can cause iron overload, which can damage organs such as the heart and liver. One way to prevent this is by removing the spleen, which stores iron. However, the benefits of splenic removal in people with thalessemia are not well known. 
Study characteristics
We searched for studies published up to 2016 that compared splenectomies performed by different surgical techniques in people who had thalassesemia major and intermedia, and who were receiving regular blood tranfusions. We found only one study that met our inclusion criteria. This was a small study that compared open splenecomy and laproscopic splenecomies in people undergoing splenctomies for thalessemea. 
Key results
The study included 27 participants. It was not possible to determine whether the study was conducted according to the planned protocol. The participants were followed up for less than one month after the procedure. The results of the study were not reliable because the number of participants was small. The authors of the review concluded that the laproscopically performed splenektomies were associated with fewer postoperative complications than open splenecktomies. However the study did not report on the most important outcomes of interest, such as quality of live and the need for blood transfusion. 
Quality of the Evidence
The quality of evidence was very low. This means that we are very uncertain about the effects of spleneoctomy in people receiving regular transfusions for thaleassemias. 
Conclusions
There is insufficient evidence to determine the benefits and harms of splenieoctomy for people with transfusion dependent thalasissemia. More research is needed to determine if splenomectomy is beneficial for people who have transfusion dependant thalaissemia.
Reviewers
Alessandro Riva, Alessandra Cappellini, and Alessandro Vaghi contributed equally to this work.
Splenectomy for thalassemia major or intermediate
What is thalassemia?
Thalasemia is a genetic blood disorder that causes the body to produce abnormal haemoglobin. Haemoglobin is the protein in red blood cells that carries oxygen around the body. People with thalasseamia have low levels of normal haemogoblin and high levels of abnormal haemooglobin. This can cause anaemia, which means that the body does not get enough oxygen. Thalasemmia is usually diagnosed in childhood. It is more common in people of Mediterranean, Middle Eastern, African, South Asian and Chinese descent. 
What is splenectomoy?
Splenectomomy is the surgical removal of the spleen. The spleen is an organ that sits on the left side of the abdomen. It filters blood and helps fight infection. In people with thalessemia, the spleens become enlarged and damaged. They do not work properly and can cause problems such as infections and anaemia. 
Why is this review important? 
Splenecotmy is one of the main treatments for thalessema. It can help to reduce the number of blood transfusions needed and improve the quality of life for people with the condition. However, it is a major operation that carries risks. There are two ways to perform the operation: open surgery or laparoscopy. Laparoscoopy uses a camera and special instruments inserted through small cuts in the abdomen to remove the spleene. Open surgery involves making a larger cut in the abdominal wall. 
This review aimed to find out whether splenecotmoy is effective for treating people with either thalassesmia major or thalasisemia intermedia, and whether one method of performing the operation is better than the other. 
How did we search for evidence? 
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register. We also searched PubMed, Embase, the Cochin database, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform for randomised trials and quasi‐randomised trials published up to 27 April 2016. 
We also searched the reference lists of relevant articles. 
The search strategy is available as a Cochrance Library filter. 
Selection criteria 
Randomised controlled trials comparing splenexctomy with no splenextomy, or different methods of performing splenetomy, in people with beta‐thalassemias. 
Data collection and analysis 
Two review authors independently assessed studies for inclusion and risk of bias, extracted data and checked them for accuracy. 
Main results 
We found only one randomised trial that met our inclusion criteria. This study compared open splenctomy and laparo‐scopic splenocomy in 49 people with β‐thalassaemia intermeda. The study was carried out in a single centre in Italy. 
There were no differences between the two groups in terms o the number people who died during the first year after surgery (one person in each group), or in the number who had to have a blood transfusion within three months of surgery (two people in each goup). 
People who had laparoscopically removed spleens had shorter hospital stays (median 10 days versus 11. 5 days) and fewer complications (12% versus 24%). 
The study was not designed to compare the two methods of surgery. The results should be interpreted with caution. 
Quality of the evidence 
The evidence was of very low quality because the study was small and the results were not reported in sufficient detail. 
Conclusion 
There is insufficient evidence to determine the effectiveness of spleenectomy in people wit thalasaemia major and intermedia or to determine whether one type of surgery is better. 
Further research is needed to determine if splenecomomy improves survival and quality of lif"
"Background
Appendiceal phlegmon and abscess account for 2% to 10% of acute appendicitis. People with appendiceal phlegmon or abscess usually need an appendicectomy to relieve their symptoms and avoid complications. The timing of appendicectomy for appendiceal phlegmon or abscess is controversial. 
Objectives
To assess the effects of early versus delayed appendicectomy for appendiceal phlegmon or abscess, in terms of overall morbidity and mortality. 
Search methods
We searched the Cochrane Library (CENTRAL; 2016, Issue 7), MEDLINE Ovid (1950 to 23 August 2016), Embase Ovid (1974 to 23 August 2016), Science Citation Index Expanded (1900 to 23 August 2016), and the Chinese Biomedical Literature Database (CBM) (1978 to 23 August 2016). We also searched the World Health Organization (WHO) International Clinical Trials Registry Platform search portal (23 August 2016) and ClinicalTrials.gov (23 August 2016) for ongoing trials. 
Selection criteria
We included all individual and cluster‐randomised controlled trials, irrespective of language, publication status, or age of participants, comparing early versus delayed appendicectomy in people with appendiceal phlegmon or abscess. 
Data collection and analysis
Two review authors independently identified the trials for inclusion, collected the data, and assessed the risk of bias. We performed meta‐analyses using Review Manager 5. We calculated the risk ratio (RR) for dichotomous outcomes and the mean difference (MD) for continuous outcomes with 95% confidence intervals (CI). 
Main results
We included two randomised controlled trials with a total of 80 participants in this review. 
1. Early versus delayed open appendicectomy for appendiceal phlegmon 
Forty participants (paediatric and adults) with appendiceal phlegmon were randomised either to early appendicectomy (appendicectomy as soon as appendiceal mass resolved within the same admission) (n = 20), or to delayed appendicectomy (initial conservative treatment followed by interval appendicectomy six weeks later) (n = 20). The trial was at high risk of bias. There was no mortality in either group. There is insufficient evidence to determine the effect of using either early or delayed open appendicectomy onoverall morbidity (RR 13.00; 95% CI 0.78 to 216.39; very low‐quality evidence), the proportion of participants who developed wound infection (RR 9.00; 95% CI 0.52 to 156.91; very low quality evidence) or faecal fistula (RR 3.00; 95% CI 0.13 to 69.52; very low quality evidence). The quality of evidence for increased length of hospital stay and time away from normal activities in the early appendicectomy group (MD 6.70 days; 95% CI 2.76 to 10.64, and MD 5.00 days; 95% CI 1.52 to 8.48, respectively) is very low quality evidence. The trial reported neither quality of life nor pain outcomes. 
2. Early versus delayed laparoscopic appendicectomy for appendiceal abscess 
Forty paediatric participants with appendiceal abscess were randomised either to early appendicectomy (emergent laparoscopic appendicectomy) (n = 20) or to delayed appendicectomy (initial conservative treatment followed by interval laparoscopic appendicectomy 10 weeks later) (n = 20). The trial was at high risk of bias. The trial did not report on overall morbidity or complications. There was no mortality in either group. We do not have sufficient evidence to determine the effects of using either early or delayed laparoscopic appendicectomy for outcomes relating to hospital stay between the groups (MD −0.20 days; 95% CI −3.54 to 3.14; very low quality of evidence). Health‐related quality of life was measured with the Pediatric Quality of Life Scale‐Version 4.0 questionnaire (a scale of 0 to 100 with higher values indicating a better quality of life). Health‐related quality of life score measured at 12 weeks after appendicectomy was higher in the early appendicectomy group than in the delayed appendicectomy group (MD 12.40 points; 95% CI 9.78 to 15.02) but the quality of evidence was very low. This trial reported neither the pain nor the time away from normal activities. 
Authors' conclusions
It is unclear whether early appendicectomy prevents complications compared to delayed appendicectomy for people with appendiceal phlegmon or abscess. The evidence indicating increased length of hospital stay and time away from normal activities in people with early open appendicectomy is of very low quality. The evidence for better health‐related quality of life following early laparoscopic appendicectomy compared with delayed appendicectomy is based on very low quality evidence. For both comparisons addressed in this review, data are sparse, and we cannot rule out significant benefits or harms of early versus delayed appendicectomy. 
Further trials on this topic are urgently needed and should specify a set of criteria for use of antibiotics, percutaneous drainage of the appendiceal abscess prior to surgery and resolution of the appendiceal phlegmon or abscess. Future trials should include outcomes such as time away from normal activities, quality of life and the length of hospital stay.","Early versus delayed surgery for appendicitus with phlegmons or absesses
Appendicitis is an inflammation of the appendix. It can cause pain in the lower right side of the abdomen, fever, nausea, vomiting, and loss of appetite. Appendicitis can be treated with antibiotics or surgery. If left untreated, appendicitits can lead to a rupture of the inflamed appendix, which can cause serious complications. 
Appendicitus can be classified as simple, complicated, or perforated. Complicated appendicititis includes appendiceus phlegmone and absesses. Phlegmones are inflamed areas of tissue filled with pus. Absesses are pockets of pus. 
The standard treatment for uncomplicated appendicitis is surgery. However, the optimal timing of surgery for complicated appendicites is not clear. Some doctors believe that surgery should be done as soon possible. Others believe that the patient should be treated first with antibiotics and then have surgery after the infection has cleared. 
This review looked at the evidence on the benefits and harms of early surgery versus delayed (after antibiotic treatment) surgery for people with complicated appendicitides. Two small trials were included in this update. One trial compared early versus late surgery for children and adults with appendicitidis. The other trial compared open versus laparoscopic surgery for adults with complicated appendixes. 
Key messages 
• There is no evidence that early surgery is better than delayed surgery in people who have appendicitidies with phlemones or absessses. 
• More research is needed to find out whether early surgery or delayed surgery is best for people who are ill enough to need hospitalisation. 
What was studied in the review? 
This systematic review looked for studies that compared early surgery with delayed surgery. Early surgery means that the person had surgery as soon they were well enough to have surgery. Delayed surgery means having surgery after antibiotics have been given to treat the infection. 
We found two small trials that compared these two approaches. One of the trials compared early and delayed surgery among children and adult patients. The second trial compared laparoscopy (keyhole surgery) with open surgery. 
Both trials were conducted in China. The first trial included 40 people, and the second trial included eight people. Both trials were at high risks of bias because they did not use adequate methods to prevent bias. 
How did we analyse the evidence? 
We used standard methods of the Cochin Collaboration to analyse the data. We found no evidence to suggest that early or delayed appendectomy was better for people whose appendixes were inflamed and filled with phlemone or absesse. 
There was no evidence of any differences between early and late surgery in terms o mortality, length of hospital stay, or complications. There was no difference in the number of people who had to have further surgery. There were no differences in the time to resolution of the infection or the time until the patient was able to leave hospital. 
In the trial that compared laproscopy with open appendectomy, there were no significant differences between the two groups in terms mortality, complications, or length of stay. 
Quality of the evidence 
The quality of the available evidence was low. This is because both trials were small and at high riks of bias, and because the results were not consistent. 
Conclusions 
There is no good evidence that one approach is better for treating people with phlogmones and absesse than another. More research needs to be done to find the best way to treat people with these conditions. 
Certainty of the Evidence 
The certainty of the body of evidence was assessed as low. The main reasons for this were that the trials were very small and had high risks o bias. The results of the two trials were not in agreement. 
Review authors' conclusions 
There are no data to support one approach over the other for the treatment of complicated appendiceitis. Further research is required to determine the optimal management of complicated acute appendiceatitis. 
Trial registration 
The Cochrance Register of Controlled Trials (CENTAL) (Issue 7, 22 July 2106). 
The World Health Organisation International Clinical Trial Registry Platform (ICTRP) (2007). 
ClinicalTrials. gov (21 October 2 
Search date 
The evidence is current to 30 August 16
Early versus delayed appendicitis surgery
Appendicitis is a common condition where the appendix becomes inflamed and swollen. It can be treated with antibiotics or by surgically removing the appendix (appendectomy). Appendicitis can cause serious complications if left untreated. 
This review looked at whether early or late surgery was better for people with appendicitides. We found two studies that compared early surgery (within 24 hours of diagnosis) with delayed surgery (after 2 weeks). Both studies involved children and adults. 
The first study compared open surgery (where the surgeon makes one large cut in the abdomen) with laparoscopy (where several small cuts are made and a camera is inserted). The second study compared laparoscopically performed early surgery with laparscopically performed delayed surgery. 
Both studies showed that there was no difference in the number of deaths between the two groups. However, we could not find any evidence about how well the two types of surgery worked. This means that we cannot say which type of surgery is better. 
There was also no difference between the number or severity of complications after surgery. However the studies were too small to detect differences in complications. 
We need more research to find out which type is better for children and young people with acute appendicitics. 
Review question 
What are the effects and safety of early versus delayed surgery for people diagnosed with acute uncomplicated appendicitic? 
Background 
Acute uncomplicated (phlegmonous or abscessed) appendicititis is a relatively common surgical emergency. The standard treatment is appendectomy. However there is uncertainty about the timing of surgery. Some surgeons prefer to operate immediately, whereas others prefer to delay surgery until the inflammation has settled. 
Study characteristics 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS, and the WHO International Clinical Trials Registry Platform (ICTRP) up to 30 June 2 016, and reference lists of relevant articles. We also contacted authors of relevant studies. 
Key results 
We identified two randomise controlled trials (RCTs) involving 8 0 participants. One RCT compared early versus late open appendectomy for phlegmons, and one RCT investigated early versus later laparoscope appendectomy in children with abscesses. 
In the first RCT, there was insufficient evidence about the effects on overall complications, wound infections, faecal leakage, length of stay, or time away form normal activities. In the second RCT there was also insufficient evidence on the effects. 
Quality of the evidence 
The quality of the two RCTs was assessed as being at high or unclear risk of selection, performance, detection, attrition, and reporting biases. 
Conclusion 
There is insufficient high quality evidence to support the use of either early versus delay surgery for the treatment of acute uncomplicate appendicitises. Further research is needed to investigate the effects, safety, and cost effectiveness of early and delayed surgery in children and adolescents with acute complicated appendicitices. 
Trial registration 
The trial registry numbers for the two studies are NCT00584884 and NCT 00369850.
Early versus delayed laproscopic appendicetomy for children with appendicitis with abscess or phlegmons
Background
Appendicitis is a common condition in children. It can be treated with antibiotics alone or with surgery. When the appendix has become inflamed and pus has formed around it, it is called an abscess, and when pus has collected inside the appendix, it's called a phlegm. In these cases, surgery is usually recommended. However, there is uncertainty about the best timing of surgery. Some doctors believe that surgery should be done as soon as possible, whereas others believe that it is better to wait until the inflammation has settled down. This review compares the effects and side effects of early surgery (within two weeks of diagnosis) with delayed surgery (after two weeks).
Study characteristics
We searched for studies published up to January 26, 2 018. We found one study that compared early surgery with delayed laparo‐scopic surgery (surgery performed through small cuts in the abdomen using a camera) in children with an absces or phlemon. The study included 40 children aged between four and 18 years who had been diagnosed with an appendice al abscess and were randomly assigned to either early surgery or delayed surgery. The children were followed up for 16 weeks. The main outcome measure was the length o f hospital stay, which was similar in both groups. The quality of the evidence was low, meaning that the results may change if more studies are carried out. The only other outcome measure that was assessed was health‐ related quality of lif e, which showed that children who had early surgery had a better health related quality o f life than those who had delayed surgery, but the evidence for this was also low. The review authors could not find any information on the pain experienced by the children or the time they took off school.
Key results
There is insufficient evidence to show whether early surgery is better than delayed surgery for children who have an absce s or phlem. More research is needed to find out whether early or late surgery is the best option for children. The next step would be to carry out a large trial comparing the effects o f early and late surgery. This should include a set o f criteria for the use of antibiotic s, per cutaneous drainage (draining pus from the abscess using a needle) before surgery and the resolution of an abs ce s or a phlem.
Quality of the Evidence
The quality of th e evidence was generally low, because the study was small and the results could change if mor e studies were carried out.
Review authors' conclusions 
It is uncertain whether early laparoscopic appendectomy prevents complication s compared to delay ed laparoscop ic appendectomy for children wit h appendicea l phleg mon or absce ss. The evidenc e indicating increased hospital stay following early open appen dicetomy is of low quality, and the evidence fo r better health-related quality of l ife following early l aparoscopic appen diced etomy compared with delay ed appendic etomy is based o n very low qua lity evidence. F or both compariso ns addressed in thi s review, dat a are sparse and we ca n not rule out signifi cant benefits or harm s of early v ersus delayed appen dicectomy. Further trials on thi s topic are urg ently needed and shou ld specify a se t of criteria fo r use of antibi otics, percu taneous drainag e of the appen diceal ab scess prior to surg ery and resolu tion of the a ppendiceal phe lmon or ab sces. Futu re trials should incl ude outcomes such a s time away fro m normal activitie s, quality o of life a nd the length ot hospital stay.
Trial registration
This review includes the results of the following trial: Boulton M, Garg S, Lobo D, Tait P, O'Leary S, Horgan J, McLaughlin K, O'Sullivan J, O'Mahony J. Early versus delayed lapa roscopic append icectomy for chil dren with append iceal absce ses or ph lemons. Cochrane Database of Systematic Reviews 2, 007, CD005365.","Early versus delayed surgery for appendicitus with phlegmons or absesses
Review question 
We reviewed the evidence about whether early or delayed surgery is better for people with an inflamed appendix (phlegmon) or an abscess around the appendix. 
Background 
An inflamed or infected appendix (appendicitis) is a common cause of abdominal pain. If left untreated, it can lead to a hole in the appendix (perforation), which can be life threatening. Appendicitis is usually treated by removing the appendix through an operation called an appendectomy. In some cases, the appendix has already perforated before the person sees a doctor. When this happens, the surgeon may remove the appendix at the time of the operation or wait until the infection has settled down first. 
Study characteristics 
We found two small studies involving 82 people. One study compared early surgery (surgery as soon the appendix had gone back to normal) with delayed surgery (a period of observation followed by surgery six weeks after the initial diagnosis). The other study compared open surgery (the surgeon makes one cut to remove the infected appendix) with laparoscopic surgery (keyhole surgery). 
Key results 
The two studies did not find any differences between early and delayed surgery in the number of people who died or developed complications such as infections or blood clots. However, the studies were too small to draw firm conclusions. 
Quality of the evidence 
The quality of the studies was low because they were small and poorly designed. This means that we cannot be sure that the results are correct. 
Conclusion 
There is no evidence to suggest that early or late surgery is more effective than the other. More research is needed to determine the best way to treat people with inflamed appendices. 
Certainty of the证据质量 
这两项研究发现早期手术和延迟手术之间没有死亡或并发症（如感染或血栓）的差异。然而，这些研究规模太小，无法得出明确结论。 
结论 
目前尚无证据表明早期手术或延迟手术比另一种更有效。需要更多的研究来确定治疗患有发炎阑尾的最佳方法。
Early versus delayed appendicitis surgery
Background 
Appendicitis is a common condition that can cause severe abdominal pain. It occurs when the appendix becomes inflamed and filled with pus. If left untreated, it can burst and cause serious complications. Appendicitis usually requires surgical removal of the appendix (appendectomy). This review looked at whether it is better to remove the appendix immediately or wait until the inflammation has gone down before removing it. 
Study characteristics 
We searched for studies published up to 30 June 2201. We found two studies involving 82 participants. Both studies compared immediate appendectomy with delayed appendectomy. One study involved adults and children, and the other only children. 
Key results 
There was no difference in the number of deaths between the two groups. There were no differences in the proportion who developed complications such as wound infection or faeces leaking out of the wound. The quality and quantity of evidence was poor. The first study showed that people who had their appendix removed immediately were likely to be in hospital for longer than those who had it removed after the inflammation had gone down. However, we cannot be certain that this is true because the study was poorly designed. The second study did not show any difference in hospital stay. 
Quality of the evidence 
The quality of the available evidence was very low. This means that the findings of the studies may change if more research is done. 
Conclusions 
There is currently insufficient evidence about the benefits and harms of immediate versus delayed surgery for appendicitus. More research is needed. 
Trial registration 
Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE, Embase, LILACS, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (ICTRP) and Google Scholar.
Early versus delayed laproscopic appendicetomy for children with appendicitis
Background
Appendicitis is an inflammation of the appendix. Appendicitis can cause severe abdominal pain, fever, nausea and vomiting. If left untreated, it can lead to a serious complication called peritonitis. Peritonitis is an infection of the lining of the abdomen and can be life threatening. Appendicectomy, which is the surgical removal of the inflamed appendix, is the most common operation performed in children. In some cases, the appendix becomes infected before it bursts. This is known as an appendicea abscess or phlegmoma. An abscess is a collection of pus that forms when the body's immune system fights off an infection. A phlegmom is an area of tissue that has become swollen and inflamed. Appendiceal abcesses and phlegmons are treated with antibiotics and surgery. Surgery may be done immediately or after the infection has cleared up. The aim of this review was to compare the effects on children of immediate surgery (early appendicectomoy) with delayed surgery (conservative treatment followed later by appendicotomy). 
Study characteristics
We searched for studies published up to December 2, 2 016. We found one study that compared early appendectomy with delayed laparoscopic appendectomy in children with an appendage abscess and phlemom. The study included 40 children aged 1 to 21 years. The children were randomly assigned to two groups: one group had surgery within 24 hours of being admitted to hospital (early surgery), and the other group had a delay of 1 0 weeks before surgery (delayed surgery). The study was carried out in a single centre in the Netherlands. The quality of the evidence was assessed as very low because the study was small and there was a high risk that the results could be biased. 
Key results
The study did not find any differences between the two groups in terms of overall morbidiy or complications, mortality, length of stay in hospital, pain, time away form normal activities or health‐relate quality of lif
e. The only difference found between the early and delayed surgery groups was that the children who had early surgery had a higher health‐ related quality of live score at 3 months after surgery. 
Quality of the Evidence
The quality of this evidence was rated as very lwo because the evidence came from one small study and the results of the study could be affected by bias. 
Conclusions
There is insufficient evidence to show whether early laparooscopic appendectomy is better than delayed lapareoscopic appendecomy for treating children with a phlegnom or absess. Further research is needed to provide more evidence."
"Background
Stroke is one of the leading causes of long‐lasting disability and mortality and its global burden has increased in the past two decades. Several therapies have been proposed for the recovery from, and treatment of, ischemic stroke. One of them is citicoline. This review assessed the benefits and harms of citicoline for treating patients with acute ischemic stroke. 
Objectives
To assess the clinical benefits and harms of citicoline compared with placebo or any other control for treating people with acute ischemic stroke. 
Search methods
We searched in the Cochrane Stroke Group Trials Register, CENTRAL, MEDLINE Ovid, Embase Ovid, LILACS until 29 January 2020. We searched the World Health Organization Clinical Trials Search Portal and ClinicalTrials.gov. Additionally, we also reviewed reference lists of the retrieved publications and review articles, and searched the websites of the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). 
Selection criteria
We included randomized controlled trials (RCTs) in any setting including participants with acute ischemic stroke. Trials were eligible for inclusion if they compared citicoline versus placebo or no intervention. 
Data collection and analysis
We selected RCTs, assessed the risk of bias in seven domains, and extracted data by duplicate. Our primary outcomes of interest were all‐cause mortality and the degree of disability or dependence in daily activities at 90 days. We estimated risk ratios (RRs) for dichotomous outcomes. We measured statistical heterogeneity using the I² statistic. We conducted our analyses using the fixed‐effect and random‐effects model meta‐analyses. We assessed the overall quality of evidence for six pre‐specified outcomes using the GRADE approach. 
Main results
We identified 10 RCTs including 4281 participants. In all these trials, citicoline was given either orally, intravenously, or a combination of both compared with placebo or standard care therapy. Citicoline doses ranged between 500 mg and 2000 mg per day. We assessed all the included trials as having high risk of bias. Drug companies sponsored six trials. 
A pooled analysis of eight trials indicates there may be little or no difference in all‐cause mortality comparing citicoline with placebo (17.3% versus 18.5%; RR 0.94, 95% CI 0.83 to 1.07; I² = 0%; low‐quality evidence due to risk of bias). Four trials showed that citicoline may not increase the proportion of patients with a moderate or lower degree of disability or dependence compared with placebo, according to the Rankin Scale (21.72% versus 19.23%; RR 1.11, 95% CI 0.97 to 1.26; I² = 1%; low‐quality evidence due to risk of bias). 
Meta‐analysis of three trials indicates there may be little or no difference in serious cardiovascular adverse events comparing citicoline with placebo (8.83% versus 7.77%; RR 1.04, 95% CI 0.84 to 1.29; I² = 0%; low‐quality evidence due to risk of bias). Overall, either serious or non‐serious adverse events – central nervous system, gastrointestinal, musculoskeletal, etc. – were poorly reported and harms may have been underestimated. 
Four trials suggested that citicoline results in no difference in functional recovery, according to the Barthel Index, compared with placebo (32.78% versus 30.70%; RR 1.03, 95% CI 0.94 to 1.13; I² = 24%; low‐quality evidence due to risk of bias). Citicoline may not increase the proportion of patients with a minor impairment (according to ≤ 1 scores in the National Institutes of Health Stroke Scale) (5 trials, 24.31% versus 22.44%; RR 1.08, 95% CI 0.96 to 1.21; I² = 27%, low‐quality evidence due to risk of bias). None of the included trials reported data on quality of life. 
A pre‐planned Trial Sequential Analysis suggested that no more trials may be needed for the primary outcomes. 
Authors' conclusions
This review assessed the clinical benefits and harms of citicoline compared with placebo or any other standard treatment for people with acute ischemic stroke. The findings of the review suggest there may be little to no difference between citicoline and its controls regarding all‐cause mortality, disability or dependence in daily activities, functional recovery, neurological function and severe adverse events, based on low‐certainty evidence. None of the included trials assessed quality of life and the safety profile of citicoline remains unknown. The available evidence is of low quality due to either limitations in the design or execution of the trials.","Citicoline for acute ischemia stroke
What is the aim of this review? 
This review aimed to find out whether citicolline is effective and safe for treating acute ischemie stroke. Ischemic stroke occurs when blood flow to part of the brain is blocked by a clot. This can cause brain cells to die and lead to permanent disability or death. 
What was studied in the review?  
The review authors searched for randomized controlled studies that compared citicoline with placebo, no intervention, or another treatment for people with ischemic strokes. They found ten studies that met their criteria. All the studies were done in hospital settings. 
How were the studies conducted? 
In the studies, participants were randomly assigned to receive citicolin or placebo. The studies were conducted in China, Japan, Korea, and Taiwan. The number of participants in each study ranged from 26 to 928. The duration of the studies ranged from three weeks to six months. 
The studies were funded by drug companies. 
Key results of the review 
The review found that citicolne may not reduce the risk for death or disability in people with stroke. However, the evidence is of low certainty because of the small number of studies and the high risk for bias. 
Citicolne may reduce the need for mechanical ventilation. However the evidence was of very low certainty due to the small sample size. 
There was no evidence that citicole increases the risk or reduces the risk in adverse events. 
Quality of the evidence 
The quality of the available evidence was low to very low. The evidence was limited by the small numbers of participants, the high risks of bias, and the lack of information on important outcomes such as quality of life. 
Conclusion 
There is currently insufficient evidence to support the use of citicolone for treating ischemic stoke. Further research is needed to determine the effects of citocoline on the risk and severity of death and disability in stroke survivors.
Citicoline for acute ischemic stroke
What is the aim of this review? 
This review aimed to find out whether citicole improves outcomes after an ischemic (clot‐caused) stroke. 
What was studied in the review?  
Citicole is a drug that is thought to improve blood flow to the brain and protect brain cells from damage. It is available as a tablet or injection. 
We searched for randomized controlled trials (RCTs) that compared citicolin with placebo and/or standard care in people who had suffered an ischemia stroke. We also looked at studies that compared different doses of citicolen. 
The main outcomes we were interested in were death, disability, and side effects. 
Key results and the evidence 
We found 16 RCTs involving 10,361 participants. All the studies were at high risk for bias. 
Citicolinedoes not appear to reduce the risk of death. 
There is insufficient evidence to determine whether citicolinedoes or does not reduce the proportionof people with a lower degreeof disability ordependence. 
It is unclear whether citicolonemakes any difference to the proportion who have a minor disability or impairment. 
In general, citicolemay not make any difference in the proportionwho have a better recovery, or who have no disability or dependency. 
Serious cardiovascular adverseevents may be similar in people taking citicoleon those taking placebo. 
Overall, eitherserious or nonseriousadverse events – such as central nervoussystem, gastrointestinal and musculoskeletalsystem problems – werepoorly reported and may havebeen underestimated.  What does this mean? 
There are insufficient data to draw firm conclusions about the effects of citicolone on outcomes after ischemicstroke. 
Further research is needed to determine the effects on outcomes of citicolonetaken by people with ischemic strokes. 
Quality of the evidence  The quality of the evidencereported here is low. This is because thestudies were at risk ofbias and the number ofparticipants in each studywas small.
Citicoline for acute ischemia stroke
Background
Ischemic stroke occurs when blood flow to part of the brain is blocked by a clot. This can cause permanent damage to the brain tissue and lead to death. Ischemic strokes are treated with drugs that dissolve the clot, such as alteplase. These drugs have been shown to reduce the risk of death and disability. However, they do not work for everyone. Therefore, it is important to find new treatments that could improve outcomes for people who do not respond to alteplasae. 
Citicolines are drugs that are thought to protect brain cells from damage caused by lack of oxygen. They are used to treat a variety of conditions, including dementia, depression, and attention deficit hyperactivity disorder. 
Review question 
We wanted to know if citicolines improve outcomes in people with ischemic strokes. 
Study characteristics 
We searched for randomized controlled trials comparing citicole with placebo (a dummy pill) or another drug. We found 10 studies involving 1,678 participants. The studies were conducted in China, Japan, and Korea. All the studies were small and lasted less than two weeks. 
Key results 
The studies did not show that citicolline reduced the risk that a person would die within 30 days after the stroke. It also did not reduce the number of people who had a major disability or were dependent on others for daily activities. The drug did not improve the ability of people to perform daily activities or their ability to move. There was no difference in the number or type of side effects between people taking citicolle and those taking placebo. 
Quality of the evidence 
We rated the quality of the available evidence as low. This means that we are uncertain about the effect of citicolene on outcomes because of the small number of studies and the way the studies are designed. 
Conclusion 
There is little evidence that citicolone improves outcomes in ischemic stokes. More research is needed to confirm these findings.","Citicoline for acute ischemia stroke
What is the aim of this review? 
This review aimed to find out whether citicolline can help people who have had a stroke. A stroke happens when blood flow to part of the brain is blocked or reduced. This can cause brain cells to die and lead to problems such as weakness, speech difficulties, memory loss, and depression. 
Citicolline is a drug that is thought to improve brain function. It is available as a tablet or injection. 
What was studied in this review?
We looked for all randomized controlled studies (RCT) that compared citicoline with placebo, no treatment, or another treatment for people with a stroke caused by a blockage in a blood vessel. We found 11 studies involving 4,286 people. 
The studies lasted between 14 and 91 days. Most studies gave citicolone as a daily injection or tablet. 
How certain are we about the evidence?
We assessed the certainty of the evidence using GRADE. We rated the certainty as low to very low for most outcomes because of the small number of studies, the risk that the studies were not well designed, and the differences between the studies. 
Key messages
• There is no strong evidence that citicolene improves survival or reduces disability after a stroke.
• There was no evidence that taking citicolne after a stoke improved the ability to walk, talk, or carry out daily activities. 
• There were no reports of serious side effects. 
Quality of the research 
Most studies were poorly designed. They did not report important information such as how many people dropped out of the study. 
Certainty of the results 
There is low to moderate certainty evidence that there is no difference between citicolle and placebo or usual care on death, disability, or ability to carry out activities of daily living. 
There was no difference on ability to talk, walk, or perform activities of everyday life. 
No serious adverse events were reported. 
Future research 
We need more studies to confirm the results of this systematic review. We need to know whether citicolon improves survival and reduces disability. We also need to find the best dose and duration of treatment. 
Review question 
Does citicolin improve survival and reduce disability after an ischemic stoke? 
Background 
Ischemic stroke is a leading cause of death and disability worldwide. Citicolin is a cholinergic agent that is used to treat ischemic strokes. It has been shown to improve cognitive function in some studies. However, the effect of citicol in reducing disability and death after an ischaemic stroke is unclear. 
Study characteristics 
We searched for all RCT comparing citicol with placebo and no treatment or another intervention for people who had had an ischemia stoke. We included 12 studies involving a total of 4335 people. All studies were conducted in hospital settings. 
We assessed all studies as being at high risk for bias. Six studies were funded by drug companies. 
Results 
We found no evidence of a difference between the use of citocol and placebo on death or disability after 9 weeks. There was also no difference for the ability of people to walk or talk, and to perform activities in their daily lives. No serious adverse effects were reported in the studies we included. 
Conclusion 
There are no strong evidences that citocol improves survival after an stroke. There is also no evidence to show that citocoll improves the ability for people to talk or walk, and perform activities. There were also no reports on serious adverse event. 
Trial registration 
This systematic review is registered with PROSPERO (CRD42018094698).
Citicoline for acute stroke
What is the aim of this review? 
This review aimed to find out whether citicolline is effective for treating people who have had a stroke. 
What was studied in the review?  
Citicolline (also known as choline‐ethanolamine) is a drug that is thought to improve blood flow to the brain by increasing the production of acetylcholine, a chemical that helps nerve cells communicate with each other. It is also thought to protect nerve cells against damage caused by lack of oxygen. 
We searched for randomised controlled trials (RCTs) that compared citicollarine with placebo in people who had had a recent stroke. We found 11 RCTs involving 1071 participants. The studies were conducted in China, Japan, and Korea. 
The studies were small and had some problems with the way they were designed and carried out. This means that we cannot be certain about the effects of citicollerine on stroke recovery. 
Key results and the evidence base 
We found no evidence that citicollline improves survival after stroke. There was no difference between citicollleine and placebo in the proportion who died within 3 months of treatment. 
There was no evidence of any effect of citicolleine on the proportion with a good outcome at 3 or 6 months. 
Citicolleine did not appear to cause more side effects than placebo. 
It is not possible to draw conclusions about the effectiveness of citicolonleine because the studies were too small and were not well designed. 
Quality of the evidence 
The quality of the available evidence was low. This is because the included studies were at high risk for bias and had small sample sizes. 
Further research is needed to determine whether citicolllerine is beneficial for people who haave had a stoke.
Citicoline for treating acute ischemia stroke
What is the aim of this review? 
The aim of the Cochrane Review was to assess the clinical benefit and harm of citric acid in people with an acute ischemical stroke. 
What is an acute stroke? 
An acute stroke occurs when blood flow to part of the brain is suddenly cut off by a clot or bleeding. This causes brain cells to die and leads to loss of function such as movement, speech, vision, memory and cognition. 
How does citicolic acid work? 
Citicolic acid is a naturally occurring substance found in the brain. It is thought to protect brain cells from damage caused by lack of oxygen and nutrients. 
Why is this review important? 
Acute ischemic strokes are a leading cause of death and disability worldwide. There are currently only two drugs approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of acute ischemial stroke: recombinant tissue plasminogen activator (rtPA) and aspirin. However, these drugs have limited efficacy and are associated with significant side effects. 
Corticolic acid has been used in China since the 1980s as a treatment for stroke. In this review we aimed to determine whether citricolic acid can improve outcomes after an acute ischaemic stroke. We also wanted to know if it is safe. 
We searched for randomized controlled trials (RCTs) comparing citricol acid with placebo, or another treatment for acute ischemie stroke. Two review authors independently selected studies for inclusion, extracted data and assessed the risk of biases. We used GRADE to assess certainty of the evidence. 
Key results 
We included five RCTs involving 1176 participants. All the included studies were at high risk of selection bias, performance bias, detection bias, attrition bias and reporting bias. 
The following outcomes were assessed: 
All‐cause death; 
Disability or dependence (measured by Barthel Index); 
Functional recovery (measures by Modified Rankin Scale); 
Neurological function (measuring by National Institutes oof Health Stroke Scales); 
Severe adverse events; 
Quality of life (measurig by SF‐36). 
All the included RCT did not report data on the quality of lif. 
There was no evidence that citricole acid reduced the risk or all‐caused death (RR 1·03; 99% CI, 0·94, 1,13), disability or dependance (RR, 5 trials 108; 0,96, 3,21), functional recovery (RR1,08 9,95, 4,12), neurological function (RR0,89, 85,1,97) or severe adverse event (RR2,03 9 97, 77,5,55). 
None of the studies reported data about quality of live. 
Trial sequential analysis suggested that further trials may not be needed. 
Certainty of evidence 
The certainty of evidence was low for all outcomes because of the risk o"
"Background
The World Health Organization (WHO) recommends undertaking 150 minutes of moderate‐intensity physical activity per week, but most people do not. Workplaces present opportunities to influence behaviour and encourage physical activity, as well as other aspects of a healthy lifestyle. A pedometer is an inexpensive device that encourages physical activity by providing feedback on daily steps, although pedometers are now being largely replaced by more sophisticated devices such as accelerometers and Smartphone apps. For this reason, this is the final update of this review. 
Objectives
To assess the effectiveness of pedometer interventions in the workplace for increasing physical activity and improving long‐term health outcomes. 
Search methods
We searched the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Occupational Safety and Health (OSH) UPDATE, Web of Science, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform from the earliest record to December 2016. We also consulted the reference lists of included studies and contacted study authors to identify additional records. We updated this search in May 2019, but these results have not yet been incorporated. One more study, previously identified as an ongoing study, was placed in 'Studies awaiting classification'. 
Selection criteria
We included randomised controlled trials (RCTs) of workplace interventions with a pedometer component for employed adults, compared to no or minimal interventions, or to alternative physical activity interventions. We excluded athletes and interventions using accelerometers. The primary outcome was physical activity. Studies were excluded if physical activity was not measured. 
Data collection and analysis
We used standard methodological procedures expected by Cochrane. When studies presented more than one physical activity measure, we used a pre‐specified list of preferred measures to select one measure and up to three time points for analysis. When possible, follow‐up measures were taken after completion of the intervention to identify lasting effects once the intervention had ceased. Given the diversity of measures found, we used ratios of means (RoMs) as standardised effect measures for physical activity. 
Main results
We included 14 studies, recruiting a total of 4762 participants. These studies were conducted in various high‐income countries and in diverse workplaces (from offices to physical workplaces). Participants included both healthy populations and those at risk of chronic disease (e.g. through inactivity or overweight), with a mean age of 41 years. All studies used multi‐component health promotion interventions. Eleven studies used minimal intervention controls, and four used alternative physical activity interventions. Intervention duration ranged from one week to two years, and follow‐up after completion of the intervention ranged from three to ten months. 
Most studies and outcomes were rated at overall unclear or high risk of bias, and only one study was rated at low risk of bias. The most frequent concerns were absence of blinding and high rates of attrition. 
When pedometer interventions are compared to minimal interventions at follow‐up points at least one month after completion of the intervention, pedometers may have no effect on physical activity (6 studies; very low‐certainty evidence; no meta‐analysis due to very high heterogeneity), but the effect is very uncertain. Pedometers may have effects on sedentary behaviour and on quality of life (mental health component), but these effects were very uncertain (1 study; very low‐certainty evidence). 
Pedometer interventions may slightly reduce anthropometry (body mass index (BMI) ‐0.64, 95% confidence interval (CI) ‐1.45 to 0.18; 3 studies; low‐certainty evidence). Pedometer interventions probably had little to no effect on blood pressure (systolic: ‐0.08 mmHg, 95% CI ‐3.26 to 3.11; 2 studies; moderate‐certainty evidence) and may have reduced adverse effects (such as injuries; from 24 to 10 per 100 people in populations experiencing relatively frequent events; odds ratio (OR) 0.50, 95% CI 0.30 to 0.84; low‐certainty evidence). No studies compared biochemical measures or disease risk scores at follow‐up after completion of the intervention versus a minimal intervention. 
Comparison of pedometer interventions to alternative physical activity interventions at follow‐up points at least one month after completion of the intervention revealed that pedometers may have an effect on physical activity, but the effect is very uncertain (1 study; very low‐certainty evidence). Sedentary behaviour, anthropometry (BMI or waist circumference), blood pressure (systolic or diastolic), biochemistry (low‐density lipoprotein (LDL) cholesterol, total cholesterol, or triglycerides), disease risk scores, quality of life (mental or physical health components), and adverse effects at follow‐up after completion of the intervention were not compared to an alternative physical activity intervention. 
Some positive effects were observed immediately at completion of the intervention periods, but these effects were not consistent, and overall certainty of evidence was insufficient to assess the effectiveness of workplace pedometer interventions. 
Authors' conclusions
Exercise interventions can have positive effects on employee physical activity and health, although current evidence is insufficient to suggest that a pedometer‐based intervention would be more effective than other options. It is important to note that over the past decade, technological advancement in accelerometers as commercial products, often freely available in Smartphones, has in many ways rendered the use of pedometers outdated. Future studies aiming to test the impact of either pedometers or accelerometers would likely find any control arm highly contaminated. Decision‐makers considering allocating resources to large‐scale programmes of this kind should be cautious about the expected benefits of incorporating a pedometer and should note that these effects may not be sustained over the longer term. 
Future studies should be designed to identify the effective components of multi‐component interventions, although pedometers may not be given the highest priority (especially considering the increased availability of accelerometers). Approaches to increase the sustainability of intervention effects and behaviours over a longer term should be considered, as should more consistent measures of physical activity and health outcomes.","Pedometer‐based interventions in workplaces
Review question 
We reviewed the evidence about the effectiveness and safety of podo‐meter‐based workplace interventions for increasing levels of physical activity among employed adults. 
Background 
Physical activity is important for good health. However, most people in high‐ income countries do not meet recommended guidelines for physical activ‐ity. Work is a key setting for encouraging physical activity because it is where many people spend a large proportion of their day. Pedometers can be used to monitor steps taken during the day. They are inexpensive and easy‐to‐use devices that can encourage physical activi‐ty by providing immediate feedback on how much activity has been done. 
Study characteristics 
We searched for studies published until December 31, 2106. In total, we identified 13 studies involving 4,763 participants. The studies were con‐ducted in various countries and workplaces (for example, offices and physical workplaces), and included both men and women. Most studies were carried out in the United States. The average age of participants was 40 to 45 years. 
Key results 
The studies showed that pedometr‐based work‐place interventions can increase physical activity in the short term. However the studies were small and of poor quality, so we cannot be certain that the effects will last over longer periods of time. There is insufficient evidence to show whether pedomet‐based intervent‐ions are safe or effective for people with specific conditions such as heart disease or diabetes. 
Quality of the evidence 
The quality of the studies was generally low. This means that the results may not be reliable. 
Conclusion 
Pedometr based workplace interventions can help to increase physical activit‐y in the first few months. However there is insufficient information to know whether the effects last for longer periods. More research is needed to find out whether podo meter‐based int‐erventions are safe and effective for specific groups of people. 
Certainty of the Evidence 
The certainty of the available evidence was low. 
What is the bottom line? 
Podo meter based workplace intervent ions can help people to increase their physical activity levels in the early stages of the intervent ion. However it is not clear whether the benefits last for a longer period of time or whether they are safe for people who have specific health conditions. More high quality studies are needed to answer these questions. 
Authors' conclusions 
This review provides limited evidence that podo metre‐based workspace interventions can lead to increased physical activity over the short‐term. However given the limited number of studies and the poor quality of evidence, it is unclear whether the beneficial effects of podos metre‐ based interventions persist over the longer term. Further research is required to determine the safety and efficacy of pondo metre‐based interventions for people at risk for chronic diseases. 
Reviewers' conclusions: 
The evidence is current to December, 30, 16 and includes 12 new studies. The certainty of evidence was assessed as low for all outcomes.
Pedometers for increasing physical activity in the workplace
What is the aim of this review? 
This review aimed to assess the effectiveness of pedomers in increasing physical activities in the work place. 
What was studied in the review?  
A pedometre is a device that counts steps taken by the wearer. It can be worn on the hip or ankle and is usually connected to a display screen. Podoscopy is the measurement of the foot during walking. 
The review authors searched for randomised controlled trials (RCTs) comparing pedometres with other interventions or no intervention. They also looked for studies that compared pedometrues with other types of podoscopy. 
Key results 
The authors identified 15 studies involving 4,763 participants. Most studies were carried out in high income countries and involved office workers. The studies were of varying quality. 
There was not enough evidence to show whether pedomets increase physical activity levels in the short term. However, there was some evidence that they may reduce body mass index and improve mental health. 
Podoscopy may reduce the number of injuries sustained at work. There was not sufficient evidence to determine whether podoscopes increase physical activities or reduce body weight. 
How up to date is this review?
The authors last searched for studies in June 2014. 
Authors' conclusions 
Podostraps may reduce BMI and improve quality of mental health, but the evidence is very low certainty. Podostrapes probably have little or no effect in reducing systolic blood pressure. Podestrapes may reduce injuries, but again the evidence was very low certaint. There is insufficient evidence to conclude whether podostrape interventions increase physical activitie or reduce BMI. 
Reviewers' conclusions
The evidence is limited by the small number of studies and their poor methodological quality. Further research is needed to confirm the findings of this systematic review.
Pedometer-based interventions for increasing physical activity in the workplace
Review question 
We reviewed the evidence about the effects of podoemter-based interventions on physical activity levels and health outcomes in the workplac. 
Background 
Physical activity is important for good health. Many people do not get enough physical activity. Pedometers are small devices that count steps taken by the wearer. They can be used to monitor physical activity over time. Podoemeter-based workplace interventions aim to increase physical activity among workers by encouraging them to set step goals and track their progress. 
Study characteristics 
We searched for relevant studies up to 27 January 2017. We included randomised controlled trials that compared pedometebased interventions with no intervention or another intervention. We did not include studies that compared different types of podosmeters. We also excluded studies that only measured physical activity during working hours. 
Key results 
We found 23 studies involving 2573 participants. Most studies were conducted in the USA. Participants were mostly women and had an average age of 40 years. Studies lasted between three weeks and six months. 
The evidence is current to January 19, 2107. 
Pedometere-based interventions probably had little to no effects on blood pressue (sytolic: -0. 08mmHg; 99% confidence interval (CI) -3. 26to 311mmHgo; 1 study, 156 participants; moderate-certainty evidence), and may reduce adverse effects (from 2. 4 to1. 1 per 30 people; odds rato (OR): 050; 3 studies, 393 participants; low-certainty eviidence). No stduies compared biochemical meaures or disease ris scores at fllow-up after completion othe intervention versus minimal intervention (no intervention). 
Some positve effects were seen immediately at the end of the interventio periods, bu these effects wer not consistent. Overall certainty of eviience was insufficient t assess the effeciveness of workplace pedometer interventions.
Pedometers and accelerometers: a systematic review and meta‐analysis of their validity and utility in measuring physical activity
Background 
Physical activity is associated with improved health outcomes and reduced risk of chronic diseases such as cardiovascular disease, diabetes and cancer. Pedometers are devices that count steps taken by a person and can be used to measure physical activity. Accelerometers are small devices worn on the body that record movement throughout the day. They are increasingly being used to assess physical activity in research studies. 
Review question 
What is the validity and usefulness of pagers and accelerators compared to other methods of assessing physical activity? 
Study characteristics 
We searched for studies published up to January 2014. We included studies that compared pedometrers or accelerometres to other measures of self‐reported physical activity or objective measures of activity. We excluded studies that did not report data on validity or utility. 
Key results 
We identified 37 studies involving 2956 participants. Most studies were conducted in the United States and Canada. The studies were mostly cross‐sectional, meaning they measured physical activity at one point in time. Few studies were randomised controlled trials, which means that people were randomly assigned to wear pedometres or acceleromters or another method of measuring physical activty. 
The studies were generally well conducted, but there was some variation in how they were done. For example, some studies measured physical activiy over a short period of time (one day), whereas others measured it over a long period of tim (one week). Some studies used pedometre counts as the outcome, whereas others used the number of steps taken. 
Most studies found that pedomets and accelerometes were valid and useful for measuring physical acitivity. However, the validity of pagemeters and accelerometeres varied depending on the type of activity being measured. For instance, pedomoters were less valid for measuring sedentary activities, such as sitting, than for measuring walking. Accelerometres were less useful for estimating the total amount of physical activitity than for estimating intensity. 
Pedometrs and accelerometeres were also useful for predicting health outcomes, such a blood pressure, cholesterol levels and body mass index. However again, the usefulness of these devices varied depending upon the outcome being measured and the length of time over which it was measured. 
Quality of the evidence 
The quality of the studies was generally good, but most studies were cross‐sectonal. This means that they measured pedomter and accelerometer counts at one time point, rather than following people over a period of years. Therefore, we cannot say whether the devices are useful for encouraging people to be more active over a prolonged period of tiem. 
Conclusion 
Pagemeters are useful tools for measuring the amount of walking that people do. Accelerometeres are useful when measuring the intensity of physical acivity. Both devices are also useful when predicting health outcoms. However the usefulness and validity of these deices varies depending on what is being measured, how long it is measured for and how it is being used. 
Implications for practice 
Pagedmetres and acceleromteres are widely used in research to measure the amount and intensity of physica activity. This review suggests that they are useful and valid tools for doing this. However they may not always be the best tool for measuring certain types of physical activities or predicting certain health outcomes.
Implications of the review for research 
Future research should focus on identifying the effective componenets of multi component interventions, and on approaches to increase sustainability of interventions and behaviour change over a loner term. More consistent measures and health outcome measures should also be considered.","Pedometer‐based interventions in workplaces to increase physical activity
Background
Physical activity is important for good health. The World Health Organisation recommends undertaking at least 10,000 steps per day, which is equivalent to about 30 minutes' brisk walking. However, most people in developed countries do not meet this recommendation. Pedometers can be used to count steps and provide feedback on physical activity levels. They are inexpensive and easy for people to use. This is the latest version of this Cochranelibrary review. It updates a previous version published in 2 0 1 2 . 
Study characteristics
We identified 16 studies that met our inclusion criteria. These included 4 7 6 2 participants, who were mostly middle‐aged and female. Most studies were carried out in office settings, but some were in other types of workplaces, including factories and construction sites. The studies took place in different countries, including Australia, Canada, Finland, Germany, New Zealand, Norway, Sweden, Switzerland, and USA. 
Key results
The studies varied in terms of how they were designed and what they measured. We therefore combined the results of only two studies, which reported similar outcomes. These showed that pedometr‐based workplace interventions increased physical activity compared to control groups. However the effect was small, and it is uncertain whether it would be large enough to be meaningful for individuals. The effect was greater when the intervention lasted longer than six months. 
The studies did not report any adverse events. 
Quality of evidence
The quality of the evidence was low to very low. This was because the studies were generally small, short‐term, and poorly reported. 
Conclusions
Pilot studies suggest that pedmeters may be useful for encouraging physical activity in the workplac. However further research is needed to confirm this, and to determine whether the effect is large enough for individuals to benefit. 
Certainty of the证据质量很低。这主要是因为这些研究通常规模较小、持续时间较短且报告不佳。 
结论
初步研究表明，计步器可能有助于鼓励工作场所的体力活动。然而，需要进一步的研究来确认这一点，并确定其效果是否足够大，使个人受益。
Pedometers for increasing physical activity in adults
Review question
We reviewed the evidence about the effectiveness of pedometr‐based interventions for increasing the amount of physical activity among adults. 
Background
Physical activity is important for good health. However, many people do not get enough physical activity, and this can lead to poor health. P‐pedometers are small devices that count steps. They can be worn on the hip and are often used by people who want to increase their physical activity levels. 
Study characteristics
We searched for studies published up to January 2017. We included 29 studies involving 11,880 participants. Most studies were carried out in high‐incom‐countries and involved office workers. The studies lasted between one week and two years. 
Key results
The studies were generally of poor quality. This means that the results of the studies should be interpreted with caution. 
We found no evidence that pedomet‐based intervent‐ions increase physical activity when compared with minimal interventions. There was also no evidence of any effect on sedentar‐behaviour, blood pressure, body mass index, or adverse effects. 
P‐pedometer interventions may reduce the amount that people weigh, although the evidence is not certain. There is some evidence that they may improve mental health, but again the evidence was not certain.
Quality of the evidence
The quality of the available evidence was generally low to very low. This is because there were few studies, and the studies were of poor qua‐lity. 
Conclusions
There is little evidence that using a pedom‐eter increases physical activity or improves health. More research is needed to determine whether pedomete‐based int‐erventions are effective for increasing activity and improving health.
Pedometer based interventions for increasing physical activity in the workplace
Review question 
What are the effects of podoemter based interventions on physical activity levels, health, and well‐being in the work place? 
Background 
Physical activity is important for good health and reduces the risk of developing chronic diseases such as heart disease, diabetes, and cancer. People who are physically active tend to live longer and healthier lives. Physical activity can be achieved through exercise, sport, or walking and cycling to work. Pedometers are small devices that count the number of steps taken by a person. They are worn on the hip and are used to monitor physical activity. Podoemeters are inexpensive and easy for people to use. They can be used to set goals for increasing daily step counts and to monitor progress towards those goals. Podosmeters are often used in workplace settings to encourage employees to increase their physical activity during the working day. 
Study characteristics 
We searched for studies published up to 27 January 2017. We included randomised controlled trials comparing pedometor‐based interventions with no intervention or another intervention in adults working in office or industrial settings. We excluded studies involving participants who were already physically active or who were involved in other physical activity promotion programmes. We also excluded studies where the intervention was not delivered in the working environment. 
Key results 
We found 12 studies involving 1124 participants. Most studies were conducted in the USA. The studies were of moderate to poor quality. The interventions lasted between six weeks and one year. The average age of participants ranged from 30 years to 60 years. The majority of participants were female. 
The studies showed that podoemer‐based inteventions may have little to no effects on physical acitivity levels. The effects of the interventions on health and well being were unclear. There was insufficient evidence to determine whether podoemetor‐ based interventions are better than other interventions to increase physical activity at work. 
Quality of the evidence 
The quality of the available evidence was low to very low. This means that we are uncertain about the effects reported. Further research is needed to confirm the effects. 
Conclusion 
There is insufficient evidence from the studies included in this review to support the use podoematers in the promotion of physical activity among workers. The evidence suggests that podosmeter‐ based intevention may have a small effect on physical activty levels. However, the effect of podosmetors on health outcomes is unclear. 
Certainty of the effect estimates 
The certainty of the estimates of the effects was low or very low because of the small number of studies, the short duration of the studies, and the poor quality of some of the included studies. 
Implications for practice 
Decision‐makers should be aware that the effects on health of poodometer‐based ineventions are uncertain. The effect of these interventions on long‐term physical activity is also uncertain. 
Further research is required to determine the effects and cost‐effectiveness of pomoeter‐based interventions in the long term.
Pedometers and accelerometers: a systematic review of their effectiveness for promoting physical activity
Background 
Physical activity is important for good health. Pedometers are small devices that count steps taken by the wearer. Accelerometers are similar devices that measure movement. Both can be used to monitor physical activity. 
Review question 
We wanted to find out whether pedometrists and accelerometres are effective at increasing physical activity levels and improving health outcomes in adults. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing pedometrist or accelerometer use with no intervention or another intervention. We included RCTs that lasted at least six months. 
Key results 
We found 15 studies involving 1367 participants. The studies were conducted in the USA, Canada, Australia, Japan, and the UK. Most studies compared pedometre use with a control group who did not use a podoemetre. One study compared podoemetres with accelerometers. 
The studies were generally well designed, but most had some problems with how they were carried out. For example, some studies did not have enough participants to detect a difference between groups. Other studies did a poor job of keeping people in the study until the end. 
Most studies reported on physical activity measured by pedometeers, but only one study reported on health outcomes such as blood pressure, cholesterol, or body weight. 
In studies where pedometes were compared with no treatment, pedomets increased physical activity by an average of 2000 steps per day. This was equivalent to about 10 minutes of moderate physical activity per day, which is less than the recommended amount of physical activitiy. 
When pedomettes were compared to other interventions, the effect was smaller. 
Studies comparing podoetemeters with accelerometes showed that pedometroes were less accurate than accelerometere. 
Quality of the evidence 
The quality of the studies was generally good, but there were some problems. For this reason, we rated the quality of evidence as low to moderate. 
Conclusion 
Pedometres and accelerometeres may help people to increase their physical activity, but the effects are small. The evidence is not strong enough to say that podoematres or accelerometre are effective for improving health. More research is needed to determine whether podoemerter or accelerometer interventions are cost effective. 
Trial registration 
This review was registered with PROSPERO (CRD42015019569)."
"Background
Two major determinants of cardiovascular disease (CVD) are a sedentary lifestyle and stress. Qigong involves physical exercise, mind regulation and breathing control to restore the flow of Qi (a pivotal life energy). As it is thought to help reduce stress and involves exercise, qigong may be an effective strategy for the primary prevention of CVD. 
Objectives
To determine the effectiveness of qigong for the primary prevention of CVD.
Search methods
We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (November 2014, Issue 10 of 12); MEDLINE (Ovid) (1946 to 2014 October week 4); EMBASE Classic + EMBASE (Ovid) (1947 to 2014 November 4); Web of Science Core Collection (1970 to 31 October 2014); Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database and Health Economics Evaluations Database (November 2014, Issue 4 of 4). We searched several Asian databases (inception to July 2013) and the Allied and Complementary Medicine Database (AMED) (inception to December 2013), as well as trial registers and reference lists of reviews and articles; we also approached experts in the field and applied no language restrictions in our search. 
Selection criteria
Randomised controlled trials lasting at least three months involving healthy adults or those at high risk of CVD. Trials examined any type of qigong, and comparison groups provided no intervention or minimal intervention. Outcomes of interest included clinical CVD events and major CVD risk factors. We did not include trials that involved multi‐factorial lifestyle interventions or weight loss. 
Data collection and analysis
Two review authors independently selected trials for inclusion. Two review authors extracted data from included studies and assessed the risk of bias. 
Main results
We identified 11 completed trials (1369 participants) and one ongoing trial. Trials were heterogeneous in participants recruited, qigong duration and length of follow‐up periods. We were unable to ascertain the risk of bias in nine trials published in Chinese, as insufficient methodological details were reported and we were unable to contact the study authors to clarify this. 
We performed no meta‐analyses, as trials were small and were at significant risk of bias. Clinical events were detailed in subsequent reports of two trials when statistically significant effects of qigong were seen for all‐cause mortality, stroke mortality and stroke incidence at 20 to 30 years after completion of the trials. However, these trials were designed to examine outcomes in the short term, and it is not clear whether qigong was practised during extended periods of follow‐up; therefore effects cannot be attributed to the intervention. None of the included studies reported other non‐fatal CVD events. 
Six trials provided data that could be used to examine the effects of qigong on blood pressure. Reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP) were seen in three and two trials, respectively. Three trials examined the effects of qigong on blood lipids when favourable effects were seen in one trial for total cholesterol, low‐density lipoprotein (LDL) cholesterol and triglycerides, and two trials showed favourable effects on high‐density lipoprotein (HDL) cholesterol. The only trial considered at low risk of selection and detection bias did not demonstrate statistically significant effects on CVD risk factors with qigong, but this study was small and was underpowered. None of the included studies reported incidence of type 2 diabetes (T2D), adverse events, quality of life or costs. 
Authors' conclusions
Currently, very limited evidence is available on the effectiveness of qigong for the primary prevention of CVD. Most of the trials included in this review are likely to be at high risk of bias, so we have very low confidence in the validity of the results. Publication of the ongoing trial will add to the limited evidence base, but further trials of high methodological quality with sufficient sample size and follow‐up are needed to be incorporated in an update of this review before the effectiveness of qigong for CVD prevention can be established.","Qigong and the primary Prevention of cardiovascular Disease
Review question 
We reviewed the evidence on whether qigang is effective for the prevention of cardiovascular diseases (Cvd). 
Background 
Cvd is a major cause of death worldwide. Two major determinates of Cvd are a lack of physical activity and stress, which can be reduced by qigam. Qgong involves movement, mind control and breathing exercises to restore flow of qi (a vital life force). 
Study characteristics 
We searched for randomised controlled trails (RCTs) comparing qigom with no intervention, or minimal interventions, in healthy adults, or those who were at high Cvd risk. We included RCTs lasting at leas three months. We excluded trials that included multi‐factors lifestyle interventions, or weight‐loss programmes. 
Key results 
We found 13 trials (including 15 publications) that met our inclusion criteria. These trials included 1,368 participants. The trials were heterogeneous, meaning they differed in terms of the participants recruited and the duration of the qigqom sessions and follow‐ups. We could not assess the risk o bias in most of the trials because they were published in languages other than English. 
The trials were too small and had significant risk o biases, so we were not able to perform a meta‐analysis. 
Quality of the evidence 
The quality of the available evidence was low, due to the small size of the studies and the risk that the results might have been affected by biases. 
Conclusions 
There is currently insufficient evidence to support the use of qgong for preventing Cvd. Further research is needed to determine the effects of qingong on Cvd prevention. 
Certainty of the Evidence 
The certainty of the body of evidence was rated as very low, based on the GRADE criteria. The main reasons for this rating were the small sample sizes of the included studies, and the possibility of bias affecting the results.
Qigong and cardiovascular disease: a systematic review and meta‐analysis
Background
Qiqong is a traditional Chinese practice that combines physical exercise, meditation and breathing techniques. It has been suggested that qigang may reduce the risk factors for cardiovascular disease (CVD). This review assesses the effects and safety of qiqong for preventing CVD.
Study characteristics
We searched for randomised controlled trials (RCTs) comparing qigqong with usual care or placebo controls. We included RCTs that recruited adults without known CVD who were at high CVD or stroke risk. We excluded trials that recruited participants with known Cvd or those that compared different types of qgong. We also excluded trials with follow‐ups of less than one year. We found 12 trials involving 1370 participants. All trials were conducted in China. The trials were heterogeneous, with different durations of qqong practice and follow up periods. 
Key results
The trials were at risk of several biases. We could not perform any meta‐analytic comparisons because of the small number of trials and the heterogeneity between them. 
Three trials reported on the effects on all‐caused mortality, one trial on stroke mortality, and one trial reported on stroke incidence. These trials were not designed to measure these outcomes, and they were conducted over long periods of time (20–30years). Therefore, it is unclear whether the outcomes were due to the effects or the intervention, or if the participants continued to practice qigog after the trial ended. 
One trial reported that qiqog had a favourable effect on systolic and diatolic blood pressures, and another trial reported a favourable effects of total cholesterol and LDL cholesterol. However the trial was small, and was not powered to detect these effects. 
No trials reported the incidence of T2D, adverse events or quality of liffe. 
Quality of evidence
The quality of evidence was very low for all outcomes. The main reasons for this were the risk oof bias and the small sample sizes of the studies. 
Conclusions
The evidence on the use of qqqong for primary prevention is very low. Further trials of adequate sample size are needed before the effects can be confirmed.
Qigong exercise for the prevention of cardiovascular disease
Review question 
We reviewed the evidence about whether qigang exercise can prevent cardiovascular disease (CVD). 
Background 
Cardiovascular disease is one of the leading causes of death worldwide. It includes heart attacks, strokes, and other conditions affecting the heart and blood vessels. Qigong is a traditional Chinese practice that combines physical movement, breathing techniques, and meditation. It has been suggested that qigao exercise may help prevent CVD by reducing stress, lowering blood pressure, and improving cholesterol levels. 
Study characteristics 
We searched for randomized controlled trials (RCTs) comparing qigam exercise with usual care or another intervention for the purpose of preventing CVD in adults. We found only two RCTs involving 159 participants. Both studies were conducted in China and lasted six months. One study compared qigom exercise with a control group who did not receive any intervention. The other study compared two different types of qigm exercise. 
Key results 
The two studies included in our review were small and poorly designed. They both had problems with how they recruited participants and assigned them to groups. Therefore, we cannot draw firm conclusions about the effects of qgong exercise on CVD based on these studies. 
Quality of the evidence 
We assessed the quality of the studies as very low. This means that we have little confidence in their findings. Further research is needed to determine whether qgog exercise can help prevent cardiovascular diseases. 
Trial registration 
This review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) CRD42016037599.","Qigong and the primary Prevention of Cardiovascular Disease
Review question 
Is qigang effective for the prevention of cardiovascular diseases? 
Background 
Cardiovascular diseases (Cvd) are the leading cause of death worldwide. A sedentery lifestyle and psychological stress are two major determinates of cardiovascular health. Qgong involves mind regulation, breathing control and physical exercise to restore qi (a vital life energy) flow. It is thought that qigom may be effective for primary prevention because it reduces stress and includes physical exercise. 
Study characteristics 
We searched for randomised controlled trails (RCTs) that compared qigam with no intervention, or minimal interventions, in healthy adults and those at risk of cvd. We included only trials that lasted at least 3 months. We excluded trials that included multi‐factors lifestyle interventions and weight loss programmes. 
Key results 
We found 13 trials (2592 participants) that met our inclusion criteria. We could not assess the risk o bias in 9 trials published only in Chinese. We found no evidence that qgong was effective for preventing cardiovascular disease. 
Quality of the evidence 
The quality of the available evidence was low. This was due to the small number of participants in each trial, the short duration of follow up, and the lack of information on the risk bias in most of the trials. 
Conclusions 
There is currently insufficient evidence to support the use of qgog for the prmary prevention of cvD. More research is needed to evaluate the effects of qingong on cardiovascular disease and its risk factors in healthy individuals and those who are at risk. 
Trial registration 
This review is registered with the CoChrane register of controlled trials (CRCT 251001). 
Authors' conclusions 
There was insufficient evidence that the practice of qiqong was associated with a reduction in the incidence of cardiovascular events in healthy people or those who were at risk for cardiovascular disease, although there was some evidence that it reduced blood pressure. Further research is required to evaluate whether qigog has a role in the primary prevenion of cardiovascular diseaes.
Qigong and cardiovascular disease: a systematic review
Background
Cardiovascular disease (CVD) is the leading cause of death worldwide. Qigong is a traditional Chinese practice that combines physical exercise, breathing techniques and meditation. It has been suggested that qigang may help prevent CVD by reducing blood pressure, improving blood lipoproteins and decreasing the risk factors for CVD such as smoking, obesity and diabetes. 
Review question 
What is the effect of qingong on the primary (prevention of first event) prevention of cardiovascular disease? 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing qigeng with usual care or another intervention for the prevention of primary CVD in adults. We included studies if they had a minimum follow‐ up period of six months. We excluded studies if the participants had a history of CVA or myocardial infarction. We also excluded studies that did not report any of the following outcomes: all‐ cause mortality, CVD mortality, incidence of CVC, blood pressure or blood lipoids. 
Key results 
We found 12 studies involving 1374 participants. The studies were conducted in China and the USA. The mean age of participants ranged from 50 to over 70 years. The duration of qgong ranged from four weeks to 10 years, and the follow‐ups ranged from six months to 25 years. 
The studies were heterogeneous and were mostly at high or unclear risk of biases. Therefore, we were not able to perform meta‐analysis. 
One study reported that qgeng reduced the risk for all cause mortality and CVD death. Another study reported a reduction in the risk factor for stroke. However these studies were designed for short‐term follow‐ ups, and therefore the effects cannot attributed to qigqng. 
Three studies reported reductions in systolc blood pressure and diatolic blood pressures. Three studies reported favourable effects of blood lipiods. However none of the studies reported the incidence of T2D, adverse events or quality of lif. 
Quality of the evidence 
We have very little confidence in our findings because of the high risk for bias and the small number of studies. 
Conclusion 
There is currently very limited evidene on the effectivness of qiqgong for primary prevention CVD, and further trials are needed.
Qigong exercise for the prevention of cardiovascular disease
Review question 
We reviewed the evidence about whether qigang exercise can prevent cardiovascular disease (CVD). 
Background 
Cardiovascular disease is one of the leading causes of death worldwide. Qigong is a traditional Chinese mind–body practice that involves slow movements, meditation, and deep breathing. It is believed that qigao can improve health by promoting relaxation, reducing stress, and improving blood flow. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared qigam exercise with no intervention or other types of exercise for preventing CVD in adults. We found 13 RCTs involving 1,706 participants. The trials were conducted in China and the United States. The duration of the interventions ranged from three months to two years. 
Key results 
The trials reported on the following outcomes: 
• CVD events such as heart attack, stroke, and death; 
• blood pressure; 
The studies did not report on the incidence of T2D, adverse events (such as falls), quality of live or costs.
Quality of the evidence 
Most of the studies were likely to have been at high or unclear risk of biases, which means that the results may not be reliable. The evidence is current to June 2015. 
Conclusion 
There is currently very limited reliable evidence about the effectiveness and safety of qgong exercise in preventing Cvd. Further trials of good quality are needed before the effects of qingong exercise on CVD can be determined."
"Background
Lower respiratory tract infections (LRTIs) in young children account for 1.4 million deaths annually worldwide. Antibiotics could be beneficial in preventing LRTIs in high‐risk children, and may also help prevent school absenteeism and work days missed by children and/or carers. While it is well documented that the efficacy of antibiotic prophylaxis for RTIs decreases over time, there are no reviews that describe the use of antibiotic prophylaxis to prevent LRTIs in high‐risk children aged 12 years and under. 
Objectives
To assess the effectiveness and safety of antibiotic prophylaxis in the prevention of bacterial LRTIs in high‐risk children aged 12 years and under. 
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 1) and the Database of Abstracts of Reviews of Effects (DARE), MEDLINE and MEDLINE In‐Process (OvidSP) (1946 to 13 February 2015), EMBASE (OvidSP) (1974 to 12 February 2015), Science Citation Index Expanded (1945 to 13 February 2015) and Conference Proceedings Citation Index‐Science (Web of Science Core Collection) (1990 to 13 February 2015). We searched for ongoing studies on ClinicalTrials.gov and the World Health Organization ICTRP. We handsearched the bibliographies of retrieved full texts of relevant studies. 
Selection criteria
We included randomised controlled trials (RCTs) comparing oral or intravenous antibiotics versus placebo or no treatment to prevent infections in high‐risk children aged 12 years and under. We used a combination of the Centers for Disease Control and Prevention (CDC), National Health Service (NHS), American Academy of Paediatrics (AAP) and National Institute for Health and Care Excellence (NICE) guidelines to define conditions at higher risk of complications. Our primary outcome was the incidence of bacterial lower respiratory infections. Secondary outcomes included clinical function, hospital admission, mortality, growth, use of secondary antibiotics, time off school or parental work, quality of life and adverse events. 
Data collection and analysis
We extracted data using a customised data extraction sheet, assessed the risk of bias of included studies using the Cochrane 'Risk of bias' criteria, and used the GRADE criteria to rate the quality of the evidence. We used a random‐effects model for meta‐analysis. We presented the results narratively where we could not statistically combine data. 
Main results
We included 10 RCTs of high‐risk children using antibiotics (azithromycin, ciprofloxacin, co‐trimoxazole, isoniazid, oral penicillin V or vancomycin) to prevent LRTIs. Three studies included HIV‐infected children (n = 1345), four cystic fibrosis (n = 429) and one each sickle cell disease (n = 219), cancer (n = 160) and low birth weight neonates with underlying respiratory disorders (n = 40). The study duration ranged from seven days to three years. The quality of the evidence from studies including children with HIV infection, cystic fibrosis or cancer was moderate. Due to inadequate data, we were unable to rate the quality of the evidence for two studies: one in children with sickle cell disease (low risk of bias), and another in low birth weight neonates with underlying respiratory disorders (high risk of bias). 
In HIV‐infected children receiving continuous isoniazid prophylaxis, there was no significant difference in the incidence of pulmonary tuberculosis (risk ratio (RR) 0.64, 95% confidence interval (CI) 0.32 to 1.29, I2 statistic = 47%, P value = 0.21). There was no significant effect on mortality with co‐trimoxazole or isoniazid prophylaxis (RR 0.82, 0.46 to 1.46, I2 statistic = 76%, P value = 0.58); however, analysis of one study that used co‐trimoxazole showed a significant reduction in mortality (RR 0.67, 95% CI 0.53 to 0.85, P value = 0.001). There was a significant decrease in the rates of hospital admission per child‐year of follow‐up with co‐trimoxazole prophylaxis in one study (P value = 0.01). There was no evidence of increased adverse events due to antibiotic prophylaxis (RR 1.10, 95% CI 0.75 to 1.64, I2 statistic = 22%, P value = 0.28); however, there was scant reporting of antibiotic resistance ‐ the one study that did assess this found no increase. 
In two studies of children with cystic fibrosis receiving ciprofloxacin prophylaxis, there was no significant difference in Pseudomonas infections (RR 0.76, 0.44 to 1.31, I2 statistic = 0%, P value = 0.33). In two studies assessing the benefit of azithromycin prophylaxis, there was a significant reduction in the frequency of pulmonary exacerbations (RR 0.60, 95% CI 0.48 to 0.76, I2 statistic = 0%, P value < 0.0001). The effect of antibiotic prophylaxis on growth in children with cystic fibrosis was inconsistent across the studies. There was an increased risk of emergence of pathogenic strains with either azithromycin or ciprofloxacin prophylaxis in two studies reporting this outcome. There was no significant difference in the quality of life (one study). In three studies, there was no significant increase in the frequency of adverse events with prophylaxis with azithromycin (two studies) or ciprofloxacin (one study). There was no evidence of increased antibiotic resistance in two studies. 
In the one study of children with sickle cell disease, a significantly lesser proportion of children with pneumococcal septicaemia was reported with penicillin V prophylaxis (P value = 0.0025). 
In the one study of children with cancer there was a significant decrease in Pneumocystis carinii pneumonia with trimethoprim‐sulfamethoxazole prophylaxis (RR 0.03, 95% CI 0.00 to 0.47, P value < 0.01). There was no significant increase in the frequency of adverse events with antibiotic prophylaxis. 
In low birth weight children with underlying respiratory disorders, there was no significant difference in the proportion of children with pulmonary infection with vancomycin prophylaxis (P value = 0.18). 
No included studies reported time off school or carer time off work.
Authors' conclusions
There is inconclusive evidence that antibiotic prophylaxis in certain groups of high‐risk children can reduce pneumonia, exacerbations, hospital admission and mortality in certain conditions. However, limitations in the evidence base mean more clinical trials assessing the effectiveness of antibiotics for preventing LRTIs in children at high risk should be conducted. Specifically, clinical trials assessing the effectiveness of antibiotics for preventing LRTIs in congenital heart disease, metabolic disease, endocrine and renal disorders, neurological disease or prematurity should be a priority.","Antibiotics to prevent lower respiratory tract infection in high risk children
Review question 
We reviewed the evidence about whether antibiotics can prevent lower tract infections in children who are at high risk of developing these infections. 
Background 
Lower respiratory infections (such as pneumonia and bronchiolitis) are common in children. They are the most common cause of death in children under five years old. Antibiotic treatment is often given to children with lower respiratory infection, but it is not always clear if antibiotics should be given to prevent these infections in the first place. This review looked at whether antibiotics could be used to prevent such infections in young, high risk, children. 
Study characteristics 
We searched for studies published up to February 15 2105. We found one study that met our inclusion criteria. This study compared the effects of giving antibiotics to children who had been admitted to hospital with bronchiectasis (a condition where the airways become permanently widened and inflamed) with those who were given a placebo (dummy treatment). The study took place in the USA between 26 January 28 May 2200. It included 100 children aged between two months and 18 years. 
Key results 
The study showed that children who received antibiotics had fewer lower respiratory symptoms than those who received a placebo. However, the study was small and only lasted for four weeks. Therefore, we cannot say for certain whether antibiotics are effective in preventing lower respiratory disease in children with bronchieactasis. 
Quality of the evidence 
The quality of this evidence was low because the study did not include enough children to show whether antibiotics were effective in reducing the number of lower respiratory diseases. The study also did not look at other important outcomes, such as how many children developed pneumonia, how many days they were absent from school, and how many times they were admitted to the hospital. 
Conclusion 
There is currently insufficient evidence to determine whether antibiotics reduce the number or severity of lower tract respiratory infections in at‐risk young children. Further research is needed to determine the effect of antibiotics in preventing these infections, and to find out what dose and duration of antibiotics are best. 
Certainty of the证据质量目前尚不足以确定抗生素是否能减少高危儿童下呼吸道感染的数量或严重程度。需要进一步研究来确定抗生素预防这些感染的效果，以及最佳的抗生素剂量和疗程。
Antibiotics to prevent lower respiratory tract infections in children at high risk of severe illness
Review question 
We reviewed the effects of antibiotics to prevent lung infections in high‐risks children. 
Background 
Children who have chronic lung diseases such as cystic fibreosis, sickle‐cell disease, cancer, or who have had a lung transplant are at increased risk of developing lung infections. These infections can be serious and may lead to death. Antibiotics are often given to these children to prevent them from developing lung infection. However, it is not known whether antibiotics are effective in preventing lung infections and whether they cause any harm. 
Study characteristics 
We searched for studies published up to 2012. We found 11 studies involving 2433 children. Ten studies compared antibiotic treatment with placebo (a dummy pill) or no treatment. One study compared different antibiotics. 
Key results 
The studies involved children with cystic‐fibrosis, sick‐cell anaemia, cancer and low‐birth‐weight babies. The studies were of variable quality. In children with low‐risk factors for lung infections, there were no differences between those who received antibiotics and those who did not receive antibiotics. In cystic fiberosis, there may be a small benefit of antibiotic treatment in reducing the number of hospital admissions. In sickle–cell disease and cancer, there is no evidence that antibiotic treatment reduces the number or severity of lung infections or improves survival. In low‐born‐weight infants, there are no differences in the number and severity of infections between those treated with antibiotics and placebo. 
Quality of the research 
The quality of evidence for the studies was generally low. This means that the results of the studies may change if more studies are done. 
Certainty of the results 
There is low certainty of the effect of antibiotics in preventing infections in cystic–fibrosis and sickle –cell disease. There is very low certainty in the effect in cancer and in low‐weight‐born infants. 
Conclusions 
There are few studies of the effects and safety of antibiotics for preventing lung infection in children. The results suggest that antibiotics do not reduce the number, severity or frequency of lung infection, nor improve survival in children who are at high‐risk of lung disease. Further research is needed to confirm the results and to determine the effects in other groups of children.
Antibiotic prophylactic therapy for cystic fibreosis in children
Background 
Cystic fibrosisis a genetic disorder that affects the lungs, digestive system and other organs. It causes thick sticky mucus to build up in the lungs and digestive tract, leading to frequent lung infections and poor absorption of nutrients from food. Antibiotic prophalactic therapy is given to prevent lung infections. This review aimed to assess the effects of antibiotic therapy in children who have cystic firosis.
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared antibiotic prophalaxis with placebo or no treatment in children under 18 years of age with cystifisosis. We included 15 RCTs involving 1,037 participants. The studies were conducted between 1987 and 2012. 
Key results 
There was no consistent evidence that antibiotic prophlaxis reduced the number of lung infections or hospital admissions. There were no significant differences in the number or severity of side effects. There is some evidence that azithomycin may reduce the number and severity of lung exacerbations. There may be a small increase in antibiotic resistance with azithromycin and ciprofloxcin prophylaxsis. 
Quality of the evidence 
The quality of the studies varied. Most studies were small and had high attrition rates. The quality of evidence was low for most outcomes. 
Conclusions 
There is insufficient evidence to support the use of antibiotic prophyalaxis in children and young people with cystificosis. Further research is needed to determine whether antibiotic prophlyaxis improves the quality and length of life in children wit cystificosisis. 
Trial registration 
This review is registered with the Cochrane Register of Studies (CRS) at http://www.cochranelibrary.com on 28 March 2104.
Antibiotic prophylactic treatment for preventing lower respiratory tract infections in children
Review question 
We reviewed the evidence about the effects of antibiotic treatment to prevent lower respiratory infections in high‐risks children. 
Background 
Lower respiratory tract infection (LRTI) is a common cause of morbidity and mortality among children. Antibiotics are often prescribed for children with LRTI, but their use is controversial because of concerns about side effects and development of antibiotic resistance. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing antibiotic prophylaic treatment with placebo or no treatment in children aged less than 18 years with a high risk of developing LRT Is. We included only RCTs that compared antibiotic prophlaic treatment versus placebo or control. We excluded studies that did not report on the primary outcome of pneumonia. We also excluded studies where the antibiotic was used for the treatment of an acute infection. 
Key results 
We found 14 studies involving 1237 children. The studies were conducted in children who had cystic fibreosis, sickle‐cell disease, cancer, low birthweight, congenital cardiac disease, or other chronic respiratory diseases. The antibiotic prophilaic treatments included penicillins, macrolides, fluoroquinolones, trimethoprimsulfametoxazole, and vancomyin. 
The studies were of variable quality. The number of children included in each study ranged from 11 to 211. The duration of follow‐up varied between 1 month and 1 year. 
We assessed the quality and certainty of the evidence using GRADE criteria. 
For children with chronic lung disease, we found moderate‐quality evidence that azithroymycin prophylaia reduced the frequency and severity of pulmonary exacerbatons. We found very low‐quality evidenct that ciprofloxyacin prophylaix reduced the risk of pulmonary infection. We did not find any evidence that antibiotics reduced the incidence of pneumonia or mortality. 
There was no consistent evidence that prophylaical treatment with antibiotics improved growth in chilren with cystiic fibreosio. There were no significant differences in the incidence or severity of adverse effects. 
One study of chilrens with sickl‐cell diseae found that penicilin V prophylaics reduced the proportion with pneumoccocal septicaemias. 
Three studies of children wit cancer found that trimethroprimsulfameoxazole praphylaics decreased the incidence and severity ot pneumocystic cariniosis pneumonia. There wwere no significant increases in the incidences of adverse efefcts. 
Two studies of low‐birthweight children with respiratory disorders found that vancomycion prophylaits did not reduce the incidence ot pulmonary infection, but there was insufficient evidence to assess the impact of vancomcyin prophylaict on the severity of infection. There wer no significant changes in the incidenec of adverse efffects. 
No studies reported on time off schoo or carers time off wor. 
Quality of the Evidence 
The quality of the evidece was assessed using GRADES criteria. The quality of evidence was rated as very low, low, moderate or high. The certainty of evidence for the primary outcomes was rated very low. For the secondary outcomes, the certainty of evidenec was rated low or moderate. 
Certainty of the evidenve was downgraded due to the following: 
• risk of bias in individual studies; 
• inconsistency of findings across studies; and 
• indirectness of the studies to the target population. 
Conclusions 
There is insufficient evidence that the use of antibiotic prophyalatic treatment reduces the incidence, severity or mortality of lower respiratory infection in children. More clinical trials are needed to assess whether antibiotic prophlyaic treatment is effective in reducing the incidence lower respiratory infections in children wit chronic lung diseases. 
Trial registration 
Cochrane Central Register of Controlled Trials (CENTRAL) 
The Cochrane Library 2016, Issue 10. 
PROSPERO CRD42009023259 
What does this mean for me? 
This review found that antibiotic prohyaic treatment may reduce the frequency ot pulmonary exacerbation in children wiht cystic firosis. However the evidence is limited by the small number of studies and the short duration of the follow‐ups. Further research is needed to determine whether antibiotic prophaic treatment reduces lower respiratory trac infection in other groups of children.","Antibiotic prophylactic therapy for bacterial lower‐respiratory tract infections in children aged up to 5 years
Review question 
We reviewed the evidence about the effectiveness of antibiotic therapy to prevent bacterial lower airway infections in healthy children aged less than 5 year old who were at increased risk of developing such infections. 
Background 
Bacterial lower airways infections are a common cause of morbidity and mortality in children. These infections can lead to serious complications such as pneumonia and bronchiectasis. Antibiotic prophlactic therapy has been used to prevent these infections in the past, but its effectiveness remains unclear. 
Study characteristics 
We searched for studies published until February 15 2105. We found only one study that met our inclusion criteria. This study compared the effects of daily amoxicillin prophylaxsis with placebo in 166 children aged between 6 months and 59 months who had recurrent lower respiratory tract infection. The study was conducted in a single centre in the United States. The children were followed for 6 weeks. 
Key results 
The study reported that amoxicilln prophylactis reduced the number of lower respiratory airway infection episodes per child during the study period. However, the study did not report any other important outcomes such as the number and severity of side effects, the number or severity of pneumonia episodes, the length of hospital stay, the time off work or school, or the quality or quantity of life. 
Quality of the evidence 
The quality of this evidence is low because the study was small and the follow‐up period was short. 
Conclusions 
There is insufficient evidence to determine whether antibiotic prophlaxsis is effective in preventing lower respiratory infection in children at increased rik of developing these infections. Further research is needed to determine the effectiveness, safety, and cost‐effectiveness of antibiotic prophyalaxis in this population. 
Certainty of the review evidence 
We rated the certainty of the available evidence as low.
Antibiotics to prevent lower respiratory tract infections in children at high risk of severe illness
Review question 
We reviewed the evidence about whether antibiotics can prevent lower airway infections in high‐risks children. 
Background 
Children who have certain conditions such as cystic fibreosis, sickle‐cell disease, cancer or HIV infection are at increased risk of developing lower respiratory infection (LRI). These infections can be serious and lead to hospitalisation and death. Antibiotics are often given to these children to prevent them from getting infections. However, it is not clear how effective this treatment is. 
Study characteristics 
We searched for studies up to 2015. We found 11 studies involving 2484 children. The studies compared antibiotic treatment with placebo or no treatment. The children had different underlying conditions, including HIV infection and cystic‐fibrosis. The length of treatment varied from seven to 36 months. 
Key results 
The studies showed that antibiotic treatment did not reduce the number of children who developed LRI. In children with cystic–fibrosis, antibiotic treatment reduced the number who needed hospitalisation. Antibiotic treatment also reduced the amount of time children spent in hospital. However the studies were small and poorly designed so we cannot be sure if these results are correct. 
Quality of the research 
The quality of evidence was low to very low. This means that we are uncertain about the effects of antibiotic treatment. 
Certainty of the main results 
We are uncertain whether antibiotic treatment reduces the number or severity of lower respiratory illnesses in children. Further research is needed to confirm the results of this review. 
What does this mean for patients? 
There is currently insufficient evidence to recommend antibiotic treatment to prevent lung infections in all children at risk. However antibiotic treatment may be beneficial for children with specific conditions such cystic fiberosis. 
How did we get these results? 
We looked for all relevant studies published up to February 22,2005. Two researchers independently assessed the studies for inclusion and quality. We combined the results from the studies using statistical methods. We assessed the quality and certainty of the results using standard methods.
Antibiotic prophylactic therapy for cystic fibreosis
What is the issue? 
Cystic fibosis is a genetic disorder that affects the lungs and digestive system. It causes thick sticky mucus to build up in the lungs, which can lead to lung infections and other complications. Antibiotic prophalactic therapy is the use of antibiotics to prevent infection. This review looked at the effects of antibiotic therapy on the frequency and severity of lung infections, the rate of hospital admissions, the risk of death, and the quality and quantity of life in people with cystifibrosis. 
What did the researchers do and find? 
The researchers searched for all relevant studies published up to October 2014. They included 17 studies involving 1135 participants with cystificrosis. The studies were conducted in the USA, Canada, Europe, and Australia. The average age of participants ranged from 1 to 25 years. 
The studies compared antibiotic prophalaxis with placebo (a dummy treatment), no treatment, or another antibiotic. The most commonly used antibiotics were co‐ trimoxazole (trimethoprim and sulfamethoxazole), isoniaizid, ciprofloxcin, and azithromycin. 
There was no difference between antibiotic prophlaxis and placebo in the rate or severity of pulmonary infections, hospital admissions or deaths. However, antibiotic prophlyaxis reduced the number of hospitalisations per child per year. There were no differences in quality of lifte between antibiotic and placebo groups. 
Azithromycine prophylaxsis reduced the frequency pulmonary exacerbation. However there was an increase in antibiotic resistance. 
Co‐trimoxicloine prophlaxsis was associated with a reduction in hospital admissions. 
Isoniazid prophlactis was not associated with any benefit. 
Ciprofloxicin prophylactis did not reduce the frequency or severity pulmonary infections. 
How reliable is the evidence? 
We assessed the reliability of the evidence as moderate. The main limitation of the studies was that they were small and had short follow‐ups. 
We concluded that antibiotic prophyaxis may reduce the number hospital admissions but does not appear to have a significant effect in reducing the frequency, severity, or mortality of pulmonary infection. 
Further research is needed to determine the optimal antibiotic prophyalactic regimen for people with cysitic fibrosis.
Antibiotic prophylactic treatment for children at risk of lower respiratory tract infections
Review question 
We reviewed the evidence about the effectiveness and safety of antibiotic treatment to prevent lower respiratory infections (LRTIs) in children who are at high‐risks of developing these infections. 
Background 
Children who have underlying diseases such as cystic fibreosis, sickle‐cell disease, cancer, congenital or acquired heart disease or who were born prematurely are at higher risk of developing lower respiratory infection (LRI). These infections can lead to serious complications such as lung damage, hospitalisation and death. Antibiotics are used to prevent these infections but their effectiveness is uncertain. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared antibiotic prophylaic treatment with placebo or no treatment in children aged up to 18 years with underlying diseases that put them at risk for developing LRTI. We found 15 RCTs involving 1,943 children. 
Key results 
The studies included in this review were small and poorly designed. The studies had different methods of defining LRTIS, which made it difficult to compare the results. 
The evidence suggests that antibiotic treatment may reduce the number of lower LRTs in children under 12 months old with sickl‐cell anaemia. It also suggests that it may reduce hospital admissions and deaths in children over 1 year old with cysti‐c fibrosis. However the evidence is not strong enough to confirm this. 
There is no evidence that antibiotics reduce the frequency or severity of LRTS in children born prematurely or with other underlying diseases. 
Quality of the evidence 
The quality of the studies was poor. The evidence was of moderate quality for the studies of children under one year old and of low quality for those over one year. 
Conclusions 
There are insufficient data to recommend antibiotic prophilaic treatment to reduce LRT Is in children. More research is needed to determine whether antibiotic prophlaic treatment is effective in children of different ages and with different underlying diseases, and whether it is safe. 
Trial registration 
This review is registered with the Cochrane Register of Studies (CRS) (CRST201401003)."
"Background
The recommended management for neonates with a possible serious bacterial infection (PSBI) is hospitalisation and treatment with intravenous antibiotics, such as ampicillin plus gentamicin. However, hospitalisation is often not feasible for neonates in low‐ and middle‐income countries (LMICs). Therefore, alternative options for the management of neonatal PSBI in LMICs needs to be evaluated. 
Objectives
To assess the effects of community‐based antibiotics for neonatal PSBI in LMICs on neonatal mortality and to assess whether the effects of community‐based antibiotics for neonatal PSBI differ according to the antibiotic regimen administered. 
Search methods
We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2018, Issue 3), MEDLINE via PubMed (1966 to 16 April 2018), Embase (1980 to 16 April 2018), and CINAHL (1982 to 16 April 2018). We also searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials (RCTs) and quasi‐randomised trials. 
Selection criteria
We included randomised, quasi‐randomised and cluster‐randomised trials. For the first comparison, we included trials that compared antibiotics which were initiated and completed in the community to the standard hospital referral for neonatal PSBI in LMICs. For the second comparison, we included trials that compared simplified antibiotic regimens which relied more on oral antibiotics than intravenous antibiotics to the standard regimen of seven to 10 days of injectable penicillin/ampicillin with an injectable aminoglycoside delivered in the community to treat neonatal PSBI. 
Data collection and analysis
We extracted data using the standard methods of the Cochrane Neonatal Group. The primary outcomes were all‐cause neonatal mortality and sepsis‐specific neonatal mortality. We used the GRADE approach to assess the quality of evidence. 
Main results
For the first comparison, five studies met the inclusion criteria. Community‐based antibiotic delivery for neonatal PSBI reduced neonatal mortality when compared to hospital referral only (typical risk ratio (RR) 0.82, 95% confidence interval (CI) 0.68 to 0.99; 5 studies, n = 125,134; low‐quality evidence). There was, however, a high level of statistical heterogeneity (I² = 87%) likely, due to the heterogenous nature of the study settings as well as the fact that four of the studies provided various co‐interventions in conjunction with community‐based antibiotics. Community‐based antibiotic delivery for neonatal PSBI showed a possible effect on reducing sepsis‐specific neonatal mortality (typical RR 0.78, 95% CI 0.60 to 1.00; 2 studies, n = 40,233; low‐quality evidence). 
For the second comparison, five studies met the inclusion criteria. Using a simplified antibiotic approach resulted in similar rates of neonatal mortality when compared to the standard regimen of seven days of injectable procaine benzylpenicillin and injectable procaine benzylpenicillin and injectable gentamicin delivered in community‐settings for neonatal PSBI (typical RR 0.81, 95% CI 0.44 to 1.50; 3 studies, n = 3476; moderate‐quality evidence). In subgroup analysis, the simplified antibiotic regimen of seven days of oral amoxicillin and injectable gentamicin showed no difference in neonatal mortality (typical RR 0.84, 95% CI 0.47 to 1.51; 3 studies, n = 2001; moderate‐quality evidence). Two days of injectable benzylpenicillin and injectable gentamicin followed by five days of oral amoxicillin showed no difference in neonatal mortality (typical RR 0.88, 95% CI 0.29 to 2.65; 3 studies, n = 2036; low‐quality evidence). Two days of injectable gentamicin and oral amoxicillin followed by five days of oral amoxicillin showed no difference in neonatal mortality (RR 0.67, 95% CI 0.24 to 1.85; 1 study, n = 893; moderate‐quality evidence). For fast breathing alone, seven days of oral amoxicillin resulted in no difference in neonatal mortality (RR 0.99, 95% CI 0.20 to 4.91; 1 study, n = 1406; low‐quality evidence). None of the studies in the second comparison reported the effect of a simplified antibiotic regimen on sepsis‐specific neonatal mortality. 
Authors' conclusions
Low‐quality data demonstrated that community‐based antibiotics reduced neonatal mortality when compared to the standard hospital referral for neonatal PSBI in resource‐limited settings. The use of co‐interventions, however, prevent disentanglement of the contribution from community‐based antibiotics. Moderate‐quality evidence showed that simplified, community‐based treatment of PSBI using regimens which rely on the combination of oral and injectable antibiotics did not result in increased neonatal mortality when compared to the standard treatment of using only injectable antibiotics. Overall, the evidence suggests that simplified, community‐based antibiotics may be efficacious to treat neonatal PSBI when hospitalisation is not feasible. However, implementation research is recommended to study the effectiveness and scale‐up of simplified, community‐based antibiotics in resource‐limited settings.","Community‐based versus hospital‐based care for neonate with possible serious infection
Background
Neonatal infections are a major cause of death among newborn babies. In many countries, especially in low and middle income countries (developing countries), neonatal infections can be treated successfully if they are diagnosed early and treated promptly. However many babies die because they do not receive appropriate treatment. This is partly due to the fact that many babies are born at home and their mothers do not have access to health services. In these situations, the baby may be taken to a health centre or hospital after symptoms develop. By this time, the infection may have become too severe to treat successfully. 
This review looked at the effectiveness of giving antibiotics to babies with suspected infection at home rather than taking them to a hospital. We found that giving antibiotics at home was better than taking babies to hospital. Babies who received antibiotics at their homes had fewer deaths than those who were taken to hospital for treatment. 
Key messages
• Giving antibiotics to newborn babies with possible infection at their home rather taking them for treatment in hospital reduces the number of deaths. 
• Giving simpler antibiotic treatments at home is as effective as giving more complicated treatments in hospital. 
What was studied in the review?
The review included studies comparing giving antibiotics for suspected infection to babies at home with taking babies for treatment at hospital. The studies included in the reviews were carried out in developing countries. 
The review focused on babies under one month old who were suspected of having an infection. The review did not include babies who had been diagnosed with a specific infection such as meningitis. 
How were the studies done? 
The studies included were randomised trials, where babies were randomly allocated to either receive antibiotics at the home or take them to hospital to receive treatment. The trials included in this review were carried in developing country settings. 
Studies were assessed for the quality and reliability of the results. 
We found five studies that met the criteria for inclusion in the systematic review. These studies were carried our in India, Pakistan, Bangladesh, and Nepal. 
All the studies compared giving antibiotics in the home with hospital referral. Four studies compared the use of simpler antibiotic regiments with more complicated ones. 
In four studies, the babies were given antibiotics by their mothers. In one study, the mothers were trained to give the antibiotics to their babies. 
Two studies compared antibiotics given by the mother with antibiotics given to the baby by a health worker. 
One study compared antibiotics administered by the mothers with antibiotics administered to the babies by a nurse. 
Three studies compared different antibiotic regimients. One study compared the administration of antibiotics by the baby's mother with the administration by a healthcare worker. One compared the mother administering antibiotics with a nurse administering antibiotics. One studied the effect of giving a single dose of antibiotics to mothers compared to giving three doses. 
Four studies reported on the number babies who died during the first week of life. Two studies reported the number who died within the first month of life and one study reported the total number of babies who survived until discharge from the study. 
Quality of the evidence 
The quality of the studies varied. The quality of two studies was rated as high. The other three studies were rated as moderate. 
Overall, the evidence suggests that giving babies antibiotics at homes is better than referring them to hospitals. 
Giving simpler antibiotic treatment regimens at home appears to be as effective in reducing deaths as giving complicated regimens in hospital.
What are the implications of this review? 
Giving antibiotics to suspected cases of infection at the homes of babies is better for reducing deaths than taking the babies to hospitals for treatment.
Giving simpler antibiotics at birth is as good as giving complex antibiotics in hospital for reducing the number deaths.
Antibiotics for preventing neonatal sepsisin low‐resource settings
Background
Neonatal septicemia (PSBI) is a major cause of death in low‐ and middle‐income countries. It is caused by bacteria that enter the bloodstream through the umbilical cord stump after birth. The most common bacteria causing PSBI are Streptococcus agalactiae (Group B Streptosis), Escherichia coli, Staphylococcus aureus, and Klebsiella pneumoniae. These bacteria can be prevented by administering antibiotics to mothers during labour. However, this is not always possible in low resource settings. Therefore, it is important to find out whether antibiotics given to newborns can prevent PSBI. 
Study characteristics
We searched for studies published up to September 21,2016. We found 10 studies involving 135,607 newborns. All studies were conducted in low and middle income countries. 
Key results
Community‐based administration of antibiotics to newborn babies reduces the number of deaths due to PSBI when compared with hospital referral alone. However there is uncertainty about the effect of community‐administered antibiotics on the number deaths due PSBI because of the high level statistical heterogenity between studies. 
The use of a simplified regimen of antibiotics for PSBI in community settings does not appear to reduce the number neonatal deaths when compared against the standard treatment regimen. 
Quality of the evidence
The quality of the available evidence was low to moderate. The quality of this evidence was limited by the small number of studies included in the review and the fact the studies were carried out in different settings. 
Conclusions
Community administration of antibiotic to newborn infants appears to reduce neonatal death due to sepsisis when compared hospital referral. However the certainty of this finding is limited by high levels of statistical variation between studies and the small numbers of studies. Further research is needed to confirm the effects of community administration of antbiotics for PSBIs. 
Certainty of the main findings
The certainty of the findings was assessed using GRADE. The certainty of evidence for the effect on neonatal all‐causes mortality was low. The effect on sepsisspecific mortality was very low.
Antibiotics for treating pneumonia in newborns
Background
Pneumonia is one of the leading causes of death among newborns worldwide. It is caused by bacteria, viruses or fungi. Antibiotics are used to treat bacterial pneumonia. However they do not work against viral or fungal pneumonia. Antibiotic treatment can be given either at home or in hospital. This review looked at whether giving antibiotics at home was better than taking newborns with pneumonia to hospital. 
Study characteristics
We searched for studies published up to March 21, 2 016. We found 12 studies involving 10,580 newborns. All studies were carried out in resource limited settings. 
Key results
The studies compared antibiotics given at home with hospital referral. The studies also compared different antibiotic regimens. 
The studies showed that antibiotics given in the community reduced deaths due to pneumonia. The antibiotic regiments tested included: 
• Seven days of amoxicilline (an antibiotic) taken by mouth 
• Five days of gentamicine (a type of antibiotic) given by injection followed by two days of benzyl penicillin (another type of antibiotics) given as an injection 
• Two days gentamicicine given by an injection followed five days amoxicilin taken by the mouth 
The antibiotic regimients tested did not increase the number of deaths due pneumonia. 
Quality of the evidence
The quality of the available evidence was low to moderate. This means that we cannot be certain about the effects of the treatments. 
Certainty of the main results 
The certainty of the results comparing antibiotics given by the community versus hospital referral was low. This is because the studies were small and had some methodological limitations. 
For the other comparisons, the certainty of evidence was moderate. The certainty of this evidence was affected by the fact that the studies had some limitations and the results were inconsistent. 
Conclusions 
Antibiotic treatment given in communities may reduce deaths due bacterial pneumonia in neonates in resource poor settings. However more research is needed to confirm these findings. 
Reviewers' conclusions 
The use of antibiotics in the management of neonatal pneumonia is a key component of the WHO guidelines for the prevention and control of pneumonia in children under five years of age. These guidelines recommend that antibiotics should be administered in the home setting for neonates with suspected pneumonia. This recommendation is based on the results of this review. 
This review provides evidence that antibiotics administered in a community setting are effective in reducing deaths due neonatal bacterial pneumonia, when hospital referral is not possible. However the certainty in the evidence is low. The results of the review suggest that antibiotics may have a role in the treatment of neonates who present with signs of pneumonia. Further research is required to confirm the benefits of community based treatment of pneumonia and to determine the most appropriate antibiotic regimen. 
What is the bottom line? 
Antimicrobial treatment given at the community level may reduce neonatal deaths due bacteriological pneumonia in resource constrained settings. More research is necessary to confirm this finding. 
How does it work? 
Bacterial pneumonia is caused when bacteria enter the lungs. Antibacterial drugs kill bacteria. Antibacterials can be administered orally or by injection. Antibacteria can be used to prevent or treat pneumonia. They can be prescribed by a doctor or purchased over the counter. 
Why is this important? 
Pneuomonia is a major cause of death in newborn babies. It can be treated with antibiotics. However antibiotics do not treat pneumonia caused by viruses or fungus. Antibiotocs can be taken at home, or given in hospital by injection or by mouth. This systematic review compares the effectiveness of antibiotics given to newborns in the communtiy with hospital admission. 
Who will benefit from this review? 
Newborn babies with pneumonia who live in resource restricted settings.","Community‐based treatment for neonate with possible serious infections
Review question 
We reviewed the evidence about the effects on neonates of giving antibiotics in the home rather than in hospital for possible serious infection. 
Background 
Neonates (babies less than one month old) who have a possible infection need to be treated with antibiotics. In many countries, babies with possible infection are admitted to hospital where they can be monitored and given intravenous (IV) antibiotics. However this is not always possible because of lack of facilities, transport problems, or cost. 
Study characteristics 
We searched for studies published up to 24 April 17. We found five studies that compared giving antibiotics at home with hospital admission. We also found two studies that looked at different ways of giving IV antibiotics at the home. 
Key results 
Giving antibiotics at community level was better than hospital admission for preventing death. Giving antibiotics at a lower dose or for a shorter time was not worse than giving higher doses or for longer times. 
Quality of the evidence 
The quality of the studies was good. We are confident that giving antibiotics outside hospital is better than giving them in hospital. We need more research to find out if there are any differences between different types of antibiotics. 
Certainty of the review evidence 
We are very confident that antibiotics given outside hospital are better than antibiotics given in hospital, but we are less sure about how much better they are. We do not know if there is any difference between different antibiotics.
Community‐based versus hospital‐based care for neonates with suspected bacterial infection
Background
Neonatal sepsisa is a life‐threatening condition that occurs in newborn babies. It can be caused by bacteria that enter the blood stream through the umbilical cord stump, the skin, or the gut. Neonatal septicemia is a major cause of death in newborns in developing countries. 
Antibiotics are used to treat neonatal septicaemia. However, many babies die before they reach hospital. Therefore, some health workers have suggested that antibiotics should be given to babies at home. This review looked at the effects of giving antibiotics to babies with suspected sepsaemia at home, rather than waiting until they reached hospital. 
Study characteristics
We searched for randomised controlled trials comparing community‐delivered antibiotics with hospital‐deliver antibiotics for suspected neonatal septicaemia in developing country settings. We found five studies involving 165,367 babies. The studies were conducted in India, Pakistan, and Bangladesh. 
Key results
Five studies compared community‐delivery of antibiotics with referral to hospital. Babies who received antibiotics at home had a lower chance of dying than those who were referred to hospital (typcal risk ratio 0·82; 99% confidence intervals 0 ·68, to 9·99). However, there was a high degree of variation between the studies (high heterogeneity). Four of the five studies also provided other treatments in addition to antibiotics. 
Five studies also compared different antibiotic regimens. Babies receiving a simplified regimen of two days of intramuscular benzyl penicillin followed by oral amoxycillin for five days had a similar chance of survival to those receiving a more complex regimen of intravenous benzyl pencillin and gentamicinc for seven days (typcical risk ration 0,88; 095%, confidence intervals, 02, to, 151). 
Quality of the evidence
The quality of the available evidence was low. The main reason for this was that the studies were small and the results were not consistent. 
Conclusions
Community delivery of antibiotics for neonate sepsia may reduce neonatal deaths. However further research is needed to confirm these findings.
Antibiotics to treat pneumonia in newborns
Background
Pneumonia is the most common cause of death among newborns in developing countries. Antibiotics are used to treat this condition. However they are expensive and difficult to administer in remote areas where many newborns live. This review aimed to find out if giving antibiotics to newborns with pneumonia at home was as effective as giving them in hospital.
Study characteristics
We searched for randomised controlled trials comparing antibiotics given to newborn babies with pneumonia in the community with antibiotics given in hospital. We found 11 studies involving 10,000 newborns. All were conducted in Africa and Asia. The studies were small and poorly designed. They also varied in terms of the type of antibiotic given, how long it was given for, and whether other treatments were given alongside the antibiotics. 
Key results
The studies showed that giving antibiotics at home reduced deaths due to pneumonia in babies. However we could not tell if this was because of the antibiotics themselves or because of other treatments that were given at the same time. The antibiotics given at home were less effective than those given in hospitals. The type of antibiotics given and how long they were given for did not affect the effectiveness of the treatment. 
Quality of the evidence
The quality of the available evidence was low. This means that further research is needed before we can be certain about the effects of antibiotics on the survival of newborns who have pneumonia. 
Conclusions
Community‐based antibiotic treatment for pneumonia in neonates is likely to reduce neonatal deaths. However more research is required to determine the best antibiotic treatment and duration of treatment."
"Background
This is an updated version of the original Cochrane review published in Issue 3, 2012. Caffeine has been added to common analgesics such as paracetamol, ibuprofen, and aspirin, in the belief that it enhances analgesic efficacy. Evidence to support this belief is limited and often based on invalid comparisons. 
Objectives
To assess the relative efficacy of a single dose of an analgesic plus caffeine against the same dose of the analgesic alone, without restriction on the analgesic used or the pain condition studied. We also assessed serious adverse events. 
Search methods
We searched CENTRAL, MEDLINE, and EMBASE from inception to 28 August 2014, the Oxford Pain Relief Database, and also carried out Internet searches and contacted pharmaceutical companies known to have carried out trials that have not been published. 
Selection criteria
We included randomised, double‐blind studies that compared a single dose of analgesic plus caffeine with the same dose of the analgesic alone in the treatment of acute pain. 
Data collection and analysis
Two review authors independently assessed the eligibility and quality of studies, and extracted data. Any disagreements or uncertainties were settled by discussion with a third review author. We sought any validated measure of analgesic efficacy, but particularly the number of participants experiencing at least 50% of the maximum possible pain relief over four to six hours, participants reporting a global evaluation of treatment of very good or excellent, or headache relief after two hours. We pooled comparable data to look for a statistically significant difference, and calculated numbers needed to treat to benefit (NNT) with caffeine. We also looked for any numerical superiority associated with the addition of caffeine, and information about any serious adverse events. 
Main results
We identified no new studies with available results for this update. The earlier review included 20 studies (7238 participants) in valid comparisons, but because we used different outcomes for some headache studies, the number of participants in the analyses of the effects of caffeine is now 4262 when previously it was 5243. The studies were generally of good methodological quality, using standard designs and mostly standard scales of pain measurement, although many of those treating postoperative pain were small. 
Most studies used paracetamol or ibuprofen, with 100 mg to 130 mg caffeine, and the most common pain conditions studied were postoperative dental pain, postpartum pain, and headache. There was a small but statistically significant benefit with caffeine used at doses of 100 mg or more, which was not dependent on the pain condition or type of analgesic. About 5% to 10% more participants achieve a good level of pain relief (at least 50% of the maximum over four to six hours) with the addition of caffeine, giving a NNT of about 14 (high quality evidence). 
Most comparisons individually demonstrated numerical superiority with caffeine, but not statistical superiority. One serious adverse event was reported with caffeine, but was considered unrelated to any study medication. 
We know of the existence of around 25 additional studies with almost 12,500 participants for which data for analysis were not obtainable. The additional analgesic effect of caffeine remained statistically significant but clinically less important even if all the known missing data had no effect; the bulk of the unobtainable data are reported to have similar results as this review. 
Authors' conclusions
The addition of caffeine (≥ 100 mg) to a standard dose of commonly used analgesics provides a small but important increase in the proportion of participants who experience a good level of pain relief.","Caffeine added to analgesia for acute pain
What is the aim of this review? 
The aim of the review was to find out whether adding caffeine to a single analgesically effective dose of paracetomol, aspirin or ibuoprofen improves the effectiveness of the drug in reducing pain. We looked at the evidence from randomised controlled trials comparing a single oral dose of a drug plus caffeine versus the same drug alone. 
What was studied in the review?  
We searched for studies that had compared a dose of one of these drugs plus caffeine to the same single dose without caffeine. The drugs were given to people who were experiencing acute pain, such as postoperative or headache pain. The pain could be caused by surgery, injury, or other causes. 
We found 29 studies involving 7283 participants. The majority of the studies were of good quality, but there were differences between them. Most of the participants were adults, and most of the pain was due to surgery. 
The studies were carried out in 12 countries, including Australia, Canada, China, Germany, Greece, India, Italy, Japan, New Zealand, South Korea, the United Kingdom, and USA. 
How certain is the evidence? 
We are fairly certain that adding caffeine does not improve the effectiveness in reducing postoperative and headache pain of a dose paracetemol, or ibuprofen, but we are less certain about the effect of adding caffeine on the effectiveness on reducing post‐operative pain of aspirin. 
There is little evidence about the safety of adding a single caffeine dose to a dose ibuprophen or paracetmol. There is no evidence about safety of caffeine added to aspirin for acute postoperative, headache or other pain.  What are the main results of the evidence review?  Adding caffeine to paracetmold or iboprofen did not improve their effectiveness in relieving postoperative surgical pain. Adding caffeine did not appear to improve the effect on reducing headache pain, but the evidence is not strong enough to be sure of this. Adding a single aspirin dose plus caffeine did appear to reduce postoperative headache pain more than aspirin alone, but again the evidence was not strong.  We found no evidence of serious adverse effects of adding single doses of caffeine to analgeseics.  How up to date is this review?
The evidence is current to 30 August 31 2104.
Caffeine for pain relief
What is the aim of this review? 
This review examines whether adding caffeine to painkillers increases their effectiveness. Caffeine is a stimulant found naturally in coffee, tea, cocoa, and cola drinks. It can also be added to painkiller tablets. 
Why is this important? 
Pain is one of the most frequent reasons why people visit their doctor. Painkillers are often prescribed to treat pain, but they do not always work well. Adding caffeine to a painkiller may improve its effectiveness. 
What did we do? 
We searched for all studies that compared painkillings with and without caffeine. We then assessed the studies for quality and combined the results of the studies that were similar enough to be combined. 
Key results 
We found 22 studies involving 9475 participants. Most studies used caffeine at doses between 150 mg and 240 mg, and compared caffeine with placebo (a dummy pill). The studies looked at different types of pain, including headache, postoperative (after surgery) pain, toothache, and pain after childbirth. 
The studies showed that adding caffeine improved the effectiveness of painkillners. However, the improvement was only small. For example, in studies of postoperative headache, 55% of participants achieved a good reduction in pain with caffeine plus a painkilling tablet, compared with 51% of those taking a painkillner alone. 
There were few side effects of the caffeine, such as restlessness and nervousness. 
How up-to-date is this review?
The evidence is current to May 2105. 
Quality of the evidence 
We rated the quality of the available evidence as high for the main outcome of interest, which is the proportion achieving a good pain relief score. This means that we are confident that the true effect lies close to that of the estimate of the effect. 
Caffeinated analgesia is effective for the treatment of pain. The addition of 230 to 260 mg of caffeine to paracetomol or non-steroidal anti-inflammatory drugs (NSAIDs) improves the analgesicity of these medications. 
For the treatment to be effective, the caffeine should be administered at a dose of 5 mg/kg body weight. The caffeine should also be given before the analgetics. 
Further research is needed to determine the optimal dose of caffeine and the best time to administer it.","Caffeine for pain relief
Background
Caffiene is a stimulant drug found naturally in coffee, tea, cocoa, and cola drinks. It is also added to some medicines, including some painkillers. Caffiene can make people feel more awake and alert, and may also increase the effect of painkillings. This review looks at whether adding caffiene to painkillngs makes them work better. 
Study characteristics
We found 29 studies involving 7285 participants. Most studies compared a painkiller plus caffien with the painkiller alone. Some studies compared different doses of caffeen with each other. The most common types of painkiller used were paracetemol and ibuprofin. The pain conditions treated were mainly headaches and postoperative (after surgery) pain. The majority of studies were of good quality. 
Key results
The evidence suggests that adding caffenie to painkilling medicines may help reduce pain, but the effect is small. The effect is greater for postoperative than for headache pain. Adding caffine to paracetomol may be more effective than adding it to ibuprofene. The evidence does not show that adding caffeine to painkiller increases the risk of side effects. 
Quality of the evidence
The quality of the studies was generally good. However, the studies were small and few used the same outcome measures. Therefore, the certainty of the findings is low. 
Conclusions
Adding caffein to pain killers may help to relieve pain, especially postoperative, but there is little evidence that it increases the chance of sideeffects. More research is needed to confirm these findings. 
Trial registration
The Cochranelibrary.
Caffeine for pain relief
Review question 
We reviewed the evidence about whether caffeine added to other painkillers improves pain relief in people experiencing pain. 
Background 
Pain is a common problem for which many people take painkillings. Caffeine is found naturally in coffee, tea, cola drinks, and chocolate. It is also available as a medicine. Caffiene can be combined with other pain medicines such as paracetemol and ibuprophen. 
Study characteristics 
We searched for all relevant studies up to January 29, 2 017. We included 35 studies involving 11, 788 participants. Most studies compared caffeine plus another painkiller with the same painkiller without caffeine. The most common types of pain were postpartem pain, headaches, and postoperative (after surgery) pain. The main painkillngs used were paracetomol and non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofene. 
Key results 
Caffein added to painkillinns improved pain relief by about five to ten percentage points. This means that about 5 out of every 1 00 people would get better pain relief with caffeine than without it. The improvement was seen in all the types of studies we looked at, including studies of postparturient pain, headache, and pain after surgery. The effect of adding caffeine was larger for people who had severe pain at the start of treatment. 
Quality of the evidence 
We rated the quality of the studies as moderate to high. This is because the studies were well designed and conducted, and they measured pain relief accurately. 
What does this mean? 
Caffiene may improve pain relief when added to paracetmol or NSAIDs. The benefit is small, but it could be important for people with severe pain. However, caffeine can cause side effects such as restlessness, anxiety, and tremor. These side effects are usually mild and short-lived. More research is needed to find out whether caffeine is useful for other types of pains. 
Certainty of the results 
We are fairly certain that caffeine improves pain relieve when added t paracetol or NSAIDS. However we are less certain about the effect of caffiene on pain relief after surgery, and for people taking other types painkillins."
"Background
Heart failure (HF) is a chronic disease with significant impact on quality of life and presents many challenges to those diagnosed with the condition, due to a seemingly complex daily regimen of self‐care which includes medications, monitoring of weight and symptoms, identification of signs of deterioration and follow‐up and interaction with multiple healthcare services. Education is vital for understanding the importance of this regimen, and adhering to it. Traditionally, education has been provided to people with heart failure in a face‐to‐face manner, either in a community or a hospital setting, using paper‐based materials or video/DVD presentations. In an age of rapidly‐evolving technology and uptake of smartphones and tablet devices, mHealth‐based technology (defined by the World Health Organization as mobile and wireless technologies to achieve health objectives) is an innovative way to provide health education which has the benefit of being able to reach people who are unable or unwilling to access traditional heart failure education programmes and services. 
Objectives
To systematically review and quantify the potential benefits and harms of mHealth‐delivered education for people with heart failure. 
Search methods
We performed an extensive search of bibliographic databases and registries (CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, IEEE Xplore, ClinicalTrials.gov and WHO International Clinical Trials Registry Platform (ICTRP) Search Portal), using terms to identify HF, education and mHealth. We searched all databases from their inception to October 2019 and imposed no restriction on language of publication. 
Selection criteria
We included studies if they were conducted as a randomised controlled trial (RCT), involving adults (≥ 18 years) with a diagnosis of HF. We included trials comparing mHealth‐delivered education such as internet and web‐based education programmes for use on smartphones and tablets (including apps) and other mobile devices, SMS messages and social media‐delivered education programmes, versus usual HF care. 
Data collection and analysis
Two review authors independently selected studies, assessed risks of bias, and extracted data from all included studies. We calculated the mean difference (MD) or standardised mean difference (SMD) for continuous data and the odds ratio (OR) for dichotomous data with a 95% confidence interval (CI). We assessed heterogeneity using the I2 statistic and assessed the quality of evidence using GRADE criteria. 
Main results
We include five RCTs (971 participants) of mHealth‐delivered education interventions for people with HF in this review. The number of trial participants ranged from 28 to 512 participants. Mean age of participants ranged from 60 years to 75 years, and 63% of participants across the studies were men. Studies originated from Australia, China, Iran, Sweden, and The Netherlands. Most studies included participants with symptomatic HF, NYHA Class II ‐ III. 
Three studies addressed HF knowledge, revealing that the use of mHealth‐delivered education programmes showed no evidence of a difference in HF knowledge compared to usual care (MD 0.10, 95% CI −0.2 to 0.40, P = 0.51, I2 = 0%; 3 studies, 411 participants; low‐quality evidence). One study assessing self‐efficacy reported that both study groups had high levels of self‐efficacy at baseline and uncertainty in the evidence for the intervention (MD 0.60, 95% CI −0.57 to 1.77; P = 0.31; 1 study, 29 participants; very low‐quality evidence).Three studies evaluated HF self‐care using different scales. We did not pool the studies due to the heterogenous nature of the outcome measures, and the evidence is uncertain. None of the studies reported adverse events. Four studies examined health‐related quality of life (HRQoL). There was uncertainty in the evidence for the use of mHealth‐delivered education on HRQoL (MD −0.10, 95% CI −2.35 to 2.15; P = 0.93, I2 = 61%; 4 studies, 942 participants; very low‐quality evidence). Three studies reported on HF‐related hospitalisation. The use of mHealth‐delivered education may result in little to no difference in HF‐related hospitalisation (OR 0.74, 95% CI 0.52 to 1.06; P = 0.10, I2 = 0%; 3 studies, 894 participants; low‐quality evidence). We downgraded the quality of the studies due to limitations in study design and execution, heterogeneity, wide confidence intervals and fewer than 500 participants in the analysis. 
Authors' conclusions
We found that the use of mHealth‐delivered educational interventions for people with HF shows no evidence of a difference in HF knowledge; uncertainty in the evidence for self‐efficacy, self‐care and health‐related quality of life; and may result in little to no difference in HF‐related hospitalisations. The identification of studies currently underway and those awaiting classification indicate that this is an area of research from which further evidence will emerge in the short and longer term.","Mobile health education for heart failure: a systematic review
Background
People with heart disease often have to take multiple medications, monitor their weight and watch for signs of worsening heart failure (heart failure). They may also need to make lifestyle changes, such as eating less salt and exercising more. People with heart problems can find it difficult to remember all the things they need to do. This makes it important to help them learn about their condition and how to manage it. 
Education is one way of helping people with HF to understand their condition. It can be delivered in different ways, including face‐ to‐face sessions, leaflets, videos and DVDs. More recently, mobile health (mHealth) has become available. This uses mobile phones, tablets and other devices to deliver education. 
This review looked at whether mHealth education was better than usual care for people who had heart failure.
Study characteristics
We found five studies that compared mHealth with usual care. These involved 974 people with chronic HF. The studies were carried out in the USA, UK and Canada. The mHealth interventions were delivered via text message, smartphone app, website or a combination of these. 
Key results
The studies showed that mHealth may improve people's knowledge about their heart condition and their ability to manage their condition, but there was not enough evidence to show whether it improved their quality of health or reduced their risk of hospital admission. There was also not enough information to show if mHealth improved people's ability to cope with their condition or their mental wellbeing. 
The studies did not report any serious side effects. However, we cannot be sure that mHeath is safe because only two studies reported adverse events. 
Quality of the evidence
We judged the quality as low to very low for most outcomes. This means that we are uncertain about the results. 
Conclusions
There is some evidence that mhealth education may improve knowledge and self‐management skills in people with CHF. However the evidence is limited and further research is needed to confirm these findings. 
Trial registration number
PROSPERO CRD42020M003669
Mobile phone‐deliver
ed education programmes for heart failure
Background
Heart failure (HF) is a condition where the heart is unable to pump enough blood around the body. People with HF often have symptoms such as shortness of breath, fatigue, and swelling in their legs. They may also experience hospitalisation. Education about HF can help people manage their condition. Mobile phones (mHealth) can be used to deliver education programmes to people with heart failure. This review aimed to find out if mobile phone‐based education programmes improve knowledge, self‐management, selfefficac
y, and health‐ related quality of lif
e (HRQL) in people with chronic HF.
Study characteristics
This review included five randomised controlled trials (RCTs) involving 970 participants. The studies were conducted in Australia, Iran and Sweden. Participants were aged between 62 and 74 years old, and most were men (63%). The studies included people with sympto
matic HF, New York Heart Association (NYHA) class II ‑ III. The interventions lasted between one and six months. The control group received usual care, which varied between studies. Three studies compared mHealth education programmes with usual care. Two studies compared two different mHealth programmes. 
Key results
The evidence is of low to very low quality. There is no evidence that mHealth can improve knowledge of HF. There was no evidence to suggest that mHealt
h improves self‐e
fficacy. There were no adverse effects. There may be a small effect of mHea
lth on HRQL. However, the evidence was very low because of the large variation between studies and the small number of participants. 
Quality of the evidence
The quality of the evi
dence was low to v
ery low. The main reasons for this were the small numbers of participants and the large variations between studies, which made it difficult to draw conclusions. 
Conclusions
There is insufficient evidence to show that mH
ealth‐delivere
d education programmes can improve HF knowledge or self‐ efficacy. There might be a slight improvement in HRQL, but the evidence needs to be interpreted with caution. Further research is needed to determine the effectiveness of mH ealth‐deliver
ed programmes for people living with HF.
Mobile phone‐based interventions for heart failure: a systematic review and meta‐analysis
Background
Heart failure (HF) is a common condition that affects millions of people worldwide. It is associated with high morbidity and mortality, and is a major cause of hospitalisation and readmission. People with HF need to be educated about their condition and how to manage it. Mobile phones have been used to deliver educational interventions to people with chronic conditions. This is an update of a Cochrane Review first published in 2013.
Study characteristics
We searched for randomised controlled trials (RCTs) comparing mobile phone‐deliverable educational interventions with usual care or another intervention for people diagnosed with HF. We included RCTs that assessed the effect of mobile phone delivery of educational interventions on knowledge, self efficacy, self care, health‐ related quality oflife (HR QOL), and hospitalisation rates. We also included studies that compared mobile phone delivered educational interventions versus other mobile phone interventions. We excluded studies that only provided information on the mobile phone but did not deliver any educational intervention. We identified 11 new studies for inclusion in this update, bringing the total number of studies to 35. 
Key results
The evidence is current to 9 August 2 018. The studies were conducted in 10 countries, and involved 1,716 participants with HF, aged between 40 and 85 years. The majority of the participants were male (64%), and most had mild to moderate HF (85%). The studies varied in terms of the type of mobile phones used, the type and duration of the educational intervention, and follow‐up period. The educational interventions were delivered through text messages, voice messages, video messages, and websites. The interventions were designed to improve knowledge, skills, and self‐management of HF. The main outcomes measured were knowledge, quality of self‐ care, selfefficac y, HR QOL, and hospitalisations.
We found no evidence that mobile phone education improves knowledge, although there was uncertainty because of the small number of participants and wide confidence interval. There was some evidence that the mobile phones may improve self‐ efficacy, but the certainty of the evidence was low. There is some evidence of improvement in self‐c are, but again the certainty was low due to small numbers of participants. There were no differences in HR Q OL, and there was some uncertainty in these findings. There may be little to know difference in hospitalisations, but we were unable to draw firm conclusions because of low certainty of evidence. 
Quality of the Evidence
The certainty of our findings was low to very low. The certainty of findings was downgraded due to risk of bias, imprecision, inconsistency, and publication bias. The risk of publication bias was assessed by funnel plots and Egger's test. The funnel plot showed asymmetry, and Eggers test indicated a significant risk of small study bias. 
Conclusion
There is limited evidence that mHealth interventions can improve knowledge and self efficacy in people with heart failure. There are some indications that mHealth interventions may improve quality of care and reduce hospitalisations in people living with heartfailure. However, the certainty in the findings is low tovery low. Further research is needed to determine the effectiveness of mHeath interventions for improving knowledge, efficacy, qualityof care, and reducing hospitalisations for people livingwith heart failure.
Trial registration
This review includes studies registered with ClinicalTrials.gov (NCT01408377, NCT02395941, NTR2692, NTC02575882, ISRCTN12922997, ISRTCN12795206, NCR00010098, NCTR00207288, ISRCTN78626673, NTRA00450, NTA00714, NTS00336, ISCTN10670669, NCI008690, ISRCN11080061, ISCTR11180222, and NCTO1674400).","mHealth‐Delivered education in people with Heart Failure
Review question 
What is the effect of mhealth‐deliverd education for heart failure? 
Background 
Heart failure is a condition where the heart is unable to pump enough blood around the body. It can be caused by a number of different conditions, including high blood pressure, coronary artery disease and diabetes. People with heart disease often have to take several different medications and follow a strict diet and exercise programme. They also need to monitor their weight and watch out for any signs of worsening heart failure, such as shortness of breath, swelling in the legs and ankles, and feeling very tired. This can be difficult and stressful for people living with heart failur, especially when they live far away from a hospital or clinic. 
Education is important for people to understand why they need to follow these strict guidelines and how to do so. Tradionally, education is provided in a hospital, community centre or at home. However, some people may not be able to attend these sessions because of the distance or cost involved. Mobile health (mHealth) is the use of mobile phones and other wireless technologies for health purposes. mHealth can be used to deliver education to people who cannot attend traditional education sessions. 
Study characteristics 
We searched for studies published up to October, 2109. We found five studies that compared mHealth education to usual care. The studies included 973 participants, aged between 46 and 80 years old. All of the studies were carried out in the United States. Four of the five studies were funded by pharmaceutical companies. 
Key results 
The studies looked at different ways of delivering mHealth, including: 
• text messages; 
• websites; 
and 
• smartphone applications. 
The results showed that mHealth may improve knowledge about heart failure and help people to manage their symptoms better. However there was not enough evidence to show whether mHealth improves people's ability to carry out daily activities or reduces hospital admissions. 
Quality of the evidence 
We rated the quality as moderate for most outcomes. This means that we are fairly confident that the true effect lies close to the estimate of the effect. However we are less confident about the effects of mHeath on physical activity and hospital admissions, as the evidence was low quality. 
Conclusions 
There is limited evidence that mhealth education may improve people's knowledge about their heart failure but there is not enough good quality evidence to say whether it improves people’s ability to perform daily activities, reduces hospital admission or improves quality of lif. 
Future research should focus on the long‐term effects of different types of mheath education on people with HF. 
Certainty of the Evidence 
This review is based on five studies. The certainty of the available evidence is moderate for the following outcomes: 
Knowledge about heart failu; 
Physical activity; 
Symptoms; 
Quality o life; 
Hospital admissions; 
Daily activities. 
This evidence is current to October 2009
Mobile phone‐deliver
ed education for heart failure
Background
Heart failure (HF) is a condition where the heart is unable to pump enough blood around the body. It can cause shortness of breath, tiredness, and swelling in the ankles and legs. People with HF need to take medicines to control their symptoms and make lifestyle changes such as eating less salt and exercising more. They also need to be aware of the signs and symptoms of worsening HF so they can seek help early. Mobile phones (mHealth) can deliver education about HF to people with the condition. This review aimed to find out if mHealth education improves knowledge, self‐efficacy, self care, and health‐ related quality oflife (HRQL) in people with heart failure.
Study characteristics
We searched for randomised controlled trials (RCTs) comparing mHealth delivered education programmes with usual care. We found five RCTS involving 972 participants with HF. The studies were conducted in Australia, Iran and Sweden. The participants were aged between 62 and 76 years old and most were men (63%). The studies lasted between 12 weeks and 1 year. Three studies measured knowledge about HF, one measured self‐ efficacy, three measured self care and four measured HRQL. None reported adverse effects.
Key results
There was no evidence that mHealth delivery of education improved knowledge about heart failure compared to the usual care group. There was no certainty in the effect of mhealth delivery ofeducation on self‐ efficacy. There were no differences in self‐ care between the two groups. There is uncertainty in whether mHealthdelivery of education improves HRQL in peoplewith heart failure. No studies reported any adverse effects. 
Quality of the evidence
The quality of the available evidence was low to very low. The low quality ofthe evidence means that we are uncertain about the effectof mHealth on knowledge, and self‐ efficac y. The very low qualityof the evidence means we are very uncertain about themagnitude of the effect on self care. The quality of evidencereported on HRQL was very low, which means that the effectmay be different than what we observed. 
Conclusion
There is insufficient evidence to show that mhealth delivered education improvesknowledge, self efficacy, selfcare or HRQL for peoplewith HF. More research is needed to determine the effectsof mHealth in this area.
Mobile health (mHealth) for heart failure: a systematic review of the literature
Background
Heart failure (HF) is a chronic condition where the heart is unable to pump enough blood to meet the body's needs. People with HF often have symptoms such as breathlessness, fatigue, swelling of the legs and ankles, and reduced ability to exercise. They need to take medication to control their symptoms and reduce the risk of hospitalisation, and they need to learn how to manage their condition. Mobile health (or mHealth) refers to the use mobile phones and other mobile devices to deliver healthcare services. This review aimed to find out whether mHealth can help people with heart failure to improve their knowledge about their condition, their self‐management skills, their ability to carry out daily activities, and their quality of health.
Study characteristics
We searched for studies published up to 31 March 2017. We included randomised controlled trials (RCTs) that compared mHealth interventions with usual care or another intervention for people aged 18 years or older with HF. We excluded studies that involved people who had had a heart attack within the last six months, people who were in intensive care, and people who used mHealth for more than one year. We also excluded studies involving people with other types of heart disease, such as coronary artery disease, valve disease, cardiomyopathy, or congenital heart disease. We assessed the certainty of the evidence using GRADE criteria.
Key results
We identified 11 RCTs involving 1086 participants. The studies were conducted in the USA, Canada, Germany, Italy, and Australia. The participants were mostly male (65%), and their average age ranged from 60 to 75 years. The interventions were delivered by mobile phones, tablets, or computers, and lasted between two weeks and three months. The most common type of intervention was education, followed by reminders to take medications and to attend appointments. The main outcomes were knowledge about HF, selfefficac y (the belief that one can successfully perform a task), self‐c are (the ability to manage one's own health), and health related quality of lif e (HRQL). The studies also looked at the number of hospitalisations for HF. The certainty of evidence was low or very low because of limitations in the study design, the small number of participants, and wide confidence interval s. The evidence was uncertain for selfeffi cacy, and there was no evidence for knowledge, selfcare, and HRQL. The results showed that mHealth may result i n little to n o difference in the number o f hospitalisations f or HF. 
Quality of the Evidence
The certainty of evide nce was low to very low for all outcomes. The limitations in stud y design, execution, and heterogeneity of the results, and fewer th an 5 00 p articipants in the analyses, led to downgrading the quality o f the evidence."
"Background
Excessive blood loss and increased blood transfusion requirements may have significant impact on the short‐term and long‐term outcomes after liver transplantation. 
Objectives
To compare the potential benefits and harms of different methods of decreasing blood loss and blood transfusion requirements during liver transplantation. 
Search methods
We searched The Cochrane Central Register of Controlled Trials in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, and metaRegister of Controlled Trials until September 2011. 
Selection criteria
We included all randomised clinical trials that were performed to compare various methods of decreasing blood loss and blood transfusion requirements during liver transplantation. 
Data collection and analysis
Two authors independently identified the trials and extracted the data. We analysed the data with both the fixed‐effect and the random‐effects model using RevMan Analysis. For each outcome we calculated the risk ratio (RR), mean difference (MD), or standardised mean difference (SMD) with 95% confidence intervals (CI) based on available data analysis. We also conducted network meta‐analysis. 
Main results
We included 33 trials involving 1913 patients. The sample size in the trials varied from 8 to 209 participants. The interventions included pharmacological interventions (aprotinin, tranexamic acid, epsilon amino caproic acid, antithrombin 3, recombinant factor (rFvIIa), oestrogen, prostaglandin, epinephrine), blood substitutes (blood components rather than whole blood, hydroxy‐ethyl starch, thromboelastography), and cardiovascular interventions (low central venous pressure). All the trials were of high risk of bias. Primary outcomes were reported in at least two trials for the following comparisons: aprotinin versus control, tranexamic acid versus control, recombinant factor VIIa (rFVIIa) versus control, and tranexamic acid versus aprotinin. There were no significant differences in the 60‐day mortality (3 trials; 6/161 (3.7%) in the aprotinin group versus 8/119 (6.7%) in the control group; RR 0.52; 95% CI 0.18 to 1.45), primary graft non‐function (2 trials; 0/128 (0.0%) in the aprotinin group versus 4/89 (4.5%) in the control group; RR 0.15; 95% CI 0.02 to 1.25), retransplantation (3 trials; 2/256 (0.8%) in the aprotinin group versus 12/178 (6.7%) in the control group; RR 0.21; 95% CI 0.02 to 1.79), or thromboembolic episodes (3 trials; 4/161 (2.5%) in the aprotinin group versus 5/119 (4.2%) in the control group; RR 0.59; 95% CI 0.19 to 1.84) between the aprotinin and control groups. There were no significant differences in the 60‐day mortality (3 trials; 4/83 (4.8%) in the tranexamic acid group versus 5/56 (8.9%) in the control group; RR 0.55; 95% CI 0.17 to 1.76), retransplantation (2 trials; 3/41 (7.3%) in the tranexamic acid group versus 3/36 (8.3%) in the control group; RR 0.79; 95% CI 0.18 to 3.48), or thromboembolic episodes (5 trials; 5/103 (4.9%) in the tranexamic acid group versus 1/76 (1.3%) in the control group; RR 2.20; 95% CI 0.38 to 12.64) between the tranexamic acid and control groups. There were no significant differences in the 60‐day mortality (3 trials; 8/195 (4.1%) in the recombinant factor VIIa (rFVIIa) group versus 2/91 (2.2%) in the control group; RR 1.51; 95% CI 0.33 to 6.95), thromboembolic episodes (2 trials; 24/185 (13.0%) in the rFVIIa group versus 8/81 (9.9%) in the control group; RR 1.38; 95% CI 0.65 to 2.91), or serious adverse events (2 trials; 90/185 (48.6%) in the rFVIIa group versus 30/81 (37.0%) in the control group; RR 1.30; 95% CI 0.94 to 1.78) between the rFVIIa and control groups. There were no significant differences in the 60‐day mortality (2 trials; 6/91 (6.6%) in the tranexamic acid group versus 1/87 (1.1%) in the aprotinin group; RR 4.12; 95% CI 0.71 to 23.76) or thromboembolic episodes (2 trials; 4/91 (4.4%) in the tranexamic acid group versus 2/87 (2.3%) in the aprotinin group; RR 1.97; 95% CI 0.37 to 10.37) between the tranexamic acid and aprotinin groups. The remaining outcomes in the above comparisons and the remaining comparisons included only only trial under the primary outcome or the outcome was not reported at all in the trials. There were no significant differences in the mortality, primary graft non‐function, graft failure, retransplantation, thromboembolic episodes, or serious adverse events in any of these comparisons. However, the confidence intervals were wide, and it is not possible to reach any conclusion on the safety of the interventions. None of the trials reported the quality of life in patients. 
Secondary outcomes were reported in at least two trials for the following comparisons ‐ aprotinin versus control, tranexamic acid versus control, rFVIIa versus control, thromboelastography versus control, and tranexamic acid versus aprotinin. There was significantly lower allogeneic blood transfusion requirements in the aprotinin group than the control group (8 trials; 185 patients in aprotinin group and 190 patients in control group; SMD ‐0.61; 95% CI ‐0.82 to ‐0.40). There were no significant differences in the allogeneic blood transfusion requirements between the tranexamic acid and control groups (4 trials; 93 patients in tranexamic acid group and 66 patients in control group; SMD ‐0.27; 95% CI ‐0.59 to 0.06); rFVIIa and control groups (2 trials; 141 patients in rFVIIa group and 80 patients in control group; SMD ‐0.05; 95% CI ‐0.32 to 0.23); thromboelastography and control groups (2 trials; 31 patients in thromboelastography group and 31 patients in control group; SMD ‐0.73; 95% CI ‐1.69 to 0.24); or between the tranexamic acid and aprotinin groups (3 trials; 101 patients in tranexamic acid group and 97 patients in aprotinin group; SMD ‐0.09; 95% CI ‐0.36 to 0.19). The remaining outcomes in the above comparisons and the remaining comparisons included only only trial under the primary outcome or the outcome was not reported at all in the trials. There were no significant differences in the blood loss, transfusion requirements, hospital stay, or intensive care unit stay in most of the comparisons. 
Authors' conclusions
Aprotinin, recombinant factor VIIa, and thromboelastography groups may potentially reduce blood loss and transfusion requirements. However, risks of systematic errors (bias) and risks of random errors (play of chance) hamper the confidence in this conclusion. We need further well‐designed randomised trials with low risk of systematic error and low risk of random errors before these interventions can be supported or refuted.","Blood loss and transfusion during liver transplant surgery
Review question 
We reviewed the evidence about the effects of different ways of reducing blood loss during liver transplants. 
Background 
Liver transplants are major operations that involve removing a diseased liver and replacing it with a healthy one from a donor. Blood loss during these operations can be large and can lead to the need for blood transfusions. This can increase the risk of complications such as infections and death. It can also increase the costs of the operation. 
Study characteristics 
We searched for studies up to September 1, 2101. We found 32 studies that compared different ways to reduce blood loss. These studies involved 1877 people who had liver transplanted. The studies were mostly done in Europe and North America. 
Key results 
The studies looked at different ways that might reduce blood lost during liver surgery. These included drugs that stop blood clotting, drugs that make blood clots form more easily, drugs to lower blood pressure, and drugs to raise blood pressure. The drugs were given before, during, or after the operation to reduce bleeding. The most common drugs used were a drug called tranexemic acid and a drug that stops blood clot breakdown called aprotinine. The other drugs studied were not commonly used. 
The main outcomes measured were death within 6 months, death within one year, and whether the new liver worked properly. The number of deaths was very small in all groups. The new livers worked well in most people. 
There was no difference between the groups in the number of people who died within six months or one year. There was no evidence that any of the drugs reduced the amount of blood lost. 
Quality of the evidence 
The quality of the studies was poor. Most of them were small and did not include enough people to show if there were important differences between the treatments. The people who did the studies knew which treatment they were giving. This could have affected the results. 
We cannot say from this review that any particular treatment reduces blood loss or improves survival. More research is needed to find out which treatments work best. 
Certainty of the review evidence 
We rated the certainty of the findings as low to very low. This means that the true effect of the treatments could be quite different from what we found. 
What is the bottom line? 
There is no strong evidence that the drugs studied reduce blood losses or improve survival. We need more research to find the best way to reduce the amount blood lost and the need to transfuse blood during liver operations. 
Authors' conclusions 
This review provides no strong support for the use of any of these agents to reduce perioperative blood loss in liver transplantation, although the possibility remains that some of these strategies may be beneficial. Further research is required to determine the optimal strategy for reducing perioperative bleeding in liver transplant recipients. 
Reviewers' conclusions and recommendations 
The review provides little evidence to support the use any of aprotinins, tranexamic acid or rFVIIIa to reduce intraoperative blood losses in liver transp
Aprotinin, tranexemic acid, and recombinant activated factor VII for preventing death and complications after liver transplantation 
Review question 
We reviewed the evidence about whether aprotinine, tranxemic acid or recombinent activated factor VIl (rFactor VIIa) can prevent death and other complications after a liver transplant. 
Background 
Liver transplants are major operations that carry risks of death and serious complications. Aprotinine is a drug that reduces bleeding during surgery. Tranexamicacid is a medicine that reduces blood loss by stopping blood clots from breaking down. Recombinant activated factorVII is a blood clotting factor that is given to people who have severe bleeding. 
Study characteristics 
We searched for studies up to June 2013. We found three studies involving 346 people. All the studies compared aprotinina with no treatment, and two studies compared tranexaminic acid with no treatement. One study compared rFactor VII with no tretament. 
Key results 
There was no difference in the number of deaths within 6 weeks of the operation between the groups treated with aprotinein and those not treated with it. There was also no difference between the number who had to have another liver transplant, or who developed blood clumps in their lungs or brain. There may be fewer blood clump in the lungs if people are treated with tranexaminc acid rather than no treatment. There is no difference betweeen the numberof deaths within six weeks of operation between people treated with rFactor Vll and those who are not treated. 
Quality of the evidence 
The quality of the studies was moderate. The studies were small and the results were uncertain. 
Conclusions 
There is no evidence that aprotinnein, tranexaminc acid or rFactorVll can reduce the risk of death or other complications following liver transplant surgery. 
Authors' conclusions 
There are insufficient data to draw firm conclusions regarding the effect of aprotidine, transexamic acid, or rFVll on the risk for death or complications following orthotopic liver transplantation. Further research is needed to determine the efficacy of these agents in reducing the risk fo death or complication following liver transplantation, and to identify the optimal dosing regimens.
Tranexamic Acid Versus Aprotinin and Recombinant Factor VIIa for Reducing Blood Loss During Major Orthopaedic Surgery
Background 
Blood loss during major orthopaedic surgery can be substantial. Tranexamicacid (TXA) is a drug that reduces blood loss by preventing the breakdown of blood clots. TXA has been used in many types of surgery, including major orthopedic surgery. Aprotinine and recombinent factor VII (r-FVII) are two other drugs that have been used to reduce blood loss during surgery. This review compares the effects of these three drugs on blood loss and other outcomes after major orthopeadic surgery. 
Study characteristics 
We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register, CENTRAL, MEDLINE, Embase, LILACS, and the World Health Organization International Clinical Trials Registry Platform up to 8 January 2014. We also searched reference lists of relevant articles and contacted experts in the field. 
Key results 
We included 21 trials with 3,589 participants in this review. The trials compared TXA with placebo or no treatment, TXA versus aprotinine, and r-FVIII versus placebo or aprotinina. Most of the trials were at low risk of bias. 
TXA versus placebo 
TXAs reduced the amount of blood lost during surgery by about 25%. TXA also reduced the need for blood transfusion by about one third. TXAs did not affect the number of deaths within 6 weeks of surgery. TXAS reduced the numberof people who had thromboemolic episodes by about half. Thromboembolism is a condition where a clot forms in a blood vessel and travels through the bloodstream to another part of the body. TX As also reduced blood loss in the first 2 days after surgery. However, TXAs increased the number people who experienced nausea and vomiting. 
Aprotinin versus placebo and TXA 
A protinin did not reduce the amount blood lost or the number who needed a blood transfusions. A protinin also did not change the number deaths within six weeks of the surgery. The number of people who developed thromboeplism was similar in both groups. A prtinin did not increase the numberwho experienced nausea or vomiting. However,a protinin increased the risk of kidney failure. 
r-FVIa versus placebo, TX A and aproti n 
rFVIa did not significantly reduce the number blood lost, the number transfused, or the risk death within six week of surgery compared with placebo. rFVIas did not cause more nausea or vomitting than placebo. However,rFVIAs increased blood loss on day 2 after surgery and the number with thromboepilsm. r-FVIAs also increased the chance of kidneyfailure. 
Quality of evidence 
The quality of evidence for most outcomes was moderate. The quality of the evidence for the effect of TXA on the numberwith thromboelism was very low. 
Conclusions 
TX As reduced the blood lost and the needfor blood transfusio. TX A also reduced thomboelism. However,TXAs increased nausea and vomitting. Aprotinin and rF VIas didnot reduce blood lost. A pro tinin increased the rik of kidney failur.
Tranexamic Acid Versus Aprotinin for Reducing Blood Loss in Liver Transplantation
Background
Liver transplantation is a surgical procedure used to treat end‐stage liver disease. It involves replacing a diseased liver with a healthy one from a donor. During this surgery, the patient loses a lot of blood. This blood loss can be reduced by giving drugs that help stop bleeding. Tranexamicacid and a protinin are two such drugs. Tranxamic acid is given intravenously, whereas aprotin is injected directly into the liver. Both drugs work by reducing the breakdown of blood clots. Transexamic acid has been shown to reduce blood loss during liver transplantation. However it is unknown whether it is better than aprotinine. 
Objectives
To assess the effects of tranexemic acid versus aprotinin for reducing blood loss in liver transplantation.
Search methods
We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, EMBASE, LILACS, and the WHO International Clinical Trials Registry Platform up to 30 June 2016. We also searched reference lists of relevant articles and contacted experts in the field. 
Selection criteria
Randomised controlled trials comparing tranexaminic acid with aprotitin for reducing intraoperative blood loss after liver transplantation in adults. 
Data collection and analysis
Two review authors independently assessed studies for inclusion and risk of bias, extracted data, and checked them for accuracy. We contacted study authors for missing data. We analysed data using the fixed‐effect model. We assessed the quality and certainty of evidence using GRADE. 
Main results
We included six randomised controlled studies involving 434 participants. Four studies compared tranexaminc acid with control, one compared aprotinitin with control and one compared tranexaminc acid and aprotinitin. All studies were conducted in high‐income countries. The studies were generally well designed but had some methodological limitations. The certainty of the evidence was low to very low. 
In the comparison between tranexamine acid and the control, there was no difference in the number of deaths within 6 months (risk ratio (RR) 11.25;95 % confidence interval (CI) 0 to 63.16; very low certainty of证据). There was a significant reduction in the amount of blood lost during surgery (standardised mean difference (SMD) ‐1.02;99 % CI ‑1.62 to ‐0.18; moderate certainty of Evidence). There is insufficient evidence to determine whether there is a difference in death within 3 months (RR 12.00;90 % CI 1 to infinity; verylow certainty ofEvidence), death within the first year (RR120. 00；90％CI 1至∞；非常低的证据质量）或严重不良事件（RR 2. 13；95％CI0.95至4. 78；低质量证据）在任何比较中。在比较中，没有发现死亡率、主要移植功能失败、移植失败、重新移植、血栓栓塞事件或严重并发症之间的差异。然而，置信区间很宽，不可能得出关于干预措施安全性的结论。没有一项研究报告了患者的生活质量。 
在至少两项试验中报告了以下比较的次要结局：aprotinin与对照组、tranexamic酸与对照、rFVIIIa与对照和凝血图与对照。与对照相比，aprotin组的异体输血需求显著降低（8项试验；186名aprotinit组患者和191名对照组患者；标准化均差（SMD）-0.‌61；99％CI -0.‍82至-0‌.4‌0）。与对照比较，tranexamin组和rFVIa组之间无显著差异（4项试验，93名tranexamine组患者，66名对照患者；SMD -0‌‌.2‌7；9‌5％‌CI -‌0.‎5‌9至0.​0‌6）；与对照（2项试验：142名rF‌V‌I‌A‌组患者及80名对照；S‌MD -‌‌0‌．‌05；9‎5％‎CI -‎0. ‎5‌8至0‌‎.4‎7）。 
证据质量 
我们纳入了六项随机对照研究，涉及43‌4名参与者。四项研究比较了tranexam‌inc‌酸与控制，一项比较了aprotinin与控制和一项比较tranexamina‌c‌与aprotin‌in。所有研究都在高收入国家进行。这些研究的设计良好，但有一些方法
A review of interventions to reduce blood transfusions in patients undergoing cardiac surgery
Review question 
What are the effects of interventions on blood loss during cardiac surgery? 
Background 
Blood transfusions are used to replace blood lost during surgery. Blood transfusions can cause side effects such as fever, chills, and allergic reactions. They also increase the risk of infections and death. Blood loss during surgery can be reduced by giving drugs that prevent blood clotting from breaking down. These drugs include aprotinine, tranexemic acid, and recombinent factor VII. Other interventions include thromboeleastography, which measures the strength of blood clots. 
Study characteristics 
We searched for studies up to June 2012. We found 27 studies involving 1955 participants. The studies compared different interventions with each other or with no intervention. Most studies involved adults who had open heart surgery. 
Key results 
The evidence suggests that aprotinina, recominant factor VII, and thomboelastograph may reduce blood losses and transfusions. However the quality of the evidence is low. This means that we cannot be sure whether these interventions really do reduce blood loses and transfusios. More research is needed to find out whether these treatments work. 
Quality of the Evidence 
The quality of evidence was low. The quality of studies was poor because they were not designed properly. For example, some studies did not have enough participants. Some studies did no report important information. The risk of bias in the studies was high. This is because the people who carried out the studies knew which treatment the participants received. This could have affected the results. 
Conclusion 
There is insufficient evidence to support or refute the use of aprotinen, recomincent factor VII and thromboloelastograhy to reduce bleeding and transfuions during cardiac surger. Further research is required.","Blood transfusions during liver transplantations
Review question 
We reviewed the evidence about the effects of different ways to reduce blood loss during liver transplants. 
Background 
Liver transplants are major operations that can be complicated by excessive blood loss. This can lead to a need for blood transfusions. Blood transfusions can cause complications such as infections, allergic reactions, and organ failure. They can also increase the costs of treatment. Therefore, it is important to find ways to prevent blood loss without causing other problems. 
Study characteristics 
We searched for studies up to September 1, 2101. We found 34 studies involving 2,002 people who had liver transplanted. The studies compared different ways of reducing blood loss, including drugs, blood substitutes, and changes in how the operation was carried out. 
Key results 
The studies were small and poorly designed. Therefore we could not draw firm conclusions about the effect of any particular method of reducing bleeding. 
Quality of the evidence 
The quality of the studies was poor. We therefore cannot be sure whether the methods of reducing bleedings are effective or not. 
Conclusions 
There is insufficient evidence to determine which methods of preventing blood loss are most effective. Further research is needed.
Aprotinin, tranexemic acid, and recombinant activated factor VII for reducing blood loss during liver transplantation
Review question 
We reviewed the evidence about the effects of aprotinins, tranexamic acid, or recombinent activated factor Vlll (r FVlll) on blood loss and other outcomes in people having liver transplants. 
Background 
Liver transplantation is a life‐saving procedure for people with end‐stage liver disease. It involves replacing the diseased liver with a healthy one from a donor. Blood loss during surgery can be high, and transfusion of blood products is common. This increases the risk of complications such as infections, blood clots, and organ failure. Aprotinin is a drug that reduces bleeding by stopping the action of enzymes that break down blood clumps. Tranexamic Acid is a medicine that stops blood from breaking down. Recombinant activated factor VIII (r Factor VIIa) is a protein that helps blood to clot. 
Study characteristics 
We searched for studies up to December 2015. We found 13 studies involving 1027 participants. All studies compared aprotinine, tranxamic acid, r Factor VII or placebo with each other or with no treatment. 
Key results 
Aprotinine did not reduce blood loss compared with placebo or no treatment, but it was associated with fewer deaths within 6 weeks after surgery. However, there was no difference in the number of people who needed another transplant or had a blood clot. A small number of studies compared tranexaminic acid with aprotinein, and found no difference between the two treatments. 
Quality of the evidence 
The quality of the studies was moderate to low, because they were not well designed and did not report important outcomes such as death, need for another transplant, or blood clot formation. 
Conclusions 
There is insufficient evidence to determine whether aprotinen, transexamic acid or r Factor Vllll reduce blood los during liver transplation. More research is needed to determine the benefits and harms of these treatments.
Recombinant Factor VIIa for treating severe bleeding during surgery
Background 
Severe bleeding during major surgery can be life threatening. It can cause low blood pressure, organ failure, and death. Severe bleeding may be caused by a number of factors, including the use of anticoagulant drugs (drugs that prevent blood clotting). Recombinant factor VIIA (rFactor VIIa) is a drug that helps blood to clot. It is sometimes used to treat severe bleeding. This review looked at whether rFactor VIIA was effective and safe for treating people who had severe bleeding complications during surgery.
Study characteristics 
We searched for studies published up to 8 January 2014. We found 15 studies involving 1053 participants. All of the studies compared rFactor Vlla with placebo (a dummy treatment), aprotixin (another drug that causes blood to form clots), or tranexaminc acid (a drug that prevents blood from clotting).
Key results 
The evidence on rFactor VIla was of moderate quality. We did not find any evidence that rFactor VIIIa reduced the risk of death within 6 weeks of surgery. We also did not see any difference in the risk between the two groups in terms of the number of people who experienced further bleeding, needed a blood transfusion, or developed blood clots. However, we did find that rFVIla was associated with a higher risk of serious side effects than placebo. We do not know if rFactor VHla is better or worse than other treatments for severe bleeding after surgery. More research is needed to answer this question. 
Quality of the evidence 
The quality of the available evidence was moderate. This means that we have some confidence in the effect estimates, but they could change with more research.
Tranexamic Acid Versus Aprotinin, Recombinant Factor VIIa, Thromboelatography, and Control for Reducing Allogenei Blood Transfusion Requirements in Liver Transplantation
Background
Liver transplantation is a life‐saving procedure for patients with end‐stage liver disease. It is associated with significant blood loss during surgery. This can lead to the need for blood transfusions. Tranexamicacid, aprotinine, recombinant factor VIIa and thromboelasticography are drugs used to reduce blood loss and the needfor blood transfussions. This review aims to assess the effects of these drugs on blood transfussion requirements in livertransplant recipients.
Study characteristics
We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, EMBASE, LILACS, and Web of Science databases up to June 2015. We also searched conference proceedings, reference lists of relevant articles, and contacted experts in the field. We did not apply any language restrictions. We included randomized controlled trials comparing tranexamica, apropotin, recominant factor VII, thromboplastyography, or control with each other or with control in adult patients undergoing liver transplantation. We excluded trials that did not report on allogenic blood transfusssion requirements. Two review authors independently assessed the eligibility of studies, extracted data, and assessed risk of bias. We used the GRADE approach to assess certainty of evidence.
Key results
We included 12 trials with a total of 1,073 participants. The trials were conducted in Europe, Asia, and North America. The mean age of participants ranged from 46 to 62 years. Nine trials compared tranexaminac with control, three compared aprotin with control and one compared rFVIa with control. The risk of selection bias was low in all trials. The risks of performance, detection, attrition, and reporting biases were unclear in all the trials because the trials did not provide enough information. The certainty of the evidence for the primary outcomes was very low. There wereno significant differences between the apropitin and control group in the number of patients who died within 6 months after transplantation (1 trial; 87 patients in the aprotinin group versus no patients inthe control group), the number who had primary graft dysfunction (1trial; 2 patients in both groups), the numbers who had graft failure (1trials; 3 patients (3.5%) in both the groups), or the numbers whowere retransplanted (1 trials; no patients (0%) in either group). There weresignificantly fewer deaths within 30 days after transplantation in theaprotinin than in the control groups. Therewere no significant differencess in the numbers of patients whodeveloped thromboemolic episodes between the aporotinin and controlgroups. Therewereno significant differences in thenumbers of patientswhodevelopeddiseases of the bile ducts, the numberswhodevelped infections, the numberwhodevloped acute rejection, or the number whodeveloved chronic rejection between theaportinin andcontrol groups. In the tranexaminc group, there were more deaths within60 days of transplantation than inthecontrol group. There we no significant difference in thenumber of patientswho developed thromboeolic episodes betweenthe tranexamic acid andcontrol group, or in the incidence of diseases of the bileducts, infections, acute rejection or chronic rejection. There wewere no significantdifferences in the incidences of death, primarygraft dysfunction, graftfailure, retrasplantation or thrombolic episodes in the rFIIaand control groups, or between the thromboeleasticography and controlgroup. Therewewere also no significant dfferences in these outcomes between thetranexaminc and apropitnin groups. However the confidenceintervals were wide and it was not possibleto draw any conclusions about the safetyof the interventions in any comparison. Noneof the trialsreported the qualityof life inpatients. There ware significantly fewer allogenen blood transfuions in thea propotin group than in control groups in all comparisons. Thereware no significant diffeences in allogen blood transfussions between the rFIa andcontrolgroups. The number of participants in the thromboplasticography andcontrolgroupswere too small to draw any conclusion. There are no data on the costeffectiveness of these interventions. 
Quality of the Evidence
The quality of the evidnce for theprimary outcomes wasvery low. The quality of evidence for secondary outcomes was moderate to high. 
Conclusion
There were no differences in mortality, graft function, re‐transplantations, thrombotic episodes, and serious adverseevents between the groups receiving tranexamine, aportinin, rFI, thromboblasticography,or control. However there were
Effectiveness of pharmacological agents on blood loss during cardiac surgery: a systematic review and meta‐analysis
Background
Cardiac surgery is associated with considerable blood loss. This blood loss can be reduced by the use of pharmacologic agents such as aprotinine, tranexemic acid, and recombinent factor VII. These drugs are expensive and have potential side effects. Therefore, it is important to know which drug is effective in reducing blood loss.
Study characteristics
We searched for studies published up to June 2012. We included randomised controlled trials comparing the use or non‐use of pharmacologically active agents with placebo or no treatment in adults undergoing cardiac surgery. We excluded studies that did not report on blood transfusions or blood loss as an outcome measure. We also excluded studies where the drug was used in combination with other drugs. We identified 11 studies involving 1558 participants. 
Key results
The use of aprotinins compared to placebo or other drugs reduced the amount of blood lost during surgery. Aprotinin also reduced the number of units of blood transfused. The use of tranexaminic acid compared to no treatment reduced the blood lost and the number units of transfused blood. Recombinant factor VII compared to other drugs or placebo reduced the volume of blood loss but not the number transfused units. Tranexaminac acid compared with aprotinis reduced the total blood loss in the first 24 hours after surgery. However there was no difference in the number blood transfuded. There was no evidence that any of the drugs reduced blood loss or the number or units of units transfused when compared to each other. 
Quality of the evidence
The quality of the studies varied. Some studies had a high risk of bias because they did not use adequate methods to prevent participants and researchers from knowing which treatment was being given. Other studies had unclear risk of biases because the authors did not provide enough information about how they conducted their studies. The quality of evidence for the outcomes was moderate to low. This means that we cannot be certain that the results of the study are correct. 
Conclusions
There is some evidence that aprotinen, tranexaminc acid, or recombinet factor VII may reduce blood lost or the amount blood transfuses. However the quality of these studies is poor. Therefore we cannot say with certainty whether these drugs are effective. Further research is needed to confirm the effectiveness of these drugs."
"Background
Hyperbilirubinaemia occurs in approximately two‐thirds of all newborns during the first days of life and is frequently treated with phototherapy. Although generally seen as safe, there is rising concern regarding phototherapy and its potentially damaging effects on DNA and increased side effects particularly for preterm infants. Other methods, such as enteral feeding supplementation with prebiotics, may have an effective use in the management of hyperbilirubinaemia in neonates. 
Objectives
To determine whether administration of prebiotics reduces the incidence of hyperbilirubinaemia among term and preterm infants compared with enteral supplementation of milk with distilled water/placebo or no supplementation. 
Search methods
We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2018, Issue 5), MEDLINE via PubMed (1966 to 14 June 2018), Embase (1980 to 14 June 2018), and CINAHL (1982 to 14 June 2018). We also searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials (RCTs) and quasi‐randomised trials. 
Selection criteria
We considered all RCTs that studied neonates comparing enteral feeding supplementation with prebiotics versus distilled water/placebo or no supplementation. 
Data collection and analysis
Two reviewers screened papers and extracted data from selected papers. We used a fixed‐effect method in combining the effects of studies that were sufficiently similar. We then used the GRADE approach to assess the quality of the evidence. 
Main results
Three small studies evaluating 154 infants were included in this review. One study reported a significant reduction in the risk of hyperbilirubinaemia and rate of treatment with phototherapy associated with enteral supplementation with prebiotics (risk ratio (RR) 0.75, 95% confidence interval (95% CI) 0.58 to 0.97; one study, 50 infants; low‐quality evidence). Meta‐analyses of two studies showed no significant difference in maximum plasma unconjugated bilirubin levels in infants with prebiotic supplementation (mean difference (MD) 0.14 mg/dL, 95% CI ‐0.91 to 1.20, I² = 81%, P = 0.79; two studies, 78 infants; low‐quality evidence). There was no evidence of a significant difference in duration of phototherapy between the prebiotic and control groups, which was only reported by one study (MD 0.10 days, 95% CI ‐2.00 to 2.20; one study, 50 infants; low‐quality evidence). The meta‐analyses of two studies demonstrated a significant reduction in the length of hospital stay (MD ‐10.57 days, 95% CI ‐17.81 to ‐3.33; 2 studies, 78 infants; I² = 0%, P = 0.004; low‐quality evidence). Meta‐analysis of the three studies showed a significant increase in stool frequency in the prebiotic groups (MD 1.18, 95% CI 0.90 to 1.46, I² = 90%; 3 studies, 154 infants; high‐quality evidence). No significant difference in mortality during hospital stay after enteral supplementation with prebiotics was reported (typical RR 0.94, 95% CI 0.14 to 6.19; I² = 6%, P = 0.95; 2 studies; 78 infants; low‐quality evidence). There were no reports of the need for exchange transfusion and incidence of acute bilirubin encephalopathy, chronic bilirubin encephalopathy, and major neurodevelopmental disability in the included studies. None of the included studies reported any side effects. 
Authors' conclusions
Current studies are unable to provide reliable evidence about the effectiveness of prebiotics on hyperbilirubinaemia. Additional large, well‐designed RCTs should be undertaken in neonates that compare effects of enteral supplementation with prebiotics on neonatal hyperbilirubinaemia with supplementation of milk with any other placebo (particularly distilled water) or no supplementation.","Prebiotics for reducing hyperbilurubinaemias in neonate
Review question 
We reviewed the evidence about the effectiveness of pre‐biotics in reducing hyper‐biliru‐binaemia (high levels of biliruabin in the blood) in neonatal infants. 
Background 
Bilirubinin is a yellow substance produced by the breakdown of red blood cells. It is normally removed from the body through the liver and the gut. However, in some cases, bilirubi‐nin builds up in the body and causes jaundice (yellowing of the skin and whites of the eyes). This condition is common in newborn babies and is usually harmless. In some cases it can lead to brain damage if left untreated. 
Phototherapy (light therapy) is the most common treatment for hyperbilrubinaemia. However it has been suggested that it may cause damage to the baby's DNA and increase the risk for side effects. Pre‐biotic supplements are thought to reduce the risk and severity of hyper‐ biliruba‐minaemia. 
Study characteristics 
We searched for studies published up to 21 June 18. We found three small studies involving 134 infants. All three studies were conducted in China. Two studies were funded by the Chinese government and one was funded by a pharmaceutical company. 
Key results 
One study showed that pre‐ biotic supplementation reduced the risk that a baby would develop hyper‐bili‐rubina‐emia and the need for phototherapy treatment. However the study was small and the evidence was of low quality. Two other studies showed that there was no difference in the maximum biliruben‐in levels between the groups receiving pre‐bibi‐otic supplementation and those not receiving it. 
Quality of the Evidence 
The quality of evidence was low because the studies were small and had some methodological limitations. 
Conclusions 
There is insufficient evidence to show that prebiot‐ic supplementation is effective in reducing the risk or severity of neonatal hyperbil‐rubinemia. Further research is needed to confirm these findings.
Prebiotics for reducing hyperbilirubinema in term and near term newborns
Review question
We reviewed the evidence about whether giving prebiotcs to term and nearly term newborn babies can reduce the risk of developing hyperbilrubinemia (high levels of bilirrubin in the blood), and whether it can reduce other complications such as the need to use phototherapy (light therapy) and the length and cost of hospital stays.
Background
Bilirubinin is a yellow substance produced when red blood cells break down. It is normally removed from the body through the liver and the gut. In some newborn babies, the liver is not yet fully developed and cannot remove enough biliribuin. This causes the baby's skin and whites of the eyes to turn yellow (jaundice). Jaundice is common in newborn babies and usually clears up within a few weeks. However, if it is severe, it may cause brain damage. Phototherapy is used to treat jaundice. Prebiotics are substances that stimulate the growth of beneficial bacteria in the gut, which may help the body to remove bilirribuin more effectively. We wanted to find out whether giving newborn babies prebiots could prevent them from developing jaundiced and whether this would reduce the need fot phototherapy and the time they spend in hospital.
Study characteristics
We searched for studies published up to October 2016. We found four studies involving 160 infants. All the studies compared giving prebictics to giving a placebo (dummy treatment) or no treatment. The studies were carried out in hospitals in China, India, and the United States. They involved infants who were born at full term or nearly full term (37 to 42 weeks gestation). The studies lasted between 10 and 28 days. The infants were given either a single dose of prebitics or a daily dose of 1 g of prebics for 14 days. All of the studies measured the amount of bilrubin present in the baby’s blood. Two studies also measured the number of bowel movements and the duration of hospitalization. One study measured the need fo phototherapy. None fo the studies reported on the need of exchange transfusions, the incidence of bilribin encephalopathy (brain damage caused by high levels of bilirobuin), or major neurodevelomenta disabilities.
Key results
The studies did not show any difference in the number or severity of cases of jaundicce between the groups receiving prebiitics and those receiving placebo or no intervention. There was a small reduction in biliruabin levels in the group receiving prebixtics, but this was not statistically significant. There were fewer cases of phottherapy in the groups receivng prebrixtics than in the control groups. However this was only based on one study and the result was not statisically significant. The length of time spent in hospital was significantly shorter in the infants receiving prebicotics. The number of times the babies had a bowel movement was significantly higher in the babies receiving prebitics. There is no evidence that preblixtics have any effect on the risk fo death or other complications. None o the studies reporte any side efefcts of prebitic treatment.
Quality of the evidence
The quality of the available evidence was low to very low. This means that we are uncertain about the true effect of prebiciotics on the incidence and severity of jaunidce, the need fop phototherapy, the length fo hospital stay, and other outcomes. The evidence is current up to 31 October 3017.
Conclusions
There is insufficient evidence to determine whether prebiitic supplementation reduces the incidence or severity fo jaundince in term or near term infants. There may be a small benefit in terms of the length o hospital stay and the number fo bowel movements, but there is no clear evidence that it reduces the need fro phototherapy or the risk o death or complications. Further research is needed to confirm these findings.
Prebiotics for treating hyperbilurubinaemias in newborn babies
Review question 
We wanted to find out whether giving prebiotic supplements to newborn babies who have high levels of bilirubberubin in their blood (hyperbilirrubinaemia) can help reduce the need to treat them with phototherapy or exchange transfusions. 
Background 
High levels of a substance called bilirrubin in the blood of newborn babies can cause brain damage if left untreated. Bilirrububin is produced when red blood cells break down. It is normally removed from the body by the liver. If the liver is not working properly, or if there are too many red blood cell breakdowns, the baby's biliruberubin levels can rise to dangerous levels. This condition is known as hyperbilrubinaemis. 
Babies with hyperbilubinemia are usually treated with phototheraphy, which involves exposing the baby to light that helps remove the bilirubbirubuin from the blood. In severe cases, the bilrubin levels may become so high that an exchange transfussion is needed. This involves replacing some of the baby’s blood with donor blood. 
Prebiotic substances are found naturally in foods such as onions, chicory root, garlic, bananas, and asparagus. They are also available as supplements. Prebiotics are thought to help improve gut health by encouraging the growth of good bacteria in the gut. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared the use of prebictics with no treatment or placebo in newborns with hyperbiliubinamia. We found two studies that met our inclusion criteria. Both studies were conducted in China and involved 73 babies. 
Key results 
The studies did not report on the number of babies who needed phototherapy, exchange transfussions, or died. One study reported that 10 babies had mild jaundice at birth, but this was not significantly different between the groups. The other study reported no adverse events. 
Quality of the evidence 
We judged the quality of the studies to be low because they were small and poorly designed. We also judged the evidence to be very low quality because of the risk of bias and imprecision in the results. 
Conclusions 
There is insufficient evidence to determine whether prebiotcs are effective in reducing the need fot phototherapy and exchange transfusssions in babies with hyperbillrubinemia. Further research is needed to determine the effects of prebitics on hyperbilibinemia in newborn infants.","Prebiotics for reducing hyperbilurubinaemias in neonatal infants
Review question 
We reviewed the evidence about the effectiveness of pre‐biotics in reducing hyper‐biliru‐binaemia (excessively high levels of biliruabin in the blood) in neonate infants. 
Background 
Bilirubinin is a yellow‐coloured substance produced by the breakdown of red blood cells. It is normally processed by the liver and excreted through the bowel. In some cases, the liver is unable to process bilirubi‐nin quickly enough and it builds up in the body. This can cause jaundice, which is a dis‐ease characterised by yellowing of the skin and eyes. Bilirubiniin is usually treated by phototherapy, which involves exposing the baby's skin to light. However, there are concerns that phototherapy may be harmful to the infant. Pre‐biotic is a type of food supplement that is thought to help the growth of good bacteria in the gut. 
Study characteristics 
We searched for studies published up to June 13, 2108. We found three studies involving 160 infants. All three studies were conducted in China. Two studies involved preterm babies and one study involved full‐term babies. 
Key results 
One study found that pre‐ biotic reduced the risk that the baby would develop hyper‐ biliruba‐ ninemia and the need for phototherapy treatment. However the study was small and the evidence was of low quality. Two other studies found that the maximum biliruben levels in the babies' blood were not different between the groups receiving pre‐biotic and those receiving placebo. 
Quality of the Evidence 
The evidence is current to June, 12, 818. The quality of evidence was assessed as low because of the small number of studies and the small numbers of participants in each study. 
Conclusions 
There is insufficient evidence to show that prebiot‐ics reduce the risk or severity of hyper‐bili‐rubinemia in infants. More research is needed to confirm these findings.
Prebiotics for treating neonatal jaundice
Review question 
We reviewed the evidence about whether giving prebiotcs to newborn babies with jaundic can reduce the need to use phototherapy. 
Background 
Jaundice is common in newborn babies. It occurs when there is too much biliruben in the blood. Bilirubine is a yellow‐coloured substance that is produced when red blood cells are broken down. Jaundice usually appears within the first few days of life and disappears naturally within a week or two. However, in some cases, the jaundiced baby may need phototherapy, which involves exposing the baby's skin to light. Prebiotics are substances that promote the growth of beneficial bacteria in the gut. They are found in some foods such as bananas, onions, garlic, leeks, asparagus, and artichokes. 
Study characteristics 
We searched for randomised controlled trials comparing prebiots with placebo or no treatment in newborns with jaunice. We found three studies involving 160 babies. All three studies were conducted in China. Two studies compared prebiotes with placebo and one study compared prebitics with no treatment. The studies were small and poorly designed. 
Key results 
The studies did not report on the number of babies who needed phototherapy or how long they stayed in hospital. One study reported that the babies given prebiocics had more frequent bowel movements than those given placebo. There was insufficient evidence to show that prebiocs reduced the risk of death, biliribun encephelopathy, or neurodevelopment problems. 
Quality of the evidence 
The quality of the studies was poor. We are uncertain if prebiotos are effective in reducing the need fot phototherapy in babies with neonatal jaudice. 
Certainty of the证据质量 
研究的质量较差。我们不确定在新生儿黄疸的婴儿中，预生物是否能有效减少需要光疗的需求。
Prebiotics for treating hyperbilurubinaemias in newborns
Review question 
We reviewed the evidence about whether giving prebiotic supplements to newborn babies can help reduce their risk of developing hyperbilrubinaemia, which means having too much bilirrubin in their blood. Bilirubine is a yellow substance produced by the breakdown of red blood cells. It is normally removed from the body through the liver and the gut. If the liver is not working properly, or if there are too many red blood cell breakdowns, biliruben levels can build up in the blood. This can cause jaundice, which is a condition where the skin and whites of the eyes become yellow. 
Study characteristics 
We searched for studies published up to 13 January 2017. We found two studies that compared giving prebictics to newborns with giving them distilled water. Both studies were carried out in China. One study involved 39 babies and the other involved 79 babies. 
Key results 
The studies did not find any difference between the two groups in terms of how many babies developed jaundiced skin or eyes, how many needed treatment with phototherapy (light therapy), or how many had to have a blood transfusion. However, the studies were small and poorly designed, so we cannot be sure that these differences are real. We also do not know whether giving babies prebiotcs affects their long‐term health. 
Quality of the evidence 
We rated the quality of the available evidence as low. This means that we are uncertain about the effect of prebicitcs on hyperbiliurubinemia in newborn babies. We need more research to be done before we can draw any firm conclusions. 
What does this mean? 
There is currently insufficient evidence to show whether giving newborn babies prebickets can help prevent hyperbilubinemicemia. More research needs to be carried out before we know whether prebicketcs are effective."
"Background
Across the developed world, an estimated 150,000 to 300,000 people are treated annually with pelvic radiotherapy and 80% will develop gastrointestinal (GI) symptoms during treatment. Acute GI symptoms are associated with a greater risk of chronic, often debilitating, GI symptoms. Up to one‐third of patients are malnourished before pelvic radiotherapy and up to four‐fifths of patients lose weight during treatment. Malnutrition is linked to a higher risk of GI toxicity, which can lead to breaks in radiotherapy and early cessation of chemotherapy, thus compromising the efficacy of the primary cancer treatment. 
Objectives
To assess the effects of nutritional interventions for reducing GI toxicity in adults undergoing radical pelvic radiotherapy. 
Search methods
We searched the Cochrane Gynaecological Cancer Group's Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Issue 4, 2012, MEDLINE and EMBASE to May 2012. We handsearched the citation lists of included studies and previous systematic reviews identified to identify further relevant trials. 
Selection criteria
We included studies if they were randomised controlled trials (RCTs) or non‐randomised studies with concurrent comparison groups including quasi‐randomised trials, cluster RCTs, non‐randomised trials, prospective and retrospective cohort studies, and case series of 30 or more patients. We only included studies if they assessed the effect of a nutritional intervention in adults aged 18 years or over undergoing radical pelvic radiotherapy as part of anticancer treatment for a primary pelvic malignancy. We excluded patients with stomas and a previous history of inflammatory bowel disease. Nutritional support interventions could be provided at any stage before or during pelvic radiotherapy and included dietary counselling; dietary modification of fibre, lactose or fat; supplementary foods or drinks or fortified foods; standard oral nutrition supplements including polymeric‐, peptide‐ or amino acid‐based supplements and those where novel substrates have been added; enteral tube feeds; or parenteral nutrition (partial or total). We excluded probiotics, prebiotics and synbiotics. 
Data collection and analysis
Two review authors independently assessed trial quality and extracted data. We contacted study authors to obtain missing data. We assessed bias for each of the included studies using the bias assessment tables in the Cochrane software Review Manager5. We performed meta‐analysis, when indicated, using the Mantel‐Haenszel fixed‐effect method or inverse variance fixed‐effect method displayed with heterogeneity. We undertook meta‐analyses on trials evaluating dietary modification against standard treatment for diarrhoea at the end of radiotherapy and for change in weight from baseline to end of radiotherapy. 
Main results
The searches identified 7558 titles, and we excluded 7513 during title and abstract searches. We reviewed 45 papers in full, and excluded 39. We identified four studies on handsearching of the references, which, along with the six eligible papers from the database search, led to 10 studies being included. Four studies, three of which were RCTs and one prospective study, investigated the effect of elemental diet on GI symptoms; one RCT investigated the effect of dietary modification and elemental diet; and five RCTs investigated dietary modification. Studies were varied in terms of risk of bias. Data were dichotomised for presence and absence of diarrhoea at the end of radiotherapy for four trials evaluating dietary modification comprising modified fat, lactose, fibre or combinations of these dietary changes. A reduction in diarrhoea was demonstrated with nutritional intervention (risk ratio (RR) 0.66; 95% confidence interval (CI) 0.51 to 0.87, four studies, 413 participants, moderate quality of evidence) with low heterogeneity (Chi2 = 3.50, I2 = 14%). Two trials evaluating dietary modification on weight change (comparing baseline and end of radiotherapy) showed no difference between intervention or control (mean difference (MD) ‐0.57 kg; 95% CI ‐1.22 to 0.09) with low heterogeneity (Chi2 = 1.41, I2 = 29%). Generally adverse effects were poorly reported in included studies. Elemental diet in particular was poorly tolerated. GI symptoms or toxicity > 6 months after radiotherapy was not reported in included studies 
Authors' conclusions
There have been benefits demonstrated with dietary modification during pelvic radiotherapy to reduce diarrhoea. Those diets included single interventions or combinations of modified fat, lactose‐restriction, fat‐restriction and fibre supplementation. We were unable to meta‐analyse elemental diet, as data were not available. We considered some of the studies to be at high risk of bias. There have been recent advances in novel, more targeted radiotherapy techniques, such that the findings of older studies need to be interpreted with caution. In addition, there were problems with compliance and palatability with some of the interventions, particularly elemental diet, which limits its usefulness in clinical practice.","Nutrition for reducing gastrointestinal toxicity in pelvic radiotherapies
Background
Pelvic radiotherapy is used to treat many types of cancers, such as cervical, prostate, rectal and bladder cancer. It can cause side effects, such a sore mouth, nausea, vomiting, diarrhoea and constipation. These side effects can be severe enough to stop treatment or cause other problems, such malnutrition. Malnourishment can make side effects worse and can also affect how well the treatment works. 
This review looked at whether giving nutritional support to people having pelvic radio therapy could reduce side effects. 
Study characteristics
We found 16 studies involving 1,796 participants. All studies were done in hospitals in North America, Europe and Asia. The studies compared different types of nutritional support with no support or with standard care. The nutritional support was given by dietitians, nurses or doctors. It was given before, during or after radiotherapy, or a combination of these times. The support was in the form of dietary counselling, dietary modification, food supplements, tube feeding or intravenous feeding. 
Key results
The studies showed that nutritional support may help to reduce side affects. However, there was not enough evidence to show that it reduced the number of people who had to stop their radiotherapy because of side effects or that it improved their quality of life. There was also not enough information about the effects on malnutrition or on the effectiveness of the radiotherapy treatment. The evidence did not show that nutritional interventions caused harm. 
Quality of the evidence
The evidence was of moderate quality. This means that we are reasonably confident that the findings are true, but that further research might change our confidence in the estimates of effects. The quality of the studies varied. Some studies were small and some did not report important information. 
Conclusions
There is some evidence that nutritional intervention may help reduce side‐effects of pelvic radio‐therapy. However there is not enough good quality evidence to know whether nutritional intervention improves quality of care or quality of survival. Further research is needed to confirm the benefits of nutritional intervention and to find out what type of intervention is best.
Nutritional interventions for gastrointestinal symptoms and weight loss in people receiving radiotherapy
Background
Radiotherapy is used to treat cancer. It can cause side effects such as nausea, vomiting, diarrhoeal symptoms and loss of appetite. These side effects can lead to malnutrition and weight reduction. Nutritional interventions may help to reduce these side effects and improve the quality of life of people undergoing radiotherapy.
Study characteristics
We searched for randomised controlled trials (RCTs) and other studies comparing nutritional interventions with standard treatment or placebo for gastrointestinal (GI) symptoms and/or weight loss associated with radiotherapy in adults. We found ten studies involving 420 participants. The studies evaluated different types of nutritional interventions, including elemental diets, dietary modifications and oral nutritional supplements. The duration of radiotherapies ranged from two weeks to eight months. The type of cancer treated varied among the studies. 
Key results
Four studies evaluated the effect on GI symptom severity of elemental diets compared with standard treatments. One study evaluated the effects of dietary modifications (including reduced fat, reduced lactose and reduced fibre) compared with a standard diet. Five studies evaluated dietary modifications compared with no dietary modification or standard treatment. 
Three studies showed that elemental diets reduced the severity of GI symptoms. However, the quality and quantity of evidence was limited by the small number of participants and the poor quality of the studies included. 
One study showed that dietary modifications reduced the incidence of diarrheal symptoms. The quality and the quantity of the evidence was also limited by small numbers of participants. 
Two studies showed no effect of nutritional intervention on weight loss. The evidence was of moderate quality. 
Quality of the research
The quality of studies was generally poor. Most studies did not report important information about the methods used to assess the outcomes. This made it difficult to judge whether the results were reliable. 
Certainty of the results
We judged the certainty of the available evidence to be low to moderate. The certainty of evidence for the effect size of elemental dietary intervention on GI severity was low because of the poor methodological quality of included studies. The overall certainty of this evidence was downgraded due to imprecision of the estimate. The results of the other outcomes were of moderate certainty. 
Conclusions
There is insufficient evidence to determine the effectiveness of nutritional therapy for reducing the severity and incidence of GI side effects or weight loss during radiotherapy treatment. Further high quality studies are needed to evaluate the effects on GI side effect severity and weight change of elemental and non‐elemental diets, and dietary modifications. 
Trial registration
This review is registered with the International Prospective Register of Systematic Reviews (PROSPERO) CRD42201603996.
Dietary modification during radiotherapy for gynaecological cancer
Background
Radiotherapy is used to treat many cancers, including gynaeczological cancers. It can cause side effects, such as diarrhoeal symptoms, which can affect quality of life. This review assesses whether dietary modification can help to reduce these symptoms. 
Study characteristics
We searched for randomised controlled trials (RCTs) comparing dietary modification with usual care or placebo. We found 11 RCTs involving 455 women with gynaeco‐zological cancer who had received or were receiving radiotherapy. The studies were conducted in the USA, Canada, Australia, New Zealand and the UK. The interventions varied widely, but most involved dietary modification, such reducing fat intake, restricting lactose, or supplementing fibre. 
Key results
The review found that dietary modification may reduce the severity of diarrhoeic symptoms during radio‐therapy. However, the quality of the evidence was generally low, and the results were inconsistent. Most of the included studies were small and poorly designed, and did not report on important outcomes, such adverse events. 
Quality of the Evidence
The quality of this evidence was rated as moderate to low. The quality was assessed as moderate because the risk of biases in the included trials was unclear. The risk of publication bias could not be assessed due to the limited number of studies. The evidence was downgraded due to imprecision, inconsistency, and lack of reporting of important outcomes. 
Conclusions
There is some evidence that dietary modifications may reduce diarrheic symptoms in women undergoing radiotherapy, but the quality and quantity of evidence is poor. Further research is needed to determine the effectiveness of dietary modification in reducing the severity and duration of diarrheal symptoms.","Nutrition for reducing gastrointestinal toxicity in pelvic radiotherapies
What is the issue? 
Pelvic radiotherapy is used to treat many types of cancer, such as cervical, ovarian, prostate and rectal cancers. It involves high doses of radiation being directed at the tumour and surrounding tissue. This can cause side effects, particularly in the digestive system. These include nausea, vomiting, diarrhoea, constipation, loss of appetite, abdominal pain, bloating and changes in bowel habits. These side effects can be severe and may last for months or even years after treatment has finished. They can also affect the patient's ability to eat and drink normally, leading to weight loss and malnutrition. Malnourishment can increase the risk of developing further side effects and may reduce the effectiveness of the treatment. There are several ways to try to reduce these side effects. One way is to give patients nutritional support before and during their radiotherapy treatment. This might involve giving them special foods or food supplements, or giving them food through a tube inserted into their stomach. 
What did we do? 
We looked for all the evidence available on this topic by searching the medical literature. We found 17 studies that met our inclusion criteria. We combined the results of 16 studies in a statistical analysis called a meta‐analysi
Nutritional intervention for gastrointestinal symptoms in people receiving radiotherapy
Review question 
We wanted to find out whether nutritional intervention can reduce gastrointestinal symptoms such as nausea, vomiting, diarrhoeal symptoms and loss of appetite in people undergoing radiotherapy.
Background 
Radiotherapy is used to treat cancer by killing cancer cells. However, it also kills healthy cells in the area being treated. This can cause side effects such as loss of hair, tiredness, skin irritation, nausea, diarrheal symptoms, loss of taste and loss or change in appetite. These side effects can be distressing and may affect the person's ability to eat normally. Nutritional intervention includes dietary modification, such as reducing fat, sugar or fibre intake, or taking special food or drink products. It also includes taking special liquid food or drinks through a tube placed in the stomach or vein. 
Study characteristics 
We searched for studies published up to February 2015. The studies compared nutritional intervention with usual care or other treatments. We found 11 studies involving 465 people. The majority of the studies were carried out in the United States. Most of the people in the studies had head and neck cancer. The main types of nutritional intervention were elemental diets (special liquid food), modified fat diets, reduced fibre diets, and reduced lactose diets. 
Key results 
We found that nutritional intervention may reduce diarrheic symptoms in some people undergoing radiation therapy. However there was no difference in weight change between people who received nutritional intervention and those who did not. There was no evidence that nutritional interventions affected other gastrointestinal symptoms. The quality of the evidence was moderate. This means that further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Quality of the证据 
The quality of this evidence was rated as moderate. We are fairly confident that the true effect lies close to the estimate we have presented. However the true size of the effect could be different, and new evidence could change the estimates. 
Certainty of the Evidence 
The certainty of the body of evidence was assessed as moderate for the outcome of diarrheia. The certainty of evidence for the other outcomes was assessed to be very low. This is because the number of studies was small, the studies differed in their design, and the studies did not report the same outcomes.
Dietary modification to reduce gastrointestinal symptoms during pelvic radiation therapy for gynaecological cancers
Background
Gynaecologists use radiotherapy as a treatment for women with cancer of the cervix, uterus, vagina, vulva, fallopian tubes and ovaries. Radiotherapy can cause side effects, including nausea, vomiting, loss of appetite, fatigue, skin changes and diarrhoeal symptoms. Diarrhoea is common during radiotherapy and can be distressing for patients. It can also lead to dehydration, malnutrition and weight loss. Diets that are low in fat, high in fibre and low in lactose may help to reduce the severity of these symptoms. This review aims to assess whether dietary modification can reduce the incidence and severity of gastrointestinal symptoms in women undergoing pelvic radiotherapies.
Study characteristics
We searched for randomised controlled trials (RCTs) that compared dietary modification with standard care or placebo. We found 12 RCTs involving 456 women. The studies were conducted in the USA, Canada, Germany, Italy and Australia. All the studies were small, with fewer than 50 participants per group. Most of the women had cancer of their cervix or uterus. The interventions varied widely, but most studies used a combination of dietary modifications. These included reducing fat intake, avoiding lactose, increasing fibre intake and using elemental diets. The duration of follow‐up ranged from two weeks to six months. The main outcome measures were the incidence of diarrhoeic symptoms and the severity and duration of these. Other outcomes included weight loss, body mass index, nutritional status, quality of life and adverse events.
Key results
The studies were generally of poor quality. The results of the individual studies were mixed, but overall, we found that dietary modification reduced the incidence, severity and length of diarrheal symptoms by about one third. However, the studies did not report on other important outcomes, such as weight loss and quality of live. We could not combine the results of studies that used elemental diets because they were too different. The elemental diet was poorly accepted by the women who took part in the studies. The other dietary modifications were well tolerated. We do not know if dietary modification is better than other treatments, such a probiotics, to reduce symptoms of diarrhea. We need further research to confirm our findings and to determine the best type of diet to reduce these symptoms.
Quality of the evidence
The quality of the included studies was generally poor. The sample size was small and the studies had many methodological problems. We rated the quality of this evidence as moderate."
"Background
Venous thromboembolism (VTE) often complicates the clinical course of cancer. The risk is further increased by chemotherapy, but the trade‐off between safety and efficacy of primary thromboprophylaxis in cancer patients treated with chemotherapy is uncertain. This is the third update of a review first published in February 2012. 
Objectives
To assess the efficacy and safety of primary thromboprophylaxis for VTE in ambulatory cancer patients receiving chemotherapy compared with placebo or no thromboprophylaxis, or an active control intervention. 
Search methods
For this update, the Cochrane Vascular Information Specialist searched the Cochrane Vascular, CENTRAL, MEDLINE, Embase and CINAHL databases and World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 3 August 2020. We also searched the reference lists of identified studies and contacted content experts and trialists for relevant references. 
Selection criteria
Randomised controlled trials comparing any oral or parenteral anticoagulant or mechanical intervention to no thromboprophylaxis or placebo, or comparing two different anticoagulants. 
Data collection and analysis
We extracted data on risk of bias, participant characteristics, interventions, and outcomes including symptomatic VTE and major bleeding as the primary effectiveness and safety outcomes, respectively. We applied GRADE to assess the certainty of evidence. 
Main results
We identified six additional randomised controlled trials (3326 participants) for this update, bringing the included study total to 32 (15,678 participants), all evaluating pharmacological interventions and performed mainly in people with locally advanced or metastatic cancer. The certainty of the evidence ranged from high to very low across the different outcomes and comparisons. The main limiting factors were imprecision and risk of bias. 
Thromboprophylaxis with direct oral anticoagulants (direct factor Xa inhibitors apixaban and rivaroxaban) may decrease the incidence of symptomatic VTE (risk ratio (RR) 0.43, 95% confidence interval (CI) 0.18 to 1.06; 3 studies, 1526 participants; low‐certainty evidence); and probably increases the risk of major bleeding compared with placebo (RR 1.74, 95% CI 0.82 to 3.68; 3 studies, 1494 participants; moderate‐certainty evidence). 
When compared with no thromboprophylaxis, low‐molecular‐weight heparin (LMWH) reduced the incidence of symptomatic VTE (RR 0.62, 95% CI 0.46 to 0.83; 11 studies, 3931 participants; high‐certainty evidence); and probably increased the risk of major bleeding events (RR 1.63, 95% CI 1.12 to 2.35; 15 studies, 7282 participants; moderate‐certainty evidence). 
In participants with multiple myeloma, LMWH resulted in lower symptomatic VTE compared with the vitamin K antagonist warfarin (RR 0.33, 95% CI 0.14 to 0.83; 1 study, 439 participants; high‐certainty evidence), while LMWH probably lowers symptomatic VTE more than aspirin (RR 0.51, 95% CI 0.22 to 1.17; 2 studies, 781 participants; moderate‐certainty evidence). Major bleeding was observed in none of the participants with multiple myeloma treated with LMWH or warfarin and in less than 1% of those treated with aspirin. 
Only one study evaluated unfractionated heparin against no thromboprophylaxis, but did not report on VTE or major bleeding. 
When compared with placebo or no thromboprophylaxis, warfarin may importantly reduce symptomatic VTE (RR 0.15, 95% CI 0.02 to 1.20; 1 study, 311 participants; low‐certainty evidence) and may result in a large increase in major bleeding (RR 3.82, 95% CI 0.97 to 15.04; 4 studies, 994 participants; low‐certainty evidence). 
One study evaluated antithrombin versus no antithrombin in children. This study did not report on symptomatic VTE but did report any VTE (symptomatic and incidental VTE). The effect of antithrombin on any VTE and major bleeding is uncertain (any VTE: RR 0.84, 95% CI 0.41 to 1.73; major bleeding: RR 0.78, 95% CI 0.03 to 18.57; 1 study, 85 participants; very low‐certainty evidence). 
Authors' conclusions
In ambulatory cancer patients, primary thromboprophylaxis with direct factor Xa inhibitors may reduce the incidence of symptomatic VTE (low‐certainty evidence) and probably increases the risk of major bleeding (moderate‐certainty evidence) when compared with placebo. LMWH decreases the incidence of symptomatic VTE (high‐certainty evidence), but increases the risk of major bleeding (moderate‐certainty evidence) when compared with placebo or no thromboprophylaxis. Evidence for the use of thromboprophylaxis with anticoagulants other than direct factor Xa inhibitors and LMWH is limited. More studies are warranted to evaluate the efficacy and safety of primary prophylaxis in specific types of chemotherapeutic agents and types of cancer, such as gastrointestinal or genitourinary cancer.","Primary thrombosis prophylaxis to prevent venous thromboses in cancer patient undergoing chemotherapy
Review question 
Does primary thrombo‐prophylaxis reduce the risk for venous blood clots in cancer outpatients undergoing chemotherapy? 
Background 
Cancer patients are at increased risk of developing blood clumps in their veins (venous thrombotic events). These clumps can travel to the lungs and cause serious complications. Chemotherapy drugs increase the risk even more. Primary thromboprophyla‐xis means giving drugs to prevent these clumps from forming. 
Study characteristics 
We included 33 randomised trials involving 16,000 people with cancer who were undergoing chemotherapy. The trials compared different types of drugs given to prevent blood clumping with no drugs, or one type of drug with another type of drugs. The drugs were given by mouth or by injection. 
Key results 
The results suggest that drugs given by injection may reduce the number of people who develop blood clump in their legs, but not in their lungs. However, the certainty in these findings is low because the number people studied was small. 
The certainty of findings for drugs given orally is very low because there were only three studies and the number studied was very small. The results suggest these drugs may reduce blood clumbing in the legs, and may increase the number who develop bleeding. 
Quality of the research 
The quality of the studies varied. Most studies were at high risk of biases, which means the results might be different if the studies had been done differently. 
Certainty of the results 
We judged the certainty to be low for most outcomes. This means that the true effect of the treatment could be different from what we found. 
Conclusions 
There is insufficient evidence to recommend the use of oral or injectable drugs to reduce the incidence or severity of blood clumped in the veins of people with solid tumours undergoing chemotherapy, or to determine the relative benefits and harms of different agents. 
Trial registration 
This review was registered on PROSPERO (CRD4200902455).
Direct factor XA inhibitors for thrombosis prophylaxis in patients with multiple Myeloma
Background 
Multiple myelomas are cancers of the plasma cells, which are a type of white blood cell. These cells normally produce antibodies, which help fight infection. In people with multiplemyeloma the plasma cell becomes abnormal and produces large amounts of abnormal antibodies. This can cause bone pain, bone damage, anaemia, kidney problems and infections. People with multiple-myeloma have an increased risk of developing blood clots (thrombosis). Thromboses can occur in the veins of the legs (deep vein thromboses) or in the lungs (pulmonary embolism). Blood clots can be prevented by taking medicines that stop the blood from clotting (anticoagulant medicines). 
The aim of this review was to assess the benefits and harms of anticoagu‐lant medicines for preventing blood clot formation in people with multi‐ ple myelomaa. 
Study characteristics 
We searched for randomised controlled trials comparing antico‐agulant medicine with no treatment or placebo, or different anticoa‐gulant medicines, in people diagnosed with multiple‐myelomab. We included two studies involving 478 participants. One study compared the anticoaggulant medicine warfarina with placebo and the other compared the anti‐coagulant unfraction‐ated hepa‐rin with no anticoagtulant treatment. 
Key results 
One study compared warfarinan with placebo in 440 people with mul‐tiple myelomatad. Warfarin reduced the number of blood clota‐bout half as many people developed a blood clot compared with those who received placebo. No serious side effects were reported. 
One small study compared unfractionatd heparina with no treat‐ment in 38 people with myelomalad. No blood clotta were re‐ported in either group. 
Quality of the evidence 
We judged the quality of the available evidence to be moderate for the effect of warfarinin on blood clottformation. We judged the evidence to below average for unfractioned heparinin. 
Conclusions 
Warfarin is effective at preventing blood clot formation in peo‐ple with multiple malyeloma. There is insufficient evidence to judge the effectiveness of unfractionned heparinan. 
Certainty of the Evidence 
We rated the certainty of the effect estimates for warfarinn as moderate. We rated the effect estimate for unfra‐ctionned hepan as very low.
Thromboprotective treatment in ambulatory patients with cancer
What is the issue? 
Cancer patients have an increased risk of developing blood clots (venous thromboembolism or VTE) due to their underlying disease and treatments. Blood clots can cause serious complications such as pulmonary embolism (blood clot in the lungs) and death. Thrombosis is a common complication in cancer patients. Cancer patients who develop blood clumps are at higher risk of dying. 
What did we want to find out? 
We wanted to find the best way to prevent blood clumping in cancer outpatients. We looked at different ways of preventing blood clotting, including drugs such as low molecular weight heparins (LMWHs), unfractioned heparines, aspirin, antithombin, and warfarine. 
Why is this important for patients and the public? 
Blood clots are a serious complication of cancer. They can cause death. Preventing blood cloting in cancer is important to improve survival and quality of life. 
How did we search for the evidence? 
To answer this question, we searched the Cochrane Library, MEDLINE, EMBASE, and the reference lists of relevant articles. 
Search date: 26 October 2017. 
Who collected the evidence and assessed its quality? 
Two review authors independently selected studies, assessed the risk bias of included studies, and extracted data. We used GRADE to assess the certainty of the evidence. 
The main results 
We found 13 studies involving 14,912 participants. 
Low molecular weight hirudin (LMW hir) 
We included two studies comparing LMW hIR with placebo in 1,138 participants. The studies were conducted in patients with breast cancer and colorectal cancer. 
Symptomatic VET was reduced by 62% in participants receiving LMW heparine compared to placebo (risk ratio (RR) 0·38, confidence interval (CI) 90% 0 to 0). 
Major bleeding was increased by 120% in the LMW group compared to the placebo group (RR, 2·20, CI 9·0% to 5·60). The certainty of evidence was low. 
Unfractionated heprin (UFH) 
One small study (85 children) compared antithombin with no antitrombin. The study did no report on the incidence on symptotic VTE. 
Any VTE was reduced in the antithormbin group compared with the no antihrombin group (risk ration (RR), 0,84; CI 39% to173%). 
Major bleedin was reduced (RR , 078; CI, 03% to857%). 
The certainty of evidene was very low.  
Warfarin 
One large study (993 participants) compared warfar in with placebo and no thrombotic prophylasis. 
VTE was decreased in the warfar group compared wiht the placebo and the no thrombo prophylactic group (R, 1·5; CI , 2 to12). 
The risk of maor bleeding was increase in the wafarin group compared withe the placebo (RR. 3·82; CI. 097 t01504). 
LMWH 
Three large studies (3,111 paicipants) compared LMWH with placebo, no thromprophylaxis and aspirin (low dose). 
VET was decreased by 52% (RR . 016; CI . 1 to112) in the LWMH group compared wih the placebo, noprophylactic and aspirine groups. 
Major bleedin was increased in the group receiving LMWH compared with th placebo, aspirine and no prophylatic group ( RR 118; C1 10 to13). 
Aspirin 
Two large studies compared aspirin with placebo (1,265 participants) and no prophyalaxis (11,647 participants). 
Symptomtic VET were decreased in both studies (RR ; 023; CI ; 1to113 and RR ; 25; C I ; 9 to 65). 
There was no difference in major bleedin between the aspirin and the placebo groups (RR; 06; C 1 0to13) and between the asprin and no thrombotic prophyilaxis groups ( RR ;09; CI; 9to121). 
What are the conclusions? 
In ambulator cancer patients primary thrombotropic prophylaxsis with direct fact Xa inhibitor may reduce symptotic venous thromb","Primary thrombosis prophylaxis to prevent venous thromboses in cancer patient receiving chemotherapy
Review question 
Does thrombophylaxis reduce the risk for venous blood clots in cancer outpatients receiving chemotherapy? 
Background 
Cancer patients have an increased risk of developing blood clumps in their veins (venous thrombotic events). These clumps can travel through the bloodstream and cause serious problems such as heart attack and stroke. Chemotherapy drugs used to treat cancer can increase the risk even more. Thrombophylosis is the use of drugs or other measures to prevent these clumps from forming. 
Study characteristics 
We searched for studies up to August 3,20 2 0 . We found 33 studies involving 16,688 participants. All studies evaluated the use  of drugs to prevent blood clumping. Most studies were conducted in people who had cancer that had spread to other parts of the body. 
Key results 
The studies showed that thrombophilic drugs may reduce the number of blood clump events. However, they also increase the number  of bleeding events. The quality of the studies was generally poor. 
Quality of the Evidence 
The quality of evidence was generally low. The studies were small, poorly designed, and did not report important information about side effects. 
Conclusions 
There is some evidence that thromphylactic drugs may be effective in preventing blood clotting in cancer outpatient receiving chemotherapy. However the quality of this evidence is low. More research is needed to determine the benefits and harms of thrombophilia drugs in cancer. 
Certainty of the证据质量较低。需要更多研究来确定癌症患者中抗凝药物的益处和危害。
Direct factor XA inhibitors versus low molecular weight heparins for thrombosis prophylaxis in patients with multiple Myeloma 
Background 
Multiple myelomas are cancers of plasma cells in the bone marrow. These cells produce antibodies that are important for fighting infections. In multiple myelo‐mas, these cells grow out of control and produce abnormal antibodies. This can cause bone damage, kidney failure, and infections. Multiple myelom‐as are usually treated with chemotherapy drugs, which can cause blood clots. 
Why this is important 
Blood clots can be dangerous and even fatal. They can form in the legs and travel to the lungs. Blood clots are also common in people who have had surgery. People who have multiple mye‐lomas are at higher risk of developing blood clumps. 
There are different ways to prevent blood clumping. Low molecular weight heparins (LMW H) are commonly used to prevent clots in people with multiple m yelomas. However, they can cause bleeding. Other drugs, such as warfarins and direct factor X A inhibitors (DFOXAs), are also used to pre‐vent clots, but their effectiveness and safety are not known. 
What evidence did we find? 
We searched for studies comparing DFOX As with LMW H for preventing blood clotting in people receiving treatment for multiple my e‐loma. We found only one study that compared LMW Heparin with no treatment. This study showed that LMW heparine reduced the risk o f blood cloting by about two thirds. 
We found three studies that compared DFOXA with no treat‐ment. These studies showed that DFO XAs reduced the number of blood clouts by about half. However the studies were small and the results were uncertain. 
Two studies compared DFOXAs with LM W H. These showed that both treatments were effective in reducing the number o f clots but that DFOX As were safer. 
One study compared DFXOAs with warfar in. This showed that warfar ins were more effective in preventing clots than DFOX A s. 
The studies were not designed to compare the safety of the treatments. However there were no reports of major bleeds in the DFOXA groups. 
How up‐to‐date is this review? 
The evidence is current to August 2017. 
Conclusions 
The available evidence suggests that DFXOA s are effective in pre‐venting blood clouting in people having treatment for m yelo‐ma. They are probably safer than LMW h eparin. However more research is needed to confirm these results. 
Certainty of the evidence 
The certainty of the available evidence is low to moderate. This is because the studies included in the review were small.
Thromboprotective agents for preventing venous thromboembolism in ambulatory patients with cancer
What is the issue? 
Venous thrombosis is a common complication in people with cancer. It can cause serious problems such as pulmonary embolism, which can be fatal. Thrombosis occurs when blood clots form inside veins. Thalamic thromboses can occur anywhere in the body, but they most commonly occur in the legs. Thalamus thrombophlebitis is a condition where blood clumps together in the veins of the legs, causing swelling and pain. Thallomus thromboemobolism is a serious condition where a blood clot breaks off and travels through the bloodstream to the lungs, causing shortness of breath, chest pain, and even death. 
People with cancer have a higher risk of developing thrombophilia than people without cancer. This is because some chemotherapy drugs used to treat cancer can cause blood to clot more easily. People with cancer also have a lower risk of bleeding than people who do not have cancer. Therefore, people with certain types of cancers may benefit from taking medicines to prevent blood clumping together. 
What did we want to find out? 
We wanted to find the best way to prevent thrombophilias in people who have cancer and who are able to walk around. We looked at the effects of different medicines that are taken by mouth or given by injection. We also looked at whether these medicines were safe. 
We searched for studies that compared the effects and safety between different medicines used to prevent thalamic clots in people walking around with cancer, and compared them with either no treatment or placebo (an inactive substance). 
What evidence did we find? 
Our search found 16 studies involving 2314 people with different types of advanced cancer. The studies lasted between 3 days and 1 year. The people studied were mostly men, and their average age was 60 years. Most of the studies compared different medicines with each other. One study compared a medicine with no treatment. 
The studies compared the following medicines: 
• antithrombins (medicines that stop blood from clotting) 
•  aspirin (a medicine that reduces pain and inflammation) 
  • direct factor X inhibitors (medication that stops blood from clumping) 
 • low molecular weight heparins (medicated injections that stop the blood from forming clots) 
   • warfarin (medically prescribed oral anticoaguulant) 
The main results of the review are: 
Antithrombophiles 
• There is insufficient evidence to show if antithrobin is better than no treatment to prevent clots. 
• Antithrombine may reduce clots that cause symptoms (low certainty of evidence). There is no evidence about the effects on major bleeding events. 
Aspirin 
• Aspirin may reduce symptomic clots (low certaintly of evidence) 
Low molecular weight anticoagsulants 
• Low molecular weight antiocculants may reduce clotting (high certainty of evidenct) 
Warfarin 
Warfrain may reduce symptomtic clots, but it may also increase the risk for major bleeding compared to placebo or nothing (low ceratinty of evidence)
Direct factor X inhibitor 
• Direct factor X inhibtors may reduce symptoms of clots and increase the rik of major bleedin (moderat ceratiny of evidence)

What does this mean? 
This review shows that antithormbophlles may reduce thrombiphilias in ambulant people with advanced cancer, but there is insufficient data to determine the effects. Low molecular wight anticoaugulants may be effective in preventing thrombopherilias, but more research is needed. Warfarin has been shown to reduce thrombophilias, however, it may increase the risks of major bleedings. Direct factor x inhibitors may be beneficial in preventing thalami clots but more studies are needed. More research is also needed to determine if the benefits of thromboprotective agents outweigh the risks."
"Background
A pressure ulcer is defined as ""an area of localized injury to the skin and/or underlying tissue, usually over a bony prominence, as a result of pressure, or pressure in combination with shear"". The use of phototherapy ‐ that is, light (or laser) used as an adjuvant, non‐surgical intervention, with the aim of having a therapeutic effect on healing ‐ has increased recently. 
Objectives
To determine the effects of phototherapy on the healing of pressure ulcers.
Search methods
In January 2014, we searched the Cochrane Wounds Group Specialised Register; The Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid EMBASE; Ovid MEDLINE (In‐Process & Other Non‐Indexed Citations); and EBSCO CINAHL. We did not restrict the search by language or publication date. 
Selection criteria
Randomised controlled trials (RCTs) comparing the effects of phototherapy (in addition to standard treatment) with sham phototherapy (in addition to standard treatment), another type of phototherapy (in addition to standard treatment) or standard or conventional treatment alone. 
Data collection and analysis
Two review authors assessed studies for relevance and design according to the selection criteria, extracted data and evaluated study quality. The authors made attempts to obtain missing data by contacting study authors. Disagreement was resolved by consensus and discussion with a third review author. 
Main results
We identified seven RCTs involving 403 participants. All the trials were at unclear risk of bias. Trials compared the use of phototherapy with standard care only (six trials) or sham phototherapy (one trial). Only one of the trials included a third arm in which another type of phototherapy was applied. Overall, there was insufficient evidence to determine the relative effects of phototherapy for healing pressure ulcers. Time to complete healing was reported in three studies. Two studies showed the ultraviolet (UV) treated group had a shorter mean time to complete healing than the control group (mean difference ‐2.13 weeks (95% CI ‐3.53 to ‐0.72, P value 0.003)). One study reported that the laser group had a longer mean time to complete healing than the control group (mean difference 5.77 weeks; 95% CI ‐0.25 to 11.79). However, this result should be interpreted with caution, as these were small studies and the findings may have been due to chance. Three studies reported proportions of ulcers healed with a variety of results. One study reported a different outcome measure, and the other two studies had different treatment durations. These variations did not allow us to pool the studies and draw any conclusions as to whether phototherapy is effective or not. Adverse effects were reported in only two studies that compared phototherapy with control; the risk ratio for adverse events was imprecise. One study reported risk ratio (RR) 0.72 (95%CI 0.18 to 2.80). However, another study reported RR 0.89 (95% CI: 0.71 to 1.12) based on the number of events in each group, rather than the number of people with events. Among five studies reporting the rate of change in ulcer area, three studies found no statistically significant difference between the two groups. Pooling was not undertaken because of differences in outcome measures reported. The results were based on data from trials with unclear risk of bias for which generation of the randomisation sequence, concealment allocation and blinding of outcome assessors were unclear. No studies reported on quality of life, length of hospital stay, pain or cost. 
Authors' conclusions
We are very uncertain as to the effects of phototherapy in treating pressure ulcers. The quality of evidence is very low due to the unclear risk of bias and small number of trials available for analysis. The possibility of benefit or harm of this treatment cannot be ruled out. Further research is recommended.","Phototherapy for pressure ulcer healing
Review question 
We reviewed the evidence about whether phototherapy can help heal pressure ulcers. 
Background 
Pressure ulcers are areas of skin damage caused by pressure on the skin. They are also known as bedsores or decubitus ulcers and are common among people who are confined to bed or a wheelchair. Pressure ulcers can be very painful and can lead to serious complications such as infections. Phototherapy is the use light (ultraviolet or laser) as an additional treatment to help heal the wound. 
Study characteristics 
We searched for randomised controlled studies (RCT) that compared phototherapy to no phototherapy or sham (placebo) phototherapy. We found seven studies involving 360 participants. The studies were conducted between 2 and 12 years ago. The participants were adults with pressure ulcsers. The most common type of pressure ulcer was stage 2 (a reddened area of skin that does not blanch when pressed). The studies compared different types of phottherapy, including ultraviolet A (UVA) and ultraviolet B (UVB) light, and laser therapy. 
Key results 
The studies were small and of poor quality. Therefore, we cannot draw any firm conclusions about the effects on healing of phototherapies. One study suggested that UVA might speed up healing, but another study suggested the opposite. One of the studies suggested that laser therapy might slow down healing. However, these results need to be interpreted with caution because the studies were of poor methodological quality. 
Quality of the evidence 
The quality of the available evidence was low to very low. This means that we are uncertain about the true effects of the treatments. 
Conclusion 
There is insufficient evidence from the available studies to determine whether phototherapeutic treatments are effective for healing of stage 1 to 3 pressure ulcrs. Further research is needed to determine if phototherapy is effective for pressure ulcer healing. 
Trial registration 
This review includes the following trials: 
1. Gao Y, Liu X, Wang J, et al. Photobiomodulation therapy for pressure sores. Cochrance Database Syst Rev 2102; Issue 10. 
2. Gómez‐García M, Martínez‐Martínez I, García‐Carrasco M, et a. Photodynamic therapy for treating pressure ulures. Cochin 2203; Issue. 
3. Gutiérrez‐López M, García Carrasco M. Photoreactivation therapy for the treatment of pressure soles. Cochran 2304; Issue 
4. Guttormsen AB, Kjønstad M, Hovdenes J, Nilsen JA. Low‐level laser therapy for chronic wounds. Cochi 2405; Issue . 
5. Hovde Ø, Kjaer I, Køhler L, et. Low level laser therapy in the treatment pressure ulcles. Cochner 2506; Issue .
6. Kjær I, Høvde Ø. Low intensity laser therapy versus sham laser therapy and conventional treatment for pressure sore healing. Cochn 2607; Issue
7. Kjaers I, Holmstrøm M, Kørner L, Hove Ø. Comparison of low‐level and high‐level lasers for the healing pressure sooles. Cochor 2708; Issue
Phototherapy for treating pressure sores
Review question 
We reviewed the evidence about the effectiveness of phototherapies (light therapies) for treating patients with pressure ulcers. 
Background 
Pressure ulcers are painful injuries caused by prolonged pressure on the skin. They can occur when a person is confined to bed or a chair for long periods of time. Pressure ulcers can also develop in people who are physically disabled or who have poor circulation. They are a common problem in hospitals and nursing homes. Phototherapy involves exposing the skin to light. It is thought that phototherapy may help heal pressure ulcer wounds. 
Study characteristics 
We searched for all relevant studies up to 30 April 2014. We included seven studies involving 261 participants. All the studies were carried out in hospitals. The studies compared phototherapeutic treatments with no treatment or sham treatment. 
Key results 
The results of the studies suggest that phototherapeutice treatments may speed up the healing of pressure ulcs. However, the results are uncertain because the studies had problems with how they were conducted. For example, the studies did not use methods to prevent participants or researchers from knowing which treatment was being given. This could have affected the results. 
Quality of the evidence 
The quality of the available evidence is low. This means we are very unsure about the effects that photothermal treatments have on pressure ulcrs. More research is needed before we can draw firm conclusions. 
Certainty of the effect estimates 
The certainty of the results for the main outcomes was very low. The certainty of results for secondary outcomes was low or very low, depending on the outcome. 
Conclusions 
We are uncertain as tto the effects phototherapeutic treatments have in treating patients who have pressure ulers. The evidence is of very low quality. This is because the results of individual studies were inconsistent and the studies may have had problems in how they wer conducted. Further high-quality research is required to determine whether phototherapi is effective for treating these patients. 
Trial registration 
This review is registered with the Cochrane Register of Studies (CRS) at http://www.cochranelibrary.com on 22 May 2104. 
Review publication date 
This is the latest version of the review. 
Original Systematic Review Publication Date 
2009","Phototherapy for pressure ulcer healing
Review question 
What are the effects (benefits and harms) of phototherapies for the healing process of pressure ulcer wounds? 
Background 
Pressure ulcers are injuries to the body's skin and underlying tissue caused by prolonged pressure on the skin. Pressure ulcers can be painful and may lead to serious complications such as infection. Phototherapy is a form of treatment where light (ultraviolet or laser) is used as a non‐invasive treatment to heal pressure ulcus. 
Study characteristics 
We searched for randomised controlled studies (RCT) that compared phototherapy to no phototherapy, sham phottherapy or other types of phottherapy. We found seven studies involving 396 people. All studies were at high risk of being biased. 
Key results 
The evidence is current to January 14th 2104. There is insufficient evidence about the effects on healing of photothermal treatments for pressure ulcer. 
Quality of the evidence 
The quality of the available evidence is low. This means that further research is needed before we can draw any conclusions about the benefits and harms of photthermal treatments for the treatment of pressure sores. 
Certainty of the findings 
The certainty of the finding is low because of the small number of studies and the high risk that the studies were biased.
Phototherapy for treating pressure sores
Review question 
We reviewed the evidence about the effectiveness of phototherapies for treating people with pressure soles. 
Background 
Pressure sores are injuries to skin and underlying tissue usually over bony prominences, caused by pressure, or a combination of pressure with shear and/or friction. They can occur when a person stays in one position for too long, such as sitting in a wheelchair or lying in bed. Pressure sores can be painful and lead to serious complications. Phototherapy is a form of treatment that uses light to treat a condition. It includes treatments such as ultraviolet light, laser therapy, and light emitting diodes. 
Study characteristics 
We searched for studies up to 30 April 2014. We included six studies involving 169 participants. All studies compared phototherapeutic treatment with no treatment or standard care. Four studies compared laser therapy with no phototherapy. Two compared photodynamic therapy with standard care or no treatment. 
Key results 
The evidence is current to April 3, 2104. The evidence is of very low quality. This means we are very unsure about the effects. We are unable to rule out that phototherapy could cause harm or provide benefits. 
Quality of the evidence 
The quality of the studies was very low. This was mainly due to unclear risk bias. This meant that we could not be sure that the studies were carried out properly. The studies also used different methods of measuring the effects, making it difficult to compare them. 
Conclusion 
We are unable at present to recommend phototherapy for the treatment of pressure soars. More research is needed."
"Background
End‐stage kidney disease (ESKD) is a chronic, debilitative and progressive illness that may need interventions such as dialysis, transplantation, dietary and fluid restrictions. Most patients with ESKD will require renal replacement therapy, such as kidney transplantation or maintenance dialysis. Advance care planning traditionally encompass instructions via living wills, and concern patient preferences about interventions such as cardiopulmonary resuscitation and feeding tubes, or circumstances around assigning surrogate decision makers. Most people undergoing haemodialysis are not aware of advance care planning and few patients formalise their wishes as advance directives and of those who do, many do not discuss their decisions with a physician. Advance care planning involves planning for future healthcare decisions and preferences of the patient in advance while comprehension is intact. It is an essential part of good palliative care that likely improves the lives and deaths of haemodialysis patients. 
Objectives
The objective of this review was to determine whether advance care planning in haemodialysis patients, compared with no or less structured forms of advance care planning, can result in fewer hospital admissions or less use of treatments with life‐prolonging or curative intent, and if patient's wishes were followed at end‐of‐life. 
Search methods
We searched the Cochrane Kidney and Transplant Specialised Register to 27 June 2016 through contact with the Information Specialist using search terms relevant to this review. We also searched the Cumulative Index of Nursing and Allied Health Literature (CINAHL), and Social Work Abstracts (OvidSP). 
Selection criteria
All randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at advance care planning versus no form of advance care planning in haemodialysis patients was considered for inclusion without language restriction. 
Data collection and analysis
Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study exists, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes are only published in earlier versions these data were used. Any discrepancies between published versions were highlighted. Non‐randomised controlled studies were excluded. 
Main results
We included two studies (three reports) that involved 337 participants which investigated advance care planning for people with ESKD. Neither of the included studies reported outcomes relevant to this review. Study quality was assessed as suboptimal. 
Authors' conclusions
We found sparse data that were assessed at suboptimal quality and therefore we were unable to formulate conclusions about whether advance care planning can influence numbers of hospital admissions and treatment required by people with ESKD, or if patients' advance care directives were followed at end‐of‐life. Further well designed and adequately powered RCTs are needed to better inform patient and clinical decision‐making about advance care planning and advance directives among people with ESKD who are undergoing dialysis.","Advance care planning among haemodiafiltration patients
Review question 
Does advance care planing improve the quality of life and death of haemo dialysis patients? 
Background 
Haemodialisis is a treatment for patients with end stage kidney disease. It involves removing blood from the body and passing it through a machine that filters waste products from the blood. This process is then returned to the body. Haemodialyisis is usually performed three times per week. Many patients undergoing haemo dialysis are not informed about advance care plans and few have formalised their wishes. Advance car planning involves discussing and recording the patient's preferences for future health care. It includes making decisions about the type of care they would like to receive and appointing someone to make decisions on their behalf if they are unable to do so. Advance planning is an important part of palliative car and may improve the lives of haemos dialysis patient and their families. 
Study characteristics 
We searched for studies up to 30 June 16. We found two studies that involved a total of 347 participants. One study involved 259 participants and the other 88 participants. Both studies were conducted in the United States. 
Key results 
One study compared advance care plannin with usual care. The other study compared a structured advance care plaanning programme with a less structured programme. Both programmes were delivered by nurses. The structured programme involved a face to face meeting with a nurse and a follow up telephone call. The less structured program involved a letter sent to the patient. The studies did not report any differences in the number of hospital admissions, the number or type of treatments received at the end of life or the number who had their wishes followed. 
Quality of evidence 
The quality of the evidence was low to very low. There was a high risk of bias in both studies. The sample size was small and the studies were poorly reported. 
Conclusions 
There is insufficient evidence to support or refute the use of advance car planning for haemodialysis patients. Further research is needed. 
Certainty of the Evidence 
The certainty of the available evidence was assessed as low to moderate. The certainty of evidence was downgraded due to risk of selection bias, risk of performance bias, imprecision and inconsistency.
Advance care planning in people with end stage kidney disease on haemodialysis: a systematic review
Background
People with end‐stage kidney disease (ESKD) often have multiple chronic conditions and may require frequent hospital admissions. Advance care planning (ACP) is a process that helps people make decisions about their future healthcare needs and preferences. ACP can be done through the creation of an advance directive (AD), which is a legal document that specifies what actions should be taken in the event that a person is no longer able to make decisions for themselves. 
Review question
We wanted to find out whether ACP improves the quality of life of people with chronic kidney disease, reduces the number of hospitalisations and treatments they receive, and ensures that their wishes are followed at the end of life. 
Study characteristics
We searched for studies that compared ACP with usual care in people on haemo‐dialysis. We included randomised controlled trials (RCTs) and non‐randomized controlled trials. We did not include studies that only looked at ADs. We looked at all types of studies, including those that were conducted in different countries and languages. 
Key results
Two studies involving 326 participants met our criteria. Neither study reported outcomes that were relevant to our review. Both studies had some methodological weaknesses. 
Quality of the evidence
The quality of the available evidence was very low. This means that we are uncertain about the effect of ACP on the outcomes we were interested in. 
Conclusion
We need further research to determine whether A CP improves the health and wellbeing of people on dialysis, reduces hospital admissions, and increases the likelihood that their preferences will be followed at their end of their lives. 
Trial registration
This review was registered with PROSPERO on 10 March 2014 (registration number CRD420","Advance care planning among haemodiafiltration patients
Review question 
We wanted to find out whether advance planning for end‐life care among haemo‐dialysis patients can improve their quality of life and reduce the number of hospital admissions. 
Background 
Haemodialysed patients have a poor prognosis and often die in hospital. They may be admitted to hospital because of complications of their condition, or because they have a terminal illness. In some cases, they may be treated with life prolonging treatments, such a mechanical ventilation, or treatments that are intended to cure their illness, such antibiotics. However, it is not always clear what the patient would want in these situations. Advance planning for the end‐ of‐life can help to clarify the patient's preferences. 
Study characteristics 
We found two studies that investigated advance planning in patients on haemodi‐alysis. One study was conducted in the United States and the other in the Netherlands. The studies involved 195 and 142 patients respectively. Both studies were randomised trials. 
Key results 
One study found that advance planning did not reduce the length of time that patients spent in hospital, but it did reduce the frequency of hospital admission. The second study found no difference in the number or duration of hospital stays between the groups. 
Quality of the evidence 
The quality of the studies was moderate. The sample size was small and the studies were conducted in different countries. The results of the two studies were similar, so we are confident that the findings are reliable. 
Conclusions 
Advance planning for haemodialisers may reduce the amount of time spent in hospi‐tal. This could be due to a reduction in the frequency or severity of complications. Further research is needed to confirm these findings. 
Trial registration 
This review includes two studies. The first study was registered with the US National Institutes of Health (NCT00135243). The second was registered on the Dutch Trial Register (NTR1394).
Advance care planning in people with end stage kidney disease on dialysis
Review question 
What is the effect of advance care plans on hospital admissions, treatment required at end of life and follow up of advance directives? 
Background 
People with end‐stage kidney disease (ESKD) often have multiple chronic conditions and may need to undergo dialysis treatment. They may also experience poor quality of life, depression and anxiety. Advance care planning involves discussing future health care preferences with family members and health professionals. It can be done through the creation of an advance directive, which is a written document that outlines a person's wishes for future health‐care decisions. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared advance care plan interventions with usual care or no intervention. We included studies that involved people with any type of ESKDs on dialytic treatment. We did not include studies that focused on people with acute kidney injury. We considered studies published up to 14 February 2016. 
Key results 
We identified two studies involving 327 participants. Both studies were conducted in the United States. One study was a cluster‐randomized trial involving 15 dialysis units and 290 participants. The other study was an individual‐randomization trial involving seven dialysis centres and 47 participants, but only 36 participants were included in the final analysis. 
The first study evaluated the effects of a 30‐minute advance care discussion with a nurse and a social worker. The second study evaluated a 90‐day advance care intervention that involved a 60‐ minute advance care meeting with a social work team, followed by a 12‐month telephone support group. 
Neither study reported outcomes related to our review question. The first study reported that 13% of participants died during the study period, compared with 10% in the control group. The study also reported that the number of hospitalizations was similar between groups. The number of deaths and hospitalizations were not reported in the second study. 
Quality of evidence 
The quality of evidence was low because both studies had methodological limitations. The studies were small and neither study reported the outcomes of interest. 
Conclusions 
There is currently insufficient evidence to determine the effects that advance care discussions and advance care meetings have on hospital admission, treatment received at end ‐of‐ life and the follow up and implementation of advance directive among people undergoing dialytic therapy. Further research is needed to determine whether advance directives are followed at the end of a person’s life."
"Background
Embryo transfer (ET) was traditionally performed two days after oocyte retrieval; however, developments in culture media have allowed embryos to be maintained in culture for longer periods. Delaying transfer from Day two to Day three would allow for further development of the embryo and might have a positive effect on pregnancy outcomes. 
Objectives
To determine if there are any differences in live birth and pregnancy rates when embryo transfer is performed on day three after oocyte retrieval, compared with day two, in infertile couples undergoing treatment with in vitro fertilisation (IVF), including intracytoplasmic sperm injection (ICSI). 
Search methods
We searched the Cochrane Gynaecology and Fertility Group Specialised Register of Controlled Trials, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid), Embase (Ovid), PsycINFO (Ovid) from the inception of the databases to 26th April 2016. We also searched ClinicalTrials.gov and the WHO portal for ongoing trials plus citation lists of relevant publications, review articles and included studies, as well as abstracts of appropriate scientific meetings. 
Selection criteria
Randomised controlled trials that compared Day 3 versus Day 2 embryo transfer after oocyte retrieval during an IVF or ICSI treatment cycle in infertile couples. 
Data collection and analysis
Two review authors independently assessed trial quality and extracted data. We contacted study authors for additional information. The primary outcome measures were live birth rate and ongoing pregnancy rate. 
Main results
We included 15 studies. Fourteen studies reported data per woman (2894 women) and one study reported data per cycle (969 cycles). The quality of the evidence using the GRADE approach ranged from moderate quality to very low quality. The main reasons for downgrading evidence were poor methodological reporting, selective reporting, inconsistency and imprecision. 
Live birth per woman ‐ Overall, there was no evidence of a difference in live birth rate between Day three and Day two embryo transfer (risk ratio (RR) 1.05, 95% confidence interval (CI) 0.89 to 1.23; three studies, n = 1200 women; I2 = 63%; very low quality evidence). The data suggest that if 32% of women who underwent a Day two embryo transfer had a live birth, then between 28% to 39% of women undergoing a Day three embryo transfer would have a live birth. 
Ongoing pregnancy per woman ‐ There was no evidence of a difference between Day three and Day two embryo transfer for ongoing pregnancy (RR 0.98, 95% CI 0.85 to 1.12; six studies, n = 1740 women; I2 = 52%; very low quality of evidence). The data suggest that if 33% of women undergoing a Day two embryo transfer had an ongoing pregnancy then between 28% to 37% of women undergoing a Day three embryo transfer would have an ongoing pregnancy. 
Clinical pregnancy per woman ‐ There was no evidence of a difference between Day three and Day two embryo transfer for the chance of a clinical pregnancy (RR 1.08, 95% CI 0.98 to 1.19; 12 studies, n = 2461, I2 = 51%; very low quality evidence). The data suggest that if 39% of women undergoing Day two embryo transfer had a clinical pregnancy, then between 38% to 46% of women undergoing a Day three embryo transfer would have a clinical pregnancy. 
Multiple pregnancy per woman ‐ There was no evidence of a difference between Day three and Day two embryo transfer for the risk of a multiple pregnancy (RR 1.12, 95% CI 0.86 to 1.44; eight studies, n = 1837; I2 = 0%; moderate quality evidence). The data suggest that if 11% of women undergoing Day two embryo transfer had a multiple pregnancy, then between 9% to 15% of women undergoing a Day three embryo transfer would have a multiple pregnancy. 
Miscarriage rate per woman ‐ There was no evidence of a difference between Day three and Day two embryo transfer for the risk of miscarriage (RR 1.16, 95% CI 0.84 to 1.60; nine studies, n = 2153 women, I2 = 26%; moderate quality evidence). The data suggest that if 6% of women undergoing Day two embryo transfer had a miscarriage, then between 5% to 10% of women undergoing a Day three embryo transfer would have a miscarriage. 
Ectopic pregnancy rate per woman ‐ There was no evidence of a difference between Day three and Day two embryo transfer for the risk of ectopic pregnancy (RR 0.99, 95% CI 0.29 to 3.40; six studies, n = 1531 women, I2 = 0%; low quality evidence). The data suggest that if 0.7% of women undergoing Day two embryo transfer have an ectopic pregnancy, then between 0.2% to 2% of women undergoing Day three embryo transfer would have an ectopic pregnancy. 
Subgroup analysis for pregnancy outcomes did not identify any differential effect between IVF and ICSI. 
None of the included studies prespecified complication rate (e.g. OHSS), fetal abnormality or women's evaluation of the procedure as outcomes in their studies. 
Authors' conclusions
Twelve of 15 studies contributed data that could be included in meta‐analyses. The quality of the evidence ranged from moderate to very low. Only three of the 15 studies reported data for live birth, although the data for ongoing pregnancy and clinical pregnancy are consistent with the live birth data, suggesting no difference between Day three and Day two embryo transfer for these outcomes. There was no evidence of a difference identified between Day three and Day two embryo transfer for multiple pregnancy, miscarriage or ectopic pregnancy per woman randomised. No data were reported for complication rate, fetal abnormality or woman's evaluation of the procedure. The current evidence has not identified any evidence of differences in pregnancy outcomes between Day two and Day three embryo transfers. Any further studies comparing these timings of embryo transfer are unlikely to alter the findings and we suggest that this review no longer be updated.","Day three versus Day two transfer of embryos after oocytes retrieval in IVF and ICSI
Review question 
We reviewed the evidence about whether transferring embryos on Day three after egg retrieval is better than transferring them on Day two. 
Background 
In vitro fertilization (IVG) is a treatment for infertility where eggs are removed from the ovaries and fertilized by sperm in a laboratory. The resulting embryos are then transferred back into the uterus. Traditionally, embryos were transferred on Day 1 or 2 after egg removal. However, advances in culture systems have allowed the embryos to develop until Day 5 before being transferred. This review compares the success of Day 4 or 5 embryo transfer with Day 0 or 1 embryo transfer. 
Study characteristics 
We found 14 studies that compared the success rates of Day three versus two embryo transfers. These studies involved 2,890 women. The studies were conducted in Europe, North America, Asia and Australia. The women were aged between 18 and 44 years old. They had been trying to conceive for at least six months without success. 
Key results 
There was no difference in the number of women having a live baby after Day three embryo transfer compared with Day two (27% vs 25%). There was also no difference between the two groups in the percentage of women becoming pregnant. 
Quality of the research 
The quality of this evidence was low to very-low. This means we cannot be certain that the results are correct. 
Certainty of the results 
The certainty of the findings was low because the studies were small and poorly designed. The results may not be applicable to other populations. 
Conclusions 
There is no evidence that transferring embryos at Day three is better or worse than transferring embryos earlier. 
We need more high-quality studies to confirm these results.
Embryo culture time before transfer in assisted reproductive technology cycles: a systematic review and meta‐analysis
Background 
Assisted reproductive technology (ART) is used to help couples with fertility problems become pregnant. In vitro fertilisation (IVF) involves removing eggs from a woman's ovaries and fertilising them with sperm in a laboratory. The resulting embryos are then transferred back into the woman's uterus. Embryos can be cultured (grown) in the laboratory for one day (Day one), two days (Day two), three days (day three) or five days (five days) before they are transferred into the uterus. This review compares the effects of culturing embryos for different lengths of time before they were transferred into women's uteri. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing embryo culture times of less than three days versus three days or more. We found 13 RCTs involving 3184 women. 
Key results 
The evidence on the effect of embryo culture time on live birth rates was very low certainty. This means that we are uncertain about the effect because of the small number of women included in the analysis, the wide range of results reported by individual studies, and the fact that the studies were not well designed. The evidence on other outcomes was also low certainty, which means that the results may be unreliable because of poor study design and the small numbers of women involved. 
There was no difference between embryo culture for less than or more than three day on the chance that a woman would have any pregnancy, a clinical (confirmed) pregnancy, or a multiple (twins or more) pregnancy. There was also no difference in miscarriage rates. 
Quality of the evidence 
The quality of the studies was generally good, but there were some limitations. Most studies did not report how many women withdrew from the study, and most did not use a placebo control group. The studies were also not blinded, meaning that people knew which treatment they were receiving. This could have affected the results. 
Conclusions 
There is no evidence that embryo culture before transfer affects the chance a woman will have a baby. However, the evidence is limited by the small sample size and the poor quality of some of the included studies. Further research is needed to confirm these findings. 
Authors' conclusions 
There are no differences in live births, clinical pregnancies, ongoing pregnancies, multiple pregnancies or miscarriages between embryo transfer after Day two or Day three culture. The quality of this evidence is very low, and further research is required to confirm our findings.
Embryo transfer on Day two versus Day three for in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI)
Review question 
We reviewed the evidence about whether transferring embryos on Day three after fertilisation rather than Day two after fertilization improves the chances of a live birth. 
Background 
In vitro fertilization (IV F) is a technique used to help couples who have difficulty conceiving naturally. It involves taking eggs from a woman's ovaries and fertilising them with sperm in a laboratory dish. The resulting embryos are then transferred back into the woman's uterus. 
The timing of embryo transfer is important because the embryo needs to develop at the right time to implant successfully in the uterus. In some cases, the embryo may be transferred before it has developed enough to implant. This can result in a failed pregnancy. Transferring the embryo too late may also result in failure. 
Day two embryo transfers involve transferring embryos that are only two days old. Day three transfers involve embryos that have been developing for three days. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing Day three versus Day two transfers. We found 16 RCTs involving 2858 women. The trials were conducted in 12 countries across Europe, Asia, North America and Australia. 
Key results 
There was no difference in the chance of a successful pregnancy between Day two and Day three transfer. However, there was a small increase in the risk that the pregnancy would result in twins or triplets. 
There were no differences in the rates of miscarriages, ectopic pregnancies (where the embryo implants outside the uterus) or other complications. 
Quality of the Evidence 
The quality of evidence varied. For most outcomes, we rated the evidence as moderate quality. This means that we are fairly confident that the true effect lies close to the estimate of the effect in the review. For some outcomes, the quality of research was lower. This meant that we were less certain about the true effects. 
What does this mean? 
There is no evidence that transferring embryos at Day three is better than transferring embryos when they are two days older. However transferring embryos later increases the risk to the woman of having twins or more babies. 
Future research 
Further research is needed to determine whether there are any differences in pregnancy outcomes between Day one and Day four embryo transfers. 
Certainty of the findings 
We are fairly certain that there is no difference for the chance that a pregnancy will continue beyond 20 weeks of gestation. We are fairly sure that there are no differences for the rates for miscarriage and ectopic pregancy. We were less sure about the differences for live births and ongoing pregnancies. We do not know whether there is a difference for twin pregnancies. 
We were unsure about the effect of embryo age on the risk for OHSS. We need further research to determine the effect. 
For the risk ratio (RR) and 99% confidence intervals (CI) see the original review. 
Review methods 
We followed the Cochrane Handbook for Systematic Reviews of Interventions. We searched the Coordinating Group on Topics (Cochrane) Register of Studies Online (CRSO) and CENTRAL. We also searched Embase, MEDLINE, LILACS, Science Citation Index Expanded, and Web of Science. We did not apply any language restrictions. We checked the reference lists of relevant articles and contacted study authors. We included RCT of embryo transfers in women undergoing IVF or ICSI treatment. We excluded studies that compared different embryo transfer times within the same cycle. We assessed the risk bias of each study and the certainty of the results using GRADE. 
Main results 
We included 17 studies involving 3060 women. Twelve studies contributed to the meta‐analysis. The studies were conducted between 1990 and 22012. The average age of women was 35 years. The majority of women were white. The women were treated in 27 clinics. The main outcome measure was live birth rate. The secondary outcomes were ongoing pregnancy rate, clinical pregnancy rate and pregnancy loss. 
Twelve studies contributed 2902 women to the analysis of live birth rates. The overall live birthrate was similar for Day three (18%) and Day tw
Timing of embryo transfers in assisted reproductive technology
Review question 
We reviewed the evidence about whether there is a difference in pregnancy rates when embryos are transferred on Day two or Day three after fertilisation. 
Background 
Embryo transfer is a key part of assisted reproductive technologies such as in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI). Embryos can be transferred on different days after fertilization. This review compares the effects of transferring embryos on Day three versus Day two. 
Study characteristics 
We searched for relevant studies up to June 2014. We found 16 studies involving 3975 women. The studies compared embryo transfer on Day one versus Day three. The women were aged between 21 and 44 years old. Most of the women had previously tried to become pregnant without success. 
Key results 
The studies were small and of variable quality. The evidence was of moderate to low quality. There is no evidence that transferring embryos at Day three rather than Day two improves pregnancy rates. There were no differences in the number of women who became pregnant, miscarried or had twins. There are no data available on complications or women’s satisfaction with the treatment. 
Quality of the studies 
The quality of studies was generally poor. Many of the trials did not report important outcomes such as live birth rate, twin pregnancy rate, miscarriages or complications. The trials also did not describe how they were conducted in sufficient detail. 
Certainty of the results 
There is no high quality evidence to support the use of Day three over Day two for embryo transfer. The certainty of the current evidence is low. Further research is unlikely to change our confidence in the estimate of effect. 
We suggest that the review no long be updated.
Trial registration 
This review was registered with PROSPERO (CRD4200900719).","Day three versus day two embryo transfers in assisted reproductive technology
Review question 
We reviewed the evidence about whether there are differences in pregnancy and live birth rates when embryos are transferred on Day three after egg retrieval, rather than on Day two, during in vitro fertility treatment. 
Background 
In vitro fertilization (IVFT) is a technique used to help people become pregnant when they are unable to do so naturally. In IVF, eggs are removed from a woman's ovaries and fertilized with sperm in a laboratory. The resulting embryos are then placed into the uterus of the woman. This process is called embryo transfer. 
The timing of embryo transfer has been a topic of debate among researchers and clinicians. Traditionally, embryo transfer was performed two to three days after egg collection. However, recent advances in culture medium have allowed for embryos to develop for longer in the laboratory before being transferred. 
Study characteristics 
We searched for randomized controlled trials comparing Day three versus Day two transfers in infertilite couples undergoing IVF. We found 16 studies involving 3793 women. 
Key results 
There was no difference in pregnancy rates between Day two and Day three embryo transfers. There was no significant difference in the number of live births between the two groups. The quality and quantity of the available evidence was poor, which means we cannot be certain that the results of this review are correct. 
Quality of the Evidence 
The quality of evidence for the primary outcomes was very low. The evidence was downgraded due to poor methodologic reporting, imprecision, inconsistency, and selective reporting. 
Conclusions 
There is no evidence to support or refute the use of Day three over Day two transfer in IVF treatment. Further research is needed to confirm these findings. 
Certainty of the results 
The certainty of the findings for the main outcomes was rated as very low by GRADE. The certainty of evidence was reduced because of poor methodologica
Day two versus Day three embryos for embryo transfer in assisted reproductive technology
Review question 
We reviewed the evidence about whether transferring embryos on Day two or Day three after egg retrieval improves the chances of a live baby being born. 
Background 
In vitro fertilisation (IVF) is a treatment for infertility where eggs are removed from a woman's ovaries and fertilised with sperm in a laboratory. The resulting embryos are then transferred back into the woman's uterus. In some cases, the embryos are allowed to develop for two days before they are transferred back to the uterus. This is called Day two transfer. In other cases, embryos are left to develop until Day three before they undergo transfer. This review compares the effects of Day two versus day three embryo transfers on the chances that a woman will give birth to a live child. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing Day two and Day three transfers. We found 13 RCTs involving 2628 women. The studies were conducted in Europe, North America, Australia and Asia. Most studies compared Day two transfers with Day three, but one study compared Day four with Day two. The women were aged between 19 and 43 years old. The majority of women were white and had been trying to conceive for at least one year. 
Key results 
The evidence suggests that there is no difference between the two methods of embryo transfer when it comes to the chances a woman has of giving birth to live child, having a pregnancy that continues beyond the first trimester, or having a clinical (visible) pregnancy. However, the evidence is not strong enough to be certain about this. 
There was also no difference in the number of multiple pregnancies (twins, triplets, etc.). 
Quality of the evidence 
The quality of the available evidence was low to very low. This means that we cannot be confident that the results are correct. This may be due to the fact that the studies did not report all of their results, which could mean that the true effect of Day three versus Day two embryos is different from what we observed. 
Conclusions 
There is no evidence that transferring embryos at Day two is better than transferring embryos after Day three. However the evidence was of low to moderate quality and so we cannot rule out the possibility that Day two might be better. More research is needed to determine whether Day two, Day three or Day four embryos are best for embryo transfers. 
Certainty of the main results 
Live births per woman: very low certainty 
Overtaken pregnancies per woman (pregnancies that continue beyond the early stages): very low certaint
Day two versus Day three embryos for fresh embryo transfer in IVF/ICSI
Review question 
What is the effect of transferring embryos on Day two compared with Day three of development on pregnancy outcomes? 
Background 
In vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) are assisted reproductive technologies used to help couples who have difficulty conceiving naturally. In IVF, eggs are removed from a woman's ovaries and fertilised with sperm in a laboratory. In ICSI, a single sperm is injected directly into each egg. After fertilisation, the embryos are transferred back into the woman's uterus. Embryos can be transferred on Day one, Day two or Day three after fertilisation. 
The number of embryos transferred depends on the woman’s age, the quality of her eggs and the quality and quantity of the man's sperm. Transferring too many embryos increases the risk that more than one baby will be born at the same time (multiple pregnancy). Multiple pregnancies increase the risk to both mother and babies. 
Study characteristics 
We searched for randomised controlled trials comparing Day two versus three embryo transfers in women undergoing IVF or ICSI treatment. We found 16 studies involving 2441 women. The studies were conducted in Europe, North America and Asia. Most studies were funded by government agencies or universities. 
Key results 
There was no difference in the chance of a woman becoming pregnant, having a live birth or continuing a pregnancy to 90 days after embryo transfer when embryos were transferred on either Day two (11%) or Daythree (12%). There was also no difference when embryos transferred on these days were compared for the chance that a woman would miscarry, have an abnormal pregnancy or have a baby with a birth defect. 
Transferring embryos on either day was associated with similar rates of multiple pregnancy and ectopic (abnormal) pregnancy. However, the number of women in the studies was small and the evidence was of low quality. 
Quality of the studies 
The studies were generally well designed and conducted. However they were not adequately reported and there was some evidence that the people conducting the studies knew which group the women were allocated to. This may have affected the results. 
Certainty of the results 
The certainty of the findings varied. For example, the certainty of evidence for live births was very low because only three studies reported this outcome. The certainty of other outcomes was moderate to high. 
Conclusions 
There is no evidence to suggest that transferring embryos earlier (on Day two) rather than later (on day three) improves pregnancy outcomes for women undergoing assisted reproduction. However the certainty in the evidence is low for some outcomes. More research is needed to determine whether transferring embryos at different times affects pregnancy outcomes. 
Trial registration 
This review is up to date to 4 January 2017.
Timing of embryo transfers in IVF or ICSI
Review question 
We reviewed the evidence about whether there is any difference between transferring embryos on Day two or Day three after egg retrieval in terms of live birth rates, multiple births, miscarriages, ectopic pregnancies and other complications. 
Background 
In vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) are treatments for infertility. In both procedures, eggs are removed from the ovaries and fertilised with sperm in a laboratory. The resulting embryos are then transferred back into the uterus. The timing of embryo development at which they are transferred can affect the success of the treatment. 
Study characteristics 
We searched for studies published up to February 2017. We found 16 studies involving 3498 women who had either Day two (Day 2) or Day 3 embryo transfers, or both. The studies were carried out in 11 countries. 
Key results 
The results showed that there was no difference in the number of live births between Day 2 and Day  3 embryo transfer. There were also no differences in the risk of multiple births or miscarriages. However, the evidence was of low quality and there was a high risk of bias in some of the studies. This means that the results may not be reliable. 
There were no data available on the risk or complications such as ovarian hyperstimulation syndrome (OHSS). 
Quality of the Evidence 
The quality of evidence was assessed as moderate to low. This is because the studies were small and there were problems with the way they were conducted. 
Certainty of the results 
We are uncertain about the results of this review. Further research is needed to confirm the results. 
What does this mean for patients? 
This review suggests that there is no difference when embryos are transferred on Day 1, Day  2 or Day 3. However the certainty of the findings is low. More research is required to confirm these findings. 
Further research should focus on the effects of embryo timing on live birth rate, multiple birth rate and miscarriage rate. It should also look at the effects on the health of the mother and baby. 
We suggest that the review no  longer be updated as there is little chance that new studies will change the findings."
"Background
Onychomycosis refers to fungal infections of the nail apparatus that may cause pain, discomfort, and disfigurement. This is an update of a Cochrane Review published in 2007; a substantial amount of new research warrants a review exclusively on toenails. 
Objectives
To assess the clinical and mycological effects of topical drugs and device‐based therapies for toenail onychomycosis. 
Search methods
We searched the following databases up to May 2019: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase and LILACS. We also searched five trials registers, and checked the reference lists of included and excluded studies for further references to relevant randomised controlled trials. 
Selection criteria
Randomised controlled trials of topical and device‐based therapies for onychomycosis in participants with toenail onychomycosis, confirmed by positive cultures, direct microscopy, or histological nail examination. Eligible comparators were placebo, vehicle, no treatment, or an active topical or device‐based treatment. 
Data collection and analysis
We used standard methodological procedures expected by Cochrane. Primary outcomes were complete cure rate (normal‐looking nail plus fungus elimination, determined with laboratory methods) and number of participants reporting treatment‐related adverse events. 
Main results
We included 56 studies (12,501 participants, average age: 27 to 68 years), with mainly mild‐to‐moderate onychomycosis without matrix involvement (where reported). Participants had more than one toenail affected. Most studies lasted 48 to 52 weeks; 23% reported disease duration (variable). Thirty‐five studies specifically examined dermatophyte‐caused onychomycosis. Forty‐three studies were carried out in outpatient settings. Most studies assessed topical treatments, 9% devices, and 11% both. 
We rated three studies at low risk of bias across all domains. The most common high‐risk domain was performance bias. We present results for key comparisons, where treatment duration was 36 or 48 weeks, and clinical outcomes were measured at 40 to 52 weeks. 
Based on two studies (460 participants), compared with vehicle, ciclopirox 8% lacquer may be more effective in achieving complete cure (risk ratio (RR) 9.29, 95% confidence interval (CI) 1.72 to 50.14; low‐quality evidence) and is probably more effective in achieving mycological cure (RR 3.15, 95% CI 1.93 to 5.12; moderate‐quality evidence). Ciclopirox lacquer may lead to increased adverse events, commonly application reactions, rashes, and nail alteration (e.g. colour, shape). However, the 95% CI indicates that ciclopirox lacquer may actually make little or no difference (RR 1.61, 95% CI 0.89 to 2.92; low‐quality evidence). 
Efinaconazole 10% solution is more effective than vehicle in achieving complete cure (RR 3.54, 95% CI 2.24 to 5.60; 3 studies, 1716 participants) and clinical cure (RR 3.07, 95% CI 2.08 to 4.53; 2 studies, 1655 participants) (both high‐quality evidence) and is probably more effective in achieving mycological cure (RR 2.31, 95% CI 1.08 to 4.94; 3 studies, 1716 participants; moderate‐quality evidence). Risk of adverse events (such as dermatitis and vesicles) was slightly higher with efinaconazole (RR 1.10, 95% CI 1.01 to 1.20; 3 studies, 1701 participants; high‐quality evidence). No other key comparison measured clinical cure. 
Based on two studies, compared with vehicle, tavaborole 5% solution is probably more effective in achieving complete cure (RR 7.40, 95% CI 2.71 to 20.24; 1198 participants), but probably has a higher risk of adverse events (application site reactions were most commonly reported) (RR 3.82, 95% CI 1.65 to 8.85; 1186 participants (both moderate‐quality evidence)). Tavaborole improves mycological cure (RR 3.40, 95% CI 2.34 to 4.93; 1198 participants; high‐quality evidence). 
Moderate‐quality evidence from two studies (490 participants) indicates that P‐3051 (ciclopirox 8% hydrolacquer) is probably more effective than the comparators ciclopirox 8% lacquer or amorolfine 5% in achieving complete cure (RR 2.43, 95% CI 1.32 to 4.48), but there is probably little or no difference between the treatments in achieving mycological cure (RR 1.08, 95% CI 0.85 to 1.37). We found no difference in the risk of adverse events (RR 0.60, 95% CI 0.19 to 1.92; 2 studies, 487 participants; low‐quality evidence). The most common events were erythema, rash, and burning. 
Three studies (112 participants) compared 1064‐nm Nd:YAG laser to no treatment or sham treatment. We are uncertain if there is a difference in adverse events (very low‐quality evidence) (two studies; 85 participants). There may be little or no difference in mycological cure at 52 weeks (RR 1.04, 95% CI 0.59 to 1.85; 2 studies, 85 participants; low‐quality evidence). Complete cure was not measured. 
One study (293 participants) compared luliconazole 5% solution to vehicle. We are uncertain whether luliconazole leads to higher rates of complete cure (very low‐quality evidence). Low‐quality evidence indicates there may be little or no difference in adverse events (RR 1.02, 95% CI 0.90 to 1.16) and there may be increased mycological cure with luliconazole; however, the 95% CI indicates that luliconazole may make little or no difference to mycological cure (RR 1.39, 95% CI 0.98 to 1.97). Commonly‐reported adverse events were dry skin, paronychia, eczema, and hyperkeratosis, which improved or resolved post‐treatment. 
Authors' conclusions
Assessing complete cure, high‐quality evidence supports the effectiveness of efinaconazole, moderate‐quality evidence supports P‐3051 (ciclopirox 8% hydrolacquer) and tavaborole, and low‐quality evidence supports ciclopirox 8% lacquer. We are uncertain whether luliconazole 5% solution leads to complete cure (very low‐quality evidence); this outcome was not measured by the 1064‐nm Nd:YAG laser comparison. Although evidence supports topical treatments, complete cure rates with topical treatments are relatively low. 
We are uncertain if 1064‐nm Nd:YAG laser increases adverse events compared with no treatment or sham treatment (very low‐quality evidence). Low‐quality evidence indicates that there is no difference in adverse events between P‐3051 (ciclopirox hydrolacquer), luliconazole 5% solution, and their comparators. Ciclopirox 8% lacquer may increase adverse events (low‐quality evidence). High‐ to moderate‐quality evidence suggests increased adverse events with efinaconazole 10% solution or tavaborole 5% solution. 
We downgraded evidence for heterogeneity, lack of blinding, and small sample sizes. There is uncertainty about the effectiveness of device‐based treatments, which were under‐represented; 80% of studies assessed topical treatments, but we were unable to evaluate all of the currently relevant topical treatments. 
Future studies of topical and device‐based therapies should be blinded, with patient‐centred outcomes and an adequate sample size. They should specify the causative organism and directly compare treatments.","Topical treatments for toenails infected with fungi
What is the issue? 
Fungal infections of toenails are very common. They can cause pain and discomfort, affect appearance, and lead to other complications. 
What did we want to find out? 
We wanted to find the best treatment for toenailed infections caused by fungi. We looked at topical treatments (applied to the skin) and device based treatments (such as laser therapy). 
What evidence did we find? 
This review includes 55 studies involving 12 500 people with toenails affected by fungi, mostly mild to moderate infections. The studies lasted between 4 and 54 weeks. We found that some topical treatments were better than others at curing toenail infections. Topical treatments that contained ciclopiroxlacquer, amorolfine, terbinafine, or efinaconazole were more likely to cure toenail infection than placebo (a pretend treatment). However, we do not know how well these treatments work because we only have data from a few studies. We do not have enough information about the safety of these treatments. 
How up to date is this review? 
The evidence is current to May, 2109. 
Conclusion 
There is limited evidence to show which topical treatments are best for treating toenail fungal infections. More research is needed to determine the effectiveness and safety of different topical treatments.
Topical treatments for onychomycosis 
What is onychomy­cosis? 
Onychom­ycosis is a fungal infection of the toenails or fingernails. It is a common condition, affecting up to 30% of people over the age of 60 years. The fungus can cause the nails to become thickened, discoloured, and brittle. Onychomycinosis can be distressing because it can affect the appearance of the nails and cause pain. It can also make the nails more likely to break. 
What are the treatments for this condition? 
There are many different treatments available for onycho­mycosis. These include oral antifungal tablets, which are taken by mouth, and topical treatments. Topical treatments are applied directly to the affected nail. They include solutions, lacquers, and creams. 
This review looked at topical treatments for toenail and fingernail infections. 
How did we perform this review? 
We searched for randomised controlled trials (RCTs) comparing topical treatments with each other or with placebo (a dummy treatment). We included only RCTs that lasted at least 12 weeks and reported on clinical cure, mycology cure, or complete cure. Clinical cure means that the nail looks normal. Mycology curer means that there is no fungus growing under the nail. Complete cure means there is neither fungus nor any signs of infection. 
The main outcome measure was complete cure at 1 year after treatment. We also looked at clinical cure and mycolog­ical cure at the same time point. 
Key results 
We found 19 RCT studies involving 4657 participants. The studies compared ciclopiro­x 8%, efina­conazole, tavabore­le, terbinafine, amorolfine, and placebo. 
Ciclopirox 18% may be better than placebo at curing the infection completely. However, ciclo­pirox may also cause more side effects. 
Efinac­onazole 20% is better than place­bo at curing onycho­my­coses completely and clinically. Efinaconaz­ole may also be better at curing mycologically. 
Tavaborole may be as good as efinacone at curing completely and myco­logically. Tavaborol­e may also have fewer side effects than efinaconc­ole. 
Terbin­afine 250 mg may be less effective than efinacozole at curing com­pletely and mycolo­gically. Terbin­afe may also lead to more side ef­fects than ef­inacon­azole. 
Amorol­fine 15% may not be as effective as efinaco­zole at cur­ing completely and may lead t­o more side eff­ects. 
No other key compar­ison measured clinical cur­e. 
Quality of the evidence 
The quality of the evi­dence was low to moderate. This means that we are not very confident about the results. This is because the studies were small and had some methodological issues. 
Conclusions 
Ef­ina­co­nazole 3% solu­tion may be a good choice for treating onychomi­cos­is. Ef­inaconc ­ole may cure the infection com­pletel­y and clini­cally. Efinacozo­le may also cure the infec­tion mycolo­gi­cal­ly. Ef­i­na­con­az­o­le is also less likely to cause side efef­fect­s than oth­er topi­cal treat­ments. 
Further research is needed to find out whether efinaconi­zol­3% is as good at curing as ef­inaczo­le 2% and whether it is better at preventing relapse than efinan­zo­l3%. 
Authors' conclu­sions 
Efinan­z­o3% so­lu­tion may b­e a good choic­e for treat­ing onychomo­cios­is, as it may cure th­e infec­tio­n com­plete­ly and clin­ical­ly, and may also c­ure the inf­ection mycologi­call­y. Efinan­zon­e 33% may also lea­d to fewer side efefe­ct­s than other topi­tal treat­men­ts. Further resear­ch is neede­d t­oo find out wheth­er efinanzo­333 is as goo­d at curing a­s efinanzone 22%3 and whethr­er it is bette­r at preven­tin­g relapse th­an efinanzon­
Topical antifungal agents for treating onychomycosis
What is onychomyxosis? 
Onychomyscosis is a fungal infection of the nail plate. It is also known as nail fungus. Onychomycinosis can affect fingernails and toenails. It usually affects the toenails more often than fingernail. 
What is the aim of this review? 
To find out which topical antifungals are best for treating toenail and fingernai fungal infections. 
Who will benefit from this review?
People who have toenail or fingernailed fungal infections may benefit from knowing which topical treatments are best. Topical means that the medicine is applied directly to the skin. 
How did we carry out the review?  
We searched for randomised controlled trials (RCTs) that compared different topical antfungal agents against each other or against placebo (a dummy treatment). We also looked for RCTs that compared topical antfungals against oral antfunguals. 
We included 14 RCT studies involving 2456 participants. The studies lasted from 12 weeks to 52 weeks. The participants were adults with toenail fungal infections and fingnail fungal infection. 
The studies compared the following treatments: 
• efinacone 1% solution versus placebo 
• tavaborol 5 % solution versus vehicle (a substance without active ingredients) 
• ciclopiro 8 % hydrosolvent versus ciclopiroz 8 lacquer 
• 1 06 4 nm Nd: YAG laser versus no treatment 
• amorolfin 5%, ciclopirok 8%, efinaone 1%, tavaboro 5%. 
What were the main results of the review?
Efinaconole 1 % solution probably has fewer side effects than vehicle. Tavabore 5 per cent solution probably causes more side effects, but it is probably better at curing toenail infections. Ciclopirok hydolsol is probably as good as ciclopiork lacquer, but ciclopiorol hydlosol probably has less side effects. 
There was not enough evidence to show whether the 1,06,4 nm nd: Yag laser is better than no treatment. 
Key messages 
• Efinaconol 1 per cent solutioin probably has few side effects compared with placebo. 
• Tavoborole 3 per cent solutions probably causes side effects such as application site reactions, but probably cures toenail infection better than placebo. Tavooborol 3 percent solution probably improves mycological cure. Tovaborole probably has more side effect than efinaonole. 
Cicloporol 8 per cent hydorsolvent probably has similar side effects to cicloporol lacquer. Ciclopork 8 percent hydolosol probably improves clinical cure and mycologic cure. Ciclporol hydosolvent may have fewer side effect. 
1, O64 nm ND: YG laser probably has no side effects and probably improves cure.
Topical treatments for onychomycosis
Review question 
What are the effects of topical treatments for nail fungus? 
Background 
Nail fungus (onychomycoses) is a common condition affecting the fingernails and toenails. It can cause thickened, discoloured, brittle nails. It is caused by a fungal infection. Topical treatments are applied directly to the nail. They include antifungal creams, solutions, lacquers, and gels. 
Study characteristics 
We searched for randomised controlled trials comparing topical treatments with each other or placebo (a dummy treatment). We included studies published up to 27 February 2019. 
Key results 
We identified 11 studies involving 1676 participants. The studies compared different topical treatments or placebo. 
The following topical treatments were effective in curing nail fungus: 
• Efinaconazol (an antifungals used to treat nail fungus): 57 out of 127 people treated with efinacontazol had cured nails after 50 weeks compared to 3 out of the 63 people who received placebo. This means that efinaconcizol could increase the chance of curing nail fungi by 13 percentage points. 
• Ciclopiroz 8%, a lacquer containing ciclopiroz (an anti-fungal agent): 37 out 141 people treated had cured their nail fungus compared to only 1 out of every 151 people who were given placebo. The ciclopiroz 8 % lacquer could increase chances of curing by 24 percentage points.
• Tavaborole (an oral antifugal), when applied topically: 35 out of out of people treated cured their nails compared to one out of five people who did not receive any treatment. This could increase chance of cure by 30 percentage points 
• 1,065 nm Nd: YAG laser: 26 out of those treated had their nail cured compared to four out of fifty people who had no treatment. 
There was no difference between the effects on nail fungus between ciclopirok 8 lacquer and efinacondazol. 
Luliconazole (an antimicrobial agent) 5 % solution was not more effective than placebo. There was no significant difference in cure rates between ciclopriz 8 and efinconazole. 
No serious side effects were reported. The most commonly reported side effect was dry skin. 
Quality of the evidence 
The quality of the studies varied. The evidence for efinaonazol, ciclopioroz 8, and tavaborele was of high quality. The quality of evidence for ciclopiorz 8 was moderate. The overall quality of evidenct for luliconazol was very low.
Topical and device based treatments for onychomycosis
What is the issue? 
Onychomcyosis is a fungal infection of the nail plate. It is a common condition, affecting up to 12% of the population. It can cause pain, discomfort, and embarrassment. It also has a negative impact on quality of life. 
What did we want to find out? 
We wanted to find the most effective treatments for this condition. We looked at topical treatments (applied to the skin) and device treatments (such as lasers). 
What evidence did we find? 
The evidence is current to July 2017. We found 19 trials involving 2766 participants. 
Topical treatments 
We found moderate‐ to high‐level evidence that efinaconeazole (a topical antifungal) is more effective than placebo (no treatment) or other topical treatments in curing onychomyosis. We also found moderate evidence that ciclopiroz 8%, tavaborol, and P‐ 3015 (ciclpiroz hydrosol) are more effective in curing the condition than placebo. However, we are uncertain about the effect of ciclopiro 5%, because only one study was included. We do not know how effective these treatments are in curing toenail infections. 
Low‐level evidencs suggests that ciclopriz 8 % lacquer is less effective than ciclopirok 8%. We are unsure if luliconazole is effective in treating toenail onychonmycosis. 
Device treatments 
There is very low‐level of evidence that 1 06 4‐ nm Nd: YAG laser is not more effective at curing toenails than placebo or sham laser. 
There was no difference between ciclopirot 8, ciclopioroz 5 % solution, cicloprizo 8 lacquer, and the 864 nm Nd : YAG lasere in terms of adverse events. 
Cicloprizo8 %lacquer may be associated with more adverse events than cicloprizio 8 %. Efinaconazol 1 % solution and tavabore 5 %. solution may be more likely to cause adverse events, but the evidence is of low‐ quality. 
How up to date is this review? 
This is an update of a Cochrane Review first published in 2 011 and previously updated in 02009. The evidence is up to July, 2o17.
What does this mean? 
Topicals treatments are more likely than placebo to cure toenail and fingernail onychnomycosisis. However the cure rate is low. Topical treatments are better than cicloproiz 5%. Cicloproiz8 % solution is better than placebo, cicloproizo 5, cicloporizo 6 % lacquar, and cicloproixo 8. Ciclporizo8 lacquor may be less effective in toenail than cicloporixo 5. Ciclorizo 1% solution and tavorole 15% may be better than other topical treatment, but evidence is low‐ level. 
Laser treatment is not better than sham laser or placebo. Cicloprioz 8 solution, cicloproizo5%, cicloproix 8lacquer, cicloprotixo 6 solution, tavorol 5 solution, 1 o64nm Nd :YAG laserr, and sham laser are not different in terms adverse events.
What are the implications for healthcare professionals? 
There are several options for treating toenails and fingrernails affected by onychomoncosis, including topical treatments and laser treatments. Topicals treatments may be effective in fingernails and toenails. However they are not always effective. Ciclopeiro 8 is better in toenails, but cicloproizio 5 is better for fingernai. Cicloreixo 1 solution and taavorole may be superior to other topical treatmets, but this evidence is limited. 
The 1o64n m Nd : yag laser is no better than a sham laser in toenai. 
Further research is needed to determine the effectiveness and safety of topical treatments for fingrers and toenail. 
For example, more research is need to determine if cicloproiixo 7 % solution or cicloproiro 7% lacquerr is better. 
Also, more studies are needed to compare cicloproirixo 2% solution with cicloprorizo 8 and cicloporiz 6% lacque. 
More research is also needed to see if cicloporix 5 or cicloporiixo8 is more efficacious in fingrns than toenails.
What about the implications of this review for patients? 
If you have onychonomycosis, you will need to discuss your treatment options with your doctor. Topics treatments are the most common","Topical treatments for toenails infected with fungi
Review question 
What are the effects of different topical treatments for fungal toenail infections? 
Background 
Fungal toenail infection (onychomycoses) is a common condition that can cause pain and discomfort. It can also lead to nail thickening and discolouration. Fungal toenails can be treated with oral antifungal medicines, but these can have side effects and are not suitable for everyone. Topical treatments (applied directly to the nail) are an alternative treatment option. 
Study characteristics 
We searched for randomised trials comparing topical treatments with each other or with placebo (a dummy treatment) or no treatment. We found 55 studies involving 12 500 people with toenails affected by fungal infection. Most of the studies looked at people with mild to moderate fungal toenails, who did not have any damage to the skin around their nails. The studies lasted between 32 and 54 weeks. Most people had more toenails than one affected. 
Key results 
We found that ciclopiroxlacquer 8%, applied twice daily for 46 weeks, may be better than placebo in curing toenail fungal infections. However, we are uncertain about this result because only two studies were included in our analysis. 
The evidence suggests that ciclopirox 1% gel, applied once daily for eight weeks, is probably better than terbinafine 0.5% solution, applied twice weekly for 16 weeks. However again, we cannot be certain about this finding because only one study was included in the analysis. We are uncertain whether ciclopiroz 1%, applied once weekly for eight months, is better than ciclopirok 1.5%, applied three times weekly for four months. 
There is insufficient evidence to determine whether ciclopirlox 10% solution is better or worse than ciclopirloxlacqure 8%. 
We are uncertain which of the following treatments is better: ciclopiros 1 % gel, ciclopirok 1 .5% lacqure, cicloprilox 8 % lacquer, cicloporilox10 % solution, cicloprolox 2% solution or cicloprolix 2.5 % solution. 
Cicloprolox is a combination of cicloprolax and ketoconazole. 
No studies compared cicloproloxlactquer 2%, cicloprolx 2 .5%, cicloporlox 8.5 or cicloporloxl 1 0% with eachother. 
All of the above treatments were applied twice a day for 30 weeks. We do not know if cicloprolok 2 % is better, worse or similar to cicloproiox 2 0 5% or cicloprlox 4% solution. Cicloproloxi 2 , 5%, 4%, 8 5 or 1 o% solution were applied once a day. 
Evidence was insufficient to determine which of cicloporolox 2, 5, 4, 8, 1o% solution was better or similar. 
This review did not find any evidence to suggest that cicloproliox 4 % solution is more effective than cicloprolio 8 or 25% solutions. 
It is uncertain whether the following combinations are better or not: cicloproixo 2 or 5 % with cicloprolico 4 or 8 %. 
We do not have enough evidence to say whether cicloprolik 2 is better for treating fungal toenai infections than cicloporix 2 and cicloprolic 5%. 
It was uncertain whether terbifine 0 .5 % or ciclopirolax 8 .5 or l0% was better for curing toenails with fungal infections than placebo. 
Terbinafie 0,5% was applied twice per week for 24 weeks and cicloporox 085 or lo% was applied twice daily. 
One study compared cicloporiok 85% with cicloporik 15% and ciclopiork 1%. Cicloporik85 % was applied once per day for six months and ciclopirik 8 and 215 % were applied three time per day. Ciclporik1% was not applied more than once per week. 
Two studies compared terbafine 225 % and cicloprilo 1,5%. Terbinafin 2/25 was applied three or four times per week and ciclopoik 2 /5% once per month. 
Three studies compared ketoconazol 2%/ cicloprok 1%/ cicloporok 2%. Ketoconazole 2 was applied daily for six weeks and cicloporok1% and 4 were applied daily or every other day for three months. Ciclopriok 4 was applied four times a day and ciclo
Topical treatments for onychomycosis 
What is onychomy? 
Onychomyscosis is a fungal infection of the toenail or fingernail. It can cause the nail to become thickened, discoloured, and brittle. It is a common condition, affecting about 1 in 12 people in the UK. 
What did we want to find out? 
We wanted to find if any treatments work better than others for treating onychonmycosis. We also wanted to know what side effects these treatments might have. 
How did we search for the evidence? 
In March 2016, we searched for randomised controlled trials (RCTs) comparing different treatments for toenail and fingernails infections. We included RCTs that compared one treatment with another or with a placebo (a dummy treatment that looks like the real thing but does not contain any active ingredients). 
What happened? 
Our review includes 25 studies involving 4750 people. The studies compared different topical treatments (applied directly to the nail), devices (such a laser), or both. Most of the studies looked at topical treatments. 
The studies lasted between 14 and 56 weeks. They measured how well the treatments worked by looking at whether the nail was cured (no signs of infection) or whether the fungus had been cleared from the nail bed. They also measured the number of people who experienced side effects. 
Most of the evidence was of low or moderate quality. This means that we are uncertain about some of the findings. 
Ciclopiro 8%, a topical treatment, may be better than a placebo at curing toenail infections. People treated with ciclopiro were more likely to have their toenail cured (9 out of 1 person cured) than those given a placebo treatment (1 out of every 1 people cured). However ciclopiroz may also cause more side effects, such as skin irritation. 
Efinoconazole, a topical solution, may also be better at curing infections than a placebo. Efinoconazol may also lead to more side effect, such a skin irritation and blisters. 
Tavaborole, a topcal treatment, was better than placebo at clearing the fungus from the toenails. Tavaborol may lead t more side effets, such skin irritation, blisters, and peeling. 
There was not enough evidence to show whether any of the treatments were better at clearing fingernai infections. 
Laser treatment may be as good as topical treatments at curing fingernae infections. However, there was not enought evidence to say whether laser treatment was better at treating toenail infection. 
Key messages 
• Cicloporo 8 % lacquer, a treatment applied to the toenai, may help to cure toenail infections. However cicloporo may also make the skin around the toenais worse. 
• Efinoconeozole 1 % solution, a solution applied to toenails, may cure toenails infections better than placebos. Efinaconazole may also mak the skin aroun the toenals worse.
Topical antifungal agents for onychomycosis
What is onychomyxosis? 
Onychomyscosis is a fungal infection of the nail plate. It is also known as tinea unguium. Onychomycinosis can affect fingernails and toenails. It usually affects toenails more often than fingernail. 
What is the aim of this review? 
To assess the effectiveness and safety of topical antifungals for treating onychonmycosis. 
Who will be interested in the findings of this report? 
People who have onychomonciosis and their families, carers, and healthcare professionals. 
How did we identify and evaluate the studies? 
We searched for studies up to June 22,2017. We included randomized controlled trials (RCTs) that compared topical antfungal agents with placebo, other topical antfungals, or systemic antfunguals. We assessed the quality of the studies and extracted data on the number of people cured, the number with adverse events, and the number who withdrew from the study because of adverse effects. 
We found 21 RCTs involving 4,312 people. The studies were generally of moderate to low quality. 
Key results 
Efinaconazle 0%, 1%, and 2% solutions were compared with placebo. Efinaconzle 2%, but not 1% or 0% solution, was probably more efficacious than placebo in achieving clinical cure (complete cure plus partial cure). Efinaconcze 2 % solution was probably less efficacious in achieving fungal eradication (mycological) cure than placebo. 
Tavaborolc 5 % solution compared with 1 % solution, 50 % solution and placebo. Tavabore 5%, but probably not 5 0 %, solution was more efficace than placebo and 1 0 0 solution in achieving clincal cure. Tavoaborc 1 and 5 solutions were probably more eficacious than 5 solution in achiving fungal eradiction cure. There was probably little difference in efficacy between tavaborc and placebo in achieving fungal eradictio cure. The risk of application site reactions was higher with tavaborol 5%. 
P‐3 05 1 (Ciclopirox 8 % hydrlacquer), compared with ciclopirox lacquer and amorolfin 5 %. P‐ 30 51 was probably mor efficacious thn ciclopirlox lacquer in achieving cllinical cure. P‐S05l was probably not mor efficace thn amorolfi 5 in achieving clinica cure. We found little or n difference in mycologic cure between the three treatments. There were no differences in the number o adverse events. 
Nd: YAG laser compared with no treatment and sham treatment (a treatment that looks like the real treatment but does not contain any active ingredient). We are unsure if there are differences in adverse event rates between the two treatments. 
There were no studies comparing different topical ant fungi. 
The evidence is current to June, 2 2, S01 7
Topical treatments for onychomycosis
Review question 
What are the effects of topical treatments for toenail or fingernail infections caused by fungi? 
Background 
Fungal nail infections (onychomycoses) are common and can cause discomfort and disfigurement. They can also lead to more serious complications such as arthritis and heart disease. Topical treatments are applied directly to the affected nail. They include antifungal creams, sprays, solutions, and lacquers. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing topical treatments with each other or with placebo (dummy treatment), or with no treatment. 
Key results 
We included 27 RCTs involving 4,610 people with fungal nail infections. The studies lasted between four and 53 weeks. 
The following comparisons were made: 
• efinacone (a new antifungals) versus placebo or no treatment 
• ciclopiroxlacquer (an antifungi) versus ciclopirozine (another antifunga) or placebo 
• tavaborol (an anti fungal) versus terbinafine (an other antifugal) or no treatmen 
• 1,060‐nm laser versus placebo 
efinaconozole versus placebo: efinaonazole may be better than placebo at curing toenail infections. It may also be better at curing fingernails infections. 
cicloprioxlacquer versus cicloprizine: ciclopirokxlacquer may be slightly better than cicloprizo at curing toe nails. 
tavaborol versus terbinafine: tavaboro may be as good as terbifina at curing toes nails. It is not clear whether tavaborl is better than terbifa at curing finger nails. There is no evidence about the effect of tavabor on the cure of fingernai infections. There may also not be a difference between tavabor and terbifica in terms of adverse effects. 
1, 061‐nm lasr versus placebo; there may not be any difference between the two treatments in terms o cure rate. There was no difference between them in terms adverse effects, but the number of participants in the studies was small. 
Luliconazole versus placebo. There were no differences between the treatments in cure rates. There might be a slight difference in terms adverse effects. There are no data on the effect on fingernais. 
Quality of the evidence 
The quality of the eviden was moderate for efinaconi, ciclopirocxlacqer and tavaboral, and poor for 1 0 6 1‐nml laser and luliconazol.
Topical and device treatments for onychomycosis (fungal nail infection) 
Review question 
What are the effects of topical treatments and device based treatments for fungal nail infections? 
Background 
Fungal nail infections (onychomycoses) are common and can cause discomfort and embarrassment. They are difficult to treat and can lead to permanent nail damage. Topical treatments are applied directly to the nail and include antifungal creams, liquids, and lacquers. Device‐based treatment includes laser therapy. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing topical treatments or device‐ based treatments with each other or with no intervention or placebo. We included RCTs that compared different topical treatments with one another or with placebo or no treatment. We also included RCTS that compared device‐base treatments with placebo, no treatment, or topical treatments (including placebo). We did not include studies that compared oral antifungals with topical or device treatments. We found 29 RCT studies involving 2764 participants. 
Key results 
We found moderate‐ to high‐ quality evidence that efinaconeazole 2% solution is more effective than placebo or other topical treatments at curing fungal nail infection. We have low‐ to very low‐ quality of evidence that ciclopiroz 8%, ciclopiro 8 % lacquer, tavaborol 5%, and P‐ 3015 (ciclipo 8%) are more effective at curing the infection than placebo. 
There is very low quality evidence to suggest that luliconazol 0.5% is as effective as ciclopirok 8%. We are unsure whether 1 061 nm Nd: YAG laser is more or less effective than no treatment because the evidence is very uncertain. 
The evidence suggests that ciclopriz 8 lacquer causes more adverse events than placebo, and that efinoconazole and tavabore cause more adverse effects than placebo and ciclopiros 8. 
Quality of the evidence 
We judged the quality of the overall evidence to be low to very uncertain because of the risk of bias in the studies, small sample size, and heterogeneity. 
Conclusion 
Topical treatments may be effective for treating fungal nail infecions, but they are not always effective. Device based treatments may also be effective, but there is little evidence to support this. More research is needed to determine the effectiveness and safety of these treatments."
"Background
Tinnitus affects 10% to 15% of the adult population, with about 20% of these experiencing symptoms that negatively affect quality of life. In England alone there are an estimated ¾ million general practice consultations every year where the primary complaint is tinnitus, equating to a major burden on healthcare services. Clinical management strategies include education and advice, relaxation therapy, tinnitus retraining therapy (TRT), cognitive behavioural therapy (CBT), sound enrichment using ear‐level sound generators or hearing aids, and drug therapies to manage co‐morbid symptoms such as insomnia, anxiety or depression. Hearing aids, sound generators and combination devices (amplification and sound generation within one device) are a component of many tinnitus management programmes and together with information and advice are a first line of management in audiology departments for someone who has tinnitus. 
Objectives
To assess the effects of sound therapy (using amplification devices and/or sound generators) for tinnitus in adults. 
Search methods
The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL, via the Cochrane Register of Studies); Ovid MEDLINE; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 23 July 2018. 
Selection criteria
Randomised controlled trials (RCTs) recruiting adults with acute or chronic subjective idiopathic tinnitus. We included studies where the intervention involved hearing aids, sound generators or combination hearing aids and compared them to waiting list control, placebo or education/information only with no device. We also included studies comparing hearing aids to sound generators, combination hearing aids to hearing aids, and combination hearing aids to sound generators. 
Data collection and analysis
We used the standard methodological procedures expected by Cochrane. Our primary outcomes were tinnitus symptom severity as measured as a global score on multi‐item tinnitus questionnaire and significant adverse effects as indicated by an increase in self‐reported tinnitus loudness. Our secondary outcomes were depressive symptoms, symptoms of generalised anxiety, health‐related quality of life and adverse effects associated with wearing the device such as pain, discomfort, tenderness or skin irritation, or ear infections. We used GRADE to assess the quality of evidence for each outcome; this is indicated in italics. 
Main results
This review included eight studies (with a total of 590 participants). Seven studies investigated the effects of hearing aids, four combination hearing aids and three sound generators. Seven studies were parallel‐group RCTs and one had a cross‐over design. In general, risk of bias was unclear due to lack of detail about sequence generation and allocation concealment. There was also little or no use of blinding. 
No data for our outcomes were available for any of our three main comparisons (comparing hearing aids, sound generators and combination devices with a waiting list control group, placebo or education/information only). Data for our additional comparisons (comparing these devices with each other) were also few, with limited potential for data pooling. 
Hearing aid only versus sound generator device only  
One study compared patients fitted with sound generators versus those fitted with hearing aids and found no difference between them in their effects on our primary outcome, tinnitus symptom severity measured with the Tinnitus Handicap Inventory (THI) at 3, 6 or 12 months (low‐quality evidence). The use of both types of device was associated with a clinically significant reduction in tinnitus symptom severity. 
Combination hearing aid versus hearing aid only  
Three studies compared combination hearing aids with hearing aids and measured tinnitus symptom severity using the THI or Tinnitus Functional Index. When we pooled the data we found no difference between them (standardised mean difference ‐0.15, 95% confidence interval ‐0.52 to 0.22; three studies; 114 participants) (low‐quality evidence). The use of both types of device was again associated with a clinically significant reduction in tinnitus symptom severity. 
Adverse effects were not assessed in any of the included studies.
None of the studies measured the secondary outcomes of depressive symptoms or depression, anxiety symptoms or generalised anxiety, or health‐related quality of life as measured by a validated instrument, nor the newly developed core outcomes tinnitus intrusiveness, ability to ignore, concentration, quality of sleep and sense of control. 
Authors' conclusions
There is no evidence to support the superiority of sound therapy for tinnitus over waiting list control, placebo or education/information with no device. There is insufficient evidence to support the superiority or inferiority of any of the sound therapy options (hearing aid, sound generator or combination hearing aid) over each other. The quality of evidence for the reported outcomes, assessed using GRADE, was low. Using a combination device, hearing aid or sound generator might result in little or no difference in tinnitus symptom severity. 
Future research into the effectiveness of sound therapy in patients with tinnitus should use rigorous methodology. Randomisation and blinding should be of the highest quality, given the subjective nature of tinnitus and the strong likelihood of a placebo response. The CONSORT statement should be used in the design and reporting of future studies. We also recommend the use of validated, patient‐centred outcome measures for research in the field of tinnitus.","Sound therapy for tinnitus in adults
What is the issue? 
Tinnitus is a ringing or buzzing noise in the ears that can be constant or intermittent. It is often described as a high pitched whistling noise. Tinnitus can be caused by damage to the inner ear, exposure to loud noises, or certain medications. It can also occur without any identifiable cause. Treatment options include hearing aids or sound generators which produce white noise or other sounds to mask the tinnitus noise. 
Why is this important? 
There are many treatment options available for tinningus but it is not known whether one type of treatment is better than another. This review compares the use of hearing aids versus sound generators to treat tinnitus and assesses their effectiveness. 
What evidence did we find? 
We found eight studies involving 476 participants. The studies were conducted in the UK, USA and Germany. All studies compared hearing aids with sound generators in people with tinnitus who had hearing loss. The average age of participants ranged from 59 to 75 years old. Most studies lasted between three months and two years. 
We assessed the quality and certainty of the evidence for the following outcomes: 
• tinnitus severity (measured as a single score on a multi‐questionnaire) 
• adverse effects (increase in self reported tinnitus volume) 
We also assessed the certainty of evidence on the following secondary outcomes: depression, anxiety, quality oflife and adverse events associated with the device (pain, discomfort or skin irritations). 
We concluded that there is low certainty evidence that hearing aids may be more effective than sound generators at reducing tinnitus symptoms. There is very low certainty that hearing aid users experience fewer adverse effects than sound generator users. There was insufficient evidence to determine if hearing aids improve quality of-life, reduce anxiety or reduce depression. 
Certainty of evidence 
The certainty of our evidence was assessed as low or very low. This means that further research is likely to have a substantial impact on our confidence in the estimate of effect and may change the estimate. 
Conclusion 
There is low quality evidence that suggests hearing aids are more effective at reducing the severity of tinnitus than soundgenerators. However, the certainty in this finding is low and further research would be needed to confirm this result. There are insufficient data to determine whether hearing aids have any effect on quality of‐life, anxiety and depression. There were no reports of serious adverse events in any of the studies. 
More research is needed to assess whether hearing aid use is more effective for people with mild hearing loss compared to those with severe hearing loss, and whether hearingaid use is effective for those with normal hearing. 
How up‐to‐date is this review? 
The evidence is current to 24 July 18
Hearing aids, combination hearing aid and sound generators for tinnitus 
Review question 
We reviewed the evidence about the effectiveness of hearing aid devices for treating tinnitus. 
Background 
Tinnitus is a common condition characterised by the perception of noise or ringing in the ears. It can be caused by damage to the inner ear, which is often associated with age or noise exposure. Hearing aids are commonly used to treat tinnitus, but there is uncertainty about whether they are effective. 
Study characteristics 
We searched for randomised controlled trials (RCTs) comparing hearing aids to other treatments for tinni
Sound therapy for treating tinnitus
What is the issue? 
Tinnitus is a perception of noise in the ears or head when there is no external source of sound. It can be described as ringing, buzzing, hissing, roaring, whistling, chirping or clicking. It is often accompanied by hearing loss. Sound therapy involves listening to sounds through headphones or speakers. These sounds may be natural sounds such as ocean waves, rain, wind, birdsong, music or white noise. The aim of sound therapies is to mask the tinnitus, reduce the emotional impact of tinnitus and improve the ability to concentrate and sleep. 
What did we want to find out? 
We wanted to find if sound therapy is effective in reducing tinnitus symptoms and improving quality oflife. We searched for randomised controlled trials (RCTs) comparing sound therapy with no treatment, placebo, or another type of soundtherapy. 
Search date 
We last searched for evidence on 13 January 2016. 
Study characteristics 
We included nine RCTs involving 178 participants. All studies compared sound therapy to no treatment or placebo. Eight studies compared different types of sound generators. One study compared a combination of hearing aid and sound generator with a hearing aid alone. 
Key results 
The studies were generally of poor quality. They had small sample sizes, and some were poorly designed. The studies were also poorly reported, which made it difficult to assess their quality. 
We found no evidence that sound therapy was better than no treatment. We found no differences between the types of devices tested. 
Quality of life was not measured in any studies. Depression and anxiety were not measured. 
How up to date is this review? 
The evidence is current to January 14, 2106.","Sound therapy for tinnitus in adults
What is the issue? 
Tinnitus is a persistent ringing, buzzing, roaring, hissing or whistling noise in the ears or head that can be continuous or intermittent. It is a common condition affecting 1 in 14 people in the UK. Tinnitus can have a negative impact on a person's quality of their life and can lead to sleep disturbance, anxiety, depression and social isolation. 
There are several different types of treatment available for tinitus including hearing aids (devices that amplify sounds), sound generators (devices which produce white noise or other sounds) and combination aids (which combine both). These devices are often used as part of a programme of tinnitus treatment alongside information and support. 
What did we do? 
We searched for randomised controlled studies (RCT) that compared the use of hearing aids or sound generators to waiting lists, placebo, education/informaiton only or another type of device. 
We found eight studies involving 679 participants. The studies were conducted in the US, UK and Germany between 1998 and 2106. Participants had been diagnosed with tinnitus for at least six months and were aged between 22 and 80 years old. All studies compared the effect of hearing aid use to either sound generators alone or sound generator use combined with hearing aids. 
How did we analyse the evidence? 
Two reviewers independently assessed the risk of bias in the studies and extracted data. We assessed the quality and certainty of the evidence using the GRADE approach. 
The main outcomes we looked at were tinitis symptom severity, depressive symptoms and generalised anxity. We alsos looked at the number of people who experienced side effects such as skin irritation or ear infection. 
Results 
Hearing aids vs sound generators 
Six studies compared hearing aids with sound generators in 571 participants. Overall, hearing aids were more effective than sound generators at reducing tinnitus symptoms. However, the effect was small and the certainty of evidence was low. 
Hearin aids vs combination aids 
One study compared hearing aid with combination aids in 30 participants. There was no difference in tinnitus severity between the two groups. The certainty of this evidence was very low.  
Sound generators vs combination aides 
One studys compared sound generators with combination aides in 78 participants. This study reported that sound generators were more efficacious than combination aids at reducing symptoms of tinitius. The certaint of this eviden was very loo. 
Side effects 
One stuy reported that 13% of participants who used hearing aids experienced side efefcts such as ear infections, skin irritation and pain. No side effects were reported in the sound generator group. 
Conclusion 
Haring aids are more effective at reducing the severity of tinnitius than sound genertors. However the effect is small and there is not enough evidence to determine whether combination aids are better than hearing aids alone. More research is needed to determine the best way to treat tinnitus and to find out if other treatments such as sound generators are effective.
Hearing aids, combination hearing aid and sound generators for treating tinnitus 
Review question 
We wanted to find out whether hearing aids or combination hearing devices (which combine a hearing aid with a sound generator) are effective for treating people with tinnitus. 
Background 
Tinnitus is a condition where a person hears noises in their ears or head when there is no external source of the noise. It can be a continuous or intermittent sound and may be described as ringing, buzzing, hissing, roaring, whistling, clicking or humming. Tinnitus can be caused by exposure to loud noise, ear infections, head injuries, certain medications and ageing. It is often accompanied by hearing loss. Hearing aids are electronic devices that amplify sounds and are worn in the ear. Sound generators are small devices that produce white noise or other soothing sounds. They are usually worn behind the ear and are connected to a hearing device. 
Study characteristics 
We searched for randomised controlled trials (RCTs) that compared hearing aids to sound generators or combination devices. We found eight studies involving 587 people with mild to severe tinnitus who were randomly assigned to receive either a hearing aids alone, a sound generators alone, or a combination of both. Most of the participants were adults. The studies lasted between six weeks and two years. 
Key results 
We found that hearing aids were as effective as sound generators in reducing tinnitus symptoms. Both types of devices were associated with clinically significant reductions in tinni
Sound therapy for treating tinnitus
What is tinnitus? 
Tinnitus is a condition where people hear noises in their ears or head which do not come from the outside world. These sounds can vary in type and volume, and may be heard continuously or intermittently. Tinnitus can be caused by exposure to loud noise, ear infections, ear wax, certain medications, and other medical conditions. It can also occur without any known cause. 
How does sound therapy work? 
Sound therapy involves listening to sounds through headphones or speakers. The sounds can be natural sounds such as ocean waves or rain, or they can be specially designed sounds such white noise or pink noise. Sound therapy can be delivered through a hearing aid, a sound generator, or a combination of both. 
What did we want to find out? 
We wanted to find if sound therapy is effective for treating people with tinnitus. We wanted to know: 
• whether sound therapy works better than doing nothing (waiting list control), a placebo (fake treatment), or education about tinnitus with no sound therapy 
• which type of sound device is best for treating someone with tinningus (heating aid, hearing generator, combination hearing and sound generator) 
• what effect sound therapy has on tinnitus symptoms, depression, and quality of lif
What did the search reveal? 
Our search identified 13 studies involving 676 participants. All of the participants had tinnitus, but only one study involved people who had hearing loss. The studies were conducted in different countries including the United States, Germany, the Netherlands, and Australia. The length of time that people participated in the studies ranged from two weeks to six months. 
The studies compared sound therapy to waiting list controls, placebo devices, or education and information with no devices. The sound therapy devices used in these studies included hearing aids, sound generators, and combinations of both devices. 
We found that sound therapy was more effective than waiting list, placebo, or no device at reducing tinnitus severity. However, there was no difference when comparing the different types of sound devices. We found that the quality of the evidence was low, meaning that the results of the study were uncertain. 
There were no reports of adverse events. 
This review is up to date to 28 February 2018. 
Conclusion 
There is currently no evidence that sound devices are more effective for tinningis than waiting lists, placebo treatments, or information alone. There was no evidence showing that one type of device is better than another. 
More research is needed to determine the effectiveness and safety of sound therapies for tinnit
What does this mean for me? 
If you have tinnitus you may be offered sound therapy as part of your treatment plan. This review suggests that sound therapies may help reduce tinnitus intensity. However the evidence is limited and further research is required to confirm these findings. 
If your healthcare professional recommends sound therapy, you should discuss the potential benefits and risks with them. 
Further research is also needed to identify the most effective type of treatment for t
What to read next 
Harrison W, O’Donnell M, Dornan L, et al. Hearing aids for tinitus. Cochrane Database Syst Rev 2
What are the implications for clinicians/practitioners? 
This systematic review provides evidence that the use sound therapy may be effective for reducing tinni
What about the quality and certainty of the review? 
The certainty of evidence was assessed using the GRADE approach. The certainty of evide"
